

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.



Overview for Request: cder mpl1r wp077, Report 1 of 3

Request ID: cder_mpl1p_wp077

Request Description: In this report, we describe the incidence rate of hospitalized tachyarrhythmia, defined as tachyarrhythmia, overall and by subtype, that occurred from May 13, 2022 (the approval date of Mounjaro (tirzepatide) in the U.S.) to June 30, 2023, in adult type 2 diabetes mellitus (T2DM) patients who newly initiated Mounjaro (tirzepatide) or other long-acting glucagon-like peptide-1 (LA GLP-1) receptor agonists (RAs), by product and patient characteristics including race/ethnicity groups.

This is report 1 of 3 and contains the results from the primary analysis. For the primary analysis, the lookback period for enrollment, inclusion or exclusion criteria, and most covariates was 365 days in length, and patients were excluded from the analysis if an event occurred on the index date (i.e., the blackout period is set to 1 day). Reports 2 and 3 contain the results from two sensitivity analyses. For the first sensitivity analysis, the lookback period was 183 days in length. For the second sensitivity analysis, events were allowed to occur on the index date.

<u>Sentinel Routine Querying Module:</u> Cohort Identification and Descriptive Analysis (CIDA) module, version 12.1.2 with custom programming.

<u>Data Source:</u> We distributed this query to seven Sentinel Data Partners (DPs) on September 28, 2023. Six of these Data Partners are a subset of the SDD that rapidly refresh to provide freshest feasible data. The study period included data from May 13, 2022 through June 30, 2023. See Appendix A for a list of dates of available data for each DP.

<u>Study Design:</u> We identified all individuals with incident use of tirzepatide or other LA GLP-1 RAs and evaluated the occurrence of hospitalized tachyarrhythmia within each LA GLP-1 RA exposure cohorts.

In addition to the overall exposure cohorts, analyses were also conducted by the following subgroups:

- Age groups (0-40, 41-64, 65-74, 75-84, 85 years of age or greater)
- Sex (male, female)
- Calendar year of index date
- Race (White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Unknown, Multi-Racial)
- Calendar year * race
- Age group * race
- Other cardiac disease at baseline (heart failure, ischemic heart disease/coronary artery disease/myocardial infarction, hypertension, valvular disease, obstructive sleep apnea, and hypertrophic cardiomyopathy)

For the primary analysis, the lookback period for enrollment, inclusion or exclusion criteria, and most covariates was 365 days in length, and patients were excluded from the analysis if an event occurred on the index date (i.e., the blackout period is set to 1 day). Two sensitivity analyses were conducted. For the first sensitivity analysis, the lookback period was 183 days in length. For the second sensitivity analysis, events were allowed to occur on the index date.

This is a Type 2 analysis with custom programming in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were defined as the first qualifying dispensing of one of the following LA GLP-1 RA brand names, each as its own separate cohort: Mounjaro (tirzepatide), Bydureon or Bydureon BCISE (exenatide synthetic), Ozempic (semaglutide), Rybelsus (semaglutide), Wegovy (semaglutide), Saxenda (liraglutide), Victoza (liraglutide), Trulicity (dulaglutide) or Xultophy (insulin degludec/liraglutide). We defined exposures using National Drug Codes (NDCs). Only the first qualifying (index) dispensings of the exposures of interest were included; cohort re-entry was not allowed. See Appendix B for generic and brand names of medical products used to define exposures of interest.

<u>Stockpiling Rules:</u> Brand names within a single exposure definition were stockpiled together, and dispensing dates were not adjusted in case of early refills. If multiple dispensings occurred on the same day, the maximum value for days supply and amount supply among these dispensings were taken to be days supply and amount supply values on that day.

cder_mpl1p_wp077 Page 1 of 1023



Overview for Request: cder_mpl1r_wp077, Report 1 of 3

<u>Outcomes of Interest:</u> The following health outcomes of interest (HOI) were evaluated for each of the exposure definitions:

- · Hospitalized tachyarrhythmia (defined as the presence of any of the conditions below)
- Atrial fibrillation and flutter
- · Sinus tachycardia
- · Supraventricular tachycardia
- · Other tachycardia
- · Cardiac arrest
- · Ventricular fibrillation and flutter
- Ventricular tachycardia

Outcomes were defined in the inpatient caresetting in principal position (IPP) and in the emergency department caresetting (ED*).

We defined outcomes using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. See Appendix C for diagnosis codes used to define the outcome.

<u>Cohort Eligibility Criteria:</u> We required eligible members to be continuously enrolled in health plans with medical and drug coverage for at least 365 days prior to the index date, during which gaps in coverage of up to 45 days were allowed. We defined new use as no evidence use of the index-defining exposure or any other LA GLP-1 RA in the 365 days prior to index date.

<u>Inclusion Criteria:</u> We required exposure episodes to have a T2DM diagnosis and usage of any oral anti-diabetic drug in the 365 days prior to index date.

<u>Exclusion Criteria:</u> We excluded exposure episodes with a T1DM diagnosis, gestational diabetes, other secondary diabetes illnesses, use of any short-acting (SA) GLP-1 RAs, pregnancy, or insulin-only use (defined as evidence of insulin use without evidence of use of any other anti-diabetic drug) in the 365 days prior to the index date.

We defined inclusion and exclusion criteria using NDCs, ICD-10-CM diagnosis and procedure codes, Healthcare Common Procedure Coding System (HCPCS), Level II codes, and Current Procedural Terminology, Fourth Edition (CPT-4) codes.

See Appendix D for diagnosis or procedure codes used to define inclusion and exclusion characteristics and Appendix E for generic and brand names of medical products.

<u>Follow-up Time:</u> We created exposure episodes based on the number of days of product supplied per dispensing in the outpatient pharmacy dispensing data. We bridged together episodes less than 5 days apart and added 5 days to the end of each episode.

Outcome evaluation began on the day after index date and continued until the earliest occurrence of the following:

- Outcome
- Treatment discontinuation
- Disenrollment
- Death (except for when all-cause mortality is the outcome)
- End of DP data
- Pregnancy
- Inpatient (IP*) or ED* encounter (other than the HOI-defining hospitalized tachyarrhythmia)
- Non-index LA GLP-1 RA

<u>Baseline Characteristics</u>: The following demographic and clinical characteristics of our study population were ascertained on index date: continuous age, age groups (0-40, 41-64, 65-74, 75-84, 85 years of age or greater), sex (male, female), race (American Indian or Alaska native, Asian, Black or African American, Native Hawaiian or other Pacific Islander, White, Unknown, Multiracial), calendar year of treatment initiation, tachyarrhythmia, hospitalized tachyarrhythmia, drugs with a known risk of prolonged QT and torsades de pointes, drugs with a known or possible or conditional risk of prolonged QT and torsades de pointes.

cder mpl1p wp077 Page 2 of 1023



Overview for Request: cder_mpl1r_wp077, Report 1 of 3

The following clinical characteristics were ascertained in the 365 days prior to cohort entry in the primary analysis and second sensitivity analysis or in the 183 days prior to cohort entry in the first sensitivity analysis: alcohol use or abuse, obesity, tobacco use, arrhythmia, cerebrovascular disease or stroke or transient ischemic attack, chronic kidney disease, chronic obstructive pulmonary disease, congenital heart disease, heart failure, hyperlipidemia, hypertensive disease, thyroid disease, ischemic heart disease or coronary artery disease or myocardial infarction, left ventricular hypertrophy, peripheral artery disease, valvular or mitral valve disease, disease of veins and lymphatics and other diseases of the circulatory system, obstructive sleep apnea, hypertrophic cardiomyopathy, other cardiac disease (heart failure, ischemic heart disease/coronary artery disease/myocardial infarction, hypertension, valvular disease, obstructive sleep apnea or hypertrophic cardiomyopathy), history of serious hypoglycemia (ED* or IP*), antidiabetic drugs [alpha-glucosidase inhibitors, amylin analogs, dipeptidyl peptidase 4 (DPP-4) inhibitors, incretin mimetics, meglitinides, insulin, biguanides, sodium-glucose cotransporter-2 (SGLT2) inhibitors, sulfonylureas, and thiazolidinediones], no baseline use of any of the previous antidiabetic drugs, other antidiabetic drugs (bromocriptine, mifepristone), antiarrhythmic agents [sodium channel blocker, beta blocker, potassium channel blockers or openers, nondihydropyridine calcium channel blockers, digoxin, other antiarrhythmic agents], any of the previous antiarrhythmic agents, antihypertensives [angiotensin-converting-enzyme (ACE) inhibitor, angiotensin II receptor blockers (ARB), dihydropyridines, diuretics, other antihypertensives], any of the previous antihypertensives, cardiac medications [oral anticoagulants, vitamin K antagonists, other cardiac medications (not including oral anticoagulants or vitamin K antagonists)], any of previous cardiac medications, lipid lowering therapy, drugs with a known risk of prolonged QT and torsades de pointes, drugs with a known or possible or conditional risk of prolonged QT and torsades de pointes, health care services and drug utilization metrics, continuous Charlson/Elixhauser combined comorbidity index (CCI), CCI groups (0, 1-2, 3-4, 5 or greater), continuous adapted diabetes complications severity index² (ADCSI), and ADCSI groups (0, 1-2, 3-4, 5 or greater).

These characteristics were defined using NDCs; ICD-10-CM diagnosis codes; ICD-10-PCS procedure codes; HCPCS, Level II codes; CPT-4, Category I; and CPT-4, Category III codes. See Appendix F for diagnosis or procedure codes used to define baseline characteristics and Appendix G for generic and brand names of medical products.

Please see Appendices H-J for the specifications of parameters used in this request.

Please see Appendix K for a diagram detailing the design of this request.

<u>Limitations:</u> Algorithms to define exposures, outcomes, inclusion and exclusion criteria, and covariates are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind.

<u>Notes:</u> Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse).

cder mpl1p wp077 Page 3 of 1023

¹Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

²Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6



Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. **Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

cder mpl1p wp077 Page 4 of 1023



Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module*

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest. **Switch Evaluation Step Value** - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

cder_mpl1p_wp077 Page 5 of 1023



- Glossary (CIDA) List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
 - <u>Table 1a</u> Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1b</u> Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1c</u> Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1d</u> Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1e</u> Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1f</u> Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1g</u> Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1h</u> Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1i</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1j</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1k</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 11</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1m</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1n</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 10</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1p</u> Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1q</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 1r</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

cder mpl1p wp077 Page 6 of 1023



- <u>Table 1s</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1t</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1u</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1v</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1w</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1x</u> Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1y</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1z</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1aa</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ab</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ac</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ad</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ae</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1af</u> Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ag</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ah</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ai</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

cder_mpl1p_wp077 Page 7 of 1023



- <u>Table 1aj</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ak</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1al</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1am</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1an</u> Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ao</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ap</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1aq</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ar</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1as</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1at</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1au</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1av</u> Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1aw</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ax</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1ay</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1az</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

cder mpl1p wp077 Page 8 of 1023



- <u>Table 1ba</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bb</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bc</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bd</u> Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1be</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bf</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bg</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bh</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bi</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bj</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bk</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bl</u> Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bm</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bn</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bo</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bp</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bq</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

cder_mpl1p_wp077 Page 9 of 1023



- <u>Table 1br</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bs</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 1bt</u> Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 2</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
 - <u>Table 3</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex
 - <u>Table 4</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group
 - <u>Table 5</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year
 - <u>Table 6</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race
 - <u>Table 7</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease
 - <u>Table 8</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group
 - <u>Table 9</u> Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year
- <u>Table 10</u> Summary of Time to End of At-Risk Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 11</u> Summary of Time to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 12</u> Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 13</u> Summary of Time to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 14</u> Summary of Time to End of At-Risk Period due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 15</u> Summary of Time to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 16</u> Summary of Time to End of At-Risk Period due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 17</u> Summary of Time to End of At-Risk Period due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

cder_mpl1p_wp077 Page 10 of 1023



- <u>Table 18</u> Summary of Time to End of Observable Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 19</u> Summary of Time to End of Observable Data due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 20</u> Summary of Time to End of Observable Data due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 21</u> Summary of Time to End of Observable Data due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 22</u> Summary of Time to End of Observable Data due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- <u>Table 23a</u> Full Code Distribution of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23b</u> Total Code Counts of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23c</u> Full Code Distribution of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23d</u> Total Code Counts of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23e</u> Full Code Distribution of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23f</u> Total Code Counts of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23g</u> Full Code Distribution of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23h</u> Total Code Counts of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23i</u> Full Code Distribution of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23i</u> Total Code Counts of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23k</u> Full Code Distribution of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23I</u> Total Code Counts of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23m</u> Full Code Distribution of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23n</u> Total Code Counts of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23o</u> Full Code Distribution of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23p</u> Total Code Counts of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

cder mpl1p wp077 Page 11 of 1023



- <u>Table 23q</u> Full Code Distribution of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23r</u> Total Code Counts of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23s</u> Full Code Distribution of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23t</u> Total Code Counts of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23u</u> Full Code Distribution of Bydureon, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23v</u> Total Code Counts of Bydureon, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23w</u> Full Code Distribution of Ozempic, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23x</u> Total Code Counts of Ozempic, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23y</u> Full Code Distribution of Rybelsus, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23z</u> Total Code Counts of Rybelsus, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23aa</u> Full Code Distribution of Wegovy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ab</u> Total Code Counts of Wegovy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ac</u> Full Code Distribution of Saxenda, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ad</u> Total Code Counts of Saxenda, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ae</u> Full Code Distribution of Victoza, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23af</u> Total Code Counts of Victoza, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ag</u> Full Code Distribution of Trulicity, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ah</u> Total Code Counts of Trulicity, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ai</u> Full Code Distribution of Xultophy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ai</u> Total Code Counts of Xultophy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ak</u> Full Code Distribution of Mounjaro, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

cder mpl1p wp077 Page 12 of 1023



- <u>Table 23al</u> Total Code Counts of Mounjaro, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23am</u> Full Code Distribution of Bydureon, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23an</u> Total Code Counts of Bydureon, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ao</u> Full Code Distribution of Ozempic, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ap</u> Total Code Counts of Ozempic, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23aq</u> Full Code Distribution of Rybelsus, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ar</u> Total Code Counts of Rybelsus, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23as</u> Full Code Distribution of Wegovy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23at</u> Total Code Counts of Wegovy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23au</u> Full Code Distribution of Saxenda, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23av</u> Total Code Counts of Saxenda, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23aw</u> Full Code Distribution of Victoza, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ax</u> Total Code Counts of Victoza, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ay</u> Full Code Distribution of Trulicity, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23az</u> Total Code Counts of Trulicity, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ba</u> Full Code Distribution of Xultophy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bb</u> Total Code Counts of Xultophy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bc</u> Full Code Distribution of Mounjaro, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bd</u> Total Code Counts of Mounjaro, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23be</u> Full Code Distribution of Bydureon, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bf</u> Total Code Counts of Bydureon, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bg</u> Full Code Distribution of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bh</u> Total Code Counts of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

cder_mpl1p_wp077 Page 13 of 1023



- <u>Table 23bi</u> Full Code Distribution of Rybelsus, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bj</u> Total Code Counts of Rybelsus, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bk</u> Full Code Distribution of Wegovy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bl</u> Total Code Counts of Wegovy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bm</u> Full Code Distribution of Saxenda, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bn</u> Total Code Counts of Saxenda, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bo</u> Full Code Distribution of Victoza, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bp</u> Total Code Counts of Victoza, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bq</u> Full Code Distribution of Trulicity, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23br</u> Total Code Counts of Trulicity, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bs</u> Full Code Distribution of Xultophy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bt</u> Total Code Counts of Xultophy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bu</u> Full Code Distribution of Mounjaro, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bv</u> Total Code Counts of Mounjaro, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bw</u> Full Code Distribution of Bydureon, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bx</u> Total Code Counts of Bydureon, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23by</u> Full Code Distribution of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23bz</u> Total Code Counts of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ca</u> Full Code Distribution of Rybelsus, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cb</u> Total Code Counts of Rybelsus, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cc</u> Full Code Distribution of Wegovy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

cder mpl1p wp077 Page 14 of 1023



- <u>Table 23cd</u> Total Code Counts of Wegovy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ce</u> Full Code Distribution of Saxenda, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cf</u> Total Code Counts of Saxenda, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cg</u> Full Code Distribution of Victoza, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ch</u> Total Code Counts of Victoza, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ci</u> Full Code Distribution of Trulicity, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ci</u> Total Code Counts of Trulicity, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ck</u> Full Code Distribution of Xultophy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cl</u> Total Code Counts of Xultophy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cm</u> Full Code Distribution of Mounjaro, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cn</u> Total Code Counts of Mounjaro, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23co</u> Full Code Distribution of Bydureon, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cp</u> Total Code Counts of Bydureon, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cq</u> Full Code Distribution of Ozempic, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cr</u> Total Code Counts of Ozempic, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cs</u> Full Code Distribution of Rybelsus, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ct</u> Total Code Counts of Rybelsus, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cu</u> Full Code Distribution of Wegovy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cv</u> Total Code Counts of Wegovy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cw</u> Full Code Distribution of Saxenda, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cx</u> Total Code Counts of Saxenda, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

cder_mpl1p_wp077 Page 15 of 1023



- <u>Table 23cy</u> Full Code Distribution of Victoza, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23cz</u> Total Code Counts of Victoza, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23da</u> Full Code Distribution of Trulicity, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23db</u> Total Code Counts of Trulicity, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed
 Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dc</u> Full Code Distribution of Xultophy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dd</u> Total Code Counts of Xultophy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23de</u> Full Code Distribution of Mounjaro, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23df</u> Total Code Counts of Mounjaro, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dg</u> Full Code Distribution of Bydureon, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dh</u> Total Code Counts of Bydureon, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23di</u> Full Code Distribution of Ozempic, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dj</u> Total Code Counts of Ozempic, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dk</u> Full Code Distribution of Rybelsus, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dl</u> Total Code Counts of Rybelsus, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dm</u> Full Code Distribution of Wegovy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dn</u> Total Code Counts of Wegovy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23do</u> Full Code Distribution of Saxenda, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dp</u> Total Code Counts of Saxenda, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dq</u> Full Code Distribution of Victoza, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dr</u> Total Code Counts of Victoza, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ds</u> Full Code Distribution of Trulicity, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

cder_mpl1p_wp077 Page 16 of 1023



- <u>Table 23dt</u> Total Code Counts of Trulicity, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23du</u> Full Code Distribution of Xultophy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dv</u> Total Code Counts of Xultophy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dw</u> Full Code Distribution of Mounjaro, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed
 Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dx</u> Total Code Counts of Mounjaro, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dy</u> Full Code Distribution of Bydureon, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed
 Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23dz</u> Total Code Counts of Bydureon, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ea</u> Full Code Distribution of Ozempic, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23eb</u> Total Code Counts of Ozempic, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ec</u> Full Code Distribution of Rybelsus, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ed</u> Total Code Counts of Rybelsus, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ee</u> Full Code Distribution of Wegovy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ef</u> Total Code Counts of Wegovy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23eg</u> Full Code Distribution of Saxenda, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23eh</u> Total Code Counts of Saxenda, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ei</u> Full Code Distribution of Victoza, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ej</u> Total Code Counts of Victoza, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23ek</u> Full Code Distribution of Trulicity, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23el</u> Total Code Counts of Trulicity, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23em</u> Full Code Distribution of Xultophy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
- <u>Table 23en</u> Total Code Counts of Xultophy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

cder mpl1p wp077 Page 17 of 1023



- <u>Table 24</u> Summary of Patient Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
- Appendix A Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (September 28, 2023)
- Appendix B Generic and Brand Names of Medical Products Used to Define Exposures or Exposure Washout in this Request
- <u>Appendix C</u> List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes
 Used to Define Tachyarrhythmia in this Request
- Appendix D List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request
- Appendix E Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request
- Appendix F List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request
- Appendix G Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request
- Appendix H Specifications Defining Parameters for this Request (Primary Analysis)
- Appendix I Specifications Defining Parameters for Baseline Characteristics in this Request (Primary Analysis)
- Appendix J Specifications Defining Combination Code Parameters Used in this Request (Primary Analysis)
- Appendix K Design Diagram Detailing this Request

cder mpl1p wp077 Page 18 of 1023



Table 1a. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	1,321	N/A
Demographic Characteristics		
Age (years)	64.0	10.2
Age		
0-40 years	78	5.9%
41-64 years	498	37.7%
65-74 years	535	40.5%
75-84 years	195	14.8%
≥ 85 years	15	1.1%
Sex		
Female	675	51.1%
Male	646	48.9%
Race ²		
American Indian or Alaska Native	****	****
Asian	44	3.3%
Black or African American	165	12.5%
Multi-racial	****	****
Native Hawaiian or Other Pacific Islander	****	****
Unknown	234	18.5%
White	833	63.1%
lispanic origin		
Yes	76	5.8%
No	960	72.7%
Unknown	285	21.6%
'ear		
2022	1,075	81.4%
2023	236	18.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	429	32.5%
1-2	462	35.0%
3-4	262	19.8%
5+	168	12.7%
Combined comorbidity score ⁴	2.5	2.6
Combined comorbidity score categories ⁴	2.5	2.0
<0	53	4.0%
0	252	19.1%
1-2	507	38.4%
3-4	254	19.2%
5+	255	19.3%

cder_mpl1p_wp077 Page 19 of 1023



Table 1a. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Database and Sentiner Distributed Database from May 15, 2022 to June 50, 2		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	31	2.3%
Obesity	722	54.7%
Tobacco use	358	27.1%
Arrhythmia	335	25.4%
Cerebrovascular disease/stroke/transient ischemic attack	179	13.6%
Chronic kidney disease	250	18.9%
Chronic obstructive pulmonary disease	164	12.4%
Congenital heart disease	164	12.4%
Heart failure	173	13.1%
Hyperlipidemia	1,052	79.6%
Hypertensive disease	1,105	83.6%
Thyroid disease	292	22.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	334	25.3%
Left ventricular hypertrophy	66	5.0%
Peripheral artery disease	66	5.0%
Valvular/mitral valve disease	54	4.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	175	13.2%
Obstructive sleep apnea	339	25.7%
Hypertrophic cardiomyopathy	74	5.6%
Other cardiac disease	597	45.2%
Tachyarrhythmia day 0	15	1.1%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	15	1.1%
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	198	15.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	16	1.2%
Insulin	444	33.6%
Biguanides (metformin, phenformin, etc.)	1,093	82.7%
SGLT2 inhibitors	436	33.0%
Sulfonylurea	549	41.6%
Thiazolidinedione	148	11.2%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	****
Sodium channel blockers	****	****
Beta blockers	545	41.3%
Potassium channel blockers/openers	15	1.1%
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	13	1.0%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 20 of 1023



Table 1a. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	555	42.0%
Angiotensin-converting-enzyme (ACE) inhibitor	550	41.6%
Angiotensin ii receptor blockers (ARBs)	460	34.8%
Dihydropyridines	323	23.50%
Diuretics	511	38.7%
Other antihypertensives	102	7.7%
Antihypertensives (any of the above antihypertensives)	1,101	83.3%
Oral anticoagulants	141	10.7%
Vitamin K antagonists	25	1.9%
Other cardiac medications not mentioned above	84	6.4%
Other cardiac medications (any of the other cardiac medications)	223	16.9%
Lipid lowering therapy	1,111	84.1%
Baseline known risk of prolonged QT and torsades de pointes	579	43.8%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	1,130	85.5%
torsades de pointes	179	13.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.9	17.6
Mean number of emergency room encounters	0.6	1.5
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	6.7	14.7
Mean number of filled prescriptions	48.5	36.7
Mean number of generics dispensed	12.9	6.3
Mean number of unique drug classes dispensed	11.2	5.5

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 21 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1b. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
atient Characteristics	Number/Mean	Deviation ¹
Inique patients	234	N/A
Demographic Characteristics		
ge (years)	62.2	11.2
ge		
0-40 years	****	****
41-64 years	118	48.4%
65-74 years	87	35.7%
75-84 years	26	10.7%
≥ 85 years	****	****
ex		
Female	117	48.0%
Male	127	52.0%
ace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	234	100.0%
White	0	0.0%
ispanic origin		
Yes	****	****
No	****	****
Unknown	181	74.2%
ear		
2022	179	73.4%
2023	65	26.6%
lealth Characteristics		
dapted Diabetes Complications Severity Index (aDCSI) ³	1.9	2.0
dapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	85	34.8%
1-2	88	36.1%
3-4	43	17.6%
5+	28	11.5%
ombined comorbidity score ⁴	2.1	2.5
ombined comorbidity score categories ⁴	2.1	2.5
<0	11	4.5%
0	59	23.20%
1-2	98	40.2%
± -		
3-4	42	17.2%

cder_mpl1p_wp077 Page 22 of 1023



Table 1b. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	128	52.5%
Tobacco use	54	22.1%
Arrhythmia	55	22.5%
Cerebrovascular disease/stroke/transient ischemic attack	34	13.9%
Chronic kidney disease	36	14.8%
Chronic obstructive pulmonary disease	21	8.6%
Congenital heart disease	21	8.6%
Heart failure	26	10.7%
Hyperlipidemia	194	79.5%
Hypertensive disease	202	82.8%
Thyroid disease	43	17.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	53	21.7%
Left ventricular hypertrophy	13	5.3%
Peripheral artery disease	13	5.3%
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	32	13.1%
Obstructive sleep apnea	55	22.5%
Hypertrophic cardiomyopathy	11	4.5%
Other cardiac disease	96	39.3%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	36	14.8%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
Insulin	85	34.8%
Biguanides (metformin, phenformin, etc.)	203	83.2%
SGLT2 inhibitors	91	37.3%
Sulfonylurea	99	40.6%
Thiazolidinedione	26	10.7%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	****
Sodium channel blockers	****	****
Beta blockers	101	41.4%
Potassium channel blockers/openers	****	****
	****	****
Non-uniyaropyriame calcium chamier blockers		
Non-dihydropyridine calcium channel blockers Digoxin	****	****

cder_mpl1p_wp077 Page 23 of 1023



Table 1b. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	102	41.8%
Angiotensin-converting-enzyme (ACE) inhibitor	103	42.2%
Angiotensin ii receptor blockers (ARBs)	76	31.1%
Dihydropyridines	56	23.0%
Diuretics	84	34.4%
Other antihypertensives	16	6.6%
Antihypertensives (any of the above antihypertensives)	197	80.7%
Oral anticoagulants	23	9.4%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	13	5.3%
Other cardiac medications (any of the other cardiac medications)	36	14.8%
Lipid lowering therapy	209	85.7%
Baseline known risk of prolonged QT and torsades de pointes	99	40.6%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	192	78.7%
torsades de pointes	31	12.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.1	15.7
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.2	0.9
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.0	7.2
Mean number of filled prescriptions	43.4	32.4
Mean number of generics dispensed	12.3	6.4
Mean number of unique drug classes dispensed	10.6	5.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 24 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1c. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	****	N/A
Demographic Characteristics		
Age (years)	57.8	7.4
Age		
0-40 years	0	0.0%
41-64 years	****	66.7%
65-74 years	****	33.3%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	****	66.7%
Male	****	33.3%
Race ²		
American Indian or Alaska Native	****	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	****	16.7%
No	****	83.3%
Unknown	0	0.0%
'ear		
2022	****	50.0%
2023	****	50.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.2	0.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	66.7%
1-2	0	0.0%
3-4	****	33.3%
5+	0	0.0%
Combined comorbidity score ⁴	0.8	1.0
Combined comorbidity score categorie ⁴		-
<0	****	16.7%
0	****	16.7%
1-2	****	66.7%
3-4	0	0.0%
	•	3.070

cder_mpl1p_wp077 Page 25 of 1023



Table 1c. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	****	50.0%
Tobacco use	****	33.3%
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	0	0.0%
Chronic obstructive pulmonary disease	****	16.7%
Congenital heart disease	****	16.7%
Heart failure	0	0.0%
Hyperlipidemia	****	50.0%
Hypertensive disease	****	66.7%
Thyroid disease	****	16.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	****	16.7%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	****	16.7%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	****	33.3%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	50.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	****	33.3%
Biguanides (metformin, phenformin, etc.)	****	83.3%
SGLT2 inhibitors	****	33.3%
Sulfonylurea	****	50.0%
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	****	16.7%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
outer and arrivation agents	O	0.070

cder_mpl1p_wp077 Page 26 of 1023



Table 1c. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	****	16.7%
Angiotensin-converting-enzyme (ACE) inhibitor	****	33.3%
Angiotensin ii receptor blockers (ARBs)	****	50.0%
Dihydropyridines	****	33.3%
Diuretics	****	16.7%
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	****	66.7%
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	****	100.0%
Baseline known risk of prolonged QT and torsades de pointes	****	16.7%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	****	100.0%
torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.8	4.9
Mean number of emergency room encounters	0.5	0.4
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.3	0.0
Mean number of other ambulatory encounters	2.5	1.4
Mean number of filled prescriptions	48.0	16.8
Mean number of generics dispensed	11.2	2.3
Mean number of unique drug classes dispensed	9.5	2.3

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 27 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1d. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentiner Distributed Database from May 13, 20	, 	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	44	N/A
Demographic Characteristics		
Age (years)	57.2	10.6
Age		
0-40 years	11	25.0%
41-64 years	17	38.6%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	27	61.4%
Male	17	38.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	44	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	****	****
Unknown	****	****
'ear		
2022	29	65.9%
2023	15	34.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.2	1.6
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	22	50.0%
1-2	****	****
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	1.8	1.8
Combined comorbidity score categories ⁴		
<0	****	****
0	12	27.3%
1-2	16	36.4%
3-4	****	****
5+	****	****

cder_mpl1p_wp077 Page 28 of 1023



Table 1d. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentiner Distributed Database from May 13, 2022	10 Julie 30, 2023	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	15	34.1%
Tobacco use	****	****
Arrhythmia	****	****
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	****	****
Hyperlipidemia	23	54.5%
Hypertensive disease	27	61.4%
Thyroid disease	****	****
Ischemic heart disease/coronary artery disease/myocardial infarction	****	****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	****	****
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	15	34.1%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	13	29.5%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
nsulin	17	38.6%
Biguanides (metformin, phenformin, etc.)	41	93.2%
SGLT2 inhibitors	14	31.8%
Sulfonylurea	20	45.5%
Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	11	25.0%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
, -		

cder_mpl1p_wp077 Page 29 of 1023



Table 1d. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	·	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	11	25.0%
Angiotensin-converting-enzyme (ACE) inhibitor	12	27.3%
Angiotensin ii receptor blockers (ARBs)	18	40.9%
Dihydropyridines	11	25.0%
Diuretics	12	27.3%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	32	72.7%
Oral anticoagulants	****	****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	32	72.7%
Baseline known risk of prolonged QT and torsades de pointes	15	34.1%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	29	65.9%
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.1	16.2
Mean number of emergency room encounters	0.3	0.4
Mean number of inpatient hospital encounters	0.0	0.1
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.8	3.0
Mean number of filled prescriptions	42.6	29.7
Mean number of generics dispensed	10.2	4.9
Mean number of unique drug classes dispensed	8.6	4.5

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 30 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1e. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	165	N/A
Demographic Characteristics		
Age (years)	58.9	11.2
Age		
0-40 years	14	8.5%
41-64 years	88	53.3%
65-74 years	49	29.7%
75-84 years	****	****
≥ 85 years	****	****
Sex Sex		
Female	99	60.0%
Male	66	40.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	165	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	****	****
No	152	92.1%
Unknown	****	****
/ear		
2022	120	72.7%
2023	45	27.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	-	
<0	0	0.0%
0	56	33.9%
1-2	64	38.8%
3-4	27	16.4%
5+	18	10.4%
Combined comorbidity score ⁴	2.2	2.4
Combined comorbidity score categories ⁴	۷.۷	۷.٦
<0	****	****
0	35	21.2%
		21.2% 46.7%
1-2	77 ****	40./% ****
3-4		
5+	32	19.4%

cder_mpl1p_wp077 Page 31 of 1023



Table 1e. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Dbesity	95	57.6%
obacco use	38	23.0%
Arrhythmia	35	21.2%
Cerebrovascular disease/stroke/transient ischemic attack	19	11.5%
Chronic kidney disease	25	15.2%
Chronic obstructive pulmonary disease	16	9.7%
Congenital heart disease	16	9.7%
leart failure	21	12.7%
Hyperlipidemia	114	69.1%
lypertensive disease	139	84.2%
hyroid disease	20	12.1%
schemic heart disease/coronary artery disease/myocardial infarction	31	18.8%
eft ventricular hypertrophy	****	****
Peripheral artery disease	****	****
alvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	12	7.3%
Dbstructive sleep apnea	38	23.0%
lypertrophic cardiomyopathy	14	8.5%
Other cardiac disease	69	41.8%
achyarrhythmia day 0	****	****
Jospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	****	****
Nedical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	26	15.8%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
nsulin	64	38.8%
siguanides (metformin, phenformin, etc.)	137	83.0%
GLT2 inhibitors	56	33.9%
ulfonylurea	75	45.5%
hiazolidinedione	****	****
lo baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	****	****
Beta blockers	66	40.0%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%

cder_mpl1p_wp077 Page 32 of 1023



Table 1e. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	67	40.6%
Angiotensin-converting-enzyme (ACE) inhibitor	58	35.2%
Angiotensin ii receptor blockers (ARBs)	68	41.2%
Dihydropyridines	56	33.9%
Diuretics	61	37.0%
Other antihypertensives	26	15.8%
Antihypertensives (any of the above antihypertensives)	136	82.4%
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	12	7.3%
Other cardiac medications (any of the other cardiac medications)	19	11.5%
Lipid lowering therapy	130	78.8%
Baseline known risk of prolonged QT and torsades de pointes	62	37.6%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	137	83.0%
torsades de pointes	14	8.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.6	17.3
Mean number of emergency room encounters	0.8	2.1
Mean number of inpatient hospital encounters	0.2	0.8
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.6	11.6
Mean number of filled prescriptions	44.0	32.3
Mean number of generics dispensed	12.7	5.6
Mean number of unique drug classes dispensed	11.0	4.9

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 33 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 1f. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	****	N/A
Demographic Characteristics		
Age (years)	84.8	NaN
Age		
0-40 years	0	0.0%
41-64 years	0	0.0%
65-74 years	0	0.0%
75-84 years	****	****
≥ 85 years	0	0.0%
ex		
Female	0	0.0%
Male	****	****
tace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	****	****
Unknown	0	0.0%
White	0	0.0%
ispanic origin	·	0.075
Yes	0	0.0%
No	****	****
Unknown	0	0.0%
ear	· ·	0.070
2022	****	****
2023	0	0.0%
lealth Characteristics	<u> </u>	0.070
dapted Diabetes Complications Severity Index (aDCSI) ³	1.0	NaN
dapted Diabetes Complications Severity Index (aDCSI) dapted Diabetes Complications Severity Index (aDCSI) categories ³	1.0	Ivaiv
<0	0	0.0%
	0	0.0%
0 1-2	V ****	U.U% ****
3-4	0	0.0%
5+	0	0.0%
ombined comorbidity score ⁴	1.0	NaN
ombined comorbidity score categories ⁴	_	0.554
0	0	0.0%
	0	0.0%
-2	****	****
-4	0	0.0%
+	0	0.0%

cder_mpl1p_wp077 Page 34 of 1023

Table 1f. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Deviation ¹	
llcohol use or abuse	0	0.0%	
Desity	0	0.0%	
obacco use	0	0.0%	
rrhythmia	0	0.0%	
erebrovascular disease/stroke/transient ischemic attack	0	0.0%	
hronic kidney disease	0	0.0%	
hronic obstructive pulmonary disease	0	0.0%	
ongenital heart disease	0	0.0%	
eart failure	0	0.0%	
lyperlipidemia	****	****	
ypertensive disease	****	****	
hyroid disease	0	0.0%	
schemic heart disease/coronary artery disease/myocardial infarction	0	0.0%	
eft ventricular hypertrophy	0	0.0%	
eripheral artery disease	0	0.0%	
alvular/mitral valve disease	0	0.0%	
iseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%	
bstructive sleep apnea	0	0.0%	
ypertrophic cardiomyopathy	0	0.0%	
ther cardiac disease	0	0.0%	
achyarrhythmia day 0	0	0.0%	
ospitalized tachyarrhythmia day 0	0	0.0%	
listory of serious hypoglycemia (ED and/or IP)	0	0.0%	
1edical Product Use			
lpha-glucosidase inhibitors	0	0.0%	
mylin analogs (pramlintide)	0	0.0%	
PP-4 inhibitors	0	0.0%	
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%	
Meglitinides	0	0.0%	
nsulin	****	****	
iguanides (metformin, phenformin, etc.)	****	****	
GLT2 inhibitors	0	0.0%	
ulfonylurea	0	0.0%	
hiazolidinedione	0	0.0%	
o baseline use of any of the above antidiabetic drugs	0	0.0%	
ther antidiabetics	0	0.0%	
odium channel blockers	0	0.0%	
eta blockers	0	0.0%	
otassium channel blockers/openers	0	0.0%	
on-dihydropyridine calcium channel blockers	0	0.0%	
igoxin	0	0.0%	
Other antiarrhythmic agents	0	0.0%	

cder_mpl1p_wp077 Page 35 of 1023

Table 1f. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Angiotensin-converting-enzyme (ACE) inhibitor	****	****
Angiotensin ii receptor blockers (ARBs)	****	****
Dihydropyridines	0	0.0%
Diuretics	****	****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	0	0.0%
Baseline known risk of prolonged QT and torsades de pointes	0	0.0%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	0	0.0%
torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.0	NaN
Mean number of emergency room encounters	0.0	NaN
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	0.0	NaN
Mean number of filled prescriptions	21.0	NaN
Mean number of generics dispensed	12.0	NaN
Mean number of unique drug classes dispensed	9.0	NaN

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 36 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1g. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar	
Patient Characteristics	Number/Mean	Deviation ¹	
Jnique patients	833	N/A	
Demographic Characteristics			
Age (years)	66.4	9.4	
Age			
0-40 years	34	4.1%	
41-64 years	251	30.1%	
65-74 years	387	46.5%	
75-84 years	149	17.9%	
≥ 85 years	12	1.4%	
Sex			
Female	410	49.2%	
Male	423	50.8%	
Race ²			
American Indian or Alaska Native	0	0.0%	
Asian	0	0.0%	
Black or African American	0	0.0%	
Multi-racial	0	0.0%	
Native Hawaiian or Other Pacific Islander	0	0.0%	
Unknown	0	0.0%	
White	833	100.0%	
lispanic origin			
Yes	12	1.4%	
No	744	89.3%	
Unknown	77	9.2%	
/ear			
2022	723	86.8%	
2023	110	13.2%	
Health Characteristics			
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.1	
Adapted Diabetes Complications Severity Index (aDCSI) categories ³			
<0	0	0.0%	
0	239	29.9%	
1-2	285	34.2%	
3-4	180	21.6%	
5+	119	14.3%	
Combined comorbidity score ⁴	2.8	2.7	
Combined comorbidity score categories ⁴	-		
<0	33	4.0%	
0	137	16.4%	
1-2	300	36.0%	
3-4	181	21.7%	
5+	182	21.8%	

cder_mpl1p_wp077 Page 37 of 1023



Table 1g. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Stributed Database and Sentinei Distributed Database from May 15, 2022 to June 50, 2025		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	23	2.8%
Obesity	467	56.1%
Tobacco use	255	30.6%
Arrhythmia	233	28.0%
Cerebrovascular disease/stroke/transient ischemic attack	118	14.2%
Chronic kidney disease	181	21.7%
Chronic obstructive pulmonary disease	122	14.6%
Congenital heart disease	122	14.6%
Heart failure	122	14.6%
Hyperlipidemia	697	83.7%
Hypertensive disease	716	86.0%
Thyroid disease	218	26.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	230	28.8%
Left ventricular hypertrophy	44	5.3%
Peripheral artery disease	44	5.3%
Valvular/mitral valve disease	42	5.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	125	15.0%
Obstructive sleep apnea	230	27.6%
Hypertrophic cardiomyopathy	48	5.8%
Other cardiac disease	406	48.7%
Tachyarrhythmia day 0	13	1.6%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	1.1%
Medical Product Use		
Alpha-glucosidase inhibitors	****	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	116	13.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	0.7%
Insulin	266	31.9%
Biguanides (metformin, phenformin, etc.)	680	81.6%
SGLT2 inhibitors	267	32.1%
Sulfonylurea	345	41.4%
Thiazolidinedione	110	13.2%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	0.1%
Sodium channel blockers	****	0.6%
Beta blockers	359	43.1%
Potassium channel blockers/openers	****	1.0%
Non-dihydropyridine calcium channel blockers	****	0.6%
Digoxin	****	1.2%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 38 of 1023



Table 1g. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	·	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	367	44.1%
Angiotensin-converting-enzyme (ACE) inhibitor	366	43.9%
Angiotensin ii receptor blockers (ARBs)	289	34.7%
Dihydropyridines	196	23.5%
Diuretics	348	41.8%
Other antihypertensives	57	6.8%
Antihypertensives (any of the above antihypertensives)	716	86.0%
Oral anticoagulants	111	13.3%
Vitamin K antagonists	18	2.2%
Other cardiac medications not mentioned above	57	6.8%
Other cardiac medications (any of the other cardiac medications)	165	19.8%
Lipid lowering therapy	714	85.7%
Baseline known risk of prolonged QT and torsades de pointes	394	47.3%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	741	89.0%
torsades de pointes	131	15.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.3	18.3
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	7.6	17.3
Mean number of filled prescriptions	51.2	39.0
Mean number of generics dispensed	13.2	6.4
Mean number of unique drug classes dispensed	11.6	5.6

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 39 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1h. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentiner Distributed Database from May 13, 20		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	****	N/A
Demographic Characteristics		
Age (years)	48.7	12.5
Age		
0-40 years	****	25.0%
41-64 years	****	71.4%
65-74 years	****	3.6%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	****	64.3%
Male	****	35.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	****	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	****	17.9%
No	17	60.7%
Unknown	****	21.4%
Year		
2022	****	71.4%
2023	****	28.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.0	1.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	46.4%
1-2	****	39.3%
3-4	****	14.3%
5+	0	0.0%
Combined comorbidity score ⁴	1.9	1.9
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	****	28.6%
1-2	11	39.3%
3-4	****	21.4%
5+	****	10.7%

cder_mpl1p_wp077 Page 40 of 1023



Table 1h. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	14	50.0%
Tobacco use	****	14.3%
Arrhythmia	****	21.4%
Cerebrovascular disease/stroke/transient ischemic attack	****	7.1%
Chronic kidney disease	****	7.1%
Chronic obstructive pulmonary disease	****	7.1%
Congenital heart disease	****	7.1%
Heart failure	****	3.6%
Hyperlipidemia	19	67.9%
Hypertensive disease	16	57.1%
Thyroid disease	****	17.9%
schemic heart disease/coronary artery disease/myocardial infarction	****	10.7%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	****	14.3%
Obstructive sleep apnea	****	25.0%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	****	32.1%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	3.6%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	14.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
nsulin	****	32.1%
Biguanides (metformin, phenformin, etc.)	26	92.9%
SGLT2 inhibitors	****	21.4%
Sulfonylurea	****	25.0%
Thiazolidinedione	****	3.6%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	****	25.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
	· ·	
Digoxin	0	0.0%

cder_mpl1p_wp077 Page 41 of 1023



Table 1h. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	****	25.0%
Angiotensin-converting-enzyme (ACE) inhibitor	****	28.6%
Angiotensin ii receptor blockers (ARBs)	****	17.9%
Dihydropyridines	****	10.7%
Diuretics	****	14.3%
Other antihypertensives	****	3.6%
Antihypertensives (any of the above antihypertensives)	15	53.6%
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
ipid lowering therapy	20	71.4%
Baseline known risk of prolonged QT and torsades de pointes	****	28.6%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	25	89.3%
torsades de pointes	****	3.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.0	16.8
Mean number of emergency room encounters	0.9	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.4	3.6
Mean number of filled prescriptions	48.0	37.9
Mean number of generics dispensed	12.5	7.3
Mean number of unique drug classes dispensed	11.2	6.3

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 42 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1i. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	18,842	N/A
Demographic Characteristics		
Age (years)	61.6	10.0
Age		
0-40 years	1,034	5.5%
41-64 years	9,239	49.1%
65-74 years	6,597	35.0%
75-84 years	1,867	9.9%
≥ 85 years	95	0.5%
Sex		
Female	10,809	57.4%
Male	8,033	42.6%
Race ²		
American Indian or Alaska Native	32	0.2%
Asian	108	0.6%
Black or African American	1,640	8.7%
Multi-racial	60	0.3%
Native Hawaiian or Other Pacific Islander	57	0.3%
Unknown	8,006	42.5%
White	8,939	47.4%
Hispanic origin		
Yes	321	1.7%
No	10,283	54.6%
Unknown	8,238	43.7%
/ear		
2022	9,509	50.5%
2023	9,333	49.5%
Health Characteristics	,	
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.6	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	7,429	39.4%
1-2	6,577	34.9%
3-4	3,152	16.7%
5+	1,684	8.9%
Combined comorbidity score ⁴	2.2	2.4
Combined comorbidity score categories ⁴		
<0	1,478	7.8%
0	3,997	21.2%
1-2	6,850	36.4%
	3,475	18.4%
3-4		

cder_mpl1p_wp077 Page 43 of 1023



Table 1i. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	328	1.7%
Obesity	12,882	68.4%
Tobacco use	4,423	23.5%
Arrhythmia	4,370	23.2%
Cerebrovascular disease/stroke/transient ischemic attack	1,945	10.3%
Chronic kidney disease	3,057	16.2%
Chronic obstructive pulmonary disease	2,074	11.0%
Congenital heart disease	2,074	11.0%
Heart failure	2,190	11.6%
Hyperlipidemia	15,602	82.8%
Hypertensive disease	16,145	85.7%
Thyroid disease	4,723	25.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	4,259	22.6%
Left ventricular hypertrophy	992	5.3%
Peripheral artery disease	992	5.3%
Valvular/mitral valve disease	688	3.7%
Diseases of veins and lymphatics, and other diseases of circulatory system	2,291	12.2%
Obstructive sleep apnea	5,977	31.7%
Hypertrophic cardiomyopathy	785	4.2%
Other cardiac disease	8,953	47.5%
Tachyarrhythmia day 0	250	1.3%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	116	0.6%
Medical Product Use		
Alpha-glucosidase inhibitors	55	0.3%
Amylin analogs (pramlintide)	****	0.0%
DPP-4 inhibitors	2,215	11.8%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	123	0.7%
Insulin	4,501	23.9%
Biguanides (metformin, phenformin, etc.)	15,590	82.7%
SGLT2 inhibitors	5,037	26.7%
Sulfonylurea	5,321	28.2%
Thiazolidinedione	1,730	9.2%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	0.0%
Sodium channel blockers	148	0.8%
Beta blockers	7,323	38.9%
Potassium channel blockers/openers	239	1.3%
Non-dihydropyridine calcium channel blockers	28	0.1%
Digoxin	103	0.5%
Other antiarrhythmic agents	0	0.0%

Page 44 of 1023 $cder_mpl1p_wp077$



Table 1i. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	7,421	39.4%
Angiotensin-converting-enzyme (ACE) inhibitor	6,967	37.0%
Angiotensin ii receptor blockers (ARBs)	7,089	37.6%
Dihydropyridines	4,713	25.0%
Diuretics	6,901	36.6%
Other antihypertensives	1,620	8.6%
Antihypertensives (any of the above antihypertensives)	15,654	83.1%
Oral anticoagulants	1,441	7.6%
Vitamin K antagonists	288	1.5%
Other cardiac medications not mentioned above	1,140	6.1%
Other cardiac medications (any of the other cardiac medications)	2,609	13.8%
Lipid lowering therapy	15,018	79.7%
Baseline known risk of prolonged QT and torsades de pointes	9,532	50.6%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	16,298	86.5%
torsades de pointes	3,159	16.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.2	16.7
Mean number of emergency room encounters	0.6	1.7
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.7	9.4
Mean number of filled prescriptions	46.1	32.0
Mean number of generics dispensed	13.6	6.6
Mean number of unique drug classes dispensed	11.9	5.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 45 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1j. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Tibuteu Database and Sentinei Distributeu Database Irom May 13, 2022 to June 30, 2023	
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	8,006	N/A
Demographic Characteristics		
Age (years)	54.2	10.3
Age		
0-40 years	855	10.7%
41-64 years	6,086	76.0%
65-74 years	898	11.2%
75-84 years	****	****
≥ 85 years	****	****
Sex Sex		
Female	4,326	54.0%
Male	3,680	46.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	8,006	100.0%
White	0	0.0%
Hispanic origin		
Yes	300	3.7%
No	0	0.0%
Unknown	7,706	96.3%
rear		
2022	4,058	50.7%
2023	3,948	49.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.9	1.4
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	4,656	58.2%
1-2	2,388	29.8%
3-4	716	8.9%
5+	236	3.1%
Combined comorbidity score ⁴	1.2	1.9
Combined comorbidity score categories ⁴		
<0	951	11.9%
0	2,360	29.5%
1-2	3,192	39.9%
3-4	1,018	12.7%
5+	485	6.1%

cder_mpl1p_wp077 Page 46 of 1023



Table 1j. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	112	1.4%
Dbesity	5,158	64.4%
obacco use	1,209	15.1%
ırrhythmia	1,234	15.5%
erebrovascular disease/stroke/transient ischemic attack	376	4.7%
chronic kidney disease	608	7.6%
hronic obstructive pulmonary disease	309	3.9%
Congenital heart disease	309	3.9%
leart failure	374	4.7%
lyperlipidemia	6,070	75.8%
lypertensive disease	6,177	77.2%
hyroid disease	1,596	19.9%
schemic heart disease/coronary artery disease/myocardial infarction	1,007	12.6%
eft ventricular hypertrophy	262	3.3%
Peripheral artery disease	262	3.3%
alvular/mitral valve disease	144	1.8%
viseases of veins and lymphatics, and other diseases of circulatory system	614	7.7%
Obstructive sleep apnea	2,196	27.4%
lypertrophic cardiomyopathy	181	2.3%
Other cardiac disease	2,932	36.6%
achyarrhythmia day 0	37	0.5%
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	23	0.3%
Nedical Product Use		
Alpha-glucosidase inhibitors	21	0.3%
Amylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	855	10.7%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Neglitinides	32	0.4%
nsulin	1,521	19.0%
iguanides (metformin, phenformin, etc.)	6,960	86.9%
GLT2 inhibitors	2,202	27.5%
ulfonylurea	1,798	22.5%
, hiazolidinedione	570	7.1%
Io baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	****
odium channel blockers	43	0.5%
seta blockers	2,233	28.0%
otassium channel blockers/openers	50	0.6%
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	16	0.2%
O-		=-=/5

cder_mpl1p_wp077 Page 47 of 1023



Table 1j. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentinel Distributed Database from May 13, 2022 to		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	2,266	28.3%
Angiotensin-converting-enzyme (ACE) inhibitor	2,902	36.2%
Angiotensin ii receptor blockers (ARBs)	2,613	32.6%
Dihydropyridines	1,533	19.1%
Diuretics	2,098	26.2%
Other antihypertensives	432	5.4%
Antihypertensives (any of the above antihypertensives)	6,061	75.7%
Oral anticoagulants	357	4.5%
Vitamin K antagonists	57	0.7%
Other cardiac medications not mentioned above	251	3.1%
Other cardiac medications (any of the other cardiac medications)	621	7.8%
Lipid lowering therapy	5,705	71.3%
Baseline known risk of prolonged QT and torsades de pointes	3,732	46.6%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	6,450	80.6%
torsades de pointes	1,076	13.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.6	14.7
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.2	7.1
Mean number of filled prescriptions	38.0	29.0
Mean number of generics dispensed	11.5	6.3
Mean number of unique drug classes dispensed	10.1	5.5

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 48 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1k. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	32	N/A
Demographic Characteristics		
Age (years)	62.2	12.7
Age		
0-40 years	****	****
41-64 years	15	46.9%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
ex		
Female	18	56.3%
Male	14	43.8%
tace ²		
American Indian or Alaska Native	32	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	0	0.0%
No	****	****
Unknown	****	****
ear		
2022	****	****
2023	****	****
lealth Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	2.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	13	40.6%
1-2	****	****
3-4	****	****
5+	****	****
ombined comorbidity score ⁴	3.2	2.8
ombined comorbidity score categories ⁴	3.2	2.0
<0	****	****
0	****	****
	****	****
1-2	****	****
3-4		
5+	11	34.4%

cder_mpl1p_wp077 Page 49 of 1023



Table 1k. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	C 110111 Way 13, 2022 to	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	****	****
Tobacco use	****	****
Arrhythmia	****	****
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	****	****
Hyperlipidemia	****	****
Hypertensive disease	****	****
Thyroid disease	****	****
Ischemic heart disease/coronary artery disease/myocardial infarction	****	****
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	****	****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	14	43.8%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	****	****
Biguanides (metformin, phenformin, etc.)	****	****
SGLT2 inhibitors	****	****
Sulfonylurea	****	****
Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	12	37.5%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 50 of 1023



Table 1k. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	12	37.5%
Angiotensin-converting-enzyme (ACE) inhibitor	****	****
Angiotensin ii receptor blockers (ARBs)	14	43.8%
Dihydropyridines	****	****
Diuretics	12	37.5%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	26	81.3%
Baseline known risk of prolonged QT and torsades de pointes	16	50.0%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	30	93.8%
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.3	19.2
Mean number of emergency room encounters	1.0	1.7
Mean number of inpatient hospital encounters	0.3	0.8
Mean number of non-acute institutional encounters	0.1	0.2
Mean number of other ambulatory encounters	6.6	8.3
Mean number of filled prescriptions	53.4	38.3
Mean number of generics dispensed	14.5	6.6
Mean number of unique drug classes dispensed	12.9	5.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 51 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1l. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	108	N/A
Demographic Characteristics		
Age (years)	65.1	10.6
Age		
0-40 years	****	****
41-64 years	29	26.9%
65-74 years	53	49.1%
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	55	50.9%
Male	53	49.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	108	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	86	79.6%
Unknown	22	20.4%
'ear		
2022	68	63.0%
2023	40	37.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.8	1.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	35	32.4%
1-2	42	38.9%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	2.4	2.6
ombined comorbidity score categories ⁴		
<0	****	****
0	25	23.1%
1-2	41	38.0%
3-4	23	21.3%
5+	****	****

cder_mpl1p_wp077 Page 52 of 1023



Table 1l. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	47	43.5%
Tobacco use	17	15.7%
Arrhythmia	16	14.8%
Cerebrovascular disease/stroke/transient ischemic attack	16	14.8%
Chronic kidney disease	17	15.7%
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	****	****
Hyperlipidemia	97	89.8%
lypertensive disease	95	88.0%
Thyroid disease	29	26.9%
schemic heart disease/coronary artery disease/myocardial infarction	29	26.9%
eft ventricular hypertrophy	****	****
Peripheral artery disease	****	****
/alvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	16	14.8%
Dbstructive sleep apnea	16	14.8%
lypertrophic cardiomyopathy	****	****
Other cardiac disease	41	38.0%
achyarrhythmia day 0	****	****
lospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	33	30.6%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
nsulin	34	31.5%
Biguanides (metformin, phenformin, etc.)	81	75.0%
GLT2 inhibitors	36	33.3%
iulfonylurea	38	35.2%
, hiazolidinedione	22	20.4%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	****	****
Beta blockers	43	39.8%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 53 of 1023



Table 1l. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentinei Distributed Database from May 13, 2022 to	<u> </u>	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	43	39.8%
Angiotensin-converting-enzyme (ACE) inhibitor	33	30.6%
Angiotensin ii receptor blockers (ARBs)	54	50.0%
Dihydropyridines	29	26.9%
Diuretics	31	28.7%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	15	13.9%
Lipid lowering therapy	95	88.0%
Baseline known risk of prolonged QT and torsades de pointes	40	37.0%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	85	78.7%
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.0	16.2
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.7
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	5.2	8.1
Mean number of filled prescriptions	46.1	34.5
Mean number of generics dispensed	13.3	7.0
Mean number of unique drug classes dispensed	11.3	6.2

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 54 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1m. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	1,640	N/A
Demographic Characteristics		
Age (years)	64.8	9.7
Age		
0-40 years	****	****
41-64 years	671	40.9%
65-74 years	744	45.4%
75-84 years	173	10.5%
≥ 85 years	****	****
Sex		
Female	1,199	73.1%
Male	441	26.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	1,640	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	0	0.0%
No	1,572	95.9%
Unknown	68	4.1%
'ear		
2022	634	38.7%
2023	1,006	61.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.3	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	370	22.6%
1-2	636	38.8%
3-4	368	22.4%
5+	266	16.2%
Combined comorbidity score ⁴	3.0	2.8
Combined comorbidity score categories ⁴		-
<0	68	4.1%
0	252	15.4%
1-2	522	31.8%
3-4	363	22.1%
	303	-2.1/0

cder_mpl1p_wp077 Page 55 of 1023



Table 1m. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	23	1.5%
Dbesity	1,316	80.2%
obacco use	432	26.3%
Arrhythmia	404	23.60%
Cerebrovascular disease/stroke/transient ischemic attack	250	15.2%
Chronic kidney disease	445	27.1%
Chronic obstructive pulmonary disease	235	14.3%
Congenital heart disease	235	14.3%
leart failure	329	20.1%
lyperlipidemia	1,419	86.5%
lypertensive disease	1,579	96.3%
hyroid disease	282	17.2%
schemic heart disease/coronary artery disease/myocardial infarction	401	23.50%
eft ventricular hypertrophy	145	8.8%
Peripheral artery disease	145	8.8%
/alvular/mitral valve disease	67	4.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	251	15.3%
Dbstructive sleep apnea	512	31.2%
lypertrophic cardiomyopathy	117	7.1%
Other cardiac disease	834	50.9%
achyarrhythmia day 0	18	1.1%
, , , , , , , , , , , , , , , , , , ,	0	0.0%
History of serious hypoglycemia (ED and/or IP)	19	1.2%
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	186	11.3%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
nsulin	493	30.1%
siguanides (metformin, phenformin, etc.)	1,273	77.6%
GLT2 inhibitors	433	26.4%
ulfonylurea	482	29.4%
, hiazolidinedione	128	7.8%
lo baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	****	****
Beta blockers	798	48.7%
Potassium channel blockers/openers	16	1.0%
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%
and and my diffine agents	U	0.070

cder_mpl1p_wp077 Page 56 of 1023



Table 1m. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	806	49.1%
Angiotensin-converting-enzyme (ACE) inhibitor	483	29.5%
Angiotensin ii receptor blockers (ARBs)	829	50.5%
Dihydropyridines	759	46.3%
Diuretics	905	55.2%
Other antihypertensives	287	17.5%
Antihypertensives (any of the above antihypertensives)	1,536	93.7%
Oral anticoagulants	132	8.0%
Vitamin K antagonists	22	1.3%
Other cardiac medications not mentioned above	118	7.2%
Other cardiac medications (any of the other cardiac medications)	230	14.6%
Lipid lowering therapy	1,400	85.4%
Baseline known risk of prolonged QT and torsades de pointes	804	49.0%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	1,510	92.1%
torsades de pointes	233	14.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.2	19.1
Mean number of emergency room encounters	1.2	3.0
Mean number of inpatient hospital encounters	0.1	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.8	11.0
Mean number of filled prescriptions	50.5	32.7
Mean number of generics dispensed	15.4	7.0
Mean number of unique drug classes dispensed	13.6	5.9

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 57 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1n. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	57	N/A
Demographic Characteristics		
Age (years)	71.4	6.6
Age		
0-40 years	0	0.0%
41-64 years	****	****
65-74 years	38	66.7%
75-84 years	****	****
≥ 85 years	****	****
ex		
Female	26	45.6%
Male	31	54.4%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	57	100.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	0	0.0%
No	57	100.0%
Unknown	0	0.0%
'ear		
2022	19	33.3%
2023	38	66.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	****
1-2	25	43.9%
3-4	16	28.1%
5+	****	****
combined comorbidity score ⁴	2.9	2.9
Combined comorbidity score categories ⁴		
<0	****	****
0	****	****
1-2	18	31.6%
3-4	11	19.3%
5+	15	26.3%

cder_mpl1p_wp077 Page 58 of 1023



Table 1n. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Dbesity	33	57.9%
obacco use	****	****
Arrhythmia	12	21.1%
Perebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	22	38.6%
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
leart failure	****	****
Hyperlipidemia	****	****
Hypertensive disease	****	****
hyroid disease	14	23.60%
schemic heart disease/coronary artery disease/myocardial infarction	17	29.8%
eft ventricular hypertrophy	****	****
Peripheral artery disease	****	****
/alvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	11	19.3%
Dbstructive sleep apnea	12	21.1%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	23	40.4%
achyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	****
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
nsulin	17	29.8%
Biguanides (metformin, phenformin, etc.)	46	80.7%
GLT2 inhibitors	16	28.1%
ulfonylurea	20	35.1%
Thiazolidinedione	12	21.1%
lo baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	0	0.0%
Beta blockers	26	45.6%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
_	-	
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 59 of 1023



Table 1n. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	26	45.6%
Angiotensin-converting-enzyme (ACE) inhibitor	23	40.4%
Angiotensin ii receptor blockers (ARBs)	26	45.6%
Dihydropyridines	19	33.3%
Diuretics	20	35.1%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	27	47.4%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	****	****
torsades de pointes	11	19.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.9	19.6
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.1	0.6
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	1.9	5.1
Mean number of filled prescriptions	40.6	22.7
Mean number of generics dispensed	13.5	6.6
Mean number of unique drug classes dispensed	11.5	5.5

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 60 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1o. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard	
Patient Characteristics	Number/Mean	Deviation ¹	
Jnique patients	8,939	N/A	
Demographic Characteristics			
Age (years)	67.5	8.9	
Age			
0-40 years	115	1.3%	
41-64 years	2,394	26.8%	
65-74 years	4,850	54.3%	
75-84 years	1,505	16.8%	
≥ 85 years	75	0.8%	
Sex			
Female	5,154	57.7%	
Male	3,785	42.3%	
Race ²			
American Indian or Alaska Native	0	0.0%	
Asian	0	0.0%	
Black or African American	0	0.0%	
Multi-racial	0	0.0%	
Native Hawaiian or Other Pacific Islander	0	0.0%	
Unknown	0	0.0%	
White	8,939	100.0%	
lispanic origin			
Yes	****	****	
No	8,538	95.5%	
Unknown	****	****	
/ear			
2022	4,671	52.3%	
2023	4,268	47.7%	
Health Characteristics			
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.0	
Adapted Diabetes Complications Severity Index (aDCSI) categories ³			
<0	0	0.0%	
0	2,304	25.8%	
1-2	3,461	38.7%	
3-4	2,022	22.6%	
5+	1,152	12.9%	
Combined comorbidity score ⁴	2.8	2.7	
Combined comorbidity score categories ⁴			
<0	446	5.0%	
0	1,322	14.8%	
1-2	3,050	34.1%	
3-4	2,045	22.9%	
5+	2,076	23.2%	

cder_mpl1p_wp077 Page 61 of 1023



Table 1o. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	185	2.1%
Obesity	6,268	70.1%
Tobacco use	2,740	30.7%
Arrhythmia	2,678	30.0%
Cerebrovascular disease/stroke/transient ischemic attack	1,296	14.5%
Chronic kidney disease	1,953	21.8%
Chronic obstructive pulmonary disease	1,511	16.9%
Congenital heart disease	1,511	16.9%
Heart failure	1,467	16.4%
Hyperlipidemia	7,892	88.3%
Hypertensive disease	8,165	91.3%
Thyroid disease	2,777	31.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	2,798	31.3%
Left ventricular hypertrophy	564	6.3%
Peripheral artery disease	564	6.3%
Valvular/mitral valve disease	466	5.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,393	15.6%
Obstructive sleep apnea	3,214	36.0%
Hypertrophic cardiomyopathy	478	5.3%
Other cardiac disease	5,089	56.9%
Tachyarrhythmia day 0	191	2.1%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	70	0.8%
Medical Product Use		
Alpha-glucosidase inhibitors	29	0.3%
Amylin analogs (pramlintide)	****	****
DPP-4 inhibitors	1,121	12.5%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	78	0.9%
Insulin	2,422	27.1%
Biguanides (metformin, phenformin, etc.)	7,149	80.0%
SGLT2 inhibitors	2,329	26.1%
Sulfonylurea	2,962	33.1%
Thiazolidinedione	989	11.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	****
Sodium channel blockers	97	1.1%
Beta blockers	4,189	46.9%
Potassium channel blockers/openers	176	2.0%
Non-dihydropyridine calcium channel blockers	20	0.2%
Digoxin	81	0.9%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 62 of 1023



Table 1o. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	4,256	47.6%
Angiotensin-converting-enzyme (ACE) inhibitor	3,497	39.1%
Angiotensin ii receptor blockers (ARBs)	3,536	39.6%
Dihydropyridines	2,361	26.4%
Diuretics	3,826	42.8%
Other antihypertensives	880	9.8%
Antihypertensives (any of the above antihypertensives)	7,839	87.7%
Oral anticoagulants	941	10.5%
Vitamin K antagonists	205	2.3%
Other cardiac medications not mentioned above	761	8.5%
Other cardiac medications (any of the other cardiac medications)	1,723	19.3%
Lipid lowering therapy	7,700	86.1%
Baseline known risk of prolonged QT and torsades de pointes	4,894	54.7%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	8,129	90.9%
torsades de pointes	1,822	20.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.5	17.7
Mean number of emergency room encounters	0.7	1.8
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.1	10.8
Mean number of filled prescriptions	52.6	33.9
Mean number of generics dispensed	15.1	6.7
Mean number of unique drug classes dispensed	13.3	5.8

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 63 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1p. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentiner Distributed Database from May 13, 20		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	60	N/A
Demographic Characteristics		
Age (years)	53.2	10.6
Age		
0-40 years	****	****
41-64 years	46	76.7%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
Sex		
Female	31	51.7%
Male	29	48.3%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	60	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	****	****
No	****	****
Unknown	41	68.3%
Year		
2022	34	56.7%
2023	26	43.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	41	68.3%
1-2	****	****
3-4	****	****
5+	0	0.0%
Combined comorbidity score ⁴	1.3	1.9
Combined comorbidity score categories ⁴		
<0	****	****
0	22	36.7%
1-2	18	30.0%
3-4	****	****
5+	****	****

cder_mpl1p_wp077 Page 64 of 1023



Table 1p. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standa
Patient Characteristics	Number/Mean	Deviation ¹
alcohol use or abuse	****	****
Desity	35	58.3%
obacco use	****	****
rrhythmia	****	****
erebrovascular disease/stroke/transient ischemic attack	****	****
hronic kidney disease	****	****
hronic obstructive pulmonary disease	****	****
ongenital heart disease	****	****
eart failure	****	****
yperlipidemia	48	80.0%
ypertensive disease	45	75.0%
hyroid disease	15	25.0%
chemic heart disease/coronary artery disease/myocardial infarction	****	****
eft ventricular hypertrophy	****	****
eripheral artery disease	****	****
alvular/mitral valve disease	****	****
iseases of veins and lymphatics, and other diseases of circulatory system	****	****
bstructive sleep apnea	17	28.3%
ypertrophic cardiomyopathy	****	****
ther cardiac disease	20	33.3%
achyarrhythmia day 0	****	****
ospitalized tachyarrhythmia day 0	0	0.0%
istory of serious hypoglycemia (ED and/or IP)	0	0.0%
ledical Product Use		
lpha-glucosidase inhibitors	0	0.0%
mylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	****	****
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
1eglitinides	0	0.0%
nsulin	****	****
iguanides (metformin, phenformin, etc.)	****	****
GLT2 inhibitors	17	28.3%
ulfonylurea	11	18.3%
hiazolidinedione	****	****
o baseline use of any of the above antidiabetic drugs	0	0.0%
ther antidiabetics	0	0.0%
odium channel blockers	0	0.0%
eta blockers	12	20.0%
otassium channel blockers/openers	****	****
on-dihydropyridine calcium channel blockers	0	0.0%
igoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 65 of 1023



Table 1p. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	12	20.0%
Angiotensin-converting-enzyme (ACE) inhibitor	21	35.0%
Angiotensin ii receptor blockers (ARBs)	17	28.3%
Dihydropyridines	****	****
Diuretics	****	****
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	41	68.3%
Oral anticoagulants	****	****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	40	66.7%
Baseline known risk of prolonged QT and torsades de pointes	19	31.7%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	43	71.7%
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.7	10.7
Mean number of emergency room encounters	0.4	0.6
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.7	3.5
Mean number of filled prescriptions	33.8	23.7
Mean number of generics dispensed	9.9	4.4
Mean number of unique drug classes dispensed	8.5	3.9

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 66 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1q. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	117,008	N/A
Demographic Characteristics		
Age (years)	63.2	10.2
Age		
0-40 years	5,493	4.7%
41-64 years	50,784	43.4%
65-74 years	44,381	37.9%
75-84 years	15,103	12.9%
≥ 85 years	1,237	1.1%
Sex		
Female	65,494	56.0%
Male	51,514	44.0%
Race ²		
American Indian or Alaska Native	826	0.7%
Asian	1,393	1.2%
Black or African American	9,832	8.4%
Multi-racial	816	0.7%
Native Hawaiian or Other Pacific Islander	333	0.3%
Unknown	45,367	38.8%
White	58,441	49.9%
Hispanic origin	·	
Yes	3,235	2.8%
No	62,161	53.1%
Unknown	51,602	44.1%
'ear		
2022	79,091	67.6%
2023	37,917	32.4%
Health Characteristics	,	
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	43,316	37.0%
1-2	41,147	35.2%
3-4	20,519	17.5%
5+	12,026	10.3%
Combined comorbidity score ⁴	2.3	2.5
Combined comorbidity score categories ⁴		
<0	8,676	7.4%
0	23,129	20.6%
1-2	41,625	35.6%
3-4	22,050	18.8%
- ·	22,000	17.5%

cder_mpl1p_wp077 Page 67 of 1023



Table 1q. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	2,056	1.8%
Obesity	72,913	62.3%
Tobacco use	28,078	23.00%
Arrhythmia	29,326	25.1%
Cerebrovascular disease/stroke/transient ischemic attack	14,018	12.0%
Chronic kidney disease	20,745	17.7%
Chronic obstructive pulmonary disease	12,960	11.1%
Congenital heart disease	12,960	11.1%
Heart failure	14,535	12.4%
Hyperlipidemia	96,908	82.8%
Hypertensive disease	100,211	85.6%
Thyroid disease	26,991	23.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	29,134	23.90%
Left ventricular hypertrophy	6,816	5.8%
Peripheral artery disease	6,816	5.8%
Valvular/mitral valve disease	4,608	3.9%
Diseases of veins and lymphatics, and other diseases of circulatory system	15,132	12.9%
Obstructive sleep apnea	34,548	29.5%
Hypertrophic cardiomyopathy	5,772	4.9%
Other cardiac disease	55,966	47.8%
Tachyarrhythmia day 0	1,942	1.7%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	916	0.8%
Medical Product Use		
Alpha-glucosidase inhibitors	403	0.3%
Amylin analogs (pramlintide)	****	****
DPP-4 inhibitors	16,890	14.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	1,021	0.9%
Insulin	29,144	23.90%
Biguanides (metformin, phenformin, etc.)	97,762	83.6%
SGLT2 inhibitors	30,413	26.0%
Sulfonylurea	36,658	31.3%
Thiazolidinedione	9,450	8.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	31	0.0%
Sodium channel blockers	841	0.7%
Beta blockers	48,316	41.3%
Potassium channel blockers/openers	1,789	1.5%
Non-dihydropyridine calcium channel blockers	157	0.1%
Digoxin	843	0.7%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 68 of 1023



Table 1q. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

and Sentinei Distributed Database from May 13, 2022 to June 30, 2023		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	48,852	41.8%
Angiotensin-converting-enzyme (ACE) inhibitor	44,027	37.6%
Angiotensin ii receptor blockers (ARBs)	42,983	36.7%
Dihydropyridines	30,487	26.1%
Diuretics	43,232	37.0%
Other antihypertensives	9,664	8.3%
Antihypertensives (any of the above antihypertensives)	97,051	82.9%
Oral anticoagulants	10,151	8.7%
Vitamin K antagonists	2,185	1.9%
Other cardiac medications not mentioned above	8,054	6.9%
Other cardiac medications (any of the other cardiac medications)	18,420	15.7%
Lipid lowering therapy	94,793	81.0%
Baseline known risk of prolonged QT and torsades de pointes	54,758	46.8%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	99,693	85.2%
torsades de pointes	17,852	15.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.9	18.6
Mean number of emergency room encounters	0.6	1.6
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.5	10.7
Mean number of filled prescriptions	45.5	33.7
Mean number of generics dispensed	13.0	6.4
Mean number of unique drug classes dispensed	11.4	5.6

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 69 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1r. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard	
atient Characteristics	Number/Mean	Deviation ¹	
nique patients	45,367	N/A	
emographic Characteristics			
ge (years)	56.4	10.8	
ge			
0-40 years	4,021	8.9%	
41-64 years	31,654	69.8%	
65-74 years	7,739	17.1%	
75-84 years	1,811	4.0%	
≥ 85 years	142	0.3%	
ex			
Female	23,280	53.5%	
Male	21,087	46.5%	
ace ²			
American Indian or Alaska Native	0	0.0%	
Asian	0	0.0%	
Black or African American	0	0.0%	
Multi-racial	0	0.0%	
Native Hawaiian or Other Pacific Islander	0	0.0%	
Unknown	45,367	100.0%	
White	0	0.0%	
ispanic origin			
Yes	****	****	
No	****	****	
Unknown	42,385	93.4%	
ear			
2022	27,580	60.8%	
2023	17,787	39.2%	
ealth Characteristics	,		
dapted Diabetes Complications Severity Index (aDCSI) ³	1.1	1.5	
dapted Diabetes Complications Severity Index (aDCSI) categories ³			
<0	0	0.0%	
0	23,400	53.8%	
1-2	14,252	31.4%	
3-4	4,665	10.3%	
5+	2,050	4.5%	
ombined comorbidity score ⁴	1.4	2.0	
ombined comorbidity score categories ⁴	4. 7	2.0	
<0	5,069	11.2%	
0	12,821	28.3%	
	17,633	38.9%	
1-7			
1-2 3-4	6,145	13.5%	

cder_mpl1p_wp077 Page 70 of 1023



Table 1r. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standa
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	634	1.4%
Dbesity	27,400	60.4%
obacco use	7,631	16.8%
rrhythmia	7,913	17.4%
Cerebrovascular disease/stroke/transient ischemic attack	2,899	6.4%
Chronic kidney disease	4,294	9.5%
Chronic obstructive pulmonary disease	2,435	5.4%
Congenital heart disease	2,435	5.4%
leart failure	2,911	6.4%
lyperlipidemia	34,725	76.5%
lypertensive disease	35,654	78.6%
hyroid disease	8,262	18.2%
schemic heart disease/coronary artery disease/myocardial infarction	6,787	15.0%
eft ventricular hypertrophy	1,736	3.8%
eripheral artery disease	1,736	3.8%
alvular/mitral valve disease	980	2.2%
iseases of veins and lymphatics, and other diseases of circulatory system	3,881	8.6%
bstructive sleep apnea	11,872	26.2%
ypertrophic cardiomyopathy	1,369	3.0%
ther cardiac disease	17,100	37.7%
achyarrhythmia day 0	419	0.9%
ospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	184	0.4%
Nedical Product Use		
lpha-glucosidase inhibitors	129	0.3%
mylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	6,063	13.4%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
1eglitinides	286	0.6%
nsulin	8,721	19.2%
iguanides (metformin, phenformin, etc.)	39,797	87.7%
GLT2 inhibitors	11,723	25.8%
ulfonylurea	11,723	25.8%
hiazolidinedione	2,842	6.3%
o baseline use of any of the above antidiabetic drugs	0	0.0%
ther antidiabetics	12	0.0%
odium channel blockers	220	0.5%
eta blockers	14,273	31.5%
otassium channel blockers/openers	334	0.7%
lon-dihydropyridine calcium channel blockers	40	0.1%
oigoxin	162	0.4%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 71 of 1023



Table 1r. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	·	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	14,390	31.7%
Angiotensin-converting-enzyme (ACE) inhibitor	16,623	36.6%
Angiotensin ii receptor blockers (ARBs)	14,940	32.9%
Dihydropyridines	9,599	21.2%
Diuretics	12,858	28.3%
Other antihypertensives	2,592	5.7%
Antihypertensives (any of the above antihypertensives)	34,827	76.8%
Oral anticoagulants	2,380	5.2%
Vitamin K antagonists	431	1.0%
Other cardiac medications not mentioned above	1,857	4.1%
Other cardiac medications (any of the other cardiac medications)	4,318	9.5%
Lipid lowering therapy	33,518	73.9%
Baseline known risk of prolonged QT and torsades de pointes	19,695	43.4%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	36,173	79.7%
torsades de pointes	5,808	12.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.5	16.6
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.6	7.1
Mean number of filled prescriptions	38.5	29.9
Mean number of generics dispensed	11.5	6.2
Mean number of unique drug classes dispensed	10.1	5.4

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 72 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1s. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	826	N/A
Demographic Characteristics		
Age (years)	67.1	10.9
Age		
0-40 years	23	2.8%
41-64 years	259	31.4%
65-74 years	361	43.7%
75-84 years	165	20.0%
≥ 85 years	18	2.2%
ex		
Female	474	57.4%
Male	352	42.6%
tace ²		
American Indian or Alaska Native	826	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	****	****
No	771	93.3%
Unknown	****	****
'ear		
2022	695	84.1%
2023	131	15.9%
lealth Characteristics		
dapted Diabetes Complications Severity Index (aDCSI) ³	1.9	2.0
dapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	274	33.2%
1-2	276	33.4%
3-4	186	22.5%
5+	90	10.9%
ombined comorbidity score ⁴	2.5	2.6
ombined comorbidity score categories ⁴		
<0	48	5.8%
0	153	18.5%
1-2	289	35.0%
3-4	183	22.2%
5+	153	18.5%

cder_mpl1p_wp077 Page 73 of 1023



Table 1s. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	21	2.5%
Obesity	376	45.5%
Tobacco use	256	31.0%
Arrhythmia	205	23.80%
Cerebrovascular disease/stroke/transient ischemic attack	104	12.6%
Chronic kidney disease	180	21.8%
Chronic obstructive pulmonary disease	120	14.5%
Congenital heart disease	120	14.5%
Heart failure	126	15.3%
Hyperlipidemia	591	71.5%
Hypertensive disease	694	84.0%
Thyroid disease	186	22.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	227	27.5%
Left ventricular hypertrophy	47	5.7%
Peripheral artery disease	47	5.7%
Valvular/mitral valve disease	40	4.8%
Diseases of veins and lymphatics, and other diseases of circulatory system	121	14.6%
Obstructive sleep apnea	190	23.0%
Hypertrophic cardiomyopathy	46	5.6%
Other cardiac disease	367	44.4%
Tachyarrhythmia day 0	20	2.4%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	13	1.6%
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	163	19.7%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
Insulin	370	44.8%
Biguanides (metformin, phenformin, etc.)	653	79.1%
SGLT2 inhibitors	223	27.0%
Sulfonylurea	277	33.5%
Thiazolidinedione	94	11.4%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	****
Beta blockers	329	39.8%
Potassium channel blockers/openers	14	1.7%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	****	****

cder_mpl1p_wp077 Page 74 of 1023



Table 1s. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	332	40.2%
Angiotensin-converting-enzyme (ACE) inhibitor	358	43.3%
Angiotensin ii receptor blockers (ARBs)	305	36.9%
Dihydropyridines	225	27.2%
Diuretics	343	41.5%
Other antihypertensives	81	9.8%
Antihypertensives (any of the above antihypertensives)	716	86.7%
Oral anticoagulants	92	11.1%
Vitamin K antagonists	20	2.4%
Other cardiac medications not mentioned above	73	8.8%
Other cardiac medications (any of the other cardiac medications)	163	19.7%
Lipid lowering therapy	681	82.4%
Baseline known risk of prolonged QT and torsades de pointes	376	45.5%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	706	85.5%
torsades de pointes	99	12.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.8	15.0
Mean number of emergency room encounters	0.8	1.9
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	5.0	9.8
Mean number of filled prescriptions	69.3	47.4
Mean number of generics dispensed	13.6	6.2
Mean number of unique drug classes dispensed	12.1	5.4

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 75 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1t. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentine Distributed Database from May 13, 20		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	1,393	N/A
Demographic Characteristics		
Age (years)	65.9	10.3
Age		
0-40 years	79	5.7%
41-64 years	360	25.8%
65-74 years	655	47.0%
75-84 years	251	18.0%
≥ 85 years	48	3.4%
Sex		
Female	777	55.8%
Male	616	44.2%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	1,393	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	****	****
No	1,051	75.4%
Unknown	****	****
Year		
2022	1,022	73.4%
2023	371	26.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	1.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	461	33.1%
1-2	492	35.3%
3-4	267	19.2%
5+	173	12.4%
Combined comorbidity score ⁴	2.4	2.5
Combined comorbidity score categories ⁴		
<0	85	6.1%
0	273	19.6%
1-2	487	35.0%
3-4	277	19.9%
5+	271	19.5%

cder_mpl1p_wp077 Page 76 of 1023



Table 1t. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentiner Distributed Database from May 15, 2022 t	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	16	1.1%
Obesity	507	36.4%
Tobacco use	183	13.1%
Arrhythmia	299	21.5%
Cerebrovascular disease/stroke/transient ischemic attack	174	12.5%
Chronic kidney disease	344	23.70%
Chronic obstructive pulmonary disease	97	7.0%
Congenital heart disease	97	7.0%
Heart failure	177	12.7%
Hyperlipidemia	1,210	86.9%
Hypertensive disease	1,182	84.9%
Thyroid disease	328	23.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	383	27.5%
Left ventricular hypertrophy	79	5.7%
Peripheral artery disease	79	5.7%
Valvular/mitral valve disease	49	3.5%
Diseases of veins and lymphatics, and other diseases of circulatory system	147	10.6%
Obstructive sleep apnea	204	14.6%
Hypertrophic cardiomyopathy	57	4.1%
Other cardiac disease	570	40.9%
Tachyarrhythmia day 0	14	1.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	13	0.9%
Medical Product Use		
Alpha-glucosidase inhibitors	21	1.5%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	298	21.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	30	2.2%
Insulin	455	32.7%
Biguanides (metformin, phenformin, etc.)	1,189	85.4%
SGLT2 inhibitors	478	34.3%
Sulfonylurea	513	36.8%
Thiazolidinedione	153	11.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	****
Sodium channel blockers	****	****
Beta blockers	589	42.3%
Potassium channel blockers/openers	17	1.2%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 77 of 1023



Table 1t. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	592	42.5%
Angiotensin-converting-enzyme (ACE) inhibitor	401	28.8%
Angiotensin ii receptor blockers (ARBs)	696	50.0%
Dihydropyridines	464	33.3%
Diuretics	381	27.4%
Other antihypertensives	130	9.3%
Antihypertensives (any of the above antihypertensives)	1,155	82.9%
Oral anticoagulants	81	5.8%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	119	8.5%
Other cardiac medications (any of the other cardiac medications)	196	14.1%
Lipid lowering therapy	1,193	85.6%
Baseline known risk of prolonged QT and torsades de pointes	523	37.5%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	1,056	75.8%
torsades de pointes	142	10.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.9	20.1
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.7	10.4
Mean number of filled prescriptions	42.6	33.7
Mean number of generics dispensed	12.4	6.2
Mean number of unique drug classes dispensed	10.6	5.4

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 78 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1u. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	9,832	N/A
Demographic Characteristics		
sge (years)	64.6	10.3
sge		
0-40 years	313	3.2%
41-64 years	3,802	38.7%
65-74 years	4,502	45.8%
75-84 years	1,113	11.3%
≥ 85 years	102	1.0%
ex		
Female	7,071	71.9%
Male	2,761	28.1%
ace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	9,832	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
ispanic origin		
Yes	0	0.0%
No	8,627	87.7%
Unknown	1,205	12.3%
ear	,	
2022	6,058	61.6%
2023	3,774	38.4%
lealth Characteristics	,	
dapted Diabetes Complications Severity Index (aDCSI) ³	2.3	2.1
dapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	2,332	23.7%
1-2	3,571	36.3%
3-4	2,353	23.9%
5+	1,576	16.0%
ombined comorbidity score ⁴	3.0	2.8
ombined comorbidity score categories ⁴	5.0	2.0
<0	456	4.6%
0	1,463	14.9%
1-2	3,023	30.8%
3-4	2,254	22.9%
5+	2,635	26.8%

cder_mpl1p_wp077 Page 79 of 1023



Table 1u. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	199	2.0%
Obesity	7,118	72.4%
Tobacco use	2,661	27.1%
Arrhythmia	2,642	26.9%
Cerebrovascular disease/stroke/transient ischemic attack	1,519	15.4%
Chronic kidney disease	2,747	27.9%
Chronic obstructive pulmonary disease	1,297	13.2%
Congenital heart disease	1,297	13.2%
Heart failure	1,998	20.3%
Hyperlipidemia	8,355	85.0%
Hypertensive disease	9,306	94.7%
Thyroid disease	1,527	15.5%
schemic heart disease/coronary artery disease/myocardial infarction	2,439	23.80%
eft ventricular hypertrophy	794	8.1%
Peripheral artery disease	794	8.1%
/alvular/mitral valve disease	386	3.9%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,461	14.9%
Dbstructive sleep apnea	2,961	30.1%
Hypertrophic cardiomyopathy	739	7.5%
Other cardiac disease	4,983	50.7%
achyarrhythmia day 0	126	1.3%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	142	1.4%
Medical Product Use		
Alpha-glucosidase inhibitors	40	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	1,565	15.9%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	75	0.8%
nsulin	3,206	32.6%
siguanides (metformin, phenformin, etc.)	7,565	76.9%
GLT2 inhibitors	2,533	25.8%
iulfonylurea	3,231	33.0%
hiazolidinedione	685	7.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
) Other antidiabetics	****	****
odium channel blockers	51	0.5%
Beta blockers	4,761	48.4%
Potassium channel blockers/openers	122	1.2%
Non-dihydropyridine calcium channel blockers	13	0.1%
Digoxin	68	0.7%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 80 of 1023



Table 1u. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	4,788	48.7%
Angiotensin-converting-enzyme (ACE) inhibitor	3,144	32.0%
Angiotensin ii receptor blockers (ARBs)	4,656	47.4%
Dihydropyridines	4,536	46.1%
Diuretics	5,129	52.2%
Other antihypertensives	1,551	15.8%
Antihypertensives (any of the above antihypertensives)	9,048	92.0%
Oral anticoagulants	794	8.1%
Vitamin K antagonists	157	1.6%
Other cardiac medications not mentioned above	752	7.6%
Other cardiac medications (any of the other cardiac medications)	1,537	15.6%
Lipid lowering therapy	8,239	83.9%
Baseline known risk of prolonged QT and torsades de pointes	4,455	45.3%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	8,860	90.1%
torsades de pointes	1,302	13.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.6	20.6
Mean number of emergency room encounters	1.0	2.2
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.1	13.7
Mean number of filled prescriptions	49.1	34.6
Mean number of generics dispensed	14.3	6.5
Mean number of unique drug classes dispensed	12.6	5.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 81 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1v. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standa
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	333	N/A
Demographic Characteristics		
Age (years)	69.1	8.3
Age		
0-40 years	****	****
41-64 years	****	****
65-74 years	184	55.3%
75-84 years	81	23.30%
≥ 85 years	****	****
Sex		
Female	158	47.4%
Male	175	52.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	333	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	315	94.6%
Unknown	18	5.4%
/ear		
2022	156	46.8%
2023	177	53.2%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.3	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	83	23.90%
1-2	114	34.2%
3-4	87	26.1%
5+	49	14.7%
Combined comorbidity score ⁴	2.7	2.7
Combined comorbidity score categories ⁴		
<0	14	4.2%
0	55	16.5%
1-2	122	36.6%
3-4	75	22.5%
5+	67	20.1%

cder_mpl1p_wp077 Page 82 of 1023



Table 1v. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	177	53.2%
Tobacco use	72	21.6%
Arrhythmia	72	21.6%
Cerebrovascular disease/stroke/transient ischemic attack	57	17.1%
Chronic kidney disease	98	29.4%
Chronic obstructive pulmonary disease	26	7.8%
Congenital heart disease	26	7.8%
Heart failure	50	15.0%
Hyperlipidemia	306	91.9%
Hypertensive disease	302	90.7%
Thyroid disease	73	21.9%
schemic heart disease/coronary artery disease/myocardial infarction	92	27.6%
eft ventricular hypertrophy	20	6.0%
Peripheral artery disease	20	6.0%
/alvular/mitral valve disease	14	4.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	35	10.5%
Dbstructive sleep apnea	64	19.2%
Hypertrophic cardiomyopathy	22	6.6%
Other cardiac disease	149	44.7%
achyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	44	13.2%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
nsulin	111	33.3%
Biguanides (metformin, phenformin, etc.)	281	84.4%
GGLT2 inhibitors	90	27.0%
Sulfonylurea	135	40.5%
l'hiazolidinedione	43	12.9%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	0	0.0%
Beta blockers	146	43.8%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 83 of 1023



Table 1v. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	147	44.1%
Angiotensin-converting-enzyme (ACE) inhibitor	131	39.3%
Angiotensin ii receptor blockers (ARBs)	148	44.4%
Dihydropyridines	112	33.6%
Diuretics	113	33.9%
Other antihypertensives	26	7.8%
Antihypertensives (any of the above antihypertensives)	293	88.0%
Oral anticoagulants	23	6.9%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	17	5.1%
Other cardiac medications (any of the other cardiac medications)	43	12.9%
Lipid lowering therapy	299	89.8%
Baseline known risk of prolonged QT and torsades de pointes	125	37.5%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	270	81.1%
torsades de pointes	31	9.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.9	14.2
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.8	7.5
Mean number of filled prescriptions	40.7	27.7
Mean number of generics dispensed	13.0	5.8
Mean number of unique drug classes dispensed	11.2	5.0

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 84 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1w. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	58,441	N/A
Demographic Characteristics		
Age (years)	68.2	9.2
Age		
0-40 years	930	1.6%
41-64 years	14,028	23.00%
65-74 years	30,872	52.8%
75-84 years	11,675	20.0%
≥ 85 years	936	1.6%
ex		
Female	32,293	55.3%
Male	26,148	44.7%
tace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	58,441	100.0%
lispanic origin		
Yes	26	0.0%
No	51,332	87.8%
Unknown	7,083	12.1%
'ear		
2022	43,173	73.9%
2023	15,268	26.1%
lealth Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	15,256	26.1%
1-2	22,228	38.0%
3-4	12,890	22.1%
5+	8,067	13.8%
ombined comorbidity score ⁴	2.8	2.8
ombined comorbidity score categories ⁴		
<0	2,907	5.0%
0	9,121	15.6%
1-2	19,737	33.8%
3-4	13,017	22.3%
5+	13,659	23.4%

cder_mpl1p_wp077 Page 85 of 1023



Table 1w. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	1,169	2.0%
Obesity	36,835	63.0%
Tobacco use	17,167	29.4%
Arrhythmia	18,063	30.9%
Cerebrovascular disease/stroke/transient ischemic attack	9,229	15.8%
Chronic kidney disease	13,019	22.3%
Chronic obstructive pulmonary disease	8,971	15.4%
Congenital heart disease	8,971	15.4%
Heart failure	9,238	15.8%
Hyperlipidemia	51,110	87.5%
Hypertensive disease	52,488	89.8%
Thyroid disease	16,473	28.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	19,111	32.7%
Left ventricular hypertrophy	4,121	7.1%
Peripheral artery disease	4,121	7.1%
Valvular/mitral valve disease	3,131	5.4%
Diseases of veins and lymphatics, and other diseases of circulatory system	9,431	16.1%
Obstructive sleep apnea	19,040	32.6%
Hypertrophic cardiomyopathy	3,518	6.0%
Other cardiac disease	32,519	55.6%
Tachyarrhythmia day 0	1,351	2.3%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	556	1.0%
Medical Product Use		
Alpha-glucosidase inhibitors	204	0.3%
Amylin analogs (pramlintide)	****	****
DPP-4 inhibitors	8,680	14.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	621	1.1%
Insulin	16,115	27.6%
Biguanides (metformin, phenformin, etc.)	47,548	81.4%
SGLT2 inhibitors	15,159	25.9%
Sulfonylurea	20,602	35.3%
Thiazolidinedione	5,590	9.6%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	16	0.0%
Sodium channel blockers	556	1.0%
Beta blockers	28,013	47.9%
Potassium channel blockers/openers	1,292	2.2%
Non-dihydropyridine calcium channel blockers	104	0.2%
Digoxin	595	1.0%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 86 of 1023



Table 1w. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	28,398	48.6%
Angiotensin-converting-enzyme (ACE) inhibitor	23,080	39.5%
Angiotensin ii receptor blockers (ARBs)	21,968	37.6%
Dihydropyridines	15,399	26.3%
Diuretics	23,233	41.5%
Other antihypertensives	5,235	9.0%
Antihypertensives (any of the above antihypertensives)	50,423	86.3%
Oral anticoagulants	6,750	11.6%
Vitamin K antagonists	1,557	2.7%
Other cardiac medications not mentioned above	5,211	8.9%
Other cardiac medications (any of the other cardiac medications)	12,108	20.7%
Lipid lowering therapy	50,285	86.0%
Baseline known risk of prolonged QT and torsades de pointes	29,264	50.1%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	52,029	89.0%
torsades de pointes	10,394	17.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.9	19.7
Mean number of emergency room encounters	0.7	1.8
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.2	12.3
Mean number of filled prescriptions	50.2	35.8
Mean number of generics dispensed	13.9	6.4
Mean number of unique drug classes dispensed	12.3	5.6

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 87 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1x. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	816	N/A
Demographic Characteristics		
Age (years)	52.5	10.1
Age		
0-40 years	118	14.5%
41-64 years	623	76.3%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
Sex		
Female	441	54.0%
Male	375	46.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	816	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	239	29.3%
No	61	7.5%
Unknown	516	63.2%
'ear		
2022	407	49.9%
2023	409	50.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.8	1.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	510	62.5%
1-2	214	26.2%
3-4	71	8.7%
5+	21	2.6%
combined comorbidity score ⁴	1.2	1.8
Combined comorbidity score categories ⁴		
<0	97	11.9%
0	233	29.8%
1-2	333	40.8%
3-4	99	12.1%
5+	44	5.4%
JT	44	5.470

cder_mpl1p_wp077 Page 88 of 1023



Table 1x. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	11	1.3%
Dbesity	500	61.3%
obacco use	108	13.2%
Arrhythmia	132	16.2%
Perebrovascular disease/stroke/transient ischemic attack	36	4.4%
Chronic kidney disease	63	7.7%
Chronic obstructive pulmonary disease	14	1.7%
Congenital heart disease	14	1.7%
leart failure	35	4.3%
lyperlipidemia	611	74.9%
lypertensive disease	585	71.7%
hyroid disease	142	17.4%
schemic heart disease/coronary artery disease/myocardial infarction	95	11.6%
eft ventricular hypertrophy	19	2.3%
Peripheral artery disease	19	2.3%
/alvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	56	6.9%
bstructive sleep apnea	217	26.6%
lypertrophic cardiomyopathy	21	2.6%
Other cardiac disease	278	34.1%
achyarrhythmia day 0	****	****
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	****	****
Nedical Product Use		
lpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	77	9.4%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
/leglitinides	****	****
nsulin	166	20.3%
iguanides (metformin, phenformin, etc.)	729	89.3%
GLT2 inhibitors	207	25.4%
ulfonylurea	167	20.5%
hiazolidinedione	43	5.3%
lo baseline use of any of the above antidiabetic drugs	0	0.0%
ther antidiabetics	0	0.0%
odium channel blockers	****	****
seta blockers	205	25.1%
otassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 89 of 1023



Table 1x. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentinei Distributed Database from May 13, 2022 to		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	205	25.1%
Angiotensin-converting-enzyme (ACE) inhibitor	289	35.4%
Angiotensin ii receptor blockers (ARBs)	270	33.1%
Dihydropyridines	152	18.6%
Diuretics	185	22.7%
Other antihypertensives	39	4.8%
Antihypertensives (any of the above antihypertensives)	589	72.2%
Oral anticoagulants	31	3.8%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	25	3.1%
Other cardiac medications (any of the other cardiac medications)	55	6.7%
Lipid lowering therapy	568	69.6%
Baseline known risk of prolonged QT and torsades de pointes	320	39.2%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	599	73.4%
torsades de pointes	76	9.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.3	15.7
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.5	6.6
Mean number of filled prescriptions	34.3	25.4
Mean number of generics dispensed	10.3	5.5
Mean number of unique drug classes dispensed	9.1	4.8

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 90 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1y. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	34,058	N/A
Demographic Characteristics		
Age (years)	65.8	10.2
Age		
0-40 years	1,132	3.3%
41-64 years	12,264	36.0%
65-74 years	13,680	40.2%
75-84 years	6,100	17.9%
≥ 85 years	882	2.6%
ex		
Female	17,466	51.3%
Male	16,592	48.7%
tace ²		
American Indian or Alaska Native	68	0.2%
Asian	1,087	3.2%
Black or African American	3,392	10.0%
Multi-racial	181	0.5%
Native Hawaiian or Other Pacific Islander	128	0.4%
Unknown	12,788	37.5%
White	16,414	48.2%
Hispanic origin	-,	
Yes	1,271	3.7%
No	18,712	54.9%
Unknown	14,075	41.3%
/ear	_ 1,070	12.075
2022	25,230	74.1%
2023	8,818	25.9%
Health Characteristics	0,010	23.370
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	12,947	38.0%
1-2	12,115	35.6%
3-4	5,837	17.1%
5+	3,159	9.3%
Combined comorbidity score ⁴	2.1	2.5
Combined comorbidity score categories ⁴	2.1	۷.5
<0	2,836	8.3%
0		
1-2	7,571 12,116	22.2%
	12,116	35.6%
3-4	6,165	18.1%
5+	5,370	15.8%

cder_mpl1p_wp077 Page 91 of 1023



Table 1y. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	514	1.5%
Obesity	16,968	49.8%
Tobacco use	7,048	20.7%
Arrhythmia	7,648	22.5%
Cerebrovascular disease/stroke/transient ischemic attack	4,055	11.9%
Chronic kidney disease	6,315	18.5%
Chronic obstructive pulmonary disease	3,131	9.2%
Congenital heart disease	3,131	9.2%
Heart failure	3,547	10.4%
Hyperlipidemia	28,660	84.2%
Hypertensive disease	29,230	85.9%
Thyroid disease	6,972	20.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	7,664	22.5%
Left ventricular hypertrophy	1,658	4.9%
Peripheral artery disease	1,658	4.9%
Valvular/mitral valve disease	1,255	3.7%
Diseases of veins and lymphatics, and other diseases of circulatory system	3,868	11.4%
Obstructive sleep apnea	7,094	20.8%
Hypertrophic cardiomyopathy	1,421	4.2%
Other cardiac disease	13,748	40.4%
Tachyarrhythmia day 0	510	1.5%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	218	0.6%
Medical Product Use		
Alpha-glucosidase inhibitors	180	0.5%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	6,790	19.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	478	1.4%
Insulin	4,352	12.8%
Biguanides (metformin, phenformin, etc.)	28,279	83.0%
SGLT2 inhibitors	11,336	33.3%
Sulfonylurea	13,337	39.2%
Thiazolidinedione	3,445	10.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	****
Sodium channel blockers	199	0.6%
Beta blockers	13,213	38.8%
Potassium channel blockers/openers	441	1.3%
Non-dihydropyridine calcium channel blockers	45	0.1%
Digoxin	239	0.7%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 92 of 1023



Table 1y. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	13,369	39.3%
Angiotensin-converting-enzyme (ACE) inhibitor	13,334	39.2%
Angiotensin ii receptor blockers (ARBs)	12,334	36.2%
Dihydropyridines	9,144	26.8%
Diuretics	10,973	32.2%
Other antihypertensives	2,606	7.7%
Antihypertensives (any of the above antihypertensives)	28,268	83.0%
Oral anticoagulants	2,698	7.9%
Vitamin K antagonists	534	1.6%
Other cardiac medications not mentioned above	1,898	5.6%
Other cardiac medications (any of the other cardiac medications)	4,672	13.7%
Lipid lowering therapy	28,502	83.7%
Baseline known risk of prolonged QT and torsades de pointes	13,708	40.2%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	27,233	80.0%
torsades de pointes	3,991	11.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.6	16.7
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.6	8.4
Mean number of filled prescriptions	40.8	30.5
Mean number of generics dispensed	11.7	5.7
Mean number of unique drug classes dispensed	10.1	5.0

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 93 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1z. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standa	
Patient Characteristics	Number/Mean	Deviation ¹	
Jnique patients	12,788	N/A	
Demographic Characteristics			
age (years)	59.4	10.9	
age			
0-40 years	773	6.0%	
41-64 years	7,936	62.1%	
65-74 years	3,034	23.7%	
75-84 years	894	7.0%	
≥ 85 years	151	1.2%	
ex			
Female	6,020	47.1%	
Male	6,768	52.9%	
tace ²			
American Indian or Alaska Native	0	0.0%	
Asian	0	0.0%	
Black or African American	0	0.0%	
Multi-racial	0	0.0%	
Native Hawaiian or Other Pacific Islander	0	0.0%	
Unknown	12,788	100.0%	
White	0	0.0%	
lispanic origin			
Yes	****	****	
No	****	****	
Unknown	11,568	90.5%	
ear			
2022	8,899	69.6%	
2023	3,889	30.4%	
lealth Characteristics			
dapted Diabetes Complications Severity Index (aDCSI) ³	1.1	1.5	
dapted Diabetes Complications Severity Index (aDCSI) categories ³			
<0	0	0.0%	
0	6,767	52.9%	
1-2	4,064	31.8%	
3-4	1,388	10.9%	
5+	569	4.4%	
ombined comorbidity score ⁴	1.4	2.1	
ombined comorbidity score categories ⁴			
<0	1,530	12.0%	
0	3,760	29.4%	
1-2	4,838	37.8%	
3-4	1,617	12.6%	
5+	1,043	8.2%	

cder_mpl1p_wp077 Page 94 of 1023



Table 1z. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
alcohol use or abuse	157	1.2%
Dbesity	6,210	48.6%
obacco use	1,820	14.2%
nrhythmia	2,011	15.7%
Cerebrovascular disease/stroke/transient ischemic attack	897	7.0%
Chronic kidney disease	1,377	10.8%
chronic obstructive pulmonary disease	612	4.8%
Congenital heart disease	612	4.8%
leart failure	730	5.7%
lyperlipidemia	10,163	79.5%
lypertensive disease	10,134	79.2%
hyroid disease	2,099	16.4%
schemic heart disease/coronary artery disease/myocardial infarction	1,834	14.3%
eft ventricular hypertrophy	395	3.1%
eripheral artery disease	395	3.1%
alvular/mitral valve disease	268	2.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,043	8.2%
Obstructive sleep apnea	2,425	19.0%
lypertrophic cardiomyopathy	335	2.6%
Other cardiac disease	4,057	31.7%
achyarrhythmia day 0	111	0.9%
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	46	0.4%
Nedical Product Use		
Alpha-glucosidase inhibitors	52	0.4%
mylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	2,328	18.2%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Лeglitinides	121	0.9%
nsulin	1,349	10.5%
iguanides (metformin, phenformin, etc.)	11,140	87.1%
GLT2 inhibitors	4,347	34.0%
ulfonylurea	4,259	33.3%
hiazolidinedione	1,119	8.8%
lo baseline use of any of the above antidiabetic drugs	0	0.0%
ther antidiabetics	0	0.0%
odium channel blockers	54	0.4%
eta blockers	3,747	29.3%
otassium channel blockers/openers	95	0.7%
Ion-dihydropyridine calcium channel blockers	****	****
Digoxin	50	0.4%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 95 of 1023



Table 1z. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	·	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	3,774	29.5%
Angiotensin-converting-enzyme (ACE) inhibitor	4,897	38.3%
Angiotensin ii receptor blockers (ARBs)	4,260	33.3%
Dihydropyridines	2,817	22.0%
Diuretics	3,193	25.0%
Other antihypertensives	659	5.2%
Antihypertensives (any of the above antihypertensives)	9,915	77.5%
Oral anticoagulants	637	5.0%
Vitamin K antagonists	112	0.9%
Other cardiac medications not mentioned above	455	3.6%
Other cardiac medications (any of the other cardiac medications)	1,122	8.8%
Lipid lowering therapy	10,144	79.3%
Baseline known risk of prolonged QT and torsades de pointes	4,752	37.2%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	9,439	73.8%
torsades de pointes	1,193	9.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.8	14.7
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.0	6.0
Mean number of filled prescriptions	35.3	27.1
Mean number of generics dispensed	10.5	5.6
Mean number of unique drug classes dispensed	9.0	4.9

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 96 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1aa. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	68	N/A
Demographic Characteristics		
Age (years)	61.3	13.6
Age		
0-40 years	****	****
41-64 years	25	36.8%
65-74 years	23	35.3%
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	41	60.3%
Male	27	39.7%
Race ²		
American Indian or Alaska Native	68	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	****	****
No	****	****
Unknown	****	****
/ear		
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.5	1.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	27	39.7%
1-2	26	38.2%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	2.2	2.2
Combined comorbidity score categories ⁴		
<0	****	****
0	12	17.6%
1-2	30	44.1%
3-4	****	****
5+	15	22.1%
.	13	22.1/0

cder_mpl1p_wp077 Page 97 of 1023



Table 1aa. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	38	55.9%
Tobacco use	18	26.5%
Arrhythmia	13	19.1%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	****	****
Hyperlipidemia	51	75.0%
Hypertensive disease	52	76.5%
Thyroid disease	16	23.5%
schemic heart disease/coronary artery disease/myocardial infarction	14	20.6%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Dbstructive sleep apnea	****	****
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	20	29.4%
Fachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	19	27.9%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
nsulin	12	17.6%
Biguanides (metformin, phenformin, etc.)	58	85.3%
GGLT2 inhibitors	18	26.5%
Sulfonylurea	25	36.8%
, Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	25	36.8%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
Since and any annie agence	O .	3.070

cder_mpl1p_wp077 Page 98 of 1023



Table 1aa. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	25	36.8%
Angiotensin-converting-enzyme (ACE) inhibitor	31	45.6%
Angiotensin ii receptor blockers (ARBs)	14	20.6%
Dihydropyridines	15	22.1%
Diuretics	19	27.9%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	53	77.9%
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	55	80.9%
Baseline known risk of prolonged QT and torsades de pointes	34	50.0%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	61	89.7%
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.9	11.2
Mean number of emergency room encounters	0.9	2.0
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	7.0	14.7
Mean number of filled prescriptions	61.9	45.9
Mean number of generics dispensed	12.9	5.5
Mean number of unique drug classes dispensed	11.1	4.8

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 99 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ab. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	1,087	N/A
Demographic Characteristics		
sge (years)	70.6	9.9
age .		
0-40 years	26	2.4%
41-64 years	173	15.9%
65-74 years	523	48.2%
75-84 years	292	26.9%
≥ 85 years	72	6.6%
ex		
Female	601	55.3%
Male	486	44.7%
tace ²		
American Indian or Alaska Native	0	0.0%
Asian	1,087	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	****	****
No	931	85.6%
Unknown	****	****
ear		
2022	923	84.9%
2023	164	15.1%
lealth Characteristics		
dapted Diabetes Complications Severity Index (aDCSI) ³	1.8	1.9
dapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	361	33.2%
1-2	401	36.9%
3-4	207	19.0%
5+	118	10.9%
ombined comorbidity score ⁴	2.4	2.6
ombined comorbidity score categories ⁴	∠. →	2.0
<0	66	6.1%
0	222	20.4%
1-2	382	35.1%
3-4	225	20.7%
5+	192	17.7%

cder_mpl1p_wp077 Page 100 of 1023



Table 1ab. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	.o Julie 30, 2023	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	251	23.1%
Tobacco use	121	11.1%
Arrhythmia	220	20.2%
Cerebrovascular disease/stroke/transient ischemic attack	148	13.6%
Chronic kidney disease	306	28.2%
Chronic obstructive pulmonary disease	85	7.8%
Congenital heart disease	85	7.8%
Heart failure	115	10.6%
Hyperlipidemia	955	87.9%
Hypertensive disease	951	87.5%
Thyroid disease	206	19.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	267	23.60%
Left ventricular hypertrophy	43	4.0%
Peripheral artery disease	43	4.0%
Valvular/mitral valve disease	42	3.9%
Diseases of veins and lymphatics, and other diseases of circulatory system	91	8.4%
Obstructive sleep apnea	87	8.0%
Hypertrophic cardiomyopathy	41	3.8%
Other cardiac disease	376	34.6%
Tachyarrhythmia day 0	15	1.4%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	25	2.3%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	338	31.1%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	35	3.2%
Insulin	158	14.5%
Biguanides (metformin, phenformin, etc.)	915	84.2%
SGLT2 inhibitors	492	45.3%
Sulfonylurea	503	46.3%
Thiazolidinedione	172	15.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	****
Beta blockers	440	40.5%
Potassium channel blockers/openers	13	1.2%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 101 of 1023



Table 1ab. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	446	41.0%
Angiotensin-converting-enzyme (ACE) inhibitor	294	27.0%
Angiotensin ii receptor blockers (ARBs)	577	53.1%
Dihydropyridines	397	36.5%
Diuretics	259	23.8%
Other antihypertensives	101	9.3%
Antihypertensives (any of the above antihypertensives)	933	85.8%
Oral anticoagulants	67	6.2%
Vitamin K antagonists	11	1.0%
Other cardiac medications not mentioned above	106	9.8%
Other cardiac medications (any of the other cardiac medications)	166	15.3%
Lipid lowering therapy	989	91.0%
Baseline known risk of prolonged QT and torsades de pointes	344	31.6%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	778	71.6%
torsades de pointes	79	7.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.6	18.8
Mean number of emergency room encounters	0.3	0.7
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.2	8.7
Mean number of filled prescriptions	42.9	32.7
Mean number of generics dispensed	11.9	6.0
Mean number of unique drug classes dispensed	9.9	5.2

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 102 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ac. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	3,392	N/A
Demographic Characteristics		
Age (years)	67.1	10.3
Age		
0-40 years	88	2.6%
41-64 years	984	29.0%
65-74 years	1,680	49.5%
75-84 years	564	16.6%
≥ 85 years	76	2.2%
Sex		
Female	2,238	66.3%
Male	1,144	33.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	3,392	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	****	****
No	2,987	88.1%
Unknown	****	****
/ear		
2022	2,336	68.9%
2023	1,056	31.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	937	27.6%
1-2	1,294	38.1%
3-4	728	21.5%
5+	433	12.8%
Combined comorbidity score ⁴	2.6	2.7
Combined comorbidity score categories ⁴	-	
<0	208	6.1%
0	615	18.1%
1-2	1,123	33.1%
3-4	753	22.2%
· ·	693	20.4%

cder_mpl1p_wp077 Page 103 of 1023



Table 1ac. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	73	2.2%
Obesity	1,998	58.9%
Tobacco use	836	23.60%
Arrhythmia	734	21.6%
Cerebrovascular disease/stroke/transient ischemic attack	440	13.0%
Chronic kidney disease	896	26.4%
Chronic obstructive pulmonary disease	370	10.9%
Congenital heart disease	370	10.9%
Heart failure	501	14.8%
Hyperlipidemia	2,885	85.1%
Hypertensive disease	3,191	94.1%
Thyroid disease	469	13.8%
Ischemic heart disease/coronary artery disease/myocardial infarction	685	20.2%
Left ventricular hypertrophy	232	6.8%
Peripheral artery disease	232	6.8%
Valvular/mitral valve disease	126	3.7%
Diseases of veins and lymphatics, and other diseases of circulatory system	442	13.0%
Obstructive sleep apnea	665	19.6%
Hypertrophic cardiomyopathy	184	5.4%
Other cardiac disease	1,352	39.9%
Tachyarrhythmia day 0	31	0.9%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	44	1.3%
Medical Product Use		
Alpha-glucosidase inhibitors	19	0.6%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	687	20.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	44	1.3%
Insulin	551	16.2%
Biguanides (metformin, phenformin, etc.)	2,627	77.4%
SGLT2 inhibitors	1,012	29.8%
Sulfonylurea	1,408	41.5%
Thiazolidinedione	307	9.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	****
Beta blockers	1,454	42.9%
Potassium channel blockers/openers	26	0.8%
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	13	0.4%
_	0	
Other antiarrhythmic agents		0.0%

cder_mpl1p_wp077 Page 104 of 1023



Table 1ac. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	1,470	43.3%
Angiotensin-converting-enzyme (ACE) inhibitor	1,196	35.3%
Angiotensin ii receptor blockers (ARBs)	1,502	44.3%
Dihydropyridines	1,511	44.5%
Diuretics	1,554	45.8%
Other antihypertensives	469	13.8%
Antihypertensives (any of the above antihypertensives)	3,101	91.4%
Oral anticoagulants	211	6.2%
Vitamin K antagonists	40	1.2%
Other cardiac medications not mentioned above	188	5.5%
Other cardiac medications (any of the other cardiac medications)	402	11.9%
Lipid lowering therapy	2,844	83.8%
Baseline known risk of prolonged QT and torsades de pointes	1,332	39.3%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	2,915	85.9%
torsades de pointes	327	9.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.2	17.7
Mean number of emergency room encounters	0.8	1.9
Mean number of inpatient hospital encounters	0.1	0.6
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	4.7	10.8
Mean number of filled prescriptions	42.2	29.0
Mean number of generics dispensed	12.4	5.9
Mean number of unique drug classes dispensed	10.9	5.2

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 105 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ad. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	128	N/A
Demographic Characteristics		
Age (years)	71.4	7.6
Age		
0-40 years	****	****
41-64 years	****	****
65-74 years	66	51.6%
75-84 years	35	27.3%
≥ 85 years	****	****
Sex		
Female	53	41.4%
Male	75	58.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	128	100.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	0	0.0%
No	****	****
Unknown	****	****
'ear		
2022	70	54.7%
2023	58	45.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	33	25.8%
1-2	49	38.3%
3-4	26	20.3%
5+	20	15.6%
Combined comorbidity score ⁴	2.5	2.7
Combined comorbidity score categories ⁴		
<0	15	11.7%
0	19	14.8%
1-2	34	26.6%
3-4	37	28.9%
5+	23	18.0%

cder_mpl1p_wp077 Page 106 of 1023



Table 1ad. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	50	39.1%
Tobacco use	19	14.8%
Arrhythmia	35	27.3%
Cerebrovascular disease/stroke/transient ischemic attack	16	12.5%
Chronic kidney disease	43	33.6%
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	17	13.3%
Hyperlipidemia	116	90.6%
Hypertensive disease	116	90.6%
Thyroid disease	22	17.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	33	25.8%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	16	12.5%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	50	39.1%
	0	0.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	****	U.U% ****
History of serious hypoglycemia (ED and/or IP) Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	_	
	26 0	20.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	V ****	0.0%
Meglitinides		
Insulin	17	13.3%
Biguanides (metformin, phenformin, etc.)	106	82.8%
SGLT2 inhibitors	41	32.0%
Sulfonylurea	71	55.5%
Thiazolidinedione	26	20.3%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	****
Sodium channel blockers	0	0.0%
Beta blockers	56	43.8%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 107 of 1023



Table 1ad. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	57	44.5%
Angiotensin-converting-enzyme (ACE) inhibitor	45	35.2%
Angiotensin ii receptor blockers (ARBs)	58	45.3%
Dihydropyridines	39	30.5%
Diuretics	38	29.7%
Other antihypertensives	11	8.6%
Antihypertensives (any of the above antihypertensives)	114	89.1%
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	17	13.3%
Lipid lowering therapy	112	87.5%
Baseline known risk of prolonged QT and torsades de pointes	42	32.8%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	93	72.7%
torsades de pointes	11	8.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.1	13.6
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	1.9	6.9
Mean number of filled prescriptions	33.2	18.4
Mean number of generics dispensed	11.2	5.0
Mean number of unique drug classes dispensed	9.3	4.3

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 108 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ae. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar	
Patient Characteristics	Number/Mean	Deviation ¹	
Jnique patients	16,414	N/A	
Demographic Characteristics			
Age (years)	70.2	9.3	
Age			
0-40 years	209	1.3%	
41-64 years	2,999	18.3%	
65-74 years	8,327	50.7%	
75-84 years	4,305	26.2%	
≥ 85 years	574	3.5%	
ex			
Female	8,414	51.3%	
Male	8,000	48.7%	
tace ²			
American Indian or Alaska Native	0	0.0%	
Asian	0	0.0%	
Black or African American	0	0.0%	
Multi-racial	0	0.0%	
Native Hawaiian or Other Pacific Islander	0	0.0%	
Unknown	0	0.0%	
White	16,414	100.0%	
lispanic origin			
Yes	****	****	
No	14,602	89.0%	
Unknown	****	****	
'ear			
2022	12,838	78.2%	
2023	3,576	21.8%	
Health Characteristics			
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	2.0	
dapted Diabetes Complications Severity Index (aDCSI) categories ³			
<0	0	0.0%	
0	4,705	28.7%	
1-2	6,231	38.0%	
3-4	3,466	21.1%	
5+	2,012	12.3%	
combined comorbidity score ⁴	2.6	2.7	
Combined comorbidity score categories ⁴			
<0	988	6.0%	
0	2,893	17.6%	
1-2	5,628	34.3%	
3-4	3,510	21.4%	
5+	3,395	20.7%	

cder_mpl1p_wp077 Page 109 of 1023



Table 1ae. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Percent/Standard
Patient Characteristics Number/Mean	Deviation ¹
Alcohol use or abuse 264	1.6%
Obesity 8,321	50.7%
Tobacco use 4,209	25.6%
Arrhythmia 4,607	28.1%
Cerebrovascular disease/stroke/transient ischemic attack 2,539	15.5%
Chronic kidney disease 3,673	22.4%
Chronic obstructive pulmonary disease 2,049	12.5%
Congenital heart disease 2,049	12.5%
Heart failure 2,171	13.2%
Hyperlipidemia 14,358	87.5%
Hypertensive disease 14,663	89.3%
Thyroid disease 4,135	25.2%
Ischemic heart disease/coronary artery disease/myocardial infarction 4,812	29.3%
Left ventricular hypertrophy 973	5.9%
Peripheral artery disease 973	5.9%
Valvular/mitral valve disease 809	4.9%
Diseases of veins and lymphatics, and other diseases of circulatory system 2,266	13.8%
Obstructive sleep apnea 3,854	23.5%
Hypertrophic cardiomyopathy 852	5.2%
Other cardiac disease 7,838	47.8%
Tachyarrhythmia day 0 352	2.1%
Hospitalized tachyarrhythmia day 0 0	0.0%
History of serious hypoglycemia (ED and/or IP) 119	0.7%
Medical Product Use	
Alpha-glucosidase inhibitors 84	0.5%
Amylin analogs (pramlintide) 0	0.0%
DPP-4 inhibitors 3,372	20.5%
ncretin mimetics (albiglutide, dulaglutide, etc.) 0	0.0%
Meglitinides 275	1.7%
Insulin 2,256	13.7%
Biguanides (metformin, phenformin, etc.) 13,271	80.9%
SGLT2 inhibitors 5,370	32.7%
Sulfonylurea 7,012	42.7%
Thiazolidinedione 1,796	10.9%
No baseline use of any of the above antidiabetic drugs 0	0.0%
Other antidiabetics *****	****
Sodium channel blockers 135	0.8%
Beta blockers 7,450	45.4%
Potassium channel blockers/openers 305	1.9%
Non-dihydropyridine calcium channel blockers 28	0.2%
Digoxin 176	1.1%

cder_mpl1p_wp077 Page 110 of 1023



Table 1ae. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	7,556	46.0%
Angiotensin-converting-enzyme (ACE) inhibitor	6,803	41.4%
Angiotensin ii receptor blockers (ARBs)	5,867	35.7%
Dihydropyridines	4,331	26.4%
Diuretics	5,874	35.8%
Other antihypertensives	1,356	8.3%
Antihypertensives (any of the above antihypertensives)	14,018	85.4%
Oral anticoagulants	1,766	10.8%
Vitamin K antagonists	363	2.2%
Other cardiac medications not mentioned above	1,130	6.9%
Other cardiac medications (any of the other cardiac medications)	2,945	17.9%
ipid lowering therapy	14,229	86.7%
Baseline known risk of prolonged QT and torsades de pointes	7,140	43.5%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	13,830	84.3%
corsades de pointes	2,366	14.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.4	17.8
Mean number of emergency room encounters	0.5	1.4
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.1	9.5
Mean number of filled prescriptions	44.7	32.9
Mean number of generics dispensed	12.4	5.8
Mean number of unique drug classes dispensed	10.8	5.1

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 111 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1af. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Percent/Standard	
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	181	N/A
Demographic Characteristics		
Age (years)	53.3	10.7
Age		
0-40 years	25	13.8%
41-64 years	129	71.3%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
ex		
Female	89	49.2%
Male	92	50.8%
cace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	181	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin	•	
Yes	46	25.4%
No	12	6.6%
Unknown	123	68.0%
ear		
2022	111	61.3%
2023	70	38.7%
Health Characteristics	,,,	30.770
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	0.0	
<0	0	0.0%
0	117	64.6%
1-2	50	27.6%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	1.0	1.8
Combined comorbidity score categories ⁴	1.0	1.0
<0	26	14.4%
0	50	27.6%
1-2	81	44.8%
	**** O T	44.8% ****
3-4	****	****

cder_mpl1p_wp077 Page 112 of 1023



Table 1af. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics Number / Mass	
Patient Characteristics Number/Mean I	Deviation ¹
Alcohol use or abuse ****	****
Obesity 100	55.2%
Tobacco use 25	13.8%
Arrhythmia 28	15.5%
Cerebrovascular disease/stroke/transient ischemic attack *****	****
Chronic kidney disease 12	6.6%
Chronic obstructive pulmonary disease *****	****
Congenital heart disease *****	****
Heart failure *****	****
Hyperlipidemia 132	72.9%
Hypertensive disease 133	73.5%
Thyroid disease 25	13.8%
Ischemic heart disease/coronary artery disease/myocardial infarction 19	10.5%
Left ventricular hypertrophy *****	****
Peripheral artery disease *****	****
Valvular/mitral valve disease *****	****
Diseases of veins and lymphatics, and other diseases of circulatory system *****	****
Obstructive sleep apnea 38	21.0%
Hypertrophic cardiomyopathy *****	****
Other cardiac disease 55	30.4%
Tachyarrhythmia day 0	****
Hospitalized tachyarrhythmia day 0 0	0.0%
History of serious hypoglycemia (ED and/or IP) 0	0.0%
Medical Product Use	
Alpha-glucosidase inhibitors 0	0.0%
Amylin analogs (pramlintide) 0	0.0%
DPP-4 inhibitors 20	11.0%
Incretin mimetics (albiglutide, dulaglutide, etc.) 0	0.0%
Meglitinides *****	****
Insulin ****	****
Biguanides (metformin, phenformin, etc.) 162	89.5%
SGLT2 inhibitors 56	30.9%
Sulfonylurea 59	32.6%
Thiazolidinedione 16	8.8%
No baseline use of any of the above antidiabetic drugs 0	0.0%
Other antidiabetics 0	0.0%
Sodium channel blockers 0	0.0%
Beta blockers 41	22.7%
Potassium channel blockers/openers 0	0.0%
Non-dihydropyridine calcium channel blockers 0	0.0%
Digoxin 0	0.0%
Other antiarrhythmic agents 0	0.0%

cder_mpl1p_wp077 Page 113 of 1023



Table 1af. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentiner Distributed Database from May 15, 2022 to	,	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	41	22.7%
Angiotensin-converting-enzyme (ACE) inhibitor	68	37.6%
Angiotensin ii receptor blockers (ARBs)	56	30.9%
Dihydropyridines	34	18.8%
Diuretics	36	19.9%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	134	74.0%
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	14	7.7%
Lipid lowering therapy	129	71.3%
Baseline known risk of prolonged QT and torsades de pointes	64	35.4%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	127	70.2%
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.0	10.7
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	1.3	2.3
Mean number of filled prescriptions	30.3	20.0
Mean number of generics dispensed	9.6	4.6
Mean number of unique drug classes dispensed	8.1	3.9

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 114 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ag. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	386	N/A
Demographic Characteristics		
Age (years)	50.6	10.0
Age		
0-40 years	70	18.1%
41-64 years	292	75.6%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
Sex		
Female	294	76.2%
Male	92	23.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	****	****
Multi-racial	****	****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	342	88.6%
White	31	8.0%
Hispanic origin		
Yes	0	0.0%
No	13	3.4%
Unknown	373	96.6%
Year		
2022	333	86.3%
2023	53	13.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	276	71.5%
1-2	88	22.8%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	1.2	1.9
Combined comorbidity score categories ⁴		
<0	44	11.4%
0	123	31.9%
1-2	144	37.3%
	53	13.7%
3-4		

cder_mpl1p_wp077 Page 115 of 1023



Table 1ag. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standa
atient Characteristics	Number/Mean	Deviation ¹
llcohol use or abuse	****	****
Dbesity	332	86.0%
obacco use	50	13.0%
rrhythmia	67	17.4%
erebrovascular disease/stroke/transient ischemic attack	****	****
hronic kidney disease	18	4.7%
hronic obstructive pulmonary disease	****	****
ongenital heart disease	****	****
eart failure	14	3.6%
yperlipidemia	257	66.6%
ypertensive disease	274	71.0%
hyroid disease	105	27.2%
schemic heart disease/coronary artery disease/myocardial infarction	25	6.5%
eft ventricular hypertrophy	12	3.1%
eripheral artery disease	12	3.1%
alvular/mitral valve disease	****	****
iseases of veins and lymphatics, and other diseases of circulatory system	38	9.8%
bstructive sleep apnea	137	35.5%
ypertrophic cardiomyopathy	****	****
ther cardiac disease	159	41.2%
achyarrhythmia day 0	0	0.0%
ospitalized tachyarrhythmia day 0	0	0.0%
istory of serious hypoglycemia (ED and/or IP)	****	****
ledical Product Use		
lpha-glucosidase inhibitors	****	****
mylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	21	5.4%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
. Teglitinides	0	0.0%
nsulin	18	4.7%
iguanides (metformin, phenformin, etc.)	358	92.7%
GLT2 inhibitors	47	12.2%
ulfonylurea	39	10.1%
hiazolidinedione	****	****
o baseline use of any of the above antidiabetic drugs	0	0.0%
ther antidiabetics	0	0.0%
odium channel blockers	0	0.0%
eta blockers	115	29.8%
otassium channel blockers/openers	0	0.0%
on-dihydropyridine calcium channel blockers	0	0.0%
igoxin	0	0.0%
other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 116 of 1023



Table 1ag. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	115	29.8%
Angiotensin-converting-enzyme (ACE) inhibitor	101	26.2%
Angiotensin ii receptor blockers (ARBs)	106	27.5%
Dihydropyridines	72	18.7%
Diuretics	152	39.4%
Other antihypertensives	26	6.7%
Antihypertensives (any of the above antihypertensives)	281	72.8%
Oral anticoagulants	16	4.1%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	21	5.4%
Lipid lowering therapy	206	53.4%
Baseline known risk of prolonged QT and torsades de pointes	213	55.2%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	345	89.4%
torsades de pointes	68	17.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.0	16.9
Mean number of emergency room encounters	0.5	1.2
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	5.2	5.2
Mean number of filled prescriptions	38.7	26.9
Mean number of generics dispensed	12.7	6.4
Mean number of unique drug classes dispensed	11.5	5.6

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 117 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ah. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	342	N/A
Demographic Characteristics		
Age (years)	50.0	9.9
Age		
0-40 years	64	18.7%
41-64 years	266	77.8%
65-74 years	12	3.5%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
ex		
Female	263	76.9%
Male	79	23.1%
tace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	342	100.0%
White	0	0.0%
lispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	342	100.0%
'ear		
2022	298	87.1%
2023	44	12.9%
lealth Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	234	71.3%
1-2	78	22.8%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	1.2	1.9
Combined comorbidity score categories ⁴		
<0	39	11.4%
0	112	32.7%
1-2	127	37.1%
3-4	45	13.2%
5+	19	5.6%

cder_mpl1p_wp077 Page 118 of 1023



Table 1ah. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Dbesity	296	86.5%
obacco use	40	11.7%
nrhythmia	56	16.4%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	16	4.7%
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
leart failure	13	3.8%
lyperlipidemia	220	64.3%
lypertensive disease	235	71.6%
hyroid disease	93	27.2%
schemic heart disease/coronary artery disease/myocardial infarction	21	6.1%
eft ventricular hypertrophy	****	****
Peripheral artery disease	****	****
/alvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	32	9.4%
Dbstructive sleep apnea	119	34.8%
lypertrophic cardiomyopathy	****	****
Other cardiac disease	136	39.8%
achyarrhythmia day 0	0	0.0%
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
PPP-4 inhibitors	19	5.6%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
nsulin	14	4.1%
siguanides (metformin, phenformin, etc.)	318	93.0%
GLT2 inhibitors	39	11.4%
ulfonylurea	29	8.5%
, hiazolidinedione	****	****
Io baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	0	0.0%
Beta blockers	99	28.9%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
	· ·	0.070

cder_mpl1p_wp077 Page 119 of 1023



Table 1ah. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	99	28.9%
Angiotensin-converting-enzyme (ACE) inhibitor	93	27.2%
Angiotensin ii receptor blockers (ARBs)	94	27.5%
Dihydropyridines	61	17.8%
Diuretics	133	38.9%
Other antihypertensives	23	7.0%
Antihypertensives (any of the above antihypertensives)	250	73.1%
Oral anticoagulants	13	3.8%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	16	4.7%
Lipid lowering therapy	179	52.3%
Baseline known risk of prolonged QT and torsades de pointes	192	56.1%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	305	89.2%
torsades de pointes	59	17.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.4	16.8
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.5	5.1
Mean number of filled prescriptions	37.9	26.2
Mean number of generics dispensed	12.6	6.4
Mean number of unique drug classes dispensed	11.4	5.6

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 120 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ai. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)		
Age		
0-40 years	•	
41-64 years	•	
65-74 years	•	
75-84 years		
≥ 85 years		
Sex		
Female		
Male		
Race ²		
American Indian or Alaska Native	•	
Asian	·	
Black or African American		
Multi-racial		
Native Hawaiian or Other Pacific Islander		
Unknown		
White		
Hispanic origin	•	·
Yes		
No	•	•
Unknown	•	•
Year	•	•
2022		
2023	•	•
Health Characteristics	•	·
Adapted Diabetes Complications Severity Index (aDCSI) ³		
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	•	•
<0		
0	•	•
1-2	•	•
3-4	•	•
5+	•	•
	•	•
Combined comorbidity score ⁴	•	•
Combined comorbidity score categories ⁴		
<0	•	•
0	•	•
1-2	•	•
3-4	•	•
5+	•	

cder_mpl1p_wp077 Page 121 of 1023



Table 1ai. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

the rupid sentiner distributed butdade and sentiner distributed butdade in	10111 Way 13, 2022 to Jul	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse		
Obesity		٠
Tobacco use		
Arrhythmia		
Cerebrovascular disease/stroke/transient ischemic attack		
Chronic kidney disease		
Chronic obstructive pulmonary disease		
Congenital heart disease		
Heart failure		
Hyperlipidemia		
Hypertensive disease		
Thyroid disease		
Ischemic heart disease/coronary artery disease/myocardial infarction		
Left ventricular hypertrophy		
Peripheral artery disease		
Valvular/mitral valve disease		
Diseases of veins and lymphatics, and other diseases of circulatory system		
Obstructive sleep apnea		
Hypertrophic cardiomyopathy		
Other cardiac disease		
Tachyarrhythmia day 0		
Hospitalized tachyarrhythmia day 0		
History of serious hypoglycemia (ED and/or IP)		
Medical Product Use		
Alpha-glucosidase inhibitors		
Amylin analogs (pramlintide)		
DPP-4 inhibitors		
Incretin mimetics (albiglutide, dulaglutide, etc.)		
Meglitinides		
Insulin		
Biguanides (metformin, phenformin, etc.)		
SGLT2 inhibitors		
Sulfonylurea		
Thiazolidinedione		
No baseline use of any of the above antidiabetic drugs		
Other antidiabetics		
Sodium channel blockers		
Beta blockers		
Potassium channel blockers/openers		
Non-dihydropyridine calcium channel blockers		
Digoxin		
Other antiarrhythmic agents		
, 5		

cder_mpl1p_wp077 Page 122 of 1023



Table 1ai. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)		
Angiotensin-converting-enzyme (ACE) inhibitor		
Angiotensin ii receptor blockers (ARBs)		
Dihydropyridines		
Diuretics		
Other antihypertensives		
Antihypertensives (any of the above antihypertensives)		
Oral anticoagulants		
Vitamin K antagonists		
Other cardiac medications not mentioned above		
Other cardiac medications (any of the other cardiac medications)		
Lipid lowering therapy		
Baseline known risk of prolonged QT and torsades de pointes		
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	•	·
torsades de pointes		
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters		
Mean number of emergency room encounters		
Mean number of inpatient hospital encounters		
Mean number of non-acute institutional encounters		
Mean number of other ambulatory encounters		
Mean number of filled prescriptions		•
Mean number of generics dispensed		
Mean number of unique drug classes dispensed		•

¹Value represents standard deviation where no % follows the value.

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

N/A: Not applicable

cder_mpl1p_wp077 Page 123 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051



Table 1aj. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentiner Distributed Database from May 15, 20		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	•	
Age		
0-40 years	•	
41-64 years		
65-74 years	•	
75-84 years	•	
≥ 85 years		
Sex		
Female		
Male		
Race ²		
American Indian or Alaska Native		
Asian		
Black or African American		
Multi-racial		
Native Hawaiian or Other Pacific Islander		
Unknown		
White		
Hispanic origin		
Yes		
No		
Unknown		
Year		
2022		
2023		
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³		
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0		
0		
1-2		
3-4		
5+		
Combined comorbidity score ⁴		
Combined comorbidity score categories ⁴		
<0		
0		
1-2		
3-4		
5+		
	· · · · · · · · · · · · · · · · · · ·	=

cder_mpl1p_wp077 Page 124 of 1023



Table 1aj. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse		•
Obesity		
Tobacco use		
Arrhythmia		
Cerebrovascular disease/stroke/transient ischemic attack		
Chronic kidney disease		
Chronic obstructive pulmonary disease		
Congenital heart disease		
Heart failure		
Hyperlipidemia		
Hypertensive disease		
Thyroid disease		
Ischemic heart disease/coronary artery disease/myocardial infarction		
Left ventricular hypertrophy		
Peripheral artery disease		
Valvular/mitral valve disease		
Diseases of veins and lymphatics, and other diseases of circulatory system		
Obstructive sleep apnea		
Hypertrophic cardiomyopathy		
Other cardiac disease		
Tachyarrhythmia day 0		
Hospitalized tachyarrhythmia day 0		
History of serious hypoglycemia (ED and/or IP)		
Medical Product Use		
Alpha-glucosidase inhibitors		•
Amylin analogs (pramlintide)		
DPP-4 inhibitors		
Incretin mimetics (albiglutide, dulaglutide, etc.)		
Meglitinides		
Insulin		
Biguanides (metformin, phenformin, etc.)		
SGLT2 inhibitors		
Sulfonylurea		
Thiazolidinedione		
No baseline use of any of the above antidiabetic drugs		
Other antidiabetics		
Sodium channel blockers		
Beta blockers		
Potassium channel blockers/openers		
Non-dihydropyridine calcium channel blockers		
Digoxin		
Other antiarrhythmic agents		

cder_mpl1p_wp077 Page 125 of 1023



Table 1aj. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)		
Angiotensin-converting-enzyme (ACE) inhibitor		
Angiotensin ii receptor blockers (ARBs)		•
Dihydropyridines		
Diuretics		
Other antihypertensives		
Antihypertensives (any of the above antihypertensives)		
Oral anticoagulants		
Vitamin K antagonists		•
Other cardiac medications not mentioned above		•
Other cardiac medications (any of the other cardiac medications)		•
Lipid lowering therapy		•
Baseline known risk of prolonged QT and torsades de pointes		•
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and		
torsades de pointes		
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters		
Mean number of emergency room encounters		
Mean number of inpatient hospital encounters		
Mean number of non-acute institutional encounters		•
Mean number of other ambulatory encounters		•
Mean number of filled prescriptions		•
Mean number of generics dispensed		
Mean number of unique drug classes dispensed		·

¹Value represents standard deviation where no % follows the value.

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

N/A: Not applicable

cder_mpl1p_wp077 Page 126 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051



Table 1ak. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	****	N/A
Demographic Characteristics		
Age (years)	51.1	10.1
Age		
0-40 years	****	****
41-64 years	****	****
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	****	****
Male	****	****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	****	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	****	****
Unknown	****	****
'ear		
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.2	0.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	****
1-2	****	****
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	0.8	1.5
Combined comorbidity score categories ⁴		
<0	****	****
0	****	****
1-2	****	****
3-4	****	****
5+	0	0.0%

cder_mpl1p_wp077 Page 127 of 1023



Table 1ak. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
alcohol use or abuse	0	0.0%
Desity	****	100.0%
obacco use	0	0.0%
rrhythmia	0	0.0%
erebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
leart failure	0	0.0%
lyperlipidemia	****	****
ypertensive disease	****	****
hyroid disease	****	****
schemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
eft ventricular hypertrophy	0	0.0%
eripheral artery disease	0	0.0%
alvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	****	****
lypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	****	****
achyarrhythmia day 0	0	0.0%
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	0	0.0%
Nedical Product Use		
lpha-glucosidase inhibitors	0	0.0%
tmylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	0	0.0%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
/leglitinides	0	0.0%
nsulin	0	0.0%
iguanides (metformin, phenformin, etc.)	****	100.0%
GLT2 inhibitors	0	0.0%
ulfonylurea	0	0.0%
hiazolidinedione	0	0.0%
o baseline use of any of the above antidiabetic drugs	0	0.0%
ther antidiabetics	0	0.0%
odium channel blockers	0	0.0%
eta blockers	****	****
otassium channel blockers/openers	0	0.0%
on-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
.0	•	3.070

cder_mpl1p_wp077 Page 128 of 1023



Table 1ak. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	****	****
Angiotensin-converting-enzyme (ACE) inhibitor	0	0.0%
Angiotensin ii receptor blockers (ARBs)	****	****
Dihydropyridines	0	0.0%
Diuretics	****	****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	****	****
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	****	****
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.8	23.8
Mean number of emergency room encounters	0.9	1.5
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.4	8.0
Mean number of filled prescriptions	29.4	20.9
Mean number of generics dispensed	10.1	5.6
Mean number of unique drug classes dispensed	9.4	4.7

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 129 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1al. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)		
Age		
0-40 years		
41-64 years		
65-74 years	•	
75-84 years	·	
≥ 85 years		
Sex		
Female		
Male		
Race ²		
American Indian or Alaska Native		
Asian	·	
Black or African American		
Multi-racial		
Native Hawaiian or Other Pacific Islander		
Unknown		
White	•	
Hispanic origin	•	·
Yes		
No	•	·
Unknown	•	•
Year	•	•
2022		
2022	•	•
Health Characteristics	•	·
Adapted Diabetes Complications Severity Index (aDCSI) ³		
Adapted Diabetes Complications Severity Index (aDCSI) categories ³	•	•
<0		
0	•	•
1-2	•	•
	•	•
3-4	•	•
5+	•	•
Combined comorbidity score ⁴	•	•
Combined comorbidity score categories ⁴		
<0	•	•
0	•	•
1-2	•	•
3-4	•	•
5+	•	•

cder_mpl1p_wp077 Page 130 of 1023



Table 1al. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Percent/Standard

Percent/St	
Patient Characteristics Number/Mean Deviati	ion ¹
Alcohol use or abuse	
Obesity	
Tobacco use	
Arrhythmia	
Cerebrovascular disease/stroke/transient ischemic attack	
Chronic kidney disease	
Chronic obstructive pulmonary disease	
Congenital heart disease	
Heart failure	
Hyperlipidemia	
Hypertensive disease	
Thyroid disease	
Ischemic heart disease/coronary artery disease/myocardial infarction	
Left ventricular hypertrophy	
Peripheral artery disease	
Valvular/mitral valve disease	
Diseases of veins and lymphatics, and other diseases of circulatory system	
Obstructive sleep apnea	
Hypertrophic cardiomyopathy	
Other cardiac disease	
Tachyarrhythmia day 0	
Hospitalized tachyarrhythmia day 0	
History of serious hypoglycemia (ED and/or IP)	
Medical Product Use	
Alpha-glucosidase inhibitors	
Amylin analogs (pramlintide)	
DPP-4 inhibitors	
Incretin mimetics (albiglutide, dulaglutide, etc.)	
Meglitinides	
Insulin	
Biguanides (metformin, phenformin, etc.)	
SGLT2 inhibitors	
Sulfonylurea	
Thiazolidinedione	
No baseline use of any of the above antidiabetic drugs	
Other antidiabetics	
Sodium channel blockers	
Beta blockers	
Potassium channel blockers/openers	
Non-dihydropyridine calcium channel blockers	
Digoxin	
Other antiarrhythmic agents	

cder_mpl1p_wp077 Page 131 of 1023



Table 1al. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)		•
Angiotensin-converting-enzyme (ACE) inhibitor		•
Angiotensin ii receptor blockers (ARBs)		
Dihydropyridines		
Diuretics		
Other antihypertensives		
Antihypertensives (any of the above antihypertensives)		
Oral anticoagulants		
Vitamin K antagonists		•
Other cardiac medications not mentioned above		
Other cardiac medications (any of the other cardiac medications)		
Lipid lowering therapy		
Baseline known risk of prolonged QT and torsades de pointes		
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and		•
torsades de pointes		•
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters		
Mean number of emergency room encounters		
Mean number of inpatient hospital encounters		
Mean number of non-acute institutional encounters		
Mean number of other ambulatory encounters		
Mean number of filled prescriptions	•	•
Mean number of generics dispensed		•
Mean number of unique drug classes dispensed		

¹Value represents standard deviation where no % follows the value.

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

N/A: Not applicable

cder_mpl1p_wp077 Page 132 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051



Table 1am. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	31	N/A
Demographic Characteristics		
Age (years)	57.2	10.6
Age		
0-40 years	****	****
41-64 years	14	45.2%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
ex		
Female	20	64.5%
Male	11	35.5%
tace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	31	100.0%
lispanic origin		
Yes	0	0.0%
No	12	38.7%
Unknown	19	61.3%
'ear		
2022	****	****
2023	****	****
lealth Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	****
1-2	****	****
3-4	****	****
5+	****	****
ombined comorbidity score ⁴	1.7	2.1
ombined comorbidity score categories ⁴		
<0	****	****
0	****	****
1-2	14	45.2%
3-4	****	****
5+	****	****

cder_mpl1p_wp077 Page 133 of 1023



Table 1am. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentiner Distributed Database from May 15, 2022 (Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	****	****
Tobacco use	****	****
Arrhythmia	11	35.5%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	****	****
Hyperlipidemia	****	****
Hypertensive disease	****	****
Thyroid disease	****	****
Ischemic heart disease/coronary artery disease/myocardial infarction	****	****
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	13	41.9%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	18	58.1%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	****	****
Biguanides (metformin, phenformin, etc.)	****	****
SGLT2 inhibitors	****	****
Sulfonylurea	****	****
Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	15	48.4%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%
onici andarmytinine agents	U	0.070

cder_mpl1p_wp077 Page 134 of 1023



Table 1am. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentinei Distributed Database from May 13, 2022 to		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	15	48.4%
Angiotensin-converting-enzyme (ACE) inhibitor	****	****
Angiotensin ii receptor blockers (ARBs)	11	35.5%
Dihydropyridines	****	****
Diuretics	16	51.6%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	****	****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	18	58.1%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	****	****
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.8	16.3
Mean number of emergency room encounters	0.9	3.0
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	3.8	5.1
Mean number of filled prescriptions	51.4	35.5
Mean number of generics dispensed	15.2	6.8
Mean number of unique drug classes dispensed	13.3	5.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 135 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1an. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	****	N/A
Demographic Characteristics		
Age (years)	47.7	6.3
Age		
0-40 years	0	0.0%
41-64 years	****	100.0%
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	****	100.0%
Male	0	0.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	****	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	****	100.0%
/ear		
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.0	1.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	****
1-2	****	****
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	1.8	2.1
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	****	****
1-2	0	0.0%
3-4	****	****
5+	0	0.0%

cder_mpl1p_wp077 Page 136 of 1023



Table 1an. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	0	0.0%
besity	****	100.0%
obacco use	****	****
Arrhythmia	0	0.0%
erebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	0	0.0%
hronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
leart failure	0	0.0%
lyperlipidemia	****	****
lypertensive disease	****	****
hyroid disease	0	0.0%
schemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
eft ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
/alvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	****	****
lypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	****	****
achyarrhythmia day 0	0	0.0%
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
nsulin	****	****
siguanides (metformin, phenformin, etc.)	****	****
GLT2 inhibitors	****	****
ulfonylurea	****	****
, hiazolidinedione	0	0.0%
Io baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	0	0.0%
Beta blockers	0	0.0%
Potassium channel blockers/openers	0	0.0%
Von-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
	5	0.070

cder_mpl1p_wp077 Page 137 of 1023



Table 1an. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Angiotensin-converting-enzyme (ACE) inhibitor	****	****
Angiotensin ii receptor blockers (ARBs)	0	0.0%
Dihydropyridines	****	****
Diuretics	****	****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	0	0.0%
/itamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
ipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	****	****
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	****	100.0%
orsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	32.5	20.1
Mean number of emergency room encounters	1.3	0.5
Mean number of inpatient hospital encounters	0.5	0.6
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.0	2.8
Mean number of filled prescriptions	26.8	17.0
Mean number of generics dispensed	11.0	6.3
Mean number of unique drug classes dispensed	9.5	4.7

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 138 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ao. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	66,978	N/A
Demographic Characteristics		
Age (years)	65.7	10.5
Age		
0-40 years	2,425	3.6%
41-64 years	23,743	35.4%
65-74 years	27,390	40.9%
75-84 years	11,847	17.7%
≥ 85 years	1,573	2.3%
Sex		
Female	34,815	52.0%
Male	32,163	48.0%
Race ²		
American Indian or Alaska Native	258	0.4%
Asian	1,202	1.8%
Black or African American	6,428	9.6%
Multi-racial	293	0.4%
Native Hawaiian or Other Pacific Islander	238	0.4%
Unknown	21,774	32.5%
White	36,775	54.9%
lispanic origin		
Yes	2,477	3.7%
No	40,947	61.1%
Unknown	23,554	35.2%
'ear		
2022	52,917	79.0%
2023	14,061	21.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	21,378	31.9%
1-2	23,333	34.8%
3-4	13,032	19.5%
5+	9,235	13.8%
Combined comorbidity score ⁴	2.7	2.8
combined comorbidity score categories ⁴		
<0	3,992	6.0%
0	12,482	18.6%
1-2	22,773	34.0%
3-4	13,084	19.5%
	14,647	21.9%

cder_mpl1p_wp077 Page 139 of 1023



Table 1ao. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics Alcohol use or abuse Obesity	Number/Mean	Deviation ¹
Obesity	1,370	2.0%
Obesity	35,956	53.7%
Tobacco use	17,593	26.3%
Arrhythmia	17,988	26.9%
Cerebrovascular disease/stroke/transient ischemic attack	9,793	14.6%
Chronic kidney disease	14,796	22.1%
Chronic obstructive pulmonary disease	8,288	12.4%
Congenital heart disease	8,288	12.4%
Heart failure	9,669	14.4%
Hyperlipidemia	56,189	83.9%
Hypertensive disease	58,287	87.0%
Thyroid disease	14,775	22.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	18,264	27.3%
Left ventricular hypertrophy	4,264	6.4%
Peripheral artery disease	4,264	6.4%
Valvular/mitral valve disease	2,932	4.4%
Diseases of veins and lymphatics, and other diseases of circulatory system	9,323	13.9%
Obstructive sleep apnea	16,638	23.80%
Hypertrophic cardiomyopathy	3,676	5.5%
Other cardiac disease	31,389	46.9%
Tachyarrhythmia day 0	1,233	1.9%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	893	1.3%
Medical Product Use		
Alpha-glucosidase inhibitors	273	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	12,181	18.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	905	1.4%
Insulin	20,294	30.3%
Biguanides (metformin, phenformin, etc.)	54,620	81.5%
SGLT2 inhibitors	19,602	29.3%
Sulfonylurea	26,616	39.7%
Thiazolidinedione	6,286	9.4%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	11	0.0%
Sodium channel blockers	369	0.6%
Beta blockers	28,774	43.0%
Potassium channel blockers/openers	1,081	1.6%
Non-dihydropyridine calcium channel blockers	95	0.1%
	606	0.9%
Digoxin	-	

Page 140 of 1023 $cder_mpl1p_wp077$



Table 1ao. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	29,096	43.4%
Angiotensin-converting-enzyme (ACE) inhibitor	27,314	40.8%
Angiotensin ii receptor blockers (ARBs)	23,305	34.8%
Dihydropyridines	18,425	27.5%
Diuretics	23,675	36.8%
Other antihypertensives	5,845	8.7%
Antihypertensives (any of the above antihypertensives)	56,405	84.2%
Oral anticoagulants	6,376	9.5%
Vitamin K antagonists	1,474	2.2%
Other cardiac medications not mentioned above	4,986	7.4%
Other cardiac medications (any of the other cardiac medications)	11,459	17.1%
Lipid lowering therapy	56,298	84.1%
Baseline known risk of prolonged QT and torsades de pointes	29,700	44.3%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	56,429	84.3%
torsades de pointes	9,950	14.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.8	19.4
Mean number of emergency room encounters	0.6	1.7
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	6.8	14.8
Mean number of filled prescriptions	47.2	37.4
Mean number of generics dispensed	12.8	6.2
Mean number of unique drug classes dispensed	11.1	5.5

¹Characteristics in blue show a standardized difference greater than 0.1.

N/A: Not applicable

cder_mpl1p_wp077 Page 141 of 1023

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁵Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051



Table 1ap. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	21,774	N/A
Demographic Characteristics		
Age (years)	58.8	11.3
Age		
0-40 years	1,577	7.2%
41-64 years	13,585	62.4%
65-74 years	4,882	22.4%
75-84 years	1,533	7.0%
≥ 85 years	197	0.9%
ex		
Female	10,589	48.6%
Male	11,185	51.4%
tace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	21,774	100.0%
White	0	0.0%
lispanic origin		
Yes	****	10.9%
No	****	0.0%
Unknown	19,400	89.1%
'ear		
2022	15,411	70.8%
2023	6,363	29.2%
lealth Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.3	1.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	10,552	48.5%
1-2	7,054	32.4%
3-4	2,659	12.2%
5+	1,509	6.9%
Combined comorbidity score ⁴	1.7	2.3
ombined comorbidity score categories ⁴		
<0	2,075	9.5%
0	5,955	27.3%
1-2	8,259	37.9%
3-4	3,115	14.3%
5+	2,370	10.9%

cder_mpl1p_wp077 Page 142 of 1023



Table 1ap. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	331	1.5%
Dbesity	11,145	51.2%
obacco use	3,994	18.3%
Arrhythmia	3,977	18.3%
Cerebrovascular disease/stroke/transient ischemic attack	1,788	8.2%
Chronic kidney disease	2,755	12.7%
Chronic obstructive pulmonary disease	1,393	6.4%
Congenital heart disease	1,393	6.4%
Heart failure	1,697	7.8%
Hyperlipidemia	16,962	77.9%
Hypertensive disease	17,377	79.8%
Thyroid disease	3,610	16.6%
schemic heart disease/coronary artery disease/myocardial infarction	3,653	16.8%
eft ventricular hypertrophy	886	4.1%
Peripheral artery disease	886	4.1%
/alvular/mitral valve disease	528	2.4%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,952	9.0%
Dbstructive sleep apnea	4,719	21.7%
lypertrophic cardiomyopathy	711	3.3%
Other cardiac disease	7,752	35.6%
achyarrhythmia day 0	234	1.1%
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	157	0.7%
Medical Product Use		
Alpha-glucosidase inhibitors	71	0.3%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	3,737	17.2%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	188	0.9%
nsulin	5,567	25.6%
Biguanides (metformin, phenformin, etc.)	18,674	85.8%
GLT2 inhibitors	6,491	29.8%
ulfonylurea	7,649	35.1%
hiazolidinedione	1,749	8.0%
Io baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	0.0%
odium channel blockers	87	0.4%
Beta blockers	6,978	32.0%
Potassium channel blockers/openers	196	0.9%
Non-dihydropyridine calcium channel blockers	23	0.1%
Digoxin	119	0.5%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 143 of 1023



Table 1ap. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	7,050	32.4%
Angiotensin-converting-enzyme (ACE) inhibitor	8,887	40.8%
Angiotensin ii receptor blockers (ARBs)	6,743	31.0%
Dihydropyridines	4,841	22.2%
Diuretics	6,071	27.9%
Other antihypertensives	1,321	6.1%
Antihypertensives (any of the above antihypertensives)	17,073	78.4%
Oral anticoagulants	1,237	5.7%
Vitamin K antagonists	221	1.0%
Other cardiac medications not mentioned above	997	4.6%
Other cardiac medications (any of the other cardiac medications)	2,250	10.3%
Lipid lowering therapy	17,082	78.5%
Baseline known risk of prolonged QT and torsades de pointes	8,626	39.6%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	16,829	77.3%
torsades de pointes	2,569	11.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.0	17.6
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.9	9.4
Mean number of filled prescriptions	39.0	31.1
Mean number of generics dispensed	11.3	6.1
Mean number of unique drug classes dispensed	9.7	5.3

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 144 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1aq. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	258	N/A
Demographic Characteristics		
Age (years)	64.8	11.8
Age		
0-40 years	****	****
41-64 years	100	38.8%
65-74 years	95	36.8%
75-84 years	43	16.7%
≥ 85 years	****	****
ex		
Female	147	57.0%
Male	111	43.0%
Race ²		
American Indian or Alaska Native	258	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	0	0.0%
No	230	93.0%
Unknown	18	7.0%
'ear		
2022	234	90.7%
2023	23	9.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	72	27.9%
1-2	96	37.2%
3-4	49	19.0%
5+	41	15.9%
Combined comorbidity score ⁴	2.6	2.5
Combined comorbidity score categories ⁴	2.0	2.5
<0	13	5.0%
0	40	15.5%
1-2	97	37.6%
3-4	59	22.9%
5+	49	19.0%

cder_mpl1p_wp077 Page 145 of 1023



Table 1aq. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	13	5.0%
Obesity	116	45.0%
Tobacco use	85	32.9%
Arrhythmia	59	22.9%
Cerebrovascular disease/stroke/transient ischemic attack	43	16.7%
Chronic kidney disease	53	20.5%
Chronic obstructive pulmonary disease	29	11.2%
Congenital heart disease	29	11.2%
Heart failure	35	13.6%
Hyperlipidemia	201	77.9%
Hypertensive disease	225	87.2%
Thyroid disease	55	21.3%
Ischemic heart disease/coronary artery disease/myocardial infarction	67	26.0%
Left ventricular hypertrophy	15	5.8%
Peripheral artery disease	15	5.8%
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	35	13.6%
Obstructive sleep apnea	57	22.1%
Hypertrophic cardiomyopathy	14	5.4%
Other cardiac disease	107	41.5%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	55	21.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
Insulin	117	45.3%
Biguanides (metformin, phenformin, etc.)	210	81.4%
SGLT2 inhibitors	66	25.6%
Sulfonylurea	96	37.2%
Thiazolidinedione	26	10.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	92	35.7%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	****	****
-	0	0.0%
Invular/mitral valve disease seases of veins and lymphatics, and other diseases of circulatory system structive sleep apnea pertrophic cardiomyopathy her cardiac disease chyarrhythmia day 0 spitalized tachyarrhythmia day 0 story of serious hypoglycemia (ED and/or IP) edical Product Use oha-glucosidase inhibitors nylin analogs (pramlintide) IP-4 inhibitors cretin mimetics (albiglutide, dulaglutide, etc.) eglitinides sulin guanides (metformin, phenformin, etc.) LT2 inhibitors Ifonylurea iazolidinedione o baseline use of any of the above antidiabetic drugs her antidiabetics dium channel blockers tassium channel blockers/openers on-dihydropyridine calcium channel blockers	***** 35 57 14 107 ***** 0 ***** 0 0 55 0 ***** 117 210 66 96 26 0 0 0 92 ***** 0 *****	***** 13.6% 22.1% 5.4% 41.5% ***** 0.0% ***** 0.0% 21.3% 0.0% 21.3% 0.0% ***** 45.3% 81.4% 25.6% 37.2% 10.1% 0.0% 0.0% 0.0% 35.7% ***** 0.0% *****

cder_mpl1p_wp077 Page 146 of 1023



Table 1aq. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	93	36.0%
Angiotensin-converting-enzyme (ACE) inhibitor	135	52.3%
Angiotensin ii receptor blockers (ARBs)	73	28.3%
Dihydropyridines	64	23.80%
Diuretics	87	33.7%
Other antihypertensives	27	10.5%
Antihypertensives (any of the above antihypertensives)	221	85.7%
Oral anticoagulants	18	7.0%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	20	7.8%
Other cardiac medications (any of the other cardiac medications)	35	13.6%
Lipid lowering therapy	215	83.3%
Baseline known risk of prolonged QT and torsades de pointes	119	46.1%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	220	85.3%
torsades de pointes	42	16.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.8	18.8
Mean number of emergency room encounters	0.8	1.7
Mean number of inpatient hospital encounters	0.2	0.8
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	10.1	31.0
Mean number of filled prescriptions	62.9	49.5
Mean number of generics dispensed	13.4	6.6
Mean number of unique drug classes dispensed	11.6	5.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 147 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ar. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	1,202	N/A
Demographic Characteristics		
sge (years)	69.3	10.7
Age		
0-40 years	46	3.8%
41-64 years	221	18.4%
65-74 years	570	47.4%
75-84 years	297	23.70%
≥ 85 years	68	5.7%
ex		
Female	630	52.4%
Male	572	47.6%
tace ²		
American Indian or Alaska Native	0	0.0%
Asian	1,202	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	0	0.0%
No	1,046	87.0%
Unknown	156	13.0%
ear		
2022	1,045	86.9%
2023	157	13.1%
lealth Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	2.0
dapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	312	26.0%
1-2	441	36.7%
3-4	275	22.9%
5+	174	14.5%
ombined comorbidity score ⁴	2.9	2.8
ombined comorbidity score categories ⁴		
<0	29	2.4%
0	210	17.5%
1-2	414	34.4%
3-4	256	21.3%
5+	293	23.40%

cder_mpl1p_wp077 Page 148 of 1023



Table 1ar. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentiner Distributed Database from May 15, 2022 t	2 7 3 110 20, 2020	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	18	1.5%
Obesity	306	25.5%
Tobacco use	177	14.7%
Arrhythmia	312	26.0%
Cerebrovascular disease/stroke/transient ischemic attack	203	16.9%
Chronic kidney disease	371	30.9%
Chronic obstructive pulmonary disease	97	8.1%
Congenital heart disease	97	8.1%
Heart failure	179	14.9%
Hyperlipidemia	1,047	87.1%
Hypertensive disease	1,050	87.4%
Thyroid disease	271	22.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	347	28.9%
Left ventricular hypertrophy	63	5.2%
Peripheral artery disease	63	5.2%
Valvular/mitral valve disease	50	4.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	144	12.0%
Obstructive sleep apnea	148	12.3%
Hypertrophic cardiomyopathy	61	5.1%
Other cardiac disease	497	41.3%
Tachyarrhythmia day 0	20	1.7%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	20	1.7%
Medical Product Use		
Alpha-glucosidase inhibitors	31	2.6%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	359	29.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	43	3.6%
Insulin	437	36.4%
Biguanides (metformin, phenformin, etc.)	982	81.7%
SGLT2 inhibitors	475	39.5%
Sulfonylurea	549	45.7%
Thiazolidinedione	137	11.4%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	****
Beta blockers	531	44.2%
Potassium channel blockers/openers	18	1.5%
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 149 of 1023



Table 1ar. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	·	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	535	44.5%
Angiotensin-converting-enzyme (ACE) inhibitor	359	29.9%
Angiotensin ii receptor blockers (ARBs)	596	49.6%
Dihydropyridines	421	35.0%
Diuretics	346	28.8%
Other antihypertensives	131	10.9%
Antihypertensives (any of the above antihypertensives)	1,030	85.7%
Oral anticoagulants	97	8.1%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	105	8.7%
Other cardiac medications (any of the other cardiac medications)	193	16.1%
Lipid lowering therapy	1,095	91.1%
Baseline known risk of prolonged QT and torsades de pointes	430	35.8%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	933	77.6%
torsades de pointes	141	11.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.9	26.0
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	7.2	15.4
Mean number of filled prescriptions	45.4	35.2
Mean number of generics dispensed	12.4	6.0
Mean number of unique drug classes dispensed	10.5	5.2

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 150 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1as. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	6,428	N/A
Demographic Characteristics		
Age (years)	66.1	10.8
Age		
0-40 years	218	3.4%
41-64 years	2,117	32.9%
65-74 years	2,953	45.9%
75-84 years	1,022	15.9%
≥ 85 years	118	1.8%
Sex		
Female	4,237	65.9%
Male	2,191	34.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	6,428	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	5,794	90.1%
Unknown	634	9.9%
'ear		
2022	4,894	76.1%
2023	1,534	23.9%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.6	2.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	1,346	20.9%
1-2	2,277	35.4%
3-4	1,531	23.8%
5+	1,274	19.8%
Combined comorbidity score ⁴	3.3	3.0
Combined comorbidity score categories ⁴		
<0	228	3.5%
0	859	13.4%
1-2	2,002	31.1%
3-4	1,438	22.4%
5+	1,901	29.6%

cder_mpl1p_wp077 Page 151 of 1023



Table 1as. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standa
Patient Characteristics	Number/Mean	Deviation ¹
lcohol use or abuse	152	2.4%
besity	3,922	61.0%
obacco use	1,926	30.0%
rrhythmia	1,771	27.6%
erebrovascular disease/stroke/transient ischemic attack	1,207	18.8%
Chronic kidney disease	2,014	31.3%
thronic obstructive pulmonary disease	888	13.8%
ongenital heart disease	888	13.8%
leart failure	1,303	20.3%
yperlipidemia	5,482	85.3%
ypertensive disease	6,054	94.2%
hyroid disease	992	15.4%
chemic heart disease/coronary artery disease/myocardial infarction	1,691	26.3%
eft ventricular hypertrophy	566	8.8%
eripheral artery disease	566	8.8%
alvular/mitral valve disease	272	4.2%
iseases of veins and lymphatics, and other diseases of circulatory system	1,028	16.0%
bstructive sleep apnea	1,496	23.3%
ypertrophic cardiomyopathy	463	7.2%
ther cardiac disease	3,052	47.5%
achyarrhythmia day 0	81	1.3%
ospitalized tachyarrhythmia day 0	0	0.0%
istory of serious hypoglycemia (ED and/or IP)	163	2.5%
ledical Product Use		
lpha-glucosidase inhibitors	23	0.4%
mylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	1,223	19.0%
cretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
leglitinides	95	1.5%
sulin	2,549	39.7%
guanides (metformin, phenformin, etc.)	4,822	75.0%
GLT2 inhibitors	1,813	28.2%
ulfonylurea	2,505	39.0%
niazolidinedione	488	7.6%
o baseline use of any of the above antidiabetic drugs	0	0.0%
ther antidiabetics	0	0.0%
odium channel blockers	21	0.3%
eta blockers	3,075	47.8%
otassium channel blockers/openers	72	1.1%
on-dihydropyridine calcium channel blockers	****	****
igoxin	33	0.5%
ther antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 152 of 1023



Table 1as. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	3,097	48.2%
Angiotensin-converting-enzyme (ACE) inhibitor	2,225	34.6%
Angiotensin ii receptor blockers (ARBs)	2,839	44.2%
Dihydropyridines	3,069	47.7%
Diuretics	3,145	48.9%
Other antihypertensives	1,030	16.0%
Antihypertensives (any of the above antihypertensives)	5,919	92.1%
Oral anticoagulants	576	9.0%
Vitamin K antagonists	118	1.8%
Other cardiac medications not mentioned above	517	8.0%
Other cardiac medications (any of the other cardiac medications)	1,073	16.7%
Lipid lowering therapy	5,508	85.7%
Baseline known risk of prolonged QT and torsades de pointes	2,734	42.5%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	5,684	88.4%
torsades de pointes	826	12.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.6	21.5
Mean number of emergency room encounters	1.0	2.2
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	8.2	18.6
Mean number of filled prescriptions	50.4	38.9
Mean number of generics dispensed	13.7	6.4
Mean number of unique drug classes dispensed	12.0	5.5

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 153 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1at. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	238	N/A
Demographic Characteristics		
Age (years)	71.0	7.3
Age		
0-40 years	****	****
41-64 years	39	15.7%
65-74 years	136	54.8%
75-84 years	62	25.0%
≥ 85 years	****	****
Sex		
Female	116	46.8%
Male	132	53.2%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	238	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	****	****
No	****	****
Unknown	****	****
'ear		
2022	145	58.5%
2023	103	41.5%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	59	23.8%
1-2	99	39.9%
3-4	59	23.8%
5+	31	12.5%
Combined comorbidity score ⁴	2.7	2.7
Combined comorbidity score categories ⁴		
<0	13	5.2%
0	40	16.1%
1-2	92	37.1%
3-4	51	20.6%
5+	52	21.0%

cder_mpl1p_wp077 Page 154 of 1023



Table 1at. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

islander in the Kapid Sentiner Distributed Database and Sentiner Distributed		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	108	43.5%
Tobacco use	59	23.8%
Arrhythmia	48	19.4%
Cerebrovascular disease/stroke/transient ischemic attack	39	15.7%
Chronic kidney disease	85	34.3%
Chronic obstructive pulmonary disease	23	9.3%
Congenital heart disease	23	9.3%
Heart failure	33	13.3%
Hyperlipidemia	217	87.5%
Hypertensive disease	221	89.1%
Thyroid disease	34	13.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	64	25.8%
Left ventricular hypertrophy	11	4.4%
Peripheral artery disease	11	4.4%
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	28	11.3%
Obstructive sleep apnea	36	14.5%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	91	36.7%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	46	18.5%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
Insulin	82	33.1%
Biguanides (metformin, phenformin, etc.)	204	82.3%
SGLT2 inhibitors	71	28.6%
Sulfonylurea	125	50.4%
Thiazolidinedione	32	12.9%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	103	41.5%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 155 of 1023



Table 1at. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	103	41.5%
Angiotensin-converting-enzyme (ACE) inhibitor	114	46.0%
Angiotensin ii receptor blockers (ARBs)	97	39.1%
Dihydropyridines	84	33.9%
Diuretics	74	29.8%
Other antihypertensives	23	9.7%
Antihypertensives (any of the above antihypertensives)	220	88.7%
Oral anticoagulants	18	7.3%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	18	7.3%
Other cardiac medications (any of the other cardiac medications)	35	14.1%
Lipid lowering therapy	223	89.9%
Baseline known risk of prolonged QT and torsades de pointes	89	35.9%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	200	80.6%
torsades de pointes	13	5.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.0	17.0
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	2.3	5.9
Mean number of filled prescriptions	35.9	20.3
Mean number of generics dispensed	12.4	5.3
Mean number of unique drug classes dispensed	10.4	4.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 156 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1au. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
atient Characteristics	Number/Mean	Deviation ¹
Inique patients	36,775	N/A
Demographic Characteristics		
ge (years)	69.6	9.6
ge		
0-40 years	536	1.5%
41-64 years	7,457	20.3%
65-74 years	18,730	50.9%
75-84 years	8,880	23.10%
≥ 85 years	1,172	3.2%
ex		
Female	18,955	51.5%
Male	17,820	48.5%
cace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	36,775	100.0%
ispanic origin		
Yes	****	0.0%
No	33,614	91.4%
Unknown	****	8.6%
ear		
2022	30,998	84.3%
2023	5,777	15.7%
lealth Characteristics	,	
dapted Diabetes Complications Severity Index (aDCSI) ³	2.4	2.2
dapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	8,863	23.10%
1-2	13,277	36.1%
3-4	8,437	22.9%
5+	6,198	16.9%
ombined comorbidity score ⁴	3.1	3.0
ombined comorbidity score categories ⁴		
<0	1,613	4.4%
0	5,293	14.4%
-	11,771	32.0%
1-2	/ /	
1-2 3-4	8,131	22.1%

cder_mpl1p_wp077 Page 157 of 1023



Table 1au. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	849	2.3%
Obesity	20,204	54.9%
Tobacco use	11,323	30.8%
Arrhythmia	11,776	32.0%
Cerebrovascular disease/stroke/transient ischemic attack	6,500	17.7%
Chronic kidney disease	9,494	25.8%
Chronic obstructive pulmonary disease	5,854	15.9%
Congenital heart disease	5,854	15.9%
Heart failure	6,412	17.4%
Hyperlipidemia	32,059	87.2%
Hypertensive disease	33,158	90.2%
Thyroid disease	9,774	26.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	12,417	33.8%
Left ventricular hypertrophy	2,714	7.4%
Peripheral artery disease	2,714	7.4%
Valvular/mitral valve disease	2,063	5.6%
Diseases of veins and lymphatics, and other diseases of circulatory system	6,119	16.6%
Obstructive sleep apnea	10,119	27.5%
Hypertrophic cardiomyopathy	2,412	6.6%
Other cardiac disease	19,808	53.9%
Tachyarrhythmia day 0	903	2.5%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	544	1.5%
Medical Product Use		
Alpha-glucosidase inhibitors	144	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	6,718	18.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	573	1.6%
Insulin	11,478	31.2%
Biguanides (metformin, phenformin, etc.)	29,464	80.1%
SGLT2 inhibitors	10,598	28.8%
Sulfonylurea	15,591	42.4%
Thiazolidinedione	3,831	10.4%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	0.0%
Sodium channel blockers	256	0.7%
Beta blockers	17,931	48.8%
Potassium channel blockers/openers	785	2.1%
Non-dihydropyridine calcium channel blockers	63	0.2%
Digoxin		
Digoxiii	438	1.2%

cder_mpl1p_wp077 Page 158 of 1023



Table 1au. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	18,153	49.4%
Angiotensin-converting-enzyme (ACE) inhibitor	15,495	42.1%
Angiotensin ii receptor blockers (ARBs)	12,862	35.0%
Dihydropyridines	9,899	26.9%
Diuretics	14,887	40.5%
Other antihypertensives	3,296	9.0%
Antihypertensives (any of the above antihypertensives)	31,739	86.3%
Oral anticoagulants	4,418	12.0%
Vitamin K antagonists	1,119	3.0%
Other cardiac medications not mentioned above	3,318	9.0%
Other cardiac medications (any of the other cardiac medications)	7,848	21.3%
Lipid lowering therapy	31,958	86.9%
Baseline known risk of prolonged QT and torsades de pointes	17,592	47.8%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	32,360	88.0%
torsades de pointes	6,330	17.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.5	19.8
Mean number of emergency room encounters	0.7	1.8
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	7.8	16.5
Mean number of filled prescriptions	51.5	40.4
Mean number of generics dispensed	13.5	6.3
Mean number of unique drug classes dispensed	11.8	5.5

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 159 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1av. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	293	N/A
Demographic Characteristics		
sge (years)	53.7	10.8
Age		
0-40 years	35	11.9%
41-64 years	223	76.5%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
ex		
Female	141	48.1%
Male	152	51.9%
ace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	293	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
ispanic origin		
Yes	95	32.4%
No	12	4.1%
Unknown	186	63.5%
ear		
2022	190	64.8%
2023	103	35.2%
lealth Characteristics		
dapted Diabetes Complications Severity Index (aDCSI) ³	0.8	1.3
dapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	174	59.4%
1-2	89	30.4%
3-4	****	****
5+	****	****
ombined comorbidity score ⁴	1.3	2.0
ombined comorbidity score categories ⁴	1.5	2.0
<0	21	7.2%
0	85	7.2% 29.0%
1-2	138	47.1%
3-4	34	11.6%
5+	15	5.1%

cder_mpl1p_wp077 Page 160 of 1023



Table 1av. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	155	52.9%
Tobacco use	28	9.6%
Arrhythmia	45	15.4%
Cerebrovascular disease/stroke/transient ischemic attack	13	4.4%
Chronic kidney disease	23	8.2%
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	****	****
Hyperlipidemia	221	75.4%
Hypertensive disease	202	68.9%
Thyroid disease	39	13.3%
schemic heart disease/coronary artery disease/myocardial infarction	25	8.5%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	17	5.8%
Obstructive sleep apnea	63	21.5%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	82	28.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	43	14.7%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
nsulin	64	21.8%
Biguanides (metformin, phenformin, etc.)	264	90.1%
SGLT2 inhibitors	88	30.0%
Sulfonylurea	101	34.5%
Thiazolidinedione	23	7.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	64	21.8%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 161 of 1023



Table 1av. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	·	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	65	22.2%
Angiotensin-converting-enzyme (ACE) inhibitor	99	33.8%
Angiotensin ii receptor blockers (ARBs)	95	32.4%
Dihydropyridines	47	16.0%
Diuretics	65	22.2%
Other antihypertensives	16	5.5%
Antihypertensives (any of the above antihypertensives)	203	69.3%
Oral anticoagulants	12	4.1%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	11	3.8%
Other cardiac medications (any of the other cardiac medications)	25	8.5%
Lipid lowering therapy	217	74.1%
Baseline known risk of prolonged QT and torsades de pointes	110	37.5%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	203	69.3%
torsades de pointes	29	9.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.2	14.8
Mean number of emergency room encounters	0.5	2.8
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.7	7.6
Mean number of filled prescriptions	32.8	27.9
Mean number of generics dispensed	9.7	5.7
Mean number of unique drug classes dispensed	8.4	4.9

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 162 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1aw. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	5,354	N/A
Demographic Characteristics		
Age (years)	63.6	11.4
Age		
0-40 years	308	5.8%
41-64 years	2,151	40.2%
65-74 years	2,042	38.1%
75-84 years	754	14.1%
≥ 85 years	99	1.8%
Sex		
Female	3,117	58.2%
Male	2,237	41.8%
Race ²		
American Indian or Alaska Native	59	1.1%
Asian	92	1.7%
Black or African American	556	10.4%
Multi-racial	67	1.3%
Native Hawaiian or Other Pacific Islander	14	0.3%
Unknown	1,435	26.8%
White	3,131	58.5%
Hispanic origin	·	
Yes	223	4.2%
No	3,491	65.2%
Unknown	1,640	30.6%
/ear	·	
2022	4,105	76.7%
2023	1,239	23.3%
Health Characteristics	,	
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	1,647	30.8%
1-2	1,892	35.3%
3-4	1,075	20.1%
5+	740	13.8%
Combined comorbidity score ⁴	2.8	2.8
Combined comorbidity score categories ⁴	-1-	
<0	231	4.5%
0	900	16.8%
1-2	1,825	34.1%
3-4	1,181	22.1%
	1,207	22.5%

cder_mpl1p_wp077 Page 163 of 1023



Table 1aw. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	145	2.7%
Dbesity	3,218	60.1%
obacco use	1,538	28.7%
nrhythmia	1,442	26.9%
erebrovascular disease/stroke/transient ischemic attack	695	13.0%
Chronic kidney disease	1,196	22.3%
hronic obstructive pulmonary disease	714	13.3%
Congenital heart disease	714	13.3%
leart failure	843	15.7%
lyperlipidemia	4,199	78.4%
lypertensive disease	4,519	84.4%
hyroid disease	1,164	21.7%
schemic heart disease/coronary artery disease/myocardial infarction	1,402	26.2%
eft ventricular hypertrophy	354	6.6%
eripheral artery disease	354	6.6%
alvular/mitral valve disease	216	4.0%
piseases of veins and lymphatics, and other diseases of circulatory system	766	14.3%
bstructive sleep apnea	1,522	28.4%
lypertrophic cardiomyopathy	285	5.3%
Other cardiac disease	2,610	48.7%
achyarrhythmia day 0	65	1.2%
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	89	1.7%
Nedical Product Use		
lpha-glucosidase inhibitors	25	0.5%
Amylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	714	13.3%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	69	1.3%
nsulin	2,046	38.2%
iguanides (metformin, phenformin, etc.)	4,363	81.5%
GLT2 inhibitors	1,415	26.4%
ulfonylurea	1,817	33.9%
hiazolidinedione	447	8.3%
lo baseline use of any of the above antidiabetic drugs	0	0.0%
)ther antidiabetics	****	****
odium channel blockers	41	0.8%
seta blockers	2,311	43.2%
otassium channel blockers/openers	79	1.5%
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	50	0.9%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 164 of 1023



Table 1aw. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	2,339	43.7%
Angiotensin-converting-enzyme (ACE) inhibitor	2,168	40.5%
Angiotensin ii receptor blockers (ARBs)	1,827	34.1%
Dihydropyridines	1,457	27.2%
Diuretics	2,167	40.5%
Other antihypertensives	498	9.3%
Antihypertensives (any of the above antihypertensives)	4,490	83.9%
Oral anticoagulants	464	8.7%
Vitamin K antagonists	155	2.9%
Other cardiac medications not mentioned above	439	8.2%
Other cardiac medications (any of the other cardiac medications)	946	17.7%
Lipid lowering therapy	4,394	82.1%
Baseline known risk of prolonged QT and torsades de pointes	2,479	46.3%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	4,646	86.8%
torsades de pointes	815	15.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.2	22.5
Mean number of emergency room encounters	0.8	2.4
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	8.5	18.2
Mean number of filled prescriptions	50.9	41.1
Mean number of generics dispensed	13.5	6.6
Mean number of unique drug classes dispensed	11.9	5.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 165 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ax. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	1,435	N/A
Demographic Characteristics		
sge (years)	58.1	12.8
age		
0-40 years	140	9.8%
41-64 years	848	59.1%
65-74 years	337	23.5%
75-84 years	93	6.5%
≥ 85 years	17	1.2%
ex		
Female	853	59.4%
Male	582	40.6%
tace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	1,435	100.0%
White	0	0.0%
ispanic origin		
Yes	193	13.4%
No	0	0.0%
Unknown	1,232	86.6%
ear	,	
2022	1,026	71.5%
2023	409	28.5%
lealth Characteristics		20.070
dapted Diabetes Complications Severity Index (aDCSI) ³	1.4	1.8
dapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	670	46.7%
1-2	463	32.3%
3-4	185	12.9%
5+	117	8.2%
ombined comorbidity score ⁴	1.9	2.4
ombined comorbidity score categories ⁴	1.5	۷.٦
<0	109	7.6%
0	341	23.8%
1-2	560	39.0%
3-4	255	17.8%
5+	170	11.8%

cder_mpl1p_wp077 Page 166 of 1023



Table 1ax. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	22	1.5%
Desity	851	59.3%
obacco use	293	20.4%
ırrhythmia	271	18.9%
erebrovascular disease/stroke/transient ischemic attack	116	8.1%
hronic kidney disease	196	13.7%
hronic obstructive pulmonary disease	111	7.7%
Congenital heart disease	111	7.7%
leart failure	125	8.7%
lyperlipidemia	1,037	72.3%
lypertensive disease	1,111	77.4%
hyroid disease	256	17.8%
schemic heart disease/coronary artery disease/myocardial infarction	232	16.9%
eft ventricular hypertrophy	57	4.0%
Peripheral artery disease	57	4.0%
'alvular/mitral valve disease	33	2.3%
Diseases of veins and lymphatics, and other diseases of circulatory system	122	8.5%
bstructive sleep apnea	336	23.4%
ypertrophic cardiomyopathy	60	4.2%
other cardiac disease	523	36.4%
achyarrhythmia day 0	11	0.8%
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	****	****
Nedical Product Use		
lpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	179	12.5%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	16	1.1%
nsulin	467	32.5%
iguanides (metformin, phenformin, etc.)	1,216	84.7%
GLT2 inhibitors	390	27.2%
ulfonylurea	436	30.4%
hiazolidinedione	103	7.2%
lo baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	****	****
seta blockers	479	33.4%
Potassium channel blockers/openers	13	0.9%
Jon-dihydropyridine calcium channel blockers	****	****
Digoxin	****	****
	Ω	O 0%
ther antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 167 of 1023



Table 1ax. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	·	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	485	33.8%
Angiotensin-converting-enzyme (ACE) inhibitor	566	39.4%
Angiotensin ii receptor blockers (ARBs)	459	32.0%
Dihydropyridines	309	21.5%
Diuretics	457	31.8%
Other antihypertensives	91	6.3%
Antihypertensives (any of the above antihypertensives)	1,123	78.3%
Oral anticoagulants	78	5.4%
Vitamin K antagonists	19	1.3%
Other cardiac medications not mentioned above	76	5.3%
Other cardiac medications (any of the other cardiac medications)	162	11.3%
Lipid lowering therapy	1,091	76.0%
Baseline known risk of prolonged QT and torsades de pointes	631	44.0%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	1,165	81.2%
torsades de pointes	196	13.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.2	23.3
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.6	8.8
Mean number of filled prescriptions	42.3	35.4
Mean number of generics dispensed	12.2	6.5
Mean number of unique drug classes dispensed	10.7	5.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 168 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ay. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	59	N/A
Demographic Characteristics		
Age (years)	62.7	10.5
Age		
0-40 years	****	****
41-64 years	27	45.8%
65-74 years	20	33.9%
75-84 years	****	****
≥ 85 years	0	0.0%
Sex		
Female	31	52.5%
Male	28	47.5%
Race ²		
American Indian or Alaska Native	59	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	****	****
No	****	****
Unknown	****	****
/ear		
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.3	1.6
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	25	42.4%
1-2	****	****
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	1.9	2.2
Combined comorbidity score categories ⁴		
<0	****	****
0	12	20.3%
1-2	23	40.7%
3-4	****	****
~ ·		****

cder_mpl1p_wp077 Page 169 of 1023



Table 1ay. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics Alcohol use or abuse Obesity	Number/Mean	Deviation ¹
	and the second second	
Dbesity	****	****
	26	44.1%
obacco use	18	30.5%
Arrhythmia	****	****
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
leart failure	****	****
Hyperlipidemia	38	64.4%
lypertensive disease	44	74.6%
hyroid disease	****	****
schemic heart disease/coronary artery disease/myocardial infarction	****	****
eft ventricular hypertrophy	****	****
Peripheral artery disease	****	****
/alvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Dbstructive sleep apnea	****	****
lypertrophic cardiomyopathy	****	****
Other cardiac disease	16	27.1%
achyarrhythmia day 0	0	0.0%
Jospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	****
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
nsulin	28	47.5%
Biguanides (metformin, phenformin, etc.)	48	81.4%
GCLT2 inhibitors	17	28.8%
iulfonylurea	13	22.0%
Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	0	0.0%
Beta blockers	21	35.6%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
	0	0.0%
Digoxin	U	0.070

cder_mpl1p_wp077 Page 170 of 1023



Table 1ay. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

the Rapid Sentinei Distributed Database and Sentinei Distributed Database ind	., .,	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	21	35.6%
Angiotensin-converting-enzyme (ACE) inhibitor	28	47.5%
Angiotensin ii receptor blockers (ARBs)	16	27.1%
Dihydropyridines	16	27.1%
Diuretics	19	32.2%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	47	79.7%
Oral anticoagulants	****	****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	42	71.2%
Baseline known risk of prolonged QT and torsades de pointes	23	40.7%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	48	81.4%
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.9	15.0
Mean number of emergency room encounters	0.7	1.5
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	5.0	11.3
Mean number of filled prescriptions	56.9	47.7
Mean number of generics dispensed	12.0	6.4
Mean number of unique drug classes dispensed	10.6	5.4

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 171 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017:55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.



Table 1az. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	92	N/A
Demographic Characteristics		
Age (years)	63.1	12.1
Age		
0-40 years	****	****
41-64 years	34	37.0%
65-74 years	30	32.6%
75-84 years	17	18.5%
≥ 85 years	****	****
Sex		
Female	58	63.0%
Male	34	37.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	92	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	78	84.8%
Unknown	14	15.2%
Year		
2022	74	80.4%
2023	18	19.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.3	2.4
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	30	32.6%
1-2	30	32.6%
3-4	12	13.0%
5+	20	21.7%
Combined comorbidity score ⁴	2.7	2.7
Combined comorbidity score categories ⁴		
<0	****	****
0	20	21.7%
1-2	30	32.6%
3-4	****	****
5+	21	22.8%

cder_mpl1p_wp077 Page 172 of 1023



Table 1az. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Dbesity	30	32.6%
obacco use	****	****
rrhythmia	25	27.2%
Serebrovascular disease/stroke/transient ischemic attack	17	18.5%
Chronic kidney disease	23	25.0%
hronic obstructive pulmonary disease	****	****
ongenital heart disease	****	****
leart failure	16	17.4%
lyperlipidemia	69	75.0%
lypertensive disease	76	82.6%
hyroid disease	18	19.6%
schemic heart disease/coronary artery disease/myocardial infarction	20	21.7%
eft ventricular hypertrophy	****	****
eripheral artery disease	****	****
'alvular/mitral valve disease	****	****
viseases of veins and lymphatics, and other diseases of circulatory system	****	****
bstructive sleep apnea	14	15.2%
ypertrophic cardiomyopathy	****	****
Other cardiac disease	37	40.2%
achyarrhythmia day 0	****	****
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	****	****
Nedical Product Use		
lpha-glucosidase inhibitors	****	****
tmylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	18	19.6%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
nsulin	54	58.7%
iguanides (metformin, phenformin, etc.)	67	72.8%
GLT2 inhibitors	27	29.3%
ulfonylurea	33	35.9%
hiazolidinedione	12	13.0%
o baseline use of any of the above antidiabetic drugs	0	0.0%
observed and any of the above until above and above above and above and above above and above and above above and above abov	0	0.0%
odium channel blockers	****	****
eta blockers	45	48.9%
otassium channel blockers/openers	****	****
Ion-dihydropyridine calcium channel blockers	0	0.0%
igoxin	****	****
other antiarrhythmic agents	0	0.0%
ther antiarriything agents	U	0.0%

cder_mpl1p_wp077 Page 173 of 1023



Table 1az. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	·	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	47	51.1%
Angiotensin-converting-enzyme (ACE) inhibitor	33	35.9%
Angiotensin ii receptor blockers (ARBs)	38	41.3%
Dihydropyridines	31	33.7%
Diuretics	33	35.9%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	75	81.5%
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	13	14.1%
Lipid lowering therapy	81	88.0%
Baseline known risk of prolonged QT and torsades de pointes	33	35.9%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	69	75.0%
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.1	35.7
Mean number of emergency room encounters	0.5	0.9
Mean number of inpatient hospital encounters	0.3	0.8
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	8.5	11.1
Mean number of filled prescriptions	44.7	35.4
Mean number of generics dispensed	12.1	6.6
Mean number of unique drug classes dispensed	10.6	5.4

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 174 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1ba. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	556	N/A
Demographic Characteristics		
Age (years)	61.7	11.0
Age		
0-40 years	39	7.0%
41-64 years	250	45.0%
65-74 years	223	40.1%
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	359	64.6%
Male	197	35.4%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	556	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	****	****
No	502	90.3%
Unknown	****	****
'ear		
2022	397	71.4%
2023	159	28.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.5	2.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	141	25.4%
1-2	176	31.7%
3-4	137	23.60%
5+	102	18.3%
Combined comorbidity score ⁴	3.3	3.0
Combined comorbidity score categories ⁴		
<0	23	4.1%
0	83	14.9%
1-2	163	29.3%
3-4	131	23.6%
	156	28.1%

cder_mpl1p_wp077 Page 175 of 1023



Table 1ba. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	18	3.2%
Dbesity	370	66.5%
obacco use	186	33.5%
rrhythmia	142	25.5%
Cerebrovascular disease/stroke/transient ischemic attack	90	16.2%
Chronic kidney disease	160	28.8%
hronic obstructive pulmonary disease	89	16.0%
Congenital heart disease	89	16.0%
leart failure	127	22.8%
lyperlipidemia	430	77.3%
lypertensive disease	503	90.5%
hyroid disease	69	12.4%
schemic heart disease/coronary artery disease/myocardial infarction	140	25.2%
eft ventricular hypertrophy	63	11.3%
Peripheral artery disease	63	11.3%
alvular/mitral valve disease	19	3.4%
Diseases of veins and lymphatics, and other diseases of circulatory system	71	12.8%
Obstructive sleep apnea	154	27.7%
lypertrophic cardiomyopathy	41	7.4%
Other cardiac disease	282	50.7%
achyarrhythmia day 0	****	****
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	17	3.1%
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	90	16.2%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Лeglitinides	****	****
nsulin	250	45.0%
iguanides (metformin, phenformin, etc.)	439	79.0%
GLT2 inhibitors	134	23.10%
ulfonylurea	188	33.8%
hiazolidinedione	35	6.3%
Io baseline use of any of the above antidiabetic drugs	0	0.0%
) Other antidiabetics	0	0.0%
odium channel blockers	****	****
seta blockers	263	47.3%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	****	****

cder_mpl1p_wp077 Page 176 of 1023



Table 1ba. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	265	47.7%
Angiotensin-converting-enzyme (ACE) inhibitor	196	35.3%
Angiotensin ii receptor blockers (ARBs)	236	42.4%
Dihydropyridines	251	45.1%
Diuretics	282	50.7%
Other antihypertensives	89	16.0%
Antihypertensives (any of the above antihypertensives)	504	90.6%
Oral anticoagulants	55	9.9%
Vitamin K antagonists	18	3.2%
Other cardiac medications not mentioned above	53	9.5%
Other cardiac medications (any of the other cardiac medications)	104	18.7%
Lipid lowering therapy	472	84.9%
Baseline known risk of prolonged QT and torsades de pointes	252	45.3%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	505	90.8%
torsades de pointes	60	10.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.8	27.4
Mean number of emergency room encounters	1.4	5.6
Mean number of inpatient hospital encounters	0.3	0.6
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	8.7	15.3
Mean number of filled prescriptions	52.8	41.2
Mean number of generics dispensed	14.4	6.5
Mean number of unique drug classes dispensed	12.7	5.6

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 177 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bb. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	14	N/A
Demographic Characteristics		
Age (years)	67.4	10.0
Age		
0-40 years	0	0.0%
41-64 years	****	****
65-74 years	****	****
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	****	****
Male	****	****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	14	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	14	100.0%
Unknown	0	0.0%
'ear		
2022	****	****
2023	****	****
lealth Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.7	2.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	****
1-2	****	****
3-4	****	****
5+	****	****
ombined comorbidity score ⁴	3.4	2.6
ombined comorbidity score categories ⁴		
<0	0	0.0%
0	****	****
1-2	****	****
3-4	****	****
5+	****	****

cder_mpl1p_wp077 Page 178 of 1023



Table 1bb. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

islander in the Rapid Schemer Distributed Database and Schemer Distributed E		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	****	****
Tobacco use	****	****
Arrhythmia	****	****
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	****	****
Hyperlipidemia	****	****
Hypertensive disease	****	****
Thyroid disease	****	****
Ischemic heart disease/coronary artery disease/myocardial infarction	****	****
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	****	****
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	****	****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	****	****
Biguanides (metformin, phenformin, etc.)	****	****
SGLT2 inhibitors	****	****
Sulfonylurea	****	****
Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	****
Beta blockers	****	****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 179 of 1023



Table 1bb. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

islander in the Kapid Sentiner Distributed Database and Sentiner Distributed D		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	****	****
Angiotensin-converting-enzyme (ACE) inhibitor	****	****
Angiotensin ii receptor blockers (ARBs)	****	****
Dihydropyridines	****	****
Diuretics	****	****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	****	****
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	****	****
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.8	9.6
Mean number of emergency room encounters	0.6	1.0
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	1.5	4.2
Mean number of filled prescriptions	42.1	31.6
Mean number of generics dispensed	13.6	8.3
Mean number of unique drug classes dispensed	12.1	7.1

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 180 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bc. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	3,131	N/A
Demographic Characteristics		
Age (years)	66.8	10.4
Age		
0-40 years	95	3.0%
41-64 years	947	30.2%
65-74 years	1,420	45.4%
75-84 years	597	19.1%
≥ 85 years	72	2.3%
Sex		
Female	1,762	56.3%
Male	1,369	43.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	3,131	100.0%
Hispanic origin		
Yes	15	0.5%
No	2,808	89.7%
Unknown	308	9.8%
/ear		
2022	2,510	80.2%
2023	621	19.8%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.3	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	734	23.4%
1-2	1,177	37.6%
3-4	726	23.2%
5+	494	15.8%
Combined comorbidity score ⁴	3.2	3.0
Combined comorbidity score categories ⁴		
<0	101	3.2%
0	432	13.8%
1-2	1,010	32.3%
3-4	748	23.9%
5+	840	26.8%

cder_mpl1p_wp077 Page 181 of 1023



Table 1bc. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentiner Distributed Database from May 15, 2022 t	2 7 3 11 2 2 3 7 2 2 2 3	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	98	3.1%
Obesity	1,886	60.2%
Tobacco use	1,007	32.2%
Arrhythmia	979	31.3%
Cerebrovascular disease/stroke/transient ischemic attack	466	14.9%
Chronic kidney disease	804	25.7%
Chronic obstructive pulmonary disease	498	15.9%
Congenital heart disease	498	15.9%
Heart failure	558	17.8%
Hyperlipidemia	2,573	82.2%
Hypertensive disease	2,743	87.6%
Thyroid disease	795	25.4%
Ischemic heart disease/coronary artery disease/myocardial infarction	985	31.5%
Left ventricular hypertrophy	221	7.1%
Peripheral artery disease	221	7.1%
Valvular/mitral valve disease	161	5.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	558	17.8%
Obstructive sleep apnea	994	31.7%
Hypertrophic cardiomyopathy	173	5.5%
Other cardiac disease	1,723	55.1%
Tachyarrhythmia day 0	43	1.4%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	65	2.1%
Medical Product Use		
Alpha-glucosidase inhibitors	17	0.5%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	411	13.1%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	43	1.4%
Insulin	1,216	38.8%
Biguanides (metformin, phenformin, etc.)	2,523	80.6%
SGLT2 inhibitors	827	26.4%
Sulfonylurea	1,131	36.1%
Thiazolidinedione	291	9.3%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	****	****
Sodium channel blockers	31	1.0%
Beta blockers	1,476	47.1%
Potassium channel blockers/openers	55	1.8%
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	40	1.3%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 182 of 1023



Table 1bc. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentinei Distributed Database from May 13, 2022 to		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	1,494	47.7%
Angiotensin-converting-enzyme (ACE) inhibitor	1,320	42.2%
Angiotensin ii receptor blockers (ARBs)	1,057	33.8%
Dihydropyridines	832	26.6%
Diuretics	1,350	43.1%
Other antihypertensives	296	9.5%
Antihypertensives (any of the above antihypertensives)	2,686	85.8%
Oral anticoagulants	322	10.3%
Vitamin K antagonists	114	3.6%
Other cardiac medications not mentioned above	294	9.4%
Other cardiac medications (any of the other cardiac medications)	653	20.9%
Lipid lowering therapy	2,650	84.6%
Baseline known risk of prolonged QT and torsades de pointes	1,503	48.0%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	2,793	89.2%
torsades de pointes	531	17.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.7	20.8
Mean number of emergency room encounters	0.8	1.8
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	9.8	21.7
Mean number of filled prescriptions	54.8	43.4
Mean number of generics dispensed	13.9	6.5
Mean number of unique drug classes dispensed	12.3	5.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 183 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bd. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	67	N/A
Demographic Characteristics		
Age (years)	46.6	13.4
Age		
0-40 years	****	****
41-64 years	41	61.2%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
ex		
Female	49	73.1%
Male	18	26.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	67	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	13	19.4%
No	35	52.2%
Unknown	19	28.4%
'ear		
2022	37	55.2%
2023	30	44.8%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.7	1.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	45	67.2%
1-2	****	****
3-4	****	****
5+	****	****
combined comorbidity score ⁴	2.2	2.2
Combined comorbidity score categories ⁴		
<0	****	****
0	****	****
1-2	33	49.3%
3-4	14	20.9%
5+	****	****

cder_mpl1p_wp077 Page 184 of 1023



Table 1bd. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Dbesity	44	65.7%
obacco use	21	31.3%
Arrhythmia	12	17.9%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
leart failure	****	****
Hyperlipidemia	40	59.7%
lypertensive disease	30	44.8%
Thyroid disease	13	19.4%
schemic heart disease/coronary artery disease/myocardial infarction	****	****
eft ventricular hypertrophy	****	****
Peripheral artery disease	****	****
/alvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Dbstructive sleep apnea	11	16.4%
lypertrophic cardiomyopathy	****	****
Other cardiac disease	19	28.4%
achyarrhythmia day 0	****	****
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
PPP-4 inhibitors	****	****
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
nsulin	28	41.8%
siguanides (metformin, phenformin, etc.)	59	88.1%
GLT2 inhibitors	16	23.9%
ulfonylurea	11	16.4%
hiazolidinedione	****	****
Io baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	0	0.0%
Beta blockers	20	29.9%
otassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
	•	5.070

cder_mpl1p_wp077 Page 185 of 1023



Table 1bd. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	20	29.9%
Angiotensin-converting-enzyme (ACE) inhibitor	20	29.9%
Angiotensin ii receptor blockers (ARBs)	12	17.9%
Dihydropyridines	15	22.4%
Diuretics	19	28.4%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	43	64.2%
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	46	68.7%
Baseline known risk of prolonged QT and torsades de pointes	30	44.8%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	56	83.6%
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.8	18.9
Mean number of emergency room encounters	1.0	2.6
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	11.1	18.4
Mean number of filled prescriptions	47.5	39.7
Mean number of generics dispensed	13.2	6.3
Mean number of unique drug classes dispensed	11.9	5.6

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 186 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1be. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	828	N/A
Demographic Characteristics		
nge (years)	52.1	10.3
Age		
0-40 years	132	15.9%
41-64 years	621	75.0%
65-74 years	64	7.7%
75-84 years	****	****
≥ 85 years	****	****
ex		
Female	570	68.8%
Male	258	31.2%
tace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	37	4.5%
Multi-racial	18	2.2%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	663	80.1%
White	110	13.3%
lispanic origin		
Yes	15	1.8%
No	58	7.0%
Unknown	755	91.2%
ear		
2022	72	8.7%
2023	756	91.3%
lealth Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.7	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	531	64.1%
1-2	234	28.3%
3-4	49	5.9%
5+	14	1.7%
combined comorbidity score ⁴	1.2	1.9
ombined comorbidity score categories ⁴		
<0	123	14.9%
0	232	29.2%
1-2	312	37.7%
3-4	99	12.0%
5+	52	6.3%
	JZ	0.5%

cder_mpl1p_wp077 Page 187 of 1023



Table 1be. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Dbesity	681	82.2%
obacco use	131	15.8%
arrhythmia	169	20.4%
erebrovascular disease/stroke/transient ischemic attack	41	5.0%
Chronic kidney disease	53	6.4%
hronic obstructive pulmonary disease	23	2.9%
Congenital heart disease	23	2.9%
leart failure	52	6.3%
lyperlipidemia	539	65.1%
lypertensive disease	615	74.3%
hyroid disease	198	23.9%
schemic heart disease/coronary artery disease/myocardial infarction	98	11.8%
eft ventricular hypertrophy	25	3.0%
eripheral artery disease	25	3.0%
'alvular/mitral valve disease	17	2.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	69	8.3%
bstructive sleep apnea	287	34.7%
lypertrophic cardiomyopathy	28	3.4%
Other cardiac disease	343	41.4%
achyarrhythmia day 0	****	****
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	****	****
Nedical Product Use		
lpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	39	4.7%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
nsulin	41	5.0%
iguanides (metformin, phenformin, etc.)	736	88.9%
GLT2 inhibitors	127	15.3%
ulfonylurea	79	9.5%
hiazolidinedione	21	2.5%
lo baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	****	****
seta blockers	233	29.3%
otassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%
ther antiarmythmic agents	U	U.U%

cder_mpl1p_wp077 Page 188 of 1023



Table 1be. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	234	29.5%
Angiotensin-converting-enzyme (ACE) inhibitor	226	27.3%
Angiotensin ii receptor blockers (ARBs)	265	32.0%
Dihydropyridines	167	20.2%
Diuretics	280	33.8%
Other antihypertensives	42	5.1%
Antihypertensives (any of the above antihypertensives)	598	72.2%
Oral anticoagulants	40	4.8%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	26	3.1%
Other cardiac medications (any of the other cardiac medications)	69	8.3%
Lipid lowering therapy	447	54.0%
Baseline known risk of prolonged QT and torsades de pointes	420	50.7%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	714	86.2%
torsades de pointes	131	15.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.6	16.0
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.9	7.5
Mean number of filled prescriptions	37.1	29.0
Mean number of generics dispensed	12.2	6.9
Mean number of unique drug classes dispensed	11.0	6.0

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 189 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.



Table 1bf. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	663	N/A
Demographic Characteristics		
Age (years)	50.9	10.3
Age		
0-40 years	113	17.0%
41-64 years	520	78.4%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
ex		
Female	465	70.1%
Male	198	29.9%
cace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	663	100.0%
White	0	0.0%
lispanic origin		
Yes	13	2.0%
No	0	0.0%
Unknown	650	98.0%
ear		
2022	62	9.4%
2023	601	90.6%
lealth Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		-
<0	0	0.0%
0	448	67.6%
1-2	181	27.3%
3-4	****	****
5+	****	****
ombined comorbidity score ⁴	1.0	1.8
ombined comorbidity score categories ⁴	1.0	1.0
<0	105	15.8%
0	207	31.2%
1-2	232	36.5%
3-4	74	11.2%
5+	35	5.3%

cder_mpl1p_wp077 Page 190 of 1023



Table 1bf. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
lcohol use or abuse	****	****
Desity	542	81.7%
obacco use	102	15.4%
rrhythmia	130	19.6%
erebrovascular disease/stroke/transient ischemic attack	27	4.1%
hronic kidney disease	37	5.6%
hronic obstructive pulmonary disease	16	2.4%
ongenital heart disease	16	2.4%
eart failure	37	5.6%
yperlipidemia	428	64.6%
ypertensive disease	499	75.3%
hyroid disease	160	23.10%
chemic heart disease/coronary artery disease/myocardial infarction	70	10.6%
eft ventricular hypertrophy	21	3.2%
eripheral artery disease	21	3.2%
alvular/mitral valve disease	13	2.0%
iseases of veins and lymphatics, and other diseases of circulatory system	48	7.2%
bstructive sleep apnea	211	31.8%
ypertrophic cardiomyopathy	23	3.5%
ther cardiac disease	252	38.0%
achyarrhythmia day 0	****	****
ospitalized tachyarrhythmia day 0	0	0.0%
istory of serious hypoglycemia (ED and/or IP)	****	****
ledical Product Use		
lpha-glucosidase inhibitors	****	****
mylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	30	4.5%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
nsulin	26	3.9%
iguanides (metformin, phenformin, etc.)	599	90.3%
GLT2 inhibitors	99	14.9%
ulfonylurea	55	8.3%
hiazolidinedione	12	1.8%
o baseline use of any of the above antidiabetic drugs	0	0.0%
ther antidiabetics	0	0.0%
odium channel blockers	****	****
eta blockers	187	28.2%
otassium channel blockers/openers	****	****
lon-dihydropyridine calcium channel blockers	0	0.0%
OH-UHIVUI ODVI IUHE CAICIUHI CHAHHEL DIOCKELS	•	3.0,0
igoxin	****	****

cder_mpl1p_wp077 Page 191 of 1023



Table 1bf. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	188	28.4%
Angiotensin-converting-enzyme (ACE) inhibitor	187	28.2%
Angiotensin ii receptor blockers (ARBs)	209	31.5%
Dihydropyridines	133	20.1%
Diuretics	216	32.6%
Other antihypertensives	30	4.5%
Antihypertensives (any of the above antihypertensives)	481	72.5%
Oral anticoagulants	28	4.2%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	21	3.2%
Other cardiac medications (any of the other cardiac medications)	50	7.5%
Lipid lowering therapy	344	51.9%
Baseline known risk of prolonged QT and torsades de pointes	353	53.2%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	575	86.7%
torsades de pointes	110	16.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.5	15.0
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	4.8	6.0
Mean number of filled prescriptions	35.1	25.2
Mean number of generics dispensed	12.0	6.5
Mean number of unique drug classes dispensed	10.9	5.7

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 192 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bg. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

the hapia sentinei bistributea batabase ana sentinei bistributea batabas	30 HOIH Way 13, 2022 to July	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)		
Age		
0-40 years		•
41-64 years		
65-74 years		•
75-84 years		•
≥ 85 years		
Sex		
Female		
Male		
Race ²		
American Indian or Alaska Native		
Asian		
Black or African American		
Multi-racial		
Native Hawaiian or Other Pacific Islander		
Unknown		
White		
Hispanic origin		
Yes		
No		
Unknown		
Year		
2022		
2023		
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³		
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0		
0		
1-2		
3-4		
5+		
Combined comorbidity score ⁴		
Combined comorbidity score categories ⁴		
<0		
0		
1-2		
3-4		
5+		

cder_mpl1p_wp077 Page 193 of 1023



Table 1bg. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	•	
Obesity	•	
Tobacco use	•	
Arrhythmia	•	
Cerebrovascular disease/stroke/transient ischemic attack	•	
Chronic kidney disease	•	
Chronic obstructive pulmonary disease	•	
Congenital heart disease	•	
Heart failure		
Hyperlipidemia		
Hypertensive disease	•	
Thyroid disease	•	
Ischemic heart disease/coronary artery disease/myocardial infarction		
Left ventricular hypertrophy		
Peripheral artery disease	•	
Valvular/mitral valve disease		
Diseases of veins and lymphatics, and other diseases of circulatory system		
Obstructive sleep apnea	•	
Hypertrophic cardiomyopathy		
Other cardiac disease		
Tachyarrhythmia day 0		
Hospitalized tachyarrhythmia day 0		
History of serious hypoglycemia (ED and/or IP)		
Medical Product Use		
Alpha-glucosidase inhibitors	•	•
Amylin analogs (pramlintide)	•	
DPP-4 inhibitors	•	
Incretin mimetics (albiglutide, dulaglutide, etc.)	•	•
Meglitinides	•	
Insulin	•	
Biguanides (metformin, phenformin, etc.)	•	
SGLT2 inhibitors	•	
Sulfonylurea	•	•
Thiazolidinedione	•	
No baseline use of any of the above antidiabetic drugs	•	
Other antidiabetics	•	
Sodium channel blockers	•	
Beta blockers	•	
Potassium channel blockers/openers	•	
Non-dihydropyridine calcium channel blockers	•	
Digoxin	•	•
Other antiarrhythmic agents	•	•

cder_mpl1p_wp077 Page 194 of 1023



Table 1bg. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)		
Angiotensin-converting-enzyme (ACE) inhibitor		
Angiotensin ii receptor blockers (ARBs)		
Dihydropyridines		
Diuretics		
Other antihypertensives		
Antihypertensives (any of the above antihypertensives)		
Oral anticoagulants		
Vitamin K antagonists		
Other cardiac medications not mentioned above		
Other cardiac medications (any of the other cardiac medications)		
Lipid lowering therapy		
Baseline known risk of prolonged QT and torsades de pointes		
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	•	·
torsades de pointes		
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters		
Mean number of emergency room encounters		
Mean number of inpatient hospital encounters		
Mean number of non-acute institutional encounters		
Mean number of other ambulatory encounters		
Mean number of filled prescriptions		•
Mean number of generics dispensed		
Mean number of unique drug classes dispensed		•

¹Value represents standard deviation where no % follows the value.

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

N/A: Not applicable

cder_mpl1p_wp077 Page 195 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051



Table 1bh. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	•	•
Age		
0-40 years	·	•
41-64 years	·	•
65-74 years	·	•
75-84 years		
≥ 85 years		
Sex		
Female		
Male		
Race ²		
American Indian or Alaska Native		
Asian		
Black or African American		
Multi-racial		
Native Hawaiian or Other Pacific Islander		
Unknown		
White		
Hispanic origin		
Yes		
No		
Unknown		
Year		
2022		
2023		
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³		
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0		
0		
1-2		
3-4	•	
5+	•	
Combined comorbidity score ⁴	•	
Combined comorbidity score categories ⁴		
<0	•	
0		
1-2		
3-4	•	
5+		

cder_mpl1p_wp077 Page 196 of 1023



Table 1bh. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentiner Distributed Database from May 13, 2022 t	3 34.1.2 30, 2023	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	•	
Obesity		
Tobacco use		
Arrhythmia		
Cerebrovascular disease/stroke/transient ischemic attack		
Chronic kidney disease		
Chronic obstructive pulmonary disease		
Congenital heart disease		
Heart failure		
Hyperlipidemia		
Hypertensive disease		
Thyroid disease		
Ischemic heart disease/coronary artery disease/myocardial infarction		
Left ventricular hypertrophy		
Peripheral artery disease		
Valvular/mitral valve disease		
Diseases of veins and lymphatics, and other diseases of circulatory system		
Obstructive sleep apnea		
Hypertrophic cardiomyopathy		
Other cardiac disease		
Tachyarrhythmia day 0		
Hospitalized tachyarrhythmia day 0		
History of serious hypoglycemia (ED and/or IP)		
Medical Product Use		
Alpha-glucosidase inhibitors		
Amylin analogs (pramlintide)		
DPP-4 inhibitors		
Incretin mimetics (albiglutide, dulaglutide, etc.)		
Meglitinides		
Insulin		
Biguanides (metformin, phenformin, etc.)		
SGLT2 inhibitors		
Sulfonylurea		
Thiazolidinedione		
No baseline use of any of the above antidiabetic drugs		
Other antidiabetics		
Sodium channel blockers		
Beta blockers		
Potassium channel blockers/openers		
Non-dihydropyridine calcium channel blockers		
Digoxin		
Other antiarrhythmic agents		

cder_mpl1p_wp077 Page 197 of 1023



Table 1bh. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentiner Distributed Database from May 13, 2022 to	·	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)		•
Angiotensin-converting-enzyme (ACE) inhibitor		•
Angiotensin ii receptor blockers (ARBs)		
Dihydropyridines		
Diuretics		
Other antihypertensives		
Antihypertensives (any of the above antihypertensives)		
Oral anticoagulants		
Vitamin K antagonists		•
Other cardiac medications not mentioned above		
Other cardiac medications (any of the other cardiac medications)		
Lipid lowering therapy		
Baseline known risk of prolonged QT and torsades de pointes		
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	•	٠
torsades de pointes		•
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters		
Mean number of emergency room encounters		
Mean number of inpatient hospital encounters		
Mean number of non-acute institutional encounters		
Mean number of other ambulatory encounters		
Mean number of filled prescriptions		
Mean number of generics dispensed		•
Mean number of unique drug classes dispensed	•	<u> </u>

¹Value represents standard deviation where no % follows the value.

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

N/A: Not applicable

cder_mpl1p_wp077 Page 198 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051



Table 1bi. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

andar
on ¹
*
6
*
*
,
*
*
,)
,
%
,
,
,
,
,
6
6
*
*
,)
6
*
*
*
*
*
6
0
*

cder_mpl1p_wp077 Page 199 of 1023



Table 1bi. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Dbesity	****	****
Tobacco use	****	****
Arrhythmia	****	****
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	****	****
Hyperlipidemia	****	****
Hypertensive disease	****	****
Thyroid disease	****	****
schemic heart disease/coronary artery disease/myocardial infarction	****	****
eft ventricular hypertrophy	****	****
Peripheral artery disease	****	****
/alvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Dbstructive sleep apnea	11	29.7%
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	13	35.1%
achyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use	<u> </u>	0.070
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
OPP-4 inhibitors	****	****
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
nsulin	****	****
Biguanides (metformin, phenformin, etc.)	****	****
GGLT2 inhibitors	****	****
fulfonylurea	****	****
'hiazolidinedione	****	****
		0.0%
No baseline use of any of the above antidiabetic drugs Other antidiabetics	0	
	0	0.0%
odium channel blockers	0	0.0%
Beta blockers	12	32.4%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 200 of 1023



Table 1bi. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	12	32.4%
Angiotensin-converting-enzyme (ACE) inhibitor	****	****
Angiotensin ii receptor blockers (ARBs)	19	51.4%
Dihydropyridines	12	32.4%
Diuretics	16	43.2%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	20	54.1%
Baseline known risk of prolonged QT and torsades de pointes	13	35.1%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	****	****
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.3	14.1
Mean number of emergency room encounters	0.6	1.3
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.8	4.7
Mean number of filled prescriptions	34.1	35.4
Mean number of generics dispensed	11.6	6.6
Mean number of unique drug classes dispensed	10.4	5.7

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 201 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.



Table 1bj. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)		
Age		
0-40 years		
41-64 years		•
65-74 years		•
75-84 years		•
≥ 85 years		
Sex		
Female		
Male		
Race ²		
American Indian or Alaska Native		
Asian		
Black or African American		
Multi-racial		
Native Hawaiian or Other Pacific Islander		
Unknown	•	•
White	•	•
Hispanic origin		
Yes	•	•
No		
Unknown	•	•
Year		
2022		
2023		
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³		
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0		
0		
1-2		
3-4		
5+		
Combined comorbidity score ⁴		
Combined comorbidity score categories ⁴		
<0		
0		
1-2		
3-4		
5+		

cder_mpl1p_wp077 Page 202 of 1023



Table 1bj. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse		
Obesity		
Tobacco use		
Arrhythmia		
Cerebrovascular disease/stroke/transient ischemic attack		
Chronic kidney disease		
Chronic obstructive pulmonary disease		
Congenital heart disease		
Heart failure		
Hyperlipidemia		
Hypertensive disease		
Thyroid disease		
Ischemic heart disease/coronary artery disease/myocardial infarction		
Left ventricular hypertrophy		
Peripheral artery disease		
Valvular/mitral valve disease		
Diseases of veins and lymphatics, and other diseases of circulatory system		
Obstructive sleep apnea		
Hypertrophic cardiomyopathy		
Other cardiac disease		
Tachyarrhythmia day 0		
Hospitalized tachyarrhythmia day 0		
History of serious hypoglycemia (ED and/or IP)		
Medical Product Use		
Alpha-glucosidase inhibitors	•	
Amylin analogs (pramlintide)		
DPP-4 inhibitors		
Incretin mimetics (albiglutide, dulaglutide, etc.)		
Meglitinides		
Insulin		
Biguanides (metformin, phenformin, etc.)		
SGLT2 inhibitors		
Sulfonylurea		
Thiazolidinedione		
No baseline use of any of the above antidiabetic drugs		
Other antidiabetics		
Sodium channel blockers		
Beta blockers		
Potassium channel blockers/openers		
Non-dihydropyridine calcium channel blockers		
Digoxin		
Other antiarrhythmic agents	•	•

cder_mpl1p_wp077 Page 203 of 1023



Table 1bj. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)		
Angiotensin-converting-enzyme (ACE) inhibitor	·	
Angiotensin ii receptor blockers (ARBs)	•	
Dihydropyridines		
Diuretics		
Other antihypertensives	•	
Antihypertensives (any of the above antihypertensives)	•	
Oral anticoagulants		
Vitamin K antagonists	•	
Other cardiac medications not mentioned above	•	
Other cardiac medications (any of the other cardiac medications)	•	
Lipid lowering therapy		
Baseline known risk of prolonged QT and torsades de pointes	•	
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	·	
torsades de pointes	•	
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters		
Mean number of emergency room encounters		
Mean number of inpatient hospital encounters		
Mean number of non-acute institutional encounters		
Mean number of other ambulatory encounters	•	
Mean number of filled prescriptions	•	
Mean number of generics dispensed	•	
Mean number of unique drug classes dispensed	•	

¹Value represents standard deviation where no % follows the value.

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

N/A: Not applicable

cder_mpl1p_wp077 Page 204 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051



Table 1bk. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentiner Distributed Database from May 13, 20		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	110	N/A
Demographic Characteristics		
Age (years)	58.5	10.1
Age		
0-40 years	****	****
41-64 years	64	58.2%
65-74 years	29	26.4%
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	63	57.3%
Male	47	42.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	110	100.0%
Hispanic origin		
Yes	0	0.0%
No	41	37.3%
Unknown	69	62.7%
Year		
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.3	1.5
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	53	48.2%
1-2	35	31.8%
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	1.8	2.3
Combined comorbidity score categories ⁴		
<0	****	****
0	21	19.1%
1-2	49	44.5%
3-4	19	17.3%
5+	****	****

cder_mpl1p_wp077 Page 205 of 1023



Table 1bk. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Dbesity	92	83.6%
obacco use	23	20.9%
Arrhythmia	27	23.50%
Cerebrovascular disease/stroke/transient ischemic attack	12	10.9%
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
leart failure	13	11.8%
lyperlipidemia	74	67.3%
Typertensive disease	74	67.3%
Thyroid disease	25	22.7%
schemic heart disease/coronary artery disease/myocardial infarction	25	22.7%
eft ventricular hypertrophy	****	****
Peripheral artery disease	****	****
/alvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	15	13.6%
Obstructive sleep apnea	58	52.7%
lypertrophic cardiomyopathy	****	****
Other cardiac disease	70	63.6%
achyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Npha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
PPP-4 inhibitors	****	****
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
nsulin	****	****
liguanides (metformin, phenformin, etc.)	90	81.8%
GLT2 inhibitors	20	18.2%
ulfonylurea	17	15.5%
hiazolidinedione	*****	13.3%
lo baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	0	0.0%
Beta blockers	39 ****	35.5% ****
Potassium channel blockers/openers		
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 206 of 1023



Table 1bk. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	39	35.5%
Angiotensin-converting-enzyme (ACE) inhibitor	29	26.4%
Angiotensin ii receptor blockers (ARBs)	33	30.0%
Dihydropyridines	18	16.4%
Diuretics	42	38.2%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	75	68.2%
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	16	14.5%
Lipid lowering therapy	72	65.5%
Baseline known risk of prolonged QT and torsades de pointes	47	42.7%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	94	85.5%
torsades de pointes	14	12.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	25.3	20.3
Mean number of emergency room encounters	0.6	1.5
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.2	13.3
Mean number of filled prescriptions	47.6	38.3
Mean number of generics dispensed	13.7	7.7
Mean number of unique drug classes dispensed	12.1	6.6

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 207 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.



Table 1bl. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	18	N/A
Demographic Characteristics		
Age (years)	49.6	9.0
Age		
0-40 years	****	****
41-64 years	****	****
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
ex		
Female	****	****
Male	****	****
tace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	18	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	****	****
No	****	****
Unknown	****	****
ear		
2022	****	****
2023	****	****
lealth Characteristics		
dapted Diabetes Complications Severity Index (aDCSI) ³	1.1	1.5
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	****
1-2	****	****
3-4	****	****
5+	****	****
ombined comorbidity score ⁴	1.8	2.2
ombined comorbidity score categories ⁴		
<0	****	****
0	****	****
1-2	****	****
3-4	****	****
		

cder_mpl1p_wp077 Page 208 of 1023



Table 1bl. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
atient Characteristics	Number/Mean	Deviation ¹
lcohol use or abuse	****	****
besity	****	****
obacco use	****	****
rrhythmia	****	****
erebrovascular disease/stroke/transient ischemic attack	****	****
hronic kidney disease	****	****
hronic obstructive pulmonary disease	0	0.0%
ongenital heart disease	0	0.0%
eart failure	0	0.0%
yperlipidemia	****	****
ypertensive disease	****	****
hyroid disease	****	****
chemic heart disease/coronary artery disease/myocardial infarction	****	****
eft ventricular hypertrophy	0	0.0%
eripheral artery disease	0	0.0%
'alvular/mitral valve disease	0	0.0%
iseases of veins and lymphatics, and other diseases of circulatory system	****	****
bstructive sleep apnea	****	****
lypertrophic cardiomyopathy	0	0.0%
ther cardiac disease	****	****
achyarrhythmia day 0	0	0.0%
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	0	0.0%
ledical Product Use		
lpha-glucosidase inhibitors	0	0.0%
	0	0.0%
PP-4 inhibitors	0	0.0%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides , , , ,	0	0.0%
nsulin	****	****
iguanides (metformin, phenformin, etc.)	****	****
GLT2 inhibitors	****	****
ulfonylurea	****	****
hiazolidinedione	0	0.0%
o baseline use of any of the above antidiabetic drugs	0	0.0%
ther antidiabetics	0	0.0%
odium channel blockers	0	0.0%
eta blockers	****	****
otassium channel blockers/openers	0	0.0%
on-dihydropyridine calcium channel blockers	0	0.0%
igoxin	0	0.0%
	U	0.070

cder_mpl1p_wp077 Page 209 of 1023



Table 1bl. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	****	****
Angiotensin-converting-enzyme (ACE) inhibitor	****	****
Angiotensin ii receptor blockers (ARBs)	****	****
Dihydropyridines	****	****
Diuretics	****	****
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	****	****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	****	****
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	****	****
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.9	22.0
Mean number of emergency room encounters	0.9	1.6
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	5.3	10.7
Mean number of filled prescriptions	52.1	61.1
Mean number of generics dispensed	13.8	12.7
Mean number of unique drug classes dispensed	12.1	11.2

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 210 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.



Table 1bm. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	364	N/A
Demographic Characteristics		
age (years)	69.5	8.8
Age		
0-40 years	****	****
41-64 years	74	20.3%
65-74 years	183	50.3%
75-84 years	87	23.9%
≥ 85 years	****	****
ex		
Female	172	47.3%
Male	192	52.7%
tace ²		
American Indian or Alaska Native	****	****
Asian	****	****
Black or African American	40	11.0%
Multi-racial	****	****
Native Hawaiian or Other Pacific Islander	****	****
Unknown	63	17.3%
White	237	67.9%
lispanic origin		
Yes	11	3.0%
No	274	75.3%
Unknown	79	21.7%
ear		
2022	217	59.6%
2023	147	40.4%
lealth Characteristics		
dapted Diabetes Complications Severity Index (aDCSI) ³	2.8	2.3
dapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	68	18.7%
1-2	109	29.9%
3-4	106	29.1%
5+	81	22.3%
ombined comorbidity score ⁴	3.2	2.7
ombined comorbidity score categories ⁴		
<0	****	****
0	****	****
1-2	121	33.2%
3-4	80	22.0%
- ·		28.3%

cder_mpl1p_wp077 Page 211 of 1023



Table 1bm. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	169	46.4%
Tobacco use	91	25.0%
Arrhythmia	101	27.7%
Cerebrovascular disease/stroke/transient ischemic attack	78	21.4%
Chronic kidney disease	109	29.9%
Chronic obstructive pulmonary disease	50	13.7%
Congenital heart disease	50	13.7%
Heart failure	70	19.2%
Hyperlipidemia	328	90.1%
Hypertensive disease	327	89.8%
Thyroid disease	89	23.50%
schemic heart disease/coronary artery disease/myocardial infarction	123	34.1%
_eft ventricular hypertrophy	26	7.1%
Peripheral artery disease	26	7.1%
/alvular/mitral valve disease	22	6.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	61	16.8%
Dbstructive sleep apnea	94	25.8%
lypertrophic cardiomyopathy	34	9.3%
Other cardiac disease	186	51.1%
achyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	56	15.4%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
nsulin	215	59.1%
Biguanides (metformin, phenformin, etc.)	291	79.9%
GGLT2 inhibitors	95	26.1%
Sulfonylurea	161	44.2%
, Thiazolidinedione	54	14.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	****
Beta blockers	173	47.5%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	****	****
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%
	·	5.576

cder_mpl1p_wp077 Page 212 of 1023



Table 1bm. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	174	47.8%
Angiotensin-converting-enzyme (ACE) inhibitor	178	48.9%
Angiotensin ii receptor blockers (ARBs)	136	37.4%
Dihydropyridines	106	29.1%
Diuretics	132	36.3%
Other antihypertensives	37	10.2%
Antihypertensives (any of the above antihypertensives)	323	89.0%
Oral anticoagulants	30	8.2%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	30	8.2%
Other cardiac medications (any of the other cardiac medications)	63	17.3%
Lipid lowering therapy	330	90.7%
Baseline known risk of prolonged QT and torsades de pointes	146	40.1%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	303	83.2%
torsades de pointes	44	12.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.7	16.4
Mean number of emergency room encounters	0.8	1.6
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	4.7	8.0
Mean number of filled prescriptions	41.3	23.9
Mean number of generics dispensed	12.6	5.4
Mean number of unique drug classes dispensed	10.9	4.8

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 213 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bn. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	63	N/A
Demographic Characteristics		
Age (years)	62.8	10.6
Age		
0-40 years	****	****
41-64 years	27	42.9%
65-74 years	22	34.9%
75-84 years	****	****
≥ 85 years	0	0.0%
ex		
Female	28	44.4%
Male	35	55.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	63	100.0%
White	0	0.0%
lispanic origin		
Yes	11	17.5%
No	0	0.0%
Unknown	52	82.5%
'ear		
2022	38	60.3%
2023	25	39.7%
lealth Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	2.0
dapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	21	33.3%
1-2	20	31.7%
3-4	****	****
5+	****	****
ombined comorbidity score ⁴	1.9	2.0
Combined comorbidity score categories ⁴		
<0	****	****
0	12	19.0%
1-2	32	50.8%
3-4	****	****
5+	****	****

cder_mpl1p_wp077 Page 214 of 1023



Table 1bn. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standa
Patient Characteristics	Number/Mean	Deviation ¹
alcohol use or abuse	0	0.0%
Dbesity	30	47.6%
obacco use	11	17.5%
rrhythmia	15	23.8%
erebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	****	****
hronic obstructive pulmonary disease	****	****
ongenital heart disease	****	****
leart failure	****	****
lyperlipidemia	****	****
ypertensive disease	49	77.8%
hyroid disease	14	22.2%
schemic heart disease/coronary artery disease/myocardial infarction	17	27.0%
eft ventricular hypertrophy	****	****
eripheral artery disease	****	****
'alvular/mitral valve disease	****	****
iseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	18	28.6%
ypertrophic cardiomyopathy	****	****
other cardiac disease	30	47.6%
achyarrhythmia day 0	0	0.0%
ospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	****	1.6%
Nedical Product Use		
lpha-glucosidase inhibitors	****	****
mylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	****	****
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Λeglitinides	****	****
nsulin	36	57.1%
iguanides (metformin, phenformin, etc.)	51	81.0%
GLT2 inhibitors	17	27.0%
ulfonylurea	26	41.3%
hiazolidinedione	****	****
o baseline use of any of the above antidiabetic drugs	0	0.0%
ther antidiabetics	0	0.0%
odium channel blockers	****	****
eta blockers	26	41.3%
otassium channel blockers/openers	0	0.0%
Ion-dihydropyridine calcium channel blockers	****	****
Digoxin	0	0.0%
.0~	•	3.070

cder_mpl1p_wp077 Page 215 of 1023



Table 1bn. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	27	42.9%
Angiotensin-converting-enzyme (ACE) inhibitor	37	58.7%
Angiotensin ii receptor blockers (ARBs)	15	23.8%
Dihydropyridines	12	19.0%
Diuretics	16	25.4%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	52	82.5%
Oral anticoagulants	****	****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	23	36.5%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	48	76.2%
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.0	11.8
Mean number of emergency room encounters	0.6	0.9
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.2	6.3
Mean number of filled prescriptions	36.1	25.5
Mean number of generics dispensed	11.6	5.9
Mean number of unique drug classes dispensed	10.2	5.2

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 216 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bo. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	****	N/A
Demographic Characteristics		
Age (years)	70.8	6.4
Age		
0-40 years	0	0.0%
41-64 years	0	0.0%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	0	0.0%
ex		
Female	0	0.0%
Male	****	100.0%
Race ²		
American Indian or Alaska Native	****	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	0	0.0%
No	****	100.0%
Unknown	0	0.0%
'ear		
2022	0	0.0%
2023	****	100.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	0.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	0	0.0%
1-2	****	100.0%
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	1.5	0.7
Combined comorbidity score categories 4		
0	0	0.0%
	0	0.0%
2	****	100.0%
3-4	0	0.0%
5+	0	0.0%
T .	U	0.070

cder_mpl1p_wp077 Page 217 of 1023



Table 1bo. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	0	0.0%
Tobacco use	0	0.0%
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	****	****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	****	100.0%
Hypertensive disease	****	100.0%
Thyroid disease	0	0.0%
schemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
_eft ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	0	0.0%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	0	0.0%
Fachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
nsulin	****	****
Biguanides (metformin, phenformin, etc.)	****	100.0%
SGLT2 inhibitors	0	0.0%
Sulfonylurea	****	****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	0	0.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 218 of 1023



Table 1bo. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Angiotensin-converting-enzyme (ACE) inhibitor	****	100.0%
Angiotensin ii receptor blockers (ARBs)	0	0.0%
Dihydropyridines	****	****
Diuretics	****	****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	****	100.0%
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	****	100.0%
Baseline known risk of prolonged QT and torsades de pointes	****	****
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	****	100.0%
torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.5	3.5
Mean number of emergency room encounters	0.0	NaN
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	0.0	NaN
Mean number of filled prescriptions	34.5	20.5
Mean number of generics dispensed	13.5	4.9
Mean number of unique drug classes dispensed	11.0	1.4

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 219 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bp. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	****	N/A
Demographic Characteristics		
Age (years)	74.8	6.8
Age		
0-40 years	0	0.0%
41-64 years	0	0.0%
65-74 years	****	****
75-84 years	****	****
≥ 85 years	****	****
Sex		
Female	****	****
Male	****	****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	****	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	****	****
Unknown	****	****
Year		
2022	****	****
2023	****	****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	2.6
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	****
1-2	****	****
3-4	****	****
5+	****	****
Combined comorbidity score ⁴	3.2	3.2
Combined comorbidity score categories ⁴		
<0	0	0.0%
	****	****
1-2	****	****
3-4	****	****

cder_mpl1p_wp077 Page 220 of 1023



Table 1bp. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	0	0.0%
Desity	0	0.0%
obacco use	0	0.0%
rrhythmia	****	****
erebrovascular disease/stroke/transient ischemic attack	****	****
hronic kidney disease	****	****
hronic obstructive pulmonary disease	0	0.0%
ongenital heart disease	0	0.0%
eart failure	****	****
yperlipidemia	****	****
ypertensive disease	****	****
hyroid disease	****	****
schemic heart disease/coronary artery disease/myocardial infarction	****	****
eft ventricular hypertrophy	0	0.0%
eripheral artery disease	0	0.0%
'alvular/mitral valve disease	0	0.0%
iseases of veins and lymphatics, and other diseases of circulatory system	****	****
bstructive sleep apnea	****	****
ypertrophic cardiomyopathy	****	****
other cardiac disease	****	****
achyarrhythmia day 0	0	0.0%
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	0	0.0%
Nedical Product Use		0.070
Ipha-glucosidase inhibitors	****	****
mylin analogs (pramlintide)	0	0.0%
PP-4 inhibitors	****	****
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Aglitinides	0	0.0%
nsulin	****	****
iguanides (metformin, phenformin, etc.)	****	****
GLT2 inhibitors	****	****
	****	****
ulfonylurea hiazolidinedione	****	****
o baseline use of any of the above antidiabetic drugs	0	0.0%
ther antidiabetics	0	0.0%
odium channel blockers	0 ****	0.0%
eta blockers		
otassium channel blockers/openers	0	0.0%
Ion-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 221 of 1023



Table 1bp. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	****	****
Angiotensin-converting-enzyme (ACE) inhibitor	****	****
Angiotensin ii receptor blockers (ARBs)	****	****
Dihydropyridines	****	****
Diuretics	****	****
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	****	****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	****	100.0%
Baseline known risk of prolonged QT and torsades de pointes	****	****
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	****	****
torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.4	27.7
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.3	1.0
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	7.8	14.2
Mean number of filled prescriptions	35.6	21.1
Mean number of generics dispensed	10.6	5.3
Mean number of unique drug classes dispensed	9.1	4.6

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 222 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bq. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	40	N/A
Demographic Characteristics		
Age (years)	70.1	5.5
Age		
0-40 years	****	****
41-64 years	****	****
65-74 years	27	67.5%
75-84 years	****	****
≥ 85 years	****	****
ex		
Female	25	62.5%
Male	15	37.5%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	40	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	0	0.0%
No	****	****
Unknown	****	****
'ear		
2022	18	45.0%
2023	22	55.0%
lealth Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	3.0	2.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	****
1-2	****	****
3-4	16	40.0%
5+	****	****
Combined comorbidity score ⁴	3.1	2.7
ombined comorbidity score categories ⁴		
0	****	****
	****	****
-2	11	27.5%
3-4	11	27.5%
i+	****	****

cder_mpl1p_wp077 Page 223 of 1023



Table 1bq. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Tapia Schemer Distributed Database und Schemer Distributed Database from	, ,	Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	15	37.5%
Tobacco use	****	****
Arrhythmia	12	30.0%
Cerebrovascular disease/stroke/transient ischemic attack	****	****
Chronic kidney disease	11	27.5%
Chronic obstructive pulmonary disease	****	****
Congenital heart disease	****	****
Heart failure	11	27.5%
Hyperlipidemia	****	****
Hypertensive disease	****	****
Thyroid disease	****	****
Ischemic heart disease/coronary artery disease/myocardial infarction	13	32.5%
Left ventricular hypertrophy	****	****
Peripheral artery disease	****	****
Valvular/mitral valve disease	****	****
Diseases of veins and lymphatics, and other diseases of circulatory system	****	****
Obstructive sleep apnea	****	****
Hypertrophic cardiomyopathy	****	****
Other cardiac disease	22	55.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	****	****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
Insulin	26	65.0%
Biguanides (metformin, phenformin, etc.)	****	****
SGLT2 inhibitors	13	32.5%
Sulfonylurea	16	40.0%
Thiazolidinedione	****	****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	23	60.0%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 224 of 1023



Table 1bq. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	23	60.0%
Angiotensin-converting-enzyme (ACE) inhibitor	15	37.5%
Angiotensin ii receptor blockers (ARBs)	16	40.0%
Dihydropyridines	21	52.5%
Diuretics	18	45.0%
Other antihypertensives	****	****
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	****	****
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	****	****
Other cardiac medications (any of the other cardiac medications)	****	****
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	14	35.0%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	****	****
torsades de pointes	****	****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.2	23.3
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	2.9	4.0
Mean number of filled prescriptions	34.2	16.3
Mean number of generics dispensed	12.3	5.7
Mean number of unique drug classes dispensed	10.6	4.9

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 225 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1br. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standar
Patient Characteristics	Number/Mean	Deviation ¹
Unique patients	****	N/A
Demographic Characteristics		
Age (years)	32.8	NaN
Age		
0-40 years	****	100.0%
41-64 years	0	0.0%
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	0	0.0%
Male	****	100.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	****	100.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	0	0.0%
No	****	100.0%
Unknown	0	0.0%
'ear		
2022	****	100.0%
2023	0	0.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.0	NaN
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	100.0%
1-2	0	0.0%
3-4	0	0.0%
5+	0	0.0%
ombined comorbidity score ⁴	2.0	NaN
Combined comorbidity score categories ⁴		
0	0	0.0%
	0	0.0%
-2	****	100.0%
3-4	0	0.0%
;+	0	0.0%

cder_mpl1p_wp077 Page 226 of 1023



Table 1br. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	****	100.0%
Tobacco use	****	100.0%
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	0	0.0%
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	****	100.0%
Hypertensive disease	0	0.0%
Thyroid disease	0	0.0%
schemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	****	100.0%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	****	100.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	****	100.0%
Biguanides (metformin, phenformin, etc.)	****	100.0%
SGLT2 inhibitors	0	0.0%
Sulfonylurea	0	0.0%
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	0	0.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 227 of 1023



Table 1br. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Angiotensin-converting-enzyme (ACE) inhibitor	0	0.0%
Angiotensin ii receptor blockers (ARBs)	0	0.0%
Dihydropyridines	0	0.0%
Diuretics	0	0.0%
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	0	0.0%
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	****	100.0%
Baseline known risk of prolonged QT and torsades de pointes	****	100.0%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	****	100.0%
torsades de pointes	****	100.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	49.0	NaN
Mean number of emergency room encounters	9.0	NaN
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	1.0	NaN
Mean number of other ambulatory encounters	14.0	NaN
Mean number of filled prescriptions	85.0	NaN
Mean number of generics dispensed	13.0	NaN
Mean number of unique drug classes dispensed	12.0	NaN

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 228 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bs. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	237	N/A
Demographic Characteristics		
Age (years)	71.2	8.2
Age		
0-40 years	****	****
41-64 years	42	17.0%
65-74 years	127	51.4%
75-84 years	66	26.7%
≥ 85 years	****	****
ex		
Female	113	45.7%
Male	134	54.3%
ace ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	237	100.0%
ispanic origin		
Yes	0	0.0%
No	229	92.7%
Unknown	18	7.3%
ear		
2022	153	61.9%
2023	94	38.1%
lealth Characteristics		33.2,0
dapted Diabetes Complications Severity Index (aDCSI) ³	3.1	2.3
dapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	35	14.2%
1-2	74	30.0%
3-4	74	30.0%
5+	64	25.9%
ombined comorbidity score ⁴	3.5	2.9
ombined comorbidity score categories ⁴	J.J	2.5
0	****	****
O Company of the Comp	****	****
-2	70	28.3%
-4	58	23.5%
+	83	33.6%

cder_mpl1p_wp077 Page 229 of 1023



Table 1bs. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Distributed Database and Sentiner Distributed Database from May 15, 2022		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	****	****
Obesity	123	49.8%
Tobacco use	69	27.9%
Arrhythmia	72	29.1%
Cerebrovascular disease/stroke/transient ischemic attack	64	25.9%
Chronic kidney disease	85	34.4%
Chronic obstructive pulmonary disease	46	18.6%
Congenital heart disease	46	18.6%
Heart failure	53	21.5%
Hyperlipidemia	226	91.5%
Hypertensive disease	229	92.7%
Thyroid disease	64	25.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	91	36.8%
Left ventricular hypertrophy	23	9.3%
Peripheral artery disease	23	9.3%
Valvular/mitral valve disease	19	7.7%
Diseases of veins and lymphatics, and other diseases of circulatory system	46	18.6%
Obstructive sleep apnea	66	26.7%
Hypertrophic cardiomyopathy	25	10.1%
Other cardiac disease	129	52.2%
Tachyarrhythmia day 0	****	****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	****	****
Medical Product Use		
Alpha-glucosidase inhibitors	****	****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	34	13.8%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	****	****
Insulin	148	59.9%
Biguanides (metformin, phenformin, etc.)	195	78.9%
SGLT2 inhibitors	62	25.1%
Sulfonylurea	113	45.7%
Thiazolidinedione	37	15.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	****	****
Beta blockers	121	49.0%
Potassium channel blockers/openers	****	****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	****	****
Other antiarrhythmic agents	0	0.0%

cder_mpl1p_wp077 Page 230 of 1023



Table 1bs. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	121	49.0%
Angiotensin-converting-enzyme (ACE) inhibitor	123	49.8%
Angiotensin ii receptor blockers (ARBs)	97	39.3%
Dihydropyridines	70	28.3%
Diuretics	95	38.5%
Other antihypertensives	25	10.1%
Antihypertensives (any of the above antihypertensives)	225	91.1%
Oral anticoagulants	23	9.3%
Vitamin K antagonists	****	****
Other cardiac medications not mentioned above	20	8.1%
Other cardiac medications (any of the other cardiac medications)	45	18.2%
Lipid lowering therapy	222	89.9%
Baseline known risk of prolonged QT and torsades de pointes	104	42.1%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	212	85.8%
torsades de pointes	34	13.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.6	15.4
Mean number of emergency room encounters	0.9	1.7
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	5.0	8.6
Mean number of filled prescriptions	44.0	25.8
Mean number of generics dispensed	12.9	5.3
Mean number of unique drug classes dispensed	11.3	4.7

¹Value represents standard deviation where no % follows the value.

N/A: Not applicable

cder_mpl1p_wp077 Page 231 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1bt. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Jnique patients	****	N/A
Demographic Characteristics		
Age (years)	53.0	0.0
Age		
0-40 years	0	0.0%
41-64 years	****	100.0%
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
ex		
Female	****	100.0%
Male	0	0.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	****	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
lispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	****	100.0%
'ear		
2022	****	****
2023	****	****
lealth Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.5	0.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	****	****
1-2	****	****
3-4	0	0.0%
5+	0	0.0%
combined comorbidity score ⁴	0.5	0.0
ombined comorbidity score categories ⁴		
0	0	0.0%
	****	****
-2	****	****
-4	0	0.0%
;+	0	0.0%
•	U	0.070

cder_mpl1p_wp077 Page 232 of 1023



Table 1bt. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Alcohol use or abuse	0	0.0%
Dbesity	0	0.0%
obacco use	0	0.0%
Arrhythmia	0	0.0%
Gerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	0	0.0%
hronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
leart failure	0	0.0%
lyperlipidemia	****	****
lypertensive disease	****	****
hyroid disease	****	****
schemic heart disease/coronary artery disease/myocardial infarction	****	****
eft ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
alvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Dbstructive sleep apnea	0	0.0%
lypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	****	****
achyarrhythmia day 0	0	0.0%
lospitalized tachyarrhythmia day 0	0	0.0%
listory of serious hypoglycemia (ED and/or IP)	0	0.0%
Nedical Product Use		
ulpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
PPP-4 inhibitors	0	0.0%
ncretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
∕ leglitinides	0	0.0%
nsulin	0	0.0%
siguanides (metformin, phenformin, etc.)	****	100.0%
GLT2 inhibitors	0	0.0%
ulfonylurea	****	****
hiazolidinedione	0	0.0%
lo baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
odium channel blockers	0	0.0%
eta blockers	0	0.0%
Potassium channel blockers/openers	0	0.0%
Von-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
	•	3.070

cder_mpl1p_wp077 Page 233 of 1023



Table 1bt. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Percent/Standard
Patient Characteristics	Number/Mean	Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Angiotensin-converting-enzyme (ACE) inhibitor	0	0.0%
Angiotensin ii receptor blockers (ARBs)	****	****
Dihydropyridines	0	0.0%
Diuretics	0	0.0%
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	****	****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	****	****
Baseline known risk of prolonged QT and torsades de pointes	0	0.0%
Baseline possible risk of prolonged QT and torsades de pointes Concomitant use of medical products with a known risk of prolonged QT and	****	****
torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.5	0.0
Mean number of emergency room encounters	0.5	0.0
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	0.0	NaN
Mean number of filled prescriptions	19.5	0.0
Mean number of generics dispensed	8.0	0.0
Mean number of unique drug classes dispensed	7.5	0.0

¹Value represents standard deviation where no % follows the value.

NaN: Not a number N/A: Not applicable

cder_mpl1p_wp077 Page 234 of 1023

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized	1,321	1,321	****	****	****	****	392.98 (187.35, 823.34)	2,069	2,069	518.3
Tachyarrhythmia	-, -	_,					11 11 (11 11 11 11 11 11 11 11 11 11 11	-,	_,	
Mounjaro, Hospitalized	18,842	18,842	102	0.54 (0.44, 0.65)	2,159.0	788,592	472.43 (389.09, 573.62)	31,173	31,585	5,238.20
Tachyarrhythmia	447.000	447.000	702	0.60.40.63.0.73	46 225 6	E 020 044	400 45 (455 64, 533 66)	474 424	474.050	42.222.0
Ozempic, Hospitalized Tachyarrhythmia	117,008	117,008	793	0.68 (0.63, 0.72)	16,235.0	5,929,844	488.45 (455.61, 523.66)	174,434	174,950	42,322.8
Rybelsus, Hospitalized	34,058	34,058	178	0.52 (0.45, 0.60)	4,668.5	1,705,183	381.28 (329.18, 441.61)	49,962	51,042	12,854.5
Tachyarrhythmia										
Saxenda, Hospitalized	386	386	****	****	****	****	199.10 (28.04, 1,413.48)	587	587	195.2
Tachyarrhythmia										
Trulicity, Hospitalized Tachyarrhythmia	66,978	66,978	496	0.74 (0.68, 0.81)	9,902.2	3,616,783	500.90 (458.70, 546.98)	117,542	118,288	25,876.5
Victoza, Hospitalized	5,354	5,354	45	0.84 (0.60, 1.09)	748.6	273,417	601.14 (448.83, 805.14)	7,722	7,723	2,071.3
Tachyarrhythmia										
Wegovy, Hospitalized Tachyarrhythmia	828	828	****	****	****	****	137.10 (19.31, 973.29)	1,299	1,323	137.3
Xultophy, Hospitalized	364	364	****	****	****	****	349.71 (87.46, 1,398.31)	484	484	131.2
Tachyarrhythmia Mounjaro, Atrial	18,842	18,842	64	0.34 (0.26, 0.42)	2,159.0	788,592	296.43 (232.01, 378.72)	31,173	31,585	5,238.20
Fibrillation and Flutter	•			,						
Bydureon, Atrial	1,321	1,321	****	****	****	****	280.70 (116.83, 674.41)	2,069	2,069	518.3
Fibrillation and Flutter Ozempic, Atrial Fibrillation and Flutter	117,008	117,008	506	0.43 (0.39, 0.47)	16,235.0	5,929,844	311.67 (285.66, 340.05)	174,434	174,950	42,322.8



Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years at	Total Days	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)	Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Rybelsus, Atrial	34,058	34,058	123	0.36 (0.30, 0.43)	4,668.5	1,705,183	265.61 (222.74, 316.73)	49,962	51,042	12,854.5
Fibrillation and Flutter Wegovy, Atrial Fibrillation and Flutter	828	828	****	****	****	****	137.10 (19.31, 973.29)	1,299	1,323	137.3
Saxenda, Atrial	386	386	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	587	587	195.2
Fibrillation and Flutter										
Victoza, Atrial Fibrillation	5,354	5,354	27	0.50 (0.31, 0.69)	748.6	273,417	360.69 (237.35, 525.95)	7,722	7,723	2,071.3
and Flutter										
Trulicity, Atrial Fibrillation and Flutter	66,978	66,978	344	0.51 (0.46, 0.57)	9,902.2	3,616,783	347.40 (312.56, 386.12)	117,542	118,288	25,876.5
Xultophy, Atrial Fibrillation and Flutter	364	364	****	****	****	****	174.85 (23.63, 1,231.34)	484	484	131.2
Mounjaro, Sinus Tachycardia	18,842	18,842	30	0.16 (0.10, 0.22)	2,159.0	788,592	138.95 (97.15, 198.73)	31,173	31,585	5,238.20
Bydureon, Sinus Tachycardia	1,321	1,321	****	****	****	****	56.14 (7.91, 398.56)	2,069	2,069	518.3
Ozempic, Sinus	117,008	117,008	182	0.16 (0.13, 0.18)	16,235.0	5,929,844	112.10 (96.94, 129.63)	174,434	174,950	42,322.8
Rybelsus, Sinus	34,058	34,058	45	0.13 (0.09, 0.17)	4,668.5	1,705,183	96.39 (71.97, 129.10)	49,962	51,042	12,854.5
Wegovy, Sinus	828	828	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,299	1,323	137.3
Saxenda, Sinus	386	386	****	****	****	****	199.10 (28.04, 1,413.48)	587	587	195.2
Victoza, Sinus	5,354	5,354	15	0.28 (0.14, 0.42)	748.6	273,417	200.38 (120.80, 332.38)	7,722	7,723	2,071.3
Trulicity, Sinus	66,978	66,978	108	0.16 (0.13, 0.19)	9,902.2	3,616,783	109.07 (90.32, 131.70)	117,542	118,288	25,876.5
Xultophy, Sinus Tachvcardia	364	364	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	484	484	131.2



Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro,	18,842	18,842	****	****	****	****	37.05 (18.53, 74.09)	31,173	31,585	5,238.20
Supraventricular										
Bydureon,	1,321	1,321	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,069	2,069	518.3
Supraventricular										
Ozempic,	117,008	117,008	70	0.06 (0.05, 0.07)	16,235.0	5,929,844	43.12 (34.11, 54.50)	174,434	174,950	42,322.8
Supraventricular										
Rybelsus,	34,058	34,058	16	0.05 (0.02, 0.07)	4,668.5	1,705,183	34.27 (21.00, 55.94)	49,962	51,042	12,854.5
Supraventricular	020	020	•	0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	4 200	4 222	427.2
Wegovy, Supraventricular	828	828	0	0.00 (0.00, 0.00)	****	* * * * *	0.00 (0.00, 0.00)	1,299	1,323	137.3
Tachycardia Saxenda,	386	386	****	****	****	****	199.10 (28.04, 1,413.48)	587	587	195.2
Supraventricular	360	360					199.10 (20.04, 1,413.46)	367	367	193.2
Victoza, Supraventricular	5,354	5,354	****	****	****	****	66.79 (27.80, 160.48)	7,722	7,723	2,071.3
Tachycardia	3,334	3,334					00.73 (27.00, 100.40)	7,722	7,723	2,071.0
Trulicity, Supraventricular	66,978	66,978	41	0.06 (0.04, 0.08)	9,902.2	3,616,783	41.40 (30.49, 56.23)	117,542	118,288	25,876.5
Tachycardia	,	,		, , ,	,	, ,	, , ,	•	•	,
Xultophy,	364	364	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	484	484	131.2
Supraventricular										
Mounjaro, Other	18,842	18,842	****	****	****	****	23.16 (9.64, 55.64)	31,173	31,585	5,238.20
Tachycardia										
Bydureon, Other	1,321	1,321	****	****	****	****	112.28 (28.08, 448.96)	2,069	2,069	518.3
Tachycardia										
Ozempic, Other	117,008	117,008	53	0.05 (0.03, 0.06)	16,235.0	5,929,844	32.65 (23.94, 42.73)	174,434	174,950	42,322.8



Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years at	Total Dave	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)	Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Rybelsus, Other	34,058	34,058	****	****	****	****	10.71 (4.46, 25.73)	49,962	51,042	12,854.5
Tachycardia	·	•					, , ,	•	ŕ	·
Wegovy, Other	828	828	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,299	1,323	137.3
Saxenda, Other	386	386	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	587	587	195.2
Tachycardia										
Victoza, Other	5,354	5,354	****	****	****	****	40.08 (12.93, 123.26)	7,722	7,723	2,071.3
Trulicity, Other	66,978	66,978	21	0.03 (0.02, 0.04)	9,902.2	3,616,783	21.21 (13.83, 32.53)	117,542	118,288	25,876.5
Xultophy, Other	364	364	****	****	****	****	174.85 (23.63, 1,231.34)	484	484	131.2
Tachycardia										
Mounjaro, Cardiac Arrest	18,842	18,842	0	0.00 (0.00, 0.00)	2,159.0	788,592	0.00 (0.00, 0.00)	31,173	31,585	5,238.20
Bydureon, Cardiac Arrest	1,321	1,321	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,069	2,069	518.3
Ozempic, Cardiac Arrest	117,008	117,008	18	0.02 (0.01, 0.02)	16,235.0	5,929,844	11.09 (6.99, 17.60)	174,434	174,950	42,322.8
Rybelsus, Cardiac Arrest	34,058	34,058	****	****	****	****	4.28 (1.07, 17.13)	49,962	51,042	12,854.5
Wegovy, Cardiac Arrest	828	828	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,299	1,323	137.3
Saxenda, Cardiac Arrest	386	386	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	587	587	195.2
Victoza, Cardiac Arrest	5,354	5,354	****	****	****	****	40.08 (12.93, 123.26)	7,722	7,723	2,071.3
Trulicity, Cardiac Arrest	66,978	66,978	12	0.02 (0.01, 0.03)	9,902.2	3,616,783	12.12 (6.88, 21.34)	117,542	118,288	25,876.5
Xultophy, Cardiac Arrest	364	364	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	484	484	131.2
Mounjaro, Ventricular Tachycardia	18,842	18,842	0	0.00 (0.00, 0.00)	2,159.0	788,592	0.00 (0.00, 0.00)	31,173	31,585	5,238.20
Bydureon, Ventricular Tachycardia	1,321	1,321	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,069	2,069	518.3
Ozempic, Ventricular Tachycardia	117,008	117,008	****	****	****	****	4.31 (2.06, 9.04)	174,434	174,950	42,322.8



Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

, ,							•	•		
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable Years
Dubalana Mantrianlan									Dispensings)	
Rybelsus, Ventricular	34,058	34,058	0	0.00 (0.00, 0.00)	4,668.5	1,705,183	0.00 (0.00, 0.00)	49,962	51,042	12,854.5
Tachycardia Wegovy, Ventricular	828	828	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,299	1,323	137.3
Tachycardia Saxenda, Ventricular Tachycardia	386	386	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	587	587	195.2
Victoza, Ventricular Tachycardia	5,354	5,354	0	0.00 (0.00, 0.00)	748.6	273,417	0.00 (0.00, 0.00)	7,722	7,723	2,071.3
Trulicity, Ventricular Tachycardia	66,978	66,978	****	****	****	****	3.03 (0.98, 9.39)	117,542	118,288	25,876.5
Xultophy, Ventricular Tachycardia	364	364	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	484	484	131.2
Mounjaro, Ventricular Fibrillation and Flutter	18,842	18,842	****	****	****	****	4.63 (0.65, 32.88)	31,173	31,585	5,238.20
Bydureon, Ventricular Fibrillation and Flutter	1,321	1,321	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,069	2,069	518.3
Ozempic, Ventricular Fibrillation and Flutter	117,008	117,008	****	****	****	****	2.46 (0.92, 6.56)	174,434	174,950	42,322.8
Rybelsus, Ventricular Fibrillation and Flutter	34,058	34,058	0	0.00 (0.00, 0.00)	4,668.5	1,705,183	0.00 (0.00, 0.00)	49,962	51,042	12,854.5
Wegovy, Ventricular Fibrillation and Flutter	828	828	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,299	1,323	137.3
Saxenda, Ventricular Fibrillation and Flutter	386	386	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	587	587	195.2



Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure				Number of Exposure Episode Defining- Dispensings (Adjusted	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Total		Event Rate per 10,000	for Same-	Adjusted for	Total
	of	Exposure	with an	Confidence	Years at	Total Days	Patient-Years at Risk (95%	Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Victoza, Ventricular	5,354	5,354	0	0.00 (0.00, 0.00)	748.6	273,417	0.00 (0.00, 0.00)	7,722	7,723	2,071.3
Fibrillation and Flutter										
Trulicity, Ventricular	66,978	66,978	****	****	****	****	5.05 (2.10, 12.13)	117,542	118,288	25,876.5
Fibrillation and Flutter										
Xultophy, Ventricular	364	364	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	484	484	131.2
Fibrillation and Flutter										

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



	,						entiner Distributed Database no	,,		,
			Number of Exposure	Number of Exposure				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
		Number of	Episodes	Episodes with an Event	Total	Total	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	per 100 Exposure Episodes	Years	Days at	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	(95% Confidence Interval)	at Risk	Risk	Interval)	Dispensings)	Dispensings)	Years
Bydureor	n, Hospitalized	l Tachyarrhyt	:hmia							
Female	675	675	****	****	****	****	339.17 (109.39, 1,051.64)	1,071	1,071	266.7
Male	646	646	****	****	****	****	446.07 (167.41, 1,188.52)	998	998	251.7
Mounjard	o, Hospitalized	l Tachyarrhyt								
Female	10,809	10,809	****	****	****	****	381.12 (286.35, 507.25)	17,975	18,222	3,009.5
Male	8,033	8,033	****	****	****	****	594.06 (456.09, 773.76)	13,198	13,363	2,238.6
Ozempic,	Hospitalized '	Tachyarrhyth								
Female	65,494	65,494	****	****	****	****	473.98 (431.23, 520.96)	98,213	98,479	23,828.9
Male	51,514	51,514	****	****	****	****	506.78 (457.23, 561.69)	76,221	76,471	18,494.0
Rybelsus,	, Hospitalized	Tachyarrhyth								
Female	17,466	17,466	****	****	****	****	352.48 (284.25, 437.09)	25,490	25,984	6,620.4
Male	16,592	16,592	****	****	****	****	410.58 (335.79, 502.03)	23,472	25,058	6,234.1
Saxenda,	Hospitalized 1	Tachyarrhyth	mia							
Female	294	294	****	****	****	****	265.69 (37.43, 1,886.25)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	140	49.9
Trulicity,	Hospitalized T	achyarrhyth	mia							
Female	34,815	34,815	****	****	****	****	448.64 (394.13, 510.68)	61,129	61,503	13,487.5
Male	32,163	32,163	****	****	****	****	556.50 (493.59, 627.42)	56,413	56,785	12,389.0
Victoza, I	Hospitalized Ta	achyarrhythn	nia							
Female	3,117	3,117	****	****	****	****	556.80 (373.20, 830.72)	4,488	4,489	1,214.8
Male	2,237	2,237	****	****	****	****	661.33 (431.19, 1,014.31)	3,234	3,234	856.5
Wegovy,	Hospitalized T	achyarrhyth	mia							
Female	570	570	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	****	****	****	****	417.91 (58.87, 2,966.85)	414	425	42.9
Xultophy	, Hospitalized	Tachyarrhytl	hmia							
Female	172	172	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	****	****	****	****	701.19 (175.36, 2,803.74)	250	250	67.6



Tubic 5. 5	anning or Ex	iposures or ii	Trecrese iii e	ne napia sentinei sistrisate	a Databa	ise and s	entinei Distributeu Dutabase no	Way 13, 202	2 (0)4116 30, 2023,	Jy Jek
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjard	, Atrial Fibrill	•					•	, ,	, ,	
Female	10,809	10,809	****	****	****	****	202.72 (136.98, 300.02)	17,975	18,222	3,009.5
Male	8,033	8,033	****	****	****	****	421.23 (307.77, 576.54)	13,198	13,363	2,238.6
Bydureon	, Atrial Fibrilla	ation and Flu	tter							
Female	675	675	****	****	****	****	339.17 (109.39, 1,051.64)	1,071	1,071	266.7
Male	646	646	****	****	****	****	223.03 (55.78, 891.81)	998	998	251.7
Ozempic,	Atrial Fibrillat	tion and Flut	ter							
Female	65,494	65,494	****	****	****	****	282.18 (239.65, 318.96)	98,213	98,479	23,828.9
Male	51,514	51,514	****	****	****	****	349.02 (308.33, 395.08)	76,221	76,471	18,494.0
Rybelsus,	Atrial Fibrilla	tion and Flut	ter							
Female	17,466	17,466	****	****	****	****	229.33 (175.64, 299.43)	25,490	25,984	6,620.4
Male	16,592	16,592	****	****	****	****	302.53 (239.35, 382.39)	23,472	25,058	6,234.1
Wegovy,	Atrial Fibrillat	ion and Flutt	er							
Female	570	570	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	****	****	****	****	417.91 (58.87, 2,966.85)	414	425	42.9
Saxenda,	Atrial Fibrillat	ion and Flutt	ter							
Female	294	294	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, A	Atrial Fibrillation	on and Flutte								
Female	3,117	3,117	****	****	****	****	255.20 (141.33, 460.82)	4,488	4,489	1,214.8
Male	2,237	2,237	****	****	****	****	503.87 (308.68, 822.48)	3,234	3,234	856.5
	Atrial Fibrillat									
Female	34,815	34,815	****	****	****	****	293.87 (250.41, 344.87)	61,129	61,503	13,487.5
Male	32,163	32,163	****	****	****	****	404.35 (351.27, 465.44)	56,413	56,785	12,389.0
	, Atrial Fibrilla									
Female	172	172	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	****	****	****	****	350.60 (49.38, 2,488.99)	250	250	67.6



Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	,						entiner Distributed Database no			-,
	Number of	•	with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes		Days at	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
Mouniar	Patients o, Sinus Tachy	Episodes cardia	Event	(95% Confidence Interval)	at Risk	Risk	Interval)	Dispensings)	Dispensings)	Years
Female	10,809	10,809	****	****	****	****	129.74 (79.48, 211.78)	17,975	18,222	3,009.5
Male	8,033	8,033	****	****	****	****	151.21 (89.56, 255.32)	13,198	13,363	2,238.6
	n, Sinus Tachyo						(12.27)	,	-,	,
Female	675	675	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,071	1,071	266.7
Male	646	646	****	****	****	****	111.52 (15.71, 791.69)	998	998	251.7
Ozempic,	Sinus Tachyca	ardia								
Female	65,494	65,494	****	****	****	****	130.07 (108.60, 155.79)	98,213	98,479	23,828.9
Male	51,514	51,514	****	****	****	****	89.35 (69.93, 114.15)	76,221	76,471	18,494.0
Rybelsus	, Sinus Tachyca	ardia								
Female	17,466	17,466	****	****	****	****	97.68 (64.91, 146.99)	25,490	25,984	6,620.4
Male	16,592	16,592	****	****	****	****	95.08 (62.61, 144.40)	23,472	25,058	6,234.1
Wegovy,	Sinus Tachyca									
Female	570	570	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	414	425	42.9
	Sinus Tachyca									
Female	294	294	****	****	****	****	265.69 (37.43, 1,886.25)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	140	49.9
-	Sinus Tachycar									
Female	3,117	3,117	****	****	****	****	208.80 (108.64, 401.30)	4,488	4,489	1,214.8
Male	2,237	2,237	****	****	*****	****	188.95 (84.89, 420.59)	3,234	3,234	856.5
	Sinus Tachyca		district 1	4.4	did at a second	ation to a final				
Female	34,815	34,815	****	****	****	****	109.71 (84.43, 142.56)	61,129	61,503	13,487.5
Male	32,163	32,163	****	****	*****	*****	108.38 (82.59, 142.23)	56,413	56,785	12,389.0
	, Sinus Tachyc			2 2 4 2 2 2 2 2 2	ale ale altri di di	ale ale et et et	2 2 4 2 2 2 2 2 2			
Female	172	172	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	250	250	67.6



	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjard	o, Supraventri			(5576 551111451155 111151 11117			,			
Female	10,809	10,809	****	****	****	****	40.54 (16.88, 97.41)	17,975	18,222	3,009.5
Male	8,033	8,033	****	****	****	****	32.40 (10.45, 100.47)	13,198	13,363	2,238.6
Bydureor	n, Supraventri	cular Tachyca	ardia							
Female	675	675	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,071	1,071	266.7
Male	646	646	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	998	998	251.7
Ozempic,	Supraventric	ular Tachycai	dia							
Female	65,494	65,494	****	****	****	****	42.99 (31.41, 58.84)	98,213	98,479	23,828.9
Male	51,514	51,514	****	****	****	****	43.28 (30.44, 61.54)	76,221	76,471	18,494.0
Rybelsus	Supraventric	ular Tachycaı	rdia							
Female	17,466	17,466	****	****	****	****	33.97 (16.99, 67.94)	25,490	25,984	6,620.4
Male	16,592	16,592	****	****	****	****	34.57 (17.29, 69.14)	23,472	25,058	6,234.1
Wegovy,	Supraventricu	lar Tachycar	dia							
Female	570	570	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	414	425	42.9
Saxenda,	Supraventricu	ılar Tachycar								
Female	294	294	****	****	****	****	265.69 (37.43, 1,886.25)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, S	Supraventricul	ar Tachycard								
Female	3,117	3,117	****	****	****	****	23.20 (3.27, 164.70)	4,488	4,489	1,214.8
Male	2,237	2,237	****	****	****	****	125.97 (47.28, 335.64)	3,234	3,234	856.5
	Supraventricu									
Female	34,815	34,815	****	****	****	****	35.26 (22.22, 55.97)	61,129	61,503	13,487.5
Male	32,163	32,163	****	****	*****	*****	47.94 (31.86, 72.14)	56,413	56,785	12,389.0
	, Supraventric									
Female	172	172	0	0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	250	250	67.6



Tubic 5. 5	allillary of Ex	iposures or i	incoresc iii e	ne napia seminei sistrisate	a Bataba	isc and s	entinei Distributeu Dutabase no	way 13, 202	2 (0)4116 30, 2023,	Jy Jek
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjard	, Other Tachy									
Female	10,809	10,809	****	****	****	****	16.22 (4.06, 64.85)	17,975	18,222	3,009.5
Male	8,033	8,033	****	****	****	****	32.40 (10.45, 100.47)	13,198	13,363	2,238.6
Bydureor	, Other Tachy	cardia								
Female	675	675	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,071	1,071	266.7
Male	646	646	****	****	****	****	223.03 (55.78, 891.81)	998	998	251.7
Ozempic,	Other Tachyo	ardia								
Female	65,494	65,494	****	****	****	****	36.38 (25.86, 51.17)	98,213	98,479	23,828.9
Male	51,514	51,514	****	****	****	****	27.92 (18.01, 43.28)	76,221	76,471	18,494.0
Rybelsus,	Other Tachyo	ardia								
Female	17,466	17,466	****	****	****	****	4.25 (0.60, 30.15)	25,490	25,984	6,620.4
Male	16,592	16,592	****	****	****	****	17.29 (6.49, 46.06)	23,472	25,058	6,234.1
	Other Tachyca									
Female	570	570	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	414	425	42.9
	Other Tachyc									
Female	294	294	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	140	49.9
	Other Tachyca									
Female	3,117	3,117	****	****	****	****	23.20 (3.27, 164.70)	4,488	4,489	1,214.8
Male	2,237	2,237	****	****	****	****	62.98 (15.75, 251.84)	3,234	3,234	856.5
	Other Tachyca									
Female	34,815	34,815	****	****	****	****	23.51 (13.35, 41.40)	61,129	61,503	13,487.5
Male	32,163	32,163	****	****	****	****	18.76 (9.76, 36.05)	56,413	56,785	12,389.0
	Other Tachyo									
Female	172	172	0	0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	****	****	****	****	350.60 (49.38, 2,488.99)	250	250	67.6



	Number of Patients	Number of	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total	Total	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjard	o, Cardiac Arre	est								
Female	10,809	10,809	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17,975	18,222	3,009.5
Male	8,033	8,033	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13,198	13,363	2,238.6
Bydureor	n, Cardiac Arre	st								
Female	675	675	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,071	1,071	266.7
Male	646	646	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	998	998	251.7
Ozempic,	Cardiac Arres	t								
Female	65,494	65,494	****	****	****	****	11.02 (5.93, 20.49)	98,213	98,479	23,828.9
Male	51,514	51,514	****	****	****	****	11.17 (5.59, 22.33)	76,221	76,471	18,494.0
Rybelsus	, Cardiac Arres	t								
Female	17,466	17,466	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25,490	25,984	6,620.4
Male	16,592	16,592	****	****	****	****	8.64 (2.16, 34.56)	23,472	25,058	6,234.1
Wegovy,	Cardiac Arrest	t								
Female	570	570	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	414	425	42.9
Saxenda,	Cardiac Arres	t								
Female	294	294	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, (Cardiac Arrest									
Female	3,117	3,117	****	****	****	****	69.60 (22.45, 215.80)	4,488	4,489	1,214.8
Male	2,237	2,237	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,234	3,234	856.5
	Cardiac Arrest									
Female	34,815	34,815	****	****	****	****	9.80 (4.08, 23.53)	61,129	61,503	13,487.5
Male	32,163	32,163	****	****	****	****	14.59 (6.96, 30.60)	56,413	56,785	12,389.0
	, Cardiac Arres									
Female	172	172	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	250	250	67.6



Tuble 51 c	, annual y 01 2.			ne napia senime. Sistina acc		.50 0110 0	entinei Distributea Database no		_ (0) (1) (1)	oy sex
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mouniare	o, Ventricular		LVEIIC	(33% confidence interval)	at Misk	Misk	intervary	Disperisings	Disperisings	rears
Female	10,809	10,809	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17,975	18,222	3,009.5
Male	8,033	8,033	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13,198	13,363	2,238.6
	n, Ventricular						, ,	,	,	•
Female	675	675	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,071	1,071	266.7
Male	646	646	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	998	998	251.7
Ozempic,	Ventricular Ta	achycardia					·			
Female	65,494	65,494	****	****	****	****	4.41 (1.65, 11.75)	98,213	98,479	23,828.9
Male	51,514	51,514	****	****	****	****	4.19 (1.35, 12.99)	76,221	76,471	18,494.0
Rybelsus	, Ventricular T	achycardia								
Female	17,466	17,466	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25,490	25,984	6,620.4
Male	16,592	16,592	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23,472	25,058	6,234.1
Wegovy,	Ventricular Ta	chycardia								
Female	570	570	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	414	425	42.9
Saxenda,	Ventricular Ta	achycardia								
Female	294	294	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, \	/entricular Tac	chycardia								
Female	3,117	3,117	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,488	4,489	1,214.8
Male	2,237	2,237	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,234	3,234	856.5
	Ventricular Ta	-								
Female	34,815	34,815	****	****	****	****	1.96 (0.28, 13.91)	61,129	61,503	13,487.5
Male	32,163	32,163	****	****	****	****	4.17 (1.04, 16.67)	56,413	56,785	12,389.0
	, Ventricular T									
Female	172	172	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	250	250	67.6



Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	, ,							, , ,		,
	Number of Patients	Episodes	with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
	, Ventricular I									
Female	10,809	10,809	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17,975	18,222	3,009.5
Male	8,033	8,033	****	****	*****	****	10.80 (1.52, 76.68)	13,198	13,363	2,238.6
	, Ventricular I									
Female	675	675	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,071	1,071	266.7
Male	646	646	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	998	998	251.7
Ozempic, \	Ventricular Fi	brillation and								
Female	65,494	65,494	****	****	****	****	2.20 (0.55, 8.81)	98,213	98,479	23,828.9
Male	51,514	51,514	****	****	****	****	2.79 (0.70, 11.16)	76,221	76,471	18,494.0
Rybelsus,	Ventricular Fi	brillation an	d Flutter							
Female	17,466	17,466	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25,490	25,984	6,620.4
Male	16,592	16,592	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23,472	25,058	6,234.1
Wegovy, V	entricular Fil	orillation and	l Flutter							
Female	570	570	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	414	425	42.9
Saxenda, \	Ventricular Fi	brillation and	d Flutter							
Female	294	294	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, V	entricular Fib	rillation and	Flutter							
Female	3,117	3,117	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,488	4,489	1,214.8
Male	2,237	2,237	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,234	3,234	856.5
Trulicity, V	/entricular Fil	orillation and	l Flutter							
Female	34,815	34,815	****	****	****	****	3.92 (0.98, 15.67)	61,129	61,503	13,487.5
Male	32,163	32,163	****	****	****	****	6.25 (2.02, 19.39)	56,413	56,785	12,389.0
Xultophy,	Ventricular F	ibrillation an	d Flutter							
Female	172	172	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	250	250	67.6
				,						

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Page 248 of 1023



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

by Age Group			Number of	Number of Exposure Episodes with an Event per				Number of Exposure Episode Defining-	Number of Exposure Episode Defining- Dispensings	
		Number	Exposure	100 Exposure	Total	Total		Dispensings	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Interval)	Dispensings)	Dispensings)	Years
Bydureon, Hospita	llized Tachyarrhy	rthmia								
0-40 years	78	78	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	36.9
41-64 years	498	498	****	****	****	****	478.43 (154.30, 1,483.44)	767	767	198.2
65-74 years	535	535	****	****	****	****	121.44 (17.11, 862.16)	891	891	210.7
75-84 years	195	195	****	****	****	****	815.93 (204.06, 3,262.52)	282	282	67.7
≥ 85 years	15	15	****	****	****	****	9,200.25 (1,295.93, 65,315.60)	21	21	4.7
Mounjaro, Hospita	alized Tachyarrhy	/thmia								
0-40 years	1,034	1,034	****	****	****	****	173.79 (43.46, 694.91)	1,749	1,770	282.9
41-64 years	9,239	9,239	****	****	****	****	359.03 (262.32, 491.40)	15,849	16,034	2,687.4
65-74 years	6,597	6,597	****	****	****	****	601.68 (449.23, 805.85)	10,587	10,749	1,774.2
75-84 years	1,867	1,867	****	****	****	****	697.13 (412.87, 1,177.09)	2,852	2,894	483.0
≥ 85 years	95	95	****	****	****	****	2,225.78 (556.65, 8,899.86)	136	138	20.7
Ozempic, Hospitali	ized Tachyarrhyt	hmia								
0-40 years	5,493	5,493	****	****	****	****	260.71 (164.26, 413.81)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	****	****	****	****	335.37 (294.96, 381.32)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	****	****	****	****	523.50 (471.09, 583.98)	65,755	65,935	15,718.1
75-84 years	15,103	15,103	****	****	****	****	891.86 (772.47, 1,029.70)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	****	****	****	****	1,414.29 (939.83, 2,128.29)	1,761	1,763	439.1
Rybelsus, Hospital	ized Tachyarrhyt	hmia								
0-40 years	1,132	1,132	****	****	****	****	284.78 (106.88, 758.80)	1,632	1,665	416.8



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

by Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	12,264	12,264	****	****	****		232.94 (170.20, 318.83)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	****	****		****	314.57 (234.25, 405.15)	19,963	20,392	5,048.6
75-84 years	6,100	6,100	****	****		****	747.25 (582.58, 958.45)	8,935	9,099	2,172.3
≥ 85 years	882	882	****	****	****	****	1,112.99 (646.26, 1,916.80)	1,322	1,335	305.6
Saxenda, Hospitaliz	ed Tachyarrhyt	hmia								
0-40 years	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	****	****	****	****	259.32 (36.53, 1,840.99)	442	442	146.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	12.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Trulicity, Hospitalize	ed Tachyarrhyth	nmia								
0-40 years	2,425	2,425	****	****	****	****	299.74 (161.28, 557.09)	4,289	4,319	940.8
41-64 years	23,743	23,743	****	****	****	****	315.97 (262.76, 379.94)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	****	****	****	****	497.44 (433.51, 570.80)	47,354	47,631	10,357.6
75-84 years	11,847	11,847	****	****	****	****	843.38 (716.29, 993.03)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	****	****	****	****	1,274.65 (867.87, 1,872.09)	2,734	2,744	547.5
Victoza, Hospitalize	d Tachyarrhyth	mia								
0-40 years	308	308	****	****	****	****	236.03 (34.65, 1,746.62)	471	471	125.5
41-64 years	2,151	2,151	****	****	****	****	508.55 (306.59, 843.57)	3,187	3,188	871.2
65-74 years	2,042	2,042	****	****	****	****	440.23 (255.62, 758.18)	2,892	2,892	767.9



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

			Number of	Number of Exposure Episodes with an Event per				Number of Exposure Episode Defining-	Number of Exposure Episode Defining- Dispensings	
	Niconala au	Number	Exposure	100 Exposure	Total		Fromt Data way 10 000 Dations	Dispensings	(Not	Total
	Number of	of Exposure	Episodes with an	Episodes (95% Confidence	Years at	Days at	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	(Adjusted for Same-Day	Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Interval)	Dispensings)	Dispensings)	Years
75-84 years	754	754	****	****	****		1,505.64 (922.40, 2,457.68)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	36.2
Wegovy, Hospitaliz	ed Tachyarrhytl	hmia								
0-40 years	132	132	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	196	203	18.6
41-64 years	621	621	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	****	****	****	****	1,597.77 (225.06, 11,343.08)	108	112	11.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Xultophy, Hospitali	ized Tachyarrhy	thmia								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	238	238	69.8
75-84 years	87	87	****	****	****	****	1,492.64 (373.30, 5,968.40)	120	120	26.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.2
Mounjaro, Atrial Fi	brillation and Fl	utter								
0-40 years	1,034	1,034	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,749	1,770	282.9
41-64 years	9,239	9,239	****	****	****	****	211.74 (140.70, 318.63)	15,849	16,034	2,687.4
65-74 years	6,597	6,597	****	****	****	****	374.38 (258.49, 542.22)	10,587	10,749	1,774.2
75-84 years	1,867	1,867	****	****	****	****	597.54 (339.34, 1,052.18)	2,852	2,894	483.0
≥ 85 years	95	95	****	****	****	****	1,112.89 (156.76, 7,900.76)	136	138	20.7



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Bydureon, Atrial Fib	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	78	78	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	36.9
41-64 years	498	498	****	****	****	****	478.43 (154.30, 1,483.44)	767	767	198.2
65-74 years	535	535	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	891	891	210.7
75-84 years	195	195	****	****	****	****	407.96 (57.47, 2,896.27)	282	282	67.7
≥ 85 years	15	15	****	****	****	****	9,200.25 (1,295.93, 65,315.60)	21	21	4.7
Ozempic, Atrial Fibr	illation and Flu	tter								
0-40 years	5,493	5,493	****	****	****	****	28.97 (7.23, 115.83)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	****	****	****	****	165.52 (137.88, 198.72)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	****	****	****	****	351.23 (308.04, 400.51)	65,755	65,935	15,718.1
75-84 years	15,103	15,103	****	****	****	****	704.85 (599.64, 828.53)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	****	****	****	****	1,168.33 (745.22, 1,831.67)	1,761	1,763	439.1
Rybelsus, Atrial Fibr	illation and Flu	tter								
0-40 years	1,132	1,132	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,632	1,665	416.8
41-64 years	12,264	12,264	****	****	****	****	125.43 (81.78, 192.38)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	****	****	****	****	235.93 (176.15, 315.99)	19,963	20,392	5,048.6
75-84 years	6,100	6,100	****	****	****	****	566.46 (425.60, 753.93)	8,935	9,099	2,172.3
≥ 85 years	882	882	****	****	****	****	941.76 (521.54, 1,700.57)	1,322	1,335	305.6
Wegovy, Atrial Fibri	llation and Flut	ter								
0-40 years	132	132	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	196	203	18.6



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

by Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	621	621	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	****	****	****	****	1,597.77 (225.06, 11,343.08)	108	112	11.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Atrial Fib	rillation and Flut	tter								
0-40 years	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	442	442	146.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	12.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Atrial Fibri	llation and Flutt	er								
0-40 years	308	308	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	471	471	125.5
41-64 years	2,151	2,151	****	****	****	****	169.52 (70.56, 407.28)	3,187	3,188	871.2
65-74 years	2,042	2,042	****	****	****	****	270.91 (135.48, 541.73)	2,892	2,892	767.9
75-84 years	754	754	****	****	****	****	1,317.44 (780.25, 2,223.47)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	36.2
Trulicity, Atrial Fibr	illation and Flut	ter								
0-40 years	2,425	2,425	****	****	****	****	89.92 (29.00, 278.82)	4,289	4,319	940.8
41-64 years	23,743	23,743	****	****	****	****	150.99 (115.64, 197.15)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	****	****	****	****	365.12 (310.95, 428.71)	47,354	47,631	10,357.6



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

by Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	11,847	11,847	****	****	****	****	667.68 (555.70, 802.22)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	****	****	****	****	1,176.60 (788.63, 1,755.42)	2,734	2,744	547.5
Xultophy, Atrial Fib	orillation and Flu	itter								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	238	238	69.8
75-84 years	87	87	****	****	****	****	746.32 (105.13, 5,298.38)	120	120	26.4
≥85 years	13	13	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.2
Mounjaro, Sinus Ta	achycardia									
0-40 years	1,034	1,034	****	****	****	****	173.79 (43.46, 694.91)	1,749	1,770	282.9
41-64 years	9,239	9,239	****	****	****	****	138.09 (83.25, 229.06)	15,849	16,034	2,687.4
65-74 years	6,597	6,597	****	****	****	****	133.71 (71.94, 238.50)	10,587	10,749	1,774.2
75-84 years	1,867	1,867	****	****	****	****	99.59 (23.91, 398.21)	2,852	2,894	483.0
≥ 85 years	95	95	****	****	****	****	1,112.89 (156.76, 7,900.76)	136	138	20.7
Bydureon, Sinus Ta	chycardia									
0-40 years	78	78	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	36.9
41-64 years	498	498	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	767	767	198.2
65-74 years	535	535	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	891	891	210.7
75-84 years	195	195	****	****	****	****	407.96 (57.47, 2,896.27)	282	282	67.7
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	4.7



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

by Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Ozempic, Sinus Tachy	cardia									
0-40 years	5,493	5,493	****	****	****	****	217.26 (130.98, 360.39)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	****	****	****	****	122.34 (98.91, 151.33)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	****	****	****	****	97.66 (76.14, 125.26)	65,755	65,935	15,718.1
75-84 years	15,103	15,103	****	****	****	****	95.90 (61.87, 148.64)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	****	****	****	****	0.00 (0.00, 0.00)	1,761	1,763	439.1
Rybelsus, Sinus Tachy	cardia									
0-40 years	1,132	1,132	****	****	****	****	284.78 (106.88, 758.80)	1,632	1,665	416.8
41-64 years	12,264	12,264	****	****	****	****	101.54 (63.12, 163.34)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	****	****	****	****	62.91 (35.73, 110.78)	19,963	20,392	5,048.6
75-84 years	6,100	6,100	****	****	****	****	144.63 (82.13, 254.67)	8,935	9,099	2,172.3
≥ 85 years	882	882	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,322	1,335	305.6
Wegovy, Sinus Tachyo	cardia									
0-40 years	132	132	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	196	203	18.6
41-64 years	621	621	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Sinus Tachy	cardia									
0-40 years	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	107	33.9



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure		Total		Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
41-64 years	Patients 292	Episodes 292	Event ****	Interval) ****	Risk ****	Risk ****	Interval) 259.32 (36.53, 1,840.99)	Dispensings) 442	Dispensings)	Years 146.5
-	29Z ****	29Z ****				****		****	442 ****	
65-74 years			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			12.7
75-84 years	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Sinus Tach	nycardia									
0-40 years	308	308	****	****	****	****	236.03 (34.65, 1,746.62)	471	471	125.5
41-64 years	2,151	2,151	****	****	****	****	271.23 (135.64, 542.36)	3,187	3,188	871.2
65-74 years	2,042	2,042	****	****	****	****	101.59 (32.77, 315.00)	2,892	2,892	767.9
75-84 years	754	754	****	****	****	****	282.31 (91.05, 875.33)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	36.2
Trulicity, Sinus Tac	hycardia									
0-40 years	2,425	2,425	****	****	****	****	179.85 (80.80, 400.32)	4,289	4,319	940.8
41-64 years	23,743	23,743	****	****	****	****	131.42 (98.74, 174.91)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	****	****	****	****	95.57 (69.82, 130.80)	47,354	47,631	10,357.6
75-84 years	11,847	11,847	****	****	****	****	93.71 (57.41, 152.96)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,734	2,744	547.5
Xultophy, Sinus Ta	chycardia									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	238	238	69.8



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

by Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	87	87	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	26.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.2
Mounjaro, Suprave	ntricular Tachyo	cardia								
0-40 years	1,034	1,034	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,749	1,770	282.9
41-64 years	9,239	9,239	****	****	****	****	27.62 (8.91, 85.63)	15,849	16,034	2,687.4
65-74 years	6,597	6,597	****	****	****	****	66.85 (27.83, 160.62)	10,587	10,749	1,774.2
75-84 years	1,867	1,867	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,852	2,894	483.0
≥ 85 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	136	138	20.7
Bydureon, Suprave	ntricular Tachyo	ardia								
0-40 years	78	78	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	36.9
41-64 years	498	498	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	767	767	198.2
65-74 years	535	535	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	891	891	210.7
75-84 years	195	195	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	282	282	67.7
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Supraven	tricular Tachyca	rdia								
0-40 years	5,493	5,493	****	****	****	****	14.48 (2.04, 102.83)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	****	****	****	****	23.03 (14.11, 37.59)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	****	****	****	****	59.85 (43.55, 82.26)	65,755	65,935	15,718.1
75-84 years	15,103	15,103	****	****	****	****	67.13 (39.76, 113.35)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	****	****	****	****	61.49 (8.66, 436.54)	1,761	1,763	439.1



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

by Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Rybelsus, Supraventr	•		_			at at at at at				
0-40 years	1,132	1,132	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	1,632	1,665	416.8
41-64 years	12,264	12,264	****	****		****	23.89 (8.97, 63.66)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	****	****	****	****	26.21 (10.91, 62.98)	19,963	20,392	5,048.6
75-84 years	6,100	6,100	****	****	****	****	60.26 (25.08, 144.78)	8,935	9,099	2,172.3
≥ 85 years	882	882	****	****	****	****	171.23 (42.82, 684.67)	1,322	1,335	305.6
Wegovy, Supraventri	cular Tachyca	rdia								
0-40 years	132	132	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	196	203	18.6
41-64 years	621	621	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Supraventri	icular Tachyca	rdia								
0-40 years	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	****	****	****	****	259.32 (36.53, 1,840.99)	442	442	146.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	12.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Supraventric	ular Tachycar	dia								
0-40 years	308	308	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	471	471	125.5



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	2,151	2,151	****	****	****	****	67.81 (16.96, 271.13)	3,187	3,188	871.2
65-74 years	2,042	2,042	****	****	****	****	33.86 (4.77, 230.41)	2,892	2,892	767.9
75-84 years	754	754	****	****	****	****	188.21 (47.07, 752.55)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	36.2
Trulicity, Supraventric	ular Tachyca	rdia								
0-40 years	2,425	2,425	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,289	4,319	940.8
41-64 years	23,743	23,743	****	****	****	****	30.76 (17.03, 55.54)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	****	****	****	****	36.76 (22.16, 60.97)	47,354	47,631	10,357.6
75-84 years	11,847	11,847	****	****	****	****	70.28 (39.91, 123.76)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	****	****	****	****	147.07 (47.43, 456.02)	2,734	2,744	547.5
Xultophy, Supraventr	icular Tachyca	ardia								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	238	238	69.8
75-84 years	87	87	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	26.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.2
Mounjaro, Other Tach	nycardia									
0-40 years	1,034	1,034	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,749	1,770	282.9
41-64 years	9,239	9,239	****	****	****	****	9.21 (1.30, 65.36)	15,849	16,034	2,687.4



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

75-84 years	Number of Patients 1,867	Number of Exposure Episodes 1,867	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval) 0.00 (0.00, 0.00)	Total Years at Risk	Total Days at Risk *****	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval) 0.00 (0.00, 0.00)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings) 2,852	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings) 2,894	Total Observable Years 483.0
≥ 85 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	136	138	20.7
Bydureon, Other Tach	nycardia									
0-40 years	78	78	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	36.9
41-64 years	498	498	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	767	767	198.2
65-74 years	535	535	****	****	****	****	121.44 (17.11, 862.16)	891	891	210.7
75-84 years	195	195	****	****	****	****	407.96 (57.47, 2,896.27)	282	282	67.7
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Other Tachy	/cardia									
0-40 years	5,493	5,493	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	****	****	****	****	23.03 (14.11, 37.59)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	****	****	****	****	37.80 (25.34, 56.40)	65,755	65,935	15,718.1
75-84 years	15,103	15,103	****	****	****	****	47.95 (25.80, 89.12)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	****	****	****	****	184.47 (59.50, 571.98)	1,761	1,763	439.1
Rybelsus, Other Tach	ycardia									
0-40 years	1,132	1,132	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,632	1,665	416.8
41-64 years	12,264	12,264	****	****	****	****	5.97 (0.84, 42.40)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19,963	20,392	5,048.6
75-84 years	6,100	6,100	****	****	****	****	36.16 (11.66, 112.11)	8,935	9,099	2,172.3
≥ 85 years	882	882	****	****	****	****	85.61 (12.06, 607.81)	1,322	1,335	305.6



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

by Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Wegovy, Other Tachy	ycardia									
0-40 years	132	132	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	196	203	18.6
41-64 years	621	621	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Other Tach	ycardia									
0-40 years	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	442	442	146.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	12.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Other Tachy	cardia									
0-40 years	308	308	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	471	471	125.5
41-64 years	2,151	2,151	****	****	****	****	33.90 (4.78, 230.69)	3,187	3,188	871.2
65-74 years	2,042	2,042	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,892	2,892	767.9
75-84 years	754	754	****	****	****	****	188.21 (47.07, 752.55)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	36.2
Trulicity, Other Tachy	ycardia									
0-40 years	2,425	2,425	****	****	****	****	59.95 (14.99, 239.71)	4,289	4,319	940.8

Page 261 of 1023



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

by Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	23,743	23,743	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	****	****	****	****	36.76 (22.16, 60.97)	47,354	47,631	10,357.6
75-84 years	11,847	11,847	****	****	****	****	23.43 (8.79, 62.42)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,734	2,744	547.5
Xultophy, Other Ta	achycardia									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	238	238	69.8
75-84 years	87	87	****	****	****	****	746.32 (105.13, 5,298.38)	120	120	26.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.2
Mounjaro, Cardiac	Arrest									
0-40 years	1,034	1,034	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,749	1,770	282.9
41-64 years	9,239	9,239	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15,849	16,034	2,687.4
65-74 years	6,597	6,597	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	10,587	10,749	1,774.2
75-84 years	1,867	1,867	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,852	2,894	483.0
≥ 85 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	136	138	20.7
Bydureon, Cardiac	Arrest									
0-40 years	78	78	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	36.9
41-64 years	498	498	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	767	767	198.2
65-74 years	535	535	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	891	891	210.7



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

by Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	195	195	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	282	282	67.7
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Cardiac A	rrest									
0-40 years	5,493	5,493	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	****	****	****	****	10.08 (4.80, 21.13)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	****	****	****	****	11.03 (5.26, 23.13)	65,755	65,935	15,718.1
75-84 years	15,103	15,103	****	****	****	****	14.38 (4.64, 44.60)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	****	****	****	****	61.49 (8.66, 436.54)	1,761	1,763	439.1
Rybelsus, Cardiac A	rrest									
0-40 years	1,132	1,132	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,632	1,665	416.8
41-64 years	12,264	12,264	****	****	****	****	5.97 (0.84, 42.40)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	****	****	****	****	5.23 (0.74, 37.22)	19,963	20,392	5,048.6
75-84 years	6,100	6,100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	8,935	9,099	2,172.3
≥ 85 years	882	882	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,322	1,335	305.6
Wegovy, Cardiac Ar	rest									
0-40 years	132	132	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	196	203	18.6
41-64 years	621	621	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Cardiac Arrest 0-40 years	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	442	442	146.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	12.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Cardiac Arrest	-	-	-			-		-	-	
0-40 years	308	308	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	471	471	125.5
41-64 years	2,151	2,151	****	****	****	****	33.90 (4.78, 230.69)	3,187	3,188	871.2
65-74 years	2,042	2,042	****	****	****	****	67.73 (16.94, 270.82)	2,892	2,892	767.9
75-84 years	754	754	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	36.2
Trulicity, Cardiac Arrest										
0-40 years	2,425	2,425	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,289	4,319	940.8
41-64 years	23,743	23,743	****	****	****	****	5.59 (1.40, 22.36)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	****	****	****	****	9.80 (3.68, 26.12)	47,354	47,631	10,357.6
75-84 years	11,847	11,847	****	****	****	****	35.14 (15.79, 78.22)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,734	2,744	547.5
Xultophy, Cardiac Arrest	t									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.7



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

by Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	74	74	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	238	238	69.8
75-84 years	87	87	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	26.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.2
Mounjaro, Ventricu	lar Tachycardia									
0-40 years	1,034	1,034	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,749	1,770	282.9
41-64 years	9,239	9,239	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15,849	16,034	2,687.4
65-74 years	6,597	6,597	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	10,587	10,749	1,774.2
75-84 years	1,867	1,867	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,852	2,894	483.0
≥ 85 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	136	138	20.7
Bydureon, Ventricu	lar Tachycardia									
0-40 years	78	78	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	36.9
41-64 years	498	498	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	767	767	198.2
65-74 years	535	535	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	891	891	210.7
75-84 years	195	195	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	282	282	67.7
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Ventricula	ar Tachycardia									
0-40 years	5,493	5,493	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	****	****	****	****	1.44 (0.20, 10.22)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	****	****	****	****	6.30 (2.36, 16.79)	65,755	65,935	15,718.1



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

by Age Group		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure	Total	Total		Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000 Patient-	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Interval)	Dispensings)	Dispensings)	Years
75-84 years	15,103	15,103	****	****	****	****	9.59 (2.40, 38.35)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,761	1,763	439.1
Rybelsus, Ventricul	ar Tachycardia									
0-40 years	1,132	1,132	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,632	1,665	416.8
41-64 years	12,264	12,264	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19,963	20,392	5,048.6
75-84 years	6,100	6,100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	8,935	9,099	2,172.3
≥85 years	882	882	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,322	1,335	305.6
Wegovy, Ventricula	r Tachycardia									
0-40 years	132	132	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	196	203	18.6
41-64 years	621	621	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Ventricula	ar Tachycardia									
0-40 years	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	442	442	146.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	12.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

by Age Group										
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Victoza, Ventricula	•			2 22 (2 22 2 22)	ale ale ale ale	****	(2			
0-40 years	308	308	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	471	471	125.5
41-64 years	2,151	2,151	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	3,187	3,188	871.2
65-74 years	2,042	2,042	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	2,892	2,892	767.9
75-84 years	754	754	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	36.2
Trulicity, Ventricula	ar Tachycardia									
0-40 years	2,425	2,425	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,289	4,319	940.8
41-64 years	23,743	23,743	****	****	****	****	5.59 (1.40, 22.36)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	****	****	****	****	2.45 (0.35, 17.40)	47,354	47,631	10,357.6
75-84 years	11,847	11,847	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,734	2,744	547.5
Xultophy, Ventricu	lar Tachycardia									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	238	238	69.8
75-84 years	87	87	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	26.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.2
Mounjaro, Ventrico	ular Fibrillation a	and Flutter								
0-40 years	1,034	1,034	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,749	1,770	282.9



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

by Age Group									N 1 6	
	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years at	Days at	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
41-64 years	9,239	Episodes 9,239	Event 0	0.00 (0.00, 0.00)	Risk	Risk	Interval) 0.00 (0.00, 0.00)	Dispensings) 15,849	Dispensings) 16,034	Years 2,687.4
65-74 years	9,239 6,597	9,239 6,597	****	****		****	13.37 (1.88, 94.92)	10,587	10,749	2,687.4 1,774.2
75-84 years	1,867	1,867	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,852	2,894	483.0
> 85 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	136	138	20.7
Bydureon, Ventric			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	130	130	20.7
0-40 years	78	78	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	36.9
•	498	498	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	767	767	198.2
41-64 years				, , ,	****		, , ,	-		
65-74 years	535	535	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	891	891	210.7
75-84 years	195	195	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	282	282	67.7
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Ventricu										
0-40 years	5,493	5,493	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	****	****	****	****	2.88 (0.72, 11.51)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	****	****	****	****	3.15 (0.79, 12.60)	65,755	65,935	15,718.1
75-84 years	15,103	15,103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,761	1,763	439.1
Rybelsus, Ventricu	lar Fibrillation a	nd Flutter								
0-40 years	1,132	1,132	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,632	1,665	416.8
41-64 years	12,264	12,264	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19,963	20,392	5,048.6



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

			Number of	Number of Exposure Episodes with an Event per				Number of Exposure Episode Defining-	Number of Exposure Episode Defining- Dispensings	
	Number	Number of	Exposure Episodes	100 Exposure Episodes (95%	Total	Total Days	Front Data was 10 000 Dations	Dispensings (Adjusted for	(Not Adjusted for	Total
	of	Exposure	with an	Confidence	Years at	at	Event Rate per 10,000 Patient- Years at Risk (95% Confidence	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Interval)	Dispensings)	Dispensings)	Years
75-84 years	6,100	6,100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	8,935	9,099	2,172.3
≥ 85 years	882	882	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,322	1,335	305.6
Wegovy, Ventricul	ar Fibrillation an	d Flutter								
0-40 years	132	132	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	196	203	18.6
41-64 years	621	621	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Ventricul	lar Fibrillation ar	nd Flutter								
0-40 years	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	442	442	146.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	12.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Ventricula	ır Fibrillation and	d Flutter								
0-40 years	308	308	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	471	471	125.5
41-64 years	2,151	2,151	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,187	3,188	871.2
65-74 years	2,042	2,042	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,892	2,892	767.9
75-84 years	754	754	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	134	134	36.2



Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

Trulicity, Ventricular Fil	Number of Patients brillation an	Number of Exposure Episodes d Flutter	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	2,425	2,425	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,289	4,319	940.8
41-64 years	23,743	23,743	****	****	****	****	5.59 (1.40, 22.36)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	****	****	****	****	4.90 (1.23, 19.60)	47,354	47,631	10,357.6
75-84 years	11,847	11,847	****	****	****	****	5.86 (0.82, 41.58)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,734	2,744	547.5
Xultophy, Ventricular F	ibrillation a	nd Flutter								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	238	238	69.8
75-84 years	87	87	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	26.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.2

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

^{*}NaN: Not a number



Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

145.651	, aa. y 0.1 <u>2</u> ,				Datasa	e and se	Themer Distributed Database from	20, 202	10 54110 50, 2025,	, .ea.
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureo	n, Hospitalized	Tachyarrhytl	hmia	·			·			
2022	1,075	1,075	****	****	****	****	325.46 (135.46, 781.94)	1,732	1,732	473.5
2023	236	236	****	****	****	****	816.47 (204.19, 3,264.71)	337	337	44.9
Mounjar	o, Hospitalized	l Tachyarrhyt	hmia				· · · · ·			
2022	9,509	9,509	****	****	****	****	417.45 (317.26, 549.29)	16,430	16,616	3,676.3
2023	9,333	9,333	****	****	****	****	544.09 (413.50, 715.92)	14,743	14,969	1,571.8
Ozempic	, Hospitalized 1	Fachyarrhyth	mia							
2022	79,091	79,091	****	****	****	****	497.95 (460.11, 538.91)	123,021	123,332	36,506.4
2023	37,917	37,917	****	****	****	****	458.23 (395.63, 530.75)	50,413	50,618	5,816.4
Rybelsus	, Hospitalized ⁻	Tachyarrhyth	mia							
2022	25,230	25,230	****	****	****	****	363.53 (307.29, 430.07)	38,417	39,148	11,337.8
2023	8,818	8,818	****	****	****	****	452.83 (334.65, 612.75)	11,545	11,894	1,516.7
Saxenda,	Hospitalized 1	Tachyarrhythi	mia							
2022	333	333	****	****	****	****	220.73 (31.09, 1,567.07)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	71	71	8.1
Trulicity,	Hospitalized T	achyarrhythr	nia							
2022	52,917	52,917	****	****	****	****	500.60 (454.78, 551.02)	96,127	96,694	23,372.2
2023	14,061	14,061	****	****	****	****	502.50 (403.06, 626.48)	21,415	21,594	2,504.3
Victoza, I	Hospitalized Ta	achyarrhythm	iia							
2022	4,105	4,105	****	****	****	****	560.05 (400.17, 783.81)	6,092	6,093	1,829.6
2023	1,239	1,239	****	****	****	****	777.46 (430.55, 1,403.88)	1,630	1,630	231.7
Wegovy,	Hospitalized T	achyarrhythr	nia							
2022	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	110	110	41.1
2023	756	756	****	****	****	****	152.89 (21.54, 1,085.40)	1,189	1,214	96.2
	, Hospitalized									
2022	217	217	****	****	****	****	265.93 (37.46, 1,887.90)	292	292	101.7
2023	147	147	****	****	****	****	510.55 (71.92, 3,623.59)	192	192	29.5



Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

Tuble 31 c	, a	posures or in	terest iii tii	ie Kapia Sentinei Distributea	Datasa	c and sc	intiner bistributeu butubuse nor	20, 202	10 Julie 30, 2023,	by rear
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjar	o, Atrial Fibrilla	ation and Flut	tter							
2022	9,509	9,509	****	****	****	****	270.12 (192.03, 379.95)	16,430	16,616	3,676.3
2023	9,333	9,333	****	****	****	****	330.72 (232.58, 470.26)	14,743	14,969	1,571.8
Bydureo	n, Atrial Fibrilla	ation and Flut	ter							
2022	1,075	1,075	****	****	****	****	195.28 (62.98, 605.48)	1,732	1,732	473.5
2023	236	236	****	****	****	****	816.47 (204.19, 3,264.71)	337	337	44.9
Ozempic	, Atrial Fibrillat	ion and Flutt	er							
2022	79,091	79,091	****	****	****	****	329.54 (299.03, 363.16)	123,021	123,332	36,506.4
2023	37,917	37,917	****	****	****	****	254.86 (209.29, 310.35)	50,413	50,618	5,816.4
Rybelsus	, Atrial Fibrillat	tion and Flutt	er				· · · · ·			
2022	25,230	25,230	****	****	****	****	259.29 (212.50, 316.38)	38,417	39,148	11,337.8
2023	8,818	8,818	****	****	****	****	291.11 (199.63, 423.49)	11,545	11,894	1,516.7
Wegovy,	Atrial Fibrillati	ion and Flutte	er					,	,	,
2022	72	72	0	****	****	2,752	0.00 (0.00, 0.00)	110	110	41.1
2023	756	756	****	****	****	****	152.89 (21.54, 1,085.40)	1,189	1,214	96.2
Saxenda,	Atrial Fibrillat	ion and Flutt	er				• • • • •			
2022	333	333	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	71	71	8.1
Victoza,	Atrial Fibrillation	on and Flutte	r							
2022	4,105	4,105	****	****	****	****	345.91 (225.54, 530.54)	6,092	6,093	1,829.6
2023	1,239	1,239	****	****	****	****	423.07 (190.51, 943.94)	1,630	1,630	231.7
Trulicity,	Atrial Fibrillati	ion and Flutte	er							
2022	52,917	52,917	****	****	****	****	354.14 (315.95, 396.95)	96,127	96,694	23,372.2
2023	14,061	14,061	****	****	****	****	311.68 (235.56, 412.39)	21,415	21,594	2,504.3
Xultophy	, Atrial Fibrilla	tion and Flutt	ter							
2022	217	217	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	292	292	101.7
2023	147	147	****	****	****	****	510.55 (71.92, 3,623.59)	192	192	29.5



Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

141516 51 5	uniniary or Ex			ie napia seminie. Bisti izatea	Dutubu	- u.i.u o	The Distributed Database nor	10, 10, 1011	1 10 54112 50, 1015,	ay rear
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjard	, Sinus Tachyo	cardia								
2022	9,509	9,509	****	****	****	****	114.59 (67.87, 193.49)	16,430	16,616	3,676.3
2023	9,333	9,333	****	****	****	****	170.69 (104.57, 278.63)	14,743	14,969	1,571.8
Bydureor	, Sinus Tachyo	ardia								
2022	1,075	1,075	****	****	****	****	65.09 (9.17, 462.11)	1,732	1,732	473.5
2023	236	236	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	337	337	44.9
Ozempic,	Sinus Tachyca	rdia								
2022	79,091	79,091	****	****	****	****	107.69 (90.86, 127.64)	123,021	123,332	36,506.4
2023	37,917	37,917	****	****	****	****	126.14 (95.34, 166.90)	50,413	50,618	5,816.4
Rybelsus,	Sinus Tachyca	ardia								
2022	25,230	25,230	****	****	****	****	90.88 (64.94, 127.19)	38,417	39,148	11,337.8
2023	8,818	8,818	****	****	****	****	118.60 (65.68, 214.16)	11,545	11,894	1,516.7
Wegovy,	Sinus Tachyca	rdia								
2022	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	110	110	41.1
2023	756	756	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,189	1,214	96.2
Saxenda,	Sinus Tachyca	rdia								
2022	333	333	****	****	****	****	220.73 (31.09, 1,567.07)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, S	inus Tachycar	dia								
2022	4,105	4,105	****	****	****	****	164.72 (88.63, 306.14)	6,092	6,093	1,829.6
2023	1,239	1,239	****	****	****	****	353.39 (147.09, 849.04)	1,630	1,630	231.7
Trulicity,	Sinus Tachyca	rdia								
2022	52,917	52,917	****	****	****	****	103.23 (83.57, 127.54)	96,127	96,694	23,372.2
2023	14,061	14,061	****	****	****	****	139.94 (92.14, 212.53)	21,415	21,594	2,504.3
Xultophy	Sinus Tachyca	ardia								
2022	217	217	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	292	292	101.7
2023	147	147	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	192	192	29.5



Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

Table 51	, aa. y 0.1 <u>2</u> ,	posures or in	terest iii tii	ie Kapia Sentinei Distributea	Databas	c and sc	Themer Distributed Database from	20, 202	10 Julie 30, 2023,	by rear
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjar	o, Supraventri	cular Tachyca	rdia							
2022	9,509	9,509	****	****	****	****	23.56 (7.92, 76.14)	16,430	16,616	3,676.3
2023	9,333	9,333	****	****	****	****	53.34 (22.20, 128.16)	14,743	14,969	1,571.8
Bydureo	n, Supraventrio	cular Tachyca	rdia							
2022	1,075	1,075	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,732	1,732	473.5
2023	236	236	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	337	337	44.9
Ozempic	, Supraventricu	ular Tachycar	dia							
2022	79,091	79,091	****	****	****	****	39.67 (29.99, 52.49)	123,021	123,332	36,506.4
2023	37,917	37,917	****	****	****	****	54.06 (35.25, 82.92)	50,413	50,618	5,816.4
Rybelsus	, Supraventrici	ular Tachycar	dia							
2022	25,230	25,230	****	****	****	****	29.40 (16.28, 53.09)	38,417	39,148	11,337.8
2023	8,818	8,818	****	****	****	****	53.91 (22.44, 129.52)	11,545	11,894	1,516.7
Wegovy,	Supraventricu	lar Tachycard	lia							
2022	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	110	110	41.1
2023	756	756	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,189	1,214	96.2
Saxenda,	Supraventricu	ılar Tachycard								
2022	333	333	****	****	****	****	220.73 (31.09, 1,567.07)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, S	Supraventricul	ar Tachycardi								
2022	4,105	4,105	****	****	****	****	82.36 (34.28, 197.88)	6,092	6,093	1,829.6
2023	1,239	1,239	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,630	1,630	231.7
	Supraventricu									
2022	52,917	52,917	****	****	****	****	42.02 (30.17, 58.52)	96,127	96,694	23,372.2
2023	14,061	14,061	****	****	****	****	38.16 (17.15, 84.95)	21,415	21,594	2,504.3
	, Supraventric									
2022	217	217	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	292	292	101.7
2023	147	147	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	192	192	29.5



Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

141516 51 5	uniniary or Ex			ie napia semine. Bisti zatea	Dutubu	- u.i.u o	themer bistributed batabase nor	10, 10, 1011	1 10 54112 50, 1015,	zy rear
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjard	, Other Tachy	cardia								
2022	9,509	9,509	****	****	****	****	8.19 (1.15, 58.11)	16,430	16,616	3,676.3
2023	9,333	9,333	****	****	****	****	42.67 (16.02, 113.70)	14,743	14,969	1,571.8
Bydureor	, Other Tachy	cardia								
2022	1,075	1,075	****	****	****	****	130.18 (32.56, 520.54)	1,732	1,732	473.5
2023	236	236	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	337	337	44.9
Ozempic,	Other Tachyc	ardia								
2022	79,091	79,091	****	****	****	****	29.15 (21.03, 40.41)	123,021	123,332	36,506.4
2023	37,917	37,917	****	****	****	****	43.76 (27.21, 70.40)	50,413	50,618	5,816.4
Rybelsus,	Other Tachyc	ardia								
2022	25,230	25,230	****	****	****	****	2.67 (0.38, 18.98)	38,417	39,148	11,337.8
2023	8,818	8,818	****	****	****	****	43.13 (16.19, 114.91)	11,545	11,894	1,516.7
Wegovy,	Other Tachyca	ırdia								
2022	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	110	110	41.1
2023	756	756	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,189	1,214	96.2
Saxenda,	Other Tachyca	ardia								
2022	333	333	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, C	Other Tachycai	rdia								
2022	4,105	4,105	****	****	****	****	32.94 (8.23, 131.73)	6,092	6,093	1,829.6
2023	1,239	1,239	****	****	****	****	70.68 (9.96, 501.77)	1,630	1,630	231.7
Trulicity,	Other Tachyca	ırdia								
2022	52,917	52,917	****	****	****	****	19.21 (11.77, 31.35)	96,127	96,694	23,372.2
2023	14,061	14,061	****	****	****	****	31.80 (13.23, 76.41)	21,415	21,594	2,504.3
Xultophy	Other Tachyo	ardia								
2022	217	217	****	****	****	****	265.93 (37.46, 1,887.90)	292	292	101.7
2023	147	147	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	192	192	29.5



Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

Tuble 51 5	arring or Ex	posures or		e napia sentinei sistinsatea	Dutubu	,c u.i.a oc	themer bistributed batabase nor	10, 101	. 10 54110 50, 1015,	ay rear
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjard	o, Cardiac Arre			•			·	<u> </u>		
2022	9,509	9,509	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16,430	16,616	3,676.3
2023	9,333	9,333	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14,743	14,969	1,571.8
Bydureor	, Cardiac Arre	st								
2022	1,075	1,075	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,732	1,732	473.5
2023	236	236	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	337	337	44.9
Ozempic,	Cardiac Arres	t								
2022	79,091	79,091	****	****	****	****	12.95 (7.94, 21.15)	123,021	123,332	36,506.4
2023	37,917	37,917	****	****	****	****	5.15 (1.29, 20.59)	50,413	50,618	5,816.4
Rybelsus,	Cardiac Arres									
2022	25,230	25,230	****	****	****	****	5.35 (1.34, 21.38)	38,417	39,148	11,337.8
2023	8,818	8,818	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11,545	11,894	1,516.7
Wegovy,	Cardiac Arrest									
2022	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	110	110	41.1
2023	756	756	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,189	1,214	96.2
Saxenda,	Cardiac Arrest									
2022	333	333	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	71	71	8.1
	Cardiac Arrest									
2022	4,105	4,105	****	****	****	****	49.42 (15.94, 153.22)	6,092	6,093	1,829.6
2023	1,239	1,239	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,630	1,630	231.7
	Cardiac Arrest									
2022	52,917	52,917	****	****	****	****	13.21 (7.31, 23.84)	96,127	96,694	23,372.2
2023	14,061	14,061	****	****	****	****	6.36 (0.90, 45.16)	21,415	21,594	2,504.3
	, Cardiac Arres				distribute to	distribute to				
2022	217	217	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	292	292	101.7
2023	147	147	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	192	192	29.5



Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

14516 51 5	arring or Ex	posures or		ie napia sentinei Bistribatea	Dutubu	e unu se	THE DISTIBUTE DATABASE NO.	, 10, 101	1 10 10110 101, 1010,	ay rear
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjard	, Ventricular						<u> </u>			
2022	9,509	9,509	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16,430	16,616	3,676.3
2023	9,333	9,333	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14,743	14,969	1,571.8
Bydureor	, Ventricular 1	Tachycardia								
2022	1,075	1,075	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,732	1,732	473.5
2023	236	236	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	337	337	44.9
Ozempic,	Ventricular Ta	achycardia								
2022	79,091	79,091	****	****	****	****	5.67 (2.70, 11.89)	123,021	123,332	36,506.4
2023	37,917	37,917	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	50,413	50,618	5,816.4
Rybelsus,	Ventricular Ta	achycardia								
2022	25,230	25,230	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38,417	39,148	11,337.8
2023	8,818	8,818	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11,545	11,894	1,516.7
Wegovy,	Ventricular Ta	chycardia								
2022	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	110	110	41.1
2023	756	756	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,189	1,214	96.2
	Ventricular Ta	-								
2022	333	333	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	71	71	8.1
	entricular Tad	-								
2022	4,105	4,105	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,092	6,093	1,829.6
2023	1,239	1,239	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,630	1,630	231.7
	Ventricular Ta	-								
2022	52,917	52,917	****	****	****	****	3.60 (1.16, 11.17)	96,127	96,694	23,372.2
2023	14,061	14,061	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21,415	21,594	2,504.3
	, Ventricular T	-			de de de de d	distribution in				
2022	217	217	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	292	292	101.7
2023	147	147	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	192	192	29.5



Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	,	,					Trainer Distributed Database from			, , , , ,
	Number of Patients o, Ventricular I			Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	at Risk		Event Rate per 10,000 Patient- Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	9,509	9,509	****		*****	*****	8.19 (1.15, 58.11)	16,430	16,616	3,676.3
2023	9,333	9,333	O Cluster	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	14,743	14,969	1,571.8
	n, Ventricular F			0.00 (0.00 0.00)	****	****	0.00 (0.00 0.00)	4.722	4 722	472.5
2022 2023	1,075 236	1,075 236	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	1,732 337	1,732	473.5
	, Ventricular Fi			0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	337	337	44.9
	79,091		****	****	****	****	2.42.(0.70.7.52)	122.021	122 222	26 506 4
2022 2023	79,091 37,917	79,091 37,917	****	****	****		2.43 (0.78, 7.53)	123,021	123,332	36,506.4
	, Ventricular Fi						2.57 (0.36, 18.28)	50,413	50,618	5,816.4
2022	25,230	25,230	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38,417	39,148	11,337.8
2022	8,818	8,818	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11,545	11,894	1,516.7
	Ventricular Fik			0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	11,545	11,034	1,310.7
2022	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	110	110	41.1
2022	756	756	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,189	1,214	96.2
	Ventricular Fi			0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	1,103	1,214	90.2
2022	333	333	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	516	516	187.1
2022	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	71	71	8.1
	Ventricular Fib			0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	71	71	0.1
2022	4,105	4,105	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,092	6,093	1,829.6
2023	1,239	1,239	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,630	1,630	231.7
	Ventricular Fik			5.55 (5.55) 5.55)			5.55 (5.55) 5.55)	_,555	_,555	
2022	52,917	52,917	****	****	****	****	4.80 (1.80, 12.79)	96,127	96,694	23,372.2
2023	14,061	14,061	****	****	****	****	6.36 (0.90, 45.16)	21,415	21,594	2,504.3
	, Ventricular F		d Flutter				, -, -	, -	,	,
2022	217	217	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	292	292	101.7
2023	147	147	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	192	192	29.5

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhy	/thmia	•		•			,			
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	****	****	****	****	450.48 (63.45, 3,198.11)	255	255	73.0
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	15.8
Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Islander										
Unknown	234	5,354	****	****	****	****	295.44 (41.61, 2,097.41)	346	346	89.3
White	833	833	****	****	****	****	444.90 (185.17, 1,068.89)	1,336	1,336	318.3
Mounjaro, Hospitalized Tachyarrhy	ythmia									
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,640	1,640	****	****	****	****	452.36 (226.22, 904.55)	2,494	2,537	467.1
Multi-racial	60	60	****	****	****	****	1,360.34 (191.61, 9,657.46)	112	113	23.5
Native Hawaiian or Other Pacific	57	57	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	86	87	17.3
Islander										
Unknown	8,006	8,006	****	****		****	237.60 (156.45, 360.85)	13,643	13,787	2,230.00
White	8,939	8,939	****	****	*****	****	692.12 (548.48, 873.38)	14,620	14,842	2,463.4
Ozempic, Hospitalized Tachyarrhyt		026	****	****	****	****	4.472.22 (666.20. 2.065.02)	4.270	4.275	202.0
American Indian or Alaska Native Asian	826 1 202	826	****	****		****	1,173.23 (666.29, 2,065.92) 441.73 (229.83, 848.97)	1,270 2,121	1,275	282.9 488.2
Black or African American	1,393	1,393	****	****		****	. ,	•	2,125	
	9,832	9,832	****	****		****	526.22 (417.01, 664.03)	14,096	14,145	3,611.6
Multi-racial Native Hawaiian or Other Pacific	816 333	816 333	****	****		****	379.89 (142.58, 1,012.21) 400.08 (100.06, 1,599.72)	1,239 452	1,254 452	316.0 138.0
Islander	333	333					400.00 (100.00, 1,333.72)	432	432	130.0
isialiuci										



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

			Number of	Number of Exposure Episodes with an Event per 100				Number of Exposure Episode Defining-	Number of Exposure Episode Defining- Dispensings	
		Number	Exposure	Exposure		Total		Dispensings	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	(Adjusted for	-	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Unknown	45,367	45,367	****	****	****	****	236.92 (201.45, 278.65)	68,462	68,668	16,633.7
White	58,441	58,441	****	****	****	****	664.48 (611.15, 722.45)	86,784	87,031	20,852.5
Rybelsus, Hospitalized Tachyarrhyt										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,087	1,087	****	****	****	****	120.51 (30.14, 481.87)	1,655	1,684	387.9
Black or African American	3,392	3,392	****	****	****	****	400.12 (252.09, 635.07)	4,686	4,789	1,311.4
Multi-racial	181	181	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific	128	128	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	170	178	61.8
Islander										
Unknown	12,788	12,788	****	****	****	****	207.77 (149.87, 288.04)	18,631	19,067	5,022.6
White	16,414	16,414	****	****	****	****	538.58 (451.01, 643.16)	23,439	23,933	5,964.1
Saxenda, Hospitalized Tachyarrhyt										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	5.0
Multi-racial	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	1.7
Native Hawaiian or Other Pacific	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Islander										
Unknown	342	342	****	****		****	222.89 (31.40, 1,582.37)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	16.6
Trulicity, Hospitalized Tachyarrhyth										
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	****	****		****	213.52 (80.14, 568.93)	2,047	2,055	439.7
Black or African American	6,428	6,428	****	****		****	491.73 (365.93, 660.77)	10,496	10,571	2,588.8
Multi-racial	293	293	****	****		****	402.77 (100.73, 1,610.48)	600	605	131.5
Native Hawaiian or Other Pacific	238	238	****	****	****	****	518.45 (129.66, 2,073.05)	400	406	121.2
Islander										



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure	Total	Total		Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	•	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Unknown	21,774	21,774	****	****	****		322.82 (267.10, 390.16)	39,329	39,602	8,747.9
White	36,775	36,775	****	****	****	****	626.10 (562.70, 696.65)	64,191	64,567	13,755.5
Victoza, Hospitalized Tachyarrhyth										
American Indian or Alaska Native	59	59	****	****	****	****	1,592.89 (223.37,	82	82	22.6
							11.308.46)			
Asian	92	92	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	****	****		****	549.31 (206.16, 1,463.61)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	7.1
Islander										
Unknown	1,435	1,435	****	****		****	511.14 (275.02, 949.99)	2,076	2,077	576.9
White	3,131	3,131	****	****	*****	****	665.13 (465.04, 951.29)	4,574	4,574	1,173.9
Wegovy, Hospitalized Tachyarrhytl										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	37	37	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	55	57	7.0
Multi-racial	18	18	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Islander			_		ale ale ale ale d	ala ala ala ala d	/			
Unknown	663	663	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	1,023	1,044	104.6
White	110	110	****	****	****	****	859.21 (121.03, 6,099.81)	192	195	22.2
Xultophy, Hospitalized Tachyarrhy	thmia ****	****		0.00 (0.00 0.00)	4 4 4 4 4	****	0.00 (0.00 0.05)	****	****	
American Indian or Alaska Native	*****	****	0	0.00 (0.00, 0.00)	*****		0.00 (0.00, 0.00)	****	****	0.4
Asian			0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)			3.3
Black or African American	40 ****	40 ****	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	53 ****	53 ****	15.5
Multi-racial	ጥጥ ጥጥ	ጥጥ ችች	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	ጥጥ ችች	ጥጥ ጥ ጥ	0.5



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total Years	Total Days	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	•	Dispensings)	Years
Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	****	****	0.9
Islander				, , ,			, , ,			
Unknown	63	63	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	23
White	237	237	****	****	****	****	521.52 (130.43, 2,085.34)	328	328	86.6
Mounjaro, Atrial Fibrillation and Fl	utter									
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,640	1,640	****	****	****	****	339.27 (152.42, 755.18)	2,494	2,537	467.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific	57	57	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	86	87	17.3
Islander										
Unknown	8,006	8,006	****	****	****	****	129.60 (73.60, 228.21)	13,643	13,787	2,230.00
White	8,939	8,939	****	****	****	****	448.42 (335.87, 598.67)	14,620	14,842	2,463.4
Bydureon, Atrial Fibrillation and Fl										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	15.8
Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Islander										
Unknown	234	234	****	****	****	****	295.44 (41.61, 2,097.41)	346	346	89.3
White	833	833	****	****	****	****	355.92 (133.58, 948.32)	1,336	1,336	318.3
Ozempic, Atrial Fibrillation and Flu	tter									
American Indian or Alaska Native	826	826	****	****		****	879.93 (457.84, 1,691.17)	1,270	1,275	282.9
Asian	1,393	1,393	****	****	****	****	147.23 (47.49, 456.55)	2,121	2,125	488.2
Black or African American	9,832	9,832	****	****	****	****	266.82 (192.46, 369.90)	14,096	14,145	3,611.6
Multi-racial	816	816	****	****	****	****	189.95 (47.50, 759.51)	1,239	1,254	316.0



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

Native Hawaiian or Other Pacific 33 33 33 33 33 33 33		Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years at	Total Days at	Event Rate per 10,000 Patient-Years at Risk (95%	Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
Slander	Native Haveiier as Other Pacific										
Unknown		333	333					400.08 (100.06, 1,599.72)	452	452	138.0
White S8,441 S8	10.10.10.00	45 267	<i>1</i> 5 267	****	****	****	****	136 31 /110 07 168 81)	68 462	68 668	16 622 7
Rybelsus, Atrial Fibrillation and Flutter		•	- ,	****	****	****	****	, , ,	•	•	•
American Indian or Alaska Native 68 68 0 0.00 (0.00, 0.00) ************************************			30,441					++7.05 (+0+.++, +55.00)	00,704	07,031	20,032.3
Asian 1,087 1,087 1,087 ***** ***** ***** ****** ******			68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	110	27.8
Black or African American 3,392 3,392 ***** ***** ***** ****** ******				****		****	****	. , ,		1,684	
Multi-racial 181 181 181 0 0.00 (0.00, 0.00) ************************************	Black or African American	3,392	3,392	****	****	****	****			4,789	1,311.4
Sander Unknown 12,788 12,788 12,788 ******	Multi-racial	181	181	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	274		78.9
Unknown 12,788 12,788 ****** ****** ****** ******* 109.66 (69.94, 171.91) 18,631 19,067 5,022.6 White 16,414 16,414 ****** ****** ****** ******* 410.56 (335.05, 503.08) 23,439 23,933 5,964.1 Wegovy, Atrial Fibrillation and Flutter American Indian or Alaska Native 0 0 0 NaN 0.0 0 NaN 0 0 0 0.0 0.0 NaN 0 0 0 0.0	Native Hawaiian or Other Pacific	128	128	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	170	178	61.8
White 16,414 16,414 ****** ****** ******* 410.56 (335.05, 503.08) 23,439 23,933 5,964.1 Wegowy, Atrial Fibrillation and Flutter Wegowy, Atrial Fibrillation and Flutter ****** ****** ******* 410.56 (335.05, 503.08) 23,439 23,933 5,964.1 Wegowy, Atrial Fibrillation and Flutter ***** ****** ******* 410.56 (335.05, 503.08) 23,439 23,933 5,964.1 Wegowy, Atrial Fibrillation and Flutter ***** ****** ******* 410.56 (335.05, 503.08) 23,439 23,933 5,964.1 Wegowy, Atrial Fibrillation and Flutter ****** ******* ******* 410.56 (335.05, 503.08) 23,439 23,933 5,964.1 Wegowy, Atrial Fibrillation and Flutter ****** ******* ******* 410.00 (0.00, 0.00) NaN 0.00 (0.00, 0.00) 55 57 7.0 Multi-racial 18 18 18 0 0.00 (0.00, 0.00) *********************************** 0.00 (0.00, 0.00) 28 28 28 3.6 Na	Islander										
Wegovy, Atrial Fibrillation and Flutter American Indian or Alaska Native 0 0 0 NaN 0.0 0 NaN 0 0 0.0 Black or African American 37 37 0 0.00 (0.00, 0.00) ****** ******************************	Unknown	12,788	12,788	****	****	****	****	109.66 (69.94, 171.91)	18,631	19,067	5,022.6
American Indian or Alaska Native 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0.0 0 0.0			16,414	****	****	****	****	410.56 (335.05, 503.08)	23,439	23,933	5,964.1
Asian 0 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0.0 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.											
Black or African American 37 37 0 0.00 (0.00, 0.00) ****** ***** ***** ***** ***** 0.00 (0.00, 0.00) 55 57 7.0 Multi-racial 18 18 0 0.00 (0.00, 0.00) ****** ***** ***** ***** ***** ***** ****								· ·	_	_	
Multi-racial 18 18 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 28 28 3.6 Native Hawaiian or Other Pacific 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0 0 0 0.0 Islander Unknown 663 663 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 1,023 1,044 104.6 White 110 110 **** **** ***** 859.21 (121.03, 6,099.81) 192 195 22.2 Saxenda, Atrial Fibrillation and Flutter American Indian or Alaska Native 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0 0 0.0 Asian 0 0 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** **** 5.0		_	_	_			-		_	_	
Native Hawaiian or Other Pacific 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0.0 0 0 0.0 lslander Unknown 663 663 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 1,023 1,044 104.6 White 110 110 **** **** **** 859.21 (121.03, 6,099.81) 192 195 22.2 Saxenda, Atrial Fibrillation and Flutter American Indian or Alaska Native 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0 0 0 0.0 Asian 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0.0 0 ***** ***** 5.0				_				, , ,			-
Unknown 663 663 663 0 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) 1,023 1,044 104.6				_							
Unknown 663 663 0 0.00 (0.00, 0.00) ************************************		0	0	0	NaN	0.0	0	NaN	0	0	0.0
White 110 110 ***** ***** ****** 859.21 (121.03, 6,099.81) 192 195 22.2 Saxenda, Atrial Fibrillation and Flutter American Indian or Alaska Native 0 0 0 NaN 0.0 0 NaN 0 0 0 0.0 <td< td=""><td></td><td></td><td></td><td>_</td><td></td><td>ala ala ala ala ala</td><td>ala ala ala ala ala</td><td> ()</td><td></td><td></td><td></td></td<>				_		ala ala ala ala ala	ala ala ala ala ala	()			
Saxenda, Atrial Fibrillation and Flutter American Indian or Alaska Native 0 0 NaN 0.0 0 NaN 0 0 0 0.0 Asian 0 0 0 NaN 0.0 0 NaN 0 0 0 0.0 Black or African American ***** ****** 0 0.00 (0.00, 0.00) ******* ****** 5.0				-				. , ,	,	•	
American Indian or Alaska Native 0 0 0 NaN 0.0 0 NaN 0 0 0.0			110	TTTT	T T T T T T	ጥጥጥ	****	859.21 (121.03, 6,099.81)	192	195	22.2
Asian 0 0 0 NaN 0.0 0 NaN 0.0 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.			0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American ***** 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 5.0			_	_			-		_	_	
5.0 (0.00, 0.00)		_	_	_					_	_	
	Multi-racial			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			3.0 1.7



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Hawaiian or Other Pacific	0	0	0	NaN	0.0	0	NaN	O O O	Olspensings)	0.0
Islander	U	U	U	IVAIN	0.0	U	INGIN	U	U	0.0
Unknown	342	342	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Atrial Fibrillation and Flutt		<u> </u>		0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			10.0
American Indian or Alaska Native	59	59	****	****	****	****	1,592.89 (223.37,	82	82	22.6
							11.308.46)			
Asian	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	****	****	****	****	274.66 (68.69, 1,098.22)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	7.1
Islander										
Unknown	1,435	1,435	****	****	****	****	204.46 (76.73, 544.76)	2,076	2,077	576.9
White	3,131	3,131	****	****	****	****	443.42 (286.07, 687.31)	4,574	4,574	1,173.9
Trulicity, Atrial Fibrillation and Flut	ter									
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	****	****	****	****	160.14 (51.65, 496.55)	2,047	2,055	439.7
Black or African American	6,428	6,428	****	****		****	234.69 (153.02, 359.95)	10,496	10,571	2,588.8
Multi-racial	293	293	****	****	****		201.38 (28.37, 1,429.69)	600	605	131.5
Native Hawaiian or Other Pacific	238	238	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	406	121.2
Islander										
Unknown	21,774	21,774	****	****		****	190.07 (148.48, 233.31)	39,329	39,602	8,747.9
White	36,775	36,775	****	****	****	****	475.62 (420.78, 537.60)	64,191	64,567	13,755.5
Xultophy, Atrial Fibrillation and Flu										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	*****		0.00 (0.00, 0.00)	****	****	0.4
Asian	****	****	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	****	****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	15.5



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure		Total		Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	· ·	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)		Dispensings)	Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	0.5
Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Islander										
Unknown	63	63	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	84	84	23
White	237	237	****	****	****	****	260.76 (36.73, 1,851.23)	328	328	86.6
Mounjaro, Sinus Tachycardia				<u> </u>						
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,640	1,640	****	****	****	****	113.09 (28.28, 452.19)	2,494	2,537	467.1
Multi-racial	60	60	****	****	****	****	1,360.34 (191.61, 9,657.46)	112	113	23.5
Native Hawaiian or Other Pacific	57	57	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	86	87	17.3
Islander										
Unknown	8,006	8,006	****	****		****	86.40 (43.21, 172.77)	13,643	13,787	2,230.00
White	8,939	8,939	****	****	****	****	185.22 (118.14, 290.37)	14,620	14,842	2,463.4
Bydureon, Sinus Tachycardia										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	****	****		****	450.48 (63.45, 3,198.11)	255	255	73.0
Multi-racial	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	15.8
Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Islander										
Unknown	234	234	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	346	346	89.3
White	833	833	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,336	1,336	318.3
Ozempic, Sinus Tachycardia			distribute di	4.4.4.4	distribute to	distribute to				
American Indian or Alaska Native	826	826	****	****		****	195.54 (48.90, 781.88)	1,270	1,275	282.9
Asian	1,393	1,393	****	****		****	98.16 (23.55, 392.50)	2,121	2,125	488.2
Black or African American	9,832	9,832	****	****	****	****	177.88 (119.23, 265.39)	14,096	14,145	3,611.6



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	816	816	****	****	****		94.97 (13.38, 674.25)	1,239	1,254	316.0
Native Hawaiian or Other Pacific	333	333	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	452	452	138.0
Islander	45.067	45.067	****	****	***	****	54.04./47.54.00.40	60.460	50.550	46 600 7
Unknown	45,367	45,367	****	****		****	64.91 (47.61, 88.49)	68,462	68,668	16,633.7
White Rybelsus, Sinus Tachycardia	58,441	58,441	44444	4444	4,4,4,4,4	44444	136.77 (113.74, 164.46)	86,784	87,031	20,852.5
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,087	1,087	****	*****	****	****	60.26 (8.49, 427.78)	1,655	1,684	387.9
Black or African American	3,392	3,392	****	****	****	****	133.37 (59.92, 296.88)	4,686	4,789	1,311.4
Multi-racial	181	181	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific	128	128	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	170	178	61.8
Islander Unknown White	12,788 16,414	12,788 16,414	****	****		****	80.80 (47.85, 136.43) 105.95 (71.01, 158.07)	18,631 23,439	19,067 23,933	5,022.6 5,964.1
Wegovy, Sinus Tachycardia	10,111	10,717					103.33 (71.01, 130.07)	23,433	23,333	3,304.1
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	37	37	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	57	7.0
Multi-racial	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Islander										
Unknown	663	663	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,023	1,044	104.6
White	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Sinus Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.0



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Years	Total Days	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	•	Total
	of Patients	Exposure Episodes	with an Event	Confidence Interval)	at Risk	at Risk	Patient-Years at Risk (95% Confidence Interval)	Same-Day	Same-Day Dispensings)	Observable Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
Native Hawaiian or Other Pacific	0	0	0	NaN	0.0	0	0.00 (0.00, 0.00) NaN	0	0	0.0
Islander	U	U	U	INAIN	0.0	U	Ivalv	U	U	0.0
Unknown	342	342	****	****	****	****	222.89 (31.40, 1,582.37)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Sinus Tachycardia	<u> </u>	<u> </u>		0.00 (0.00) 0.00			9.00 (0.00) 0.00			
American Indian or Alaska Native	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	82	82	22.6
Asian	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	****	****	****	****	274.66 (68.69, 1,098.22)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	7.1
Islander										
Unknown	1,435	1,435	****	****	****	****	357.80 (170.57, 750.53)	2,076	2,077	576.9
White	3,131	3,131	****	****	****	****	133.03 (59.76, 296.10)	4,574	4,574	1,173.9
Trulicity, Sinus Tachycardia										
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	****	****		****	53.38 (7.52, 378.97)	2,047	2,055	439.7
Black or African American	6,428	6,428	****	****		****	201.16 (126.74, 319.28)	10,496	10,571	2,588.8
Multi-racial	293	293	****	****		****	201.38 (28.37, 1,429.69)	600	605	131.5
Native Hawaiian or Other Pacific	238	238	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	406	121.2
Islander										
Unknown	21,774	21,774	****	****		****	102.58 (73.29, 143.56)	39,329	39,602	8,747.9
White	36,775	36,775	****	****	****	****	100.33 (76.84, 130.99)	64,191	64,567	13,755.5
Xultophy, Sinus Tachycardia	****	****		0.00 (0.00 0.00)	****	****	0.00.40.00.000	****	****	0.4
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	0.4
Asian			0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)			3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	ጥጥጥ	0.00 (0.00, 0.00)	53	53	15.5



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure		Total		Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000		Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	-	Dispensings)	Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Islander										
Unknown	63	63	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	23
White	237	237	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	328	328	86.6
Mounjaro, Supraventricular Tachyo										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,640	1,640	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,494	2,537	467.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific	57	57	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	86	87	17.3
Islander										
Unknown	8,006	8,006	****	****	****	****	21.60 (5.40, 86.37)	13,643	13,787	2,230.00
White	8,939	8,939	****	****	****	****	58.49 (26.28, 130.19)	14,620	14,842	2,463.4
Bydureon, Supraventricular Tachyo										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	15.8
Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Islander										
Unknown	234	234	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	346	346	89.3
White	833	833	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,336	1,336	318.3
Ozempic, Supraventricular Tachyca			_		ala ala di di di	ale ale altri di d	2 2 4 2 2 2 2 2 2			
American Indian or Alaska Native	826	826	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	1,270	1,275	282.9
Asian	1,393	1,393	****	****		****	49.08 (6.91, 348.44)	2,121	2,125	488.2
Black or African American	9,832	9,832	****	****	****	****	51.88 (23.73, 108.83)	14,096	14,145	3,611.6



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Same-Day	Total Observable Years
Multi-racial	816	816	****	****	****	****	94.97 (13.38, 674.25)	1,239	1,254	316.0
Native Hawaiian or Other Pacific	333	333	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	452	452	138.0
Islander										
Unknown	45,367	45,367	****	****	****	****	29.21 (18.40, 46.36)	68,462	68,668	16,633.7
White	58,441	58,441	****	****	****	****	52.04 (38.60, 70.18)	86,784	87,031	20,852.5
Rybelsus, Supraventricular Tachyca				0.00 (0.00, 0.00)	****	****	0.00 (0.00 0.00)	407	110	27.0
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,087	1,087	0 ****	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,655	1,684	387.9
Black or African American	3,392	3,392			****	****	22.23 (3.13, 157.81)	4,686	4,789	1,311.4
Multi-racial Native Hawaiian or Other Pacific	181	181 128	0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	274 170	281 178	78.9 61.8
	128	128	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	170	1/8	01.8
Islander Unknown	12,788	12,788	****	****	****	****	17.31 (5.58, 53.68)	18,631	19,067	5,022.6
White	16,414	16,414	****	****	****	****	52.98 (30.08, 93.28)	23,439	23,933	5,022.0
Wegovy, Supraventricular Tachycar		10,414					32.38 (30.08, 33.28)	23,433	23,333	3,904.1
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	37	37	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	57	7.0
Multi-racial	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Islander										
Unknown	663	663	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,023	1,044	104.6
White	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Supraventricular Tachycai	rdia									
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.0



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients ****	Number of Exposure Episodes ****	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings) *****	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings) *****	Total Observable Years
Multi-racial			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			1.7
Native Hawaiian or Other Pacific	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Islander Unknown	342	342	****	****	****	****	222.89 (31.40, 1,582.37)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Supraventricular Tachycard		31		0.00 (0.00) 0.00)			0.00 (0.00) 0.00)			10.0
American Indian or Alaska Native	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	82	82	22.6
Asian	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	7.1
Islander										
Unknown	1,435	1,435	****	****	****	****	102.23 (25.57, 408.76)	2,076	2,077	576.9
White	3,131	3,131	****	****	****	****	66.51 (21.45, 206.23)	4,574	4,574	1,173.9
Trulicity, Supraventricular Tachycai										
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	2,047	2,055	439.7
Black or African American	6,428	6,428	****	****		****	22.35 (5.59, 89.37)	10,496	10,571	2,588.8
Multi-racial	293	293	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	600	605	131.5
Native Hawaiian or Other Pacific	238	238	****	****	****	****	259.23 (36.51, 1,840.33)	400	406	121.2
Islander	24 774	24 774	****	****	****	****	20.47 (46.22 56.07)	20.220	20.602	0.747.0
Unknown	21,774	21,774	****	****		****	30.17 (16.23, 56.07)	39,329	39,602	8,747.9
White	36,775	36,775	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	T T T T T T	ጥጥጥ	*****	52.02 (35.92, 75.34)	64,191	64,567	13,755.5
Xultophy, Supraventricular Tachyca American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	53	53	3.3 15.5
DIACK OF ATTICALL ATTICITED	40	40	U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	၁၁	JO	13.3



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure	Total	Total		Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	(Adjusted for	•	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	-	Dispensings)	Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	0.5
Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Islander				, ,			• • •			
Unknown	63	63	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	23
White	237	237	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	328	328	86.6
Mounjaro, Other Tachycardia										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,640	1,640	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	2,494	2,537	467.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific	57	57	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	86	87	17.3
Islander										
Unknown	8,006	8,006	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13,643	13,787	2,230.00
White	8,939	8,939	****	****	****	****	48.74 (20.29, 117.10)	14,620	14,842	2,463.4
Bydureon, Other Tachycardia										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	15.8
Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Islander										
Unknown	234	234	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	346	346	89.3
White	833	833	****	****	****	****	177.96 (44.51, 711.57)	1,336	1,336	318.3
Ozempic, Other Tachycardia	000	226		2.22 (2.22 2.25)	****	***	0.00 (0.00 0.05)	1.070	1.075	202.0
American Indian or Alaska Native	826	826	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	1,270	1,275	282.9
Asian	1,393	1,393	****	****		****	98.16 (23.55, 392.50)	2,121	2,125	488.2
Black or African American	9,832	9,832	****	****	****	****	59.29 (29.65, 118.56)	14,096	14,145	3,611.6



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	816	816	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,239	1,254	316.0
Native Hawaiian or Other Pacific	333	333	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	452	452	138.0
Islander										
Unknown	45,367	45,367	****	****	****	****	8.11 (3.38, 19.49)	68,462	68,668	16,633.7
White	58,441	58,441	****	****	****	****	45.99 (33.47, 63.21)	86,784	87,031	20,852.5
Rybelsus, Other Tachycardia				<u> </u>						
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,087	1,087	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,655	1,684	387.9
Black or African American	3,392	3,392	****	****	****	****	22.23 (3.13, 157.81)	4,686	4,789	1,311.4
Multi-racial	181	181	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific	128	128	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	170	178	61.8
Islander				****			,_ ,_ ,_ ,_ ,_ ,_ ,_ ,_ ,_ ,_ ,_ ,_			
Unknown	12,788	12,788	****			****	5.77 (0.81, 40.97)	18,631	19,067	5,022.6
White	16,414	16,414	****	****	****	****	13.23 (4.27, 41.06)	23,439	23,933	5,964.1
Wegovy, Other Tachycardia				A. A.						
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0 ****	0 ****	NaN	0	0	0.0
Black or African American	37	37	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	55 20	57	7.0
Multi-racial	18	18	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Islander Unknown	663	663	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,023	1,044	104.6
White	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,023	1,044 195	22.2
Saxenda, Other Tachycardia	110	110	U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	192	195	22.2
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	5.0
DIACK OF ATTICAL ATTICITION			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			3.0



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total Years	Total Days	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	-	Dispensings)	Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
Native Hawaiian or Other Pacific	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Islander										
Unknown	342	342	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Other Tachycardia										
American Indian or Alaska Native	59	59	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	82	82	22.6
Asian	92	92	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	7.1
Islander										
Unknown	1,435	1,435	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,076	2,077	576.9
White	3,131	3,131	****	****	****	****	66.51 (21.45, 206.23)	4,574	4,574	1,173.9
Trulicity, Other Tachycardia										
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	2,047	2,055	439.7
Black or African American	6,428	6,428	****	****		****	22.35 (5.59, 89.37)	10,496	10,571	2,588.8
Multi-racial	293	293	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	600	605	131.5
Native Hawaiian or Other Pacific	238	238	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	406	121.2
Islander	24 774	24 774	****	****	***	****	5.00 (4.54.00.40)	20.222	22.522	0.747.0
Unknown	21,774	21,774	****	****			6.03 (1.51, 23.13)	39,329	39,602	8,747.9
White	36,775	36,775	****	****	****	****	31.58 (19.63, 50.81)	64,191	64,567	13,755.5
Xultophy, Other Tachycardia	****	****		0.00.(0.00.0.00)	****	****	0.00.(0.00.0.00)	****	****	0.4
American Indian or Alaska Native	****	****	0 0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	****	****	0.4 3.3
Asian			-	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	53	53	3.3 15.5
Black or African American	40	40	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	53	53	15.5



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure		Total		Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	(Adjusted for	•	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Islander										
Unknown	63	63	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	23
White	237	237	****	****	****	****	260.76 (36.73, 1,851.23)	328	328	86.6
Mounjaro, Cardiac Arrest										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,640	1,640	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,494	2,537	467.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific	57	57	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	86	87	17.3
Islander										
Unknown	8,006	8,006	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13,643	13,787	2,230.00
White	8,939	8,939	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14,620	14,842	2,463.4
Bydureon, Cardiac Arrest										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	15.8
Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Islander										
Unknown	234	234	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	346	346	89.3
White	833	833	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,336	1,336	318.3
Ozempic, Cardiac Arrest										
American Indian or Alaska Native	826	826	****	****		****	97.77 (13.77, 694.10)	1,270	1,275	282.9
Asian	1,393	1,393	****	****		****	49.08 (6.91, 348.44)	2,121	2,125	488.2
Black or African American	9,832	9,832	****	****	****	****	7.41 (1.04, 52.62)	14,096	14,145	3,611.6



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total Years	Days	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for		Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)		Years
Multi-racial	816	816	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,239	1,254	316.0
Native Hawaiian or Other Pacific	333	333	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	452	452	138.0
Islander			4.4.4.4.							
Unknown	45,367	45,367	****	****	****	****	4.87 (1.57, 15.09)	68,462	68,668	16,633.7
White	58,441	58,441	****	****	****	****	14.52 (8.25, 25.57)	86,784	87,031	20,852.5
Rybelsus, Cardiac Arrest				<u> </u>						
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,087	1,087	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	1,655	1,684	387.9
Black or African American	3,392	3,392	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	4,686	4,789	1,311.4
Multi-racial	181	181	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific	128	128	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	170	178	61.8
Islander										
Unknown	12,788	12,788	****	****	****	****	5.77 (0.81, 40.97)	18,631	19,067	5,022.6
White	16,414	16,414	****	****	****	****	4.41 (0.62, 31.34)	23,439	23,933	5,964.1
Wegovy, Cardiac Arrest										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	37	37	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	57	7.0
Multi-racial	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Islander										
Unknown	663	663	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,023	1,044	104.6
White	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Cardiac Arrest										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.0



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total Years	Total Days	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	<u> </u>	Dispensings)	Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
Native Hawaiian or Other Pacific	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Islander										
Unknown	342	342	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Cardiac Arrest										
American Indian or Alaska Native	59	59	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	82	82	22.6
Asian	92	92	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	****	****	****	****	137.33 (19.34, 974.93)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	7.1
Islander										
Unknown	1,435	1,435	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,076	2,077	576.9
White	3,131	3,131	****	****	****	****	44.34 (11.09, 177.30)	4,574	4,574	1,173.9
Trulicity, Cardiac Arrest				· · · · · ·						
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	2,047	2,055	439.7
Black or African American	6,428	6,428	****	****		****	11.18 (1.57, 79.34)	10,496	10,571	2,588.8
Multi-racial	293	293	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	600	605	131.5
Native Hawaiian or Other Pacific	238	238	****	****	****	****	259.23 (36.51, 1,840.33)	400	406	121.2
Islander							/			
Unknown	21,774	21,774	****	****		****	3.02 (0.42, 21.42)	39,329	39,602	8,747.9
White	36,775	36,775	****	****	****	****	16.72 (8.70, 32.14)	64,191	64,567	13,755.5
Xultophy, Cardiac Arrest	****	****		0.00 (0.00 0.00)	****	****	0.00.(0.00.0.05)	****	****	0.1
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	****	****	0.4
Asian			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	15.5



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100 Exposure		Total		Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000		Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Islander										
Unknown	63	63	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	23
White	237	237	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	328	328	86.6
Mounjaro, Ventricular Tachycardia										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,640	1,640	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,494	2,537	467.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific	57	57	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	86	87	17.3
Islander										
Unknown	8,006	8,006	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13,643	13,787	2,230.00
White	8,939	8,939	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14,620	14,842	2,463.4
Bydureon, Ventricular Tachycardia				· · · · · · · · · · · · · · · · · · ·						
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	15.8
Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Islander			_	,						
Unknown	234	234	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	346	346	89.3
White	833	833	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,336	1,336	318.3
Ozempic, Ventricular Tachycardia	026	026		0.00 (0.00 0.00)	****	****	0.00.40.00.000,	4.270	4 275	202.0
American Indian or Alaska Native	826	826	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,270	1,275	282.9
Asian	1,393	1,393	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	2,121	2,125	488.2
Black or African American	9,832	9,832	****	****	****	****	14.82 (3.71, 59.27)	14,096	14,145	3,611.6



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	816	816	****	****	****		94.97 (13.38, 674.25)	1,239	1,254	316.0
Native Hawaiian or Other Pacific	333	333	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	452	452	138.0
Islander			_	()	ala ala ala ala ala	ale ale ale ale ale	()			
Unknown	45,367	45,367	0 ****	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	68,462	68,668	16,633.7
White	58,441	58,441	****	****	****	****	4.84 (1.82, 12.90)	86,784	87,031	20,852.5
Rybelsus, Ventricular Tachycardia American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,087	1,087	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,655	1,684	387.9
Black or African American	3,392	3,392	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,686	4,789	1,311.4
Multi-racial	181	181	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific	128	128	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	170	178	61.8
Islander				0.00 (0.00) 0.00)			0.00 (0.00) 0.00)	0	_, _	02.0
Unknown	12,788	12,788	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18,631	19,067	5,022.6
White	16,414	16,414	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23,439	23,933	5,964.1
Wegovy, Ventricular Tachycardia							• • •			
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	37	37	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	57	7.0
Multi-racial	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Islander										
Unknown	663	663	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,023	1,044	104.6
White	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Ventricular Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.0



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95%	Total Years	Total Days	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	•	Dispensings)	Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
Native Hawaiian or Other Pacific	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Islander										
Unknown	342	342	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Ventricular Tachycardia										
American Indian or Alaska Native	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	82	82	22.6
Asian	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	7.1
Islander										
Unknown	1,435	1,435	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,076	2,077	576.9
White	3,131	3,131	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,574	4,574	1,173.9
Trulicity, Ventricular Tachycardia				<u> </u>						
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	2,047	2,055	439.7
Black or African American	6,428	6,428	****	****		****	11.18 (1.57, 79.34)	10,496	10,571	2,588.8
Multi-racial	293	293	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	600	605	131.5
Native Hawaiian or Other Pacific	238	238	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	406	121.2
Islander			_	,						
Unknown	21,774	21,774	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39,329	39,602	8,747.9
White	36,775	36,775	****	****	****	****	3.72 (0.93, 14.86)	64,191	64,567	13,755.5
Xultophy, Ventricular Tachycardia	****	****		0.00 (0.00 0.00)	****	****	0.00.(0.00.0.05)	****	****	0.1
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	****	****	0.4
Asian			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	ጥጥጥ	0.00 (0.00, 0.00)	53	53	15.5



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

Multi-racial ****** ****** 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** ****** ****** 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** 0.00 (0.00, 0.00) ******* ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** 0.00 (0.00, 0.00) ****** ****** ****** ***** ***** ***** ***** ***** ***** ***** 0.00 (0.00, 0.00) ****** ***** ***** ***** 0.00 (0.00, 0.00) ****** ***** ***** 0.00 (0.00, 0.00) ****** ***** ***** ***** 0.00 (0.00, 0.00) ***** ***** ***** ***** ***** 0.00 (0.00, 0.00) ***** ***** ***** ***** ***** ***** 0.00 (0.00,	Total Observable Years 0.5 0.9
Multi-racial Mult	Observable Years 0.5 0.9
Multi-racial ****** ****** ****** ****** ******	0.5 0.9 23
Multi-racial ***** ****** ****** 0 0.00 (0.00, 0.00) ****** ****** ****** ****** 0 0.00 (0.00, 0.00) ****** ****** ****** ****** 0 0.00 (0.00, 0.00) ******* ****** ****** ****** ****** ****** ****** ****** 0 0.00 (0.00, 0.00) ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** 0.00 (0.00, 0.00) ******	0.5 0.9 23
Native Hawaiian or Other Pacific ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** ***** 1.00 (0.00, 0.00) ***** ***** 1.00 (0.00, 0.00) ***** ***** 1.00 (0.00, 0.00) ***** ***** 1.00 (0.00, 0.00) ***** **** 1.00 (0.00, 0.00) ***** 1.00 (0.00, 0.00) **** 1.00 (0.00, 0.00) **** 1.00 (0.00, 0.00) **** 1.00 (0.00, 0.00) **** 1.00 (0.00, 0.00) **** 1.00 (0.00, 0.00) **** 1.00 (0.00, 0.00) ***** 1.00 (0.00, 0.00) **** 1.00 (0.00, 0.00) ***** 1.00 (0.00, 0.00) ***** 1.00 (0.00, 0.00) ****	0.9
Slander	23
Unknown 63 63 63 0 0.00 (0.00, 0.00) ***** ****** 0.00 (0.00, 0.00) 84 84 White 237 237 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 328 328 Mounjaro, Ventricular Fibrillation and Flutter American Indian or Alaska Native 32 32 0 0.00 (0.00, 0.00) ***** ****** 0.00 (0.00, 0.00) 56 56 Asian 108 108 0 0.00 (0.00, 0.00) ***************** 0.00 (0.00, 0.00) 162 163 Black or African American 1,640 1,640 0 0.00 (0.00, 0.00) ****************** 0.00 (0.00, 0.00) 2,494 2,537 Multi-racial 60 60 0 0.00 (0.00, 0.00) *********************** 0.00 (0.00, 0.00) 112 113 Native Hawaiian or Other Pacific 57 57 0 0.00 (0.00, 0.00) ****************** 0.00 (0.00, 0.00) 13,643 13,787 Unknown 8,939 8,939 ****** *****	
White 237 237 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 328 328 Mounjaro, Ventricular Fibrillation and Flutter American Indian or Alaska Native 32 32 0 0.00 (0.00, 0.00) ********************************** 0.00 (0.00, 0.00) 56 56 Asian 108 108 0 0.00 (0.00, 0.00) ************************* 0.00 (0.00, 0.00) 162 163 Black or African American 1,640 1,640 0 0.00 (0.00, 0.00) ************************* 0.00 (0.00, 0.00) 2,494 2,537 Multi-racial 60 60 0 0.00 (0.00, 0.00) ************************* 0.00 (0.00, 0.00) 112 113 Native Hawaiian or Other Pacific 57 57 0 0.00 (0.00, 0.00) ************************* 0.00 (0.00, 0.00) 13,643 13,787 Unknown 8,006 8,006 0 0.00 (0.00, 0.00) ************************ 0.00 (0.00, 0.00) 13,643 13,787 White 8,939 8,939	
American Indian or Alaska Native 32 32 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 56 56 Asian 108 108 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 162 163 Black or African American 1,640 1,640 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 2,494 2,537 Multi-racial 60 60 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 112 113 Native Hawaiian or Other Pacific 57 57 0 0.00 (0.00, 0.00) **** **** **** 0.00 (0.00, 0.00) 86 87 Islander Unknown 8,006 8,006 0 0.00 (0.00, 0.00) **** **** **** 0.00 (0.00, 0.00) 13,643 13,787 White 8,939 8,939 **** **** **** 9.75 (1.37, 69.21) 14,620 14,842 Bydureon, Ventricular Fibrillation and Flutter American Indian or Alaska Native **** **** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 75 75	86.6
Asian 108 108 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 162 163 Black or African American 1,640 1,640 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 2,494 2,537 Multi-racial 60 60 0 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 112 113 Native Hawaiian or Other Pacific 57 57 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 86 87 Islander Unknown 8,006 8,006 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 13,643 13,787 White 8,939 8,939 **** **** 9.75 (1.37, 69.21) 14,620 14,842 Bydureon, Ventricular Fibrillation and Flutter American Indian or Alaska Native **** **** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 75 75	
Black or African American 1,640 1,640 0 0.00 (0.00, 0.00) ************************************	8.9
Multi-racial 60 60 0 0.00 (0.00, 0.00) ************************************	28.1
Native Hawaiian or Other Pacific 57 57 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 86 87 Islander Unknown 8,006 8,006 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 13,643 13,787 White 8,939 8,939 **** **** 9.75 (1.37, 69.21) 14,620 14,842 Bydureon, Ventricular Fibrillation and Flutter American Indian or Alaska Native **** **** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) ***** **** Asian 44 44 0 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 75 75	467.1
Islander Unknown 8,006 8,006 0 0.00 (0.00, 0.00) ***** ***** ***** ***** ***** **** **	23.5
Unknown 8,006 8,006 0 0.00 (0.00, 0.00) ****** ****** 0.00 (0.00, 0.00) 13,643 13,787 White 8,939 8,939 ***** ***** ****** 9.75 (1.37, 69.21) 14,620 14,842 Bydureon, Ventricular Fibrillation and Flutter American Indian or Alaska Native ***** 0 0.00 (0.00, 0.00) ***************** 0.00 (0.00, 0.00) ****************** Asian 44 44 0 0.00 (0.00, 0.00) ********************** 0.00 (0.00, 0.00) 75 75	17.3
White 8,939 8,939 ***** ****** ****** 9.75 (1.37, 69.21) 14,620 14,842 Bydureon, Ventricular Fibrillation and Flutter American Indian or Alaska Native ***** 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** ****** Asian 44 44 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) 75 75	
Bydureon, Ventricular Fibrillation and Flutter American Indian or Alaska Native ***** 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** ****** Asian 44 44 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) 75 75	2,230.00
American Indian or Alaska Native ***** ***** 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** ***** Asian 44 44 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) 75 75	2,463.4
Asian 44 44 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) 75 75	
, , , ,	2.7
	18.7
Black or African American 165 165 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) 255 255	73.0
Multi-racial ***** 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** ****	15.8
Native Hawaiian or Other Pacific ***** ***** 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** *****	0.5
Islander Unknown	00.0
Official of the state of the st	89.3
White 833 833 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) 1,336 1,336	318.3
Ozempic, Ventricular Fibrillation and Flutter American Indian or Alaska Native 826 826 0 0.00 (0.00, 0.00) ****** ****** ****** 0.00 (0.00, 0.00) 1,270 1,275	
American indian of Alaska Native 820 820 0 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 1,270 1,275	າດາ ດ
Asian 1,393 1,393 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) 2,121 2,125 Black or African American 9,832 9,832 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) 14,096 14,145	282.9 488.2



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	816	816	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,239	1,254	316.0
Native Hawaiian or Other Pacific	333	333	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	452	452	138.0
Islander										
Unknown	45,367	45,367	****	****	****	*****	1.62 (0.23, 11.52)	68,462	68,668	16,633.7
White	58,441	58,441	****	****	****	****	3.63 (1.17, 11.26)	86,784	87,031	20,852.5
Rybelsus, Ventricular Fibrillation ar American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,087	1,087	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	1,655	1,684	387.9
Black or African American	3,392	3,392	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,686	4,789	1,311.4
Multi-racial	181	181	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific	128	128	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	170	178	61.8
Islander	120	120	ŭ	0.00 (0.00) 0.00)			0.00 (0.00) 0.00)	1,0	170	01.0
Unknown	12,788	12,788	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18,631	19,067	5,022.6
White	16,414	16,414	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23,439	23,933	5,964.1
Wegovy, Ventricular Fibrillation and		•		, , ,				,	•	
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	37	37	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	57	7.0
Multi-racial	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Islander										
Unknown	663	663	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,023	1,044	104.6
White	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Ventricular Fibrillation an										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.0



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients ****	Number of Exposure Episodes ****	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings) *****	Same-Day	Total Observable Years
Multi-racial			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			1.7
Native Hawaiian or Other Pacific	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Islander Unknown	342	342	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Ventricular Fibrillation and	_	31		0.00 (0.00) 0.00)			0.00 (0.00) 0.00)			10.0
American Indian or Alaska Native	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	82	82	22.6
Asian	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	7.1
Islander										
Unknown	1,435	1,435	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,076	2,077	576.9
White	3,131	3,131	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,574	4,574	1,173.9
Trulicity, Ventricular Fibrillation and										
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	2,047	2,055	439.7
Black or African American	6,428	6,428	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	10,496	10,571	2,588.8
Multi-racial	293	293	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	600	605	131.5
Native Hawaiian or Other Pacific	238	238	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	406	121.2
Islander Unknown	21,774	21,774	****	****	****	****	6.03 (1.51, 23.13)	39,329	39,602	8,747.9
White	36,775	36,775	****	****	****	****	5.57 (1.80, 17.28)	64,191	64,567	13,755.5
Xultophy, Ventricular Fibrillation ar	•							- ,	- ,	-,
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	15.5



Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence		Total Days at	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	•	Dispensings)	Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	0.5
Native Hawaiian or Other Pacific	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	0.9
Islander										
Unknown	63	63	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	23
White	237	237	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	328	328	86.6

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

^{*}NaN: Not a number



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhyth	mia									
Evidence of Other cardiac disease	597	597	****	****	****	****	744.29 (334.38, 1,656.73)	935	935	233.0
No evidence of Other cardiac disease	723	723	****	****	****	****	102.55 (14.45, 728.05)	1,134	1,134	285.4
Mounjaro, Hospitalized Tachyarrhyth	mia									
Evidence of Other cardiac disease	8,953	8,953	****	****	****	****	788.80 (633.57, 982.05)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	****	****	****	****	192.17 (126.53, 291.85)	16,463	16,677	2,759.0
Ozempic, Hospitalized Tachyarrhythm	nia									
Evidence of Other cardiac disease	55,966	55,966	****	****	****	****	789.15 (728.89, 854.38)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	****	****	****	****	216.02 (186.95, 239.60)	91,231	91,495	22,255.7
Rybelsus, Hospitalized Tachyarrhythn	nia									
Evidence of Other cardiac disease	13,748	13,748	****	****	****	****	719.61 (607.52, 852.37)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	****	****	****	****	156.78 (116.67, 210.68)	29,674	30,323	7,753.6
Saxenda, Hospitalized Tachyarrhythm	iia									
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	****	****	****	****	347.10 (48.89, 2,464.15)	348	348	112.9
Trulicity, Hospitalized Tachyarrhythm	ia									
Evidence of Other cardiac disease	31,389	31,389	****	****	****	****	793.33 (715.47, 879.67)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	****	****	****	****	253.52 (214.30, 299.92)	62,987	63,392	13,896.7
Victoza, Hospitalized Tachyarrhythmi	a									
Evidence of Other cardiac disease	2,610	2,610	****	****	****	****	1,022.36 (740.74, 1,411.05)	3,723	3,723	999.2
No evidence of Other cardiac disease	2,744	2,744	****	****	****	****	206.90 (103.47, 413.72)	3,998	3,999	1,072.0
Wegovy, Hospitalized Tachyarrhythm										
Evidence of Other cardiac disease	343	343	****	****	****		314.92 (44.36, 2,235.76)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	737	746	79.9
Xultophy, Hospitalized Tachyarrhythn	nia									



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

			Number of	Number of Exposure Episodes with an Event per				Number of Exposure Episode Defining-	Number of Exposure Episode Defining- Dispensings	
		Number	Exposure	100 Exposure	Total	Total		Dispensings	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Evidence of Other cardiac disease	186	186	****	****	****	****	677.39 (169.41, 2,708.58)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	229	229	65.6
Mounjaro, Atrial Fibrillation and Flut	ter									
Evidence of Other cardiac disease	8,953	8,953	****	****	****	****	552.16 (423.93, 717.48)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	****	****	****	****	69.88 (34.95, 139.73)	16,463	16,677	2,759.0
Bydureon, Atrial Fibrillation and Flutt	er									
Evidence of Other cardiac disease	597	597	****	****	****	****	496.20 (186.23, 1,322.09)	935	935	233.0
No evidence of Other cardiac disease	723	723	****	****	****	****	102.55 (14.45, 728.05)	1,134	1,134	285.4
Ozempic, Atrial Fibrillation and Flutte	er									
Evidence of Other cardiac disease	55,966	55,966	****	****	****	****	563.68 (513.12, 619.22)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	****	****	****	****	83.35 (66.06, 105.18)	91,231	91,495	22,255.7
Rybelsus, Atrial Fibrillation and Flutte	er									
Evidence of Other cardiac disease	13,748	13,748	****	****	****	****	563.87 (465.70, 682.73)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	****	****	****	****	67.70 (43.18, 106.14)	29,674	30,323	7,753.6
Wegovy, Atrial Fibrillation and Flutte	r									
Evidence of Other cardiac disease	343	343	****	****	****	****	314.92 (44.36, 2,235.76)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	737	746	79.9
Saxenda, Atrial Fibrillation and Flutte	r									
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	348	348	112.9
Victoza, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	2,610	2,610	****	****	****	****	663.15 (444.49, 989.39)	3,723	3,723	999.2
No evidence of Other cardiac disease	2,744	2,744	****	****	****	****	77.59 (25.02, 230.57)	3,998	3,999	1,072.0
Trulicity, Atrial Fibrillation and Flutte	r									
Evidence of Other cardiac disease	31,389	31,389	****	****	****	****	606.02 (538.46, 682.05)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	****	****	****	****	128.63 (101.59, 162.86)	62,987	63,392	13,896.7



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Same-Day	Total Observable Years
Xultophy, Atrial Fibrillation and Flutte										
Evidence of Other cardiac disease	186	186	****	****	****		338.70 (47.71, 2,404.52)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	229	229	65.6
Mounjaro, Sinus Tachycardia										
Evidence of Other cardiac disease	8,953	8,953	****	****	****		157.76 (96.65, 257.51)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	****	****	****	****	122.29 (72.42, 206.48)	16,463	16,677	2,759.0
Bydureon, Sinus Tachycardia										
Evidence of Other cardiac disease	597	597	****	****	****	****	123.05 (17.47, 880.66)	935	935	233.0
No evidence of Other cardiac disease	723	723	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,134	1,134	285.4
Ozempic, Sinus Tachycardia										
Evidence of Other cardiac disease	55,966	55,966	****	****	****	****	128.28 (105.35, 156.22)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	****	****	****	****	97.44 (78.58, 120.83)	91,231	91,495	22,255.7
Rybelsus, Sinus Tachycardia										
Evidence of Other cardiac disease	13,748	13,748	****	****	****	****	123.51 (82.08, 185.87)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	****	****	****	****	78.39 (51.62, 119.06)	29,674	30,323	7,753.6
Wegovy, Sinus Tachycardia										
Evidence of Other cardiac disease	343	343	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	737	746	79.9
Saxenda, Sinus Tachycardia										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	****	****	****	****	347.10 (48.89, 2,464.15)	348	348	112.9
Victoza, Sinus Tachycardia										
Evidence of Other cardiac disease	2,610	2,610	****	****	****	****	238.68 (129.39, 477.95)	3,723	3,723	999.2
No evidence of Other cardiac disease	2,744	2,744	****	****	****	****	155.17 (69.71, 345.40)	3,998	3,999	1,072.0
Trulicity, Sinus Tachycardia										



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

			Number of	Number of Exposure Episodes with an Event per				Number of Exposure Episode Defining-	Number of Exposure Episode Defining- Dispensings	
		Number	Exposure	100 Exposure	Total	Total		Dispensings	(Not	
	Number	of	Episodes	Episodes (95%	Years	Days	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	Confidence	at	at	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Evidence of Other cardiac disease	31,389	31,389	****	****	****	****	127.82 (98.81, 165.33)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	****	****	****	****	93.21 (70.64, 122.98)	62,987	63,392	13,896.7
Xultophy, Sinus Tachycardia										
Evidence of Other cardiac disease	186	186	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	229	229	65.6
Mounjaro, Supraventricular Tachycar	dia									
Evidence of Other cardiac disease	8,953	8,953	****	****	****	****	78.88 (39.45, 157.73)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16,463	16,677	2,759.0
Bydureon, Supraventricular Tachycar	dia									
Evidence of Other cardiac disease	597	597	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	935	935	233.0
No evidence of Other cardiac disease	723	723	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,134	1,134	285.4
Ozempic, Supraventricular Tachycard	ia									
Evidence of Other cardiac disease	55,966	55,966	****	****	****	****	63.49 (47.99, 84.01)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	****	****	****	****	23.65 (16.07, 37.81)	91,231	91,495	22,255.7
Rybelsus, Supraventricular Tachycard	lia									
Evidence of Other cardiac disease	13,748	13,748	****	****	****	****	59.07 (32.71, 106.67)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	****	****	****	****	17.82 (7.42, 42.80)	29,674	30,323	7,753.6
Wegovy, Supraventricular Tachycardi	ia									
Evidence of Other cardiac disease	343	343	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	737	746	79.9
Saxenda, Supraventricular Tachycard	ia									
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	****	****	****	****	347.10 (48.89, 2,464.15)	348	348	112.9
Victoza, Supraventricular Tachycardia	9									
Evidence of Other cardiac disease	2,610	2,610	****	****	****	****	138.16 (57.50, 331.93)	3,723	3,723	999.2
No evidence of Other cardiac disease	2,744	2,744	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,998	3,999	1,072.0



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Trulicity, Supraventricular Tachycardi										
Evidence of Other cardiac disease	31,389	31,389	****	****	****		59.50 (40.80, 86.76)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	****	****	****	****	26.10 (15.46, 44.07)	62,987	63,392	13,896.7
Xultophy, Supraventricular Tachycard										
Evidence of Other cardiac disease	186	186	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	229	229	65.6
Mounjaro, Other Tachycardia										
Evidence of Other cardiac disease	8,953	8,953	****	****	****		39.44 (14.80, 105.09)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	****	****	****	****	8.73 (1.23, 62.01)	16,463	16,677	2,759.0
Bydureon, Other Tachycardia										
Evidence of Other cardiac disease	597	597	****	****	****	****	238.10 (62.05, 992.03)	935	935	233.0
No evidence of Other cardiac disease	723	723	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,134	1,134	285.4
Ozempic, Other Tachycardia										
Evidence of Other cardiac disease	55,966	55,966	****	****	****	****	50.54 (36.92, 69.17)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	****	****	****	****	16.44 (9.73, 27.75)	91,231	91,495	22,255.7
Rybelsus, Other Tachycardia										
Evidence of Other cardiac disease	13,748	13,748	****	****	****	****	16.11 (5.20, 49.95)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	****	****	****	****	7.13 (1.78, 28.50)	29,674	30,323	7,753.6
Wegovy, Other Tachycardia										
Evidence of Other cardiac disease	343	343	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	737	746	79.9
Saxenda, Other Tachycardia										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	348	348	112.9
Victoza, Other Tachycardia										



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

cardiac disease										
	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years at	Total Days at	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)	Risk	Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Evidence of Other cardiac disease	2,610	2,610	****	****		****	82.89 (26.73, 257.02)	3,723	3,723	999.2
No evidence of Other cardiac disease	2,744	2,744	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,998	3,999	1,072.0
Trulicity, Other Tachycardia		,						-,	-,	, -
Evidence of Other cardiac disease	31,389	31,389	****	****	****	****	30.85 (18.27, 52.09)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	****	****	****	****	13.05 (6.22, 27.37)	62,987	63,392	13,896.7
Xultophy, Other Tachycardia	•	,					, ,	,	,	,
Evidence of Other cardiac disease	186	186	****	****	****	****	338.70 (47.71, 2,404.52)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	229	229	65.6
Mounjaro, Cardiac Arrest										
Evidence of Other cardiac disease	8,953	8,953	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16,463	16,677	2,759.0
Bydureon, Cardiac Arrest										
Evidence of Other cardiac disease	597	597	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	935	935	233.0
No evidence of Other cardiac disease	723	723	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,134	1,134	285.4
Ozempic, Cardiac Arrest										
Evidence of Other cardiac disease	55,966	55,966	****	****		****	15.55 (8.83, 27.38)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	****	****	****	****	7.04 (3.16, 15.68)	91,231	91,495	22,255.7
Rybelsus, Cardiac Arrest										
Evidence of Other cardiac disease	13,748	13,748	****	****	****	****	10.74 (2.69, 42.95)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29,674	30,323	7,753.6
Wegovy, Cardiac Arrest										
Evidence of Other cardiac disease	343	343	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	737	746	79.9
Saxenda, Cardiac Arrest										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	348	348	112.9



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Victoza, Cardiac Arrest										
Evidence of Other cardiac disease	2,610	2,610	****	****	****		82.89 (26.73, 257.02)	3,723	3,723	999.2
No evidence of Other cardiac disease	2,744	2,744	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,998	3,999	1,072.0
Trulicity, Cardiac Arrest										
Evidence of Other cardiac disease	31,389	31,389	****	****		****	19.83 (10.32, 38.12)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	****	****	****	****	5.59 (1.80, 17.34)	62,987	63,392	13,896.7
Xultophy, Cardiac Arrest										
Evidence of Other cardiac disease	186	186	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	229	229	65.6
Mounjaro, Ventricular Tachycardia										
Evidence of Other cardiac disease	8,953	8,953	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16,463	16,677	2,759.0
Bydureon, Ventricular Tachycardia										
Evidence of Other cardiac disease	597	597	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	935	935	233.0
No evidence of Other cardiac disease	723	723	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,134	1,134	285.4
Ozempic, Ventricular Tachycardia										
Evidence of Other cardiac disease	55,966	55,966	****	****		****	6.48 (2.70, 15.57)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	****	****	****	****	2.35 (0.59, 9.39)	91,231	91,495	22,255.7
Rybelsus, Ventricular Tachycardia										
Evidence of Other cardiac disease	13,748	13,748	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29,674	30,323	7,753.6
Wegovy, Ventricular Tachycardia										
Evidence of Other cardiac disease	343	343	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	737	746	79.9
Saxenda, Ventricular Tachycardia										



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

cardiac disease										
	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years at	Total Days at	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Same-Day	Total Observable
E : I COIL II II	Patients	Episodes	Event	Interval)	Risk	Risk ****	Confidence Interval)		Dispensings)	Years
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	348	348	112.9
Victoza, Ventricular Tachycardia	2.610	2.610		0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2 722	2 722	999.2
Evidence of Other cardiac disease	2,610	2,610	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	3,723	3,723	
No evidence of Other cardiac disease	2,744	2,744	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	3,998	3,999	1,072.0
Trulicity, Ventricular Tachycardia	24 200	24 200	****	****	****	****	C C4 /2 42 20 F0\	F 4 F F F	F4.00C	11.070.0
Evidence of Other cardiac disease	31,389	31,389			****		6.61 (2.13, 20.50)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	0	0.00 (0.00, 0.00)	4444	4.4.4.4.	0.00 (0.00, 0.00)	62,987	63,392	13,896.7
Xultophy, Ventricular Tachycardia	406	406		0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	255	255	65.6
Evidence of Other cardiac disease	186	186	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	229	229	65.6
Mounjaro, Ventricular Fibrillation and			****	****	ale ale ale ale ale	****				
Evidence of Other cardiac disease	8,953	8,953					9.86 (1.39, 70.00)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	0	0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00)	16,463	16,677	2,759.0
Bydureon, Ventricular Fibrillation and				<u> </u>						
Evidence of Other cardiac disease	597	597	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	935	935	233.0
No evidence of Other cardiac disease	723	723	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	1,134	1,134	285.4
Ozempic, Ventricular Fibrillation and										
Evidence of Other cardiac disease	55,966	55,966	****	****		****	5.18 (1.95, 13.81)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	91,231	91,495	22,255.7
Rybelsus, Ventricular Fibrillation and										
Evidence of Other cardiac disease	13,748	13,748	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29,674	30,323	7,753.6
Wegovy, Ventricular Fibrillation and F										
Evidence of Other cardiac disease	343	343	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	737	746	79.9



Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

Saxenda, Ventricular Fibrillation and	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	348	348	112.9
Victoza, Ventricular Fibrillation and F	lutter						<u> </u>			
Evidence of Other cardiac disease	2,610	2,610	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,723	3,723	999.2
No evidence of Other cardiac disease	2,744	2,744	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,998	3,999	1,072.0
Trulicity, Ventricular Fibrillation and I	lutter									
Evidence of Other cardiac disease	31,389	31,389	****	****	****	****	8.81 (3.31, 23.49)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	****	****	****	****	1.86 (0.26, 13.23)	62,987	63,392	13,896.7
Xultophy, Ventricular Fibrillation and	Flutter									
Evidence of Other cardiac disease	186	186	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	229	229	65.6

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

Bydureon, Hos	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
American India		-								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	0.1	54	0.00 (0.00, 0.00)	****	****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	5,354	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.3
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or African	n American									
0-40 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	****	****	****	****	****	****	6,330.16 (891.66, 44,939.85)	****	****	4.9
≥ 85 vears <i>Multi-racial</i>	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.3
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Hawaiid										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 vears <i>Unknown</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	6.3
41-64 years	118	118	****	****	****	****	626.18 (88.20, 4,445.45)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
White										
0-40 years	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	14.0
, 41-64 years	251	251	****	****	****	****	635.05 (158.82, 2,539.28)	404	404	98.6
65-74 years	387	387	****	****	****	****	169.91 (23.93, 1,206.23)	654	654	152.2
, 75-84 years	149	149	****	****	****	****	546.54 (76.98, 3,880.04)	217	217	49.5
≥ 85 years	12	12	****	****	****	****	12,726.48 (1,792.63,	16	16	3.9
•							90,349.45			
Mounjaro, Hos	pitalized Tach	yarrhythmia								
American India	ın or Alaska Na	tive								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
≥85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian	****	****		0.00 (0.00 0.00)	****	****	0.00 (0.00 0.00)	****	****	4 =
0-40 years			0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)			1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53 ****	53 ****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22 ****	22 ****	4.2
≥ 85 years		4.4.4.4.4.	0	0.00 (0.00, 0.00)	4.4.4.4.4.	44444	0.00 (0.00, 0.00)	4. 4. 4. 4. 4.		0.2
Black or Africa	n American ****	****	0	0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	70	72	12.0
0-40 years			0 ****	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	70	73	13.0
41-64 years	671	671	****	****	****	****	809.69 (363.76, 1,802.29)	1,074	1,085	198.4
65-74 years	744 173	744			****	****	251.47 (62.89, 1,005.52)	1,100	1,125	209.6
75-84 years	1/3 ****	173 ****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	235	239	44.1
≥ 85 vears <i>Multi-racial</i>			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	15	15	2.0
0-40 years	****	****	****	****	****	****	7,423.78 (1,045.70, 52,703.85)	20	20	3.7
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	1.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
≥ 85 vears <i>Unknown</i>	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

by nace and A	ge e.e.p									
	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
0-40 years	855	855	****	****	****	****	107.06 (15.08, 760.06)	1,423	1,439	231.3
41-64 years	6,086	6,086	****	****	****	****	181.35 (105.30, 312.32)	10,484	10,593	1,733.2
65-74 years	898	898	****	****	****	****	706.07 (336.60, 1,481.08)	1,474	1,489	233.3
75-84 years	****	****	****	****	****	****	633.89 (89.29, 4,500.22)	239	253	40.5
≥ 85 vears White	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	1.7
0-40 years	115	115	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	215	217	32.5
41-64 years	2,394	2,394	20	0.84 (0.47, 1.20)	****	****	706.41 (455.74, 1,094.95)	4,115	4,179	722.7
65-74 years	4,850	4,850	36	0.74 (0.50, 0.98)	****	****	646.92 (466.64, 896.85)	7,859	7,979	1,301.9
75-84 years	1,505	1,505	****	****	****	****	787.73 (457.39, 1,356.63)	2,325	2,359	389.7
≥ 85 years	75	75	****	****	****	****	2,912.68 (728.44, 11,646.47)	106	108	16.6
Ozempic, Hosp	oitalized Tachy	arrhythmia								
American India	an or Alaska Na	ıtive								
0-40 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	****	****	****	****	1,180.42 (443.02, 3,145.16)	409	411	89.4
65-74 years	361	361	****	****	****	****	666.64 (215.00, 2,066.99)	566	569	120.7
75-84 years	165	165	****	****	****	****	2,563.52 (1,066.99, 6,159.03)	239	239	59.4
≥ 85 years <i>Asian</i>	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25	25	5.8
0-40 years	79	79	****	****	****	****	2,097.93 (523.67, 8,388.67)	111	111	29.8
41-64 years	360	360	****	****	****	****	190.21 (26.79, 1,350.40)	563	563	137.7



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	655	655	****	****	****	****	417.72 (156.77, 1,112.98)	982	985	217.5
75-84 years	251	251	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	****	****	****	****	2,778.62 (694.91, 11,110.44)	80	80	16.7
Black or African	American									
0-40 years	313	313	****	****	****	****	508.14 (127.08, 2,031.81)	434	436	110.9
41-64 years	3,802	3,802	30	0.79 (0.51, 1.07)	****	****	581.94 (406.88, 832.31)	5,615	5,642	1,405.5
65-74 years	4,502	4,502	30	0.67 (0.43, 0.90)	****	****	478.93 (334.86, 684.98)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	****	****	****	****	579.26 (301.39, 1,113.30)	1,538	1,543	408.1
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	141	37.2
Multi-racial										
0-40 years	118	118	****	****	****	****	704.84 (99.28, 5,003.92)	171	172	42.9
41-64 years	623	623	****	****	****	****	123.68 (17.56, 885.11)	953	957	230.4
65-74 years	****	****	****	****	****	****	1,057.47 (148.95, 7,507.32)	108	108	30.3
75-84 years	****	****	****	****	****	****	6,943.92 (978.11, 49,297.13)	17	17	2.4
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.2
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	92	92	23.2
65-74 years	184	184	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	236	236	77.6
75-84 years	81	81	****	****	****	****	1,683.96 (421.14, 6,733.36)	100	100	31.0
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	<u> </u>									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown										
0-40 years	4,021	4,021	****	****	****	****	160.92 (80.48, 321.78)	5,878	5,895	1,434.7
41-64 years	31,654	31,654	90	0.28 (0.23, 0.34)	****	****	208.49 (169.57, 256.33)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	32	0.41 (0.27, 0.56)	****	****	295.61 (209.05, 418.02)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	****	****	****	****	646.43 (396.02, 1,055.18)	2,610	2,616	646.6
≥ 85 vears <i>White</i>	142	142	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	195	195	48.8
0-40 years	930	930	****	****	****	****	394.42 (164.17, 947.62)	1,485	1,491	342.8
41-64 years	14,028	14,028	107	0.76 (0.62, 0.91)	****	****	551.83 (456.58, 666.95)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	263	0.85 (0.75, 0.95)	****	****	589.31 (522.23, 665.02)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	153	1.31 (1.10, 1.52)	****	****	949.63 (810.47, 1,112.69)	16,604	16,649	4,067.5
≥ 85 years	936	936	****	****	****	****	1,715.63 (1,118.60, 2,631.33)	1,320	1,321	329.8
Rybelsus, Hosp	oitalized Tachy	arrhythmia								
American India		ıtive								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
≥85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Asian										
0-40 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	173	173	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	****	****	****	****	130.84 (18.43, 928.90)	759	770	187.7
75-84 years	292	292	****	****	****	****	218.10 (30.72, 1,548.35)	457	465	98.6
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	117	117	23.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Black or Africa	n American									
0-40 years	88	88	****	****	****	****	1,949.04 (487.44, 7,793.31)	127	131	29.2
			****	****	****	****				
41-64 years	984	984	****	****	****	****	158.19 (39.56, 632.51)	1,405	1,436	392.4
65-74 years	1,680	1,680	****	****	****	****	480.99 (266.37, 868.53)	2,298	2,352	650.1
75-84 years	564	564	****	****	****		269.91 (67.50, 1,079.23)	749	760	211.0
≥ 85 vears	76	76	****	****	****	****	963.72 (135.75, 6,841.77)	107	110	28.7
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaii										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9
Unknown										
0-40 years	773	773	****	****	****	****	102.82 (14.48, 729.96)	1,106	1,127	291.8
41-64 years	7,936	7,936	****	****	****	****	195.55 (127.50, 299.92)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	****	****	****	****	213.87 (111.28, 411.05)	4,404	4,501	1,126.7
75-84 years	894	894	****	****	****	****	250.36 (80.74, 776.27)	1,316	1,338	330.7
≥ 85 vears <i>White</i>	151	151	****	****	****	****	957.28 (239.41, 3,827.72)	232	235	55.8



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

by Ruce and A	5c c . c a p									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	209	209	****	****	****	****	408.37 (57.52, 2,899.18)	303	309	70.2
41-64 years	2,999	2,999	16	0.53 (0.27, 0.79)	****	****	379.96 (232.77, 620.21)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	39	0.47 (0.32, 0.62)	****	****	334.69 (234.53, 458.08)	12,353	12,614	3,030.6
75-84 years	4,305	4,305	56	1.30 (0.96, 1.64)	****	****	963.03 (741.12, 1,251.37)	6,332	6,453	1,511.7
≥ 85 years	574	574	****	****	****	****	1,372.29 (738.36, 2,550.50)	853	860	194.4
Saxenda, Hosp										
American India	ın or Alaska Na	tive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africa										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Multi-racial



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	0 ****	0 ****	0	NaN	0.0 ****	0 ****	NaN	0 ****	0 ****	0.0
41-64 years			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0 0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears Native Hawaiiai	0 Oth Day	•	0	NaN	0.0	0	NaN	0	0	0.0
		o O	0	NaN	0.0	0	NaN	0	0	0.0
0-40 years	0	0	0 0	NaN		0	NaN	0	0	0.0
41-64 years 65-74 years	0	0	0	NaN	0.0 0.0	0	NaN	0	0 0	0.0
•	0	0	•	-	0.0	0	NaN	_	-	0.0
75-84 years	0	0	0 0	NaN		0		0 0	0 0	
≥ 85 vears Unknown	0	U	U	NaN	0.0	U	NaN	U	U	0.0
	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	100	32.2
0-40 years	266	266	****	0.00 (0.00, 0.00) ****	****	****	280.47 (39.51, 1,991.12)	410	410	32.2 132.1
41-64 years	200 12	200 12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	7.5
65-74 years		0	0	0.00 (0.00, 0.00) NaN	0.0	0	0.00 (0.00, 0.00) NaN	0		7.5 0.0
75-84 years ≥ 85 vears	0	0	0		0.0	0		0	0 0	0.0
2 85 years White	0	U	U	NaN	0.0	U	NaN	U	U	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	7.8 5.2
	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.2 2.1
75-84 years ≥ 85 years	0	0	0	0.00 (0.00, 0.00) NaN	0.0	0	0.00 (0.00, 0.00) NaN	0	0	0.0
Trulicity, Hospit			U	INAIN	0.0	U	INAIN	U	U	0.0
American Indiar										
0-40 years	I OI AIUSKU NU *****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	5.3



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
41-64 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	1.2
Asian										
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	****	****	****	****	332.41 (46.82, 2,359.87)	366	366	84.8
65-74 years	570	570	****	****	****	****	215.05 (53.78, 859.88)	973	978	208.1
75-84 years	297	297	****	****	****	****	216.10 (30.44, 1,534.16)	495	497	105.0
≥ 85 vears	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	129	129	21.6
Black or Africar	n American									
0-40 years	218	218	****	****	****	****	335.86 (47.31, 2,384.39)	376	377	83.7
41-64 years	2,117	2,117	16	0.76 (0.39, 1.12)	****	****	548.94 (336.29, 896.04)	3,613	3,644	839.2
65-74 years	2,953	2,953	12	0.41 (0.18, 0.64)	****	****	289.86 (164.61, 510.41)	4,729	4,762	1,204.7
75-84 years	1,022	1,022	****	****	****	****	826.61 (469.43, 1,455.54)	1,592	1,601	416.7
≥ 85 years	118	118	****	****	****	****	2,083.17 (671.85, 6,459.16)	186	187	44.5
Multi-racial										
0-40 years	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	223	223	****	****	****	****	527.47 (131.92, 2,109.13)	469	473	100.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	67	18.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	136	136	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	****	****	****	****	2,313.91 (578.69, 9,252.23)	90	90	30.0
≥ 85 vears Unknown	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.7
0-40 years	1,577	1,577	****	****	****	****	422.23 (219.69, 811.50)	2,730	2,751	632.6
41-64 years	13,585	13,585	45	0.33 (0.23, 0.43)	****	****	212.40 (158.58, 284.47)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	32	0.66 (0.43, 0.88)	****	****	433.93 (306.86, 613.61)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	18	1.17 (0.63, 1.71)	****	****	817.14 (514.83, 1,296.98)	2,637	2,652	594.5
≥ 85 years	197	197	****	****	****	****	1,198.85 (386.65, 3,717.20)	327	328	68.5
White										
0-40 years	536	536	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	49	0.66 (0.47, 0.84)	****	****	453.55 (342.78, 600.10)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	157	0.84 (0.71, 0.97)	****	****	562.08 (480.69, 657.25)	32,607	32,794	6,969.6
75-84 years	8,880	8,880	111	1.25 (1.02, 1.48)	****	****	866.57 (719.46, 1,043.75)	15,077	15,161	3,232.30
≥ 85 years	1,172	1,172	20	1.71 (0.96, 2.45)	****	****	1,318.81 (850.83, 2,044.18)	2,066	2,074	406.0
Victoza, Hospit	alized Tachyaı	rhythmia								
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	****	****	****	****	****	****	10,742.65 (1,513.19,	****	****	2.2
							76,265.57			



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i> 0-40 years 41-64 years	**** 34	**** 34	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	**** 43	**** 43	5.0 14.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Black or Africar	n American									
0-40 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	****	****	****	****	930.65 (300.15, 2,885.61)	342	342	100.5
65-74 years	223	223	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	300	300	94.9
75-84 years	****	****	****	****	****	****	2,261.61 (318.57, 16,055.91)	****	****	15.0
≥ 85 vears Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	7.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	ın or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

,	<u> </u>									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown										
0-40 years	140	140	****	****	****	****	539.35 (75.97, 3,829.04)	201	201	55.5
41-64 years	848	848	****	****	****	****	420.68 (175.10, 1,010.71)	1,269	1,270	356.5
65-74 years	337	337	****	****	****	****	657.36 (212.01, 2,038.23)	462	462	126.0
75-84 years	93	93	****	****	****	****	955.15 (134.54, 6,780.93)	118	118	32.5
≥ 85 vears <i>White</i>	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.5
0-40 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	164	164	41.2
41-64 years	947	947	****	****	****	****	533.27 (254.22, 1,118.60)	1,423	1,423	367.4
65-74 years	1,420	1,420	****	****	****	****	475.91 (256.06, 884.51)	2,051	2,051	525.2
75-84 years	597	597	13	2.18 (1.01, 3.35)	****	****	1,492.60 (866.68, 2,570.56)	839	839	213.7
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	26.3
Wegovy, Hosp	italized Tachya	rrhythmia								
American India	an or Alaska Na	itive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Black or Africa										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	4.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	113	113	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	165	170	14.9
41-64 years	520	520	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	804	817	84.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	2.3



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	•									
								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of		•	•			•	•	•	
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
41-64 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	****	****	****	****	4,363.80 (614.68, 30,980.04)	42	45	4.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Xultophy, Hosp	italized Tachy	arrhythmia								
American India	n or Alaska Na	tive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or African	American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.3
≥85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears Unknown	0	0	0	NaN	0.0	0	NaN	0	0	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.3
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	127	127	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	161	161	49.4
75-84 years	66	66	****	****	****	****	1,991.55 (498.07, 7,963.29)	95	95	19.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.6
Mounjaro, Atri	al Fibrillation	and Flutter								
American India 0-40 years	n or Alaska Na ****	*****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

				Number of Exposure				Number of Exposure Episode	Number of Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	4.9
· · · · · · · · · · · · · · · · · · ·	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26 19	26 19	4.9 2.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	*****	1.2
75-84 years ≥ 85 vears	0	0	0	0.00 (0.00, 0.00) NaN	0.0	0	0.00 (0.00, 0.00) NaN	0	0	0.0
Asian	U	U	U	INAIN	0.0	U	Ivalv	U	U	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Black or Africa	n American		· ·	0.00 (0.00) 0.00			0.00 (0.00) 0.00,			0. _
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	70	73	13.0
41-64 years	671	671	****	****	****	****	674.74 (280.84, 1,621.11)	1,074	1,085	198.4
65-74 years	744	744	****	****	****	****	125.74 (17.71, 892.64)	1,100	1,125	209.6
, 75-84 years	173	173	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	235	239	44.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	2.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	n or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	1.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	56	12.1



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Unknown				()	ale ale ale ale ale	ala ala ala ala ala				
0-40 years	855	855	0 ****	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,423	1,439	231.3
41-64 years	6,086	6,086	****	****	****	****	97.65 (46.55, 204.83)	10,484	10,593	1,733.2
65-74 years	898 ****	898 ****		****			403.47 (151.43, 1,075.02)	1,474	1,489	233.3
75-84 years			****		****	****	633.89 (89.29, 4,500.22)	239	253	40.5
≥ 85 vears <i>White</i>	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	1.7
	115	115	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	215	247	22.5
0-40 years	115	115	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)		217	32.5 722.7
41-64 years	2,394	2,394	11 23	0.46 (0.19, 0.73)	****	****	388.53 (215.16, 701.57)	4,115	4,179	
65-74 years	4,850	4,850	23 ****	0.47 (0.28, 0.67) ****	****	****	413.31 (274.65, 621.97)	7,859	7,979	1,301.9 389.7
75-84 years	1,505 75	1,505 75	****	****	****	****	666.54 (369.12, 1,203.58)	2,325 106	2,359 108	389.7 16.6
≥ 85 years	/5	/5					1,456.34 (205.14,	106	108	10.0
Bydureon, Atri	al Eibrillation	and Fluttor					10,339.03)			
American India										
0-40 years	n or Alaska Na O	0 0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
75-84 years	0	0	0	0.00 (0.00, 0.00) NaN	0.0	0	0.00 (0.00, 0.00) NaN	0	0	0.0
75-64 years ≥ 85 years	0	0	0		0.0	0		0	0	
2 85 vears Asian	U	U	U	NaN	0.0	U	NaN	U	U	0.0
0-40 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	11 17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	6.2
	1/ ****	1/ ****	0	0.00 (0.00, 0.00)	****	****		28	22 28	6.2 4.4
65-74 years			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	28	۷ŏ	4.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

		Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	•	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients ****	Episodes ****	Event	Interval)	****	at Risk	Confidence Interval)	Dispensings) ****	Dispensings) ****	Years
75-84 years	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	****	****	2.3
≥ 85 years		****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or Africar				0.00 (0.00 0.00)	****	****	0.00 (0.00 0.00)	22		
0-40 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49 ****	49 ****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76 ****	76 ****	22.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
Multi-racial	****	****		0.00 (0.00 0.00)	****	****	0.00 (0.00 0.00)	****	****	
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)			4.3
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35 ****	35 ****	11.1
65-74 years			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	6.3
41-64 years	118	118	****	****	****	****	626.18 (88.20, 4,445.45)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	, ı									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White										
0-40 years	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	251	251	****	****	****	****	635.05 (158.82, 2,539.28)	404	404	98.6
65-74 years	387	387	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	654	654	152.2
75-84 years	149	149	****	****	****	****	546.54 (76.98, 3,880.04)	217	217	49.5
≥ 85 years	12	12	****	****	****	****	12,726.48 (1,792.63,	16	16	3.9
							90,349.45			
Ozempic, Atria	l Fibrillation a	nd Flutter								
American India	ın or Alaska Na	ıtive								
0-40 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	****	****	****	****	590.21 (147.61, 2,359.97)	409	411	89.4
65-74 years	361	361	****	****	****	****	444.42 (111.15, 1,777.05)	566	569	120.7
75-84 years	165	165	****	****	****	****	2,563.52 (1,066.99,	239	239	59.4
							6,159.03)			
≥ 85 vears	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25	25	5.8
Asian										
0-40 years	79	79	****	****	****	****	1,048.97 (147.76, 7,446.95)	111	111	29.8
41-64 years	360	360	****	****	****	****	190.21 (26.79, 1,350.40)	563	563	137.7
65-74 years	655	655	****	****	****	****	190.21 (26.79, 1,350.40)	982	985	217.5
75-84 years	251	055 251	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	982 385	985 386	86.5
75-84 years ≥ 85 years	48	251 48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	385 80	80	16.7
Black or Africar		40	U	0.00 (0.00, 0.00)			3.00 (0.00, 0.00)	80	80	10.7
0-40 years	313	313	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	434	436	110.9
41-64 years	3,802	3,802	****	****	****	****	271.57 (160.84, 458.54)	5,615	5,642	1,405.5
i = O - y cuis	3,002	3,002					2, 1.5, (100.04, 450.54)	3,013	3,072	±,⊶05.5



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Same-Day Dispensings)	Total Observable Years
65-74 years	4,502	4,502	16	0.36 (0.18, 0.53)	****	****	255.43 (156.48, 416.94)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	****	****	****	****	386.17 (173.49, 859.59)	1,538	1,543	408.1
≥ 85 vears <i>Multi-racial</i>	102	102	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	141	37.2
0-40 years	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	171	172	42.9
41-64 years	623	623	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	953	957	230.4
65-74 years	****	****	****	****	****	****	1,057.47 (148.95, 7,507.32)	108	108	30.3
75-84 years	****	****	****	****	****	****	6,943.92 (978.11, 49,297.13)	17	17	2.4
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other Pac	cific Islander								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.2
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	92	92	23.2
65-74 years	184	184	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	236	236	77.6
75-84 years	81	81	****	****	****	****	1,683.96 (421.14, 6,733.36)	100	100	31.0
≥ 85 vears Unknown	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
0-40 years	4,021	4,021	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,878	5,895	1,434.7
41-64 years	31,654	31,654	47	0.15 (0.11, 0.19)	****	****	108.88 (81.80, 144.91)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	22	0.28 (0.17, 0.40)	****	****	203.23 (133.82, 308.66)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	15	0.83 (0.41, 1.25)	****	****	606.03 (365.35, 1,005.26)	2,610	2,616	646.6
≥ 85 vears <i>White</i>	142	142	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	195	195	48.8



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

by Ruce and Ag	,c c .oup									
								Number of Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of		with an	(95% Confidence			Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
		Exposure		•	Years	Days	· ·	•	•	
0.40	Patients	Episodes	****	Interval) ****	****	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
0-40 years	930	930			****	****	78.88 (11.11, 560.03)	1,485	1,491	342.8
41-64 years	14,028	14,028	51	0.36 (0.26, 0.46)	****	****	263.02 (199.89, 346.09)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	181	0.59 (0.50, 0.67)	****	****	405.57 (350.59, 469.18)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	118 ****	1.01 (0.83, 1.19)	****	****	732.40 (611.48, 877.22)	16,604	16,649	4,067.5
≥ 85 years	936	936	40 40 40 40	4. 4. 4. 4. 4.	4. 4. 4. 4. 4.	4.4.4.4	1,552.23 (990.09,	1,320	1,321	329.8
- 1 1		1 =1					2,433.56)			
Rybelsus, Atria										
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Asian										
0-40 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	173	173	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	****	****	****	****	130.84 (18.43, 928.90)	759	770	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	457	465	98.6
≥ 85 vears	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	117	117	23.4
Black or Africar										
0-40 years	88	88	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	131	29.2
41-64 years	984	984	****	****	****	****	79.09 (11.14, 561.50)	1,405	1,436	392.4
65-74 years	1,680	1,680	****	****	****	****	393.54 (204.76, 756.35)	2,298	2,352	650.1
75-84 years	564	564	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	749	760	211.0
≥ 85 vears	76	76	****	****	****	****	963.72 (135.75, 6,841.77)	107	110	28.7

Multi-racial



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
≥85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaii	an or Other Pac	ific Islander								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9
Unknown										
0-40 years	773	773	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,106	1,127	291.8
41-64 years	7,936	7,936	****	****	****	****	102.43 (56.72, 184.96)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	****	****	****	****	95.06 (35.68, 253.27)	4,404	4,501	1,126.7
75-84 years	894	894	****	****	****	****	250.36 (80.74, 776.27)	1,316	1,338	330.7
≥ 85 vears White	151	151	****	****	****	****	478.64 (67.42, 3.398.02)	232	235	55.8
0-40 years	209	209	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	2,999	2,999	****	****	****	****	213.73 (111.20, 410.77)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	31	0.37 (0.23, 0.50)	****	****	266.04 (187.09, 378.29)	12,353	12,614	3,030.6
75-84 years	4,305	4,305	44	1.02 (0.72, 1.32)	****	****	756.66 (563.09, 1,016.78)	6,332	6,453	1,511.7
≥ 85 years	574	574	****	****	****	****	1,235.07 (642.62, 2,373.72)	853	860	194.4

Wegovy, Atrial Fibrillation and Flutter

American Indian or Alaska Native



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total	Total	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	Number of Patients	Exposure Episodes	Event	Interval)	Years at Risk	Days at Risk	Confidence Interval)	Same-Day Dispensings)	Same-Day Dispensings)	Observable Years
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
> 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	O	O	O	IVAIV	0.0	U	IVAIV	O	O	0.0
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africa	_	J	Ü	IVAIV	0.0	U	IVAIV	O	O	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	4.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial	· ·	· ·	· ·		0.0	Ū		· ·	· ·	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaii	an or Other Pac	cific Islander	-	-		-	-	-	-	
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

		Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	113	113	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	165	170	14.9
41-64 years	520	520	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	804	817	84.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	****	****	****	****	4,363.80 (614.68,	42	45	4.9
							30,980.04)			
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Atrial	Fibrillation ar	nd Flutter								
American India	n or Alaska Na	ıtive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

		Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africa	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Atrial	Fibrillation and	d Flutter								
American India	an or Alaska Na	ıtive								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	****	****	****	****	****	****	10,742.65 (1,513.19,	****	****	2.2
							76,265.57			
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.2
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Black or Africa	n American									
0-40 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	****	****	****	****	310.22 (43.70, 2,202.33)	342	342	100.5
65-74 years	223	223	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	300	300	94.9



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

								Number of		
								Exposure	Number of	
				Number of Evensus				•		
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
75-84 years	****	****	****	****	****	****	2,261.61 (318.57,	****	****	15.0
							16,055.91)			
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	19.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiiai	n or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Unknown										
0-40 years	140	140	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	848	848	****	****	****	****	84.14 (11.85, 597.31)	1,269	1,270	356.5
65-74 years	337	337	****	****	****	****	438.23 (109.60, 1,752.31)	462	462	126.0
75-84 years	93	93	****	****	****	****	955.15 (134.54, 6,780.93)	118	118	32.5
≥ 85 vears	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.5
White										
0-40 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	164	164	41.2
41-64 years	947	947	****	****	****	****	228.54 (73.71, 708.63)	1,423	1,423	367.4
65-74 years	1,420	1,420	****	****	****	****	285.54 (128.28, 635.60)	2,051	2,051	525.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
75-84 years	597	597	****	****	****	****	1,262.97 (699.42,	839	839	213.7
							2,280.57)			
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	26.3
Trulicity , Atrial	Fibrillation an	d Flutter								
American India	n or Alaska Na	tive								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	1.2
Asian										
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	****	****	****	****	332.41 (46.82, 2,359.87)	366	366	84.8
65-74 years	570	570	****	****	****	****	107.52 (15.15, 763.35)	973	978	208.1
75-84 years	297	297	****	****	****	****	216.10 (30.44, 1,534.16)	495	497	105.0
≥ 85 vears	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	129	129	21.6
Black or Africar	American									
0-40 years	218	218	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	376	377	83.7
41-64 years	2,117	2,117	****	****	****	****	274.47 (137.26, 548.84)	3,613	3,644	839.2
65-74 years	2,953	2,953	****	****	****	****	144.93 (65.11, 322.60)	4,729	4,762	1,204.7
75-84 years	1,022	1,022	****	****	****	****	344.42 (143.35, 827.49)	1,592	1,601	416.7
≥ 85 years	118	118	****	****	****	****	1,388.78 (347.32,	186	187	44.5
							5,553.11)			
Multi-racial										
0-40 years	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	68	68	12.7



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	223	223	****	****	****	****	263.74 (37.15, 1,872.36)	469	473	100.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	-	-	Ü	11411	0.0	Ü	· · · · · · · · · · · · · · · · · · ·	· ·	Ü	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	90	90	30.0
> 85 vears Unknown	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.7
0-40 years	1,577	1,577	****	****	****	****	140.74 (45.39, 436.40)	2,730	2,751	632.6
41-64 years	13,585	13,585	21	0.15 (0.09, 0.22)	****	****	99.12 (64.63, 152.02)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	21	0.43 (0.25, 0.61)	****	****	284.76 (185.67, 436.75)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	****	****	****	****	726.35 (444.98, 1,185.63)	2,637	2,652	594.5
≥ 85 years White	197	197	****	****	****	****	799.23 (199.88, 3,195.77)	327	328	68.5
0-40 years	536	536	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	23	0.31 (0.18, 0.43)	****	****	212.89 (141.47, 320.37)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	121	0.65 (0.53, 0.76)	****	****	433.19 (362.49, 517.69)	32,607	32,794	6,969.6
75-84 years	8,880	8,880	92	1.04 (0.83, 1.25)	****	****	718.23 (585.49, 881.07)	15,077	15,161	3,232.30
≥ 85 years	1,172	1,172	20	1.71 (0.96, 2.45)	****	****	1,318.81 (850.83, 2,044.18)	2,066	2,074	406.0
Xultophy, Atria	al Fibrillation a	nd Flutter								
American India	ın or Alaska Na	tive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

			Number of	Number of Exposure Episodes with an				Number of Exposure Episode Defining-	Number of Exposure Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
41 C4				NaN	0.0					
41-64 years	0 ****	0 ****	0		0.U ****	0 ****	NaN	0 ****	0 ****	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
75-84 years			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.1
≥ 85 vears <i>Asian</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or Africa	n American		Ü	0.00 (0.00) 0.00)			0.00 (0.00) 0.007			0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Multi-racial			Ü	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.2
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
	an or Other Pac	•	· ·		0.0	•		•	· ·	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

.,										
								Number of		
								Exposure	Number of	
				Number of Functions				-		
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.3
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	127	127	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	161	161	49.4
75-84 years	66	66	****	****	****	****	995.77 (140.26, 7,069.33)	95	95	19.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.6
Mounjaro, Sinu	ıs Tachycardia									
American India	n or Alaska Na	tive								_
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	4.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
. 05	Patients ****	Episodes ****	Event	Interval)	****	at Risk	Confidence Interval)	Dispensings) ****	Dispensings) ****	Years
≥ 85 vears		****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Black or Africa	n American ****	****			****	ala ala ala ala ala				
0-40 years			0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	70	73	13.0
41-64 years	671	671	****	****			134.95 (19.01, 958.04)	1,074	1,085	198.4
65-74 years	744	744	****	****	****	****	125.74 (17.71, 892.64)	1,100	1,125	209.6
75-84 years	173	173	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	235	239	44.1
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	2.0
Multi-racial										
0-40 years	****	****	****	****	****	****	7,423.78 (1,045.70,	20	20	3.7
							52,703.85)			
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	3.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Unknown										
0-40 years	855	855	****	****	****	****	107.06 (15.08, 760.06)	1,423	1,439	231.3
41-64 years	6,086	6,086	****	****	****	****	69.75 (29.03, 167.58)	10,484	10,593	1,733.2
65-74 years	898	898	****	****	****	****	201.73 (50.45, 806.64)	1,474	1,489	233.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	253	40.5
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	1.7



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

,	· ·									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White										
0-40 years	115	115	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	215	217	32.5
41-64 years	2,394	2,394	****	****	****	****	317.89 (165.40, 610.96)	4,115	4,179	722.7
65-74 years	4,850	4,850	****	****	****	****	125.79 (59.97, 263.86)	7,859	7,979	1,301.9
75-84 years	1,505	1,505	****	****	****	****	121.19 (30.31, 484.58)	2,325	2,359	389.7
≥ 85 years	75	75	****	****	****	****	1,456.34 (205.14,	106	108	16.6
•							10,339.03)			
Bydureon, Sinu	us Tachycardia						· · ·			
American India	ın or Alaska Na	itive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.3
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or Africa	n American									
0-40 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	22.9



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

			Number of Exposure	Number of Exposure Episodes with an Event per 100				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of		with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
		Exposure		•			•	•	•	
75.04	Patients ****	Episodes ****	Event ****	Interval) ****	****	at Risk	Confidence Interval)	Dispensings) ****	Dispensings) ****	Years
75-84 years	****	****	****	***	****	****	6,330.16 (891.66,	****	***	4.9
	ale ale ale ale ale	ale ale ale ale ale			ale ale ale ale ale		44,939.85)	ale ale ale ale ale	ate ate ate ate ate	
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.3
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	ın or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	6.3
41-64 years	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
White										
0-40 years	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	251	251	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	404	404	98.6
65-74 years	387	387	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	654	654	152.2
75-84 years	149	149	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	217	217	49.5



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years Ozempic, Sinus	12 Tachycardia	12	0	0.00 (0.00, 0.00)	4. 4. 4. 4. 4		0.00 (0.00, 0.00)	16	16	3.9
American India	•	tive								
0-40 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	****	****	****	****	295.10 (41.57, 2,095.04)	409	411	89.4
65-74 years	361	361	****	****	****	****	222.21 (31.30, 1,577.56)	566	569	120.7
75-84 years	165	165	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	239	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25	25	5.8
Asian										
0-40 years	79	79	****	****	****	****	1,048.97 (147.76,	111	111	29.8
							7,446.95)			
41-64 years	360	360	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	563	563	137.7
65-74 years	655	655	****	****	****	****	104.43 (14.71, 741.37)	982	985	217.5
75-84 years	251	251	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 vears	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	80	16.7
Black or Africar	n American									
0-40 years	313	313	****	****	****	****	508.14 (127.08, 2,031.81)	434	436	110.9
41-64 years	3,802	3,802	****	****	****	****	232.78 (132.19, 409.89)	5,615	5,642	1,405.5
65-74 years	4,502	4,502	****	****	****	****	143.68 (74.76, 276.14)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	****	****	****	****	64.36 (9.07, 456.93)	1,538	1,543	408.1
≥ 85 vears	102	102	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	141	37.2
Multi-racial										
0-40 years	118	118	****	****	****	****	704.84 (99.28, 5,003.92)	171	172	42.9
41-64 years	623	623 ****	0	0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00)	953	957	230.4
65-74 years	****		0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	108	108	30.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	2.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

			Number of Exposure	Number of Exposure Episodes with an Event per 100				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.2
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	92	92	23.2
65-74 years	184	184	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	236	236	77.6
75-84 years	81	81	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	100	31.0
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Unknown										
0-40 years	4,021	4,021	****	****	****	****	140.81 (67.13, 295.36)	5,878	5,895	1,434.7
41-64 years	31,654	31,654	****	****	****	****	64.86 (44.78, 93.94)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	****	****	****	****	36.95 (13.87, 98.46)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	****	****	****	****	40.40 (5.69, 286.83)	2,610	2,616	646.6
≥ 85 vears	142	142	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	195	195	48.8
White										
0-40 years	930	930	****	****	****	****	315.54 (118.42, 840.73)	1,485	1,491	342.8
41-64 years	14,028	14,028	44	0.31 (0.22, 0.41)	****	****	226.92 (168.87, 304.93)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	47	0.15 (0.11, 0.20)	****	****	105.31 (79.13, 140.17)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	****	****	****	****	111.72 (70.39, 177.33)	16,604	16,649	4,067.5
≥ 85 years	936	936	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,320	1,321	329.8
Rybelsus, Sinus	s Tachycardia									
American India	n or Alaska Na	tive								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian				/ \						
0-40 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	173	173	0	0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	0 ****	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	759	770	187.7
75-84 years	292	292			****	****	218.10 (30.72, 1,548.35)	457	465	98.6
≥ 85 vears Black or Africar	72	72	0	0.00 (0.00, 0.00)	4.4.4.4.4.	4-4-4-4-4-	0.00 (0.00, 0.00)	117	117	23.4
0-40 years	88	88	****	****	****	****	1,949.04 (487.44, 7,793.31)	127	131	29.2
41-64 years	984	984	****	****	****	****	79.09 (11.14, 561.50)	1,405	1,436	392.4
65-74 years	1,680	1,680	****	****	****	****	87.45 (21.87, 349.68)	2,298	2,352	650.1
75-84 years	564	564	****	****	****	****	134.95 (19.01, 958.07)	749	760	211.0
≥ 85 vears <i>Multi-racial</i>	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	110	28.7
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 vears <i>Unknown</i>	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
0-40 years	773	773	****	****	****	****	102.82 (14.48, 729.96)	1,106	1,127	291.8
41-64 years	7,936	7,936	****	****	****	****	83.81 (43.60, 161.07)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	****	****	****	****	95.06 (35.68, 253.27)	4,404	4,501	1,126.7
75-84 years	894	894	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,316	1,338	330.7
, ≥ 85 vears	151	151	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	232	235	55.8
White										
0-40 years	209	209	****	****	****	****	408.37 (57.52, 2,899.18)	303	309	70.2
41-64 years	2,999	2,999	****	****	****	****	166.23 (79.25, 348.69)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	****	****	****	****	51.49 (23.13, 114.61)	12,353	12,614	3,030.6
75-84 years	4,305	4,305	****	****	****	****	171.97 (92.53, 319.62)	6,332	6,453	1,511.7
≥ 85 years	574	574	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	853	860	194.4
Wegovy, Sinus	Tachycardia									
American India	n or Alaska Na	ıtive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African	n American ****	****	•	0.00 (0.00 0.05)	****	****	0.00 (0.00 0.05)	****	****	0.5
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

		Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	4.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 vears	****	****	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	113	113	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	165	170	14.9
41-64 years	520	520	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	804	817	84.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	45	4.9



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

			Number of	Number of Exposure Episodes with an				Number of Exposure Episode Defining-	Number of Exposure Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk		Confidence Interval)	Dispensings)	Dispensings)	Years
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Sinus	Tachycardia									
American India	n or Alaska Na	ıtive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	<u> </u>									
								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		N	-	•	Takal	T-4-1	5 Data			T-4-1
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	****	****	****	****	280.47 (39.51, 1,991.12)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Sinus T	Tachycardia 💮									
American India	n or Alaska Na	tive								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian		****	_	/			/)	****		
0-40 years	****		0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)		****	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Black or Africar			_				/			
0-40 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	****	****	****	****	310.22 (43.70, 2,202.33)	342	342	100.5
65-74 years	223	223	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	300	300	94.9
75-84 years	****	****	****	****	****	****	2,261.61 (318.57, 16,055.91)	****	****	15.0
≥ 85 vears Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 vears Unknown	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

,										
								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
		•		•		-	·	-	•	
0.40	Patients	Episodes	Event ****	Interval) ****	****	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
0-40 years	140	140	****	****	****	****	539.35 (75.97, 3,829.04)	201	201	55.5
41-64 years	848	848	****	****	****	****	336.54 (126.31, 896.70)	1,269	1,270	356.5
65-74 years	337	337	****	****	****	****	219.12 (30.86, 1,555.60)	462	462	126.0
75-84 years	93	93			****		955.15 (134.54, 6,780.93)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.5
White				()	ale ale ale ale ale					
0-40 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	164	164	41.2
41-64 years	947	947	****	****	****	****	228.54 (73.71, 708.63)	1,423	1,423	367.4
65-74 years	1,420	1,420	****	****	****	****	95.18 (23.80, 380.59)	2,051	2,051	525.2
75-84 years	597	597	****	****	****	****	114.82 (16.17, 815.11)	839	839	213.7
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	26.3
Trulicity, Sinus	Tachycardia									
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	1.2
Asian										
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	366	366	84.8
65-74 years	570	570	****	****	****	****	107.52 (15.15, 763.35)	973	978	208.1
75-84 years	297	297	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 vears	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	129	129	21.6
Black or African	n American									
0-40 years	218	218	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	376	377	83.7



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
41-64 years	2,117	2,117	****	****	****	****	230.16 (114.49, 503.77)	3,613	3,644	839.2
65-74 years	2,953	2,953	****	****	****	****	144.93 (65.11, 322.60)	4,729	4,762	1,204.7
75-84 years	1,022	1,022	****	****	****	****	344.42 (143.35, 827.49)	1,592	1,601	416.7
≥85 years	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	186	187	44.5
Multi-racial										
0-40 years	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	223	223	****	****	****	****	263.74 (37.15, 1,872.36)	469	473	100.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	cific Islander								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	8.0
41-64 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	90	90	30.0
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.7
Unknown										
0-40 years	1,577	1,577	****	****	****	****	281.49 (126.46, 626.57)	2,730	2,751	632.6
41-64 years	13,585	13,585	****	****	****	****	89.68 (57.20, 140.60)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	****	****	****	****	122.04 (63.50, 234.56)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,637	2,652	594.5
≥ 85 vears	197	197	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	327	328	68.5
White										
0-40 years	536	536	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	20	0.27 (0.15, 0.39)	****	****	185.12 (119.43, 286.94)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	23	0.12 (0.07, 0.17)	****	****	82.34 (54.72, 123.91)	32,607	32,794	6,969.6



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk ****	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	8,880 1,172	8,880 1,172	11 0	0.12 (0.05, 0.20)	****	****	85.88 (47.56, 155.07)	15,077	15,161	3,232.30 406.0
≥ 85 years Xultophy, Sinu		1,1/2	U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	2,066	2,074	406.0
American India	•	tive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or Africar	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

,	<u>'</u>									
								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	•	•	Total	Total	Frant Pata nov 10 000			Total
	NI	Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	127	127	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	161	161	49.4
75-84 years	66	66	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	95	95	19.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.6
Mounjaro, Sup	raventricular 1	Γachycardia Cardia		, ,			· · · · · · · · · · · · · · · · · · ·			
American India	n or Alaska Na	tive								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
Asian	Patients	Episodes	Event	Interval)	at KISK	at Risk	Confidence interval)	Dispensings)	Dispensings)	Years
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Black or Africa	n American		-							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	70	73	13.0
, 41-64 years	671	671	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,074	1,085	198.4
65-74 years	744	744	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,100	1,125	209.6
75-84 years	173	173	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	235	239	44.1
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	2.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	1.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Unknown										
0-40 years	855	855	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,423	1,439	231.3



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

,										
								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	-	•	Total	Total	Frant Bata nov 10 000			Total
	Niahan af	Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event ****	Interval) ****	****	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
41-64 years	6,086	6,086					13.95 (1.96, 99.04)	10,484	10,593	1,733.2
65-74 years	898	898	****	****	****	****	100.87 (14.21, 716.09)	1,474	1,489	233.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	253	40.5
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	1.7
White										
0-40 years	115	115	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	215	217	32.5
41-64 years	2,394	2,394	****	****	****	****	70.64 (17.67, 282.46)	4,115	4,179	722.7
65-74 years	4,850	4,850	****	****	****	****	71.88 (26.98, 191.52)	7,859	7,979	1,301.9
75-84 years	1,505	1,505	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,325	2,359	389.7
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	108	16.6
Bydureon, Sup	raventricular 1	Tachycardia								
American India	n or Alaska Na	itive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.3
≥85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or Africar	n American									
0-40 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	139	139	38.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
65-74 years	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.3
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	6.3
41-64 years	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
White										
0-40 years	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	251	251	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	404	404	98.6
65-74 years	387	387	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	654	654	152.2
75-84 years	149	149	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	217	217	49.5



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	3.9
Ozempic, Supra				0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	10	10	3.5
American India		-								
0-40 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	409	411	89.4
65-74 years	361	361	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	566	569	120.7
75-84 years	165	165	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	239	59.4
≥ 85 vears	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25	25	5.8
Asian										
0-40 years	79	79	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	111	111	29.8
41-64 years	360	360	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	563	563	137.7
65-74 years	655	655	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	982	985	217.5
75-84 years	251	251	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	****	****	****	****	1,389.31 (195.70,	80	80	16.7
							9.863.18)			
Black or African	American									
0-40 years	313	313	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	434	436	110.9
41-64 years	3,802	3,802	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,615	5,642	1,405.5
65-74 years	4,502	4,502	****	****	****	****	63.86 (23.97, 170.14)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	****	****	****	****	193.09 (62.27, 598.69)	1,538	1,543	408.1
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	141	37.2
Multi-racial					4.4.4.4.4					
0-40 years	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	171	172	42.9
41-64 years	623	623	****	****	****	****	123.68 (17.56, 885.11)	953	957	230.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	2.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
				•				_	-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.2
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	92	92	23.2
65-74 years	184	184	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	236	236	77.6
75-84 years	81	81	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	100	31.0
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Unknown										
0-40 years	4,021	4,021	****	****	****	****	20.12 (2.83, 142.80)	5,878	5,895	1,434.7
41-64 years	31,654	31,654	****	****	****	****	23.17 (12.46, 43.05)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	****	****	****	****	64.67 (30.83, 135.64)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,610	2,616	646.6
≥ 85 vears	142	142	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	195	195	48.8
White										
0-40 years	930	930	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,485	1,491	342.8
41-64 years	14,028	14,028	****	****	****	****	25.79 (10.73, 61.95)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	27	0.09 (0.05, 0.12)	****	****	60.50 (41.49, 88.22)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	****	****	****	****	68.27 (37.81, 123.28)	16,604	16,649	4,067.5
≥ 85 years	936	936	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,320	1,321	329.8
Rybelsus, Supra	ventricular Ta	achycardia								
American Indiai	n or Alaska Na	tive								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian										
0-40 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	173	173	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	759	770	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	457	465	98.6
≥85 vears	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	117	117	23.4
Black or Africar										
0-40 years	88	88	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	131	29.2
41-64 years	984	984	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,405	1,436	392.4
65-74 years	1,680	1,680	****	****	****	****	43.73 (6.16, 310.43)	2,298	2,352	650.1
75-84 years	564	564	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	749	760	211.0
≥ 85 vears	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	110	28.7
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
≥85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9
Unknown										
0-40 years	773	773	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,106	1,127	291.8



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

				Number of Exposure				Number of Exposure Episode	Number of Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
41-64 years	7,936	7,936	****	****	****	****	18.62 (4.66, 74.47)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,404	4,501	1,126.7
75-84 years	894	894	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,316	1,338	330.7
≥ 85 vears	151	151	****	****	****	****	478.64 (67.42, 3,398.02)	232	235	55.8
White	131	131					176161 (67112, 6,656.62,	232	233	33.0
0-40 years	209	209	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	2,999	2,999	****	****	****	****	47.49 (11.88, 189.91)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	****	****	****	****	34.33 (12.88, 91.46)	12,353	12,614	3,030.6
75-84 years	4,305	4,305	****	****	****	****	85.98 (35.79, 206.58)	6,332	6,453	1,511.7
≥ 85 years	574	574	****	****	****	****	137.23 (19.33, 974.23)	853	860	194.4
Wegovy, Supra	aventricular Ta	chycardia								
American India	ın or Alaska Na	tive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africa										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	4.6



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
, 75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
0-40 years 41-64 years	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.7 2.8
65-74 years	0	0	0	0.00 (0.00, 0.00) NaN	0.0	0	0.00 (0.00, 0.00) NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
> 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	-	•	U	IVAIV	0.0	O	IVAIV	O	O	0.0
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	112	113	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	165	170	14.0
0-40 years	113 520	113 520	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	165 804		14.9
41-64 years	52U ****	52U ****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	8U4 ****	817 ****	84. <u>2</u> 4.9
65-74 years 75-84 years	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	4.9 0.6
75-84 years ≥ 85 years	0	0	0	0.00 (0.00, 0.00) NaN	0.0	0	0.00 (0.00, 0.00) NaN	0	0	0.0
2 85 years White	U	U	U	INdIN	0.0	U	INdIN	U	U	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	45	4.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk *****	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings) *****	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings) *****	Total Observable Years
≥ 85 years			0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Supr										
American India	in or Alaska Na 0	tive 0	0	NaN	0.0	0	NaN	0	0	0.0
0-40 years 41-64 years	0	0	0	NaN	0.0	0	NaN	0 0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
> 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	O	Ü	O	IVAIV	0.0	J	IValV	Ü	Ü	0.0
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africa	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Hawaiid										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears Unknown	0	0	0	NaN	0.0	0	NaN	0	0	0.0
0-40 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	****	****	****	****	280.47 (39.51, 1,991.12)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Supra	ventricular Tac	hycardia								
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.2
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

			Number of Exposure	Number of Exposure Episodes with an Event per 100				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43 39	39	9.7
75-84 years	30 17	30 17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.2
25-64 years ≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23 ****	23 ****	0.2
2 65 years Black or Africa			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.9
0-40 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	342	342	100.5
65-74 years	230	230	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	300	300	94.9
•	223 ****	223 ****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	300 ****	300 ****	94.9 15.0
75-84 years	****	****	0		****	****	• • • • •	****	****	15.0
≥ 85 vears <i>Multi-racial</i>			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			1.5
	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	7.0
0-40 years		41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	7.0 19.1
41-64 years	41 ****	41 ****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	19.1
65-74 years	****	****	0	, , ,	****	****		****	****	0.2
75-84 years ≥ 85 vears		0	0	0.00 (0.00, 0.00)		0	0.00 (0.00, 0.00)			0.2
2 85 Vears Native Hawaiia	0 nn ar Othar Dao	ū	U	NaN	0.0	U	NaN	0	0	0.0
0-40 years	in or Other Pac 0	inc isianaer 0	0	NaN	0.0	0	NaN	0	0	0.0
•	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	
41-64 years	****	****	•	• • •	****	****		****	****	1.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 vears	ran ran ran ran ra	ran ran ran ran	0	0.00 (0.00, 0.00)	100000000000000000000000000000000000000		0.00 (0.00, 0.00)	ran nan nan nan	nga nga nga nga nga	1.0
Unknown	1.40	140	0	0.00.(0.00.0.00)	****	****	0.00 (0.00, 0.00)	201	201	CC -
0-40 years	140	140	0 ****	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	848	848	4. 4. 4. 4. 4.	-aaaaa-	4. 4. 4. 4. 4.		84.14 (11.85, 597.31)	1,269	1,270	356.5



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

,	•									
								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
				•				_	-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	-	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
65-74 years	337	337	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	462	462	126.0
75-84 years	93	93	****	****	****	****	955.15 (134.54, 6,780.93)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.5
White										
0-40 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	164	164	41.2
41-64 years	947	947	****	****	****	****	76.18 (10.73, 540.83)	1,423	1,423	367.4
65-74 years	1,420	1,420	****	****	****	****	47.59 (6.70, 337.86)	2,051	2,051	525.2
75-84 years	597	597	****	****	****	****	114.82 (16.17, 815.11)	839	839	213.7
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	26.3
Trulicity, Supra	ventricular Ta	chycardia								
American India	n or Alaska Na	itive								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	1.2
Asian										
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	366	366	84.8
65-74 years	570	570	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	973	978	208.1
75-84 years	297	297	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 vears	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	129	129	21.6
Black or African	American									
0-40 years	218	218	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	376	377	83.7
41-64 years	2,117	2,117	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,613	3,644	839.2
65-74 years	2,953	2,953	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,729	4,762	1,204.7



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Same-Day	Total Observable
7F 94 years	Patients	Episodes	Event ****	Interval) ****	****	at Risk	· · · · · · · · · · · · · · · · · · ·	Dispensings)	Dispensings)	Years
75-84 years	1,022	1,022	****	****	****	****	68.88 (9.70, 489.03)	1,592	1,601	416.7
≥ 85 years	118	118	4.4.4.4.4.4	4. 4. 4. 4.	40 40 40 40	4.4.4.4.	694.39 (97.81, 4,929.71)	186	187	44.5
Multi-racial	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	68	60	12.7
0-40 years	223	223	0 0	• • • •	****	****			68 473	
41-64 years	223 ****	225 ****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	469		100.4
65-74 years	****	****	-	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45 10	13.3
75-84 years			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	n or Otner Pac ****	eitic Islanaer ****	•	0.00 (0.00 0.00)	****	****	0.00 (0.00 0.00)	****	****	0.0
0-40 years			0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)			0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	****	****	****	****	1,156.95 (162.97,	90	90	30.0
							8,213.59)			
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.7
Unknown										
0-40 years	1,577	1,577	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,730	2,751	632.6
41-64 years	13,585	13,585	****	****	****	****	18.88 (7.09, 50.30)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	****	****	****	****	54.23 (20.36, 144.52)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	****	****	****	****	45.40 (6.39, 322.29)	2,637	2,652	594.5
≥ 85 vears	197	197	****	****	****	****	399.62 (56.29, 2,837.01)	327	328	68.5
White										
0-40 years	536	536	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	****	****	****	****	64.79 (30.89, 135.91)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	****	****	****	****	39.38 (21.81, 71.11)	32,607	32,794	6,969.6
75-84 years	8,880	8,880	****	****	****	****	70.26 (36.56, 135.04)	15,077	15,161	3,232.30



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

-,	,									
≥ 85 years	Number of Patients 1,172	Number of Exposure Episodes 1,172	Number of Exposure Episodes with an Event ****	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval) *****	Total Years at Risk ****	Total Days at Risk ****	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval) 65.94 (9.29, 468.13)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings) 2,074	Total Observable Years 406.0
Zultophy, Supr							03.34 (3.23, 400.13)	2,000	2,074	400.0
American India		•								
0-40 years	or Alaska iva O	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or Africa	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.3
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Hawaii	an or Other Pac ****	ritic Islander ****	•	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
0-40 years			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.9
41-64 years	0	0 0	0 0	NaN NaN	0.0 0.0	0 0	NaN NaN	0 0	0 0	0.0 0.0
65-74 years 75-84 years	0 0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-64 years ≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 Vears Unknown	U	U	U	IValv	0.0	U	Ivaiv	U	U	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White	-	-					•	-	-	
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	127	127	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	161	161	49.4
75-84 years	66	66	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	95	95	19.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	4.6
Mounjaro, Oth	ner Tachycardia	9								
American India	an or Alaska Na	tive								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

		Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	Number of Patients	Exposure Episodes	with an	(95% Confidence	Years	Days at Risk	Patient-Years at Risk (95% Confidence Interval)	Same-Day	Same-Day	Observable
0.40	****	****	Event	Interval)	****	****		Dispensings) ****	Dispensings) ****	Years 1.7
0-40 years			0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	53	1.7 9.6
41-64 years	29 53	29 53	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52 71	53 71	9.6 12.5
65-74 years 75-84 years) ****	>>> ****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	22	22	4.2
2 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Black or African	American		U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.2
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	70	73	13.0
41-64 years	671	671	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,074	1,085	198.4
65-74 years	744	744	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,100	1,125	209.6
75-84 years	173	173	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	235	239	44.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	2.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	3.7
, 41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	1.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Unknown										
0-40 years	855	855	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,423	1,439	231.3
41-64 years	6,086	6,086	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	10,484	10,593	1,733.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

,	•									
			Number of	Number of Exposure Episodes with an				Number of Exposure Episode Defining-	Number of Exposure Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
65-74 years	898	898	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,474	1,489	233.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	253	40.5
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	1.7
White										
0-40 years	115	115	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	215	217	32.5
41-64 years	2,394	2,394	****	****	****	****	35.32 (4.98 <i>,</i> 250.75)	4,115	4,179	722.7
65-74 years	4,850	4,850	****	****	****	****	71.88 (26.98, 191.52)	7,859	7,979	1,301.9
75-84 years	1,505	1,505	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,325	2,359	389.7
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	108	16.6
Bydureon, Othe	er Tachycardia	9								
American India	n or Alaska Na	itive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or African	American									
0-40 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	22.9



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
75-84 years	Patients ****	Episodes ****	Event 0	(0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	Dispensings) ****	Dispensings) ****	Years 4.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	0.0	9	0.00 (0.00, 0.00)	****	****	0.1
Multi-racial			O	0.00 (0.00, 0.00)	0.0	,	0.00 (0.00, 0.00)			0.1
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.3
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	6.3
41-64 years	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
White										
0-40 years	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	251	251	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	404	404	98.6
65-74 years	387	387	****	****	****	****	169.91 (23.93, 1,206.23)	654	654	152.2
75-84 years	149	149	****	****	****	****	546.54 (76.98, 3,880.04)	217	217	49.5
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	3.9



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
Ozempic, Other	r Tachycardia									
American India	n or Alaska Na	tive								
0-40 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	409	411	89.4
65-74 years	361	361	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	566	569	120.7
75-84 years	165	165	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	239	59.4
≥ 85 vears	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25	25	5.8
Asian										
0-40 years	79	79	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	111	111	29.8
41-64 years	360	360	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	563	563	137.7
65-74 years	655	655	****	****	****	****	208.86 (52.23, 835.13)	982	985	217.5
75-84 years	251	251	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 vears	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	80	16.7
Black or African	American									
0-40 years	313	313	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	434	436	110.9
41-64 years	3,802	3,802	****	****	****	****	96.99 (40.37, 233.02)	5,615	5,642	1,405.5
65-74 years	4,502	4,502	****	****	****	****	47.89 (15.45, 148.50)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,538	1,543	408.1
≥ 85 vears	102	102	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	141	37.2
Multi-racial										
0-40 years	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	171	172	42.9
41-64 years	623	623	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	953	957	230.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	2.4
≥85 vears	0	0	0	NaN	****	****	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

, ,	<u> </u>									
								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
				•				_	-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.2
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	92	92	23.2
65-74 years	184	184	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	236	236	77.6
75-84 years	81	81	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	100	31.0
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Unknown										
0-40 years	4,021	4,021	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,878	5,895	1,434.7
41-64 years	31,654	31,654	****	****	****	****	9.27 (3.48, 23.69)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	****	****	****	****	9.23 (1.30, 65.58)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,610	2,616	646.6
≥ 85 vears	142	142	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	195	195	48.8
White										
0-40 years	930	930	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,485	1,491	342.8
41-64 years	14,028	14,028	****	****	****	****	36.10 (17.21, 75.73)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	****	****	****	****	40.33 (25.41, 64.02)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	****	****	****	****	62.07 (33.40, 115.36)	16,604	16,649	4,067.5
≥ 85 years	936	936	****	****	****	****	235.09 (79.05, 759.94)	1,320	1,321	329.8
Rybelsus, Othe	r Tachycardia									
American India	n or Alaska Na	itive								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Asian										
0-40 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38	39	10.9



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
41-64 years	173	173	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	759	770	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	457	465	98.6
≥ 85 vears	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	117	117	23.4
Black or African	American									
0-40 years	88	88	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	131	29.2
41-64 years	984	984	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,405	1,436	392.4
65-74 years	1,680	1,680	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,298	2,352	650.1
75-84 years	564	564	****	****	****	****	134.95 (19.01, 958.07)	749	760	211.0
≥ 85 years	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	110	28.7
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9
Unknown										
0-40 years	773	773	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,106	1,127	291.8
41-64 years	7,936	7,936	****	****	****	****	9.31 (1.31, 66.11)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,404	4,501	1,126.7



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	894	894	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,316	1,338	330.7
≥ 85 years	151	151	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	232	235	55.8
White			· ·	0.00 (0.00) 0.00)					200	33.3
0-40 years	209	209	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	2,999	2,999	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12,353	12,614	3,030.6
75-84 years	4,305	4,305	****	****	****	****	34.39 (8.60, 137.52)	6,332	6,453	1,511.7
≥ 85 years	574	574	****	****	****	****	137.23 (19.33, 974.23)	853	860	194.4
Wegovy, Other	Tachycardia									
American Indiai	n or Alaska Na	ıtive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	4.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial 0-40 years	*****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.7 2.8
41-64 years 65-74 years	0	0	0	0.00 (0.00, 0.00) NaN	0.0	0	0.00 (0.00, 0.00) NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	-	•	J	11011	0.0	ŭ	11011	· ·	Ü	0.0
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears Unknown	0	0	0	NaN	0.0	0	NaN	0	0	0.0
0-40 years	113	113	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	165	170	14.9
41-64 years	520	520	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	804	817	84.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
, 75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 vears White	0	0	0	NaN	0.0	0	NaN	0	0	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	45	4.9
, 75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

			Number of	Number of Exposure Episodes with an				Number of Exposure Episode Defining-	Number of Exposure Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
American India	ın or Alaska Na	tive								_
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africa	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other Pac									
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

.,	,									
								Number of		
									Number of	
								Exposure		
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Other	Tachycardia									
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43	43	14.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

			Number of	Number of Exposure Episodes with an				Number of Exposure Episode Defining-	Number of Exposure Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	-	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.2
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Black or Africa										
0-40 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	342	342	100.5
65-74 years	223	223	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	300	300	94.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	15.0
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other Pac	cific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Unknown										
0-40 years	140	140	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	848	848	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,269	1,270	356.5
65-74 years	337	337	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	462	462	126.0
75-84 years	93	93	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	118	118	32.5



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

.,										
	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
≥ 85 vears	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.5
White										
0-40 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	164	164	41.2
41-64 years	947	947	****	****	****	****	76.18 (10.73, 540.83)	1,423	1,423	367.4
65-74 years	1,420	1,420	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,051	2,051	525.2
75-84 years	597	597	****	****	****	****	229.63 (57.43, 918.19)	839	839	213.7
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	26.3
Trulicity, Other	Tachycardia									
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	1.2
Asian										
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	366	366	84.8
65-74 years	570	570	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	973	978	208.1
75-84 years	297	297	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 vears	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	129	129	21.6
Black or African	American									
0-40 years	218	218	****	****	****	****	335.86 (47.31, 2,384.39)	376	377	83.7
41-64 years	2,117	2,117	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,613	3,644	839.2
65-74 years	2,953	2,953	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,729	4,762	1,204.7
75-84 years	1,022	1,022	****	****	****	****	68.88 (9.70, 489.03)	1,592	1,601	416.7
≥ 85 years	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	186	187	44.5



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial										
0-40 years	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	223	223	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	469	473	100.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	90	90	30.0
≥ 85 vears <i>Unknown</i>	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.7
0-40 years	1,577	1,577	****	****	****	****	46.91 (6.61, 333.06)	2,730	2,751	632.6
41-64 years	13,585	13,585	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	****	****	****	****	45.40 (6.39, 322.29)	2,637	2,652	594.5
≥ 85 vears <i>White</i>	197	197	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	327	328	68.5
0-40 years	536	536	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	****	****	****	****	53.70 (32.37, 89.08)	32,607	32,794	6,969.6
75-84 years	8,880	8,880	****	****	****	****	15.61 (3.90, 62.43)	15,077	15,161	3,232.30
> 3-84 years ≥ 85 years	1,172	1,172	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,066	2,074	406.0
Yultonhy Othe		<u> </u>	<u> </u>	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	2,000	2,074	400.0

Xultophy, Other Tachycardia

American Indian or Alaska Native

cder_mpl1p_wp077 Page 387 of 1023



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

		Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or African	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	ın or Other Pac	ific Islander								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

.,										
								Number of Exposure	Number of	
				Number of Evenous				-		
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.3
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	127	127	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	161	161	49.4
75-84 years	66	66	****	****	****	****	995.77 (140.26, 7,069.33)	95	95	19.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.6
Mounjaro, Caro	liac Arrest									
American India	n or Alaska Na	tive								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	71	71	12.5



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

			Number of Exposure	Number of Exposure Episodes with an Event per 100				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	•	•	
75.04	****	****			*****	****		Dispensings)	Dispensings)	Years
75-84 years	****	****	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	22 ****	22 ****	4.2
≥ 85 years		****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Black or Africar										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	70	73	13.0
41-64 years	671	671	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,074	1,085	198.4
65-74 years	744	744	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,100	1,125	209.6
75-84 years	173	173	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	235	239	44.1
≥85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	2.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	ın or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	3.3
, ≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Unknown										
0-40 years	855	855	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,423	1,439	231.3
41-64 years	6,086	6,086	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	10,484	10,593	1,733.2
65-74 years	898	898	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,474	1,489	233.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	253	40.5
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	1.7



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

by Ruce and Ag	,									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White										
0-40 years	115	115	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	215	217	32.5
41-64 years	2,394	2,394	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,115	4,179	722.7
65-74 years	4,850	4,850	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,859	7,979	1,301.9
75-84 years	1,505	1,505	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,325	2,359	389.7
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	108	16.6
Bydureon, Card	liac Arrest									
American India	n or Alaska Na	ıtive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.3
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or African	American									
0-40 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
Multi-racial										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.3
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	6.3
41-64 years	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
White										
0-40 years	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	251	251	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	404	404	98.6
65-74 years	387	387	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	654	654	152.2
75-84 years	149	149	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	217	217	49.5
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	3.9
Ozempic, Card										
American India										
0-40 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.5



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

		Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
41-64 years	259	259	****	****	****	****	295.10 (41.57, 2,095.04)	409	411	89.4
65-74 years	361	361	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	566	569	120.7
75-84 years	165	165	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	239	59.4
≥ 85 vears	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25	25	5.8
Asian										
0-40 years	79	79	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	111	111	29.8
41-64 years	360	360	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	563	563	137.7
65-74 years	655	655	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	982	985	217.5
75-84 years	251	251	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	****	****	****	****	1,389.31 (195.70,	80	80	16.7
							9,863.18)			
Black or African	American									
0-40 years	313	313	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	434	436	110.9
41-64 years	3,802	3,802	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,615	5,642	1,405.5
65-74 years	4,502	4,502	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	****	****	****	****	64.36 (9.07, 456.93)	1,538	1,543	408.1
≥ 85 vears	102	102	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	141	37.2
Multi-racial										
0-40 years	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	171	172	42.9
41-64 years	623	623	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	953	957	230.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	2.4
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiiar										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.2
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	92	92	23.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

, ,										
								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	•		•		at Risk	·	•	•	
CE 74		Episodes 184	Event	Interval)	****	****	Confidence Interval)	Dispensings)	Dispensings)	Years
65-74 years	184 81	184 81	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	236 100	236 100	77.6
75-84 years ≥ 85 vears	***** OT	***** OT	0 0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	*****	31.0 0.9
Unknown			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.9
0-40 years	4,021	4,021	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,878	5,895	1,434.7
41-64 years	31,654	31,654	****	****	****	****	6.95 (2.23, 21.55)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,610	2,616	646.6
≥ 85 years	142	142	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	195	195	48.8
White			•	0.00 (0.00) 0.00)			0.00 (0.00) 0.00,			.0.0
0-40 years	930	930	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,485	1,491	342.8
41-64 years	14,028	14,028	****	****	****	****	15.47 (4.99, 47.97)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	****	****	****	****	15.69 (7.48, 32.90)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	****	****	****	****	12.41 (3.10, 49.64)	16,604	16,649	4,067.5
≥ 85 years	936	936	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,320	1,321	329.8
Rybelsus, Cardi	ac Arrest									
American India	n or Alaska Na	tive								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Asian										
0-40 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	173	173	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	759	770	187.7



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

								Number of Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
75-84 years	292	292	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	457	465	98.6
≥85 vears	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	117	117	23.4
Black or Africar	n American									
0-40 years	88	88	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	131	29.2
41-64 years	984	984	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,405	1,436	392.4
65-74 years	1,680	1,680	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,298	2,352	650.1
75-84 years	564	564	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	749	760	211.0
≥85 vears	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	110	28.7
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
≥85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	57	16.9
≥85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9
Unknown										
0-40 years	773	773	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,106	1,127	291.8
41-64 years	7,936	7,936	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	****	****	****	****	23.76 (3.35, 168.71)	4,404	4,501	1,126.7
75-84 years	894	894	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,316	1,338	330.7
≥ 85 years	151	151	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	232	235	55.8



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White										
0-40 years	209	209	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	2,999	2,999	****	****	****	****	23.75 (3.35, 168.59)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12,353	12,614	3,030.6
75-84 years	4,305	4,305	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,332	6,453	1,511.7
≥ 85 years	574	574	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	853	860	194.4
Wegovy, Cardi										
American India	an or Alaska Na									
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africa										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	4.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
41-64 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	113	113	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	165	170	14.9
41-64 years	520	520	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	804	817	84.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	45	4.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Card										
American India										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)			Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears <i>Asian</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africar	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

.,	,									
								Number of Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	-	Confidence Interval)	Dispensings)	Dispensings)	Years
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Cardia	c Arrest									
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

			Number of Exposure	Number of Exposure Episodes with an Event per 100				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Black or Africa										
0-40 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	****	****	****	****	310.22 (43.70, 2,202.33)	342	342	100.5
65-74 years	223	223	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	300	300	94.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	15.0
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Unknown										
0-40 years	140	140	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	848	848	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,269	1,270	356.5
65-74 years	337	337	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	462	462	126.0
75-84 years	93	93	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.5
White										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

.,	, 1									
								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
		•		•		-	·	•	•	
0.40	Patients	Episodes	Event	Interval)	****	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
0-40 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	164	164	41.2
41-64 years	947	947	0 ****	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,423	1,423	367.4
65-74 years	1,420	1,420			****	****	95.18 (23.80, 380.59)	2,051	2,051	525.2
75-84 years	597	597	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	839	839	213.7
≥ 85 years	72	72	00	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	26.3
Trulicity, Cardia										
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	1.2
Asian										
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	366	366	84.8
65-74 years	570	570	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	973	978	208.1
75-84 years	297	297	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 vears	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	129	129	21.6
Black or African	n American									
0-40 years	218	218	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	376	377	83.7
41-64 years	2,117	2,117	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,613	3,644	839.2
65-74 years	2,953	2,953	****	****	****	****	23.16 (3.40, 171.49)	4,729	4,762	1,204.7
75-84 years	1,022	1,022	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,592	1,601	416.7
≥ 85 vears	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	186	187	44.5
Multi-racial										
0-40 years	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	68	68	12.7



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	223	223	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	469	473	100.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	19	5.1
≥85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	****	****	****	****	1,156.95 (162.97,	90	90	30.0
≥ 85 vears <i>Unknown</i>	****	****	0	0.00 (0.00, 0.00)	****	****	8,213.59) 0.00 (0.00, 0.00)	****	****	5.7
0-40 years	1,577	1,577	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,730	2,751	632.6
41-64 years	13,585	13,585	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	****	****	****	****	45.40 (6.39, 322.29)	2,637	2,652	594.5
≥ 85 years	197	197	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	327	328	68.5
White										
0-40 years	536	536	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	****	****	****	****	18.51 (4.63, 74.02)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	****	****	****	****	10.74 (3.46, 33.30)	32,607	32,794	6,969.6
75-84 years	8,880	8,880	****	****	****	****	31.23 (11.72, 83.20)	15,077	15,161	3,232.30
≥ 85 years	1,172	1,172	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,066	2,074	406.0
Xultophy, Card	iac Arrest									
American India		tive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Page 402 of 1023



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or African	American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.3
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

Number of Exposure Exposure											
75-84 years 0 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0			Exposure	Exposure Episodes with an	Episodes with an Event per 100 Exposure Episodes (95% Confidence	Years	Days	Patient-Years at Risk (95%	Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Observable
≥85 vears 0 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0 0 0 0.00 Unknown								•	Dispensings)		
Unknown 0-40 years ****** ****** 0 0.00 (0.00, 0.00) ******* ****** 1.8 41-64 years 27 27 0 0.00 (0.00, 0.00) ******* 0.00 (0.00, 0.00) 39 39 39 11.6 65-74 years 22 22 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) 29 29 6.3 75-84 years ****** ****** 0 0.00 (0.00, 0.00) ******* 0.00 (0.00, 0.00) ****** 4.3 ≥85 years 0 0 0 NaN 0 0 0.0 0 0.0 0.0 0 0.0	•	_	-	_			•		-	_	
0-40 years		0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years 27 27 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 39 39 11.6 65-74 years 22 22 0 0.000 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 29 29 29 6.3 75-84 years ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** ***** 4.3 ≥ 85 years 0 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0.0 0 0.00 White 0-40 years 42 42 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 56 56 13.3 65-74 years 127 127 0 0.000 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 56 56 13.3 65-74 years 66 66 60 0.000 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 95 95 19.2 ≥ 85 years ***** ***** 0 0.000 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) **** **** 4.6 Mounjaro, Ventricular Tachycardia American Indian or Alaska Native 0-40 years **** ***** 0 0.000 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 26 26 4.9 65-74 years **** ***** 0 0.000 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 19 19 19 2.2 75-84 years **** **** 0 0.000 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 19 19 19 2.2 285 years **** **** 0 0.000 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 19 19 19 2.2 75-84 years **** **** 0 0.000 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 19 19 19 2.2 85 years **** **** 0 0.000 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 19 19 19 2.2 85 years **** **** 0 0.000 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 19 19 19 2.2 85 years **** **** 0 0.000 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 19 19 19 2.2 85 years **** **** 0 0.000 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 19 19 19 2.2 85 years **** **** 0 0.000 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 19 19 19 2.2 85 years **** **** 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 19 19 19 19 2.2 85 years 0 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0.0 0 NaN 0.0 0 Salan 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.		ate ate ate ate	ata ata ata ata ata		()	ale ale ale ale ale			ale ale ale ale ale	ate ate ate ate	
65-74 years 22 22 0 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 29 29 6.3 75-84 years ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 4.3 ≥85 years 0 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0 0 0 0.0 ***** ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** ***** 0.1 41-64 years 42 42 0 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 56 56 56 13.3 65-74 years 127 127 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 161 161 49.4 75-84 years 66 66 0 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 95 95 19.2 ≥85 years **** ***** 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) **** **** 4.6 **Mounjaro, Ventricular Tachycardia* **American Indian or Alaska Native* 0-40 years ***** ***** 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 26 26 4.9 41-64 years ***** ***** 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 19 19 2.2 75-84 years ***** ***** 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 19 19 2.2 75-84 years ***** ***** 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) **** ***** 1.2 ≥85 years 0 0 0 0 NaN 0.0 0 NaN 0 0 0 **** ***** 1.7 41-64 years 29 29 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) ***** ***** 1.7 41-64 years 29 29 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 52 53 9.6 65-74 years 53 53 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 71 71 71 12.5	•			_				• • •			
75-84 years				_	, , ,			. , ,			_
285 vears 0 0 0 0 NaN 0.0 0 NaN 0.0 0 0 NaN 0 0 0 0.0 White 0-40 years ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 56 56 13.3 65-74 years 127 127 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 161 161 49.4 75-84 years 66 66 66 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 95 95 19.2 ≥85 years **** ***** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) **** **** 4.6 Mounjaro, Ventricular Tachycardia American Indian or Alaska Native 0-40 years **** **** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 26 26 4.9 65-74 years **** **** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 26 26 4.9 65-74 years **** **** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 19 19 2.2 75-84 years **** **** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 19 19 2.2 75-84 years **** **** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 19 19 19 2.2 75-84 years **** **** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 19 19 19 2.2 75-84 years **** **** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 19 19 19 2.2 75-84 years **** **** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 19 19 19 2.2 75-84 years **** **** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 19 19 19 2.2 75-84 years **** **** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 19 19 19 2.2 75-84 years **** **** 0 0.00 (0.00, 0.00) 19 19 19 2.2 75-84 years **** **** 0 0.00 (0.00, 0.00) 19 19 19 2.2 75-84 years 53 53 0 0 0.00 (0.00, 0.00) 10 10 10 10 10 10 10 10 10 10 10 10 10				_	, , ,			` ' '	_		
White 0-40 years	•			_	• • •			, , ,			
0-40 years		0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years 42 42 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 56 56 13.3 65-74 years 127 127 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 161 161 49.4 49.4 49.4 49.4 49.4 49.4 49.4 49.				_				/			
65-74 years 127 127 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 161 161 49.4 75-84 years 66 66 0 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 95 95 19.2 ≥ 85 years **** ***** 0 0.00 (0.00, 0.00) **** **** **** 0.00 (0.00, 0.00) ***** **** 4.6 Mounjaro, Ventricular Tachycardia American Indian or Alaska Native 0-40 years **** ***** 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) **** **** 0.6 41-64 years **** ***** 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 26 26 4.9 65-74 years **** ***** 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 19 19 19 2.2 75-84 years **** ***** 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) ***** 1.2 ≥ 85 years 0 0 0 0 NaN 0.0 0 NaN 0 0 0.00 Asian 0-40 years **** ***** 0 0.00 (0.00, 0.00) **** ***** ***** 0.00 (0.00, 0.00) ***** **** 1.7 41-64 years 29 29 0 0.00 (0.00, 0.00) **** **** ***** 0.00 (0.00, 0.00) 52 53 9.6 65-74 years 53 53 0 0.00 (0.00, 0.00) **** **** ***** 0.00 (0.00, 0.00) 71 71 71 12.5	•				, , ,			• • •			
75-84 years 66 66 0 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 95 95 19.2 ≥85 years ***** ***** 0 0.00 (0.00, 0.00) **** **** 4.6 Mounjaro, Ventricular Tachycardia	-							• • •			
≥85 years **** **** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) ***** 4.6 Mounjaro, Ventricular Tachycardia				_	, , ,			• • •			
Mounjaro, Ventricular Tachycardia American Indian or Alaska Native 0-40 years ****** ****** 0 0.00 (0.00, 0.00) ****** ****** 0.06 41-64 years ****** ****** 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) 26 26 26 4.9 65-74 years ****** ****** 0 0.00 (0.00, 0.00) ******* ****** 1.2 ≥ 85 years 0 0 NaN 0.0 0 NaN 0 0 0.00 Asian 0-40 years ****** ****** 0 0.00 (0.00, 0.00) ****** ****** 1.7 41-64 years 29 29 0 0.00 (0.00, 0.00) ****** ****** 1.7 41-69 years 53 53 0 0.00 (0.00, 0.00) ****** ****** 0.00 (0.00, 0.00) ****** ****** 1.7 1.7 12.5				_							
American Indian or Alaska Native 0-40 years ****** ****** 0 0.00 (0.00, 0.00) ****** ****** 0.6 41-64 years ****** ****** 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) 26 26 26 4.9 65-74 years ****** ****** 0 0.00 (0.00, 0.00) ************ 0.00 (0.00, 0.00) 19 19 19 2.2 75-84 years ****** ****** 0 0.00 (0.00, 0.00) ****************** 0.00 (0.00, 0.00) ************************ 1.2 ≥ 85 years 0 0 0 NaN 0.0 0 NaN 0 0 0.0 Asian 0 0 0.00 (0.00, 0.00) ****************** 0.00 (0.00, 0.00) ************************* 1.7 41-64 years 29 29 0 0.00 (0.00, 0.00) ****************** 0.00 (0.00, 0.00) 52 53 9.6 65-74 years 53 53 0 0.00 (0.00, 0.00) *********************** 0.00 (0.00, 0.00) 71 71 71				0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.6
0-40 years		-									
41-64 years											
65-74 years ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 19 19 19 2.2 75-84 years **** ***** 0 0.00 (0.00, 0.00) **** **** ***** 0.00 (0.00, 0.00) ***** **** 1.2 ≥ 85 years 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0 0 0 0.00 Asian 0-40 years **** **** 0 0.00 (0.00, 0.00) **** **** ***** 0.00 (0.00, 0.00) ***** **** 1.7 41-64 years 29 29 0 0.00 (0.00, 0.00) **** **** ***** 0.00 (0.00, 0.00) 52 53 9.6 65-74 years 53 53 0 0.00 (0.00, 0.00) **** **** ***** 0.00 (0.00, 0.00) 71 71 71 12.5											
75-84 years	-			_							
2 85 years 0 0 0 NaN 0.0 0 NaN 0.0 0 0 0.00 0.00 0	-			_							
Asian 0-40 years ***** ***** 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** ***** 1.7 41-64 years 29 29 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 52 53 9.6 65-74 years 53 53 0 0.00 (0.00, 0.00) ***** ****** 0.00 (0.00, 0.00) 71 71 12.5	•			_							
0-40 years **** **** 0 0.00 (0.00, 0.00) **** 0.00 (0.00, 0.00) **** 1.7 41-64 years 29 29 0 0.00 (0.00, 0.00) **** 0.00 (0.00, 0.00) 52 53 9.6 65-74 years 53 53 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 71 71 12.5		0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years 29 29 0 0.00 (0.00, 0.00) ***** ***** ***** ***** 0.00 (0.00, 0.00) 52 53 9.6 65-74 years 53 53 0 0.00 (0.00, 0.00) ***** ***** ***** 0.00 (0.00, 0.00) 71 71 12.5		****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
65-74 years 53 53 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) 71 71 12.5		29	29	_		****	****		52	53	
	-			_	. , ,	****	****				
	· ·			_	• • • •	****	****				



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

		Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Black or Africa	n American		O	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.2
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	70	73	13.0
41-64 years	671	671	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,074	1,085	198.4
65-74 years	744	744	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,100	1,125	209.6
75-84 years	173	173	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	235	239	44.1
, ≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	2.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaii	an or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	1.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Unknown										
0-40 years	855	855	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,423	1,439	231.3
41-64 years	6,086	6,086	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	10,484	10,593	1,733.2
65-74 years	898	898	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,474	1,489	233.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	253	40.5
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	1.7
White										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

by Nace and Ag	,c c .oup									
								Numberet		
								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
0-40 years	115	115	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	215	217	32.5
41-64 years	2,394	2,394	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,115	4,179	722.7
65-74 years	4,850	4,850	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,859	7,979	1,301.9
75-84 years	1,505	1,505	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,325	2,359	389.7
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	108	16.6
Bydureon, Ven	tricular Tachy	cardia								
American India	n or Alaska Na	tive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.3
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or African	American									
0-40 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.3



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 vears <i>Unknown</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	6.3
41-64 years	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	10.5
> 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
White			O	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.5
0-40 years	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	251	251	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	404	404	98.6
65-74 years	387	387	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	654	654	152.2
75-84 years	149	149	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	217	217	49.5
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	3.9
Ozempic, Venti	ricular Tachyca	ardia								
American India										
0-40 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	409	411	89.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	361	361	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	566	569	120.7
75-84 years	165	165	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	239	59.4
> 85 years	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25 25	25	5.8
Asian	10	10	U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	23	23	5.0
0-40 years	79	79	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	111	111	29.8
41-64 years	360	360	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	563	563	137.7
65-74 years	655	655	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	982	985	217.5
75-84 years	251	251	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	385	386	86.5
, ≥ 85 vears	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	80	16.7
Black or Africar	n American									
0-40 years	313	313	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	434	436	110.9
41-64 years	3,802	3,802	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,615	5,642	1,405.5
65-74 years	4,502	4,502	****	****	****	****	31.93 (7.99, 127.67)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,538	1,543	408.1
≥ 85 vears	102	102	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	141	37.2
Multi-racial										
0-40 years	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	171	172	42.9
41-64 years	623	623	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	953	957	230.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	****	****	****	****	****	****	6,943.92 (978.11,	17	17	2.4
							49,297.13)			
≥85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.2
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	92	92	23.2
65-74 years	184	184	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	236	236	77.6



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

,	•									
								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
				•				_	-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
75-84 years	81	81	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	100	31.0
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Unknown										
0-40 years	4,021	4,021	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,878	5,895	1,434.7
41-64 years	31,654	31,654	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,610	2,616	646.6
≥ 85 vears	142	142	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	195	195	48.8
White										
0-40 years	930	930	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,485	1,491	342.8
41-64 years	14,028	14,028	****	****	****	****	5.16 (0.73, 36.61)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	****	****	****	****	4.48 (1.12, 17.92)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	****	****	****	****	6.21 (0.87, 44.06)	16,604	16,649	4,067.5
≥ 85 years	936	936	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,320	1,321	329.8
Rybelsus, Vent	ricular Tachyc	ardia								
American India	n or Alaska Na	itive								_
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Asian										
0-40 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	173	173	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	759	770	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	457	465	98.6



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
≥ 85 vears	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	117	117	23.4
Black or Africa	n American									
0-40 years	88	88	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	131	29.2
41-64 years	984	984	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,405	1,436	392.4
65-74 years	1,680	1,680	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,298	2,352	650.1
75-84 years	564	564	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	749	760	211.0
≥ 85 vears	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	110	28.7
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9
Unknown										
0-40 years	773	773	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,106	1,127	291.8
41-64 years	7,936	7,936	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,404	4,501	1,126.7
75-84 years	894	894	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,316	1,338	330.7
≥ 85 vears	151	151	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	232	235	55.8
White										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Same-Day Dispensings)	Total Observable Years
0-40 years	209	209	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	2,999	2,999	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12,353	12,614	3,030.6
75-84 years	4,305	4,305	0	0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00)	6,332	6,453	1,511.7
≥ 85 years	574	574	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	853	860	194.4
Wegovy, Ventr	-									
American India			•	A. A.	0.0	•				0.0
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NI-NI	0.0	0	Nani	0	0	0.0
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0 0	0 0	NaN	0.0 0.0	0 0	NaN NaN	0	0	0.0 0.0
65-74 years	0 0	0	_	NaN		0		0 0	0	
75-84 years ≥ 85 years	0	0	0 0	NaN NaN	0.0 0.0	0	NaN NaN	0	0 0	0.0 0.0
Black or Africar	•	U	U	INdIN	0.0	U	Ivaiv	U	U	0.0
0-40 years	*****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.6 1.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
> 85 years	0	0	0	NaN	0.0	0	0.00 (0.00, 0.00) NaN	0	0	0.2
Multi-racial	U	O	U	INGIN	0.0	U	INGIN	O	U	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	113	113	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	165	170	14.9
41-64 years	520	520	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	804	817	84.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	45	4.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Ventr	icular Tachyca	ardia		•			· · · · ·			
American India	n or Alaska Na	itive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

			Number of Exposure	Number of Exposure Episodes with an Event per 100				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	-	Confidence Interval)	Dispensings)	Dispensings)	Years
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
, 75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
, ≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africa	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears Multi-racial	0	0	0	NaN	0.0	0	NaN	0	0	0.0
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaii	an or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

,	·									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Ventric	ular Tachycar	dia								
American Indiar	or Alaska Na	tive								_
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.2
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Black or Africar	n American									
0-40 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	342	342	100.5
65-74 years	223	223	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	300	300	94.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	15.0
≥85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	19.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	ın or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Unknown										
0-40 years	140	140	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	848	848	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,269	1,270	356.5
65-74 years	337	337	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	462	462	126.0
75-84 years	93	93	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	118	118	32.5
≥ 85 vears	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.5
White										
0-40 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	164	164	41.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

-,	,									
				Number of Exposure				Number of Exposure Episode	Number of Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
41 C4 years	947	947		0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00)			367.4
41-64 years			0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,423	1,423	507.4 525.2
65-74 years 75-84 years	1,420 597	1,420 597	0 0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,051 839	2,051 839	213.7
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	26.3
Trulicity, Ventr			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	90	90	20.3
American India	-									
0-40 years	*****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	67	67	14.4
> 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	1.2
Asian			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	12	12	1.2
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	366	366	84.8
65-74 years	570	570	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	973	978	208.1
75-84 years	297	297	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 years	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	129	129	21.6
Black or Africar			· ·	0.00 (0.00) 0.00			0.00 (0.00) 0.00,			
0-40 years	218	218	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	376	377	83.7
41-64 years	2,117	2,117	****	****	****	****	34.31 (4.83, 233.57)	3,613	3,644	839.2
65-74 years	2,953	2,953	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,729	4,762	1,204.7
75-84 years	1,022	1,022	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,592	1,601	416.7
≥ 85 vears	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	186	187	44.5
Multi-racial										
0-40 years	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	223	223	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	469	473	100.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	_	Confidence Interval)	Dispensings)	•	Years
CE 74	****	****			****	****			Dispensings)	
65-74 years	****	****	0 0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45 18	45 19	13.3 5.1
75-84 years ≥ 85 years	0	0	0	0.00 (0.00, 0.00) NaN	0.0	0	0.00 (0.00, 0.00) NaN	18 0	0	0.0
2 85 Vears Native Hawaiia	-	-	U	INdIN	0.0	U	INdiv	U	U	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	90	90	30.0
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.7
Unknown			Ü	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			3.7
0-40 years	1,577	1,577	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,730	2,751	632.6
41-64 years	13,585	13,585	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,637	2,652	594.5
≥ 85 vears	197	197	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	327	328	68.5
White										
0-40 years	536	536	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	****	****	****	****	9.26 (1.30, 65.71)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	****	****	****	****	3.58 (0.50, 25.42)	32,607	32,794	6,969.6
75-84 years	8,880	8,880	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15,077	15,161	3,232.30
≥ 85 years	1,172	1,172	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,066	2,074	406.0
Xultophy, Vent	ricular Tachyc	ardia								
American India	n or Alaska Na	tive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)	at Risk		Confidence Interval)	Dispensings)	Dispensings)	Years
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian			-	-			-	-	-	
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or Africa	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other Pac	cific Islander								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown	****	****	•	0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.0
0-40 years			0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)			1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39 29	39 29	11.6
65-74 years	22 ****	22 ****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	29 ****	29 ****	6.3 4.3
75-84 years ≥ 85 years	0	0	0	0.00 (0.00, 0.00) NaN	0.0	0	0.00 (0.00, 0.00) NaN	0	0	4.3 0.0
White	U	U	U	INdIN	0.0	U	Ivaiv	U	U	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	127	127	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	161	161	49.4
75-84 years	66	66	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	95	95	19.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.6
Mounjaro, Ver	ntricular Fibrilla	ation and Flu	tter							
American India	an or Alaska Na	ıtive								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Black or Africa	n American									



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

			Number of Exposure	Number of Exposure Episodes with an Event per 100				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	70	73	13.0
41-64 years	671	671	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,074	1,085	198.4
65-74 years	744	744	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,100	1,125	209.6
75-84 years	173	173	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	235	239	44.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	15	15	2.0
Multi-racial			-							
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	3.7
, 41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	1.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Unknown										
0-40 years	855	855	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,423	1,439	231.3
41-64 years	6,086	6,086	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	10,484	10,593	1,733.2
65-74 years	898	898	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,474	1,489	233.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	253	40.5
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	1.7
White										
0-40 years	115	115	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	215	217	32.5
41-64 years	2,394	2,394	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,115	4,179	722.7



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

		Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	` Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
65-74 years	4,850	4,850	****	****	****	****	17.97 (2.53, 127.58)	7,859	7,979	1,301.9
75-84 years	1,505	1,505	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,325	2,359	389.7
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	108	16.6
Bydureon, Ven	tricular Fibrilla	ation and Flut	tter	· , , , , , , , , , , , , , , , , , , ,			, , ,			
American India	ın or Alaska Na	ıtive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	11	11	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.3
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or Africa	n American									
0-40 years	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	0.0	9	0.00 (0.00, 0.00)	****	****	0.1
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.3
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

75-84 years	Number of Patients 0	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk 0.0	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval) NaN	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years 0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander	· ·		0.0			· ·	· ·	0.0
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	6.3
41-64 years	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
White										
0-40 years	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	251	251	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	404	404	98.6
65-74 years	387	387	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	654	654	152.2
75-84 years	149	149	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	217	217	49.5
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	3.9
Ozempic, Vent	ricular Fibrillat	ion and Flutt	er							
American India										
0-40 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	409	411	89.4
65-74 years	361	361	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	566	569	120.7
75-84 years	165	165	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	239	239	59.4



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

			Number of Exposure	Number of Exposure Episodes with an Event per 100				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	November of	Number of	Episodes with an	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	•	Total
	Number of Patients	Exposure Episodes	Event	(95% Confidence Interval)	Years	Days at Risk	Patient-Years at Risk (95% Confidence Interval)	Same-Day Dispensings)	Same-Day Dispensings)	Observable Years
> QE voors		•			****	****				
≥ 85 vears	18	18	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i> 0-40 years	79	79	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	111	111	29.8
41-64 years	360	360	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	563	563	137.7
65-74 years	655	655	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	982	985	217.5
75-84 years	251	251	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	80	16.7
Black or Africa			-							
0-40 years	313	313	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	434	436	110.9
41-64 years	3,802	3,802	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	5,615	5,642	1,405.5
65-74 years	4,502	4,502	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,538	1,543	408.1
≥ 85 vears	102	102	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	140	141	37.2
Multi-racial										
0-40 years	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	171	172	42.9
41-64 years	623	623	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	953	957	230.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	2.4
≥ 85 vears	0	0	0	NaN	****	****	NaN	0	0	0.0
Native Hawaii										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.2
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	92	92	23.2
65-74 years	184	184	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	236	236	77.6
75-84 years	81	81	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	100	31.0
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Unknown										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

,	1									
								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	-	•	Total	Total	Frant Bata nov 10 000			Total
	Niahan af	Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	****	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
0-40 years	4,021	4,021	0 ****	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	5,878	5,895	1,434.7
41-64 years	31,654	31,654			*****	*****	2.32 (0.33, 16.45)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,610	2,616	646.6
≥ 85 years	142	142	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	195	195	48.8
White				()	ale ale ale ale ale	****				
0-40 years	930	930	0 ****	0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00)	1,485	1,491	342.8
41-64 years	14,028	14,028		****			5.16 (0.73, 36.61)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	****		****	****	4.48 (1.12, 17.92)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16,604	16,649	4,067.5
≥ 85 years	936	936	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,320	1,321	329.8
Rybelsus, Vent			ter							
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Asian										
0-40 years	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	173	173	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	759	770	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	457	465	98.6
≥ 85 vears	72	72	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	117	117	23.4
Black or Africar										
0-40 years	88	88	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	127	131	29.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

		Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	Number of Patients	Exposure Episodes	with an Event	(95% Confidence Interval)	Years at Risk	Days at Risk	Patient-Years at Risk (95% Confidence Interval)	Same-Day Dispensings)	Same-Day Dispensings)	Observable Years
41-64 years	984	984	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,405	1,436	392.4
65-74 years	1,680	1,680	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,298	2,352	650.1
75-84 years	564	564	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	749	760	211.0
≥ 85 years	76	76	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	110	28.7
Multi-racial	, 0	7.0	Ü	0.00 (0.00) 0.00)			0.00 (0.00) 0.00)	107	110	2017
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia	n or Other Pac	ific Islander								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.9
Unknown										
0-40 years	773	773	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,106	1,127	291.8
41-64 years	7,936	7,936	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,404	4,501	1,126.7
75-84 years	894	894	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,316	1,338	330.7
≥ 85 vears	151	151	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	232	235	55.8
White										
0-40 years	209	209	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	2,999	2,999	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12,353	12,614	3,030.6



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	(Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	4,305	4,305	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,332	6,453	1,511.7
≥ 85 years	574	574	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	853	860	194.4
Wegovy, Ventr			er							
American India										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian									_	_
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africar										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	4.6
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

,	•									
								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining-	
				•				_	-	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiia		ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	113	113	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	165	170	14.9
41-64 years	520	520	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	804	817	84.2
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	42	45	4.9
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Saxenda, Ventr	icular Fibrillat	ion and Flutt	er							
American India	n or Alaska Na	tive								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or Africa	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other Pac	ific Islander								
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	64	64	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	100	32.2



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

,	•									
								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure	
			Number of	Episodes with an				Defining-	Episode Defining	
			Exposure	Event per 100				Dispensings	Dispensings (Not	
		Number of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	Number of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
41-64 years	266	266	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
White	-	_	-					-	-	
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Ventri	cular Fibrillation	on and Flutte	r							
American India	n or Alaska Na	itive								_
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.2
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23	23	6.2
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Black or African			_		****	ale ale ale ale (*)	(:			
0-40 years	39	39	0	0.00 (0.00, 0.00)		****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	342	342	100.5



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

Patients Episodes Event Interval at Risk at Risk Confidence Interval Dispensings Dispensings Vears		Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
25-74 years 22-3		Patients		Event	·				Dispensings)	Dispensings)	
15.0	65-74 years			0	• • •			• • • •			
263 rears	75-84 years			0	0.00 (0.00, 0.00)	****	****	• • • •	****		
0-40 years ****** ****** 0 0.00 (0.00, 0.00) ****** ****** 0.00 (0.00, 0.00) 30 30 7.0 41-64 years ****** ****** ****** ****** 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 1.7 75-84 years ****** ****** 0 0.00 (0.00, 0.00) ******* 0.00 (0.00, 0.00) ****** ****** 0.2 ≥85 years 0 0 0 NaN 0.0 0 NaN 0 0 0 0.0 <td< td=""><td></td><td>****</td><td>****</td><td>0</td><td>0.00 (0.00, 0.00)</td><td>****</td><td>****</td><td>0.00 (0.00, 0.00)</td><td>****</td><td>****</td><td>1.5</td></td<>		****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.5
41-64 years	Multi-racial										
65-74 years ***** ***** 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) **** **** 1.7 75-84 years ***** ***** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) **** **** 1.7 75-84 years 0 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0 0 0 0.00 ***** ***** 0 0 0 NaN 0.0 0 NaN 0 0 0 0 0.00 ***** ***** 0 0 0 0 NaN 0.0 0 NaN 0 0 0 0 0.00 ***** ***** 0 0 0 0 0 NaN 0.0 0 NaN 0 0 0 0 0.00 ***** ***** 0 0 0 0 0 0 NaN 0 0 0 0 0.00 ***** ***** 0 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** ***** 1.6 ****** ***** 0 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** 0.00 ***** ***** 0 0 0.00 (0.00, 0.00) **** 0.00 (0.00, 0.00) ***** 0.00 ***** 0 0 0 0 0 0 0 0 0.00 ***** 0 0 0.00 (0.00, 0.00) **** 0.00 ***** 0 0 0 0 0 0.00 ***** 0 0 0 0 0 0 0.00 ***** 0 0 0 0 0 0 0.00 ***** 0 0 0 0 0 0.00 ***** 0 0 0 0 0 0.00 ***** 0 0 0 0 0 0.00 ***** 0 0 0 0 0 0 0.00 ***** 0 0 0 0 0 0 0.00 ***** 0 0 0 0 0 0 0.00 ***** 0 0 0 0 0 0 0 0 0.00 ***** 0 0 0 0 0 0 0 0 0 0 0 0 0.00 ***** 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0-40 years			0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	30	30	7.0
75-84 years ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 1.0 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 1.0 (0.00, 0.00) ***** 1.00 (0.00, 0.00) ****** 1.00 (0.00, 0.00) ***** 1.00 (0.00, 0.00) ***** 1.00 (0.00, 0.00)	•			0	, , ,			` ' '			
2 85 vears 0 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0 0 0.0 Native Hawaiian or Other Pacific Islander 0-40 years 0 0 0 0 NaN 0.0 0 NaN 0 0 0 0.0 41-64 years ***** ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** ***** 1.6 65-74 years **** ***** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) ***** **** 1.6 65-74 years **** **** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) **** **** 1.0 Unknown 0-40 years 140 140 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) **** **** 1.0 Unknown 0-40 years 140 140 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 201 201 55.5 41-64 years 848 848 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 1,269 1,270 356.5 65-74 years 337 337 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 118 118 118 32.5 ≥85 vears 17 17 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 118 118 118 32.5 ≥85 vears 95 95 95 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 1,423 1,423 367.4 65-74 years 947 947 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 1,423 1,423 367.4 65-74 years 1,420 1,420 0 0.00 (0.00, 0.00) **** **** ***** 0.00 (0.00, 0.00) 1,251 2,051 525.2	65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
Native Hawaiian or Other Pacific Islander 0-40 years 0 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0.0 0 0.0 41-64 years ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** **** 1.6 65-74 years ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** 3.9 75-84 years **** ***** 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) ***** ***** 0.6 ≥ 85 years **** ***** 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) **** 0.	75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	
0-40 years 0 0 NaN 0.0 0 NaN 0 0.0 41-64 years ****** ****** ****** 0 0.00 (0.00, 0.00) ****** ****** 1.6 65-74 years ****** ****** 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** ****** 3.9 75-84 years ***** ****** 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** ****** 0.6 ≥ 85 vears ****** ****** 0 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 1.0 Unknown Unknown ***** ***** 0.00 (0.00, 0.00) ****** ****** 0.00 (0.00, 0.00) ****** ****** 1.0 ****** ****** 0.00 (0.00, 0.00) ****** 1.0 ****** ****** 0.00 (0.00, 0.00) ****** ****** 0.00 (0.00, 0.00) 1.269 1,270 356.5 55.5 41-64 years 93 93 93 0		-	-	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years		n or Other Pac	ific Islander								
65-74 years	0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** **** 1.0 Unknown 0-40 years 140 140 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 201 201 55.5 41-64 years 848 848 848 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 1,269 1,270 356.5 65-74 years 337 337 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 462 462 126.0 75-84 years 93 93 93 0 0.00 (0.00, 0.00) **** **** ***** 0.00 (0.00, 0.00) 118 118 118 32.5 ≥ 85 years 17 17 0 0.00 (0.00, 0.00) **** **** ***** 0.00 (0.00, 0.00) 26 26 6.5 White 0-40 years 95 95 95 0 0.00 (0.00, 0.00) **** **** ***** 0.00 (0.00, 0.00) 1,423 1,423 367.4 41-64 years 947 947 0 0.00 (0.00, 0.00) **** **** ***** 0.00 (0.00, 0.00) 1,423 1,423 367.4 65-74 years 1,420 1,420 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 2,051 2,051 525.2	41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
≥ 85 vears	65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.9
Unknown 0-40 years 140 140 0 0.00 (0.00, 0.00) ***** ***** ***** ***** ***** ***** ****	75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
0-40 years 140 140 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 201 201 55.5 41-64 years 848 848 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 1,269 1,270 356.5 65-74 years 337 337 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 462 462 126.0 75-84 years 93 93 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 118 118 32.5 ≥ 85 vears 17 17 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 26 26 26 6.5 White 0-40 years 95 95 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 164 164 41.2 41-64 years 947 947 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 1,423 1,423 367.4 65-74 years 1,420 1,420 0 0.00 (0.00, 0.00) **** **** ***** 0.00 (0.00, 0.00) 2,051 2,051 525.2	≥85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
41-64 years 848 848 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 1,269 1,270 356.5 65-74 years 337 337 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 462 462 126.0 75-84 years 93 93 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 118 118 32.5 ≥ 85 years 17 17 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 26 26 6.5 White 0-40 years 95 95 95 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 164 164 41.2 41-64 years 947 947 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 1,423 1,423 367.4 65-74 years 1,420 1,420 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 2,051 2,051 525.2	Unknown										
65-74 years 337 337 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 462 462 126.0 75-84 years 93 93 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 118 118 32.5 ≥ 85 years 17 17 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 26 26 6.5 White 0-40 years 95 95 0 0.00 (0.00, 0.00) **** **** ***** 0.00 (0.00, 0.00) 164 164 41.2 41-64 years 947 947 0 0.00 (0.00, 0.00) **** **** ***** 0.00 (0.00, 0.00) 1,423 1,423 367.4 65-74 years 1,420 1,420 0 0.00 (0.00, 0.00) ***** ****** 0.00 (0.00, 0.00) 2,051 2,051 525.2	0-40 years	140	140	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	201	201	55.5
75-84 years 93 93 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 118 118 32.5 ≥ 85 years 17 17 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) 26 26 6.5 White 0-40 years 95 95 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 164 164 41.2 41-64 years 947 947 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 1,423 1,423 367.4 65-74 years 1,420 1,420 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 2,051 2,051 525.2	41-64 years	848	848	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,269	1,270	356.5
≥ 85 years 17 17 0 0.00 (0.00, 0.00) ***** ***** ***** ***** ***** 0.00 (0.00, 0.00) 26 26 6.5 White 0-40 years 95 95 0 0.00 (0.00, 0.00) ***** ***** ***** 0.00 (0.00, 0.00) 164 164 41.2 41-64 years 947 947 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 1,423 1,423 367.4 65-74 years 1,420 1,420 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 2,051 2,051 525.2	65-74 years	337	337	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	462	462	126.0
White 0-40 years 95 95 0 0.00 (0.00, 0.00) ***** ***** ***** ***** ***** 0.00 (0.00, 0.00) 164 164 41.2 41-64 years 947 947 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 1,423 1,423 367.4 65-74 years 1,420 1,420 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 2,051 2,051 525.2	75-84 years	93	93	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	118	118	32.5
0-40 years 95 95 0 0.00 (0.00, 0.00) **** *** 0.00 (0.00, 0.00) 164 164 41.2 41-64 years 947 947 0 0.00 (0.00, 0.00) **** 0.00 (0.00, 0.00) 1,423 1,423 367.4 65-74 years 1,420 1,420 0 0.00 (0.00, 0.00) **** *** 0.00 (0.00, 0.00) 2,051 2,051 525.2	≥85 vears	17	17	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	6.5
41-64 years 947 947 0 0.00 (0.00, 0.00) **** 0.00 (0.00, 0.00) 1,423 1,423 367.4 65-74 years 1,420 1,420 0 0.00 (0.00, 0.00) **** *** **** 0.00 (0.00, 0.00) 2,051 2,051 525.2	White										
65-74 years 1,420 1,420 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) 2,051 2,051 525.2	0-40 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	164	164	41.2
	41-64 years	947	947	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,423	1,423	367.4
	65-74 years	1,420	1,420	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,051	2,051	525.2
	75-84 years	597	597	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	839		213.7



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

≥ 85 years	Number of Patients 72	Number of Exposure Episodes 72	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval) 0.00 (0.00, 0.00)	Total Years at Risk ****	Total Days at Risk ****	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval) 0.00 (0.00, 0.00)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years 26.3
Trulicity, Ventr				0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	30	30	20.5
American India										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	100	100	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	12	12	1.2
Asian										
0-40 years	46	46	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	366	366	84.8
65-74 years	570	570	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	973	978	208.1
75-84 years	297	297	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 vears	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	129	129	21.6
Black or Africa	n American									
0-40 years	218	218	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	376	377	83.7
41-64 years	2,117	2,117	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,613	3,644	839.2
65-74 years	2,953	2,953	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,729	4,762	1,204.7
75-84 years	1,022	1,022	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,592	1,601	416.7
≥ 85 years	118	118	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	186	187	44.5
Multi-racial										
0-40 years	35	35	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	223	223	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	469	473	100.4
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Hawaiid	an or Other Pac	ific Islander								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	90	90	30.0
≥ 85 vears <i>Unknown</i>	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.7
0-40 years	1,577	1,577	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,730	2,751	632.6
41-64 years	13,585	13,585	****	****	****	****	4.72 (0.66, 33.51)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	****	****	****	****	13.56 (1.91, 96.27)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,637	2,652	594.5
≥ 85 vears	197	197	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	327	328	68.5
White										
0-40 years	536	536	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	****	****	****	****	9.26 (1.30, 65.71)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	****	****	****	****	3.58 (0.50, 25.42)	32,607	32,794	6,969.6
75-84 years	8,880	8,880	****	****	****	****	7.81 (1.10, 55.42)	15,077	15,161	3,232.30
≥ 85 years	1,172	1,172	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,066	2,074	406.0
Xultophy, Ven			ter							
American India										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of	Number of Exposure	Number of Exposure Episodes with an	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence	Total Years	Total Days	Event Rate per 10,000 Patient-Years at Risk (95%	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day	Total Observable
	Patients	Episodes	Event	Interval)	at Risk	-	Confidence Interval)	Dispensings)	Dispensings)	Years
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
, 75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
, ≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Black or Africa	n American									
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
65-74 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	11.2
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.3
≥ 85 vears	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.2
Multi-racial										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Native Hawaiid	an or Other Pac	cific Islander								
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 vears	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown										
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	11.6



Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.3
≥ 85 vears <i>White</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
0-40 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	127	127	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	161	161	49.4
75-84 years	66	66	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	95	95	19.2
≥ 85 years	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.6

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

^{*}NaN: Not a number



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
		zed Tachyarı								
	n Indian or A ****	llaska Native		0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.0
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
2023	ጥጥጥጥ	ጥጥጥጥ	0	0.00 (0.00, 0.00)	ተጥጥጥ	·· · · · · · · ·	0.00 (0.00, 0.00)	ጥ ጥ ጥ ጥ	ጥ ጥ ጥ ጥ	0.7
Asian	20	20	0	0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	F.3	F2	16.0
2022	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	5,354	0	0.00 (0.00, 0.00)	ተጥጥጥ	·* • • • • •	0.00 (0.00, 0.00)	22	22	2.7
	African Ame		ale ale at the state	****	ala ala di cita di	ala ala alto alto alto				
2022	120	120	****		****	****	559.77 (78.85, 3,973.99)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	58	58	9.0
Multi-ra										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	34	14.3
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	1.5
Native H		Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	1									
2022	179	179	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	****	****	****	****	1,579.80 (222.53,	84	84	9.5
							11.215.52)			
White										
2022	723	723	****	****	****	****	396.27 (148.72, 1,055.84)	1,181	1,181	297.0
2023	110	110	****	****	****	****	873.80 (123.08, 6,203.42)	155	155	21.4



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
		zed Tachyar								
	n Indian or A ****	Maska Native		0.00 (0.00 0.00)	****	****	0.00 (0.00 0.00)	4.7	4-7	7.0
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	47 ****	47 ****	7.8
2023	****	****	0	0.00 (0.00, 0.00)	***	****	0.00 (0.00, 0.00)	****	****	1.1
Asian	60	60	0	0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	100	100	24.2
2022	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	54	54	6.9
	African Ame			***						
2022	634	634	****	****	****	****	402.07 (129.67, 1,236.66)	980	999	273.7
2023	1,006	1,006	****	****	****	****	489.06 (203.56, 1,175.00)	1,514	1,538	193.4
Multi-ra										
2022	34	34	****	****	****	****	2,219.02 (312.57,	60	61	19.3
							15,753.52)			
2023	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	4.2
		Other Pacific								
2022	19	19	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	6.7
Unknowi										
2022	4,058	4,058	****	****	****	****	268.21 (161.70, 444.90)	7,434	7,510	1,698.6
2023	3,948	3,948	****	****	****	****	190.91 (91.01, 400.45)	6,209	6,277	541.4
White										
2022	4,671	4,671	****	****	****	****	563.46 (398.46, 796.77)	7,775	7,864	1,645.2
2023	4,268	4,268	****	****	****	****	851.69 (622.27, 1,165.70)	6,845	6,978	818.2
Ozempic	, Hospitalize	ed Tachyarrl	nythmia							



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
America	n Indian or A	laska Native	?							
2022	695	695	****	****	****	****	1,222.72 (677.14, 2,207.90)	1,100	1,102	260.8
2023	131	131	****	****	****	****	811.85 (114.36, 5,763.57)	170	173	22.1
Asian										
2022	1,022	1,022	****	****	****	****	311.17 (129.52, 747.60)	1,605	1,607	423.1
2023	371	371	****	****	****	****	928.92 (348.63, 2,475.06)	516	518	65.1
Black or	African Ame	rican								
2022	6,058	6,058	****	****	****	****	540.69 (409.80, 713.39)	9,102	9,130	2,926.5
2023	3,774	3,774	****	****	****	****	494.71 (322.55, 758.75)	4,994	5,015	685.0
Multi-ra	cial									
2022	407	407	****	****	****	****	308.05 (77.04, 1,231.73)	690	692	253.6
2023	409	409	****	****	****	****	495.46 (123.91, 1,981.10)	559	562	62.4
Native H	lawaiian or C	Other Pacific	Islander							
2022	156	156	****	****	****	****	691.76 (173.00, 2,766.04)	229	229	106.1
2023	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	223	223	31.8
Unknow	n									
2022	27,580	27,580	****	****	****	****	236.94 (205.36, 296.94)	45,223	45,337	14,467.1
2023	17,787	17,787	****	****	****	****	208.02 (147.89, 292.61)	23,239	23,331	2,166.6
White	•	•					, , ,	•	,	•
2022	43,173	43,173	****	****	****	****	664.07 (604.31, 729.74)	66,072	66,235	18,069.2
2023	15,268	15,268	****	****	****	****	665.99 (555.62, 798.30)	20,712	20,796	2,783.3
Rybelsus	s, Hospitalize	ed Tachyarrh	nythmia							
America	n Indian or A	laska Native	?							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	103	26.9



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

								Number of		
								Exposure	Number of	
				Number of Exposure				Episode	Exposure Episode	
			Number of	Episodes with an				Defining-	Defining-	
		Number	Exposure	Event per 100				Dispensings	Dispensings (Not	
	Number	of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Asian										
2022	923	923	****	****	****	****	135.89 (33.99, 543.38)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	210	213	32.8
Black or	African Ame	rican								
2022	2,336	2,336	****	****	****	****	391.32 (227.22, 673.94)	3,335	3,398	1,106.2
2023	1,056	1,056	****	****	****	****	423.95 (176.87, 1,020.96)	1,351	1,391	205.2
Multi-ra	cial									
2022	111	111	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	109	13.8
Native H	lawaiian or C	Other Pacific	Islander							
2022	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	80	13.4
Unknow	n									
2022	8,899	8,899	****	****	****	****	196.27 (134.60, 286.20)	13,647	13,926	4,494.3
2023	3,889	3,889	****	****	****	****	252.06 (131.15, 484.44)	4,984	5,141	528.3
White										
2022	12,838	12,838	****	****	****	****	508.70 (415.59, 622.67)	19,626	19,980	5,231.90
2023	3,576	3,576	****	****	****	****	670.87 (463.21, 971.64)	4,813	4,953	722.2
Saxenda	, Hospitalize	d Tachyarrh	nythmia							
America	n Indian or A	Maska Native	2							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
	African Ame									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
Multi-ra	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
2023	****	****	0	0.00 (0.00, 0.00)	0.0	16	0.00 (0.00, 0.00)	****	****	0.0
Native H	lawaiian or (Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	n									
2022	298	298	****	****	****	****	233.56 (34.31, 1,729.15)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	6.5
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	15.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
		d Tachyarrh								
		Naska Native								
2022	234	234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	5.0
Asian										
2022	1,045	1,045	****	****	****	****	237.34 (89.08, 632.37)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	222	223	31.7



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Black or	⁻ African Ame	rican								
2022	4,894	4,894	****	****	****	****	502.51 (362.47, 696.64)	8,231	8,302	2,271.0
2023	1,534	1,534	****	****	****	****	448.43 (223.26, 896.71)	2,255	2,269	317.8
Multi-ra	icial									
2022	190	190	****	****	****	****	532.94 (133.28, 2,130.98)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	174	175	17.5
Native I	Hawaiian or 0	Other Pacific	Islander							
2022	145	145	****	****	****	****	752.01 (188.07, 3,006.93)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	156	20.6
Unknow	<i>ı</i> n									
2022	15,411	15,411	81	0.53 (0.41, 0.64)	****	****	302.59 (233.37, 376.21)	29,665	29,856	7,853.5
2023	6,363	6,363	26	0.41 (0.25, 0.57)	****	****	407.73 (277.61, 598.84)	9,664	9,746	894.4
White										
2022	30,998	30,998	292	0.94 (0.83, 1.05)	****	****	625.00 (557.27, 700.96)	55,284	55,582	12,538.3
2023	5,777	5,777	45	0.78 (0.55, 1.01)	****	****	633.39 (472.91, 848.32)	8,907	8,985	1,217.2
Victoza,	, Hospitalized	d Tachyarrhy	rthmia							
Americo	an Indian or A									
2022	****	****	****	****	****	****	1,683.96 (237.20,	76	76	21.3
							11,954.95)			
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.3
Asian										
2022	74	74	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	95	95	32.7
2023	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25	25	3.2
Black or	⁻ African Ame	rican								



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	397	397	****	****	****	****	540.10 (174.19, 1,674.64)	550	550	193.2
2023	159	159	****	****	****	****	578.93 (81.55, 4,110.05)	199	199	33.8
Multi-ra										
2022	37	37	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	46	46	5.4
		Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.7
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.4
Unknow	n									
2022	1,026	1,026	****	****	****	****	384.16 (172.58, 855.10)	1,555	1,556	514.6
2023	409	409	****	****	****	****	1,013.81 (380.49, 2,701.25)	521	521	62.3
White										
2022	2,510	2,510	****	****	****	****	643.15 (431.08, 959.55)	3,751	3,751	1,039.7
2023	621	621	****	****	****	****	770.43 (346.12, 1,714.92)	823	823	134.2
		d Tachyarrh								
		laska Native								
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.4
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	50	52	4.6



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-ra	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	3.0
Native H	ławaiian or C	Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	n									
2022	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	928	948	70.2
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
2023	****	****	****	****	****	****	899.41 (126.69, 6,385.20)	185	188	18.4
Xultoph	y, Hospitaliz	ed Tachyarr	hythmia							
America	n Indian or A	laska Native	2							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Black or	African Ame	rican								
2022	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	33	33	4.8
Multi-ra	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
	awaiian or (****	Other Pacific ****		0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
2022			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.9
2023 Unknow	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2022	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	19.7
2022	38 25	38 25	0 0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32 32	32 32	4.3
2025 White	23	25	U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	32	32	4.5
2022	153	153	****	****	****	****	377.83 (53.22, 2,682.35)	207	207	67.3
2023	94	94	****	****	****	****	841.59 (118.55, 5,974.72)	121	121	19.3
	_	rillation and	Flutter							
		laska Native								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	47	47	7.8
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Asian										
2022	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	54	54	6.9
Black or	African Ame	rican								
2022	634	634	****	****	****	****	268.04 (67.04, 1,071.78)	980	999	273.7
2023	1,006	1,006	****	****	****	****	391.25 (146.84, 1,042.46)	1,514	1,538	193.4
Multi-ra										
2022	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	4.2
Native H	awaiian or (Other Pacific	Islander							



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	19	19	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	6.7
Unknowi										
2022	4,058	4,058	****	****	****	****	125.17 (59.67, 262.55)	7,434	7,510	1,698.6
2023	3,948	3,948	****	****	****	****	136.36 (56.76, 327.62)	6,209	6,277	541.4
White										
2022	4,671	4,671	****	****	****	****	422.59 (283.25, 630.49)	7,775	7,864	1,645.2
2023	4,268	4,268	****	****	****	****	480.44 (316.35, 729.66)	6,845	6,978	818.2
		rillation and								
	n Indian or A ****	Naska Native		0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
2023	ጥጥጥጥ	ጥጥጥጥ	0	0.00 (0.00, 0.00)	ጥጥጥጥ	·· · · · · · · ·	0.00 (0.00, 0.00)	<i>~ ~ ~ ~ ~</i>	ጥ ጥ ጥ ጥ	0.7
Asian 2022	20	20	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	F2	гэ	16.0
	29 15	29 15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	1. 1. 1. 1. 1 .		0.00 (0.00, 0.00)	22	22	2.7
	African Ame		0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	407	107	64.0
2022	120	120	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	****	ጥጥጥ	0.00 (0.00, 0.00)	58	58	9.0
Multi-rad		****		0.00 (0.00 0.05)	****	4. 4. 4. 4. 1.	0.00 (0.00 0.00)			44.0
2022	****	*****	0	0.00 (0.00, 0.00)		*****	0.00 (0.00, 0.00)	34	34	14.3
2023			0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	1.5
		Other Pacific			ala ala ala ala -t-	ale ale ale (*)		ale ale ale ale ale	ate ate ate ate	
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown										
2022	179	179	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	****	****	****	****	1,579.80 (222.53,	84	84	9.5
							11.215.52)			
White										
2022	723	723	****	****	****	****	297.20 (95.85, 921.51)	1,181	1,181	297.0
2023	110	110	****	****	****	****	873.80 (123.08, 6,203.42)	155	155	21.4
		llation and I								
		Naska Native	****	****	****	****				
2022	695	695					889.25 (444.71, 1,778.18)	1,100	1,102	260.8
2023	131	131	****	****	****	****	811.85 (114.36, 5,763.57)	170	173	22.1
Asian										
2022	1,022	1,022	****	****	****	****	123.47 (31.13, 497.69)	1,605	1,607	423.1
2023	371	371	****	****	****	****	232.23 (32.71, 1,648.67)	516	518	65.1
	frican Ame	rican								
2022	6,058	6,058	****	****	****	****	281.16 (191.43, 412.94)	9,102	9,130	2,926.5
2023	3,774	3,774	****	****	****	****	235.58 (126.75, 437.83)	4,994	5,015	685.0
Multi-raci	al									
2022	407	407	****	****	****	****	154.02 (21.70, 1,093.46)	690	692	253.6
2023	409	409	****	****	****	****	237.73 (34.89, 1,758.70)	559	562	62.4
Native Ha	waiian or C	Other Pacific	Islander							
2022	156	156	****	****	****	****	691.76 (173.00, 2,766.04)	229	229	106.1
2023	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	223	223	31.8
Unknown										



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	-	Confidence Interval)	Dispensings)	Dispensings)	Years
2022	27,580	27,580	****	****	****	****	146.42 (115.23, 186.03)	45,223	45,337	14,467.1
2023 White	17,787	17,787	****	****	****	****	107.16 (66.62, 172.38)	23,239	23,331	2,166.6
2022	43,173	43,173	****	****	****	****	462.69 (413.27, 518.03)	66,072	66,235	18,069.2
2023	15,268	15,268	****	****	****	****	392.77 (310.21, 497.29)	20,712	20,796	2,783.3
		illation and I								
		Naska Native	?							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	103	26.9
2023 Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
2022	923	923	****	****	****	****	67.95 (9.57, 482.38)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	210	213	32.8
Black or A	African Ame	rican								
2022	2,336	2,336	****	****	****	****	230.81 (120.43, 481.54)	3,335	3,398	1,106.2
2023	1,056	1,056	****	****	****	****	254.97 (82.23, 790.56)	1,351	1,391	205.2
Multi-rac	cial									
2022	111	111	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	109	13.8
Native H	awaiian or C	Other Pacific	Islander							
2022	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	80	13.4
Unknowr	1									
2022	8,899	8,899	****	****	****	****	101.77 (60.27, 171.84)	13,647	13,926	4,494.3
2023	3,889	3,889	****	****	****	****	140.03 (58.28, 336.44)	4,984	5,141	528.3



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White										
2022	12,838	12,838	****	****	****	****	400.47 (318.87, 502.94)	19,626	19,980	5,231.90
2023	3,576	3,576	****	****	****	****	455.23 (290.37, 713.71)	4,813	4,953	722.2
		lation and F								
		Naska Native								
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or A	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.4
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	50	52	4.6
Multi-rad	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	3.0
Native H	awaiian or (Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknowi	1									
2022	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	928	948	70.2
White	-	-	-	,,			,,,	-	-	
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

			Newskanaf	Number of Exposure				Number of Exposure Episode Defining-	Number of Exposure Episode	
		Number	Number of	Episodes with an Event per 100				Defining- Dispensings	Defining- Dispensings (Not	
	Number	of	Exposure Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
2023	****	****	****	****	****	****	899.41 (126.69, 6,385.20)	185	188	18.4
	Atrial Fibri	llation and F	lutter				055.41 (120.05, 0,585.20)	103	100	10.4
		laska Native								
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or A	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
Multi-rac	rial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native H	awaiian or (Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown)									
2022	298	298	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	6.5
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	15.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
America	n Indian or A	laska Native	?							
2022	****	****	****	****	****	****	1,683.96 (237.20, 11,954.95)	76	76	21.3
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.3
Asian										
2022	74	74	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	95	95	32.7
2023	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25	25	3.2
	African Ame	rican								
2022	397	397	****	****	****	****	180.03 (25.36, 1,278.11)	550	550	193.2
2023	159	159	****	****	****	****	578.93 (81.55, 4,110.05)	199	199	33.8
Multi-ra	cial									
2022	37	37	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	46	46	5.4
Native H	lawaiian or C	Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.7
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.4
Unknow	n									
2022	1,026	1,026	****	****	****	****	128.05 (32.02, 512.02)	1,555	1,556	514.6
2023	409	409	****	****	****	****	506.90 (126.77, 2,026.88)	521	521	62.3
White										
2022	2,510	2,510	****	****	****	****	455.56 (283.20, 732.82)	3,751	3,751	1,039.7
2023	621	621	****	****	****	****	385.22 (123.23, 1,194.42)	823	823	134.2
Trulicity	, Atrial Fibril	lation and F	lutter							

American Indian or Alaska Native



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

								Number of Exposure	Number of	
			Number of	Number of Exposure Episodes with an				Episode Defining-	Exposure Episode Defining-	
		Number	Exposure	Event per 100				Dispensings	Dispensings (Not	
	Number	of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
2022	234	234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	5.0
Asian										
2022	1,045	1,045	****	****	****	****	178.00 (57.41, 551.92)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	222	223	31.7
Black or	African Ame	rican								
2022	4,894	4,894	****	****	****	****	251.25 (158.30, 398.79)	8,231	8,302	2,271.0
2023	1,534	1,534	****	****	****	****	168.16 (54.23, 521.41)	2,255	2,269	317.8
Multi-ro	icial									
2022	190	190	****	****	****	****	266.47 (37.53, 1,891.76)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	174	175	17.5
Native I	Hawaiian or (Other Pacific	Islander							
2022	145	145	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	156	20.6
Unknow	/n									
2022	15,411	15,411	****	****	****	****	175.58 (131.92, 233.68)	29,665	29,856	7,853.5
2023	6,363	6,363	****	****	****	****	250.91 (153.71, 409.56)	9,664	9,746	894.4
White										
2022	30,998	30,998	****	****	****	****	483.73 (423.60, 551.09)	55,284	55,582	12,538.3
2023	5,777	5,777	****	****	****	****	422.26 (295.23, 603.93)	8,907	8,985	1,217.2
	y, Atrial Fibr									
	an Indian or A					_		_	_	
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Asian										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Black or	African Ame	rican								
2022	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	33	33	4.8
Multi-ra	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native H	awaiian or C	Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknowi	1									
2022	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	4.3
White			-					-	-	
2022	153	153	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	207	207	67.3
2023	94	94	****	****	****	****	841.59 (118.55, 5,974.72)	121	121	19.3
	o, Sinus Tac	hycardia								
		laska Native	?							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	47	47	7.8
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Asian										
2022	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	109	21.2



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	40	. 40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	54	54	6.9
	African Ame			***						
2022	634	634	****	****	****	****	134.02 (18.88, 951.47)	980	999	273.7
2023	1,006	1,006	****	****	****	****	97.81 (13.78, 694.40)	1,514	1,538	193.4
Multi-ra										
2022	34	34	****	****	****	****	2,219.02 (312.57,	60	61	19.3
							15,753.52)			
2023	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	4.2
	lawaiian or C	-	Islander							
2022	19	19	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	6.7
Unknow	n									
2022	4,058	4,058	****	****	****	****	125.17 (59.67, 262.55)	7,434	7,510	1,698.6
2023	3,948	3,948	****	****	****	****	27.27 (3.84, 193.62)	6,209	6,277	541.4
White										
2022	4,671	4,671	****	****	****	****	88.04 (36.64, 211.52)	7,775	7,864	1,645.2
2023	4,268	4,268	****	****	****	****	305.74 (181.07, 516.23)	6,845	6,978	818.2
	on, Sinus Tac									
	n Indian or A									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Asian										
2022	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	2.7



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Black or	African Ame	rican								
2022	120	120	****	****	****	****	559.77 (78.85, 3,973.99)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	58	58	9.0
Multi-ra	ıcial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	34	14.3
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	1.5
Native F	lawaiian or 0	Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	ın									
2022	179	179	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	9.5
White										
2022	723	723	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,181	1,181	297.0
2023	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	155	155	21.4
Ozempi	c, Sinus Tach	ycardia								
America	n Indian or A	Naska Native	2							
2022	695	695	****	****	****	****	222.31 (55.60, 888.93)	1,100	1,102	260.8
2023	131	131	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	170	173	22.1
Asian										
2022	1,022	1,022	****	****	****	****	62.23 (8.77, 441.82)	1,605	1,607	423.1
2023	371	371	****	****	****	****	232.23 (32.71, 1,648.67)	516	518	65.1
Black or	African Ame	rican								
2022	6,058	6,058	****	****	****	****	194.65 (122.64, 308.95)	9,102	9,130	2,926.5



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023 Multi-ra	3,774	3,774	****	****	****	****	141.35 (63.50, 314.62)	4,994	5,015	685.0
2022 2023	407 409	407 409	**** 0	**** 0.00 (0.00, 0.00)	*****	*****	154.02 (21.70, 1,093.46) 0.00 (0.00, 0.00)	690 559	692 562	253.6 62.4
Native H	lawaiian or C	Other Pacific	Islander				, , ,			
2022	156	156	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	229	229	106.1
2023	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	223	223	31.8
Unknow										
2022	27,580	27,580	****	****	****	****	69.93 (49.45, 98.89)	45,223	45,337	14,467.1
2023	17,787	17,787	****	****	****	****	50.43 (25.22, 100.84)	23,239	23,331	2,166.6
White			****	****	****	ale ale ale ale ale				
2022	43,173	43,173			4 4 4 4 4	****	121.44 (97.41, 151.40)	66,072	66,235	18,069.2
2023	15,268	15,268	****	****	****	****	193.54 (138.29, 270.86)	20,712	20,796	2,783.3
	<mark>s, Sinus Tach</mark> n Indian or A		<u> </u>							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	103	26.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Asian			•	0.00 (0.00) 0.00)			0.00 (0.00) 0.00)			
2022	923	923	****	****	****	****	67.95 (9.57, 482.38)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	210	213	32.8
Black or	African Ame	rican								
2022	2,336	2,336	****	****	****	****	150.51 (62.65, 361.61)	3,335	3,398	1,106.2
2023	1,056	1,056	****	****	****	****	84.99 (11.97, 603.37)	1,351	1,391	205.2
Multi-ra	cial									



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	111	111	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	109	13.8
	lawaiian or (-	Islander							
2022	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	80	13.4
Unknow										
2022	8,899	8,899	****	****	****	****	79.96 (44.28, 144.39)	13,647	13,926	4,494.3
2023	3,889	3,889	****	****	****	****	84.02 (27.10, 260.51)	4,984	5,141	528.3
White										
2022	12,838	12,838	****	****	****	****	92.00 (57.19, 147.99)	19,626	19,980	5,231.90
2023	3,576	3,576	****	****	****	****	167.72 (79.96, 351.81)	4,813	4,953	722.2
	, Sinus Tach									
	n Indian or A					_				
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
	African Ame									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.4
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	50	52	4.6
Multi-ra										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	3.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native F	lawaiian or (Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	'n									
2022	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	928	948	70.2
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	185	188	18.4
Saxenda	a, Sinus Tach	ycardia								
America	ın Indian or A	Naska Native	?							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
Multi-ra	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native F	lawaiian or (Other Pacific	Islander	·			·			
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023 Unknown	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2022	, 298	298	****	****	****	****	233.56 (34.31, 1,729.15)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	6.5
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	15.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
	Sinus Tachy									
		laska Native								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	21.3
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.3
Asian			_		****	****	(
2022	74	74	0	0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00)	95	95	32.7
2023	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25	25	3.2
	African Ame		****	****	****	****	260 07 (00 05 4 420 72)	550	550	102.2
2022 2023	397 159	397			****	****	360.07 (90.05, 1,439.73)	550 100	550	193.2
2023 Multi-rac		159	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	199	199	33.8
2022	37	37	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	57	57	22.5
2022	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	46	46	5.4
		วบ Other Pacific	•	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	40	40	J. 4
2022	****	*****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.7
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.4
Unknown	1		·	2.00 (0.00) 0.00)			3.00 (0.00)			<u>-</u>



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

		Number	Number of Exposure	Number of Exposure Episodes with an Event per 100				Number of Exposure Episode Defining- Dispensings	Number of Exposure Episode Defining- Dispensings (Not	
	Number	of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
2022	1,026	1,026	****	****	****	****	320.13 (133.25, 769.14)	1,555	1,556	514.6
2023	409	409	****	****	****	****	506.90 (126.77, 2,026.88)	521	521	62.3
White										
2022	2,510	2,510	****	****	****	****	80.39 (25.93, 239.27)	3,751	3,751	1,039.7
2023	621	621	****	****	****	****	385.22 (123.23, 1,194.42)	823	823	134.2
	Sinus Tachy									
		laska Native								
2022	234	234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	5.0
Asian										
2022	1,045	1,045	****	****	****	****	59.33 (8.36, 421.23)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	222	223	31.7
Black or A	African Ame	rican								
2022	4,894	4,894	****	****	****	****	195.42 (115.74, 329.96)	8,231	8,302	2,271.0
2023	1,534	1,534	****	****	****	****	223.22 (84.15, 597.42)	2,255	2,269	317.8
Multi-rad	cial									
2022	190	190	****	****	****	****	266.47 (37.53, 1,891.76)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	174	175	17.5
Native H	awaiian or C	Other Pacific	Islander							
2022	145	145	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	156	20.6
Unknowi	n									
2022	15,411	15,411	****	****	****	****	93.39 (63.11, 138.21)	29,665	29,856	7,853.5
2023	6,363	6,363	****	****	****	****	141.14 (73.43, 271.26)	9,664	9,746	894.4



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White										
2022	30,998	30,998	****	****	****	****	96.32 (71.91, 129.00)	55,284	55,582	12,538.3
2023	5,777	5,777	****	****	****	****	126.68 (65.91, 233.47)	8,907	8,985	1,217.2
	y, Sinus Tach									
		Naska Native								
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Black or	African Ame	rican								
2022	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	33	33	4.8
Multi-ra	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native H	lawaiian or (Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	n									
2022	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	4.3
White			-	(,)			3.00 (0.00)			
2022	153	153	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	207	207	67.3



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	94	94	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	121	121	19.3
		tricular Tacl								
		laska Native								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	47	47	7.8
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
Asian										
2022	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	54	54	6.9
Black or A	African Ame	rican								
2022	634	634	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	980	999	273.7
2023	1,006	1,006	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,514	1,538	193.4
Multi-rac	ial									
2022	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	4.2
Native H	awaiian or C	Other Pacific	Islander							
2022	19	19	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	6.7
Unknowr)									
2022	4,058	4,058	****	****	****	****	17.88 (2.52, 126.94)	7,434	7,510	1,698.6
2023	3,948	3,948	****	****	****	****	27.27 (3.84, 193.62)	6,209	6,277	541.4
White							. ,			
2022	4,671	4,671	****	****	****	****	35.22 (8.81, 140.81)	7,775	7,864	1,645.2
2023	4,268	4,268	****	****	****	****	87.35 (32.78, 232.75)	6,845	6,978	818.2
Bydureo		tricular Tach	nycardia						_	



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
		Naska Native								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Asian										
2022	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	2.7
Black or	African Ame	rican								
2022	120	120	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	58	58	9.0
Multi-ra	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	34	14.3
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	1.5
Native H	lawaiian or (Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	'n									
2022	179	179	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	9.5
White			-	(, - /-)				-	-	
2022	723	723	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,181	1,181	297.0
2023	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	155	155	21.4
		ricular Tachy	_							
		laska Native								
2022	695	695	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,100	1,102	260.8



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023 Asian	131	131	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	170	173	22.1
2022 2023	1,022 371	1,022 371	0 ****	0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00) 232.23 (32.71, 1,648.67)	1,605 516	1,607 518	423.1 65.1
Black or A	African Ame	rican					, , , ,			
2022	6,058	6,058	****	****	****	****	43.26 (16.23, 115.25)	9,102	9,130	2,926.5
2023	3,774	3,774	****	****	****	****	70.67 (22.79, 219.13)	4,994	5,015	685.0
Multi-rac	rial									
2022	407	407	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	690	692	253.6
2023	409	409	****	****	****	****	237.73 (34.89, 1,758.70)	559	562	62.4
		Other Pacific								
2022	156	156	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	229	229	106.1
2023	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	223	223	31.8
Unknowr	-									
2022	27,580	27,580	****	****	****	****	26.22 (14.89, 46.18)	45,223	45,337	14,467.1
2023	17,787	17,787	****	****	****	****	37.82 (16.99, 84.19)	23,239	23,331	2,166.6
White			ale ale ale ale ale	****	****	****				
2022	43,173	43,173	****	****	****	****	50.73 (36.06, 71.35)	66,072	66,235	18,069.2
2023	15,268	15,268		****	****	****	56.92 (30.63, 105.79)	20,712	20,796	2,783.3
		<mark>ricular Tach</mark> Jaska Native								
2022	*****	*****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	103	26.9
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Asian			Ü	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			1.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	923	923	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	210	213	32.8
	African Ame		ate ate ate ate	****	****	ale ale ale ale ale	(
2022	2,336	2,336	****			****	30.10 (4.23, 213.70)	3,335	3,398	1,106.2
2023	1,056	1,056	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,351	1,391	205.2
Multi-ra										
2022	111	111	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	109	13.8
	lawaiian or (-	Islander							
2022	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	80	13.4
Unknow										
2022	8,899	8,899	****	****	****	****	14.54 (3.64, 58.13)	13,647	13,926	4,494.3
2023	3,889	3,889	****	****	****	****	28.01 (3.94, 198.83)	4,984	5,141	528.3
White										
2022	12,838	12,838	****	****	****	****	43.29 (21.65, 86.57)	19,626	19,980	5,231.90
2023	3,576	3,576	****	****	****	****	95.84 (35.97, 255.36)	4,813	4,953	722.2
	, Supraventr									
	n Indian or A					_		_	_	
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	_	_	_			_		_		
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Black o	r African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.4
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.6
Multi-ro	acial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.0
Native I	Hawaiian or (Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknov	vn									
2022	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	928	948	70.2
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	18.4
	a, Supravent									
	an Indian or A									
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
	r African Ame									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.5



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023 Multi-ra	*****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
	lawaiian or C	Other Pacific	Islander	0.00 (0.00) 0.00,			0.00 (0.00) 0.00)			
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	n									
2022	298	298	****	****	****	****	233.56 (34.31, 1,729.15)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	6.5
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	15.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
	Supraventri n Indian or A									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	21.3
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.3
Asian			· ·	0.00 (0.00) 0.00)			0.00 (0.00) 0.00)			1.5
2022	74	74	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	95	95	32.7
2023	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25	25	3.2
Black or	African Ame	rican								
2022	397	397	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	550	550	193.2
2023	159	159	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	199	199	33.8
Multi-ra	cial									



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	37	37	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	46	46	5.4
	awaiian or (****	Other Pacific ****		0.00 (0.00 0.00)	****	****	0.00 (0.00 0.00)	****	****	
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.7
2023		****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	* * * * *	* * * * *	1.4
Unknowi		4.026	****	****	****	****	420.05 /22.02 542.02\	4 555	4.556	F44.6
2022	1,026	1,026			****	****	128.05 (32.02, 512.02)	1,555 521	1,556	514.6
2023 White	409	409	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	521	521	62.3
2022	2,510	2,510	****	****	****	****	80.39 (25.93, 239.27)	3,751	3,751	1,039.7
2022	621	621	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	823	823	1,039.7
		icular Tachy	-	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	823	823	134.2
		laska Native								
2022	234	234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	5.0
Asian										
2022	1,045	1,045	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	222	223	31.7
Black or	African Ame	rican								
2022	4,894	4,894	****	****	****	****	13.96 (1.97, 99.10)	8,231	8,302	2,271.0
2023	1,534	1,534	****	****	****	****	56.05 (7.90, 397.95)	2,255	2,269	317.8
Multi-ra	cial									
2022	190	190	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	174	175	17.5



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native H	lawaiian or (Other Pacific	Islander							
2022	145	145	****	****	****	****	376.00 (52.96, 2,669.37)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	156	20.6
Unknow	n									
2022	15,411	15,411	****	****	****	****	33.62 (17.49, 64.62)	29,665	29,856	7,853.5
2023	6,363	6,363	****	****	****	****	15.68 (2.21, 111.33)	9,664	9,746	894.4
White										
2022	30,998	30,998	****	****	****	****	51.37 (34.43, 76.64)	55,284	55,582	12,538.3
2023	5,777	5,777	****	****	****	****	56.30 (21.13, 150.01)	8,907	8,985	1,217.2
Xultoph	y, Supravent	ricular Tach	ycardia							
America	n Indian or A	laska Native	?							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Black or	African Ame	rican								
2022	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	33	33	4.8
Multi-ra	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native H	lawaiian or (Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023 Unknown	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2022	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	19.7
2023 White	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	4.3
2022	153	153	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	207	207	67.3
2023	94	94	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	121	121	19.3
	o, Other Ta									
		Maska Native								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	47	47	7.8
2023 Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.1
2022	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	54	54	6.9
Black or A	African Ame	rican					. , ,			
2022	634	634	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	980	999	273.7
2023	1,006	1,006	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,514	1,538	193.4
Multi-rac	ial									
2022	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	4.2
Native H	awaiian or (Other Pacific	Islander							
2022	19	19	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	6.7
Unknown	1									



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	4,058	4,058	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,434	7,510	1,698.6
2023	3,948	3,948	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,209	6,277	541.4
White	•	•		. , ,				•	•	
2022	4,671	4,671	****	****	****	****	17.61 (2.48, 125.01)	7,775	7,864	1,645.2
2023	4,268	4,268	****	****	****	****	87.35 (32.78, 232.75)	6,845	6,978	818.2
	n, Other Tac									
		Naska Native	?							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Asian										
2022	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	2.7
Black or A	African Ame	rican								
2022	120	120	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	58	58	9.0
Multi-rac	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	34	14.3
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	1.5
Native H	awaiian or C	Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknowr	1									
2022	179	179	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	9.5



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White										
2022	723	723	****	****	****	****	198.13 (49.55, 792.25)	1,181	1,181	297.0
2023	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	155	155	21.4
	Other Tack									
		laska Native		()	ala ala ala ala ala	ale ale ale ale ale	()			
2022	695	695	0	0.00 (0.00, 0.00)	****	*****	0.00 (0.00, 0.00)	1,100	1,102	260.8
2023	131	131	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	170	173	22.1
Asian										
2022	1,022	1,022	****	****	****	****	62.23 (8.77, 441.82)	1,605	1,607	423.1
2023	371	371	****	****	****	****	232.23 (32.71, 1,648.67)	516	518	65.1
	African Ame									
2022	6,058	6,058	****	****	****	****	43.26 (16.23, 115.25)	9,102	9,130	2,926.5
2023	3,774	3,774	****	****	****	****	94.23 (35.37, 251.07)	4,994	5,015	685.0
Multi-rac	ial									
2022	407	407	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	690	692	253.6
2023	409	409	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	559	562	62.4
Native H	awaiian or C	Other Pacific	Islander							
2022	156	156	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	229	229	106.1
2023	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	223	223	31.8
Unknowr)									
2022	27,580	27,580	****	****	****	****	8.74 (3.28, 23.29)	45,223	45,337	14,467.1
2023	17,787	17,787	****	****	****	****	6.30 (0.89, 44.75)	23,239	23,331	2,166.6
White										
2022	43,173	43,173	27	0.06 (0.04, 0.09)	****	****	41.50 (28.46, 60.52)	66,072	66,235	18,069.2



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	15,268	15,268	11	0.07 (0.03, 0.11)	****	****	62.61 (34.68, 113.07)	20,712	20,796	2,783.3
	Other Tack	nycardia Jaska Native								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	103	26.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Asian			· ·	0.00 (0.00) 0.00)			0.00 (0.00) 0.00)			1.0
2022	923	923	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	210	213	32.8
Black or	African Ame	rican								
2022	2,336	2,336	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,335	3,398	1,106.2
2023	1,056	1,056	****	****	****	****	84.99 (11.97, 603.37)	1,351	1,391	205.2
Multi-ra	cial									
2022	111	111	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	109	13.8
Native H	awaiian or C	Other Pacific								
2022	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	80	13.4
Unknow										
2022	8,899	8,899	****	****	****	****	7.27 (1.02, 51.61)	13,647	13,926	4,494.3
2023	3,889	3,889	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,984	5,141	528.3
White										
2022	12,838	12,838	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19,626	19,980	5,231.90
2023	3,576	3,576	****	****	****	****	71.88 (23.18, 222.87)	4,813	4,953	722.2
wegovy	Other Tach	ycardia								



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
America	n Indian or A	laska Native	?							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.4
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	50	52	4.6
Multi-ra	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	3.0
Native H	awaiian or C	Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	n									
2022	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	928	948	70.2
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	185	188	18.4
	, Other Tach									
	n Indian or A	laska Native	2							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023 Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
	African Ame	•	•		0.0	Ū		· ·	·	0.0
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
Multi-ra	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native H	lawaiian or (Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	n									
2022	298	298	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	6.5
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	15.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
	Other Tachy									
		Naska Native								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	21.3
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.3
Asian										



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	74	74	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	95	95	32.7
2023	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25	25	3.2
	African Ame									
2022	397	397	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	550	550	193.2
2023	159	159	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	199	199	33.8
Multi-rad										
2022	37	37	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	46	46	5.4
		Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.7
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.4
Unknowi										
2022	1,026	1,026	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,555	1,556	514.6
2023	409	409	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	521	521	62.3
White										
2022	2,510	2,510	****	****	****	****	53.60 (13.40, 214.30)	3,751	3,751	1,039.7
2023	621	621	****	****	****	****	128.41 (18.09, 911.59)	823	823	134.2
	Other Tach	-								
		laska Native		0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	440	4.42	06.0
2022	234	234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	ተጥጥጥ	** * * * * *	0.00 (0.00, 0.00)	39	39	5.0
Asian	4.045	4.045	0	0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	4.025	4.024	400.0
2022	1,045	1,045	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	222	223	31.7



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Black or	African Ame	rican								
2022	4,894	4,894	****	****	****	****	27.92 (6.98, 111.63)	8,231	8,302	2,271.0
2023	1,534	1,534	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,255	2,269	317.8
Multi-ra	ıcial									
2022	190	190	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	174	175	17.5
Native H	Hawaiian or C	Other Pacific	Islander							
2022	145	145	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	156	20.6
Unknow	ın									
2022	15,411	15,411	****	****	****	****	7.47 (1.87, 29.87)	29,665	29,856	7,853.5
2023	6,363	6,363	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,664	9,746	894.4
White										
2022	30,998	30,998	****	****	****	****	25.68 (14.59, 45.23)	55,284	55,582	12,538.3
2023	5,777	5,777	****	****	****	****	70.38 (29.29, 169.08)	8,907	8,985	1,217.2
	y, Other Tac									
	ın Indian or A									
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Black or	African Ame	rican								
2022	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	10.7



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023 Multi-rai	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	33	33	4.8
2022	*****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
	awaiian or (Other Pacific	•	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.0
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	n									
2022	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	4.3
White										
2022	153	153	****	****	****	****	377.83 (53.22, 2,682.35)	207	207	67.3
2023	94	94	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	121	121	19.3
	o, Cardiac A									
	n Indian or A ****	llaska Native		0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	47	47	7.0
2022 2023	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	47 ****	47 ****	7.8 1.1
2025 Asian			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			1.1
2022	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	109	21.2
2022	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	54	54	6.9
	African Ame		Ü	0.00 (0.00, 0.00)			3.00 (0.00, 0.00)	5 4	54	0.5
2022	634	634	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	980	999	273.7
2023	1,006	1,006	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,514	1,538	193.4
Multi-ra	· ·									



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	4.2
		Other Pacific								
2022	19	19	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	6.7
Unknow										
2022	4,058	4,058	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,434	7,510	1,698.6
2023	3,948	3,948	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,209	6,277	541.4
White										
2022	4,671	4,671	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,775	7,864	1,645.2
2023	4,268	4,268	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,845	6,978	818.2
	n, Cardiac A									
	n inaian or A ****	Maska Native		0.00 (0.00, 0.00)	****	****	0.00.(0.00.0.00)	****	****	1.0
2022 2023	****	****	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	1.9 0.7
2023 Asian			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.7
	20	20	0	0.00 (0.00, 0.00)	****	****	0.00.(0.00.0.00)	F2	Г2	16.0
2022	29 15	29 15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	16.0
2023	15 African Ame		0	0.00 (0.00, 0.00)	10 010 010 010	20 10 10 10 10	0.00 (0.00, 0.00)	22	22	2.7
	-		0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	107	107	64.0
2022 2023	120	120	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	197	197	64.0
2023 Multi-ra	45	45	0	0.00 (0.00, 0.00)	10 010 010 010	20 10 10 10 10	0.00 (0.00, 0.00)	58	58	9.0
2022	*****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	34	14.3
	****	****	0	• • •	****	****	• • •			
2023			0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	13	13	1.5



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native H	lawaiian or C	_	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	n									
2022	179	179	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	9.5
White										
2022	723	723	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,181	1,181	297.0
2023	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	155	155	21.4
	c, Cardiac Ar									
	n Indian or A									
2022	695	695	****	****	****	****	111.16 (15.66, 789.14)	1,100	1,102	260.8
2023	131	131	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	170	173	22.1
Asian										
2022	1,022	1,022	****	****	****	****	62.23 (8.77, 441.82)	1,605	1,607	423.1
2023	371	371	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	516	518	65.1
Black or	African Ame	rican								
2022	6,058	6,058	****	****	****	****	10.81 (1.52, 76.77)	9,102	9,130	2,926.5
2023	3,774	3,774	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,994	5,015	685.0
Multi-ra	cial									
2022	407	407	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	690	692	253.6
2023	409	409	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	559	562	62.4
Native H	lawaiian or C	Other Pacific	Islander							
2022	156	156	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	229	229	106.1



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023 Unknowr	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	223	223	31.8
2022 2023	27,580 17,787	27,580 17,787	****	****	****	*****	4.37 (1.09, 17.48) 6.30 (0.89, 44.75)	45,223 23,239	45,337 23,331	14,467.1 2,166.6
White 2022	43,173	43,173	****	****	****	****	16.91 (9.36, 30.53)	66,072	66,235	18,069.2
2022 2023	45,175 15,268	45,175 15,268	****	****	****	****	5.69 (0.80, 40.41)	20,712	20,796	2,783.3
Rybelsus	, Cardiac Ar	rest	_		_	_		_	_	_
		Naska Native								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	103	26.9
2023 Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
2022	923	923	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	210	213	32.8
	African Ame	rican								
2022	2,336	2,336	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,335	3,398	1,106.2
2023	1,056	1,056	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,351	1,391	205.2
Multi-rac										
2022	111	111	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	109	13.8
		Other Pacific	Islander							
2022	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	80	13.4
Unknowr	1									



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

by Nace	ana rear									
	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	8,899	8,899	****	****	****	****	7.27 (1.02, 51.61)	13,647	13,926	4,494.3
2023	3,889	3,889	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,984	5,141	528.3
White										
2022	12,838	12,838	****	****	****	****	5.41 (0.76, 38.42)	19,626	19,980	5,231.90
2023	3,576	3,576	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,813	4,953	722.2
	Cardiac Arr									
Americai	n Indian or A	laska Native								
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or .	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.4
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	50	52	4.6
Multi-rad	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	3.0
Native H	awaiian or C	Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknowi	n									
2022	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	928	948	70.2



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	185	188	18.4
	, Cardiac Ar									
		Naska Native								
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
Multi-ra	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native H	awaiian or (Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	n									
2022	298	298	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	6.5
White				. , ,						
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	35	35	15.6



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	*****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
	Cardiac Arre	e st Maska Native	3							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	21.3
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.3
Asian			O	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			1.5
2022	74	74	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	95	95	32.7
2023	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25	25	3.2
	African Ame		Ü	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	23	23	3.2
2022	397	397	****	****	****	****	180.03 (25.36, 1,278.11)	550	550	193.2
2023	159	159	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	199	199	33.8
Multi-ra			•	0.00 (0.00) 0.00)			0.00 (0.00) 0.00			33.3
2022	37	37	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	46	46	5.4
Native H	awaiian or C	Other Pacific	Islander	, , ,						
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.7
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.4
Unknow	n									
2022	1,026	1,026	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,555	1,556	514.6
2023	409	409	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	521	521	62.3
White										
2022	2,510	2,510	****	****	****	****	53.60 (13.40, 214.30)	3,751	3,751	1,039.7
2023	621	621	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	823	823	134.2
Trulicity	, Cardiac Arr	est								



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
America	n Indian or A	Naska Native								
2022	234	234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	5.0
Asian										
2022	1,045	1,045	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	222	223	31.7
Black or	African Ame	rican								
2022	4,894	4,894	****	****	****	****	13.96 (1.97, 99.10)	8,231	8,302	2,271.0
2023	1,534	1,534	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,255	2,269	317.8
Multi-ra	cial									
2022	190	190	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	174	175	17.5
Native H	awaiian or (Other Pacific	Islander							
2022	145	145	****	****	****	****	376.00 (52.96, 2,669.37)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	156	20.6
Unknow	n									
2022	15,411	15,411	****	****	****	****	3.74 (0.53, 26.52)	29,665	29,856	7,853.5
2023	6,363	6,363	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,664	9,746	894.4
White										
2022	30,998	30,998	****	****	****	****	17.12 (8.56, 34.23)	55,284	55,582	12,538.3
2023	5,777	5,777	****	****	****	****	14.08 (1.98, 99.92)	8,907	8,985	1,217.2
Xultoph	y, Cardiac Aı	rrest								
America	n Indian or A	Naska Native	2							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

Asian Second Color Second Colo		Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022 ***** ***** 0		****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
2023 ***** ***** 0		****	****	0	0.00 (0.00 0.00)	****	****	0.00.(0.00.0.00)	****	****	2.5
Black or African American		****	****		, , ,	****	****	, , ,	****	****	
2022 18		African Ame	rican	Ü	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.0
2023 22 22 0 0.0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 33 33 4.8 Multi-racial 2022 ***** ***** 0 0.00 (0.00, 0.00) **** ***** 0.00 (0.00, 0.00) **** **** 0.5 2023 **** **** 0 0.00 (0.00, 0.00) **** 0.00 (0.00, 0.00) **** 0.00 Native Hawaiian or Other Pacific Islander 2022 **** **** 0 0.00 (0.00, 0.00) **** 0.00 (0.00, 0.00) **** 0.00 2023 0 0 0 0 0 NaN 0.0 0 NaN 0.0 0 NaN 0 0 0 0.00 Unknown 2022 38 38 0 0.000 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 52 52 19.7 2023 25 25 0 0.000 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 32 32 4.3 White 2022 153 153 0 0.000 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 207 207 67.3 2023 94 94 0 0.000 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 121 121 19.3 Mounjaro, Ventricular Tachycardia American Indian or Alaska Native 2022 **** **** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) **** **** 1.1		=		0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	10.7
2022 ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) **** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ******* 0.0		22	22		, , ,	****	****	• • • •			4.8
2023 ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 0.00 (0.00, 0.00) ****** 0.00	Multi-ra	cial									
Native Hawaiian or Other Pacific Islander 2022 ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** **** 0.9 2023 0 0 0 0 NaN 0.0 0 NaN 0.0 0 0 0.00 Unknown 2022 38 38 0 0.000 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 52 52 19.7 2023 25 25 0 0.000 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 32 32 32 4.3 White 2022 153 153 0 0.000 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 207 207 67.3 2023 94 94 0 0.000 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 121 121 19.3 Mounjaro, Ventricular Tachycardia American Indian or Alaska Native 2022 **** ***** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) 47 47 7.8 2023 **** ***** 0 0.00 (0.00, 0.00) **** **** 0.00 (0.00, 0.00) ***** 1.1	2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2022 ****** ****** 0 0.00 (0.00, 0.00) ****** ****** 0.9 2023 0 0 0 NaN 0.0 0 NaN 0 0 0.00 Unknown 0 0 0.00 (0.00, 0.00) ****** ******* 0.00 (0.00, 0.00) 52 52 19.7 2022 38 38 0 0.00 (0.00, 0.00) ****** ****** 0.00 (0.00, 0.00) 52 52 19.7 2023 25 25 0 0.00 (0.00, 0.00) ****** ****** 0.00 (0.00, 0.00) 32 32 4.3 White 2022 153 153 0 0.00 (0.00, 0.00) *************************** 0.00 (0.00, 0.00) 207 207 67.3 2023 94 94 0 0.00 (0.00, 0.00) ******************* 0.00 (0.00, 0.00) 121 121 19.3 Mounjaro, Ventricular Tachycardia 2022 ****** ******** 0 0.00 (0.00, 0.00) ************ 0.00 (0.00, 0.00) <t< td=""><td>2023</td><td>****</td><td>****</td><td>0</td><td>0.00 (0.00, 0.00)</td><td>****</td><td>****</td><td>0.00 (0.00, 0.00)</td><td>****</td><td>****</td><td>0.0</td></t<>	2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
2023	Native F	lawaiian or (Other Pacific	Islander							
Unknown 2022 38 38 0 0.00 (0.00, 0.00) ****** ***** ***** ***** ***** ***** ****	2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
2022 38 38 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 52 52 19.7 2023 25 25 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 32 32 4.3 White 2022 153 153 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 207 207 67.3 2023 94 94 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 121 121 19.3 Mounjaro, Ventricular Tachycardia American Indian or Alaska Native 2022 ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 47 47 47 7.8 2023 ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** 1.1	2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023 25 25 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 32 32 4.3 White 2022 153 153 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 207 207 67.3 2023 94 94 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 121 121 121 19.3 Mounjaro, Ventricular Tachycardia American Indian or Alaska Native 2022 ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 47 47 47 7.8 2023 ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 1.1	•	n									
White 2022 153 153 0 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) 207 207 67.3 2023 94 94 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 121 121 121 19.3 Mounjaro, Ventricular Tachycardia American Indian or Alaska Native 2022 ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 47 47 7.8 2023 ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 1.1				0	, , ,						_
2022 153 153 0 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) 207 207 67.3 2023 94 94 0 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) 121 121 121 19.3 Mounjaro, Ventricular Tachycardia American Indian or Alaska Native 2022 ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 47 47 7.8 2023 ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 1.1		25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	4.3
2023 94 94 0 0.00 (0.00, 0.00) ***** **** 0.00 (0.00, 0.00) 121 121 121 19.3 Mounjaro, Ventricular Tachycardia American Indian or Alaska Native 2022 **** **** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 47 47 7.8 2023 **** ***** 0 0.00 (0.00, 0.00) ***** ***** 1.1											
Mounjaro, Ventricular Tachycardia American Indian or Alaska Native 2022 ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 47 47 7.8 2023 ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** 1.1					, , ,						
American Indian or Alaska Native 2022 ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) 47 47 7.8 2023 ***** ***** 0 0.00 (0.00, 0.00) ****** ***** 1.1					0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	121	121	19.3
2022 ***** ***** 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) 47 47 7.8 2023 ***** ***** 0 0.00 (0.00, 0.00) ***** ***** 0.00 (0.00, 0.00) ***** 1.1											
2023 ***** ***** 0 0.00 (0.00, 0.00) ***** 0.00 (0.00, 0.00) ***** 1.1					0.00 (0.00, 0.00)	****	****	0.00.(0.00.0.00)	47	47	7.0
2025 0 0.00 (0.00) 0.00 (0.00) 1.1					, , ,						
	2023 Asian	and the the the the	and the the the the	U	0.00 (0.00, 0.00)	1	2111-	0.00 (0.00, 0.00)	181 181 181 181	nger nger nger nger	1.1



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number	Number of	Number of Exposure Episodes	Number of Exposure Episodes with an Event per 100 Exposure Episodes	Total	Total	Event Rate per 10,000	Number of Exposure Episode Defining- Dispensings (Adjusted for	Number of Exposure Episode Defining- Dispensings (Not Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)	at Risk	at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
2022	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	54	54	6.9
	African Ame									
2022	634	634	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	980	999	273.7
2023	1,006	1,006	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,514	1,538	193.4
Multi-ra	cial									
2022	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	4.2
Native H	awaiian or C	Other Pacific	Islander							
2022	19	19	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	6.7
Unknow	n									
2022	4,058	4,058	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,434	7,510	1,698.6
2023	3,948	3,948	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,209	6,277	541.4
White										
2022	4,671	4,671	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,775	7,864	1,645.2
2023	4,268	4,268	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,845	6,978	818.2
	n, Ventricul									
	n Indian or A									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Asian										
2022	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	2.7



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Black o	r African Ame	rican								
2022	120	120	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	58	58	9.0
Multi-re	acial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	34	14.3
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	1.5
Native	Hawaiian or (Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknov	vn									
2022	179	179	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	9.5
White										
2022	723	723	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,181	1,181	297.0
2023	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	155	155	21.4
	<u>ic, Ventricula</u>									
	an Indian or A			(ala ala ala ala ala	****	()			
2022	695	695	0	0.00 (0.00, 0.00)	****		0.00 (0.00, 0.00)	1,100	1,102	260.8
2023	131	131	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	170	173	22.1
Asian	4	4 655	-	0.00/0.55 5.55	المحاجبات بالد	ماد ماد مان وان وان	0.00 (0.00 0.00)	4 65-	4 65-	405 :
2022	1,022	1,022	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,605	1,607	423.1
2023	371	. 371	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	516	518	65.1
	r African Ame				distributed to					
2022	6,058	6,058	****	****	****	****	21.63 (5.41, 86.48)	9,102	9,130	2,926.5



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023 Multi-ra	3,774	3,774	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,994	5,015	685.0
2022	407	407	****	****	****	****	154.02 (21.70, 1,093.46)	690	692	253.6
2023	409	409	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	559	562	62.4
Native F	ławaiian or C	Other Pacific	Islander							
2022	156	156	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	229	229	106.1
2023	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	223	223	31.8
Unknow										
2022	27,580	27,580	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45,223	45,337	14,467.1
2023	17,787	17,787	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23,239	23,331	2,166.6
White										
2022	43,173	43,173	****	****	****	****	6.15 (2.31, 16.38)	66,072	66,235	18,069.2
2023	15,268	15,268	. 0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20,712	20,796	2,783.3
	<mark>s, Ventricula</mark> In Indian or A									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	103	26.9
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
Asian			Ü	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			1.0
2022	923	923	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	210	213	32.8
Black or	African Ame	rican								
2022	2,336	2,336	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,335	3,398	1,106.2
2023	1,056	1,056	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,351	1,391	205.2
Multi-ra	cial									



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	111	111	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	109	13.8
		Other Pacific	Islander							
2022	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	80	13.4
Unknowi	1									
2022	8,899	8,899	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13,647	13,926	4,494.3
2023	3,889	3,889	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,984	5,141	528.3
White										
2022	12,838	12,838	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19,626	19,980	5,231.90
2023	3,576	3,576	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,813	4,953	722.2
Wegovy,	Ventricular	Tachycardia	a							
		laska Native								
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or A	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.4
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	50	52	4.6
Multi-rad	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	3.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native F	lawaiian or (Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	n									
2022	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	928	948	70.2
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	185	188	18.4
Saxenda	, Ventricula	r Tachycardi	а							
America	n Indian or A	laska Native	2							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or	African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
Multi-ra	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native F	lawaiian or (Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023 Unknowr	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2022 2023	298 44	298 44	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	*****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	470 56	470 56	165.4 6.5
White			-	(,,			(0.00)			
2022 2023	****	****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35 ****	35 ****	15.6 1.0
		Tachycardia	0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			1.0
		laska Native								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	21.3
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.3
Asian				0.00 (0.00 0.00)	****	****	0.00 (0.00 0.00)	0.5	0.5	22.7
2022	74 18	74 18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	95 25	95 35	32.7
2023 Black or A	18 African Ame		0	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	25	25	3.2
2022	397	397	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	550	550	193.2
2023	159	159	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	199	199	33.8
Multi-rac	ial									
2022	37	37	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	46	46	5.4
Native H	awaiian or (Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.7
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.4
Unknowr)									



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

				Number of Exposure				Number of Exposure Episode	Number of Exposure Episode	
			Number of	Episodes with an				Defining-	Defining-	
		Number	Exposure	Event per 100				Dispensings	Dispensings (Not	
	Number	of	Episodes	Exposure Episodes	Total	Total	Event Rate per 10,000	(Adjusted for	Adjusted for	Total
	of	Exposure	with an	(95% Confidence	Years	Days	Patient-Years at Risk (95%	Same-Day	Same-Day	Observable
	Patients	Episodes	Event	Interval)		at Risk	Confidence Interval)	Dispensings)	Dispensings)	Years
2022	1,026	1,026	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,555	1,556	514.6
2023	409	409	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	521	521	62.3
White										
2022	2,510	2,510	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,751	3,751	1,039.7
2023	621	621	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	823	823	134.2
		Tachycardia								
		laska Native								
2022	234	234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	5.0
Asian										
2022	1,045	1,045	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	222	223	31.7
Black or	African Ame	rican								
2022	4,894	4,894	****	****	****	****	13.96 (1.97, 99.10)	8,231	8,302	2,271.0
2023	1,534	1,534	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,255	2,269	317.8
Multi-ra	cial									
2022	190	190	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	174	175	17.5
Native H	awaiian or C	Other Pacific	Islander							
2022	145	145	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	156	20.6
Unknow	n									
2022	15,411	15,411	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	29,665	29,856	7,853.5
2023	6,363	6,363	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,664	9,746	894.4



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White										
2022	30,998	30,998	****	****	****	****	4.28 (1.07, 17.12)	55,284	55,582	12,538.3
2023	5,777	5,777	. 0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	8,907	8,985	1,217.2
		r Tachycard								
		Naska Native		NaN	0.0	0	NIONI	0	0	0.0
2022	0 ****	0 ****	0		0.0 ****	0 ****	NaN	0 ****	0 ****	0.0
2023	****	4. 4. 4. 4. 4.	0	0.00 (0.00, 0.00)	4.4.4.4.4.	4. 4. 4. 4.	0.00 (0.00, 0.00)	4 4 4 4		0.4
Asian	****	****		0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
2023			0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
	African Ame		_	/						
2022	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	33	33	4.8
Multi-rac										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
		Other Pacific								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown)									
2022	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	32	32	4.3
White										
2022	153	153	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	207	207	67.3



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	94	94	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	121	121	19.3
		<mark>ar Fibrillatio</mark> Jaska Native	n and Flutter							
2022	*****	*****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	47	47	7.8
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	7.8 1.1
Asian			Ü	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			1.1
2022	68	68	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	54	54	6.9
	 African Ame	_	· ·	0.00 (0.00) 0.00)			0.00 (0.00) 0.00)	3.	3.	0.5
2022	634	634	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	980	999	273.7
2023	1,006	1,006	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,514	1,538	193.4
Multi-rad	cial									
2022	34	34	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	4.2
Native H	awaiian or C	Other Pacific	Islander							
2022	19	19	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	60	61	6.7
Unknowi	1									
2022	4,058	4,058	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	7,434	7,510	1,698.6
2023	3,948	3,948	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,209	6,277	541.4
White										
2022	4,671	4,671	****	****	****	****	17.61 (2.48, 125.01)	7,775	7,864	1,645.2
2023	4,268	4,268	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	6,845	6,978	818.2
Bydureo	n, Ventricul	ar Fibrillatio	n and Flutter							



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
	n Indian or A									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.9
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.7
Asian										
2022	29	29	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	22	22	2.7
Black or	African Ame	rican								
2022	120	120	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	58	58	9.0
Multi-ra	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	34	34	14.3
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13	13	1.5
Native H	lawaiian or (Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	n									
2022	179	179	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	9.5
White										
2022	723	723	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,181	1,181	297.0
2023	110	110	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	155	155	21.4
Ozempi	c, Ventricula	r Fibrillation	and Flutter					_	_	_
America	n Indian or A	Naska Native	?							
2022	695	695	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,100	1,102	260.8



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023 Asian	131	131	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	170	173	22.1
2022 2023	1,022 371	1,022 371	0 0	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00) 0.00 (0.00, 0.00)	1,605 516	1,607 518	423.1 65.1
	371 African Ame	_	U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)	310	210	65.1
2022	6,058	6,058	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,102	9,130	2,926.5
2023	3,774	3,774	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,994	5,015	685.0
Multi-ra	cial									
2022	407	407	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	690	692	253.6
2023	409	409	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	559	562	62.4
		Other Pacific	Islander							
2022	156	156	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	229	229	106.1
2023	177	177	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	223	223	31.8
Unknow	-									
2022	27,580	27,580	****	****	****	****	2.19 (0.31, 15.51)	45,223	45,337	14,467.1
2023	17,787	17,787	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	23,239	23,331	2,166.6
White			ale ale ale ale ale	****	****	ala ala ala ala ala				
2022	43,173	43,173	****	****	****	*****	3.07 (0.77, 12.29)	66,072	66,235	18,069.2
2023	15,268	15,268		****	****	****	5.69 (0.80, 40.41)	20,712	20,796	2,783.3
		<u>r Fibrillation</u> Jaska Native	and Flutter							
2022	*****	*****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	100	103	26.9
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
2025 Asian			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			1.0
, .51411										



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)		Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	923	923	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	210	213	32.8
	African Ame									
2022	2,336	2,336	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,335	3,398	1,106.2
2023	1,056	1,056	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,351	1,391	205.2
Multi-ra										
2022	111	111	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	106	109	13.8
		Other Pacific	Islander							
2022	70	70	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	74	80	13.4
Unknow										
2022	8,899	8,899	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	13,647	13,926	4,494.3
2023	3,889	3,889	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,984	5,141	528.3
White										
2022	12,838	12,838	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	19,626	19,980	5,231.90
2023	3,576	3,576	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,813	4,953	722.2
		Fibrillation								
		llaska Native			0.0			•	0	0.0
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2022	-	0	0			-		0	•	
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Black o	r African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.4
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	50	52	4.6
Multi-ro	acial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	26	26	3.0
Native I	Hawaiian or (Other Pacific	Islander							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknov	vn									
2022	62	62	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	928	948	70.2
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.8
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	185	188	18.4
Saxend	a, Ventricula	r Fibrillation	and Flutter							
Americo	an Indian or A	laska Native	2							
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black o	r African Ame	rican								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	4.5



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.6
Multi-ra 2022	*****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.6
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
	lawaiian or C	Other Pacific	-	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			0.0
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknow	ın									
2022	298	298	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	6.5
White										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	15.6
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.0
	Ventricular									
America 2022	n Indian or A	*******	? O	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	76	76	21.3
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	/b ****	/b ****	1.3
2023 Asian			U	0.00 (0.00, 0.00)			0.00 (0.00, 0.00)			1.5
2022	74	74	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	95	95	32.7
2023	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	25	25	3.2
	African Ame		•	()			()			-
2022	397	397	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	550	550	193.2
2023	159	159	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	199	199	33.8
Multi-ra	cial									



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk		Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	37	37	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	46	46	5.4
		Other Pacific								
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	5.7
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.4
Unknow										
2022	1,026	1,026	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,555	1,556	514.6
2023	409	409	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	521	521	62.3
White										
2022	2,510	2,510	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	3,751	3,751	1,039.7
2023	621	621	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	823	823	134.2
		Fibrillation								
		llaska Native		0.00 (0.00 0.00)	****	****	0.00 (0.00, 0.00)	440	4.42	00.0
2022	234	234	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39	39	5.0
Asian	4.045	4.045		0.00 (0.00 0.00)	****	****	0.00 (0.00 0.00)	4.005	4 004	400.0
2022	1,045	1,045	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	222	223	31.7
	African Ame		_	/						
2022	4,894	4,894	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	8,231	8,302	2,271.0
2023	1,534	1,534	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,255	2,269	317.8
Multi-ra										
2022	190	190	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	174	175	17.5



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native H	lawaiian or (Other Pacific	Islander							
2022	145	145	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	154	156	20.6
Unknow	n									
2022	15,411	15,411	****	****	****	****	7.47 (1.87, 29.87)	29,665	29,856	7,853.5
2023	6,363	6,363	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	9,664	9,746	894.4
White										
2022	30,998	30,998	****	****	****	****	4.28 (1.07, 17.12)	55,284	55,582	12,538.3
2023	5,777	5,777	****	****	****	****	14.08 (1.98, 99.92)	8,907	8,985	1,217.2
			n and Flutter							
	n Indian or A	laska Native								
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian										
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.8
Black or	African Ame	rican								
2022	18	18	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	33	33	4.8
Multi-ra	cial									
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
2023	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.0
Native H	lawaiian or (Other Pacific	Islander							
2022	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9



Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	0			ter ranj	40 111011	46 11.011	community miles vary	2.5pc565,	2.000	. ca.s
	U	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	-	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown 2022	-	0 38	0	NaN 0.00 (0.00, 0.00)	0.0 ****	0 ****	NaN 0.00 (0.00, 0.00)	0 52	0 52	0.0
		-	-			****			-	
2022	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	19.7
2022 2023	38	38	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	52	52	19.7

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

^{*}NaN: Not a number



Table 10. Summary of Time to End of At-Risk Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

							Number o	f Episodes	by Episode	Length					
	Total	0-30	days	31-60) days	61-90	days	91-18	3 days	184-36	5 days	366-45	55 days	456+	- days
	Number		Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
	of	Number of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes
Bydureon	1,321	727	55.0%	236	17.9%	223	16.9%	115	8.7%	20	1.5%	0	0.0%	0	0.0%
Mounjaro	18,842	10,973	58.2%	4,395	23.3%	2,202	11.7%	1,169	6.2%	103	0.5%	0	0.0%	0	0.0%
Ozempic	117,008	54,789	46.8%	30,804	26.3%	18,795	16.1%	10,850	9.3%	1,756	1.5%	14	0.0%	0	0.0%
Rybelsus	34,058	19,925	58.5%	5,505	16.2%	5,228	15.4%	2,835	8.3%	****	1.6%	****	0.0%	0	0.0%
Saxenda	386	5,354	58.3%	72	18.7%	53	13.7%	****	8.5%	****	0.8%	0	0.0%	0	0.0%
Trulicity	66,978	32,227	48.1%	14,173	21.2%	11,634	17.4%	7,509	11.2%	1,423	2.1%	12	0.0%	0	0.0%
Victoza	5,354	2,728	51.0%	1,213	22.7%	846	15.8%	481	9.0%	****	1.6%	****	0.0%	0	0.0%
Wegovy	828	554	66.9%	193	23.3%	****	8.6%	****	1.2%	0	0.0%	0	0.0%	0	0.0%
Xultophy	364	165	45.3%	62	17.0%	85	23.4%	****	11.8%	****	2.5%	0	0.0%	0	0.0%

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 10. Summary of Time to End of At-Risk Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

				Distributio	n of At-Risk 1	Γime in Days, by Episo	de	
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard
Bydureon	1,321	1	27	28	70	344	49.3	40.4
Mounjaro	18,842	1	27	27	53	344	41.9	31.5
Ozempic	117,008	1	27	38	65	383	50.7	40.4
Rybelsus	34,058	1	29	29	62	380	50.1	41.5
Saxenda	386	2	29	29	58	277	47.5	36.9
Trulicity	66,978	5,354	27	36	77	383	54.0	44.5
Victoza	5,354	1	29	29	66	369	51.1	42.3
Wegovy	828	1	21	27	45	164	32.2	21.2
Xultophy	364	1	29	36	89	301	57.4	45.7



Table 11. Summary of Time to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		,		,	1	Number of	Episodes	Censored	due to En	d of Expos	ure Episod	de by Epis	ode Lengt	h		
			0-30	days		days		days		3 days		5 days		5 days	456+	days
	Total Number of Episodes	Total Number of Episodes Censored due to End of Exposure Episode ¹		of Total	Number of Episodes	Percent of Total Episodes	Number of Episodes	of Total	Number of Episodes	of Total	Number of Episodes	of Total	Number of Episodes	of Total	Number of Episodes	Percent of Total Episodes
Bydureon	1,321	1,061	583	54.9%	185	17.4%	190	17.9%	88	8.3%	15	1.4%	0	0.0%	0	0.0%
Mounjaro	18,842	13,251	7,868	59.4%	3,028	22.9%	1,554	11.7%	768	5.8%	33	0.2%	0	0.0%	0	0.0%
Ozempic	117,008	85,708	38,597	45.0%	22,686	26.5%	15,146	17.7%	8,272	9.7%	****	1.2%	****	0.0%	0	0.0%
Rybelsus	34,058	27,065	16,334	60.4%	4,047	15.0%	4,287	15.8%	2,085	7.7%	312	1.2%	0	0.0%	0	0.0%
Saxenda	386	5354	193	59.9%	60	18.6%	44	13.7%	****	7.5%	****	0.3%	0	0.0%	0	0.0%
Trulicity	66,978	52,689	25,345	48.1%	10,857	20.6%	9,695	18.4%	5,948	11.3%	844	1.6%	0	0.0%	0	0.0%
Victoza	5,354	4,096	2,049	50.0%	955	23.3%	674	16.5%	362	8.8%	56	1.4%	0	0.0%	0	0.0%
Wegovy	828	403	268	66.5%	102	25.3%	****	7.4%	****	0.7%	0	0.0%	0	0.0%	0	0.0%
Xultophy	364	231	111	46.1%	39	16.2%	61	25.3%	****	9.1%	****	3.3%	0	0.0%	0	0.0%

¹Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 11. Summary of Time to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

					Distribution	of At-Ri	sk Time in Days, b	y Episode	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Exposure Episode ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Bydureon	1,321	1,061	1	27	29	75	238	50.6	37.9
Mounjaro	18,842	13,251	1	27	27	53	344	43.1	27.9
Ozempic	117,008	85,708	1	27	41	69	383	53.3	37.4
Rybelsus	34,058	27,065	1	29	29	59	337	50.2	37.6
Saxenda	386	322	5	29	29	58	186	46.8	31.2
Trulicity	66,978	5,354	1	27	40	79	344	54.8	40.6
Victoza	5,354	4,096	1	29	30	70	302	53.0	39.6
Wegovy	828	403	1	27	27	48	164	36.7	17.6
Xultophy	364	231	2	29	37	89	231	60.0	44.9

¹Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.



Sentinel Distribu	ted Datab	ase from Ma	iy 13, 2022	2 to June 3		(= :			•				- · ·			
		Total Number of		days		er of Episc) days		ored due t days		nce of Ou 3 days		Interest b		Length 55 days	456+	days
	Total	Episodes Censored due to Occurrence														
	Number of	of Outcome	Number of	Percent of Total	Number of	Percent of Total	Number of	Percent of Total	Number of	Percent of Total	Number of	Percent of Total	Number of	Percent of Total	Number of	Percent of Total
		of Interest ¹	_		_										_	
Bydureon, Hospitalized Tachyarrhythmi	1,321	****	****	71.4%	****	14.3%	0	0.0%	****	14.3%	0	0.0%	0	0.0%	0	0.0%
Mounjaro, Hospitalized Tachyarrhythmi	18,842	102	66	64.7%	22	21.6%	****	10.8%	****	2.9%	0	0.0%	0	0.0%	0	0.0%
Ozempic, Hospitalized Tachyarrhythmi	117,008	793	435	54.9%	208	26.2%	85	10.7%	****	6.9%	****	1.3%	0	0.0%	0	0.0%
Rybelsus, Hospitalized Tachyarrhythmi	34,058	178	102	57.3%	47	26.4%	****	10.7%	****	5.6%	0	0.0%	0	0.0%	0	0.0%
Saxenda, Hospitalized Tachyarrhythmi	386	5354	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Trulicity, Hospitalized Tachyarrhythmi	66,978	496	300	60.5%	99	20.0%	50	10.1%	****	8.3%	****	1.2%	0	0.0%	0	0.0%
Victoza, Hospitalized Tachyarrhythmi	5,354	45	25	55.6%	****	17.8%	****	8.9%	****	17.8%	0	0.0%	0	0.0%	0	0.0%
Wegovy, Hospitalized Tachyarrhythmi	828	****	0	0.0%	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%



Sentinel Distribu	ted Datab	ase from Ma	y 13, 202	2 to June 3												
												Interest b				
		Total Number of Episodes Censored due to		days	31-60) days	61-90) days	91-18	3 days	184-36	55 days	366-45	55 days	456+	· days
	Total	Occurrence of		D	NI	D	N I	D	Ni	D	NI	D	NI	D	N 1	D
	Number of	Outcome	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	Number of	Percent of Total
	1	of Interest ¹	_										_			
Xultophy, Hospitalized Tachyarrhythmi	364	****	0	0.0%	****	50.0%	0	0.0%	****	50.0%	0	0.0%	0	0.0%	0	0.0%
Mounjaro, Atrial Fibrillation and Flutter	18,842	64	43	67.2%	****	20.3%	****	10.9%	****	1.6%	0	0.0%	0	0.0%	0	0.0%
Bydureon, Atrial Fibrillation and Flutter	1,321	****	****	80.0%	****	20.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Ozempic, Atrial Fibrillation and Flutter	117,008	506	285	56.3%	125	0.237	49	9.7%	****	7.7%	****	1.6%	0	0.0%	0	0.0%
Rybelsus, Atrial Fibrillation and Flutter	34,058	123	71	57.3%	30	0.232	****	11.3%	****	7.3%	0	0.0%	0	0.0%	0	0.0%
Wegovy, Atrial Fibrillation and Flutter	828	****	0	0.0%	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Saxenda, Atrial Fibrillation and Flutter	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Victoza, Atrial Fibrillation and Flutter	5,354	27	14	51.9%	****	22.2%	****	11.1%	****	14.8%	0	0.0%	0	0.0%	0	0.0%



Sentinel Distribu	ted Datab	ase from Ma	y 13, 2022	to June a		or of Fair	dos Como	مسمط طبید ۱	0000000	man of C	tooms of	Intorest Is	. Colorada	Lawath		
		Total	0-30	days		er of Episo) days		orea aue t days		ance of Ou 3 days		55 days	y Episode 366-45		156±	days
		Number of	0 30	uuys	31 00	uuys	01 30	days	31 10.	o uuys	104 30	os days	300 43	Judys	4301	uuys
		Episodes														
		Censored														
		due to														
	Total	Occurrence														
	Number	of	Number		Number				Number				Number		Number	Percent
	of	Outcome of Interest ¹	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of Episodes	of Total	of	of Total
Trulicity, Atrial	66,978	344	223	65.1%	67	19.5%	32	9.3%	****	5.2%	****	0.9%	0	0.0%	0	0.0%
Fibrillation and Flutter	00,370	3	223	03.170	O,	13.370	32	3.370		3.270		0.370	Ü	0.070	Ü	0.070
Xultophy, Atrial Fibrillation and Flutter	364	****	0	0.0%	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Mounjaro, Sinus Tachycardia	18,842	30	18	60.0%	****	26.7%	****	6.7%	****	6.7%	0	0.0%	0	0.0%	0	0.0%
Bydureon, Sinus Tachycardia	1,321	****	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Ozempic, Sinus Tachycardia	117,008	182	100	54.9%	55	30.2%	****	9.3%	****	4.9%	****	0.5%	0	0.0%	0	0.0%
Rybelsus, Sinus Tachycardia	34,058	45	23	53.3%	****	33.3%	****	8.9%	****	4.4%	0	0.0%	0	0.0%	0	0.0%
Wegovy, Sinus Tachycardia	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Saxenda, Sinus Tachycardia	386	****	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Victoza, Sinus Tachycardia	5,354	15	****	80.0%	****	13.3%	0	0.0%	****	6.7%	0	0.0%	0	0.0%	0	0.0%
Trulicity, Sinus Tachycardia	66,978	108	52	48.1%	23	21.3%	16	14.8%	****	14.8%	****	0.9%	0	0.0%	0	0.0%
Xultophy, Sinus Tachycardia	364	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN



Sentinei Distribui		II OIII IVIU	, 10, 2022			er of Episo	odes Cens	ored due t	o Occurre	nce of Ou	tcome of	Interest b	v Episode	Length		
		Total	0-30	days		days		days		3 days		55 days		55 days	456+	days
		Number of Episodes Censored due to Occurrence														
	Total Number	of		Dercent	Number	Dercent	Number	Dercent	Number	Dercent	Number	Dercent	Number	Dercent	Number	Percent
	of	Outcome	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
		of Interest ¹														
Mounjaro, Supraventricular Tachycardia	18,842	****	****	62.5%	****	12.5%	****	25.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bydureon, Supraventricular Tachycardia	1,321	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Ozempic, Supraventricular Tachycardia	117,008	70	34	48.6%	****	37.1%	****	12.9%	0	0.0%	****	1.4%	0	0.0%	0	0.0%
Rybelsus, Supraventricular Tachycardia	34,058	16	****	56.3%	****	18.8%	****	12.5%	****	12.5%	0	0.0%	0	0.0%	0	0.0%
Wegovy, Supraventricular Tachycardia	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Saxenda, Supraventricular Tachycardia	386	****	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Victoza, Supraventricular Tachycardia	5,354	****	****	40.0%	0	0.0%	0	0.0%	****	60.0%	0	0.0%	0	0.0%	0	0.0%



Sentinel Distribut	tea Datab	ase from Ma	y 13, 2022	to June 3		ou of Fuiss	das Caras	مرما ماريم	0.000	man of O	teems of	Interest by	, Enicods	Lougeth		
		Total	0-30	days		er of Episo) days		ored due t days		nce of Ou 3 days		Interest by	366-45		456+	days
		Number of Episodes	0 30	aays	31 00	, uuys	0130	, uuys	31 10	o days	10430	o days	300 43	J uuys	4301	uuys
	Total	Censored due to Occurrence														
	Number	of	Number		Number					Percent					Number	Percent
	of	Outcome	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
Total talks	•	of Interest ¹	_	•	Episodes ****		****	Episodes	****	_		Episodes	_	_		_
Trulicity, Supraventricular Tachycardia	66,978	41	25	61.0%		22.0%		9.8%		7.3%	0	0.0%	0	0.0%	0	0.0%
Xultophy, Supraventricular Tachycardia	364	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Mounjaro, Other	18,842	****	****	80.0%	0	0.0%	****	20.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Bydureon, Other Tachycardia	1,321	****	****	50.0%	0	0.0%	0	0.0%	****	50.0%	0	0.0%	0	0.0%	0	0.0%
Ozempic, Other Tachycardia	117,008	53	28	52.8%	11	20.8%	****	13.2%	****	13.2%	0	0.0%	0	0.0%	0	0.0%
Rybelsus, Other Tachycardia	34,058	****	****	60.0%	****	20.0%	0	0.0%	****	20.0%	0	0.0%	0	0.0%	0	0.0%
Wegovy, Other Tachycardia	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Saxenda, Other Tachycardia	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Victoza, Other Tachycardia	5,354	****	****	66.7%	0	0.0%	****	33.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Trulicity, Other Tachycardia	66,978	21	****	57.1%	****	19.0%	0	0.0%	****	19.0%	****	4.8%	0	0.0%	0	0.0%
Xultophy, Other Tachycardia	364	****	0	0.0%	0	0.0%	0	0.0%	****	100.0%	0	0.0%	0	0.0%	0	0.0%



Sentinel Distribu	ca batab	use iroin ivia	y 13, 2022	L to Julie 3		er of Episo	des Censo	ored due t	o Occurre	nce of Ou	tcome of	Interest by	y Episode	Length		
		Total Number of Episodes		days) days		days		3 days		55 days		5 days	456+	days
	Total Number	Censored due to Occurrence of	Number		Number		Number		Number		Number		Number		Number	Percent
	of	Outcome	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
N 4 =	•	of Interest ¹	_			_		•	-				_			
Mounjaro, Cardiac Arrest	18,842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bydureon, Cardiac Arrest	1,321	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Ozempic, Cardiac Arrest	117,008	18	****	50.0%	****	16.7%	****	16.7%	****	16.7%	0	0.0%	0	0.0%	0	0.0%
Rybelsus, Cardiac Arrest	34,058	****	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Wegovy, Cardiac Arrest	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Saxenda, Cardiac Arrest	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Victoza, Cardiac Arrest	5,354	****	0	0.0%	****	33.3%	0	0.0%	****	66.7%	0	0.0%	0	0.0%	0	0.0%
Trulicity, Cardiac Arrest	66,978	12	****	41.7%	****	25.0%	****	16.7%	****	8.3%	****	8.3%	0	0.0%	0	0.0%
Xultophy, Cardiac Arrest	364	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Mounjaro, Ventricular Tachycardia	18,842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Bydureon, Ventricular Tachycardia	1,321	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN



Sentinei Distribi	iteu Databa	ase irom ivia	y 13, 2022	z to June s		on of Endo	ados Cores	معما مارد ع	. Ossur	nes of C	toome of	Interest b	. Cuisada	Longth		
			0.20	days		er of Episo days	odes Censo	orea aue 1 O days		ance of Ou 3 days		55 days	-	55 days	156	days
		Total	0-30	uays	31-00	uays	01-90	uays	31-10	o uays	104-30	os uays	300-43	os uays	450+	uays
		Number of														
		Episodes														
		Censored														
		due to														
	Total	Occurrence														
	Number	of	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
	of	Outcome	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
	Episodes	of Interest ¹	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes
Ozempic, Ventricular Tachycardia	117,008	****	****	42.9%	****	42.9%	****	14.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Rybelsus, Ventricular Tachycardia	34,058	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Wegovy, Ventricular Tachycardia	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Saxenda, Ventricular Tachycardia	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Victoza, Ventricular Tachycardia	5,354	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Trulicity, Ventricular Tachycardia	66,978	****	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Xultophy, Ventricular Tachycardia	364	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN



Sentinel Distribu	ited Datab	ase irom Ma	y 13, 2024	to June s		er of Enisc	ndes Cens	ored due t	o Occurre	nce of Ou	trome of	Interest b	v Enisoda	Length		
		Total	0-30	days		days		days		3 days		55 days	-	55 days	456+	days
		Number of				, , .		, , .				,.		,.		,-
		Episodes														
		Censored														
		due to														
	Total	Occurrence														
	Number	of		Dorcont	Number	Dorcont	Number	Dorcont	Number	Dorcont	Number	Dorcont	Number	Dorcont	Number	Percent
	of	Outcome	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
		of Interest ¹														
Mounjaro,	18,842	****	0	0.0%	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Ventricular Fibrillation and Flutter	10,042		Ü	0.070		100.070	Ü	0.070	Ü	0.070	Ü	0.070	Ü	0.070	Ü	0.070
Bydureon, Ventricular Fibrillation and Flutter	1,321	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Ozempic, Ventricular Fibrillation and Flutter	117,008	****	****	75.0%	****	25.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Rybelsus, Ventricular Fibrillation and Flutter	34,058	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Wegovy, Ventricular Fibrillation and Flutter	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Saxenda, Ventricular Fibrillation and Flutter	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN



Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Sentinei Distribu	iteu Datab	ase il Ulli ivia	y 13, 2022	to June 3												
					Numbe	er of Episo	des Censo	ored due t	o Occurre	nce of Ou	tcome of	Interest b	y Episode	Length		
		Total	0-30	days	31-60) days	61-90	days	91-183	3 days	184-36	55 days	366-45	5 days	456+	days
		Number of														
		Episodes														
		Censored														
		due to														
	Total	Occurrence														
	Number	Outcome				Percent							Number		Number	Percent
	of 5	Outcome	of	of Total	of	of Total	of	of Total	of	of Total		of Total		of Total	of	of Total
		of Interest ¹	Episoaes		Episoaes										Episoaes	
Victoza, Ventricular Fibrillation and Flutter	5,354	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Trulicity, Ventricular Fibrillation and Flutter	66,978	****	****	60.0%	****	40.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Xultophy, Ventricular Fibrillation and Flutter	364	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

¹Represents episodes censored due to occurrence of request-defined event.

NaN: Not a number

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Sentinei Distributed Database from May 13	, = = = = =============================	- (Distr	ibution of I	At-Risk T	ime in Days, b	y Episode	
		Total Number of Episodes							
	Total Number of	Censored due to Occurrence							Standard
	Episodes	of Outcome of Interest ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon, Hospitalized Tachyarrhythmia	1,321	****	2	10	19	33	94	28.1	30.6
Mounjaro, Hospitalized Tachyarrhythmia	18,842	102	1	8	20	36	166	28.9	30.1
Ozempic, Hospitalized Tachyarrhythmia	117,008	793	1	12	26	51	354	38.4	39.3
Rybelsus, Hospitalized Tachyarrhythmia	34,058	178	1	13	26	48	170	36.1	33.7
Saxenda, Hospitalized Tachyarrhythmia	386	****	4	4	4	4	4	4.0	NaN
Trulicity, Hospitalized Tachyarrhythmia	66,978	496	1	9	23	49	326	37.0	41.7
Victoza, Hospitalized Tachyarrhythmia	5,354	45	1	11	22	78	174	45.9	48.2
Wegovy, Hospitalized Tachyarrhythmia	828	****	34	34	34	34	34	34.0	NaN
Xultophy, Hospitalized Tachyarrhythmia	364	****	38	38	77	116	116	77.0	55.2
Mounjaro, Atrial Fibrillation and Flutter	18,842	64	1	9	19	39	119	27.0	23.8
Bydureon, Atrial Fibrillation and Flutter	1,321	****	2	10	17	19	33	16.2	11.5
Ozempic, Atrial Fibrillation and Flutter	117,008	506	1	11	25	51	261	38.7	40.7
Rybelsus, Atrial Fibrillation and Flutter	34,058	123	1	14	26	51	170	39.2	37.4
Wegovy, Atrial Fibrillation and Flutter	828	****	34	34	34	34	34	34.0	NaN
Saxenda, Atrial Fibrillation and Flutter	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza, Atrial Fibrillation and Flutter	5,354	27	1	11	29	78	155	43.6	43.7
Trulicity, Atrial Fibrillation and Flutter	66,978	344	1	9	21	42	326	32.7	38.3
Xultophy, Atrial Fibrillation and Flutter	364	****	38	38	38	38	38	38.0	NaN
Mounjaro, Sinus Tachycardia	18,842	30	1	9	23	34	166	32.3	39.3
Bydureon, Sinus Tachycardia	1,321	****	22	22	22	22	22	22.0	NaN
Ozempic, Sinus Tachycardia	117,008	182	1	12	27	49	354	35.7	37.9
Rybelsus, Sinus Tachycardia	34,058	45	1	15	27	44	165	34.0	29.7
Wegovy, Sinus Tachycardia	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda, Sinus Tachycardia	386	****	4	4	4	4	4	4.0	NaN
Victoza, Sinus Tachycardia	5,354	15	2	9	12	25	113	23.2	28.1
Trulicity, Sinus Tachycardia	66,978	108	1	12	32	74	225	46.7	46.3
Xultophy, Sinus Tachycardia	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mounjaro, Supraventricular Tachycardia	18,842	****	4	12	23	55	86	33.8	30.6



Sentinei Distributed Database from May 1.	, 			Distr	ibution of A	At-Risk T	ime in Days, b	y Episode	
		Total Number of Episodes							
	Total Number of	Censored due to Occurrence							Standard
	Episodes	of Outcome of Interest ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon, Supraventricular Tachycardia	1,321	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Ozempic, Supraventricular Tachycardia	117,008	70	1	14	32	52	189	35.5	29.2
Rybelsus, Supraventricular Tachycardia	34,058	16	1	16	23	60	170	45.6	51.5
Wegovy, Supraventricular Tachycardia	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda, Supraventricular Tachycardia	386	****	4	4	4	4	4	4.0	NaN
Victoza, Supraventricular Tachycardia	5,354	****	6	8	121	138	174	89.4	77.6
Trulicity, Supraventricular Tachycardia	66,978	41	1	7	25	45	150	32.1	33.3
Xultophy, Supraventricular Tachycardia	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mounjaro, Other Tachycardia	18,842	****	7	7	14	18	75	23.2	28.8
Bydureon, Other Tachycardia	1,321	****	17	17	56	94	94	55.5	54.4
Ozempic, Other Tachycardia	117,008	53	1	10	29	61	155	42.3	38.1
Rybelsus, Other Tachycardia	34,058	****	5	26	28	40	165	52.8	64.0
Wegovy, Other Tachycardia	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda, Other Tachycardia	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza, Other Tachycardia	5,354	****	8	8	15	80	80	34.3	39.7
Trulicity, Other Tachycardia	66,978	21	3	13	25	59	194	46.6	50.7
Xultophy, Other Tachycardia	364	****	116	116	116	116	116	116.0	NaN
Mounjaro, Cardiac Arrest	18,842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Bydureon, Cardiac Arrest	1,321	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Ozempic, Cardiac Arrest	117,008	18	4	6	34	80	165	46.7	44.8
Rybelsus, Cardiac Arrest	34,058	****	2	2	10	18	18	10.0	11.3
Wegovy, Cardiac Arrest	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda, Cardiac Arrest	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza, Cardiac Arrest	5,354	****	39	39	133	142	142	104.7	57.0
Trulicity, Cardiac Arrest	66,978	12	1	13	49	65	192	53.6	53.9
Xultophy, Cardiac Arrest	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mounjaro, Ventricular Tachycardia	18,842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Bydureon, Ventricular Tachycardia	1,321	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN



				Distr	ibution of A	At-Risk T	ime in Days, b	y Episode	
		Total Number of Episodes							
	Total Number of	Censored due to Occurrence							Standard
	Episodes	of Outcome of Interest ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Ozempic, Ventricular Tachycardia	117,008	****	1	3	34	51	71	31.4	23.9
Rybelsus, Ventricular Tachycardia	34,058	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Wegovy, Ventricular Tachycardia	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda, Ventricular Tachycardia	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza, Ventricular Tachycardia	5,354	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Trulicity, Ventricular Tachycardia	66,978	****	2	2	5	18	18	8.3	8.5
Xultophy, Ventricular Tachycardia	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mounjaro, Ventricular Fibrillation and Flutter	18,842	****	33	33	33	33	33	33.0	NaN
Bydureon, Ventricular Fibrillation and Flutter	1,321	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Ozempic, Ventricular Fibrillation and Flutter	117,008	****	7	12	22	42	57	26.8	21.6
Rybelsus, Ventricular Fibrillation and Flutter	34,058	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Wegovy, Ventricular Fibrillation and Flutter	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda, Ventricular Fibrillation and Flutter	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza, Ventricular Fibrillation and Flutter	5,354	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Trulicity, Ventricular Fibrillation and Flutter	66,978	****	1	23	25	38	57	29.0	20.6
Xultophy, Ventricular Fibrillation and Flutter	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

¹Represents episodes censored due to occurrence of request-defined event.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number



Table 13. Summary of Time to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

				Nu	mber of E	pisodes C	ensored d	ue to Occ	urrence o	f User-Def	ined Cens	oring Crit	eria by Ep	isode Len	gth	
			0-30	days	31-60	days	61-90	days	91-18	3 days	184-36	5 days	366-45	5 days	456+	days
		Number of														
		Episodes														
		Censored														
		due to														
		Occurrence														
	Total	of User-														
	Number	Defined	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
	of	Censoring	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
	Episodes	Criteria ¹	Episodes	Episodes	Episodes											
Bydureon	1,321	151	85	56.3%	31	20.5%	23	15.2%	****	7.3%	****	0.7%	0	0.0%	0	0.0%
Mounjaro	18,842	1,259	843	67.0%	235	19.5%	120	9.5%	****	3.7%	****	0.3%	0	0.0%	0	0.0%
Ozempic	117,008	10,001	5,642	56.4%	2,552	25.5%	1,023	10.2%	688	6.9%	96	1.0%	0	0.0%	0	0.0%
Rybelsus	34,058	2,585	1,543	59.7%	514	19.9%	295	11.4%	213	8.2%	20	0.8%	0	0.0%	0	0.0%
Saxenda	386	37	22	59.5%	****	0.233	****	10.8%	****	5.4%	0	0.0%	0	0.0%	0	0.0%
Trulicity	66,978	6,761	3,968	58.7%	1,458	21.6%	726	10.7%	535	7.9%	74	1.1%	0	0.0%	0	0.0%
Victoza	5,354	727	447	61.5%	140	19.3%	78	10.7%	****	8.3%	****	0.3%	0	0.0%	0	0.0%
Wegovy	828	38	****	81.6%	****	15.8%	****	2.6%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Xultophy	364	46	23	50.0%	11	23.9%	****	13.0%	****	13.0%	0	0.0%	0	0.0%	0	0.0%

¹Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 13. Summary of Time to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

				Distr	ibution of A	\t-Risk T	ime in Days, b	y Episode	
	Tota	al Number of Episodes Censored due							
	to O	ccurrence of User-Defined Censoring							Standard
	Total Number of Episodes	Criteria ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,321	151	1	12	26	56	344	39.2	41.1
Mounjaro	18,842	1,259	1	10	20	41	231	29.4	29.7
Ozempic	117,008	10,001	1	12	26	49	356	37.2	37.5
Rybelsus	34,058	2,585	1	13	23	53	329	38.2	38.4
Saxenda	386	37	2	10	28	50	166	34.6	35.7
Trulicity	66,978	6,761	1	11	23	51	337	37.6	39.8
Victoza	5,354	727	1	11	23	48	273	36.2	36.8
Wegovy	828	38	1	7	17	27	63	19.4	14.6
Xultophy	364	46	2	15	30	62	170	43.2	41.2

¹Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 14. Summary of Time to End of At-Risk Period due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

						Number	of Episod	les Censor	ed due to	Evidence	of Death	by Episod	e Length			
			0-30	days	31-60	days	61-90	days	91-18	3 days	184-36	5 days	366-45	5 days	456+	days
		Total														
		Number of														
		Episodes														
	Total	Censored														
	Number	due to	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
	of	Evidence of	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
	Episodes	Death ¹	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes
Bydureon	1,321	****	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Mounjaro	18,842	****	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Ozempic	117,008	32	****	68.8%	****	15.6%	****	6.3%	****	9.4%	0	0.0%	0	0.0%	0	0.0%
Rybelsus	34,058	****	****	66.7%	****	33.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Saxenda	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Trulicity	66,978	49	32	65.3%	****	16.3%	****	8.2%	****	8.2%	****	2.0%	0	0.0%	0	0.0%
Victoza	5,354	****	****	75.0%	****	25.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Wegovy	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Xultophy	364	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

¹Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

^{*}NaN: Not a number



Table 14. Summary of Time to End of At-Risk Period due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

				Distr	ibution of	At-Risk T	ime in Days, b	y Episode	
	То	tal Number of Episodes Censored due							Standard
	Total Number of Episodes	to Evidence of Death ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,321	****	7	7	7	7	7	7.0	NaN
Mounjaro	18,842	****	7	7	11	15	15	11.0	5.7
Ozempic	117,008	32	3	14	21	36	165	32.9	35.2
Rybelsus	34,058	****	18	18	23	49	52	30.5	15.7
Saxenda	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Trulicity	66,978	49	1	9	17	57	192	35.8	42.5
Victoza	5,354	****	3	3	12	30	39	16.5	17.2
Wegovy	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Xultophy	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

¹Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

^{*}NaN: Not a number



Table 15. Summary of Time to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		13, 2022 to Julie				Numb	er of Epis	odes Cens	ored due	to Disenro	ollment by	Episode	Length			
			0-30	days	31-60	days		days		3 days		5 days		5 days	456+	days
	Total Number of Episodes	Total Number of Episodes Censored due to Disenrollment ¹	Number of Episodes	of Total		of Total		of Total	Number of Episodes	of Total	Number of Episodes	of Total		of Total		of Total
Bydureon	1,321	191	98	51.3%	33	17.3%	21	11.0%	****	15.2%	****	5.2%	0	0.0%	0	0.0%
Mounjaro	18,842	1,574	952	60.5%	360	22.9%	158	10.0%	****	6.5%	****	0.1%	0	0.0%	0	0.0%
Ozempic	117,008	12,066	5,410	44.8%	2,900	0.23	1,708	14.2%	1,703	14.1%	****	2.9%	****	0.0%	0	0.0%
Rybelsus	34,058	4,385	1,997	45.5%	913	20.8%	615	14.0%	696	15.9%	164	3.7%	0	0.0%	0	0.0%
Saxenda	386	****	****	75.0%	****	12.5%	0	0.0%	****	12.5%	0	0.0%	0	0.0%	0	0.0%
Trulicity	66,978	9,721	3,987	41.0%	2,280	23.5%	1,410	14.5%	1,646	16.9%	398	4.1%	0	0.0%	0	0.0%
Victoza	5,354	721	319	44.2%	184	25.5%	88	12.2%	99	13.7%	31	4.3%	0	0.0%	0	0.0%
Wegovy	828	****	****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Xultophy	364	44	12	27.3%	11	25.0%	****	15.9%	****	20.5%	****	11.4%	0	0.0%	0	0.0%

¹Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 15. Summary of Time to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

				Distr	ibution of A	t-Risk T	ime in Days, b	y Episode	
	Total	al Number of Episodes Censored due							Standard
	Total Number of Episodes	to Disenrollment ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,321	191	1	13	30	76	232	53.5	54.4
Mounjaro	18,842	1,574	1	15	25	47	189	35.1	31.1
Ozempic	117,008	12,066	1	18	38	71	383	52.1	47.9
Rybelsus	34,058	4,385	1	18	38	78	262	55.1	51.0
Saxenda	386	****	8	15	26	32	127	34.9	38.2
Trulicity	66,978	9,721	1	18	43	80	291	57.6	51.8
Victoza	5,354	721	1	17	38	72	238	54.8	52.6
Wegovy	828	****	1	1	11	21	23	11.7	8.9
Xultophy	364	44	2	28	59	119	227	76.0	64.2

¹Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 16. Summary of Time to End of At-Risk Period due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

						Num	ber of Epi	sodes Cen	sored due	to End of	Data by I	Episode Le	ength			
			0-30	days	31-60	days	61-90	days	91-18	3 days	184-36	5 days	366-45	55 days	456+	days
	Total Number of	Total Number of Episodes Censored due to End	Number of	Percent of Total		Percent of Total	Number of	Percent of Total	Number of	Percent of Total						
	Episodes	of Data ¹	Episodes		Episodes		_						-			
Bydureon	1,321	285	147	51.6%	51	17.9%	28	9.8%	45	15.8%	14	4.9%	0	0.0%	0	0.0%
Mounjaro	18,842	5,680	3,071	54.1%	1,428	25.1%	675	11.9%	439	7.7%	67	1.2%	0	0.0%	0	0.0%
Ozempic	117,008	31,994	15,252	47.7%	8,120	25.4%	4,183	13.1%	3,458	10.8%	970	3.0%	11	0.0%	0	0.0%
Rybelsus	34,058	8,350	3,822	45.8%	1,758	21.1%	1,214	14.5%	1,175	14.1%	****	4.5%	****	0.1%	0	0.0%
Saxenda	386	29	12	41.4%	****	10.3%	****	17.2%	****	23.10%	****	6.9%	0	0.0%	0	0.0%
Trulicity	66,978	16,261	6,412	39.4%	3,888	23.9%	2,497	15.4%	2,566	15.8%	886	5.4%	12	0.1%	0	0.0%
Victoza	5,354	1,187	510	43.0%	288	23.30%	179	15.1%	153	12.9%	****	4.7%	****	0.1%	0	0.0%
Wegovy	828	398	262	65.8%	88	22.1%	****	10.1%	****	2.0%	0	0.0%	0	0.0%	0	0.0%
Xultophy	364	122	45	36.9%	23	18.9%	25	20.5%	****	19.7%	****	4.1%	0	0.0%	0	0.0%

¹Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 16. Summary of Time to End of At-Risk Period due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

				Distr	ibution of A	t-Risk T	ime in Days, b	y Episode	
	Tot	al Number of Episodes Censored due							Standard
	Total Number of Episodes	to End of Data ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,321	285	1	15	30	77	319	53.8	56.4
Mounjaro	18,842	5,680	1	15	28	53	309	40.3	38.3
Ozempic	117,008	31,994	1	16	33	64	383	48.9	49.8
Rybelsus	34,058	8,350	1	17	37	77	380	56.0	56.3
Saxenda	386	29	2	14	58	96	277	70.3	71.6
Trulicity	66,978	16,261	1	19	44	80	383	61.2	59.0
Victoza	5,354	1,187	1	17	39	75	369	56.7	56.8
Wegovy	828	398	1	10	22	43	118	28.9	23.1
Xultophy	364	122	1	21	51	89	301	62.6	54.2

¹Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 17. Summary of Time to End of At-Risk Period due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

		·				Number	of Episode	es Censore	ed due to	End of Stu	dy Period	by Episod	le Length			
			0-30	days	31-60	days	61-90	days	91-18	3 days	184-36	5 days	366-45	5 days	456+	days
		Number														
		of														
		Episodes														
		Censored														
	Total	due to														
	Number	End of	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
	of	Study	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
	Episodes	Period ¹	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes
Bydureon	1,321	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Mounjaro	18,842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Ozempic	117,008	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Rybelsus	34,058	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Saxenda	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Trulicity	66,978	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Victoza	5,354	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Wegovy	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Xultophy	364	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

¹Represents episodes censored due to user-specified study end date.

^{*}NaN: Not a number



Table 17. Summary of Time to End of At-Risk Period due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

				Distr	ibution of A	At-Risk T	ime in Days, b	y Episode	
	То	tal Number of Episodes Censored due							Standard
	Total Number of Episodes	to End of Study Period ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,321	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mounjaro	18,842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Ozempic	117,008	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Rybelsus	34,058	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Trulicity	66,978	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza	5,354	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Wegovy	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Xultophy	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

¹Represents episodes censored due to user-specified study end date.

^{*}NaN: Not a number



Table 18. Summary of Time to End of Observable Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

							Number o	f Episodes	by Observ	able Time					
		0-30	days	31-60) days	61-90	O days	91-18	3 days	184-36	55 days	366-45	55 days	456+	days
	Total	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
	Number	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
	of	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes
Bydureon	1,321	167	12.6%	137	10.4%	131	9.9%	454	34.4%	414	31.3%	18	1.4%	0	0.0%
Mounjaro	18,842	3,410	18.1%	3,499	18.6%	2,949	15.7%	6,095	32.3%	2,889	15.3%	0	0.0%	0	0.0%
Ozempic	117,008	16,529	14.1%	16,599	14.2%	15,068	12.9%	34,089	29.1%	33,825	28.9%	898	0.8%	0	0.0%
Rybelsus	34,058	4,148	12.2%	4,312	12.7%	4,162	12.2%	10,803	31.7%	10,373	30.5%	260	0.8%	0	0.0%
Saxenda	386	18	4.7%	22	5.7%	22	5.7%	125	32.4%	****	51.0%	****	0.5%	0	0.0%
Trulicity	66,978	7,299	10.9%	8,134	12.1%	8,189	12.2%	21,727	32.4%	21,023	31.4%	606	0.9%	0	0.0%
Victoza	5,354	577	10.8%	683	12.8%	642	12.0%	1,730	32.3%	1,662	31.0%	60	1.1%	0	0.0%
Wegovy	828	275	33.2%	230	29.0%	192	23.2%	81	9.8%	40	4.8%	0	0.0%	0	0.0%
Xultophy	364	45	12.4%	39	10.7%	61	16.8%	125	34.3%	****	23.70%	****	1.1%	0	0.0%

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 18. Summary of Time to End of Observable Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

				Distribution of Ob	servable Time	in Days, by Episode		
								Standard
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,321	2	66	137	206	384	143.3	92.2
Mounjaro	18,842	2	42	86	147	359	101.7	73.8
Ozempic	117,008	2	53	114	199	410	132.1	93.0
Rybelsus	34,058	2	61	125	201	384	137.9	91.6
Saxenda	386	3	115	187	256	372	184.7	87.0
Trulicity	66,978	2	66	130	205	389	141.1	91.2
Victoza	5,354	2	65	130	205	412	141.3	92.3
Wegovy	828	2	23	50	75	363	60.6	61.2
Xultophy	364	2	65	112	190	381	131.7	91.6

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 19. Summary of Time to End of Observable Data due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

						Number	of Episode	es Censore	d due to	Evidence o	of Death b	y Observa	able Time			
			0-30	days	31-60	days	61-90	days	91-18	3 days	184-36	5 days	366-45	5 days	456+	days
	Total Number of Episodes	Total Number of Episodes Censored due to Evidence of Death ²	Number of Episodes	of Total	Number of Episodes	of Total	Number of Episodes	of Total	of	of Total	Number of Episodes	of Total	Number of Episodes	of Total	Number of Episodes	Percent of Total Episodes
Bydureon	1,321	****	****	25.0%	****	12.5%	****	12.5%	****	37.5%	****	12.5%	0	0.0%	0	0.0%
Mounjaro	18,842	16	****	25.0%	****	43.8%	****	12.5%	****	12.5%	****	6.3%	0	0.0%	0	0.0%
Ozempic	117,008	290	49	16.9%	40	13.8%	47	16.2%	113	39.0%	41	14.1%	0	0.0%	0	0.0%
Rybelsus	34,058	104	11	10.6%	20	19.2%	17	16.3%	****	45.2%	****	8.7%	0	0.0%	0	0.0%
Saxenda	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Trulicity	66,978	363	63	17.4%	60	16.5%	70	19.3%	127	35.0%	43	11.8%	0	0.0%	0	0.0%
Victoza	5,354	26	****	19.2%	****	38.5%	****	7.7%	****	26.9%	****	7.7%	0	0.0%	0	0.0%
Wegovy	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Xultophy	364	****	0	0.0%	0	0.0%	****	50.0%	****	50.0%	0	0.0%	0	0.0%	0	0.0%

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

^{*}NaN: Not a number



Table 19. Summary of Time to End of Observable Data due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

				Distrib	ution of Ob	servable	Time in Days	, by Episo	de
	To	tal Number of Episodes Censored due							Standard
	Total Number of Episodes	to Evidence of Death ²	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,321	****	8	43	88	156	360	117.6	112.7
Mounjaro	18,842	16	8	29	42	76	235	66.6	65.1
Ozempic	117,008	290	4	48	94	155	363	106.9	73.9
Rybelsus	34,058	104	8	51	97	128	260	98.2	57.2
Saxenda	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Trulicity	66,978	363	2	46	86	143	345	99.5	68.6
Victoza	5,354	26	4	40	60	129	220	79.0	57.5
Wegovy	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Xultophy	364	****	84	84	131	178	178	131.0	66.5

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

^{*}NaN: Not a number



Table 20. Summary of Time to End of Observable Data due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

						Numbe	er of Episo	des Censo	red due t	o Disenrol	lment by	Observab	le Time			
			0-30	days	31-60) days	61-90) days	91-18	3 days	184-36	55 days	366-45	5 days	456+	days
		Total Number														
	Total	of Episodes														
	Number	Censored due	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
	of	to	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total	of	of Total
	Episodes	Disenrollment ²	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes
Bydureon	1,321	741	101	13.6%	82	11.1%	82	11.1%	296	39.9%	180	23.30%	0	0.0%	0	0.0%
Mounjaro	18,842	3,984	987	23.80%	982	23.60%	808	20.3%	1,090	27.4%	117	2.9%	0	0.0%	0	0.0%
Ozempic	117,008	44,596	5,571	12.5%	5,699	12.8%	6,671	15.0%	16,795	37.7%	9,790	22.0%	70	0.2%	0	0.0%
Rybelsus	34,058	14,702	2,007	13.7%	1,996	13.6%	2,014	13.7%	5,425	36.9%	****	22.2%	****	0.0%	0	0.0%
Saxenda	386	29	****	20.7%	****	17.2%	****	3.4%	****	31.0%	****	27.6%	0	0.0%	0	0.0%
Trulicity	66,978	33,533	4,149	12.4%	4,573	13.6%	4,525	13.5%	12,749	38.0%	****	22.5%	****	0.0%	0	0.0%
Victoza	5,354	2,647	325	12.3%	379	14.3%	326	12.3%	1,007	38.0%	****	22.9%	****	0.2%	0	0.0%
Wegovy	828	15	****	46.7%	****	20.0%	****	26.7%	****	6.7%	0	0.0%	0	0.0%	0	0.0%
Xultophy	364	127	12	9.4%	20	15.7%	23	18.9%	47	37.0%	23	18.9%	0	0.0%	0	0.0%

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

cder_mpl1p_wp077 Page 532 of 1023

²Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 20. Summary of Time to End of Observable Data due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

				Distrib	ution of Ob	servable	Time in Days	, by Episo	de
	Tot	al Number of Episodes Censored due							Standard
	Total Number of Episodes	to Disenrollment ²	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,321	741	2	61	130	180	360	122.5	70.3
Mounjaro	18,842	3,984	2	31	61	102	328	71.7	50.8
Ozempic	117,008	44,596	2	60	112	174	410	117.3	69.0
Rybelsus	34,058	14,702	2	55	111	174	372	115.5	68.6
Saxenda	386	29	9	39	113	213	318	123.9	96.5
Trulicity	66,978	33,533	2	59	115	175	389	117.3	68.1
Victoza	5,354	2,647	2	58	117	174	412	119.0	70.1
Wegovy	828	15	2	12	31	75	94	40.7	31.6
Xultophy	364	127	3	60	104	169	233	113.4	65.7

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 21. Summary of Time to End of Observable Data due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

						Numl	er of Epis	odes Cens	sored due	to End of	Data by O	bservable	Time			
			0-30	days	31-60	days	61-90	days	91-18	3 days	184-36	5 days	366-45	55 days	456+	days
	Total	Total Number of Episodes														
	Number		Number		Number		Number		Number		Number		Number		Number	
	of	due to End of	01	of Total		of Total	of	of Total		of Total	of	of Total	of	of Total		of Total
	Episodes	Data ²	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes	Episodes
Bydureon	1,321	1,238	152	12.2%	126	10.1%	120	9.6%	430	34.5%	402	32.2%	18	1.4%	0	0.0%
Mounjaro	18,842	18,010	3,199	17.8%	3,309	18.4%	2,796	15.5%	5,856	32.5%	2,850	15.8%	0	0.0%	0	0.0%
Ozempic	117,008	110,821	15,535	14.0%	15,635	14.1%	14,113	12.7%	31,962	28.8%	32,678	29.5%	898	0.8%	0	0.0%
Rybelsus	34,058	32,166	3,823	11.9%	4,017	12.5%	3,889	12.1%	10,159	31.6%	10,017	31.1%	260	0.8%	0	0.0%
Saxenda	386	362	12	3.3%	17	4.7%	21	5.8%	116	32.0%	****	53.6%	****	0.6%	0	0.0%
Trulicity	66,978	62,950	6,621	10.5%	7,483	11.9%	7,610	12.1%	20,340	32.3%	20,290	32.2%	606	1.0%	0	0.0%
Victoza	5,354	5,028	519	10.3%	623	12.4%	598	11.9%	1,618	32.2%	1,610	32.0%	60	1.2%	0	0.0%
Wegovy	828	820	271	33.0%	238	29.0%	190	23.2%	81	9.9%	40	4.9%	0	0.0%	0	0.0%
Xultophy	364	351	45	12.8%	38	10.8%	58	16.5%	119	33.9%	****	23.80%	****	1.1%	0	0.0%

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 21. Summary of Time to End of Observable Data due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

				Distril	oution of Ol	servable	e Time in Days,	by Episode	9
	To	tal Number of Episodes Censored due							Standard
	Total Number of Episodes	to End of Data ²	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,321	1,238	2	68	139	207	384	145.5	92.7
Mounjaro	18,842	18,010	2	42	87	149	359	103.0	74.3
Ozempic	117,008	110,821	2	54	115	200	410	133.4	93.8
Rybelsus	34,058	32,166	2	62	128	204	384	139.7	92.3
Saxenda	386	362	3	123	194	261	372	190.7	84.4
Trulicity	66,978	62,950	2	67	132	207	389	143.3	91.8
Victoza	5,354	5,028	2	66	132	208	412	143.8	92.9
Wegovy	828	820	2	23	50	75	363	60.8	61.4
Xultophy	364	351	2	65	111	191	381	131.3	92.5

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

cder_mpl1p_wp077 Page 535 of 1023

²Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 22. Summary of Time to End of Observable Data due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13,2022 to June 30, 2023¹

						Number o	of Episode	s Censore	d due to E	nd of Stud	ly Period l	y Observ	able Time			
		Total	0-30	days	31-60	days	61-90) days	91-18	3 days	184-36	5 days	366-45	55 days	456+	days
		Number of														
	Total	Episodes														
	Number	Censored														
	of	due to End	Number	Percent												
	Episodes	of Study	of	of Total												
		Period ²	Episodes													
Bydureon	1,321	0	0	NaN												
Mounjaro	18,842	0	0	NaN												
Ozempic	117,008	0	0	NaN												
Rybelsus	34,058	0	0	NaN												
Saxenda	386	0	0	NaN												
Trulicity	66,978	0	0	NaN												
Victoza	5,354	0	0	NaN												
Wegovy	828	0	0	NaN												
Xultophy	364	0	0	NaN												

¹ Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, t lackout period, or delay risk period start.

²kepresents episodes censored due to user-specified study end date.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 22. Summary of Time to End of Observable Data due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13,2022 to June 30, 2023¹ (Continued)

			I	Distrib	ution of Ob	servable	Time in Days	, by Episo	de
	То	tal Number of Episodes Censored due							Standard
	Total Number of Episodes	to End of Study Period ²	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Bydureon	1,321	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mounjaro	18,842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Ozempic	117,008	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Rybelsus	34,058	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Saxenda	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Trulicity	66,978	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Victoza	5,354	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Wegovy	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Xultophy	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to user-specified study end date.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

^{*}NaN: Not a number



Table 23a. Full Code Distribution of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

			Code		Encounter Care
Code	Code Description	Code Category	Туре	Overall Counts	Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 538 of 1023



Table 23b. Total Code Counts of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	93
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 539 of 1023



Table 23c. Full Code Distribution of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Туре	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	AV
Ozempic	Ozempic .	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 540 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23d. Total Code Counts of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Inpatientencounter	Inpatient Encounter	RX	N/A	235
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
003.9	Complete Or Unspecified Spontaneous	DX	10	****
	Abortion Without Complication			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 541 of 1023



Table 23e. Full Code Distribution of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and

Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter	
Code	Code Description	Category	Туре	Counts	Care Setting	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,840	N/A	
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A	
Trulicity	Trulicity	RX	N/A	508	N/A	
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A	
Mounjaro	Mounjaro	RX	N/A	277	N/A	
Rybelsus	Rybelsus	RX	N/A	****	N/A	
Victoza	Victoza	RX	N/A	62	N/A	
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A	
Wegovy	Wegovy	RX	N/A	****	N/A	
58661	Laparoscopy, Surgical; With Removal Of Adnexal	PX	C4	****	AV	
	Structures (Partial Or Total Oophorectomy					
	And/Or Salpingectomy)					
Saxenda	Saxenda	RX	N/A	****	N/A	
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A	
58661	Laparoscopy, Surgical; With Removal Of Adnexal	PX	C4	****	IP	
	Structures (Partial Or Total Oophorectomy					
	And/Or Salpingectomy)					
Z33.2	Encounter For Elective Termination Of	DX	10	****	AV	
S0199	Pregnancy	PX	HC		AV	
S0190	Medically Induced Abortion By Oral Ingestion Of	PX	HC		AV	
	Medication Including All Associated Services					
	And Supplies (E.G., Patient Counseling, Office					
	Visits, Confirmation Of Pregnancy By Hcg,					
	Ultrasound To Conf					
	Mifepristone, Oral, 200 Mg					
003.9	Complete Or Unspecified Spontaneous Abortion	DY	10	****	AV	
003.9	Without Complication	DX	10		AV	
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	ED	
000.201	Pregnancy, First Trimester	DX	10		ED	
	Right Ovarian Pregnancy Without Intrauterine					
000 444	Pregnancy	5.4	4.0	****		
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	ED	
	Pregnancy, First Trimester					
O99.211	Obesity Complicating Pregnancy, First Trimester		10	****	AV	
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10		AV	
	Pregnancy, First Trimester					
Rybelsus	Rybelsus	RX	N/A	****	N/A	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 542 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23f. Total Code Counts of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	in May 15, 2022 to June 50, 2025 for Episode Truffcation	Code	Code	Overall
Code	Code Description	Category	Туре	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078
Trulicity	Trulicity	RX	N/A	508
Mounjaro	Mounjaro	RX	N/A	277
Rybelsus	Rybelsus	RX	N/A	191
Victoza	Victoza	RX	N/A	62
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****
023.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	****
S0190	Mifepristone, Oral, 200 Mg	PX	НС	****
099.211	Obesity Complicating Pregnancy, First Trimester	DX	10	****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 543 of 1023



Table 23g. Full Code Distribution of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,632	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	83	N/A
Mounjaro	Mounjaro	RX	N/A	51	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Emergency department encounter	Emergency Department Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	****	OA

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 544 of 1023



Table 23h. Total Code Counts of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall
Code	Code Description	Category	Type	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746
Inpatientencounter	Inpatient Encounter	RX	N/A	531
Ozempic	Ozempic	RX	N/A	265
Trulicity	Trulicity	RX	N/A	83
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of Adnexal	PX	C4	****
	Structures (Partial Or Total Oophorectomy And/Or			
	Salpingectomy)			
O02.1	Missed Abortion	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 545 of 1023



Table 23i. Full Code Distribution of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 546 of 1023



Table 23j. Total Code Counts of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code	Code	Overall
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Victoza	Victoza	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 547 of 1023



Table 23k. Full Code Distribution of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and

Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Туре	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,512	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	380	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	114	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total	PX	C4	****	AV
V II 1 10005	Oophorectomy And/Or Salpingectomy)	D.V	/.	****	A1 / A
Xultophy10036	Xultophy 100/3.6	RX PX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4		AV
Wegovy	Wegovy	RX	N/A	****	N/A
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In	DX	10	****	AV
023.011	Pregnancy, First Trimester	DX	10		AV
023.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****	ED
023.311	Unspecified Pre-Existing Diabetes Mellitus In	DX	10	****	OA
023.311	Pregnancy, First Trimester Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	****	N/A
Emergencydepartmentencounter		RX	N/A		N/A
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 548 of 1023



Table 23l. Total Code Counts of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall
Code	Code Description	Category	Type	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606
Ozempic	Ozempic	RX	N/A	380
Mounjaro	Mounjaro	RX	N/A	114
Rybelsus	Rybelsus	RX	N/A	87
Victoza	Victoza	RX	N/A	33
Bydureonbcise	Bydureon Bcise	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal	PX	C4	****
	Structures (Partial Or Total Oophorectomy And/Or			
	Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
023.311	Unspecified Pre-Existing Diabetes Mellitus In	DX	10	****
	Pregnancy, First Trimester			
Wegovy	Wegovy	RX	N/A	****
023.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy,	DX	10	****
	First Trimester			
023.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy,	DX	10	****
	First Trimester	27.		
Saxenda	Saxenda	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 549 of 1023



Table 23m. Full Code Distribution of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Туре	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic	RX	N/A	90	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal	PX	C4	****	AV
	Of Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous	DX	10	****	ED
003.9	Abortion Without Complication	DX	10		OA
003.9	Complete Or Unspecified Spontaneous	DX	10		AV
	Abortion Without Complication				
	Complete Or Unspecified Spontaneous				
	Abortion Without Complication				
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 550 of 1023



Table 23n. Total Code Counts of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall
Code	Code Description	Category	Type	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476
Inpatientencounter	Inpatient Encounter	RX	N/A	128
Ozempic	Ozempic	RX	N/A	90
Trulicity	Trulicity	RX	N/A	26
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	****
O03.9	Complete Or Unspecified Spontaneous Abortion	DX	10	****
	Without Complication			
Wegovy	Wegovy	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of Adnexal	PX	C4	****
	Structures (Partial Or Total Oophorectomy And/Or			
	Salpingectomy)			
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 551 of 1023



Table 23o. Full Code Distribution of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 552 of 1023



Table 23p. Total Code Counts of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall
Code	Code Description	Category	Type	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 553 of 1023



Table 23q. Full Code Distribution of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 554 of 1023



Table 23r. Total Code Counts of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall
Code	Code Description	Category	Type	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 555 of 1023



Table 23s. Full Code Distribution of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Туре	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous	DX	10	****	AV
	Abortion Without Complication				
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 556 of 1023



Table 23t. Total Code Counts of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall
Code	Code Description	Category	Type	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Inpatientencounter	Inpatient Encounter	RX	N/A	235
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
O03.9	Complete Or Unspecified Spontaneous Abortion	DX	10	****
	Without Complication			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 557 of 1023



Table 23u. Full Code Distribution of Bydureon, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 558 of 1023



Table 23v. Total Code Counts of Bydureon, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Overall
Code	Code Description	Category	Code Type Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A 93
Inpatientencounter	Inpatient Encounter	RX	N/A 27
Ozempic	Ozempic	RX	N/A ****
Trulicity	Trulicity	RX	N/A ****
Mounjaro	Mounjaro	RX	N/A ****
Victoza	Victoza	RX	N/A ****
Rybelsus	Rybelsus	RX	N/A ****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 559 of 1023



Encounter

ΑV

ΑV

ΑV

ED

ED

ED

ΑV

ΑV

N/A

Code

PX

PX

DX

DX

DX

DX

DX

DX

RX

RX

HC

HC

10

10

10

10

10

10

N/A

Overall

Table 23w. Full Code Distribution of Ozempic, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and

Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Pregnancy

Pregnancy

Trimester

Rybelsus

S0199

S0190

003.9

023.111

000.201

023.111

099.211

023.111

Rybelsus

Emergencydepartmentencounter

Code **Code Description Care Setting** Category **Type Counts** Emergencydepartmentencounter **Emergency Department Encounter** RX N/A 6.840 N/A Inpatientencounter Inpatient Encounter RXN/A N/A Trulicity Trulicity RXN/A 508 N/A RX N/A Inpatientencounter Inpatient Encounter N/A Emergencydepartmentencounter **Emergency Department Encounter** RXN/A N/A N/A Mounjaro Mounjaro RX277 N/A **** **Rvbelsus Rvbelsus** RX N/A N/A Victoza Victoza RXN/A 62 N/A **Bydureonbcise Bydureon Bcise** RXN/A 17 N/A Wegovy Wegovy RXN/A **** N/A 58661 Laparoscopy, Surgical; With Removal Of PX C4 ΑV Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Saxenda Saxenda RX **** N/A N/A 58661 PX Laparoscopy, Surgical; With Removal Of C4 AVAdnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Xultophy10036 Xultophy 100/3.6 RXN/A N/A **** 58661 Laparoscopy, Surgical; With Removal Of PX C4 IΡ Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) **** Z33.2 **Encounter For Elective Termination Of** 10 DX ΑV

Medically Induced Abortion By Oral Ingestion

Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf

Complete Or Unspecified Spontaneous Abortion Without Complication

Pre-Existing Type 2 Diabetes Mellitus, In

Pre-Existing Type 2 Diabetes Mellitus, In

Obesity Complicating Pregnancy, First

Pre-Existing Type 2 Diabetes Mellitus, In

Right Ovarian Pregnancy Without Intrauterine

Mifenristone Oral 200 Mg

Pregnancy, First Trimester

Pregnancy, First Trimester

Pregnancy, First Trimester

Emergency Department Encounter

cder mpl1p wp077 Page 560 of 1023

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23x. Total Code Counts of Ozempic, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	n May 13, 2022 to June 30, 2023 for Episode Truncation	Code	Code	Overall
Code	Code Description	Category	Туре	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078
Trulicity	Trulicity	RX	N/A	508
Mounjaro	Mounjaro	RX	N/A	277
Rybelsus	Rybelsus	RX	N/A	191
Victoza	Victoza	RX	N/A	62
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****
023.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	НС	****
S0190	Mifepristone, Oral, 200 Mg	PX	НС	****
099.211	Obesity Complicating Pregnancy, First Trimester	DX	10	****
000.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 561 of 1023



Table 23y. Full Code Distribution of Rybelsus, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Sentiner Distributed Database Hor		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,633	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	83	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Mounjaro	Mounjaro	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	****	OA

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 562 of 1023



Table 23z. Total Code Counts of Rybelsus, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall
Code	Code Description	Category	Type	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746
Inpatientencounter	Inpatient Encounter	RX	N/A	531
Ozempic	Ozempic	RX	N/A	265
Trulicity	Trulicity	RX	N/A	83
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of Adnexal	PX	C4	****
	Structures (Partial Or Total Oophorectomy And/Or			
	Salpingectomy)			
002.1	Missed Abortion	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 563 of 1023



Table 23aa. Full Code Distribution of Wegovy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		Overall	Encounter
Code	Code Description	Category	Code Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 564 of 1023



Table 23ab. Total Code Counts of Wegovy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code		
Code	Code Description	Category	Code Type	Counts	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	
Ozempic	Ozempic	RX	N/A	****	
Inpatientencounter	Inpatient Encounter	RX	N/A	****	
Mounjaro	Mounjaro	RX	N/A	****	
Trulicity	Trulicity	RX	N/A	****	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 565 of 1023



Table 23ac. Full Code Distribution of Saxenda, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 566 of 1023



Table 23ad. Total Code Counts of Saxenda, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Victoza	Victoza	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 567 of 1023



Table 23ae. Full Code Distribution of Victoza, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic	RX	N/A	90	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous	DX	10	****	OA
003.9	Abortion Without Complication	DX	10		AV
003.9	Complete Or Unspecified Spontaneous	DX	10		ED
	Abortion Without Complication				
	Complete Or Unspecified Spontaneous				
	Abortion Without Complication				
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 568 of 1023



Table 23af. Total Code Counts of Victoza, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		Overall
Code	Code Description	Category	Code Type	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476
Inpatientencounter	Inpatient Encounter	RX	N/A	128
Ozempic	Ozempic	RX	N/A	90
Trulicity	Trulicity	RX	N/A	26
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	****
O03.9	Complete Or Unspecified Spontaneous Abortion	DX	10	****
	Without Complication			
Wegovy	Wegovy	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of Adnexal	PX	C4	****
	Structures (Partial Or Total Oophorectomy And/Or			
	Salpingectomy)			
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 569 of 1023



Table 23ag. Full Code Distribution of Trulicity, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and

	m May 13, 2022 to June 30, 2023 for Epi	Code	Code	Overall	Encounter Care Setting
Code	Code Description	Category	Type	Counts	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,512	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	380	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	114	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal	PX	C4	****	AV
	Of Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal	PX	C4	****	AV
	Of Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Wegovy	Wegovy	RX	N/A	****	N/A
023.011	Pre-Existing Type 1 Diabetes Mellitus,	DX	10	****	AV
	In Pregnancy, First Trimester				
023.111	Pre-Existing Type 2 Diabetes Mellitus,	DX	10	****	ED
	In Pregnancy, First Trimester				
O23.311	Unspecified Pre-Existing Diabetes	DX	10	****	OA
023.311	Mellitus In Pregnancy, First Trimester	DX	10		AV
023.311	Unspecified Pre-Existing Diabetes	271			,
	Mellitus In Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Lineigencyuepartinentencounter	Emergency Department Encounter	IVA	IN/A		IN/A

RX

RX

RX

N/A

N/A

N/A

N/A

N/A

N/A

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

Victoza

Saxenda

Victoza

cder_mpl1p_wp077 Page 570 of 1023

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 23ah. Total Code Counts of Trulicity, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts		
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823		
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606		
Ozempic	Ozempic	RX	N/A	380		
Mounjaro	Mounjaro	RX	N/A	114		
Rybelsus	Rybelsus	RX	N/A	87		
Victoza	Victoza	RX	N/A	33		
Bydureonbcise	Bydureon Bcise	RX	N/A	11		
58661	Laparoscopy, Surgical; With Removal (Of PX	C4	****		
	Adnexal Structures (Partial Or Total					
	Oophorectomy And/Or Salpingectomy	')				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****		
023.311	Unspecified Pre-Existing Diabetes	DX	10	****		
	Mellitus In Pregnancy, First Trimester					
Wegovy	Wegovy	RX	N/A	****		
023.011	Pre-Existing Type 1 Diabetes Mellitus,	In DX	10	****		
	Pregnancy, First Trimester					
023.111	Pre-Existing Type 2 Diabetes Mellitus,	In DX	10	****		
	Pregnancy, First Trimester					
Saxenda	Saxenda	RX	N/A	****		

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 571 of 1023



Table 23ai. Full Code Distribution of Xultophy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 572 of 1023



Table 23aj. Total Code Counts of Xultophy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		Overall
Code	Code Description	Category	Code Type	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 573 of 1023



Table 23ak. Full Code Distribution of Mounjaro, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous	DX	10	****	AV
	Abortion Without Complication				
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 574 of 1023



Table 23al. Total Code Counts of Mounjaro, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Inpatientencounter	Inpatient Encounter	RX	N/A	235
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
003.9	Complete Or Unspecified Spontaneous	DX	10	****
	Abortion Without Complication			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 575 of 1023



Table 23am. Full Code Distribution of Bydureon, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		Overall	Encounter
Code	Code Description	Category	Code Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 576 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23an. Total Code Counts of Bydureon, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	
Code	Code Description	Category	Code Type	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	93
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 577 of 1023



Table 23ao. Full Code Distribution of Ozempic, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel

Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Туре	Counts	Care Setting
mergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,840	N/A
npatientencounter	Inpatient Encounter	RX	N/A	****	N/A
rulicity	Trulicity	RX	N/A	508	N/A
npatientencounter	Inpatient Encounter	RX	N/A	****	N/A
mergency department encounter	Emergency Department Encounter	RX	N/A		N/A
/lounjaro	Mounjaro	RX	N/A	277	N/A
ybelsus	Rybelsus	RX	N/A	190	N/A
lictoza	Victoza	RX	N/A	62	N/A
ydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Vegovy	Wegovy	RX	N/A	****	N/A
8661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
axenda	Saxenda	RX	N/A	****	N/A
Kultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
88661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	IP
33.2	Encounter For Elective Termination Of	DX	10	****	AV
0199	Pregnancy	PX	HC		AV
0190	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf Mifepristone, Oral, 200 Mg	FA	НС		AV
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	AV
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	ED
000.201	Pregnancy, First Trimester Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10		ED
023.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****	ED
099.211	Obesity Complicating Pregnancy, First	DX	10	****	AV
023.111	Trimester	DX	10		AV
	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	****	N/A
•	Emergency Department Encounter	RX	N/A		, N/A
5 / 1 /	S 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		•		•

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 578 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23ap. Total Code Counts of Ozempic, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Overall	
Code	Code Description	Category	Code Type	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078
Trulicity	Trulicity	RX	N/A	508
Mounjaro	Mounjaro	RX	N/A	277
Rybelsus	Rybelsus	RX	N/A	191
Victoza	Victoza	RX	N/A	62
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****
023.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	НС	****
S0190	Mifepristone, Oral, 200 Mg	PX	НС	****
099.211	Obesity Complicating Pregnancy, First Trimester	DX	10	****
000.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

cder_mpl1p_wp077 Page 579 of 1023



Table 23aq. Full Code Distribution of Rybelsus, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	3, 2022 to June 30, 2023 for Episode Trunci	Code		Overall	Encounter	
Code	Code Description	Category	Code Type	Counts	Care Setting	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,633	N/A	
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A	
Ozempic	Ozempic	RX	N/A	****	N/A	
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A	
Trulicity	Trulicity	RX	N/A	83	N/A	
Mounjaro	Mounjaro	RX	N/A	****	N/A	
Victoza	Victoza	RX	N/A	12	N/A	
Wegovy	Wegovy	RX	N/A	****	N/A	
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A	
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A	
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV	
	Adnexal Structures (Partial Or Total					
	Oophorectomy And/Or Salpingectomy)					
Mounjaro	Mounjaro	RX	N/A	****	N/A	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A	
Ozempic	Ozempic	RX	N/A	****	N/A	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A	
002.1	Missed Abortion	DX	10	****	OA	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 580 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23ar. Total Code Counts of Rybelsus, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746
Inpatientencounter	Inpatient Encounter	RX	N/A	531
Ozempic	Ozempic	RX	N/A	265
Trulicity	Trulicity	RX	N/A	83
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
002.1	Missed Abortion	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 581 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23as. Full Code Distribution of Wegovy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 582 of 1023



Table 23at. Total Code Counts of Wegovy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 583 of 1023



Table 23au. Full Code Distribution of Saxenda, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter Care
Code	Code Description	Category	Type	Counts	Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 584 of 1023



Table 23av. Total Code Counts of Saxenda, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Victoza	Victoza	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 585 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23aw. Full Code Distribution of Victoza, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	s, 2022 to Julie 30, 2023 for Episode Truffca	Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic .	RX	N/A	90	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous	DX	10	****	AV
003.9	Abortion Without Complication	DX	10		OA
003.9	Complete Or Unspecified Spontaneous	DX	10		ED
	Abortion Without Complication				
	Complete Or Unspecified Spontaneous				
	Abortion Without Complication				
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 586 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23ax. Total Code Counts of Victoza, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Catego	Overall	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476
Inpatientencounter	Inpatient Encounter	RX	N/A	128
Ozempic	Ozempic	RX	N/A	90
Trulicity	Trulicity	RX	N/A	26
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	****
003.9	Complete Or Unspecified Spontaneous	DX	10	****
	Abortion Without Complication			
Wegovy	Wegovy	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 587 of 1023



Table 23ay. Full Code Distribution of Trulicity, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel

Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	5, 2022 to Julie 30, 2023 for Episode Fruitcati	Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,512	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	380	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	114	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
023.011	Pre-Existing Type 1 Diabetes Mellitus, In	DX	10	****	AV
	Pregnancy, First Trimester				
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	ED
	Pregnancy, First Trimester				
023.311	Unspecified Pre-Existing Diabetes Mellitus	DX	10	****	OA
023.311	In Pregnancy, First Trimester	DX	10		AV
	Unspecified Pre-Existing Diabetes Mellitus				
	In Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 588 of 1023



Table 23az. Total Code Counts of Trulicity, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Overall	
Code	Code Description	Category	Code Type	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606
Ozempic	Ozempic	RX	N/A	380
Mounjaro	Mounjaro	RX	N/A	114
Rybelsus	Rybelsus	RX	N/A	87
Victoza	Victoza	RX	N/A	33
Bydureonbcise	Bydureon Bcise	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
023.311	Unspecified Pre-Existing Diabetes Mellitus In	DX	10	****
	Pregnancy, First Trimester			
Wegovy	Wegovy	RX	N/A	****
023.011	Pre-Existing Type 1 Diabetes Mellitus, In	DX	10	****
	Pregnancy, First Trimester			
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****
	Pregnancy, First Trimester			
Saxenda	Saxenda	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 589 of 1023



Table 23ba. Full Code Distribution of Xultophy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 590 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23bb. Total Code Counts of Xultophy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	39
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 591 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23bc. Full Code Distribution of Mounjaro, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Туре	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous	DX	10	****	AV
	Abortion Without Complication				
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 592 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bd. Total Code Counts of Mounjaro, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Inpatientencounter	Inpatient Encounter	RX	N/A	235
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
003.9	Complete Or Unspecified Spontaneous	DX	10	****
	Abortion Without Complication			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 593 of 1023



Table 23be. Full Code Distribution of Bydureon, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		Overall	Encounter
Code	Code Description	Category	Code Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 594 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23bf. Total Code Counts of Bydureon, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	93
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	15
Trulicity	Trulicity	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 595 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23bg. Full Code Distribution of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and

Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	n May 13, 2022 to June 30, 2023 for Episodo	Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,840	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	508	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	277	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	62	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	AV
Saxenda	Saxenda	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	IP
Z33.2	Encounter For Elective Termination Of	DX	10	****	AV
S0199	Pregnancy	PX	HC		AV
S0190	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf Mifepristone, Oral, 200 Mg	PX	НС		AV
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	AV
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	ED
O00.201	Pregnancy, First Trimester Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10		ED

cder_mpl1p_wp077 Page 596 of 1023



Table 23bg. Full Code Distribution of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	ED
	Pregnancy, First Trimester				
O99.211	Obesity Complicating Pregnancy, First	DX	10	****	AV
023.111	Trimester	DX	10		AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
	Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 597 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23bh. Total Code Counts of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		Overall
Code	Code Description	Category	Code Type	Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078
Trulicity	Trulicity	RX	N/A	508
Mounjaro	Mounjaro	RX	N/A	277
Rybelsus	Rybelsus	RX	N/A	191
Victoza	Victoza	RX	N/A	62
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****
	Pregnancy, First Trimester			
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
003.9	Complete Or Unspecified Spontaneous	DX	10	****
	Abortion Without Complication			
Z33.2	Encounter For Elective Termination Of	DX	10	****
	Pregnancy			
S0199	Medically Induced Abortion By Oral	PX	НС	****
30133	Ingestion Of Medication Including All	17	110	
	Associated Services And Supplies (E.G.,			
	• • • • •			
	Patient Counseling, Office Visits,			
	Confirmation Of Pregnancy By Hcg,			
	Ultrasound To Conf			
S0190	Mifepristone, Oral, 200 Mg	PX	HC	****
099.211	Obesity Complicating Pregnancy, First	DX	10	****
	Trimester			
000.201	Right Ovarian Pregnancy Without	DX	10	****
	Intrauterine Pregnancy			

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 598 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23bi. Full Code Distribution of Rybelsus, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and

Sentinel Distributed Database from Ma	v 13, 2022 to June 30, 2023 for Episode Truncation
Jentinei Distributeu Database nomi Ma	7 13, 2022 to Julie 30, 2023 for Episode Fruitcation

Service Distributed Database He.	· · ·	Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,633	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	83	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Mounjaro	Mounjaro	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	****	OA

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 599 of 1023



Table 23bj. Total Code Counts of Rybelsus, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746
Inpatientencounter	Inpatient Encounter	RX	N/A	531
Ozempic	Ozempic	RX	N/A	265
Trulicity	Trulicity	RX	N/A	83
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
002.1	Missed Abortion	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 600 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23bk. Full Code Distribution of Wegovy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code		Encounter	
Code	Code Description	Category	Code Type	Counts	Care Setting	
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A	
	Encounter					
Ozempic	Ozempic	RX	N/A	****	N/A	
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A	
Mounjaro	Mounjaro	RX	N/A	****	N/A	
Trulicity	Trulicity	RX	N/A	****	N/A	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

cder_mpl1p_wp077 Page 601 of 1023



Table 23bl. Total Code Counts of Wegovy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	25
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 602 of 1023



Table 23bm. Full Code Distribution of Saxenda, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code Category Code Type		Overall	Encounter	
Code	Code Description			Counts	Care Setting	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A	
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A	
Ozempic	Ozempic	RX	N/A	****	N/A	
Wegovy	Wegovy	RX	N/A	****	N/A	
Trulicity	Trulicity	RX	N/A	****	N/A	
Rybelsus	Rybelsus	RX	N/A	****	N/A	
Victoza	Victoza	RX	N/A	****	N/A	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 603 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23bn. Total Code Counts of Saxenda, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Victoza	Victoza	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 604 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23bo. Full Code Distribution of Victoza, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic	RX	N/A	90	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous	DX	10	****	ED
003.9	Abortion Without Complication	DX	10		AV
003.9	Complete Or Unspecified Spontaneous	DX	10		OA
	Abortion Without Complication				
	Complete Or Unspecified Spontaneous				
	Abortion Without Complication				
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 605 of 1023



Table 23bp. Total Code Counts of Victoza, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		Overall	
Code	Code Description	Category	Code Type	Counts	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476	
Inpatientencounter	Inpatient Encounter	RX	N/A	128	
Ozempic	Ozempic	RX	N/A	90	
Trulicity	Trulicity	RX	N/A	26	
Rybelsus	Rybelsus	RX	N/A	14	
Bydureonbcise	Bydureon Bcise	RX	N/A	13	
Mounjaro	Mounjaro	RX	N/A	****	
003.9	Complete Or Unspecified Spontaneous	DX	10	****	
	Abortion Without Complication				
Wegovy	Wegovy	RX	N/A	****	
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Saxenda	Saxenda	RX	N/A	****	
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 606 of 1023



Table 23bq. Full Code Distribution of Trulicity, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and

Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	n May 13, 2022 to June 30, 2023 for Episode	Code	Code	Overall	Encounter
Code	Code Description	Category	Туре	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,512	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	380	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	114	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In	DX	10	****	AV
	Pregnancy, First Trimester				
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	ED
	Pregnancy, First Trimester				
023.311	Unspecified Pre-Existing Diabetes Mellitus	DX	10	****	OA
023.311	In Pregnancy, First Trimester	DX	10		AV
	Unspecified Pre-Existing Diabetes Mellitus				
	In Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 607 of 1023



Table 23br. Total Code Counts of Trulicity, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606
Ozempic	Ozempic	RX	N/A	380
Mounjaro	Mounjaro	RX	N/A	114
Rybelsus	Rybelsus	RX	N/A	87
, Victoza	Victoza	RX	N/A	33
Bydureonbcise	Bydureon Bcise	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
023.311	Unspecified Pre-Existing Diabetes	DX	10	****
	Mellitus In Pregnancy, First Trimester			
Wegovy	Wegovy	RX	N/A	****
023.011	Pre-Existing Type 1 Diabetes Mellitus, In	DX	10	****
	Pregnancy, First Trimester			
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****
	Pregnancy, First Trimester			
Saxenda	Saxenda	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 608 of 1023



Table 23bs. Full Code Distribution of Xultophy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 609 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23bt. Total Code Counts of Xultophy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic .	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 610 of 1023



Table 23bu. Full Code Distribution of Mounjaro, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous	DX	10	****	AV
	Abortion Without Complication				
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 611 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23bv. Total Code Counts of Mounjaro, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Innationtoncounter	Innationt Encounter	RX	N/A	235
Inpatientencounter	Inpatient Encounter		•	
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
003.9	Complete Or Unspecified Spontaneous	DX	10	****
	Abortion Without Complication			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 612 of 1023



Table 23bw. Full Code Distribution of Bydureon, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 613 of 1023



Table 23bx. Total Code Counts of Bydureon, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	93
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	15
Trulicity	Trulicity	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 614 of 1023



Table 23by. Full Code Distribution of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel

Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	13, 2022 to June 30, 2023 for Episode Trun	Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounte	Emergency Department Encounter	RX	N/A	6,840	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	508	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounte	Emergency Department Encounter	RX	N/A		N/A
r					
Mounjaro	Mounjaro	RX	N/A	277	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	62	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Saxenda	Saxenda	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	IP
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Z33.2	Encounter For Elective Termination Of	DX	10	****	AV
S0199	Pregnancy	PX	HC		AV
S0190	Medically Induced Abortion By Oral	PX	HC		AV
30190		ΓA	TIC		AV
	Ingestion Of Medication Including All				
	Associated Services And Supplies (E.G.,				
	Patient Counseling, Office Visits,				
	Confirmation Of Pregnancy By Hcg,				
	Ultrasound To Conf				
	Mifepristone. Oral. 200 Mg				
O03.9	Complete Or Unspecified Spontaneous	DX	10	****	AV
	Abortion Without Complication				
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	ED
000.201	Pregnancy, First Trimester	DX	10		ED
	Right Ovarian Pregnancy Without				
	Intrauterine Pregnancy				
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	ED
	Pregnancy, First Trimester				
O99.211	Obesity Complicating Pregnancy, First	DX	10	****	AV
023.111	Trimester	DX	10		AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
	Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	****	N/A
-	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 615 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23bz. Total Code Counts of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078
Trulicity	Trulicity	RX	N/A	508
Mounjaro	Mounjaro	RX	N/A	277
Rybelsus	Rybelsus	RX	N/A	191
Victoza	Victoza	RX	N/A	62
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****
	Pregnancy, First Trimester			
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
003.9	Complete Or Unspecified Spontaneous	DX	10	****
	Abortion Without Complication			
Z33.2	Encounter For Elective Termination Of	DX	10	****
	Pregnancy			
S0199	Medically Induced Abortion By Oral	PX	НС	****
30133	Ingestion Of Medication Including All			
	Associated Services And Supplies (E.G.,			
	• • • • • •			
	Patient Counseling, Office Visits,			
	Confirmation Of Pregnancy By Hcg,			
	Ultrasound To Conf			ale ale ale ale ale
S0190	Mifepristone, Oral, 200 Mg	PX	HC	****
O99.211	Obesity Complicating Pregnancy, First	DX	10	****
	Trimester			
O00.201	Right Ovarian Pregnancy Without	DX	10	****
	Intrauterine Pregnancy			

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 616 of 1023



Table 23ca. Full Code Distribution of Rybelsus, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel

Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	<u> </u>	Code	Code	Overall	Encounter Care
Code	Code Description	Category	Type	Counts	Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,633	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	83	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Mounjaro	Mounjaro	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	****	OA

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 617 of 1023



Table 23cb. Total Code Counts of Rybelsus, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746
Inpatientencounter	Inpatient Encounter	RX	N/A	531
Ozempic	Ozempic	RX	N/A	265
Trulicity	Trulicity	RX	N/A	83
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of PX C4 *****			
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
002.1	Missed Abortion	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 618 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23cc. Full Code Distribution of Wegovy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel

Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code			Encounter Care
Code	Code Description	Category	Code Type	Overall Counts	Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A
	Encounter				
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

cder_mpl1p_wp077 Page 619 of 1023



Table 23cd. Total Code Counts of Wegovy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 620 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23ce. Full Code Distribution of Saxenda, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter Care
Code	Code Description	Category	Type	Counts	Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A
	Encounter				
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 621 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23cf. Total Code Counts of Saxenda, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Victoza	Victoza	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 622 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23cg. Full Code Distribution of Victoza, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel

Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

), 1011 to same 50, 1010 to 12,000 to 11 and	Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic	RX	N/A	90	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous	DX	10	****	ED
003.9	Abortion Without Complication	DX	10		OA
003.9	Complete Or Unspecified Spontaneous	DX	10		AV
	Abortion Without Complication				
	Complete Or Unspecified Spontaneous				
	Abortion Without Complication				
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 623 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable



Table 23ch. Total Code Counts of Victoza, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476
Inpatientencounter	Inpatient Encounter	RX	N/A	128
Ozempic	Ozempic	RX	N/A	90
Trulicity	Trulicity	RX	N/A	26
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	****
O03.9	Complete Or Unspecified Spontaneous	DX	10	****
	Abortion Without Complication			
Wegovy	Wegovy	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 624 of 1023



Table 23cj. Total Code Counts of Trulicity, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	
Code	Code Description	Category	Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606
Ozempic	Ozempic	RX	N/A	380
Mounjaro	Mounjaro	RX	N/A	114
Rybelsus	Rybelsus	RX	N/A	87
Victoza	Victoza	RX	N/A	33
Bydureonbcise	Bydureon Bcise	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
023.311	Unspecified Pre-Existing Diabetes Mellitus In	DX	10	****
	Pregnancy, First Trimester			
Wegovy	Wegovy	RX	N/A	****
023.011	Pre-Existing Type 1 Diabetes Mellitus, In	DX	10	****
	Pregnancy, First Trimester			
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****
	Pregnancy, First Trimester		-	
Saxenda	Saxenda	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 625 of 1023



Table 23ci. Full Code Distribution of Trulicity, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel

Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Distributed Butabase from May 1	3, 2022 to June 30, 2023 for Episode Truncation	711			Encounter	
		Code	Code	Overall	Care	
Code	Code Description	Category	Type	Counts	Setting	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,508	N/A	
		D.V	/.	4 205	21/2	
Inpatientencounter	Inpatient Encounter	RX	N/A	1,295	N/A	
Ozempic	Ozempic	RX	N/A	380 ****	N/A	
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A	
Mounjaro	Mounjaro	RX	N/A	114	N/A	
Rybelsus	Rybelsus	RX	N/A	****	N/A	
Victoza	Victoza	RX	N/A	****	N/A	
Bydureonbcise	Bydureon Bcise	RX	N/A	11	N/A	
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV	
	Adnexal Structures (Partial Or Total					
	Oophorectomy And/Or Salpingectomy)					
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A	
Wegovy	Wegovy	RX	N/A	****	N/A	
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In	DX	10	****	AV	
	Pregnancy, First Trimester					
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	ED	
	Pregnancy, First Trimester					
023.311	Unspecified Pre-Existing Diabetes Mellitus In	DX	10	****	OA	
023.311	Pregnancy, First Trimester	DX	10		AV	
	Unspecified Pre-Existing Diabetes Mellitus In					
	Pregnancy, First Trimester					
Rybelsus	Rybelsus	RX	N/A	****	N/A	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A	
zmergeney departmenteneounter	Emergency Department Encounter	100	14,71		14//	
Victoza	Victoza	RX	N/A	****	N/A	
${\it Emergency department} encounter$	Emergency Department Encounter	RX	N/A		N/A	
Saxenda	Saxenda	RX	N/A	****	N/A	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

cder_mpl1p_wp077 Page 626 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.



Table 23ck. Full Code Distribution of Xultophy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter Care
Code	Code Description	Category	Type	Counts	Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A
	Encounter				
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department	RX	N/A		N/A
	Encounter				
Ozempic	Ozempic	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 627 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23cl. Total Code Counts of Xultophy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department	RX	N/A	****
	Encounter			
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 628 of 1023



Table 23cm. Full Code Distribution of Mounjaro, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	AV
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 629 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23cn. Total Code Counts of Mounjaro, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Inpatientencounter	Inpatient Encounter	RX	N/A	235
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
003.9	Complete Or Unspecified Spontaneous	DX	10	****
	Abortion Without Complication			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 630 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23co. Full Code Distribution of Bydureon, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter Care
Code	Code Description	Category	Type	Counts	Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A
	Encounter				
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	15	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department	RX	N/A		N/A
	Encounter				
Victoza	Victoza	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 631 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23cp. Total Code Counts of Bydureon, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	93
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	15
Trulicity	Trulicity	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 632 of 1023



Table 23cq. Full Code Distribution of Ozempic, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel

Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Туре	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,834	N/A
npatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	508	N/A
npatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	277	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
/ictoza	Victoza	RX	N/A	62	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Vegovy	Wegovy	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
Saxenda	Oophorectomy And/Or Salpingectomy) Saxenda	DV	N/A	****	N/A
	Xultophy 100/3.6	RX RX	-	****	N/A N/A
Kultophy10036 58661	Laparoscopy, Surgical; With Removal Of		N/A C4	****	IP
90001		PA	C4		IP
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)			ale ale ale ale	
233.2	Encounter For Elective Termination Of	DX	10	****	AV
50199	Pregnancy	PX	HC		AV
60190	Medically Induced Abortion By Oral	PX	HC		AV
	Ingestion Of Medication Including All				
	Associated Services And Supplies (E.G.,				
	Patient Counseling, Office Visits,				
	Confirmation Of Pregnancy By Hcg,				
	Ultrasound To Conf				
	Mifepristone. Oral. 200 Mg				
003.9	Complete Or Unspecified Spontaneous	DX	10	****	AV
	Abortion Without Complication				
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	ED
000.201	Pregnancy, First Trimester	DX	10		ED
500.201	Right Ovarian Pregnancy Without	DX	10		LD
	= -				
023.111	Intrauterine Pregnancy	DV	10	****	ED.
J23.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10		ED
200 244	Pregnancy, First Trimester	DV	10	****	A) /
099.211	Obesity Complicating Pregnancy, First	DX	10	- ጉጥጥጥ	AV
023.111	Trimester	DX	10		AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
	Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 633 of 1023



Table 23cr. Total Code Counts of Ozempic, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed

Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	ne 30, 2023 for Episode Truncation	Code	Code	Overall	
Code	Code Description	Category	Type	Counts	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340	
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078	
Trulicity	Trulicity	RX	N/A	508	
Mounjaro	Mounjaro	RX	N/A	277	
Rybelsus	Rybelsus	RX	N/A	191	
Victoza	Victoza	RX	N/A	62	
Bydureonbcise	Bydureon Bcise	RX	N/A	17	
Wegovy	Wegovy	RX	N/A	****	
58661	Laparoscopy, Surgical; With Removal Of Adnexal	PX	C4	****	
	Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)				
023.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****	
Saxenda	Saxenda	RX	N/A	****	
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	****	
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	****	
S0190	Mifepristone, Oral, 200 Mg	PX	НС	****	
099.211	Obesity Complicating Pregnancy, First Trimester	DX	10	****	
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	****	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 634 of 1023



Table 23cs. Full Code Distribution of Rybelsus, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel

Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,633	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	83	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal	PX	C4	****	AV
	Of Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)			
Mounjaro	Mounjaro	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	****	OA

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 635 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23ct. Total Code Counts of Rybelsus, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746	
Inpatientencounter	Inpatient Encounter	RX	N/A	531	
Ozempic	Ozempic	RX	N/A	265	
Trulicity	Trulicity	RX	N/A	83	
Mounjaro	Mounjaro	RX	N/A	52	
Victoza	Victoza	RX	N/A	12	
Wegovy	Wegovy	RX	N/A	****	
Bydureonbcise	Bydureon Bcise	RX	N/A	****	
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	
58661	Laparoscopy, Surgical; With Removal O	of PX	C4	****	
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
002.1	Missed Abortion	DX	10	****	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 636 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23cu. Full Code Distribution of Wegovy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code			Encounter
Code	Code Description	Category	Code Type	Overall Counts	Care Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A
	Encounter				
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 637 of 1023



Table 23cv. Total Code Counts of Wegovy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 638 of 1023



Table 23cw. Full Code Distribution of Saxenda, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter Care
Code	Code Description	Category	Type	Counts	Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A
	Encounter				
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 639 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23cx. Total Code Counts of Saxenda, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Victoza	Victoza	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 640 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23cy. Full Code Distribution of Victoza, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic	RX	N/A	90	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous	DX	10	****	ED
003.9	Abortion Without Complication	DX	10		OA
003.9	Complete Or Unspecified Spontaneous	DX	10		AV
	Abortion Without Complication				
	Complete Or Unspecified Spontaneous				
	Abortion Without Complication				
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 641 of 1023



Table 23cz. Total Code Counts of Victoza, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476	
Inpatientencounter	Inpatient Encounter	RX	N/A	128	
Ozempic	Ozempic	RX	N/A	90	
Trulicity	Trulicity	RX	N/A	26	
Rybelsus	Rybelsus	RX	N/A	14	
Bydureonbcise	Bydureon Bcise	RX	N/A	13	
Mounjaro	Mounjaro	RX	N/A	****	
003.9	Complete Or Unspecified Spontaneous	DX	10	****	
	Abortion Without Complication				
Wegovy	Wegovy	RX	N/A	****	
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Saxenda	Saxenda	RX	N/A	****	
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 642 of 1023



Table 23da. Full Code Distribution of Trulicity, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel

Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	, 2022 to Julie 30, 2023 for Episode Hulle	Code	Code	Overall	Encounter	
Code	Code Description	Category	Type	Counts	Care Setting	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,508	N/A	
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A	
Ozempic	Ozempic	RX	N/A	380	N/A	
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A	
Mounjaro	Mounjaro	RX	N/A	114	N/A	
Rybelsus	Rybelsus	RX	N/A	****	N/A	
Victoza	Victoza	RX	N/A	****	N/A	
Bydureonbcise	Bydureon Bcise	RX	N/A	11	N/A	
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****	AV	
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A	
Wegovy	Wegovy	RX	N/A	****	N/A	
023.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****	AV	
023.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****	ED	
023.311	Unspecified Pre-Existing Diabetes	DX	10	****	OA	
023.311	Mellitus In Pregnancy, First Trimester Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10		AV	
Rybelsus	Rybelsus	RX	N/A	****	N/A	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A	
Victoza	Victoza	RX	N/A	****	N/A	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A	
Saxenda	Saxenda	RX	N/A	****	N/A	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 643 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23db. Total Code Counts of Trulicity, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	· · · · · · · · · · · · · · · · · · ·	Code	Code	
Code	Code Description	Category	Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606
Ozempic	Ozempic	RX	N/A	380
Mounjaro	Mounjaro	RX	N/A	114
Rybelsus	Rybelsus	RX	N/A	87
Victoza	Victoza	RX	N/A	33
Bydureonbcise	Bydureon Bcise	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
023.311	Unspecified Pre-Existing Diabetes Mellitus	DX	10	****
	In Pregnancy, First Trimester			
Wegovy	Wegovy	RX	N/A	****
023.011	Pre-Existing Type 1 Diabetes Mellitus, In	DX	10	****
	Pregnancy, First Trimester			
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****
	Pregnancy, First Trimester			
Saxenda	Saxenda	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 644 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23dc. Full Code Distribution of Xultophy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code		Encounter
Code	Code Description	Category	Type	Overall Counts	Care Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A
	Encounter				
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department	RX	N/A		N/A
	Encounter				
Ozempic	Ozempic	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 645 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23dd. Total Code Counts of Xultophy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 646 of 1023



Table 23de. Full Code Distribution of Mounjaro, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous	DX	10	****	AV
	Abortion Without Complication				
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 647 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23df. Total Code Counts of Mounjaro, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Inpatientencounter	Inpatient Encounter	RX	N/A	235
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
O03.9	Complete Or Unspecified Spontaneous	DX	10	****
	Abortion Without Complication			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 648 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23dg. Full Code Distribution of Bydureon, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter Care
Code	Code Description	Category	Type	Counts	Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A
	Encounter				
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department	RX	N/A		N/A
	Encounter				
Victoza	Victoza	RX	N/A	****	N/A
_Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 649 of 1023



Table 23dh. Total Code Counts of Bydureon, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 650 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23di. Full Code Distribution of Ozempic, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel

Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,840	N/A
npatientencounter	Inpatient Encounter	RX	N/A	****	N/A
rulicity	Trulicity	RX	N/A	508	N/A
npatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	277	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
/ictoza	Victoza	RX	N/A	62	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Vegovy	Wegovy	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Saxenda	Saxenda	RX	N/A	****	N/A
Kultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
88661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total	PX	C4	****	IP
	Oophorectomy And/Or Salpingectomy)				
233.2	Encounter For Elective Termination Of	DX	10	****	AV
60199	Pregnancy	PX	HC		AV
50190	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf Mifepristone, Oral, 200 Mg	PX	НС		AV
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	AV
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	ED
000.201	Pregnancy, First Trimester Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10		ED
023.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****	ED
099.211	Obesity Complicating Pregnancy, First	DX	10	****	AV
023.111	Trimester Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10		AV
	i regnancy, i not innicoter				
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 651 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23dj. Total Code Counts of Ozempic, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078
Trulicity	Trulicity	RX	N/A	508
Mounjaro	Mounjaro	RX	N/A	277
Rybelsus	Rybelsus	RX	N/A	191
Victoza	Victoza	RX	N/A	62
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	НС	****
S0190	Mifepristone, Oral, 200 Mg	PX	НС	****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	****
000.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 652 of 1023



Table 23dk. Full Code Distribution of Rybelsus, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	11 Way 13, 2022 to June 30, 2023 for Episo	Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,633	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	83	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Mounjaro	Mounjaro	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	****	OA

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 653 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable



Table 23dl. Total Code Counts of Rybelsus, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746
Inpatientencounter	Inpatient Encounter	RX	N/A	531
Ozempic	Ozempic	RX	N/A	265
Trulicity	Trulicity	RX	N/A	83
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
002.1	Missed Abortion	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 654 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23dm. Full Code Distribution of Wegovy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	Code				Encounter	
Code	Code Description	Category	Code Type	Overall Counts	Care Setting	
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A	
	Encounter					
Ozempic	Ozempic	RX	N/A	****	N/A	
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A	
Mounjaro	Mounjaro	RX	N/A	****	N/A	
Trulicity	Trulicity	RX	N/A	****	N/A	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 655 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23dn. Total Code Counts of Wegovy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 656 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23do. Full Code Distribution of Saxenda, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code		Code	Code		Encounter
	Code Description	Category	Code Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A
	Encounter				
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 657 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23dp. Total Code Counts of Saxenda, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Wegovy	Wegovy	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****
Victoza	Victoza	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 658 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23dq. Full Code Distribution of Victoza, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel

Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

	· · · · · · ·	Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
					4-
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic	RX	N/A	90	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous	DX	10	****	ED
O03.9	Abortion Without Complication	DX	10		OA
O03.9	Complete Or Unspecified Spontaneous	DX	10		AV
	Abortion Without Complication				
	Complete Or Unspecified Spontaneous				
	Abortion Without Complication				
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 659 of 1023



Table 23dr. Total Code Counts of Victoza, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476
Inpatientencounter	Inpatient Encounter	RX	N/A	128
Ozempic	Ozempic	RX	N/A	90
Trulicity	Trulicity	RX	N/A	26
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	****
O03.9	Complete Or Unspecified Spontaneous	DX	10	****
	Abortion Without Complication			
Wegovy	Wegovy	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 660 of 1023



Table 23ds. Full Code Distribution of Trulicity, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and

Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation Code Code Overall Encounter Code **Code Description** Category Type Counts **Care Setting Emergency Department Encounter** Emergencydepartmentencounter RX 4,512 N/A N/A **** Inpatientencounter Inpatient Encounter RXN/A N/A Ozempic RXOzempic N/A 380 N/A **** Inpatientencounter Inpatient Encounter RXN/A N/A Emergencydepartmentencounter **Emergency Department Encounter** RXN/A N/A RXN/A N/A Mounjaro Mounjaro 114 **** Rybelsus Rybelsus RXN/A N/A **** Victoza Victoza RXN/A N/A Bydureonbcise Bydureon Bcise RXN/A N/A 11 **** 58661 Laparoscopy, Surgical; With Removal Of PX C4 ΑV Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy) Xultophy10036 Xultophy 100/3.6 RXN/A N/A **** Wegovy Wegovy RX N/A N/A 023.011 Pre-Existing Type 1 Diabetes Mellitus, In DX 10 AVPregnancy, First Trimester **** 023.111 Pre-Existing Type 2 Diabetes Mellitus, In DX 10 ED Pregnancy, First Trimester 023.311 10 **Unspecified Pre-Existing Diabetes** DX OA 023.311 Mellitus In Pregnancy, First Trimester DX 10 ΑV **Unspecified Pre-Existing Diabetes** Mellitus In Pregnancy, First Trimester Rybelsus Rybelsus RX N/A **** N/A Emergencydepartmentencounter **Emergency Department Encounter** RXN/A N/A Victoza Victoza RXN/A N/A Emergencydepartmentencounter **Emergency Department Encounter** RXN/A N/A

RX

N/A

N/A

Saxenda

cder_mpl1p_wp077 Page 661 of 1023

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23dt. Total Code Counts of Trulicity, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code		
Code	Code Description	Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606
Ozempic	Ozempic	RX	N/A	380
Mounjaro	Mounjaro	RX	N/A	114
Rybelsus	Rybelsus	RX	N/A	87
Victoza	Victoza	RX	N/A	33
Bydureonbcise	Bydureon Bcise	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
023.311	Unspecified Pre-Existing Diabetes	DX	10	****
	Mellitus In Pregnancy, First Trimester			
Wegovy	Wegovy	RX	N/A	****
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In	DX	10	****
	Pregnancy, First Trimester			
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****
	Pregnancy, First Trimester			
Saxenda	Saxenda	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 662 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23du. Full Code Distribution of Xultophy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code		Encounter Care
Code	Code Description	Category	Type	Overall Counts	Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A
	Encounter				
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department	RX	N/A		N/A
	Encounter				
Ozempic	Ozempic	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 663 of 1023



Table 23dv. Total Code Counts of Xultophy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department	RX	N/A	****
	Encounter			
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 664 of 1023



Table 23dw. Full Code Distribution of Mounjaro, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
/ictoza	Victoza	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
(ultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	AV
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 665 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23dx. Total Code Counts of Mounjaro, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Inpatientencounter	Inpatient Encounter	RX	N/A	235
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
O03.9	Complete Or Unspecified Spontaneous	DX	10	****
	Abortion Without Complication			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 666 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23dy. Full Code Distribution of Bydureon, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter Care
Code	Code Description	Category	Type	Counts	Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A
	Encounter				
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department	RX	N/A		N/A
	Encounter				
Victoza	Victoza	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 667 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23dz. Total Code Counts of Bydureon, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	93
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Victoza	Victoza	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 668 of 1023



Table 23ea. Full Code Distribution of Ozempic, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,834	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	508	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	277	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	62	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total	PX	C4	****	AV
	Oophorectomy And/Or Salpingectomy)				
Saxenda	Saxenda	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total	PX	C4	****	IP
Z33.2	Oophorectomy And/Or Salpingectomy) Encounter For Elective Termination Of	DX	10	****	AV
S0199	Pregnancy	PX	HC		AV
S0190	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	НС		AV
003.9	Mifepristone. Oral, 200 Mg Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****	AV
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****	ED
000.201	Pregnancy, First Trimester Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10		ED
023.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****	ED
099.211	Obesity Complicating Pregnancy, First	DX	10	****	AV
023.111	Trimester Pre-Existing Type 2 Diabetes Mellitus, In	DX	10		AV
	Pregnancy, First Trimester	5 1/		ماد ماد باد باد	
Rybelsus	Rybelsus	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 669 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23eb. Total Code Counts of Ozempic, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078
Trulicity	Trulicity	RX	N/A	508
Mounjaro	Mounjaro	RX	N/A	277
Rybelsus	Rybelsus	RX	N/A	191
Victoza	Victoza	RX	N/A	62
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total	PX	C4	****
023.111	Oophorectomy And/Or Salpingectomy) Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits,	PX	НС	****
	Confirmation Of Pregnancy By Hcg, Ultrasound To Conf			
S0190	Mifepristone, Oral, 200 Mg	PX	HC	****
099.211	Obesity Complicating Pregnancy, First Trimester	DX	10	****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 670 of 1023



Table 23ec. Full Code Distribution of Rybelsus, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

and Sentiner Distributed Database		Code	Code	Overall	Encounter
Code	Code Description	Category	Туре	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,632	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	83	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	****	OA

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 671 of 1023



Table 23ed. Total Code Counts of Rybelsus, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746
Inpatientencounter	Inpatient Encounter	RX	N/A	531
Ozempic	Ozempic	RX	N/A	265
Trulicity	Trulicity	RX	N/A	83
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	****
Bydureonbcise	Bydureon Bcise	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal	PX	C4	****
	Of Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)		
002.1	Missed Abortion	DX	10	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 672 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23ee. Full Code Distribution of Wegovy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter Care
Code	Code Description	Category	Type	Counts	Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A
	Encounter				
Ozempic	Ozempic	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Trulicity	Trulicity	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 673 of 1023



Table 23ef. Total Code Counts of Wegovy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Mounjaro	Mounjaro	RX	N/A	****
Trulicity	Trulicity	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 674 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23eg. Full Code Distribution of Saxenda, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter Care	
Code	Code Description	Category	Type	Counts	Setting	
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A	
	Encounter					
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A	
Ozempic	Ozempic	RX	N/A	****	N/A	
Wegovy	Wegovy	RX	N/A	****	N/A	
Trulicity	Trulicity	RX	N/A	****	N/A	
Rybelsus	Rybelsus	RX	N/A	****	N/A	
Victoza	Victoza	RX	N/A	****	N/A	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 675 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23eh. Total Code Counts of Saxenda, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****	
Inpatientencounter	Inpatient Encounter	RX	N/A	****	
Ozempic	Ozempic	RX	N/A	****	
Trulicity	Trulicity	RX	N/A	****	
Wegovy	Wegovy	RX	N/A	****	
Rybelsus	Rybelsus	RX	N/A	****	
Victoza	Victoza	RX	N/A	****	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 676 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23ei. Full Code Distribution of Victoza, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter
Code	Code Description	Category	Type	Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic	RX	ν/Α	90	, N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	****	N/A
Wegovy	Wegovy	RX	N/A	****	N/A
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****	AV
	Adnexal Structures (Partial Or Total				
	Oophorectomy And/Or Salpingectomy)				
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A
003.9	Complete Or Unspecified Spontaneous	DX	10	****	ED
003.9	Abortion Without Complication	DX	10		OA
003.9	Complete Or Unspecified Spontaneous	DX	10		AV
	Abortion Without Complication				
	Complete Or Unspecified Spontaneous				
	Abortion Without Complication				
Saxenda	Saxenda	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

cder_mpl1p_wp077 Page 677 of 1023

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable



Table 23ej. Total Code Counts of Victoza, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476
Inpatientencounter	Inpatient Encounter	RX	N/A	128
Ozempic	Ozempic	RX	N/A	90
Trulicity	Trulicity	RX	N/A	26
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	****
003.9	Complete Or Unspecified Spontaneous	DX	10	****
	Abortion Without Complication			
Wegovy	Wegovy	RX	N/A	****
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
Saxenda	Saxenda	RX	N/A	****
Xultophy10036	Xultophy 100/3.6	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 678 of 1023



Table 23ek. Full Code Distribution of Trulicity, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database

and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code	Overall	Encounter	
Code	Code Description	Category	Type	Counts	Care Setting	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,512	N/A	
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A	
Ozempic	Ozempic	RX	N/A	380	N/A	
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A	
Mounjaro	Mounjaro	RX	N/A	114	N/A	
Rybelsus	Rybelsus	RX	N/A	****	N/A	
Victoza	Victoza	RX	N/A	****	N/A	
Bydureonbcise	Bydureon Bcise	RX	N/A	11	N/A	
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Ophorectomy And/Or Salpingectomy)	PX	C4	****	AV	
Xultophy10036	Xultophy 100/3.6	RX	N/A	****	N/A	
Wegovy	Wegovy	RX	N/A	****	N/A	
023.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****	AV	
023.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	****	ED	
023.311	Unspecified Pre-Existing Diabetes Mellitus In	DX	10	****	OA	
023.311	Pregnancy, First Trimester Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10		AV	
Rybelsus	Rybelsus	RX	N/A	****	N/A	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A	
Victoza	Victoza	RX	N/A	****	N/A	
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A	
Saxenda	Saxenda	RX	N/A	****	N/A	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 679 of 1023



Table 23el. Total Code Counts of Trulicity, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606
Ozempic	Ozempic	RX	N/A	380
Mounjaro	Mounjaro	RX	N/A	114
Rybelsus	Rybelsus	RX	N/A	87
Victoza	Victoza	RX	N/A	33
Bydureonbcise	Bydureon Bcise	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of	PX	C4	****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
Xultophy10036	Xultophy 100/3.6	RX	N/A	****
023.311	Unspecified Pre-Existing Diabetes	DX	10	****
	Mellitus In Pregnancy, First Trimester			
Wegovy	Wegovy	RX	N/A	****
023.011	Pre-Existing Type 1 Diabetes Mellitus, In	DX	10	****
	Pregnancy, First Trimester			
023.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	****
	Pregnancy, First Trimester			
Saxenda	Saxenda	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day. N/A: Not applicable

cder_mpl1p_wp077 Page 680 of 1023



Table 23em. Full Code Distribution of Xultophy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Code	Code		Encounter Care
Code	Code Description	Category	Type	Overall Counts	Setting
Emergencydepartmentencounter	Emergency Department	RX	N/A	****	N/A
	Encounter				
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	****	N/A
Emergencydepartmentencounter	Emergency Department	RX	N/A		N/A
	Encounter				
Ozempic	Ozempic	RX	N/A	****	N/A
Rybelsus	Rybelsus	RX	N/A	****	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

cder_mpl1p_wp077 Page 681 of 1023



Table 23en. Total Code Counts of Xultophy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	****
Inpatientencounter	Inpatient Encounter	RX	N/A	****
Ozempic	Ozempic	RX	N/A	****
Rybelsus	Rybelsus	RX	N/A	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

cder_mpl1p_wp077 Page 682 of 1023



Table 24. Summary of Patient-Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydu	reon	Mou	njaro	Ozer	npic	Rybe	elsus	Saxe	nda
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic	raphic require	ments								
Enrolled at any point during the query										
period Had required coverage type (medical	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A
and/or drug coverage)	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183
Enrolled during specified age range	64,062,253	435	64,062,253	435	64,062,253	435	64,062,253	435	64,062,253	435
Had requestable medical charts	64,062,253	0	64,062,253	0	64,062,253	0	64,062,253	0	64,062,253	0
Met demographic requirements (sex, race,										
and Hispanic origin)	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428
Members with a valid index event										
Had any cohort-defining claim during the										
query period	28,331	63,995,494	111,549	63,912,276	759,923	63,263,902	144,832	63,878,993	35,314	63,988,511
Claim recorded during specified age range Episode defining index claim recorded	28,331	0	111,549	0	759,923	0	144,832	0	35,314	0
during the query period	25,705	2,626	111,549	0	732,176	27,747	138,261	6,571	34,747	567
Members with required pre-index history										
Had sufficient pre-index continuous										
enrollment	21,407	4,298	85,913	25,636	577,425	154,751	109,675	28,586	29,118	5,629
Met inclusion and exclusion criteria ¹	****	****	18,996	66,917	117,721	459,704	34,260	75,415	386	28,732
Evidence of gestational diabetes Evidence of insulin with no evidence of	N/A	****	N/A	115	N/A	701	N/A	52	N/A	100
any anti-diabetic drug Evidence of other secondary diabetes	N/A	1,656	N/A	4,483	N/A	39,740	N/A	3,364	N/A	182
illness	N/A	1,751	N/A	3,897	N/A	34,029	N/A	5,946	N/A	108
Evidence of pregnancy Evidence of short-acting GLP-1 receptor	N/A	35	N/A	532	N/A	2,621	N/A	214	N/A	542
agonist	N/A	104	N/A	562	N/A	2,155	N/A	314	N/A	****
Evidence of type 1 diabetes	N/A	1,236	N/A	3,308	N/A	26,508	N/A	3,138	N/A	188
Evidence of washout	N/A	19,689	N/A	54,323	N/A	398,929	N/A	66,865	N/A	21,063
No evidence of inclusion criteria	N/A	3,737	N/A	36,260	N/A	207,285	N/A	23601	N/A	27,984
Met event incidence criteria	****	0	18,996	0	117,721	0	34,260	0	386	0
Members with required post-index follow-	-up									
Had sufficient post-index continuous										
enrollment	****	0	18,996	0	117,721	0	34,260	0	386	0
Had minimum days' supply on index date	****	0	18,996	0	117,721	0	34,260	0	386	0

cder_mpl1p_wp077



Table 24. Summary of Patient-Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon Mounjaro Ozempic		npic	Rybelsus		Saxenda				
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Had index episode of at least required										
length Had index episode longer than blackout	****	0	18,996	0	117,721	0	34,260	0	386	0
period Did not have an event during blackout	1,321	****	18,842	154	117,008	713	34,058	202	386	0
period	1,321	0	18,842	0	117,008	0	34,058	0	386	0
Final cohort										
Number of members	1,321	N/A	18,842	N/A	117,008	N/A	34,058	N/A	386	N/A
Number of episodes	1,321	N/A	18,842	N/A	117,008	N/A	34,058	N/A	386	N/A

¹Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

cder_mpl1p_wp077

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented. N/A: Not Applicable



Table 24. Summary of Patient-Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

(continued)	Truli	city	Vict	oza	Weg	govy	Xulto	ophy
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A
Had required coverage type (medical and/or drug coverage)	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183
Enrolled during specified age range	64,062,253	435	64,062,253	435	64,062,253	435	64,062,253	435
Had requestable medical charts	64,062,253	0	64,062,253	0	64,062,253	0	64,062,253	0
Met demographic requirements (sex, race, and Hispanic origin)	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428
Members with a valid index event								
Had any cohort-defining claim during the query period	600,556	63,423,269	130,989	63,892,836	75,900	63,947,925	7,954	64,015,871
Claim recorded during specified age range	600,556	0	130,989	0	75,900	0	7,954	0
Episode defining index claim recorded during the query period	563,759	36,797	119,663	11,326	75,220	680	7,348	606
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	439,194	123,565	96,267	23,396	63,144	12,076	6,067	1,281
Met inclusion and exclusion criteria ¹	67,310	371,884	5,398	90,869	842	62,302	****	****
Evidence of gestational diabetes	N/A	159	N/A	28	N/A	216	N/A	0
Evidence of insulin with no evidence of any anti-diabetic drug	N/A	41,097	N/A	11,935	N/A	365	N/A	491
Evidence of other secondary diabetes illness	N/A	35,989	N/A	7,729	N/A	175	N/A	531
Evidence of pregnancy	N/A	732	N/A	187	N/A	1,168	N/A	****
Evidence of short-acting GLP-1 receptor agonist	N/A	1,446	N/A	235	N/A	****	N/A	101
Evidence of type 1 diabetes	N/A	25,028	N/A	6,049	N/A	419	N/A	476
Evidence of washout	N/A	354,726	N/A	87,843	N/A	34,794	N/A	5,590
No evidence of inclusion criteria	N/A	92,962	N/A	26,549	N/A	60,678	N/A	1,376
Met event incidence criteria	67,310	0	5,398	0	842	0	****	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	67,310	0	5,398	0	842	0	****	0
Had minimum days' supply on index date	67,310	0	5,398	0	842	0	****	0
Had index episode of at least required length	67,310	0	5,398	0	842	0	****	0
Had index episode longer than blackout period	66,978	332	5,354	44	828	14	364	****
Did not have an event during blackout period	66,978	0	5,354	0	828	0	364	0
Final cohort								
Number of members	66,978	N/A	5,354	N/A	828	N/A	364	N/A
Number of episodes	66,978	N/A	5,354	N/A	828	N/A	364	N/A

¹Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

N/A: Not Applicable

cder_mpl1p_wp077

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (September 28, 2023)

Masked DP ID ¹	DP Start Date	DP End Date ¹
DP01	07/01/2017	05/31/2023
DP02	07/01/2017	05/31/2023
DP03	01/01/2000	10/31/2022
DP04	01/01/2017	03/31/2023
DP05	01/01/2010	12/31/2022
DP06	01/01/2017	04/30/2023
DP07	07/01/2017	06/30/2023

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

cder_mpl1p_wp077 Page 686 of 1023



Appendix B. Generic and Brand Names of Medical Products Used to Define Exposures or Exposure Washout in this Request

Generic Name	Brand Name	
	Mounjaro (tirzepatide)	
tirzepatide	Mounjaro	
	Bydureon, Bydureon BCISE (exenatide synthetic)	
exenatide microspheres	Bydureon	
exenatide microspheres	Bydureon BCise	
	Ozempic (semaglutide)	
semaglutide	Ozempic	
	Rybelsus (semaglutide)	
semaglutide	Rybelsus	
	Wegovy (semaglutide)	
semaglutide	Wegovy	
	Saxenda (liraglutide)	
liraglutide	Saxenda	
	Victoza (liraglutide)	
liraglutide	Victoza 2-Pak	
liraglutide	Victoza 3-Pak	
	Trulicity (dulaglutide)	
dulaglutide	Trulicity	
	Xultophy (insulin degludec/liraglutide)	

insulin degludec/liraglutide Xultophy 100/3.6

cder_mpl1p_wp077 Page 687 of 1023



Appendix C. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Tachyarrhythmia in this Request

		Code	
Code	Description	Category	Code Type
	Atrial Fibrillation and Flutter		
148	Atrial fibrillation and flutter	Diagnosis	ICD-10-CM
148.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
148.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
148.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
148.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
148.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
148.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
148.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
148.3	Typical atrial flutter	Diagnosis	ICD-10-CM
148.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
148.9	Unspecified atrial fibrillation and atrial flutter	Diagnosis	ICD-10-CM
148.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
148.92	Unspecified atrial flutter	Diagnosis	ICD-10-CM
	Sinus Tachycardia		
R00.0	Tachycardia, unspecified	Diagnosis	ICD-10-CM
	Supraventricular Tachycardia		
147.1	Supraventricular tachycardia	Diagnosis	ICD-10-CM
147.9	Paroxysmal tachycardia, unspecified	Diagnosis	ICD-10-CM
149.1	Atrial premature depolarization	Diagnosis	ICD-10-CM
149.2	Junctional premature depolarization	Diagnosis	ICD-10-CM
149.9	Cardiac arrhythmia, unspecified	Diagnosis	ICD-10-CM
	Other Tachycardia		
147	Paroxysmal tachycardia	Diagnosis	ICD-10-CM
149	Other cardiac arrhythmias	Diagnosis	ICD-10-CM
149.3	Ventricular premature depolarization	Diagnosis	ICD-10-CM
149.4	Other and unspecified premature depolarization	Diagnosis	ICD-10-CM
149.40	Unspecified premature depolarization	Diagnosis	ICD-10-CM
149.49	Other premature depolarization	Diagnosis	ICD-10-CM
149.8	Other specified cardiac arrhythmias	Diagnosis	ICD-10-CM
	Cardiac Arrest		
146	Cardiac arrest	Diagnosis	ICD-10-CM
146.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
146.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
146.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
	Ventricular Fibrillation and Flutter		
149.0	Ventricular fibrillation and flutter	Diagnosis	ICD-10-CM
149.01	Ventricular fibrillation	Diagnosis	ICD-10-CM
149.02	Ventricular flutter	Diagnosis	ICD-10-CM
	Ventricular Tachycardia		
147.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
147.2	Ventricular tachycardia	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 688 of 1023



	·	Code	
Code	Description	Category	Code Type
	Type 2 Diabetes Mellitus		
E11	Type 2 diabetes mellitus	Diagnosis	ICD-10-CM
E11.0	Type 2 diabetes mellitus with hyperosmolarity	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-	Diagnosis	ICD-10-CM
	hvperosmolar coma (NKHHC)		
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.1	Type 2 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.2	Type 2 diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.3	Type 2 diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E11.31	Type 2 diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.32	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema		
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, right eye		
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, left eye	_	
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, bilateral	g	
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
L11.3219		Diagnosis	ICD-10-CIVI
E44 220	edema, unspecified eye	5	100 40 614
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema		
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema, right eye		
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema, left eye		
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema, bilateral	g	
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
L11.3233		Diagnosis	ICD-10-CIVI
E44.00	edema, unspecified eye	. .	100 10 014
E11.33	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema		
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, right eye		
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, left eye		

cder_mpl1p_wp077 Page 689 of 1023



to Define I	nclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular		ICD-10-CM
	edema, bilateral	. 0	
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, unspecified eye	J	
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema	J	
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, right eye		
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, left eye		
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, bilateral		
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, unspecified eye		
E11.34	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema		
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, right eye		
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E11 2412	edema, left eye	Diamonia	ICD 10 CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
L11.3419	edema, unspecified eye	Diagnosis	ICD-10-CIVI
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
L11.545	macular edema	Diagnosis	ICD TO CIVI
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, right eye	- 110111111	
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, left eye	J	
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, bilateral	_	
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, unspecified eye		
E11.35	Type 2 diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right	Diagnosis	ICD-10-CM
	eye		
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left	Diagnosis	ICD-10-CM
	eye		
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema,	Diagnosis	ICD-10-CM
	bilateral		

cder_mpl1p_wp077 Page 690 of 1023



Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

to benne n	iciasion of Exclusion Criteria in this request	Code	
Code	Description	Category	Code Type
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema,	Diagnosis	ICD-10-CM
	unspecified eye		
E11.352	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment involving the macula		
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment involving the macula, right eye		
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment involving the macula, left eye		
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment involving the macula, bilateral		
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment involving the macula, unspecified eye		
E11.353	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment not involving the macula		
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment not involving the macula, right eye		
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment not involving the macula, left eye		
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment not involving the macula, bilateral	J	
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment not involving the macula, unspecified eye	J	
E11.354	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
	retinal detachment and rhegmatogenous retinal detachment		
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
	retinal detachment and rhegmatogenous retinal detachment, right eye		
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
	retinal detachment and rhegmatogenous retinal detachment, left eye		
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
	retinal detachment and rhegmatogenous retinal detachment, bilateral	g	
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
	retinal detachment and rhegmatogenous retinal detachment, unspecified eye	2108110010	.02 20 0
E11.355	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
	right eye		
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
	left eye		
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
	bilateral		

cder_mpl1p_wp077 Page 691 of 1023



Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

13 200 11	iciusion of Exclusion Criteria in this Nequest	Code	
Code	Description	Category	Code Type
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
	unspecified eye		
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right	Diagnosis	ICD-10-CM
	eye	Ü	
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left	Diagnosis	ICD-10-CM
	eye	_	
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment,	Diagnosis	ICD-10-CM
	bilateral		
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment,	Diagnosis	ICD-10-CM
	unspecified eye		
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.4	Type 2 diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.5	Type 2 diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.6	Type 2 diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E11.61	Type 2 diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.62	Type 2 diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with 100t dicer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin dicer	Diagnosis	ICD-10-CM
E11.63	Type 2 diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	<u> </u>	ICD-10-CM
		Diagnosis	
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.64	Type 2 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
F4.0	Type 1 Diabetes Mellitus	D: :	100.40.014
E10	Type 1 diabetes mellitus	Diagnosis	ICD-10-CM
E10.1	Type 1 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.2	Type 1 diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 692 of 1023



to Benne n	iciasion of Exclusion Citiena in this nequest	Code	
Code	Description	Category	Code Type
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.3	Type 1 diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E10.31	Type 1 diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.32	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema	Ü	
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, right eye	J	
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, left eye	_	
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, bilateral	J	
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema, unspecified eye	J	
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema	J	
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema, right eye	J	
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema, left eye	J	
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema, bilateral	Ü	
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema, unspecified eye	2.0000.0	.02 20 0
E10.33	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	-	ICD-10-CM
110.551	edema	Diagnosis	ICD-10-CIVI
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
110.5511	edema, right eye	Diagnosis	ICD-10-CIVI
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
110.5512	edema, left eye	Diagnosis	ICD 10 CIVI
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
210.5515	edema, bilateral	Diagnosis	TED TO CIVI
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
L10.5515	edema, unspecified eye	Diagnosis	100 10 0141
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
L10.333	macular edema	Piagilusis	ICD-TO-CIAI
E10 2201		Diagnosis	ICD 10 CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, right eye		

cder_mpl1p_wp077 Page 693 of 1023



to benne n	nciusion or exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, left eye		
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
F10 2200	macular edema, bilateral	Diagrapia	ICD 10 CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.34	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema	Ü	
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, left eye		
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.35	Type 1 diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left	Diagnosis	ICD-10-CM
	еуе		
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.352	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 694 of 1023



	icidsion of Exclusion Citiena in this nequest	Code	
Code	Description	Category	Code Type
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment involving the macula, bilateral		
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment involving the macula, unspecified eye		
E10.353	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment not involving the macula		
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment not involving the macula, right eye		
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment not involving the macula, left eye		
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment not involving the macula, bilateral		
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
	detachment not involving the macula, unspecified eye		
E10.354	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
	retinal detachment and rhegmatogenous retinal detachment		
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
	retinal detachment and rhegmatogenous retinal detachment, right eye		
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
	retinal detachment and rhegmatogenous retinal detachment, left eye		
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
	retinal detachment and rhegmatogenous retinal detachment, bilateral		
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction	Diagnosis	ICD-10-CM
	retinal detachment and rhegmatogenous retinal detachment, unspecified eye		
E10.355	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553 E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CW
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
	right eye	J	
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
	left eye	J	
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
	bilateral	J	
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
	unspecified eye	J	
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right	Diagnosis	ICD-10-CM
	eye		
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left	Diagnosis	ICD-10-CM
	eye		

cder_mpl1p_wp077 Page 695 of 1023



to benne n	iciusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment,	Diagnosis	ICD-10-CM
	bilateral		
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment,	Diagnosis	ICD-10-CM
	unspecified eye	.0	
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.4	Type 1 diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.5	Type 1 diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.6	Type 1 diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E10.61	Type 1 diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.62	Type 1 diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.63	Type 1 diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.64	Type 1 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
	Gestational Diabetes		
024.4	Gestational diabetes mellitus	Diagnosis	ICD-10-CM
024.41	Gestational diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
024.410	Gestational diabetes mellitus in pregnancy, diet controlled	Diagnosis	ICD-10-CM
024.414	Gestational diabetes mellitus in pregnancy, insulin controlled	Diagnosis	ICD-10-CM
024.415	Gestational diabetes mellitus in pregnancy, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
024.419	Gestational diabetes mellitus in pregnancy, unspecified control	Diagnosis	ICD-10-CM
024.42	Gestational diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
024.420	Gestational diabetes mellitus in childbirth, diet controlled	Diagnosis	ICD-10-CM
024.424	Gestational diabetes mellitus in childbirth, insulin controlled	Diagnosis	ICD-10-CM
024.425	Gestational diabetes mellitus in childbirth, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
024.429	Gestational diabetes mellitus in childbirth, unspecified control	Diagnosis	ICD-10-CM
024.43	Gestational diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
024.430	Gestational diabetes mellitus in the puerperium, diet controlled	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 696 of 1023



	inclusion of Exclusion Criteria in this request	Code	
Code	Description	Category	Code Type
024.434	Gestational diabetes mellitus in the puerperium, insulin controlled	Diagnosis	ICD-10-CM
024.435	Gestational diabetes mellitus in puerperium, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
024.439	Gestational diabetes mellitus in the puerperium, unspecified control	Diagnosis	ICD-10-CM
500	Other Secondary Diabetes Illnesses	<u>.</u>	100 10 011
E08	Diabetes mellitus due to underlying condition	Diagnosis	ICD-10-CM
E08.0	Diabetes mellitus due to underlying condition with hyperosmolarity	Diagnosis	ICD-10-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.1	Diabetes mellitus due to underlying condition with ketoacidosis	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.2	Diabetes mellitus due to underlying condition with kidney complications	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.3	Diabetes mellitus due to underlying condition with ophthalmic complications	Diagnosis	ICD-10-CM
E08.31	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.32	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 697 of 1023



	inclusion of Exclusion Criteria in this request	Code	
Code	Description	Category	Code Type
E08.33	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic	Diagnosis	ICD-10-CM
	retinopathy		
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.34	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 698 of 1023



	inclusion of Exclusion effects in this request	Code	
Code	Description	Category	Code Type
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic	Diagnosis	ICD-10-CM
	retinopathy without macular edema, unspecified eye		
E08.35	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema		
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema, left eye		
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema, bilateral		
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema, unspecified eye		
E08.352	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	traction retinal detachment involving the macula		
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	traction retinal detachment involving the macula, right eye		
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	traction retinal detachment involving the macula, left eye		
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
F00 2F20	traction retinal detachment involving the macula, bilateral	Diamonia	ICD 10 CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.353	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
EU0.333	traction retinal detachment not involving the macula	Diagnosis	ICD-10-CIVI
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	traction retinal detachment not involving the macula, right eye	- 10011011	
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	traction retinal detachment not involving the macula, left eye		
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	traction retinal detachment not involving the macula, bilateral		
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	traction retinal detachment not involving the macula, unspecified eye		
E08.354	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	combined traction retinal detachment and rhegmatogenous retinal detachment		
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	combined traction retinal detachment and rhegmatogenous retinal detachment, right eye		
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	combined traction retinal detachment and rhegmatogenous retinal detachment, left eye		
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 699 of 1023



		Code	
Code	Description	Category	Code Type
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	combined traction retinal detachment and rhegmatogenous retinal detachment,		
	unspecified eye		
E08.355	Diabetes mellitus due to underlying condition with stable proliferative diabetic	Diagnosis	ICD-10-CM
	retinopathy	g	
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic	Diagnosis	ICD-10-CM
100.0001	retinopathy, right eye	Diagnosis	100 10 0111
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic	Diagnosis	ICD-10-CM
.00.3332	retinopathy, left eye	Diagnosis	TED TO CIVI
08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic	Diagnosis	ICD-10-CM
-00.5555	retinopathy, bilateral	Diagnosis	ICD-10-CIVI
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic	Diagnosis	ICD-10-CM
.00.3333	retinopathy, unspecified eye	Diagnosis	ICD-10-CIVI
E08.359		Diagnosis	ICD 10 CM
108.339	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
TOO 2501	without macular edema	Diagnosis	ICD 10 CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
.00 2502	without macular edema, right eye	Diamonia	100 40 604
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
	without macular edema, left eye		100 10 011
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
	without macular edema, bilateral		
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
	without macular edema, unspecified eye		
08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved	Diagnosis	ICD-10-CM
	following treatment		
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved	Diagnosis	Diagnosis ICD-10-CM
	following treatment, right eye		
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved	Diagnosis	ICD-10-CM
	following treatment, left eye		
08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved	Diagnosis	ICD-10-CM
	following treatment, bilateral		
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved	Diagnosis	ICD-10-CM
	following treatment, unspecified eye		
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.4	Diabetes mellitus due to underlying condition with neurological complications	Diagnosis	ICD-10-CM
08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological	Diagnosis	ICD-10-CM
	complication		
08.5	Diabetes mellitus due to underlying condition with circulatory complications	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 700 of 1023



to Benne n	iciasion of Exclusion Citiena in this nequest	Code	
Code	Description	Category	Code Type
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without	Diagnosis	ICD-10-CM
	gangrene		
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with	Diagnosis	ICD-10-CM
	gangrene	Ü	
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.6	Diabetes mellitus due to underlying condition with other specified complications	Diagnosis	ICD-10-CM
E08.61	Diabetes mellitus due to underlying condition with diabetic arthropathy	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.62	Diabetes mellitus due to underlying condition with skin complications	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.63	Diabetes mellitus due to underlying condition with oral complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.64	Diabetes mellitus due to underlying condition with hypoglycemia	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E13	Other specified diabetes mellitus	Diagnosis	ICD-10-CM
E13.0	Other specified diabetes mellitus with hyperosmolarity	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-		ICD-10-CM
	hyperosmolar coma (NKHHC)		
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.1	Other specified diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.2	Other specified diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.3	Other specified diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E13.31	Other specified diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular	Diagnosis	ICD-10-CM
	edema		
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema	2.0800.0	.02 20 0
E12 22	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10 CM
E13.32	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with	Diagnosis Diagnosis	ICD-10-CM
E13.321		סומצווטאוא	ICD-10-CM
	macular edema		
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema, right eye		

cder_mpl1p_wp077 Page 701 of 1023



	·	Code	
Code	Description	Category	Code Type
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema, left eye		
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema, bilateral		
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema, unspecified eye		
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema		
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, right eye		
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, left eye		
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, bilateral		
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without	Diagnosis	ICD-10-CM
	macular edema, unspecified eye		
E13.33	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E12 2211	macular edema Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with	Diagnosis	ICD 10 CM
E13.3311	macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
E13.3312	macular edema, left eye	Diagnosis	ICD-10-CIVI
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
L13.3313	macular edema, bilateral	Diagnosis	ICD 10 CIVI
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
213.0013	macular edema, unspecified eye	Diagnosis	100 10 011
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
	without macular edema	. 6	
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
	without macular edema, right eye	J	
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
	without macular edema, left eye	_	
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
	without macular edema, bilateral		
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
	without macular edema, unspecified eye		
E13.34	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema		
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema, right eye		
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with	Diagnosis	ICD-10-CM
	macular edema, left eye		

cder_mpl1p_wp077 Page 702 of 1023



		Code	
Code	Description	Category	Code Type
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.35	Other specified diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.352	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.353	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 703 of 1023



to benne n	iciusion of Exclusion Citteria in this Nequest	Code	
Code	Description	Category	Code Type
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction	Diagnosis	ICD-10-CM
	retinal detachment not involving the macula, unspecified eye		
E13.354	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined	Diagnosis	ICD-10-CM
	traction retinal detachment and rhegmatogenous retinal detachment		
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined	Diagnosis	ICD-10-CM
	traction retinal detachment and rhegmatogenous retinal detachment, right eye		
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined	Diagnosis	ICD-10-CM
	traction retinal detachment and rhegmatogenous retinal detachment, left eye		
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined	Diagnosis	ICD-10-CM
	traction retinal detachment and rhegmatogenous retinal detachment, bilateral		
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined	Diagnosis	ICD-10-CM
	traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye		
E13.355	Other specified diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified	Diagnosis	ICD-10-CM
	eye		
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema		
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema, right eye		
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema, left eye		
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema, bilateral		
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
	edema, unspecified eye	J	
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.37	Other specified diabetes mellitus with diabetic macular edema, resolved following	Diagnosis	ICD-10-CM
	treatment	J	
E13.37X1	Other specified diabetes mellitus with diabetic macular edema, resolved following	Diagnosis	ICD-10-CM
	treatment, right eye		
E13.37X2	Other specified diabetes mellitus with diabetic macular edema, resolved following	Diagnosis	ICD-10-CM
213.3772	treatment, left eye	5146116313	102 10 011
E13.37X3	Other specified diabetes mellitus with diabetic macular edema, resolved following	Diagnosis	ICD-10-CM
L13.37 N3	treatment, bilateral	Diagnosis	ICD IO CIVI
E13.37X9	Other specified diabetes mellitus with diabetic macular edema, resolved following	Diagnosis	ICD-10-CM
E13.3/A9	treatment, unspecified eye	Diagnosis	ICD-10-CIVI
E12.20		Diagnasia	ICD 10 CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.4 E13.40	Other specified diabetes mellitus with neurological complications Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
E13.40 E13.41	Other specified diabetes mellitus with diabetic neuropathy, unspecified Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.41 E13.42	Other specified diabetes mellitus with diabetic monorieuropathy	Diagnosis	ICD-10-CW
E13.42	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CW
L1J.7J	other specified diabetes memoral with diabete autonomic (polymetropathy	5105110313	ICD TO CIVI

cder_mpl1p_wp077 Page 704 of 1023



to benne n	iciasion of Exclusion Criteria in this request	Code	
Code	Description	Category	Code Type
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.5	Other specified diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.6	Other specified diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E13.61	Other specified diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.62	Other specified diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.63	Other specified diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.64	Other specified diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
	Pregnancy		
O00	Ectopic pregnancy	Diagnosis	ICD-10-CM
O0000	Abdominal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O0001	Abdominal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00101	Right tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00102	Left tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00109	Unspecified tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
000111	Right tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00112	Left tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
000119	Unspecified tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00201	Right ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00202	Left ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00209	Unspecified ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00211	Right ovarian pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00212	Left ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00219	Unspecified ovarian pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
0008	Other ectopic pregnancy	Diagnosis	ICD-10-CM
00080	Other ectopic pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O0081	Other ectopic pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O009	Ectopic pregnancy, unspecified	Diagnosis	ICD-10-CM
00090	Unspecified ectopic pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O0091	Unspecified ectopic pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O01	Hydatidiform mole	Diagnosis	ICD-10-CM
001.0	Classical hydatidiform mole	Diagnosis	ICD-10-CM
001.1	Incomplete and partial hydatidiform mole	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 705 of 1023



to Benne n	icidsion of Exclusion Criteria in this nequest	Code	
Code	Description	Category	Code Type
001.9	Hydatidiform mole, unspecified	Diagnosis	ICD-10-CM
O02.0	Blighted ovum and nonhydatidiform mole	Diagnosis	ICD-10-CM
O02.1	Missed abortion	Diagnosis	ICD-10-CM
O0289	Other abnormal products of conception	Diagnosis	ICD-10-CM
O029	Abnormal products of conception, unspecified	Diagnosis	ICD-10-CM
O03	Spontaneous abortion	Diagnosis	ICD-10-CM
003.0	Genital tract and pelvic infection following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.1	Delayed or excessive hemorrhage following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.2	Embolism following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.3	Other and unspecified complications following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.30	Unspecified complication following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.31	Shock following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.32	Renal failure following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.33	Metabolic disorder following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.34	Damage to pelvic organs following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.35	Other venous complications following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.36	Cardiac arrest following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.37	Sepsis following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.38	Urinary tract infection following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.39	Incomplete spontaneous abortion with other complications	Diagnosis	ICD-10-CM
003.4	Incomplete spontaneous abortion with other complications	Diagnosis	ICD-10-CIVI
003.5	Genital tract and pelvic infection following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.5	defined tract and pervic infection following complete of unspecified spontaneous abortion	Diagnosis	ICD-10-CIVI
O03.6	Delayed or excessive hemorrhage following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.7	Embolism following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.7	Other and unspecified complications following complete or unspecified spontaneous	Diagnosis	ICD-10-CW
003.8	abortion	Diagnosis	ICD-10-CIVI
O03.80	Unspecified complication following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.81	Shock following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.82	Renal failure following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O03.83	Metabolic disorder following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O03.84	Damage to pelvic organs following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O03.85	Other venous complications following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
O03.86	Cardiac arrest following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.87	Sepsis following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.88	Urinary tract infection following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.89	Complete or unspecified spontaneous abortion with other complications	Diagnosis	ICD-10-CM
003.9	Complete or unspecified spontaneous abortion without complication	Diagnosis	ICD-10-CM
O04.5	Genital tract and pelvic infection following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.6	Delayed or excessive hemorrhage following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.7	Embolism following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.80	(Induced) termination of pregnancy with unspecified complications	Diagnosis	ICD-10-CM
004.81	Shock following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.82	Renal failure following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.83	Metabolic disorder following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.83	Damage to pelvic organs following (induced) termination of pregnancy	Diagnosis	ICD-10-CIVI
004.85	Other venous complications following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.86	Cardiac arrest following (induced) termination of pregnancy	Diagnosis	ICD-10-CIVI
304.00	caracter are est rollowing (induced) termination of pregnancy	5 105110313	LOD TO CIVI

cder_mpl1p_wp077 Page 706 of 1023



Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

	·	Code	
Code	Description	Category	Code Type
O04.87	Sepsis following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O04.88	Urinary tract infection following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
O04.89	(Induced) termination of pregnancy with other complications	Diagnosis	ICD-10-CM
O07.30	Failed attempted termination of pregnancy with unspecified complications	Diagnosis	ICD-10-CM
007.35	Other venous complications following failed attempted termination of pregnancy	Diagnosis	ICD-10-CM
O07.36	Cardiac arrest following failed attempted termination of pregnancy	Diagnosis	ICD-10-CM
O07.38	Urinary tract infection following failed attempted termination of pregnancy	Diagnosis	ICD-10-CM
O07.39	Failed attempted termination of pregnancy with other complications	Diagnosis	ICD-10-CM
0080	Genitl trct and pelvic infct fol ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O081	Delayed or excess hemor fol ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O082	Embolism following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O083	Shock following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O084	Renal failure following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O085	Metabolic disorders following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O086	Damage to pelvic organs and tiss fol an ect and molar preg	Diagnosis	ICD-10-CM
O087	Oth venous comp following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O0881	Cardiac arrest following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O0882	Sepsis following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O0883	Urinary tract infection fol an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O0889	Other complications following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O089	Unsp complication following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
O10.02	Pre-existing essential hypertension complicating childbirth	Diagnosis	ICD-10-CM
O10.12	Pre-existing hypertensive heart disease complicating childbirth	Diagnosis	ICD-10-CM
010.22	Pre-existing hypertensive chronic kidney disease complicating childbirth	Diagnosis	ICD-10-CM
O10.32	Pre-existing hypertensive heart and chronic kidney disease complicating childbirth	Diagnosis	ICD-10-CM
010.42	Pre-existing secondary hypertension complicating childbirth	Diagnosis	ICD-10-CM
010.92	Unspecified pre-existing hypertension complicating childbirth	Diagnosis	ICD-10-CM
011.4	Pre-existing hypertension with pre-eclampsia, complicating childbirth	Diagnosis	ICD-10-CM
012.04	Gestational edema, complicating childbirth	Diagnosis	ICD-10-CM
012.14	Gestational proteinuria, complicating childbirth	Diagnosis	ICD-10-CM
012.24	Gestational edema with proteinuria, complicating childbirth	Diagnosis	ICD-10-CM
013.4	Gestational [pregnancy-induced] hypertension without significant proteinuria,	Diagnosis	ICD-10-CM
	complicating childbirth	- 100.1001	
O14.04	Mild to moderate pre-eclampsia, complicating childbirth	Diagnosis	ICD-10-CM
014.14	Severe pre-eclampsia complicating childbirth	Diagnosis	ICD-10-CM
014.24	HELLP syndrome, complicating childbirth	Diagnosis	ICD-10-CM
014.94	Unspecified pre-eclampsia, complicating childbirth	Diagnosis	ICD-10-CM
016.4	Unspecified maternal hypertension, complicating childbirth	Diagnosis	ICD-10-CM
O24	Diabetes mellitus in pregnancy, childbirth, and the puerperium	Diagnosis	ICD-10-CM
O24.0	Pre-existing type 1 diabetes mellitus, in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
024.01	Pre-existing type 1 diabetes mellitus, in pregnancy	Diagnosis	ICD-10-CM
024.011	Pre-existing type 1 diabetes mellitus, in pregnancy, first trimester	Diagnosis	ICD-10-CM
024.012	Pre-existing type 1 diabetes mellitus, in pregnancy, second trimester	Diagnosis	ICD-10-CM
024.013	Pre-existing type 1 diabetes mellitus, in pregnancy, third trimester	Diagnosis	ICD-10-CM
024.019	Pre-existing type 1 diabetes mellitus, in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
024.02	Pre-existing type 1 diabetes mellitus, in childbirth	Diagnosis	ICD-10-CM
024.03	Pre-existing type 1 diabetes mellitus, in the puerperium	Diagnosis	ICD-10-CM
024.1	Pre-existing type 2 diabetes mellitus, in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
024.11	Pre-existing type 2 diabetes mellitus, in pregnancy	Diagnosis	ICD-10-CM
024.111	Pre-existing type 2 diabetes mellitus, in pregnancy, first trimester	Diagnosis	ICD-10-CM
U =		_ 105110313	

cder_mpl1p_wp077 Page 707 of 1023



	iciasion of Exclusion Criteria in this request	Code	
Code	Description	Category	Code Type
024.112	Pre-existing type 2 diabetes mellitus, in pregnancy, second trimester	Diagnosis	ICD-10-CM
024.113	Pre-existing type 2 diabetes mellitus, in pregnancy, third trimester	Diagnosis	ICD-10-CM
024.119	Pre-existing type 2 diabetes mellitus, in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
024.12	Pre-existing type 2 diabetes mellitus, in childbirth	Diagnosis	ICD-10-CM
024.13	Pre-existing type 2 diabetes mellitus, in the puerperium	Diagnosis	ICD-10-CM
024.3	Unspecified pre-existing diabetes mellitus in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
024.31	Unspecified pre-existing diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
024.311	Unspecified pre-existing diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
024.312	Unspecified pre-existing diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
024.313	Unspecified pre-existing diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
024.319	Unspecified pre-existing diabetes mellitus in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
024.32	Unspecified pre-existing diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
024.33	Unspecified pre-existing diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
024.420	Gestational diabetes mellitus in childbirth, diet controlled	Diagnosis	ICD-10-CM
024.424	Gestational diabetes mellitus in childbirth, insulin controlled	Diagnosis	ICD-10-CM
024.425	Gestational diabetes mellitus in childbirth, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
024.429	Gestational diabetes mellitus in childbirth, unspecified control	Diagnosis	ICD-10-CM
O24.8	Other pre-existing diabetes mellitus in pregnancy, childbirth, and the puerperium	Diagnosis	ICD-10-CM
024.81	Other pre-existing diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
024.811	Other pre-existing diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
024.812	Other pre-existing diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
024.813	Other pre-existing diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
024.819	Other pre-existing diabetes mellitus in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
024.82	Other pre-existing diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O24.83	Other pre-existing diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
O24.9	Unspecified diabetes mellitus in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
024.91	Unspecified diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
024.911	Unspecified diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
024.912	Unspecified diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
024.913	Unspecified diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
024.919	Unspecified diabetes mellitus in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
024.92	Unspecified diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
024.93	Unspecified diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
025.2	Malnutrition in childbirth	Diagnosis	ICD-10-CM
026.62	Liver and biliary tract disorders in childbirth	Diagnosis	ICD-10-CM
O26.72	Subluxation of symphysis (pubis) in childbirth	Diagnosis	ICD-10-CM
O31.00X0	Papyraceous fetus, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.00X1	Papyraceous fetus, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O31.00X2	Papyraceous fetus, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O31.00X3	Papyraceous fetus, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O31.00X4	Papyraceous fetus, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O31.00X5	Papyraceous fetus, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O31.00X9	Papyraceous fetus, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
O31.02X0	Papyraceous fetus, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.02X1	Papyraceous fetus, second trimester, fetus 1	Diagnosis	ICD-10-CM
O31.02X2	Papyraceous fetus, second trimester, fetus 2	Diagnosis	ICD-10-CM
O31.02X3	Papyraceous fetus, second trimester, fetus 3	Diagnosis	ICD-10-CM
O31.02X4	Papyraceous fetus, second trimester, fetus 4	Diagnosis	ICD-10-CM
O31.02X5	Papyraceous fetus, second trimester, fetus 5	Diagnosis	ICD-10-CM
O31.02X9	Papyraceous fetus, second trimester, other fetus	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 708 of 1023



Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

to benne n	icidsion of Exclusion Citiena in this nequest	Code	
Code	Description	Category	Code Type
O31.03X0	Papyraceous fetus, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.03X1	Papyraceous fetus, third trimester, fetus 1	Diagnosis	ICD-10-CM
O31.03X2	Papyraceous fetus, third trimester, fetus 2	Diagnosis	ICD-10-CM
O31.03X3	Papyraceous fetus, third trimester, fetus 3	Diagnosis	ICD-10-CM
O31.03X4	Papyraceous fetus, third trimester, fetus 4	Diagnosis	ICD-10-CM
O31.03X5	Papyraceous fetus, third trimester, fetus 5	Diagnosis	ICD-10-CM
O31.03X9	Papyraceous fetus, third trimester, other fetus	Diagnosis	ICD-10-CM
031.1	Continuing pregnancy after spontaneous abortion of one fetus or more	Diagnosis	ICD-10-CM
031.10	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester	Diagnosis	ICD-10-CM
O31.10X0	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.10X1	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O31.10X2	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O31.10X3	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O31.10X4	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O31.10X5	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O31.10X9	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
031.11	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester	Diagnosis	ICD-10-CM
O31.11X0	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, not applicable or unspecified		ICD-10-CM
O31.11X1	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 1	Diagnosis	ICD-10-CM
O31.11X2	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 2	Diagnosis	ICD-10-CM
O31.11X3	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 3	Diagnosis	ICD-10-CM
O31.11X4	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 4	Diagnosis	ICD-10-CM
O31.11X5	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 5	Diagnosis	ICD-10-CM
O31.11X9	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, other fetus	Diagnosis	ICD-10-CM
O31.12 O31.12X0	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, not applicable or unspecified	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
O31.12X1	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 1	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 709 of 1023



to benne n	nclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
O31.12X2	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 2	Diagnosis	ICD-10-CM
O31.12X3	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 3	Diagnosis	ICD-10-CM
O31.12X4	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 4	Diagnosis	ICD-10-CM
O31.12X5	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 5	Diagnosis	ICD-10-CM
O31.12X9	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, other fetus	Diagnosis	ICD-10-CM
O31.13 O31.13X0	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, not applicable or unspecified	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
O31.13X1	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 1	Diagnosis	ICD-10-CM
O31.13X2	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 2	Diagnosis	ICD-10-CM
O31.13X3	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 3	Diagnosis	ICD-10-CM
O31.13X4	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 4	Diagnosis	ICD-10-CM
O31.13X5	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 5	Diagnosis	ICD-10-CM
O31.13X9	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, other fetus	Diagnosis	ICD-10-CM
031.2	Continuing pregnancy after intrauterine death of one fetus or more	Diagnosis	ICD-10-CM
O31.20 O31.20X0	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester,	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
O31.20X1	not applicable or unspecified Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O31.20X2	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O31.20X3	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O31.20X4	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O31.20X5	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O31.20X9	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
O31.22 O31.22X0	Continuing pregnancy after intrauterine death of one fetus or more, second trimester Continuing pregnancy after intrauterine death of one fetus or more, second trimester, not applicable or unspecified	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM

cder_mpl1p_wp077 Page 710 of 1023



to benne n	iciusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
O31.22X1	Continuing pregnancy after intrauterine death of one fetus or more, second trimester,	Diagnosis	ICD-10-CM
	fetus 1		
O31.22X2	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 2	Diagnosis	ICD-10-CM
O31.22X3	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 3	Diagnosis	ICD-10-CM
O31.22X4	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 4	Diagnosis	ICD-10-CM
O31.22X5	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 5	Diagnosis	ICD-10-CM
O31.22X9	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, other fetus	Diagnosis	ICD-10-CM
031.23	Continuing pregnancy after intrauterine death of one fetus or more, third trimester	Diagnosis	ICD-10-CM
O31.23X0	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.23X1	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus	Diagnosis	ICD-10-CM
O31.23X2	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus	Diagnosis	ICD-10-CM
O31.23X3	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus	Diagnosis	ICD-10-CM
O31.23X4	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus	Diagnosis	ICD-10-CM
O31.23X5	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus	Diagnosis	ICD-10-CM
O31.23X9	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, other fetus	Diagnosis	ICD-10-CM
036.4	Maternal care for intrauterine death	Diagnosis	ICD-10-CM
O36.4XX0	Maternal care for intrauterine death, not applicable or unspecified	Diagnosis	ICD-10-CM
O36.4XX1	Maternal care for intrauterine death, fetus 1	Diagnosis	ICD-10-CM
O36.4XX2	Maternal care for intrauterine death, fetus 2	Diagnosis	ICD-10-CM
O36.4XX3	Maternal care for intrauterine death, fetus 3	Diagnosis	ICD-10-CM
O36.4XX4	Maternal care for intrauterine death, fetus 4	Diagnosis	ICD-10-CM
O36.4XX5	Maternal care for intrauterine death, fetus 5	Diagnosis	ICD-10-CM
O36.4XX9	Maternal care for intrauterine death, other fetus	Diagnosis	ICD-10-CM
O48.0	Post-term pregnancy	Diagnosis	ICD-10-CM
048.1	Prolonged pregnancy	Diagnosis	ICD-10-CM
O60.12X0	Preterm labor second trimester with preterm delivery second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
0604374		Diamaria	ICD 40 CM
O60.12X1	Preterm labor second trimester with preterm delivery second trimester, fetus 1	Diagnosis	ICD-10-CM
O60.12X2	Preterm labor second trimester with preterm delivery second trimester, fetus 2	Diagnosis	ICD-10-CM
O60.12X3	Preterm labor second trimester with preterm delivery second trimester, fetus 3	Diagnosis	ICD-10-CM
O60.12X4	Preterm labor second trimester with preterm delivery second trimester, fetus 4	Diagnosis	ICD-10-CM
O60.12X5	Preterm labor second trimester with preterm delivery second trimester, fetus 5	Diagnosis	ICD-10-CM
O60.12X9	Preterm labor second trimester with preterm delivery second trimester, other fetus	Diagnosis	ICD-10-CM
O60.13X0	Preterm labor second trimester with preterm delivery third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O60.13X1	Preterm labor second trimester with preterm delivery third trimester, fetus 1	Diagnosis	ICD-10-CM
O60.13X2	Preterm labor second trimester with preterm delivery third trimester, fetus 2	Diagnosis	ICD-10-CM
O60.13X3	Preterm labor second trimester with preterm delivery third trimester, fetus 3	Diagnosis	ICD-10-CM
O60.13X4	Preterm labor second trimester with preterm delivery third trimester, fetus 4	Diagnosis	ICD-10-CM
O60.13X5	Preterm labor second trimester with preterm delivery third trimester, fetus 5	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 711 of 1023



Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

to Define if	iciusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
O60.13X9	Preterm labor second trimester with preterm delivery third trimester, other fetus	Diagnosis	ICD-10-CM
O60.14X0	Preterm labor third trimester with preterm delivery third trimester, not applicable or	Diagnosis	ICD-10-CM
	unspecified		
O60.14X1	Preterm labor third trimester with preterm delivery third trimester, fetus 1	Diagnosis	ICD-10-CM
O60.14X2	Preterm labor third trimester with preterm delivery third trimester, fetus 2	Diagnosis	ICD-10-CM
O60.14X3	Preterm labor third trimester with preterm delivery third trimester, fetus 3	Diagnosis	ICD-10-CM
O60.14X4	Preterm labor third trimester with preterm delivery third trimester, fetus 4	Diagnosis	ICD-10-CM
O60.14X5	Preterm labor third trimester with preterm delivery third trimester, fetus 5	Diagnosis	ICD-10-CM
O60.14X9	Preterm labor third trimester with preterm delivery third trimester, other fetus	Diagnosis	ICD-10-CM
O60.22X0	Term delivery with preterm labor, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O60.22X1	Term delivery with preterm labor, second trimester, fetus 1	Diagnosis	ICD-10-CM
O60.22X2	Term delivery with preterm labor, second trimester, fetus 2	Diagnosis	ICD-10-CM
O60.22X3	Term delivery with preterm labor, second trimester, fetus 3	Diagnosis	ICD-10-CM
O60.22X4	Term delivery with preterm labor, second trimester, fetus 4	Diagnosis	ICD-10-CM
O60.22X5	Term delivery with preterm labor, second trimester, fetus 5	Diagnosis	ICD-10-CM
O60.22X9	Term delivery with preterm labor, second trimester, other fetus	Diagnosis	ICD-10-CM
O60.23X0	Term delivery with preterm labor, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O60.23X1	Term delivery with preterm labor, third trimester, fetus 1	Diagnosis	ICD-10-CM
O60.23X2	Term delivery with preterm labor, third trimester, fetus 2	Diagnosis	ICD-10-CM
O60.23X3	Term delivery with preterm labor, third trimester, fetus 3	Diagnosis	ICD-10-CM
O60.23X4	Term delivery with preterm labor, third trimester, fetus 4	Diagnosis	ICD-10-CM
O60.23X5	Term delivery with preterm labor, third trimester, fetus 5	Diagnosis	ICD-10-CM
O60.23X9	Term delivery with preterm labor, third trimester, other fetus	Diagnosis	ICD-10-CM
O63.2	Delayed delivery of second twin, triplet, etc.	Diagnosis	ICD-10-CM
O67.0	Intrapartum hemorrhage with coagulation defect	Diagnosis	ICD-10-CM
O67.8	Other intrapartum hemorrhage	Diagnosis	ICD-10-CM
067.9	Intrapartum hemorrhage, unspecified	Diagnosis	ICD-10-CM
O68	Labor and delivery complicated by abnormality of fetal acid-base balance	Diagnosis	ICD-10-CM
O69.0XX0	Labor and delivery complicated by prolapse of cord, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.0XX1	Labor and delivery complicated by prolapse of cord, fetus 1	Diagnosis	ICD-10-CM
O69.0XX2	Labor and delivery complicated by prolapse of cord, fetus 2	Diagnosis	ICD-10-CM
O69.0XX3	Labor and delivery complicated by prolapse of cord, fetus 3	Diagnosis	ICD-10-CM
O69.0XX4	Labor and delivery complicated by prolapse of cord, fetus 4	Diagnosis	ICD-10-CM
O69.0XX5	Labor and delivery complicated by prolapse of cord, fetus 5	Diagnosis	ICD-10-CM
O69.0XX9	Labor and delivery complicated by prolapse of cord, other fetus	Diagnosis	ICD-10-CM
O69.1XX0	Labor and delivery complicated by cord around neck, with compression, not applicable or	Diagnosis	ICD-10-CM
	unspecified		
O69.1XX1	Labor and delivery complicated by cord around neck, with compression, fetus 1	Diagnosis	ICD-10-CM
O69.1XX2	Labor and delivery complicated by cord around neck, with compression, fetus 2	Diagnosis	ICD-10-CM
O69.1XX3	Labor and delivery complicated by cord around neck, with compression, fetus 3	Diagnosis	ICD-10-CM
O69.1XX4	Labor and delivery complicated by cord around neck, with compression, fetus 4	Diagnosis	ICD-10-CM
O69.1XX5	Labor and delivery complicated by cord around neck, with compression, fetus 5	Diagnosis	ICD-10-CM
O69.1XX9	Labor and delivery complicated by cord around neck, with compression, other fetus	Diagnosis	ICD-10-CM
O69.2XX0	Labor and delivery complicated by other cord entanglement, with compression, not	Diagnosis	ICD-10-CM
	applicable or unspecified		
O69.2XX1	Labor and delivery complicated by other cord entanglement, with compression, fetus 1	Diagnosis	ICD-10-CM
O69.2XX2	Labor and delivery complicated by other cord entanglement, with compression, fetus 2	Diagnosis	ICD-10-CM
O69.2XX3	Labor and delivery complicated by other cord entanglement, with compression, fetus 3	Diagnosis	ICD-10-CM
O69.2XX4	Labor and delivery complicated by other cord entanglement, with compression, fetus 4	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 712 of 1023



	·	Code	
Code	Description	Category	Code Type
O69.2XX5	Labor and delivery complicated by other cord entanglement, with compression, fetus 5	Diagnosis	ICD-10-CM
O69.2XX9	Labor and delivery complicated by other cord entanglement, with compression, other	Diagnosis	ICD-10-CM
O69.3XX0	Labor and delivery complicated by short cord, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.3XX1	Labor and delivery complicated by short cord, fetus 1	Diagnosis	ICD-10-CM
O69.3XX2	Labor and delivery complicated by short cord, fetus 2	Diagnosis	ICD-10-CM
O69.3XX3	Labor and delivery complicated by short cord, fetus 3	Diagnosis	ICD-10-CM
O69.3XX4	Labor and delivery complicated by short cord, fetus 4	Diagnosis	ICD-10-CM
O69.3XX5	Labor and delivery complicated by short cord, fetus 5	Diagnosis	ICD-10-CM
O69.3XX9	Labor and delivery complicated by short cord, other fetus	Diagnosis	ICD-10-CM
O69.4XX0	Labor and delivery complicated by vasa previa, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.4XX1	Labor and delivery complicated by vasa previa, fetus 1	Diagnosis	ICD-10-CM
O69.4XX2	Labor and delivery complicated by vasa previa, fetus 2	Diagnosis	ICD-10-CM
O69.4XX3	Labor and delivery complicated by vasa previa, fetus 3	Diagnosis	ICD-10-CM
O69.4XX4	Labor and delivery complicated by vasa previa, fetus 4	Diagnosis	ICD-10-CM
O69.4XX5	Labor and delivery complicated by vasa previa, fetus 5	Diagnosis	ICD-10-CM
O69.4XX9	Labor and delivery complicated by vasa previa, other fetus	Diagnosis	ICD-10-CM
O69.5XX0	Labor and delivery complicated by vascular lesion of cord, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.5XX1	Labor and delivery complicated by vascular lesion of cord, fetus 1	Diagnosis	ICD-10-CM
O69.5XX2	Labor and delivery complicated by vascular lesion of cord, fetus 2	Diagnosis	ICD-10-CM
O69.5XX3	Labor and delivery complicated by vascular lesion of cord, fetus 3	Diagnosis	ICD-10-CM
O69.5XX4	Labor and delivery complicated by vascular lesion of cord, fetus 4	Diagnosis	ICD-10-CM
O69.5XX5	Labor and delivery complicated by vascular lesion of cord, fetus 5	Diagnosis	ICD-10-CM
O69.5XX9	Labor and delivery complicated by vascular lesion of cord, other fetus	Diagnosis	ICD-10-CM
O69.81X0	Labor and delivery complicated by cord around neck, without compression, not applicable	Diagnosis	ICD-10-CM
	or unspecified		
O69.81X1	Labor and delivery complicated by cord around neck, without compression, fetus 1	Diagnosis	ICD-10-CM
O69.81X2	Labor and delivery complicated by cord around neck, without compression, fetus 2	Diagnosis	ICD-10-CM
O69.81X3	Labor and delivery complicated by cord around neck, without compression, fetus 3	Diagnosis	ICD-10-CM
O69.81X4	Labor and delivery complicated by cord around neck, without compression, fetus 4	Diagnosis	ICD-10-CM
O69.81X5	Labor and delivery complicated by cord around neck, without compression, fetus 5	Diagnosis	ICD-10-CM
O69.81X9	Labor and delivery complicated by cord around neck, without compression, other fetus	Diagnosis	ICD-10-CM
O69.82X0	Labor and delivery complicated by other cord entanglement, without compression, not	Diagnosis	ICD-10-CM
	applicable or unspecified	_	
O69.82X1	Labor and delivery complicated by other cord entanglement, without compression, fetus 1	Diagnosis	ICD-10-CM
O69.82X2	Labor and delivery complicated by other cord entanglement, without compression, fetus 2		ICD-10-CM
O69.82X3	Labor and delivery complicated by other cord entanglement, without compression, fetus 3		ICD-10-CM
O69.82X4	Labor and delivery complicated by other cord entanglement, without compression, fetus 4		ICD-10-CM
O69.82X5	Labor and delivery complicated by other cord entanglement, without compression, fetus 5		ICD-10-CM
O69.82X9	Labor and delivery complicated by other cord entanglement, without compression, other	Diagnosis	ICD-10-CM
003.0273	fetus	Diagnosis	ICD 10 CIVI
0.60,0000		Di	ICD 40 CM
O69.89X0	Labor and delivery complicated by other cord complications, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.89X1	Labor and delivery complicated by other cord complications, fetus 1	Diagnosis	ICD-10-CM
O69.89X2	Labor and delivery complicated by other cord complications, fetus 2	Diagnosis	ICD-10-CM
O69.89X3	Labor and delivery complicated by other cord complications, fetus 3	Diagnosis	ICD-10-CM
O69.89X4	Labor and delivery complicated by other cord complications, fetus 4	Diagnosis	ICD-10-CM
O69.89X5	Labor and delivery complicated by other cord complications, fetus 5	Diagnosis	ICD-10-CM
O69.89X9	Labor and delivery complicated by other cord complications, other fetus	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 713 of 1023



		Code	
Code	Description	Category	Code Type
O69.9XX0	Labor and delivery complicated by cord complication, unspecified, not applicable or	Diagnosis	ICD-10-CM
	unspecified		
O69.9XX1	Labor and delivery complicated by cord complication, unspecified, fetus 1	Diagnosis	ICD-10-CM
O69.9XX2	Labor and delivery complicated by cord complication, unspecified, fetus 2	Diagnosis	ICD-10-CM
O69.9XX3	Labor and delivery complicated by cord complication, unspecified, fetus 3	Diagnosis	ICD-10-CM
O69.9XX4	Labor and delivery complicated by cord complication, unspecified, fetus 4	Diagnosis	ICD-10-CM
O69.9XX5	Labor and delivery complicated by cord complication, unspecified, fetus 5	Diagnosis	ICD-10-CM
O69.9XX9	Labor and delivery complicated by cord complication, unspecified, other fetus	Diagnosis	ICD-10-CM
070.0	First degree perineal laceration during delivery	Diagnosis	ICD-10-CM
070.1	Second degree perineal laceration during delivery	Diagnosis	ICD-10-CM
070.20	Third degree perineal laceration during delivery, unspecified	Diagnosis	ICD-10-CM
070.21	Third degree perineal laceration during delivery, Illa	Diagnosis	ICD-10-CM
070.22	Third degree perineal laceration during delivery, IIIb	Diagnosis	ICD-10-CM
070.23	Third degree perineal laceration during delivery, IIIc	Diagnosis	ICD-10-CM
070.3	Fourth degree perineal laceration during delivery	Diagnosis	ICD-10-CM
070.4	Anal sphincter tear complicating delivery, not associated with third degree laceration	Diagnosis	ICD-10-CM
070.9	Perineal laceration during delivery, unspecified	Diagnosis	ICD-10-CM
074.0	Aspiration pneumonitis due to anesthesia during labor and delivery	Diagnosis	ICD-10-CM
074.1	Other pulmonary complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
074.2	Cardiac complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
074.3	Central nervous system complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
074.4	Toxic reaction to local anesthesia during labor and delivery	Diagnosis	ICD-10-CM
074.5	Spinal and epidural anesthesia-induced headache during labor and delivery	Diagnosis	ICD-10-CM
074.6	Other complications of spinal and epidural anesthesia during labor and delivery	Diagnosis	ICD-10-CM
074.7	Failed or difficult intubation for anesthesia during labor and delivery	Diagnosis	ICD-10-CM
074.8	Other complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
074.9	Complication of anesthesia during labor and delivery, unspecified	Diagnosis	ICD-10-CM
075.0	Maternal distress during labor and delivery	Diagnosis	ICD-10-CM
075.1	Shock during or following labor and delivery	Diagnosis	ICD-10-CM
075.5	Delayed delivery after artificial rupture of membranes	Diagnosis	ICD-10-CM
075.81	Maternal exhaustion complicating labor and delivery	Diagnosis	ICD-10-CM
075.82	Onset (spontaneous) of labor after 37 completed weeks of gestation but before 39	Diagnosis	ICD-10-CM
	completed weeks gestation, with delivery by (planned) cesarean section	g	
075.89		Diagnosis	ICD 10 CM
	Other specified complications of labor and delivery	Diagnosis	ICD-10-CM
075.9	Complication of labor and delivery, unspecified	Diagnosis	ICD-10-CM
076	Abnormality in fetal heart rate and rhythm complicating labor and delivery	Diagnosis	ICD-10-CM
077.0	Labor and delivery complicated by meconium in amniotic fluid	Diagnosis	ICD-10-CM
077.8	Labor and delivery complicated by other evidence of fetal stress	Diagnosis	ICD-10-CM
077.9	Labor and delivery complicated by fetal stress, unspecified	Diagnosis	ICD-10-CM
080	Encounter for full-term uncomplicated delivery	Diagnosis	ICD-10-CM
082	Encounter for cesarean delivery without indication	Diagnosis	ICD-10-CM
088.02	Air embolism in childbirth	Diagnosis	ICD-10-CM
088.12	Amniotic fluid embolism in childbirth	Diagnosis	ICD-10-CM
088.22	Thromboembolism in childbirth	Diagnosis	ICD-10-CM
088.32	Pyemic and septic embolism in childbirth	Diagnosis	ICD-10-CM
088.82	Other embolism in childbirth	Diagnosis	ICD-10-CM
098.02	Tuberculosis complicating childbirth	Diagnosis	ICD-10-CM
098.12	Syphilis complicating childbirth	Diagnosis	ICD-10-CM
098.22	Gonorrhea complicating childbirth	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 714 of 1023



		Code	
Code	Description	Category	Code Type
O98.32	Other infections with a predominantly sexual mode of transmission complicating childbirth	Diagnosis	ICD-10-CM
O98.42	Viral hepatitis complicating childbirth	Diagnosis	ICD-10-CM
O98.52	Other viral diseases complicating childbirth	Diagnosis	ICD-10-CM
098.62	Protozoal diseases complicating childbirth	Diagnosis	ICD-10-CM
O98.72	Human immunodeficiency virus [HIV] disease complicating childbirth	Diagnosis	ICD-10-CM
O98.82	Other maternal infectious and parasitic diseases complicating childbirth	Diagnosis	ICD-10-CM
098.92	Unspecified maternal infectious and parasitic disease complicating childbirth	Diagnosis	ICD-10-CM
099.02	Anemia complicating childbirth	Diagnosis	ICD-10-CM
O99.12	Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating childbirth	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
099.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
099.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
099.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
099.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
099.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
099.284	Endocrine, nutritional and metabolic diseases complicating childbirth	Diagnosis	ICD-10-CM
099.314	Alcohol use complicating childbirth	Diagnosis	ICD-10-CM
099.324	Drug use complicating childbirth	Diagnosis	ICD-10-CM
099.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
099.344	Other mental disorders complicating childbirth	Diagnosis	ICD-10-CM
099.354	Diseases of the nervous system complicating childbirth	Diagnosis	ICD-10-CM
099.42	Diseases of the circulatory system complicating childbirth	Diagnosis	ICD-10-CM
099.52	Diseases of the respiratory system complicating childbirth	Diagnosis	ICD-10-CM
099.62	Diseases of the digestive system complicating childbirth	Diagnosis	ICD-10-CM
099.72	Diseases of the skin and subcutaneous tissue complicating childbirth	Diagnosis	ICD-10-CM
099.814	Abnormal glucose complicating childbirth	Diagnosis	ICD-10-CM
099.824	Streptococcus B carrier state complicating childbirth	Diagnosis	ICD-10-CM
099.834	Other infection carrier state complicating childbirth	Diagnosis	ICD-10-CM
099.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O9A.12	Malignant neoplasm complicating childbirth	Diagnosis	ICD-10-CM
O9A.22	Injury, poisoning and certain other consequences of external causes complicating	Diagnosis	ICD-10-CM
OJA.ZZ	childbirth	Diagnosis	ICD-10-CIVI
O9A.32	Physical abuse complicating childbirth	Diagnosis	ICD-10-CM
O9A.42	Sexual abuse complicating childbirth	Diagnosis	ICD-10-CM
O9A.52	Psychological abuse complicating childbirth	Diagnosis	ICD-10-CM
P03.0	Newborn affected by breech delivery and extraction	Diagnosis	ICD-10-CM
P03.2	Newborn affected by forceps delivery	Diagnosis	ICD-10-CM
P03.3	Newborn affected by delivery by vacuum extractor [ventouse]	Diagnosis	ICD-10-CM
P03.4	Newborn affected by Cesarean delivery	Diagnosis	ICD-10-CM
P03.5	Newborn affected by precipitate delivery	Diagnosis	ICD-10-CM
P07.00	Extremely low birth weight newborn, unspecified weight	Diagnosis	ICD-10-CM
P07.01	Extremely low birth weight newborn, less than 500 grams	Diagnosis	ICD-10-CM
P07.02	Extremely low birth weight newborn, 500-749 grams	Diagnosis	ICD-10-CM
P07.03	Extremely low birth weight newborn, 750-999 grams	Diagnosis	ICD-10-CM
P07.10	Other low birth weight newborn, unspecified weight	Diagnosis	ICD-10-CM
P07.14	Other low birth weight newborn, 1000-1249 grams	Diagnosis	ICD-10-CM
P07.15	Other low birth weight newborn, 1250-1499 grams	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 715 of 1023



Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

to Define i	nclusion or Exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
P07.16	Other low birth weight newborn, 1500-1749 grams	Diagnosis	ICD-10-CM
P07.17	Other low birth weight newborn, 1750-1999 grams	Diagnosis	ICD-10-CM
P07.18	Other low birth weight newborn, 2000-2499 grams	Diagnosis	ICD-10-CM
P07.20	Extreme immaturity of newborn, unspecified weeks of gestation	Diagnosis	ICD-10-CM
P07.21	Extreme immaturity of newborn, gestational age less than 23 completed weeks	Diagnosis	ICD-10-CM
P07.22	Extreme immaturity of newborn, gestational age 23 completed weeks	Diagnosis	ICD-10-CM
P07.23	Extreme immaturity of newborn, gestational age 24 completed weeks	Diagnosis	ICD-10-CM
P07.24	Extreme immaturity of newborn, gestational age 25 completed weeks	Diagnosis	ICD-10-CM
P07.25	Extreme immaturity of newborn, gestational age 26 completed weeks	Diagnosis	ICD-10-CM
P07.26	Extreme immaturity of newborn, gestational age 27 completed weeks	Diagnosis	ICD-10-CM
P07.30	Preterm newborn, unspecified weeks of gestation	Diagnosis	ICD-10-CM
P07.31	Preterm newborn, gestational age 28 completed weeks	Diagnosis	ICD-10-CM
P07.32	Preterm newborn, gestational age 29 completed weeks	Diagnosis	ICD-10-CM
P07.33	Preterm newborn, gestational age 30 completed weeks	Diagnosis	ICD-10-CM
P07.34	Preterm newborn, gestational age 31 completed weeks	Diagnosis	ICD-10-CM
P07.35	Preterm newborn, gestational age 32 completed weeks	Diagnosis	ICD-10-CM
P07.36	Preterm newborn, gestational age 33 completed weeks	Diagnosis	ICD-10-CM
P07.37	Preterm newborn, gestational age 34 completed weeks	Diagnosis	ICD-10-CM
P07.38	Preterm newborn, gestational age 35 completed weeks	Diagnosis	ICD-10-CM
P07.39	Preterm newborn, gestational age 36 completed weeks	Diagnosis	ICD-10-CM
P08.21	Post-term newborn	Diagnosis	ICD-10-CM
P08.22	Prolonged gestation of newborn	Diagnosis	ICD-10-CM
P95	Stillbirth	Diagnosis	ICD-10-CM
Z33.2	Encounter for elective termination of pregnancy	Diagnosis	ICD-10-CM
Z37.0	Single live birth	Diagnosis	ICD-10-CM
Z37.1	Single stillbirth	Diagnosis	ICD-10-CM
Z37.2	Twins, both liveborn	Diagnosis	ICD-10-CM
Z37.3	Twins, one liveborn and one stillborn	Diagnosis	ICD-10-CM
Z37.3	Twins, one liveborn and one stillborn	Diagnosis	ICD-10-CM
Z37.4	Twins, both stillborn	Diagnosis	ICD-10-CM
Z37.50	Multiple births, unspecified, all liveborn	Diagnosis	ICD-10-CM
Z37.51	Triplets, all liveborn	Diagnosis	ICD-10-CM
Z37.52	Quadruplets, all liveborn	Diagnosis	ICD-10-CM
Z37.53	Quintuplets, all liveborn	Diagnosis	ICD-10-CM
Z37.54	Sextuplets, all liveborn	Diagnosis	ICD-10-CM
Z37.59	Other multiple births, all liveborn	Diagnosis	ICD-10-CM
Z37.6	Other multiple births, some liveborn	Diagnosis	ICD-10-CM
Z37.60	Multiple births, unspecified, some liveborn	Diagnosis	ICD-10-CM
Z37.60	Multiple births, unspecified, some liveborn	Diagnosis	ICD-10-CM
Z37.61	Triplets, some liveborn	Diagnosis	ICD-10-CM
Z37.61	Triplets, some liveborn	Diagnosis	ICD-10-CM
Z37.62	Quadruplets, some liveborn	Diagnosis	ICD-10-CM
Z37.62	Quadruplets, some liveborn	Diagnosis	ICD-10-CM
Z37.63	Quintuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.63	Quintuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.64	Sextuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.64	Sextuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.69	Other multiple births, some liveborn	Diagnosis	ICD-10-CM
Z37.69	Other multiple births, some liveborn	Diagnosis	ICD-10-CM
Z37.7	Other multiple births, all stillborn	Diagnosis	ICD-10-CM
_5,.,	Care manage on this, an atmost	5.05.10313	.05 10 0141

cder_mpl1p_wp077 Page 716 of 1023



to Dennie II	icidsion of Exclusion Citiena in this request	Code	
Code	Description	Category	Code Type
Z37.9	Outcome of delivery, unspecified	Diagnosis	ICD-10-CM
Z38.00	Single liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.01	Single liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.1	Single liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z38.2	Single liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z38.30	Twin liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.31	Twin liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.4	Twin liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z38.5	Twin liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z38.61	Triplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.62	Triplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.63	Quadruplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.64	Quadruplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.65	Quintuplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.66	Quintuplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.68	Other multiple liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.69	Other multiple liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.7	Other multiple liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z38.8	Other multiple liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z3A.20	20 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.21	21 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.22	22 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.23	23 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.24	24 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.25	25 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.26	26 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.27	27 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.28	28 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.29	29 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.30	30 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.31	31 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.32	32 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.33	33 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.34	34 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.35	35 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.36	36 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.37	37 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.38	38 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.39	39 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.40	40 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.41	41 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.42	42 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.49	Greater than 42 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
0W8NXZZ	Division of Female Perineum, External Approach	Procedure	ICD-10-PCS
10900ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Open Approach	Procedure	ICD-10-PCS
10903ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Percutaneous	Procedure	ICD-10-PCS
	Approach		
10904ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 717 of 1023



to Benne n	icidsion of Exclusion Citiena in this nequest	Code	
Code	Description	Category	Code Type
10907ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Via Natural or	Procedure	ICD-10-PCS
	Artificial Opening		
10908ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Via Natural or	Procedure	ICD-10-PCS
	Artificial Opening Endoscopic		.02 20 . 00
10A00ZZ	Abortion of Products of Conception, Open Approach	Procedure	ICD-10-PCS
10A03ZZ	Abortion of Products of Conception, Open Approach Abortion of Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
10A03ZZ 10A04ZZ	Abortion of Products of Conception, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
10A07Z6	Abortion of Products of Conception, Vacuum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZW	Abortion of Products of Conception, Vacadin, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZW	Abortion of Products of Conception, Abortifacient, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZZ	Abortion of Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZZ	Abortion of Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
10D00Z0	Extraction of Products of Conception, High, Open Approach	Procedure	ICD-10-PCS
10D00Z1	Extraction of Products of Conception, Low, Open Approach	Procedure	ICD-10-PCS
10D00Z1	Extraction of Products of Conception, Extraperitoneal, Open Approach	Procedure	ICD-10-PCS
10D00ZZ	Extraction of Products of Conception, Low Forceps, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z3	Extraction of Products of Conception, Mid Forceps, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z4	Extraction of Products of Conception, Mid Porceps, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z5	Extraction of Products of Conception, Vacuum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z7	Extraction of Products of Conception, Internal Version, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z7	Extraction of Products of Conception, Internal Version, Via Natural of Artificial Opening	Procedure	ICD-10-PCS
10D0728 10D17Z9	Manual Extraction of Products of Conception, Retained, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D1723	Manual Extraction of Products of Conception, Retained, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
1001023	Endoscopic	rroccaure	100 10 1 05
10D27ZZ	Extraction of products of conception, ectopic, via natural or artificial opening	Procedure	ICD-10-PCS
10D27ZZ 10D28ZZ	Extraction of products of conception, ectopic, via natural or artificial opening endoscopic	Procedure	ICD-10-PCS
10D28ZZ 10E0XZZ	Delivery of Products of Conception, External Approach	Procedure	ICD-10-PCS
10E0XZZ 10S07ZZ	Reposition Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
1030722 10T20ZZ	Resection of products of conception, ectopic, open approach	Procedure	ICD-10-PCS
10T23ZZ	Resection of products of conception, ectopic, open approach	Procedure	ICD-10-PCS
10T24ZZ	Resection of products of conception, ectopic, percutaneous approach	Procedure	ICD-10-PCS
10T27ZZ	Resection of products of conception, ectopic, via natural or artificial opening	Procedure	ICD-10-PCS
10T27ZZ	Resection of products of conception, ectopic, via natural or artificial opening endoscopic	Procedure	ICD-10-PCS
58661	Laparoscopy, surgical; with removal of adnexal structures (partial or total oophorectomy	Procedure	CPT-4
30001	and/or salpingectomy)	rrocedure	Ci i-4
58673	Laparoscopy, surgical; with salpingostomy (salpingoneostomy)	Procedure	CPT-4
58700	Salpingectomy, complete or partial, unilateral or bilateral (separate procedure)	Procedure	CPT-4
58770	Salpingostomy (salpingoneostomy)	Procedure	CPT-4
59100	Surgical treatment of ectopic pregnancy: tubal or ovarian, requiring salpingectomy and/or		CPT-4
39100	oophorectomy, abdominal or vaginal approach	riocedure	CF 1-4
59830	TREATMENT OF SEPTIC ABORTION, COMPLETED SURGICALLY	Procedure	CPT-4
59840	INDUCED ABORTION, BY DILATION AND CURETTAGE	Procedure	CPT-4
59840 59841	INDUCED ABORTION, BY DILATION AND EVACUATION	Procedure	CPT-4 CPT-4
59841 59850	INDUCED ABORTION, BY DILATION AND EVACUATION INDUCED ABORTION, BY ONE OR MORE INTRAAMNIOTIC INJECTIONS	Procedure	CPT-4 CPT-4
59851	INDUCED ABORTION, BY ONE OR MORE INTRAAMNIOTIC INJECTIONS, WITH DILATION	Procedure	CPT-4 CPT-4
JOOT	AND CURETTAGE AND/OR EVACUATION	riocedure	CF 1-4
E00E2		Drocodure	CDT 4
59852	INDUCED ABORTION, BY ONE OR MORE INTRAAMNIOTIC INJECTIONS, WITH	Procedure	CPT-4

cder_mpl1p_wp077 Page 718 of 1023



	inclusion or exclusion Criteria in this Request	Code	
Code	Description	Category	Code Type
59855	INDUCED ABORTION, BY ONE OR MORE VAGINAL SUPPOSITORIES	Procedure	CPT-4
59856	INDUCED ABORTION, BY ONE OR MORE VAGINAL SUPPOSITORIES, WITH DILATION AND	Procedure	CPT-4
	CURETTAGE AND/OR EVACUATION	_	
59857	INDUCED ABORTION, BY ONE OR MORE VAGINAL SUPPOSITORIES, WITH HYSTEROTOMY	Procedure	CPT-4
59870	Evacuation and curettage of uterus for hydatidiform mole	Procedure	CPT-4
01964	ANESTHESIA FOR ABORTION PROCEDURES	Procedure	CPT-4
01965	Anesthesia for incomplete or missed abortion procedures	Procedure	CPT-4
01966	Anesthesia for induced abortion procedures	Procedure	CPT-4
59120	Surgical treatment of ectopic pregnancy; tubal or ovarian, requiring salpingectomy and/or oophorectomy, abdominal or vaginal approach	Procedure	CPT-4
59121	Surgical treatment of ectopic pregnancy; tubal or ovarian, without salpingectomy and/or	Procedure	CPT-4
00111	oophorectomy		C. .
59125	Surgical Treatment Of Ectopic Pregnancy	Procedure	CPT-4
59126	Surgical Treatment Of Ectopic Pregnancy	Procedure	CPT-4
59130	Surgical treatment of ectopic pregnancy; abdominal pregnancy	Procedure	CPT-4
59135	Surgical treatment of ectopic pregnancy; interstitial, uterine pregnancy requiring total hysterectomy	Procedure	CPT-4
59136	Surgical treatment of ectopic pregnancy; interstitial, uterine pregnancy with partial	Procedure	CPT-4
00200	resection of uterus		C. .
59140	Surgical treatment of ectopic pregnancy; cervical, with evacuation	Procedure	CPT-4
59150	Laparoscopic treatment of ectopic pregnancy; without salpingectomy and/or oophorectomy	Procedure	CPT-4
59151	Laparoscopic treatment of ectopic pregnancy; with salpingectomy and/or oophorectomy	Procedure	CPT-4
59400	Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care	Procedure	CPT-4
59409	Vaginal delivery only (with or without episiotomy and/or forceps);	Procedure	CPT-4
59410	Vaginal delivery only (with or without episiotomy and/or forceps); including postpartum	Procedure	CPT-4
	care		
59510	Routine obstetric care including antepartum care, cesarean delivery, and postpartum care	Procedure	CPT-4
59514	Cesarean delivery only;	Procedure	CPT-4
59515	Cesarean delivery only; including postpartum care	Procedure	CPT-4
59610	Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care, after previous cesarean delivery	Procedure	CPT-4
59612	Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or forceps);	Procedure	CPT-4
59614	Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or forceps); including postpartum care	Procedure	CPT-4
59618	Routine obstetric care including antepartum care, cesarean delivery, and postpartum care, following attempted vaginal delivery after previous cesarean delivery	Procedure	CPT-4
59620	Cesarean delivery only, following attempted vaginal delivery after previous cesarean delivery;	Procedure	CPT-4
59622	Cesarean delivery only, following attempted vaginal delivery after previous cesarean delivery; including postpartum care	Procedure	CPT-4
59812	Treatment of incomplete abortion, any trimester, completed surgically	Procedure	CPT-4

cder_mpl1p_wp077 Page 719 of 1023



		Code	
Code	Description	Category	Code Type
59820	Treatment of missed abortion, completed surgically; first trimester	Procedure	CPT-4
59821	Treatment of missed abortion, completed surgically; second trimester	Procedure	CPT-4
S0190	Mifepristone, oral, 200 mg	Procedure	HCPCS
S0191	Misoprostol, oral, 200 mcg	Procedure	HCPCS
S0199	Medically induced abortion by oral ingestion of medication including all associated	Procedure	HCPCS
	services and supplies (e.g., patient counseling, office visits, confirmation of pregnancy by		
	HCG, ultrasound to confirm duration of pregnancy, ultrasound to confirm completion of		
	abortion) except drugs		
S2260	Induced abortion, 17 to 24 weeks	Procedure	HCPCS
S2265	Induced abortion, 25 to 28 weeks	Procedure	HCPCS
S2266	Induced abortion, 29 to 31 weeks	Procedure	HCPCS
S2267	Induced abortion, 32 weeks or greater	Procedure	HCPCS

cder_mpl1p_wp077 Page 720 of 1023



Appendix E. Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request

Generic Name	s Used to Define Inclusion or Exclusion Criteria in this Request Brand Name
	otide-1 Receptor Agonists (SA GLP-1 RAs)
exenatide	Byetta
ixisenatide	Adlyxin
nsulin glargine, human recombinant analog/lixisenatide	Soliqua 100/33
	Insulin
nsulin aspart	insulin aspart U-100
nsulin aspart	Novolog FlexPen U-100 Insulin
nsulin aspart	Novolog PenFill U-100 Insulin
nsulin aspart	Novolog U-100 Insulin aspart
nsulin aspart (niacinamide)	Fiasp FlexTouch U-100 Insulin
nsulin aspart (niacinamide)	Fiasp Penfill U-100 Insulin
nsulin aspart (niacinamide)	Fiasp U-100 Insulin
nsulin aspart protamine human/insulin aspart	insulin asp prt-insulin aspart
nsulin aspart protamine human/insulin aspart	Novolog Mix 70-30 U-100 Insuln
nsulin aspart protamine human/insulin aspart	Novolog Mix 70-30FlexPen U-100
nsulin degludec	insulin degludec
nsulin degludec	Tresiba FlexTouch U-100
nsulin degludec	Tresiba FlexTouch U-200
nsulin degludec	Tresiba U-100 Insulin
nsulin detemir	Levemir FlexPen
nsulin detemir	Levemir FlexTouch U-100 Insuln
nsulin detemir	Levemir U-100 Insulin
nsulin glargine,human recombinant analog	Basaglar KwikPen U-100 Insulin
nsulin glargine,human recombinant analog	Basaglar Tempo Pen(U-100)Insln
nsulin glargine,human recombinant analog	insulin glargine
nsulin glargine,human recombinant analog	Lantus Solostar U-100 Insulin
nsulin glargine,human recombinant analog	Lantus U-100 Insulin
nsulin glargine,human recombinant analog	Semglee Pen U-100 Insulin
nsulin glargine,human recombinant analog	Semglee U-100 Insulin
nsulin glargine,human recombinant analog	Toujeo Max U-300 SoloStar
nsulin glargine,human recombinant analog	Toujeo SoloStar U-300 Insulin
nsulin glargine-yfgn	insulin glargine-yfgn
nsulin glargine-yfgn	Semglee(insulin glargine-yfgn)
nsulin glargine-yfgn	Semglee(insulin glarg-yfgn)Pen
nsulin glulisine	Apidra SoloStar U-100 Insulin
nsulin glulisine	Apidra U-100 Insulin
nsulin lispro	Admelog SoloStar U-100 Insulin
nsulin lispro	Admelog U-100 Insulin lispro
nsulin lispro	Humalog Junior KwikPen U-100
nsulin lispro	Humalog KwikPen Insulin
nsulin lispro	Humalog Tempo Pen(U-100)Insuln
nsulin lispro	Humalog U-100 Insulin
nsulin lispro	insulin lispro
nsulin lispro protamine and insulin lispro	Humalog Mix 50-50 Insuln U-100
nsulin lispro protamine and insulin lispro	Humalog Mix 50-50 KwikPen
nsulin lispro protamine and insulin lispro	Humalog Mix 75-25 KwikPen
nsulin lispro protamine and insulin lispro	Humalog Mix 75-25(U-100)Insuln
nsulin lispro protamine and insulin lispro	insulin lispro protamin-lispro
nsulin lispro-aabc	Lyumjev KwikPen U-100 Insulin
nsulin lispro-aabc	Lyumjev KwikPen U-200 Insulin
	Lvumiev Tempo Pen(U-100)insuin
nsulin lispro-aabc	Lyumjev Tempo Pen(U-100)Insuln Lyumiev U-100 Insulin
	Lyumjev Tempo Pen(U-100)Insuin Lyumjev U-100 Insulin Humulin N NPH Insulin KwikPen

cder_mpl1p_wp077 Page 721 of 1023



Appendix E. Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request

Generic Name	Brand Name
insulin NPH human isophane	Novolin N FlexPen
insulin NPH human isophane	Novolin N NPH U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 KwikPen
insulin NPH human isophane/insulin regular, human	Novolin 70/30 U-100 Insulin
insulin NPH human isophane/insulin regular, human	Novolin 70-30 FlexPen U-100
insulin regular, human	Afrezza
insulin regular, human	Humulin R Regular U-100 Insuln
insulin regular, human	Humulin R U-500 (Conc) Insulin
insulin regular, human	Humulin R U-500 (Conc) Kwikpen
insulin regular, human	Novolin R FlexPen
insulin regular, human	Novolin R Regular U-100 Insuln
insulin regular, human in 0.9 % sodium chloride	Myxredlin
Ora	al Antidiabetics
acarbose	acarbose
acarbose	Precose
alogliptin benzoate	alogliptin
alogliptin benzoate	Nesina
alogliptin benzoate/metformin HCl	alogliptin-metformin
alogliptin benzoate/metformin HCl	Kazano
alogliptin benzoate/pioglitazone HCl	alogliptin-pioglitazone
alogliptin benzoate/pioglitazone HCl	Oseni
bromocriptine mesylate	Cycloset
canagliflozin	Invokana
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
dapagliflozin propanediol	Farxiga
dapagliflozin propanediol/metformin HCl	Xigduo XR
dapagliflozin propanediol/saxagliptin HCl	Qtern
empagliflozin	Jardiance
empagliflozin/linagliptin	Glyxambi
empagliflozin/linagliptin/metformin HCl	Trijardy XR
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate	Steglatro
ertugliflozin pidolate/metformin HCl	Segluromet
ertugliflozin pidolate/sitagliptin phosphate	Steglujan
glimepiride	Amaryl
glimepiride	glimepiride
glipizide	glipizide
glipizide	Glucotrol
glipizide	Glucotrol XL
glipizide/metformin HCl	glipizide-metformin
glyburide	glyburide
glyburide,micronized	glyburide micronized
glyburide,micronized	Glynase
glyburide/metformin HCl	glyburide-metformin
linagliptin	Tradjenta
linagliptin/metformin HCl	Jentadueto
linagliptin/metformin HCl	Jentadueto XR
metformin HCl	Fortamet
metformin HCl	Glumetza
metformin HCl	metformin

cder_mpl1p_wp077 Page 722 of 1023

Riomet

metformin HCl



Appendix E. Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request

Generic Name	Brand Name		
metformin HCl	Riomet ER		
mifepristone	Korlym		
miglitol	miglitol		
nateglinide	nateglinide		
pioglitazone HCl	Actos		
pioglitazone HCl	pioglitazone		
pioglitazone HCl/glimepiride	DUETACT		
pioglitazone HCl/glimepiride	pioglitazone-glimepiride		
pioglitazone HCI/metformin HCI	Actoplus MET		
pioglitazone HCl/metformin HCl	pioglitazone-metformin		
repaglinide	repaglinide		
repaglinide/metformin HCl	repaglinide-metformin		
saxagliptin HCl	Onglyza		
saxagliptin HCI/metformin HCI	Kombiglyze XR		
sitagliptin phosphate	Januvia		
sitagliptin phosphate/metformin HCl	Janumet		
sitagliptin phosphate/metformin HCl	Janumet XR		
Non-Oral Antidiabetics			
pramlintide acetate	SymlinPen 60		

pramlintide acetate SymlinPen 120

Page 723 of 1023 $cder_mpl1p_wp077$



Alcohol related disorders Diagnosis CD-10-CM		<u> </u>	Code	
F10. Alcohol abuse, uncomplicated F10.1 Alcohol abuse, uncomplicated F10.11 Alcohol abuse, uncomplicated F10.12 Alcohol abuse, uncomplicated F10.13 Alcohol abuse, uncomplicated F10.14 Alcohol abuse, uncomplicated F10.15 Alcohol abuse, uncomplicated F10.16 Alcohol abuse, uncomplicated F10.17 Alcohol abuse with intoxication F10.18 Alcohol abuse with intoxication, uncomplicated F10.19 Alcohol abuse with intoxication, uncomplicated F10.19 Alcohol abuse with intoxication, unspecified F10.19 Alcohol abuse with intoxication, unspecified F10.19 Alcohol abuse with alcohol-induced mood disorder F10.15 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10.15 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10.15 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10.15 Alcohol abuse with alcohol-induced psychotic disorder with delusions F10.15 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10.15 Alcohol abuse with alcohol-induced psychotic disorder, unspecified F10.15 Alcohol abuse with alcohol-induced disorders F10.15 Alcohol abuse with alcohol-induced disorders F10.18 Alcohol abuse with alcohol-induced disorders F10.18 Alcohol abuse with alcohol-induced disorders F10.18 Alcohol abuse with alcohol-induced disorder F10.18 Alcohol abuse with alcohol-induced disorder F10.18 Alcohol abuse with alcohol-induced sexual dysfunction F10.18 Alcohol abuse with alcohol-induced disorder F10.19 Alcohol abuse with alcohol-induced sexual dysfunction F10.18 F10.18 Alcohol abuse with alcohol-induced sexual dysfunction F10.19 Alcohol abuse with alcohol-induced sexual dysfunction F10.19 Alcohol abuse with alcohol-induced sexual dysfunction F10.20 Alcohol dependence F10.21 Alcohol dependence F10.22 Alcohol dependence F10.23 Alcohol dependence F10.24 Alcohol dependence with introxication F10.25 Alcohol dependence with introxication F10.26 Alcohol dependence with introxication delirium F10.27 Alcohol dependence with introxication with grawal with group of the graw o	Code	Description	Category	Code Type
F10.10 Alcohol abuse, uncomplicated Diagnosis ICD-10-CM F10.10 Alcohol abuse, uncomplicated Diagnosis ICD-10-CM F10.12 Alcohol abuse, in remission Diagnosis ICD-10-CM F10.12 Alcohol abuse with intoxication Diagnosis ICD-10-CM F10.121 Alcohol abuse with intoxication delirium Diagnosis ICD-10-CM F10.129 Alcohol abuse with alcohol-induced mood disorder Diagnosis ICD-10-CM F10.13 Alcohol abuse with alcohol-induced psychotic disorder with delusions Diagnosis ICD-10-CM F10.15 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.159 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.181 Alcohol abuse with alcohol-induced sevenders Diagnosis ICD-10-CM F10.182 Alcohol abuse with alcohol-induced sevenders Diagnosis ICD-10-CM F10.183 Alcohol abuse with alcohol-induced		Alcohol Use or Abuse		
F10.10 Alcohol abuse, in remission Diagnosis ICD-10-CM F10.11 Alcohol abuse, in remission Diagnosis ICD-10-CM F10.12 Alcohol abuse with intoxication Diagnosis ICD-10-CM F10.120 Alcohol abuse with intoxication, uncomplicated Diagnosis ICD-10-CM F10.121 Alcohol abuse with intoxication, unspecified Diagnosis ICD-10-CM F10.129 Alcohol abuse with alcohol-induced mood disorder Diagnosis ICD-10-CM F10.15 Alcohol abuse with alcohol-induced psychotic disorder with delusions Diagnosis ICD-10-CM F10.150 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.152 Alcohol abuse with other alcohol-induced disorders Diagnosis ICD-10-CM F10.181 Alcohol abuse with alcohol-induced sexual dysfunction Diagnosis ICD-10-CM F10.182 Alcohol abuse with alcohol-induced sexual dysfunction Diagnosis ICD-10-CM F10.182 Alcohol abuse wit	F10	Alcohol related disorders	Diagnosis	ICD-10-CM
F10.11 Alcohol abuse, in remission Diagnosis ICD-10-CM F10.12 Alcohol abuse with intoxication Diagnosis ICD-10-CM F10.121 Alcohol abuse with intoxication, uncomplicated Diagnosis ICD-10-CM F10.121 Alcohol abuse with intoxication, unspecified Diagnosis ICD-10-CM F10.142 Alcohol abuse with alcohol-induced psychotic disorder Diagnosis ICD-10-CM F10.15 Alcohol abuse with alcohol-induced psychotic disorder with delusions Diagnosis ICD-10-CM F10.150 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.152 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.158 Alcohol abuse with alcohol-induced psychotic disorder Diagnosis ICD-10-CM F10.181 Alcohol abuse with alcohol-induced disorder Diagnosis ICD-10-CM F10.182 Alcohol abuse with alcohol-induced sexual dysfunction Diagnosis ICD-10-CM <	F10.1	Alcohol abuse	Diagnosis	ICD-10-CM
F10.12 Alcohol abuse with intoxication, uncomplicated Diagnosis ICD-10-CM F10.120 Alcohol abuse with intoxication, uncomplicated Diagnosis ICD-10-CM F10.121 Alcohol abuse with intoxication delirium Diagnosis ICD-10-CM F10.129 Alcohol abuse with alcohol-induced mood disorder Diagnosis ICD-10-CM F10.15 Alcohol abuse with alcohol-induced psychotic disorder with delusions Diagnosis ICD-10-CM F10.150 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.151 Alcohol abuse with alcohol-induced psychotic disorder, unspecified Diagnosis ICD-10-CM F10.152 Alcohol abuse with alcohol-induced disorders Diagnosis ICD-10-CM F10.183 Alcohol abuse with alcohol-induced aswid disorder Diagnosis ICD-10-CM F10.180 Alcohol abuse with alcohol-induced sexual dysfunction Diagnosis ICD-10-CM F10.181 Alcohol abuse with alcohol-induced sexual dysfunction Diagnosis ICD-10-CM F10.182 Alcohol abuse with alcohol-induced disorder Diagnosis ICD-10-CM F10.	F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.120 Alcohol abuse with intoxication, uncomplicated Diagnosis ICD-10-CM F10.121 Alcohol abuse with intoxication delirium Diagnosis ICD-10-CM F10.129 Alcohol abuse with intoxication, unspecified Diagnosis ICD-10-CM F10.15 Alcohol abuse with alcohol-induced psychotic disorder Diagnosis ICD-10-CM F10.150 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.152 Alcohol abuse with alcohol-induced psychotic disorder, unspecified Diagnosis ICD-10-CM F10.153 Alcohol abuse with alcohol-induced disorders Diagnosis ICD-10-CM F10.181 Alcohol abuse with alcohol-induced disorders Diagnosis ICD-10-CM F10.182 Alcohol abuse with alcohol-induced sexual dysfunction Diagnosis ICD-10-CM F10.183 Alcohol abuse with alcohol-induced disorder Diagnosis ICD-10-CM F10.184 Alcohol abuse with alcohol-induced disorder Diagnosis ICD-10-CM F10.185 <td>F10.11</td> <td>Alcohol abuse, in remission</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.121 Alcohol abuse with intoxication delirium Diagnosis ICD-10-CM F10.129 Alcohol abuse with intoxication, unspecified Diagnosis ICD-10-CM F10.15 Alcohol abuse with alcohol-induced mood disorder Diagnosis ICD-10-CM F10.150 Alcohol abuse with alcohol-induced psychotic disorder with delusions Diagnosis ICD-10-CM F10.151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.152 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.181 Alcohol abuse with other alcohol-induced disorder Diagnosis ICD-10-CM F10.182 Alcohol abuse with alcohol-induced sexual dysfunction Diagnosis ICD-10-CM F10.182 Alcohol abuse with alcohol-induced sexual dysfunction Diagnosis ICD-10-CM F10.183 Alcohol abuse with other alcohol-induced disorder Diagnosis ICD-10-CM F10.184 Alcohol dependence Diagnosis ICD-10-CM F10.188 Alcohol dependence Diagnosis ICD-10-CM F10.188 Alcohol dependence <td>F10.12</td> <td>Alcohol abuse with intoxication</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	F10.12	Alcohol abuse with intoxication	Diagnosis	ICD-10-CM
F10.129 Alcohol abuse with intoxication, unspecified Diagnosis ICD-10-CM F10.14 Alcohol abuse with alcohol-induced mood disorder Diagnosis ICD-10-CM F10.15 Alcohol abuse with alcohol-induced psychotic disorder Diagnosis ICD-10-CM F10.150 Alcohol abuse with alcohol-induced psychotic disorder with delusions Diagnosis ICD-10-CM F10.151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.152 Alcohol abuse with alcohol-induced psychotic disorder, unspecified Diagnosis ICD-10-CM F10.159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified Diagnosis ICD-10-CM F10.180 Alcohol abuse with alcohol-induced disorders Diagnosis ICD-10-CM F10.181 Alcohol abuse with alcohol-induced disorder Diagnosis ICD-10-CM Diagnosis ICD-10-CM P10.181 Alcohol abuse with alcohol-induced sexual dysfunction Diagnosis ICD-10-CM P10.182 Alcohol abuse with other alcohol-induced disorder Diagnosis ICD-10-CM P10.183 Alcohol abuse with other alcohol-induced disorder Diagnosis ICD-10-CM P10.19 Alcohol abuse with unspecified alcohol-induced disorder Diagnosis ICD-10-CM P10.19 Alcohol dependence Uncomplicated Diagnosis ICD-10-CM P10.20 Alcohol dependence, uncomplicated Diagnosis ICD-10-CM P10.21 Alcohol dependence, in remission Diagnosis ICD-10-CM P10.22 Alcohol dependence, in remission Diagnosis ICD-10-CM P10.22 Alcohol dependence with intoxication Diagnosis ICD-10-CM P10.23 Alcohol dependence with withdrawal delirium Diagnosis ICD-10-CM P10.23 Alcohol dependence with withdrawal delirium Diagnosis ICD-10-CM P10.23 Alcohol dependence with withdrawal delirium Diagnosis ICD-10-CM P10.23 Alcohol dependence with withdrawal wit	F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.14Alcohol abuse with alcohol-induced mood disorderDiagnosisICD-10-CMF10.15Alcohol abuse with alcohol-induced psychotic disorderDiagnosisICD-10-CMF10.150Alcohol abuse with alcohol-induced psychotic disorder with delusionsDiagnosisICD-10-CMF10.151Alcohol abuse with alcohol-induced psychotic disorder with hallucinationsDiagnosisICD-10-CMF10.159Alcohol abuse with alcohol-induced psychotic disorder, unspecifiedDiagnosisICD-10-CMF10.180Alcohol abuse with alcohol-induced disordersDiagnosisICD-10-CMF10.181Alcohol abuse with alcohol-induced anxiety disorderDiagnosisICD-10-CMF10.182Alcohol abuse with alcohol-induced sexual dysfunctionDiagnosisICD-10-CMF10.183Alcohol abuse with alcohol-induced sleep disorderDiagnosisICD-10-CMF10.184Alcohol abuse with unspecified alcohol-induced disorderDiagnosisICD-10-CMF10.195Alcohol abuse with unspecified alcohol-induced disorderDiagnosisICD-10-CMF10.20Alcohol dependenceDiagnosisICD-10-CMF10.21Alcohol dependence, uncomplicatedDiagnosisICD-10-CMF10.22Alcohol dependence with intoxicationDiagnosisICD-10-CMF10.22Alcohol dependence with intoxication, uncomplicatedDiagnosisICD-10-CMF10.229Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.231Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.232	F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.15Alcohol abuse with alcohol-induced psychotic disorderDiagnosisICD-10-CMF10.150Alcohol abuse with alcohol-induced psychotic disorder with delusionsDiagnosisICD-10-CMF10.151Alcohol abuse with alcohol-induced psychotic disorder, unspecifiedDiagnosisICD-10-CMF10.159Alcohol abuse with alcohol-induced psychotic disordersDiagnosisICD-10-CMF10.180Alcohol abuse with other alcohol-induced disordersDiagnosisICD-10-CMF10.181Alcohol abuse with alcohol-induced anxiety disorderDiagnosisICD-10-CMF10.182Alcohol abuse with alcohol-induced sexual dysfunctionDiagnosisICD-10-CMF10.183Alcohol abuse with alcohol-induced disorderDiagnosisICD-10-CMF10.188Alcohol abuse with other alcohol-induced disorderDiagnosisICD-10-CMF10.19Alcohol dependenceDiagnosisICD-10-CMF10.20Alcohol dependence, uncomplicatedDiagnosisICD-10-CMF10.21Alcohol dependence, uncomplicatedDiagnosisICD-10-CMF10.22Alcohol dependence with intoxication, uncomplicatedDiagnosisICD-10-CMF10.22Alcohol dependence with intoxication, uncomplicatedDiagnosisICD-10-CMF10.22Alcohol dependence with intoxication, unspecifiedDiagnosisICD-10-CMF10.23Alcohol dependence with intoxication, unspecifiedDiagnosisICD-10-CMF10.23Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.23Alcohol dependence with withd	F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.150Alcohol abuse with alcohol-induced psychotic disorder with hallucinationsDiagnosisICD-10-CMF10.151Alcohol abuse with alcohol-induced psychotic disorder with hallucinationsDiagnosisICD-10-CMF10.159Alcohol abuse with alcohol-induced psychotic disorder, unspecifiedDiagnosisICD-10-CMF10.180Alcohol abuse with alcohol-induced disordersDiagnosisICD-10-CMF10.181Alcohol abuse with alcohol-induced sexual dysfunctionDiagnosisICD-10-CMF10.182Alcohol abuse with alcohol-induced sleep disorderDiagnosisICD-10-CMF10.188Alcohol abuse with alcohol-induced sleep disorderDiagnosisICD-10-CMF10.188Alcohol abuse with unspecified alcohol-induced disorderDiagnosisICD-10-CMF10.19Alcohol dependenceDiagnosisICD-10-CMF10.21Alcohol dependence, uncomplicatedDiagnosisICD-10-CMF10.22Alcohol dependence, in remissionDiagnosisICD-10-CMF10.22Alcohol dependence with intoxicationDiagnosisICD-10-CMF10.220Alcohol dependence with intoxication uncomplicatedDiagnosisICD-10-CMF10.221Alcohol dependence with intoxication deliriumDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.231Alcohol dependence with withdrawal uncomplicatedDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawal with perceptual disturbanceDiagnosisICD-10-CMF10.233Alcohol	F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.151Alcohol abuse with alcohol-induced psychotic disorder with hallucinationsDiagnosisICD-10-CMF10.159Alcohol abuse with alcohol-induced psychotic disorder, unspecifiedDiagnosisICD-10-CMF10.180Alcohol abuse with alcohol-induced disordersDiagnosisICD-10-CMF10.181Alcohol abuse with alcohol-induced anxiety disorderDiagnosisICD-10-CMF10.182Alcohol abuse with alcohol-induced sexual dysfunctionDiagnosisICD-10-CMF10.183Alcohol abuse with other alcohol-induced disorderDiagnosisICD-10-CMF10.19Alcohol abuse with unspecified alcohol-induced disorderDiagnosisICD-10-CMF10.2Alcohol dependenceDiagnosisICD-10-CMF10.2Alcohol dependence, uncomplicatedDiagnosisICD-10-CMF10.2Alcohol dependence, in remissionDiagnosisICD-10-CMF10.22Alcohol dependence with intoxicationDiagnosisICD-10-CMF10.22Alcohol dependence with intoxication, uncomplicatedDiagnosisICD-10-CMF10.221Alcohol dependence with intoxication, unspecifiedDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.233Alcohol dependence with withdrawal, uncomplicatedDiagnosisICD-10-CMF10.230Alcohol dependence with withdrawal, uncomplicatedDiagnosisICD-10-CMF10.231Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawal delirium<	F10.15	Alcohol abuse with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.159Alcohol abuse with alcohol-induced psychotic disorder, unspecifiedDiagnosisICD-10-CMF10.18Alcohol abuse with other alcohol-induced disordersDiagnosisICD-10-CMF10.180Alcohol abuse with alcohol-induced anxiety disorderDiagnosisICD-10-CMF10.181Alcohol abuse with alcohol-induced seval dysfunctionDiagnosisICD-10-CMF10.182Alcohol abuse with alcohol-induced sleep disorderDiagnosisICD-10-CMF10.188Alcohol abuse with unspecified alcohol-induced disorderDiagnosisICD-10-CMF10.2Alcohol dependenceDiagnosisICD-10-CMF10.2Alcohol dependence, uncomplicatedDiagnosisICD-10-CMF10.21Alcohol dependence, in remissionDiagnosisICD-10-CMF10.22Alcohol dependence with intoxicationDiagnosisICD-10-CMF10.220Alcohol dependence with intoxication, uncomplicatedDiagnosisICD-10-CMF10.221Alcohol dependence with intoxication, unspecifiedDiagnosisICD-10-CMF10.229Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.230Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.231Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.233Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.233Alcohol dependence with alcohol-induced mood disorderDiagn	F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.18Alcohol abuse with other alcohol-induced disordersDiagnosisICD-10-CMF10.180Alcohol abuse with alcohol-induced anxiety disorderDiagnosisICD-10-CMF10.181Alcohol abuse with alcohol-induced sexual dysfunctionDiagnosisICD-10-CMF10.182Alcohol abuse with alcohol-induced slorderDiagnosisICD-10-CMF10.188Alcohol abuse with unspecified alcohol-induced disorderDiagnosisICD-10-CMF10.19Alcohol dependenceDiagnosisICD-10-CMF10.20Alcohol dependence, uncomplicatedDiagnosisICD-10-CMF10.21Alcohol dependence, in remissionDiagnosisICD-10-CMF10.22Alcohol dependence with intoxicationDiagnosisICD-10-CMF10.220Alcohol dependence with intoxication, uncomplicatedDiagnosisICD-10-CMF10.221Alcohol dependence with intoxication, unspecifiedDiagnosisICD-10-CMF10.229Alcohol dependence with intoxication, unspecifiedDiagnosisICD-10-CMF10.230Alcohol dependence with withdrawal, uncomplicatedDiagnosisICD-10-CMF10.231Alcohol dependence with withdrawal, uncomplicatedDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.233Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.234Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.235Alcohol dependence with alcohol-induced mood disorderDiagnosis	F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.180Alcohol abuse with alcohol-induced anxiety disorderDiagnosisICD-10-CMF10.181Alcohol abuse with alcohol-induced sexual dysfunctionDiagnosisICD-10-CMF10.182Alcohol abuse with alcohol-induced sleep disorderDiagnosisICD-10-CMF10.188Alcohol abuse with other alcohol-induced disorderDiagnosisICD-10-CMF10.19Alcohol abuse with unspecified alcohol-induced disorderDiagnosisICD-10-CMF10.2Alcohol dependenceDiagnosisICD-10-CMF10.20Alcohol dependence, uncomplicatedDiagnosisICD-10-CMF10.21Alcohol dependence with intoxicationDiagnosisICD-10-CMF10.22Alcohol dependence with intoxication, uncomplicatedDiagnosisICD-10-CMF10.220Alcohol dependence with intoxication, uncomplicatedDiagnosisICD-10-CMF10.221Alcohol dependence with intoxication, unspecifiedDiagnosisICD-10-CMF10.223Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.230Alcohol dependence with withdrawal, uncomplicatedDiagnosisICD-10-CMF10.231Alcohol dependence with withdrawal deliriumDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawal with perceptual disturbanceDiagnosisICD-10-CMF10.233Alcohol dependence with alcohol-induced mod disorderDiagnosisICD-10-CMF10.250Alcohol dependence with alcohol-induced psychotic disorderDiagnosisICD-10-CMF10.251Alcohol dependence with alcohol-induc	F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.181Alcohol abuse with alcohol-induced sexual dysfunctionDiagnosisICD-10-CMF10.182Alcohol abuse with alcohol-induced sleep disorderDiagnosisICD-10-CMF10.188Alcohol abuse with other alcohol-induced disorderDiagnosisICD-10-CMF10.19Alcohol abuse with unspecified alcohol-induced disorderDiagnosisICD-10-CMF10.20Alcohol dependenceDiagnosisICD-10-CMF10.21Alcohol dependence, uncomplicatedDiagnosisICD-10-CMF10.22Alcohol dependence, in remissionDiagnosisICD-10-CMF10.22Alcohol dependence with intoxicationDiagnosisICD-10-CMF10.220Alcohol dependence with intoxication, uncomplicatedDiagnosisICD-10-CMF10.221Alcohol dependence with intoxication, unspecifiedDiagnosisICD-10-CMF10.223Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.230Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.231Alcohol dependence with withdrawal deliriumDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawal with perceptual disturbanceDiagnosisICD-10-CMF10.233Alcohol dependence with alcohol-induced mood disorderDiagnosisICD-10-CMF10.234Alcohol dependence with alcohol-induced mood disorderDiagnosisICD-10-CMF10.250Alcohol dependence with alcohol-induced psychotic disorder with alcunationsDiagnosisICD-10-CMF10.251Alcohol dependence with alcohol-induced psychotic	F10.18	Alcohol abuse with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.182Alcohol abuse with alcohol-induced sleep disorderDiagnosisICD-10-CMF10.188Alcohol abuse with other alcohol-induced disorderDiagnosisICD-10-CMF10.19Alcohol abuse with unspecified alcohol-induced disorderDiagnosisICD-10-CMF10.2Alcohol dependenceDiagnosisICD-10-CMF10.20Alcohol dependence, uncomplicatedDiagnosisICD-10-CMF10.21Alcohol dependence, in remissionDiagnosisICD-10-CMF10.22Alcohol dependence with intoxicationDiagnosisICD-10-CMF10.220Alcohol dependence with intoxication, uncomplicatedDiagnosisICD-10-CMF10.221Alcohol dependence with intoxication, unspecifiedDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.233Alcohol dependence with withdrawal, uncomplicatedDiagnosisICD-10-CMF10.230Alcohol dependence with withdrawal deliriumDiagnosisICD-10-CMF10.231Alcohol dependence with withdrawal deliriumDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.239Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.250Alcohol dependence with alcohol-induced psychotic disorderDiagnosisICD-10-CMF10.251Alcohol dependence with alcohol-induced psychotic disorder with allucinationsDiagnosisICD-10-CMF10.2529Alcohol dependence with alcohol-induced psychotic disorder	F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.188Alcohol abuse with other alcohol-induced disorderDiagnosisICD-10-CMF10.19Alcohol abuse with unspecified alcohol-induced disorderDiagnosisICD-10-CMF10.2Alcohol dependenceDiagnosisICD-10-CMF10.20Alcohol dependence, uncomplicatedDiagnosisICD-10-CMF10.21Alcohol dependence, in remissionDiagnosisICD-10-CMF10.22Alcohol dependence with intoxicationDiagnosisICD-10-CMF10.220Alcohol dependence with intoxication, uncomplicatedDiagnosisICD-10-CMF10.221Alcohol dependence with intoxication, unspecifiedDiagnosisICD-10-CMF10.223Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.230Alcohol dependence with withdrawal, uncomplicatedDiagnosisICD-10-CMF10.231Alcohol dependence with withdrawal deliriumDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawal with perceptual disturbanceDiagnosisICD-10-CMF10.233Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.234Alcohol dependence with alcohol-induced mood disorderDiagnosisICD-10-CMF10.25Alcohol dependence with alcohol-induced psychotic disorderDiagnosisICD-10-CMF10.25Alcohol dependence with alcohol-induced psychotic disorder with hallucinationsDiagnosisICD-10-CMF10.25Alcohol dependence with alcohol-induced psychotic disorder with hallucinationsDiagnosisICD-10-CMF10.25Alcohol d	F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.19Alcohol abuse with unspecified alcohol-induced disorderDiagnosisICD-10-CMF10.2Alcohol dependenceDiagnosisICD-10-CMF10.20Alcohol dependence, uncomplicatedDiagnosisICD-10-CMF10.21Alcohol dependence, in remissionDiagnosisICD-10-CMF10.22Alcohol dependence with intoxicationDiagnosisICD-10-CMF10.220Alcohol dependence with intoxication, uncomplicatedDiagnosisICD-10-CMF10.221Alcohol dependence with intoxication, unspecifiedDiagnosisICD-10-CMF10.223Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.230Alcohol dependence with withdrawal, uncomplicatedDiagnosisICD-10-CMF10.231Alcohol dependence with withdrawal deliriumDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawal with perceptual disturbanceDiagnosisICD-10-CMF10.239Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.24Alcohol dependence with alcohol-induced mood disorderDiagnosisICD-10-CMF10.25Alcohol dependence with alcohol-induced psychotic disorderDiagnosisICD-10-CMF10.25Alcohol dependence with alcohol-induced psychotic disorder with hallucinationsDiagnosisICD-10-CMF10.25Alcohol dependence with alcohol-induced psychotic disorder with hallucinationsDiagnosisICD-10-CMF10.25Alcohol dependence with alcohol-induced psychotic disorder with hallucinationsDiagnosisICD-10-CM<	F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.2Alcohol dependenceDiagnosisICD-10-CMF10.20Alcohol dependence, uncomplicatedDiagnosisICD-10-CMF10.21Alcohol dependence, in remissionDiagnosisICD-10-CMF10.22Alcohol dependence with intoxicationDiagnosisICD-10-CMF10.220Alcohol dependence with intoxication, uncomplicatedDiagnosisICD-10-CMF10.221Alcohol dependence with intoxication, unspecifiedDiagnosisICD-10-CMF10.229Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.23Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.230Alcohol dependence with withdrawal deliriumDiagnosisICD-10-CMF10.231Alcohol dependence with withdrawal deliriumDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawal with perceptual disturbanceDiagnosisICD-10-CMF10.233Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.244Alcohol dependence with alcohol-induced mood disorderDiagnosisICD-10-CMF10.255Alcohol dependence with alcohol-induced psychotic disorderDiagnosisICD-10-CMF10.250Alcohol dependence with alcohol-induced psychotic disorder with delusionsDiagnosisICD-10-CMF10.251Alcohol dependence with alcohol-induced psychotic disorder with hallucinationsDiagnosisICD-10-CMF10.252Alcohol dependence with alcohol-induced psychotic disorder, unspecifiedDiagnosisICD-10-CMF10.253Alcohol depende	F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20Alcohol dependence, uncomplicatedDiagnosisICD-10-CMF10.21Alcohol dependence, in remissionDiagnosisICD-10-CMF10.22Alcohol dependence with intoxicationDiagnosisICD-10-CMF10.220Alcohol dependence with intoxication, uncomplicatedDiagnosisICD-10-CMF10.221Alcohol dependence with intoxication deliriumDiagnosisICD-10-CMF10.229Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.23Alcohol dependence with withdrawal, uncomplicatedDiagnosisICD-10-CMF10.230Alcohol dependence with withdrawal deliriumDiagnosisICD-10-CMF10.231Alcohol dependence with withdrawal with perceptual disturbanceDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.239Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.24Alcohol dependence with alcohol-induced mood disorderDiagnosisICD-10-CMF10.250Alcohol dependence with alcohol-induced psychotic disorderDiagnosisICD-10-CMF10.251Alcohol dependence with alcohol-induced psychotic disorder with delusionsDiagnosisICD-10-CMF10.259Alcohol dependence with alcohol-induced psychotic disorder with hallucinationsDiagnosisICD-10-CMF10.26Alcohol dependence with alcohol-induced psychotic disorder, unspecifiedDiagnosisICD-10-CMF10.27Alcohol dependence with alcohol-induced persisting amnestic disorderDiagnosis <td>F10.19</td> <td>Alcohol abuse with unspecified alcohol-induced disorder</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.21Alcohol dependence, in remissionDiagnosisICD-10-CMF10.22Alcohol dependence with intoxicationDiagnosisICD-10-CMF10.220Alcohol dependence with intoxication, uncomplicatedDiagnosisICD-10-CMF10.221Alcohol dependence with intoxication deliriumDiagnosisICD-10-CMF10.229Alcohol dependence with intoxication, unspecifiedDiagnosisICD-10-CMF10.23Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.230Alcohol dependence with withdrawal, uncomplicatedDiagnosisICD-10-CMF10.231Alcohol dependence with withdrawal deliriumDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawal with perceptual disturbanceDiagnosisICD-10-CMF10.239Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.24Alcohol dependence with alcohol-induced mood disorderDiagnosisICD-10-CMF10.25Alcohol dependence with alcohol-induced psychotic disorderDiagnosisICD-10-CMF10.25Alcohol dependence with alcohol-induced psychotic disorder with hallucinationsDiagnosisICD-10-CMF10.25Alcohol dependence with alcohol-induced psychotic disorder with hallucinationsDiagnosisICD-10-CMF10.25Alcohol dependence with alcohol-induced psychotic disorder, unspecifiedDiagnosisICD-10-CMF10.26Alcohol dependence with alcohol-induced persisting amnestic disorderDiagnosisICD-10-CMF10.27Alcohol dependence with other alcohol-induced diso	F10.2	Alcohol dependence	Diagnosis	ICD-10-CM
F10.22 Alcohol dependence with intoxication Diagnosis ICD-10-CM F10.220 Alcohol dependence with intoxication, uncomplicated Diagnosis ICD-10-CM F10.221 Alcohol dependence with intoxication delirium Diagnosis ICD-10-CM F10.229 Alcohol dependence with intoxication, unspecified Diagnosis ICD-10-CM F10.23 Alcohol dependence with withdrawal Diagnosis ICD-10-CM F10.230 Alcohol dependence with withdrawal, uncomplicated Diagnosis ICD-10-CM F10.231 Alcohol dependence with withdrawal delirium Diagnosis ICD-10-CM F10.232 Alcohol dependence with withdrawal with perceptual disturbance Diagnosis ICD-10-CM F10.239 Alcohol dependence with withdrawal, unspecified Diagnosis ICD-10-CM F10.24 Alcohol dependence with alcohol-induced mood disorder Diagnosis ICD-10-CM F10.25 Alcohol dependence with alcohol-induced psychotic disorder Diagnosis ICD-10-CM F10.250 Alcohol dependence with alcohol-induced psychotic disorder Diagnosis ICD-10-CM F10.251 Alcohol dependence with alcohol-induced psychotic disorder with delusions Diagnosis ICD-10-CM F10.259 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.259 Alcohol dependence with alcohol-induced psychotic disorder, unspecified Diagnosis ICD-10-CM F10.26 Alcohol dependence with alcohol-induced psychotic disorder Diagnosis ICD-10-CM F10.26 Alcohol dependence with alcohol-induced psychotic disorder Diagnosis ICD-10-CM F10.27 Alcohol dependence with alcohol-induced psychotic disorder Diagnosis ICD-10-CM F10.28 Alcohol dependence with alcohol-induced disorders Diagnosis ICD-10-CM F10.28 Alcohol dependence with other alcohol-induced disorders Diagnosis ICD-10-CM F10.28 Alcohol dependence with alcohol-induced disorders Diagnosis ICD-10-CM	F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.220 Alcohol dependence with intoxication, uncomplicated Diagnosis ICD-10-CM F10.221 Alcohol dependence with intoxication delirium Diagnosis ICD-10-CM F10.229 Alcohol dependence with intoxication, unspecified Diagnosis ICD-10-CM F10.23 Alcohol dependence with withdrawal Diagnosis ICD-10-CM Diagnosis IC	F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.221 Alcohol dependence with intoxication delirium Diagnosis ICD-10-CM F10.229 Alcohol dependence with withdrawal Diagnosis ICD-10-CM Diagnosis	F10.22	Alcohol dependence with intoxication	Diagnosis	ICD-10-CM
F10.229Alcohol dependence with intoxication, unspecifiedDiagnosisICD-10-CMF10.23Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.230Alcohol dependence with withdrawal, uncomplicatedDiagnosisICD-10-CMF10.231Alcohol dependence with withdrawal deliriumDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawal with perceptual disturbanceDiagnosisICD-10-CMF10.239Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.24Alcohol dependence with alcohol-induced mood disorderDiagnosisICD-10-CMF10.25Alcohol dependence with alcohol-induced psychotic disorderDiagnosisICD-10-CMF10.250Alcohol dependence with alcohol-induced psychotic disorder with delusionsDiagnosisICD-10-CMF10.251Alcohol dependence with alcohol-induced psychotic disorder with hallucinationsDiagnosisICD-10-CMF10.259Alcohol dependence with alcohol-induced psychotic disorder, unspecifiedDiagnosisICD-10-CMF10.26Alcohol dependence with alcohol-induced persisting amnestic disorderDiagnosisICD-10-CMF10.27Alcohol dependence with alcohol-induced persisting dementiaDiagnosisICD-10-CMF10.28Alcohol dependence with other alcohol-induced disordersDiagnosisICD-10-CMF10.28Alcohol dependence with alcohol-induced anxiety disorderDiagnosisICD-10-CM	F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.23Alcohol dependence with withdrawalDiagnosisICD-10-CMF10.230Alcohol dependence with withdrawal, uncomplicatedDiagnosisICD-10-CMF10.231Alcohol dependence with withdrawal deliriumDiagnosisICD-10-CMF10.232Alcohol dependence with withdrawal with perceptual disturbanceDiagnosisICD-10-CMF10.239Alcohol dependence with withdrawal, unspecifiedDiagnosisICD-10-CMF10.24Alcohol dependence with alcohol-induced mood disorderDiagnosisICD-10-CMF10.25Alcohol dependence with alcohol-induced psychotic disorderDiagnosisICD-10-CMF10.250Alcohol dependence with alcohol-induced psychotic disorder with delusionsDiagnosisICD-10-CMF10.251Alcohol dependence with alcohol-induced psychotic disorder with hallucinationsDiagnosisICD-10-CMF10.259Alcohol dependence with alcohol-induced psychotic disorder, unspecifiedDiagnosisICD-10-CMF10.26Alcohol dependence with alcohol-induced persisting amnestic disorderDiagnosisICD-10-CMF10.27Alcohol dependence with alcohol-induced persisting dementiaDiagnosisICD-10-CMF10.28Alcohol dependence with other alcohol-induced disordersDiagnosisICD-10-CMF10.280Alcohol dependence with alcohol-induced disordersDiagnosisICD-10-CM	F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.230 Alcohol dependence with withdrawal, uncomplicated F10.231 Alcohol dependence with withdrawal delirium F10.232 Alcohol dependence with withdrawal with perceptual disturbance F10.239 Alcohol dependence with withdrawal, unspecified F10.24 Alcohol dependence with alcohol-induced mood disorder F10.25 Alcohol dependence with alcohol-induced psychotic disorder F10.25 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10.25 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10.25 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations F10.25 Alcohol dependence with alcohol-induced psychotic disorder, unspecified F10.25 Alcohol dependence with alcohol-induced psychotic disorder, unspecified F10.26 Alcohol dependence with alcohol-induced persisting amnestic disorder F10.27 Alcohol dependence with alcohol-induced persisting dementia F10.28 Alcohol dependence with other alcohol-induced disorders F10.28 Alcohol dependence with alcohol-induced disorders F10.28 Alcohol dependence with alcohol-induced disorders F10.28 Alcohol dependence with alcohol-induced anxiety disorder F10.28 Diagnosis ICD-10-CM F10.28 Alcohol dependence with alcohol-induced anxiety disorder F10.29 Diagnosis ICD-10-CM	F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.231 Alcohol dependence with withdrawal delirium F10.232 Alcohol dependence with withdrawal with perceptual disturbance F10.239 Alcohol dependence with withdrawal, unspecified F10.24 Alcohol dependence with alcohol-induced mood disorder F10.25 Alcohol dependence with alcohol-induced psychotic disorder F10.250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10.251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations F10.252 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations F10.253 Alcohol dependence with alcohol-induced psychotic disorder, unspecified F10.250 Alcohol dependence with alcohol-induced psychotic disorder, unspecified F10.250 Alcohol dependence with alcohol-induced persisting amnestic disorder F10.26 Alcohol dependence with alcohol-induced persisting dementia F10.27 Alcohol dependence with alcohol-induced disorders F10.28 Alcohol dependence with other alcohol-induced disorders F10.28 Alcohol dependence with alcohol-induced disorders F10.28 Alcohol dependence with alcohol-induced disorders F10.28 Alcohol dependence with alcohol-induced disorders F10.28 Diagnosis ICD-10-CM F10.28 Alcohol dependence with alcohol-induced anxiety disorder F10.28 Diagnosis ICD-10-CM	F10.23	Alcohol dependence with withdrawal	Diagnosis	ICD-10-CM
F10.232 Alcohol dependence with withdrawal with perceptual disturbance Diagnosis ICD-10-CM F10.239 Alcohol dependence with withdrawal, unspecified Diagnosis ICD-10-CM F10.24 Alcohol dependence with alcohol-induced mood disorder Diagnosis ICD-10-CM F10.25 Alcohol dependence with alcohol-induced psychotic disorder Diagnosis ICD-10-CM F10.250 Alcohol dependence with alcohol-induced psychotic disorder with delusions Diagnosis ICD-10-CM F10.251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.259 Alcohol dependence with alcohol-induced psychotic disorder, unspecified Diagnosis ICD-10-CM F10.26 Alcohol dependence with alcohol-induced persisting amnestic disorder Diagnosis ICD-10-CM F10.27 Alcohol dependence with alcohol-induced persisting dementia Diagnosis ICD-10-CM F10.28 Alcohol dependence with other alcohol-induced disorders Diagnosis ICD-10-CM Diagnosis ICD-10-CM Alcohol dependence with alcohol-induced disorders Diagnosis ICD-10-CM Diagnosis ICD-10-CM Diagnosis ICD-10-CM Alcohol dependence with alcohol-induced disorders Diagnosis ICD-10-CM Diagnosis ICD-10-	F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.239 Alcohol dependence with withdrawal, unspecified F10.24 Alcohol dependence with alcohol-induced mood disorder F10.25 Alcohol dependence with alcohol-induced psychotic disorder F10.250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10.251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations F10.259 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations F10.250 Alcohol dependence with alcohol-induced psychotic disorder, unspecified F10.250 Alcohol dependence with alcohol-induced persisting amnestic disorder F10.260 Alcohol dependence with alcohol-induced persisting dementia F10.270 Alcohol dependence with alcohol-induced persisting dementia F10.280 Alcohol dependence with other alcohol-induced disorders F10.280 Alcohol dependence with alcohol-induced anxiety disorder Diagnosis ICD-10-CM Diagnosis ICD-10-CM Diagnosis ICD-10-CM Diagnosis ICD-10-CM Diagnosis ICD-10-CM	F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.24 Alcohol dependence with alcohol-induced mood disorder F10.25 Alcohol dependence with alcohol-induced psychotic disorder Diagnosis ICD-10-CM F10.250 Alcohol dependence with alcohol-induced psychotic disorder with delusions Diagnosis ICD-10-CM F10.251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.259 Alcohol dependence with alcohol-induced psychotic disorder, unspecified Diagnosis ICD-10-CM F10.26 Alcohol dependence with alcohol-induced persisting amnestic disorder Diagnosis ICD-10-CM F10.27 Alcohol dependence with alcohol-induced persisting dementia Diagnosis ICD-10-CM F10.28 Alcohol dependence with other alcohol-induced disorders Diagnosis ICD-10-CM F10.280 Alcohol dependence with alcohol-induced anxiety disorder Diagnosis ICD-10-CM	F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.25 Alcohol dependence with alcohol-induced psychotic disorder F10.250 Alcohol dependence with alcohol-induced psychotic disorder with delusions F10.251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations F10.259 Alcohol dependence with alcohol-induced psychotic disorder, unspecified F10.26 Alcohol dependence with alcohol-induced persisting amnestic disorder F10.27 Alcohol dependence with alcohol-induced persisting dementia F10.28 Alcohol dependence with other alcohol-induced disorders F10.28 Alcohol dependence with alcohol-induced disorders F10.28 Alcohol dependence with alcohol-induced disorders F10.28 Diagnosis ICD-10-CM F10.28 Alcohol dependence with alcohol-induced disorders F10.28 Diagnosis ICD-10-CM F10.28 Diagnosis ICD-10-CM	F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.250 Alcohol dependence with alcohol-induced psychotic disorder with delusions Diagnosis ICD-10-CM F10.251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations Diagnosis ICD-10-CM F10.259 Alcohol dependence with alcohol-induced psychotic disorder, unspecified Diagnosis ICD-10-CM F10.26 Alcohol dependence with alcohol-induced persisting amnestic disorder Diagnosis ICD-10-CM F10.27 Alcohol dependence with alcohol-induced persisting dementia Diagnosis ICD-10-CM F10.28 Alcohol dependence with other alcohol-induced disorders Diagnosis ICD-10-CM F10.280 Alcohol dependence with alcohol-induced anxiety disorder Diagnosis ICD-10-CM	F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.251 Alcohol dependence with alcohol-induced psychotic disorder with hallucinations F10.259 Alcohol dependence with alcohol-induced psychotic disorder, unspecified F10.26 Alcohol dependence with alcohol-induced persisting amnestic disorder F10.27 Alcohol dependence with alcohol-induced persisting dementia F10.28 Alcohol dependence with other alcohol-induced disorders F10.28 Alcohol dependence with alcohol-induced anxiety disorder F10.28 Diagnosis ICD-10-CM F10.28 Alcohol dependence with other alcohol-induced disorders F10.28 Diagnosis ICD-10-CM F10.28 Diagnosis ICD-10-CM	F10.25	Alcohol dependence with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.259 Alcohol dependence with alcohol-induced psychotic disorder, unspecified Diagnosis ICD-10-CM F10.26 Alcohol dependence with alcohol-induced persisting amnestic disorder Diagnosis ICD-10-CM F10.27 Alcohol dependence with alcohol-induced persisting dementia Diagnosis ICD-10-CM F10.28 Alcohol dependence with other alcohol-induced disorders Diagnosis ICD-10-CM F10.280 Alcohol dependence with alcohol-induced anxiety disorder Diagnosis ICD-10-CM	F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.26 Alcohol dependence with alcohol-induced persisting amnestic disorder Diagnosis ICD-10-CM F10.27 Alcohol dependence with alcohol-induced persisting dementia Diagnosis ICD-10-CM F10.28 Alcohol dependence with other alcohol-induced disorders Diagnosis ICD-10-CM F10.280 Alcohol dependence with alcohol-induced anxiety disorder Diagnosis ICD-10-CM	F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.27 Alcohol dependence with alcohol-induced persisting dementia Diagnosis ICD-10-CM F10.28 Alcohol dependence with other alcohol-induced disorders Diagnosis ICD-10-CM F10.280 Alcohol dependence with alcohol-induced anxiety disorder Diagnosis ICD-10-CM	F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.27 Alcohol dependence with alcohol-induced persisting dementia Diagnosis ICD-10-CM F10.28 Alcohol dependence with other alcohol-induced disorders Diagnosis ICD-10-CM F10.280 Alcohol dependence with alcohol-induced anxiety disorder Diagnosis ICD-10-CM	F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.28 Alcohol dependence with other alcohol-induced disorders Diagnosis ICD-10-CM P10.280 Alcohol dependence with alcohol-induced anxiety disorder Diagnosis ICD-10-CM	F10.27			
F10.280 Alcohol dependence with alcohol-induced anxiety disorder Diagnosis ICD-10-CM		·	_	
·		·		
		Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 724 of 1023



Procedure Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code Description	Category	Code Type
F10.282 Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288 Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29 Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.9 Alcohol use, unspecified	Diagnosis	ICD-10-CM
F10.92 Alcohol use, unspecified with intoxication	Diagnosis	ICD-10-CM
F10.920 Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921 Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929 Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.94 Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.95 Alcohol use, unspecified with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.950 Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951 Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959 Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96 Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97 Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.98 Alcohol use, unspecified with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.980 Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981 Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982 Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988 Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99 Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1 Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6 Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.2 Alcoholic gastritis	Diagnosis	ICD-10-CM
K29.20 Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21 Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0 Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10 Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11 Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2 Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3 Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30 Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31 Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40 Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41 Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9 Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0 Finding of alcohol in blood	Diagnosis	ICD-10-CM
T51 Toxic effect of alcohol	Diagnosis	ICD-10-CM
T51.0 Toxic effect of ethanol	Diagnosis	ICD-10-CM
T51.0X Toxic effect of ethanol	Diagnosis	ICD-10-CM
T51.0X1 Toxic effect of ethanol, accidental (unintentional)	Diagnosis	ICD-10-CM
T51.0X1A Toxic effect of ethanol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 725 of 1023



	·	Code	
Code	Description	Category	Code Type
T51.0X1D	Toxic effect of ethanol, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T51.0X1S	Toxic effect of ethanol, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T51.0X2	Toxic effect of ethanol, intentional self-harm	Diagnosis	ICD-10-CM
T51.0X2A	Toxic effect of ethanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.0X2D	Toxic effect of ethanol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.0X2S	Toxic effect of ethanol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.0X3	Toxic effect of ethanol, assault	Diagnosis	ICD-10-CM
T51.0X3A	Toxic effect of ethanol, assault, initial encounter	Diagnosis	ICD-10-CM
T51.0X3D	Toxic effect of ethanol, assault, subsequent encounter	Diagnosis	ICD-10-CM
T51.0X3S	Toxic effect of ethanol, assault, sequela	Diagnosis	ICD-10-CM
T51.0X4	Toxic effect of ethanol, undetermined	Diagnosis	ICD-10-CM
T51.0X4A	Toxic effect of ethanol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.0X4D	Toxic effect of ethanol, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T51.0X4S	Toxic effect of ethanol, undetermined, sequela	Diagnosis	ICD-10-CM
T51.8	Toxic effect of other alcohols	Diagnosis	ICD-10-CM
T51.8X	Toxic effect of other alcohols	Diagnosis	ICD-10-CM
T51.8X1	Toxic effect of other alcohols, accidental (unintentional)	Diagnosis	ICD-10-CM
T51.8X1A	Toxic effect of other alcohols, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.8X1D	Toxic effect of other alcohols, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T51.8X1S	Toxic effect of other alcohols, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T51.8X2	Toxic effect of other alcohols, intentional self-harm	Diagnosis	ICD-10-CM
T51.8X2A	Toxic effect of other alcohols, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.8X2D	Toxic effect of other alcohols, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.8X2S	Toxic effect of other alcohols, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.8X3	Toxic effect of other alcohols, assault	Diagnosis	ICD-10-CM
T51.8X3A	Toxic effect of other alcohols, assault, initial encounter	Diagnosis	ICD-10-CM
T51.8X3D	Toxic effect of other alcohols, assault, subsequent encounter	Diagnosis	ICD-10-CM
T51.8X3S	Toxic effect of other alcohols, assault, sequela	Diagnosis	ICD-10-CM
T51.8X4	Toxic effect of other alcohols, undetermined	Diagnosis	ICD-10-CM
T51.8X4A	Toxic effect of other alcohols, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.8X4D	Toxic effect of other alcohols, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T51.8X4S	Toxic effect of other alcohols, undetermined, sequela	Diagnosis	ICD-10-CM
T51.9	Toxic effect of unspecified alcohol	Diagnosis	ICD-10-CM
T51.91	Toxic effect of unspecified alcohol, accidental (unintentional)	Diagnosis	ICD-10-CM
T51.91XA	Toxic effect of unspecified alcohol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.91XD	Toxic effect of unspecified alcohol, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T51.91XS	Toxic effect of unspecified alcohol, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T51.92	Toxic effect of unspecified alcohol, intentional self-harm	Diagnosis	ICD-10-CM
T51.92XA	Toxic effect of unspecified alcohol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.92XD	Toxic effect of unspecified alcohol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.92XS	Toxic effect of unspecified alcohol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.93	Toxic effect of unspecified alcohol, assault	Diagnosis	ICD-10-CM
	•	-	

cder_mpl1p_wp077 Page 726 of 1023



		Code	
Code	Description	Category	Code Type
51.93XA	Toxic effect of unspecified alcohol, assault, initial encounter	Diagnosis	ICD-10-CN
51.93XD	Toxic effect of unspecified alcohol, assault, subsequent encounter	Diagnosis	ICD-10-CN
51.93XS	Toxic effect of unspecified alcohol, assault, sequela	Diagnosis	ICD-10-CN
51.94	Toxic effect of unspecified alcohol, undetermined	Diagnosis	ICD-10-CN
51.94XA	Toxic effect of unspecified alcohol, undetermined, initial encounter	Diagnosis	ICD-10-CN
51.94XD	Toxic effect of unspecified alcohol, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
51.94XS	Toxic effect of unspecified alcohol, undetermined, sequela	Diagnosis	ICD-10-CN
71.4	Alcohol abuse counseling and surveillance	Diagnosis	ICD-10-CN
	Obesity		
68.3	Body mass index [BMI] 30-39, adult	Diagnosis	ICD-10-CN
68.4	Body mass index [BMI] 40 or greater, adult	Diagnosis	ICD-10-CN
66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CN
66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CN
66.1	Drug-induced obesity	Diagnosis	ICD-10-CN
66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CN
66.8	Other obesity	Diagnosis	ICD-10-CN
66.9	Obesity, unspecified	Diagnosis	ICD-10-CN
95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CN
95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CN
95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CN
95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CN
99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CN
99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CN
99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CN
99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CN
99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CN
99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CN
68.30	Body mass index [BMI] 30.0-30.9, adult	Diagnosis	ICD-10-CN
68.31	Body mass index [BMI] 31.0-31.9, adult	Diagnosis	ICD-10-CN
68.32	Body mass index [BMI] 32.0-32.9, adult	Diagnosis	ICD-10-CN
68.33	Body mass index [BMI] 33.0-33.9, adult	Diagnosis	ICD-10-CN
68.34	Body mass index [BMI] 34.0-34.9, adult	Diagnosis	ICD-10-CN
68.35	Body mass index [BMI] 35.0-35.9, adult	Diagnosis	ICD-10-CN
68.36	Body mass index [BMI] 36.0-36.9, adult	Diagnosis	ICD-10-CN
68.37	Body mass index [BMI] 37.0-37.9, adult	Diagnosis	ICD-10-CN
68.38	Body mass index [BMI] 38.0-38.9, adult	Diagnosis	ICD-10-CN
68.39	Body mass index [BMI] 39.0-39.9, adult	Diagnosis	ICD-10-CN
68.41	Body mass index [BMI]40.0-44.9, adult	Diagnosis	ICD-10-CN
68.42	Body mass index [BMI] 45.0-49.9, adult	Diagnosis	ICD-10-CN
68.43	Body mass index [BMI] 50.0-59.9, adult	Diagnosis	ICD-10-CN
68.44	Body mass index [BMI] 60.0-69.9, adult	Diagnosis	ICD-10-CN
68.45	Body mass index [BMI] 70 or greater, adult	Diagnosis	ICD-10-CN
00.43	body mass muck [bivii] 70 or greater, adult	Diagnosis	ICD-10-CI

cder_mpl1p_wp077 Page 727 of 1023



		Code	
Code	Description	Category	Code Type
Z98.84	Bariatric surgery status	Diagnosis	ICD-10-CM
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open	Procedure	ICD-10-PCS
	Approach		
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 728 of 1023



riocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial	Procedure	ICD-10-PCS
	Opening Endoscopic		
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial	Procedure	ICD-10-PCS
	Opening Endoscopic		
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial	Procedure	ICD-10-PCS
	Opening Endoscopic		
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or	Procedure	ICD-10-PCS
	Artificial Opening Endoscopic		
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
	Endoscopic		
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
	Endoscopic		
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
	Endoscopic		
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial	Procedure	ICD-10-PCS
	Opening Endoscopic		
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or	Procedure	ICD-10-PCS
	Artificial Opening Endoscopic		
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or	Procedure	ICD-10-PCS
	Artificial Opening Endoscopic		
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial	Procedure	ICD-10-PCS
	Opening Endoscopic		
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or	Procedure	ICD-10-PCS
	Artificial Opening Endoscopic		
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 729 of 1023



CodeDescriptionCategoryCode Type0D1947ABypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS ICD-10-PCS Approach0D1947BBypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS Approach0D19419Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS Approach0D1941ABypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0D1941BBypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0D1944BBypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0D1944BBypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0D1944BBypass Duodenum to Ileum with Nonautologous Tissue Substitute, PercutaneousProcedureICD-10-PCS0D1947BBypass Duodenum to Duodenum, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0D1947BBypass Duodenum to Dejunum, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0D1947BBypass Duodenum to Dejunum with Autologous Tissue Substitute, Via Natural or ArtificialProcedureICD-10-PCS0D1987BBypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or ArtificialProcedureICD-10-PCS0D1987B <td< th=""></td<>
OD1947A Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach Procedure ICD-10-PCS OD1947B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach Procedure ICD-10-PCS OD194J9 Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach Procedure ICD-10-PCS OD194JA Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach Procedure ICD-10-PCS OD194JB Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach Procedure ICD-10-PCS ICD-10-PCS OD194K9 Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach Procedure ICD-10-PCS OD194KA Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS ICD-10-PCS Endoscopic Approach Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS ICD-10-PCS OD194KB Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS Procedure ICD-10-PCS OD194ZA Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS Procedure ICD-10-PCS OD194ZB Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure
0D1947BBypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS Approach0D194J9Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0D194JABypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0D194JBBypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0D194K9Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0D194KABypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0D194KBBypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0D194Z9Bypass Duodenum to Duodenum, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0D194Z9Bypass Duodenum to Jejunum, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0D194ZBBypass Duodenum to Ileum, Percutaneous Endoscopic ApproachProcedureICD-10-PCS0D198ZBBypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural orProcedureICD-10-PCS0D198ZBBypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or ArtificialProcedureICD-10-PCS0D198ZBBypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial OpeningProcedureICD-10-PCS0D1
Approach Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Procedure ICD-10-PCS Approach D194JB Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach D194JB Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS Endoscopic Approach D194KB Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS Endoscopic Approach D194KB Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS Endoscopic Approach D194KB Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS Endoscopic Approach D194ZP Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS D194ZB Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS D194ZB Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS D194ZB Bypass Duodenum to Jejunum Percutaneous Endoscopic Approach Procedure ICD-10-PCS Artificial Opening Endoscopic D1987B Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic D1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic D1987B Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic D1987B Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Opening Endoscopic D1988B Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Opening Endoscopic
OD194J9Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedure ProcedureICD-10-PCS ICD-10-PCS ApproachOD194JABypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOD194JBBypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOD194K9Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOD194KABypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOD194KBBypass Duodenum to Ileum with Nonautologous Tissue Substitute, PercutaneousProcedureICD-10-PCSEndoscopic ApproachProcedureICD-10-PCSOD194Z9Bypass Duodenum to Duodenum, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOD194ZABypass Duodenum to Ileum, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOD194ZABypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural orProcedureICD-10-PCSOD19879Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or ArtificialProcedureICD-10-PCSOpening EndoscopicOpening EndoscopicProcedureICD-10-PCSOpening EndoscopicOpening EndoscopicICD-10-PCSOpening EndoscopicProcedureICD-10-PCSOpening EndoscopicICD-10-PCSOpening EndoscopicProcedureICD-10-PCS <t< td=""></t<>
Approach D194JA Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Procedure Approach D194JB Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach D194K9 Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS Endoscopic Approach D194KA Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS Endoscopic Approach D194KB Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS Endoscopic Approach D194KB Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach D194KB Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach D194KB Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach D194KB Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach D194KB Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Procedure ICD-10-PCS Artificial Opening Endoscopic D194KB Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic D194KB Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic D194KB Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Opening Endoscopic D194KB Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Opening Endoscopic D194KB Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Opening Endoscopic D194KB Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS D194KB Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic
OD194JABypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedure ICD-10-PCSICD-10-PCSOD194JBBypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOD194K9Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOD194KABypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOD194KBBypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOD194Z9Bypass Duodenum to Duodenum, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOD194ZABypass Duodenum to Jejunum, Percutaneous Endoscopic ApproachProcedureICD-10-PCSOD194ZBBypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening EndoscopicICD-10-PCSOD1987ABypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOD1987BBypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOD1981BBypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening EndoscopicProcedureICD-10-PCSOD1981BBypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial OpeningProcedureICD-10-PCS
Approach OD194JB Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach Procedure ICD-10-PCS Endoscopic Approach OD194KA Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS Endoscopic Approach OD194KA Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS Endoscopic Approach OD194KB Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS Endoscopic Approach OD194KB Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS OD194ZB Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS OD194ZB Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS OD194ZB Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic OD1987A Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD1987B Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD1987B Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Opening Endoscopic OD1987B Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic OD1988B Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic
DD194JB Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach Procedure ICD-10-PCS
DD194K9 Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach DD194KA Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS Endoscopic Approach DD194KB Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS Endoscopic Approach DD194ZB Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach DD194ZB Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach DD194ZB Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach DD194ZB Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach DD194ZB Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Procedure ICD-10-PCS DD1987B Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic DD1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic DD1987B Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic DD1987B Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Dpening Endoscopic DD1987B Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Dpening Endoscopic DD1987B Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Dpening Endoscopic DD1987B Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Dpening Endoscopic DD1987B Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Dpening Endoscopic
Endoscopic Approach D194KA Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach D194KB Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS Endoscopic Approach D194ZB Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach D194ZA Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach D194ZB Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach D194ZB Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach D194ZB Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Procedure ICD-10-PCS Artificial Opening Endoscopic D1987B Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic D1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic D1987B Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic D1988B Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic D1989B Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic D1989B Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic
Endoscopic Approach D194KA Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach D194KB Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS Endoscopic Approach D194ZB Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach D194ZA Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach D194ZB Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach D194ZB Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Procedure ICD-10-PCS Artificial Opening Endoscopic D1987B Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic D1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic D1987B Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic D1988B Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic D1989B Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic D1989B Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic
DD194KA Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach DD194KB Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Procedure ICD-10-PCS Endoscopic Approach Procedure ICD-10-PCS Endoscopic Approach Procedure ICD-10-PCS Endoscopic Approach Procedure ICD-10-PCS DD194ZB Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS DD194ZB Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS DD194ZB Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Procedure ICD-10-PCS DD1987B Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic DD1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic DD1987B Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic DD1987B Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic DD1987B Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS DP1987B Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic DD1987B Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic DD1987B DP1887B Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic DD1987B DP1887B Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS ICD-10
Endoscopic Approach OD194KB Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach OD194Z9 Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach OD194ZA Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach OD194ZB Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach OD194ZB Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach OD1987B Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic OD1987A Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198JB Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic OD198JB Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic OD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS
DD194KB Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Frocedure Endoscopic Approach DD194Z9 Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS DD194ZA Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS DD194ZB Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS DD19879 Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic DD1987A Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic DD1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic DD198J9 Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic DD198JA Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic DD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic DD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic
Endoscopic Approach OD194Z9 Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach OD194ZA Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach OD194ZB Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach OD194ZB Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach OD19879 Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic OD1987A Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198JP Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198JA Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Opening Endoscopic OD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic OD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic
DD194Z9 Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS DD194ZA Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS DD194ZB Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach Procedure ICD-10-PCS DD19879 Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic DD1987A Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic DD1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic DD198J9 Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic DD198JA Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic DD198JB Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic DD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic DD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic
OD194ZA Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach OD194ZB Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach OD19879 Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic OD1987A Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198J9 Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198JA Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic OD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic
DD194ZB Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach DD19879 Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic DD1987A Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic DD1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic DD198J9 Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic DD198JA Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic DD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic
OD19879 Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic OD1987A Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198J9 Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198JA Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic OD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic
Artificial Opening Endoscopic OD1987A Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198J9 Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198JA Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic OD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic
OD1987A Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198J9 Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198JA Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic OD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic
Opening Endoscopic OD1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198J9 Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198JA Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic OD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic
OD1987B Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198J9 Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198JA Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic OD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS
Opening Endoscopic OD198J9 Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198JA Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic OD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS
OD198J9 Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Procedure ICD-10-PCS Opening Endoscopic OD198JA Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic OD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS
Opening Endoscopic OD198JA Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic OD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS
OD198JA Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS Endoscopic OD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS
Endoscopic OD198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS
0D198JB Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Procedure ICD-10-PCS
Litaoscopic
0D198K9 Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Procedure ICD-10-PCS
Artificial Opening Endoscopic
0D198KA Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Procedure ICD-10-PCS
Artificial Opening Endoscopic
0D198KB Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Procedure ICD-10-PCS
Opening Endoscopic
0D198Z9 Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic Procedure ICD-10-PCS
OD198ZA Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic Procedure ICD-10-PCS
OD198ZB Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic Procedure ICD-10-PCS
0D1A07A Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach Procedure ICD-10-PCS
0D1A07B Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach Procedure ICD-10-PCS
OD1AOJA Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach Procedure ICD-10-PCS
OD1AOJB Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach Procedure ICD-10-PCS

cder_mpl1p_wp077 Page 730 of 1023



		Code	
Code	Description	Category	Code Type
OD1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
OD1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
OD1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 731 of 1023



	Codes osed to Define baseline Characteristics in this nequest	Code		
Code	Description	Category	Code Type	
OD1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening	Procedure	ICD-10-PCS	
	Endoscopic			
OD1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial	Procedure	ICD-10-PCS	
	Opening Endoscopic			
OD1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS	
OD1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS	
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS	
ODB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS	
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS	
ODB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS	
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS	
ODB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS	
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS	
ODB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS	
ODBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS	
ODV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS	
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS	
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS	
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4	
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4	
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4	
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4	
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4	
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4	
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4	
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4	
Tobacco Use				
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM	
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM	
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM	
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM	
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM	
F17.21	Nicotine dependence, cigarettes	Diagnosis	ICD-10-CM	
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM	
	-	-		

cder_mpl1p_wp077 Page 732 of 1023



	codes osed to beline buseline characteristics in this request	Code	
Code	Description	Category	Code Type
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.22	Nicotine dependence, chewing tobacco	Diagnosis	ICD-10-CM
F17.220	Nicotine dependence, chewing tobacco, uncomplicated	Diagnosis	ICD-10-CM
F17.221	Nicotine dependence, chewing tobacco, in remission	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.29	Nicotine dependence, other tobacco product	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
T65.21	Toxic effect of chewing tobacco	Diagnosis	ICD-10-CM
T65.211	Toxic effect of chewing tobacco, accidental (unintentional)	Diagnosis	ICD-10-CM
T65.211A	Toxic effect of chewing tobacco, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.211D	Toxic effect of chewing tobacco, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T65.211S	Toxic effect of chewing tobacco, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T65.212	Toxic effect of chewing tobacco, intentional self-harm	Diagnosis	ICD-10-CM
T65.212A	Toxic effect of chewing tobacco, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.212D	Toxic effect of chewing tobacco, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.212S	Toxic effect of chewing tobacco, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.213	Toxic effect of chewing tobacco, assault	Diagnosis	ICD-10-CM
T65.213A	Toxic effect of chewing tobacco, assault, initial encounter	Diagnosis	ICD-10-CM
T65.213D	Toxic effect of chewing tobacco, assault, subsequent encounter	Diagnosis	ICD-10-CM
T65.213S	Toxic effect of chewing tobacco, assault, sequela	Diagnosis	ICD-10-CM
T65.214	Toxic effect of chewing tobacco, undetermined	Diagnosis	ICD-10-CM
T65.214A	Toxic effect of chewing tobacco, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.214D	Toxic effect of chewing tobacco, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T65.214S	Toxic effect of chewing tobacco, undetermined, sequela	Diagnosis	ICD-10-CM
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.221D	Toxic effect of tobacco cigarettes, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T65.221S	Toxic effect of tobacco cigarettes, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.222D	Toxic effect of tobacco cigarettes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.222S	Toxic effect of tobacco cigarettes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.223D	Toxic effect of tobacco cigarettes, assault, subsequent encounter	Diagnosis	ICD-10-CM
T65.223S	Toxic effect of tobacco cigarettes, assault, sequela	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 733 of 1023



Trocedure	codes osed to Define baseline characteristics in this nequest	Code	
Code	Description	Category	Code Type
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.224D	Toxic effect of tobacco cigarettes, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T65.224S	Toxic effect of tobacco cigarettes, undetermined, sequela	Diagnosis	ICD-10-CM
T65.291A	Toxic effect of other tobacco and nicotine, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.291D	Toxic effect of other tobacco and nicotine, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T65.291S	Toxic effect of other tobacco and nicotine, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T65.292A	Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.292D	Toxic effect of other tobacco and nicotine, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.292S	Toxic effect of other tobacco and nicotine, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.293A	Toxic effect of other tobacco and nicotine, assault, initial encounter	Diagnosis	ICD-10-CM
T65.293D	Toxic effect of other tobacco and nicotine, assault, subsequent encounter	Diagnosis	ICD-10-CM
T65.293S	Toxic effect of other tobacco and nicotine, assault, sequela	Diagnosis	ICD-10-CM
T65.294A	Toxic effect of other tobacco and nicotine, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.294D	Toxic effect of other tobacco and nicotine, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T65.294S	Toxic effect of other tobacco and nicotine, undetermined, sequela	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Z72.0	Tobacco use	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
1032F	Current tobacco smoker or currently exposed to secondhand smoke (asthma)	Procedure	HCPCS
1034F	Current tobacco smoker (cad, cap, copd, pv) (dm)	Procedure	HCPCS
1035F	Current smokeless tobacco user (eg, chew, snuff) (pv)	Procedure	HCPCS
4000F	Tobacco use cessation intervention, counseling (copd, cap, cad, asthma) (dm) (pv)	Procedure	HCPCS
4001F	Tobacco use cessation intervention, pharmacologic therapy (copd, cad, cap, pv, asthma) (dm) (pv)	Procedure	HCPCS
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling,	Procedure	HCPCS
	pharmacotherapy, or both), if identified as a tobacco user (pv, cad)		
99406	Smoking and tobacco use intermediate counseling, greater than 3 minutes up to 10 minutes	Procedure	HCPCS
99407	Smoking and tobacco use intensive counseling, greater than 10 minutes	Procedure	HCPCS
C9801	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
C9802	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
D1320	Tobacco counseling for the control and prevention of oral disease	Procedure	HCPCS
G0375	SMOKING AND TOBACCO USE CESSATION COUNSELING VISIT; INTERMEDIATE, GREATER THAN 3 MINUTES UP TO 10 MINUTES	Procedure	HCPCS
G0376	SMOKING AND TOBACCO USE CESSATION COUNSELING VISIT; INTENSIVE, GREATER THAN 10 MINUTES	Procedure	HCPCS
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS

cder_mpl1p_wp077 Page 734 of 1023



		Code	·
ode	Description	Category	Code Type
0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive,	Procedure	HCPCS
	greater than 10 minutes		
8093	Newly diagnosed chronic obstructive pulmonary disease (copd) patient documented to	Procedure	HCPCS
	have received smoking cessation intervention, within 3 months of diagnosis		
68094	Newly diagnosed chronic obstructive pulmonary disease (copd) patient not documented	Procedure	HCPCS
	to have received smoking cessation intervention, within 3 months of diagnosis		
8402	Tobacco (smoke) use cessation intervention, counseling	Procedure	HCPCS
8403	Tobacco (smoke) use cessation intervention not counseled	Procedure	HCPCS
8453	Tobacco use cessation intervention, counseling	Procedure	HCPCS
i8454	Tobacco use cessation intervention not counseled, reason not specified	Procedure	HCPCS
8455	Current tobacco smoker	Procedure	HCPCS
8456	Current smokeless tobacco user	Procedure	HCPCS
8686	Currently a tobacco smoker or current exposure to secondhand smoke	Procedure	HCPCS
38688	Currently a smokeless tobacco user (eg, chew, snuff) and no exposure to secondhand	Procedure	HCPCS
	smoke		
8690	Current tobacco smoker or current exposure to secondhand smoke	Procedure	HCPCS
8692	Current smokeless tobacco user (eg, chew, snuff) and no exposure to secondhand smoke	Procedure	HCPCS
9016	Smoking cessation counseling, individual, in the absence of or in addition to any other	Procedure	HCPCS
	evaluation and management service, per session (6-10 minutes) âdemo project code only		
9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
i9458	Patient documented as tobacco user and received tobacco cessation intervention (must	Procedure	HCPCS
.5 .50	include at least one of the following: advice given to quit smoking or tobacco use,		1101 00
	counseling on the benefits of q		
		_	
9645	Patients who did not abstain from smoking prior to anesthesia on the day of surgery or	Procedure	HCPCS
	procedure		
9792	Most recent tobacco status is not tobacco free	Procedure	HCPCS
9902	Patient screened for tobacco use and identified as a tobacco user	Procedure	HCPCS
9906	Patient identified as a tobacco user received tobacco cessation intervention (counseling	Procedure	HCPCS
	and/or pharmacotherapy)		
9908	Patient identified as tobacco user did not receive tobacco cessation intervention	Procedure	HCPCS
	(counseling and/or pharmacotherapy), reason not given		
59909	Documentation of medical reason(s) for not providing tobacco cessation intervention if	Procedure	HCPCS
	identified as a tobacco user (eg, limited life expectancy, other medical reason)		
4990	Nicotine patches, legend	Procedure	HCPCS
4991	Nicotine patches, non-legend	Procedure	HCPCS
4995	Smoking cessation gum	Procedure	HCPCS
9075	Smoking cessation treatment	Procedure	HCPCS
30.3	Arrhythmia	110000000	1101 00
14	Atrioventricular and left bundle-branch block	Diagnosis	ICD-10-CN
44.0	Atrioventricular block, first degree	Diagnosis	ICD-10-CN
44.1	Atrioventricular block, second degree	Diagnosis	ICD-10-CN
44.2	Atrioventricular block, complete	Diagnosis	ICD-10-CM
	Other and unspecified atrioventricular block	_	
	Other and unspectien attroventricular block	Diagnosis	ICD-10-CN
44.3 44.30	Unspecified atrioventricular block	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 735 of 1023



Code Description Category Code Type 144.39 Other atrioventricular block Diagnosis ICD-10-CM 144.4 Left anterior fascicular block Diagnosis ICD-10-CM 144.5 Left posterior fascicular block Diagnosis ICD-10-CM 144.6 Other and unspecified fasicular block Diagnosis ICD-10-CM 144.60 Unspecified fasicular block Diagnosis ICD-10-CM 144.60 Unspecified fasicular block Diagnosis ICD-10-CM 144.60 Unspecified block Diagnosis ICD-10-CM 144.7 Left bundle-branch block unspecified Diagnosis ICD-10-CM 145.0 Other conduction disorders Diagnosis ICD-10-CM 145.1 Other and unspecified right bundle-branch block Diagnosis ICD-10-CM 145.1 Other getifed bundle-branch block Diagnosis ICD-10-CM 145.2 Bifascicular block Diagnosis ICD-10-CM 145.2 Bifascicular block Diagnosis ICD-10-CM 145.3 Trifascicular bl	. roccaare	e Codes Used to Define Baseline Characteristics in this Request	Code	
144.4 Left anterior fascicular block Diagnosis ICD-10-CM 144.5 Left posterior fascicular block Diagnosis ICD-10-CM 144.60 Unspecified fascicular block Diagnosis ICD-10-CM 144.60 Unspecified fascicular block Diagnosis ICD-10-CM 144.60 Other fascicular block Diagnosis ICD-10-CM 144.60 Other fascicular block Diagnosis ICD-10-CM 145.1 Other conduction disorders Diagnosis ICD-10-CM 145.0 Right fascicular block Diagnosis ICD-10-CM 145.1 Other and unspecified right bundle-branch block Diagnosis ICD-10-CM 145.1.0 Unspecified right bundle-branch block Diagnosis ICD-10-CM 145.2 Bifascicular block Diagnosis ICD-10-CM 145.2 Difascicular block Diagnosis ICD-10-CM 145.3 Trifascicular block Diagnosis ICD-10-CM 145.4 Nonspecified anticular block Diagnosis ICD-10-CM 145.5 Other specified anticu	Code	Description		Code Type
144.5 Left posterior fascicular block Diagnosis ICD-10-CM 144.6 Other and unspecified fasicular block Diagnosis ICD-10-CM 144.69 Other fascicular block Diagnosis ICD-10-CM 144.79 Left bundle-branch block, unspecified Diagnosis ICD-10-CM 145.0 Other conduction disorders Diagnosis ICD-10-CM 145.1 Other and unspecified right bundle-branch block Diagnosis ICD-10-CM 145.1 Other and unspecified right bundle-branch block Diagnosis ICD-10-CM 145.10 Unspecified right bundle-branch block Diagnosis ICD-10-CM 145.10 Unspecified right bundle-branch block Diagnosis ICD-10-CM 145.2 Bifascicular block Diagnosis ICD-10-CM 145.3 Trifascicular block Diagnosis ICD-10-CM 145.3 Trifascicular block Diagnosis ICD-10-CM 145.5 Other specified heart block Diagnosis ICD-10-CM 145.5 Other specified conduction disorders Diagnosis ICD-10-CM	144.39	Other atrioventricular block	Diagnosis	ICD-10-CM
144.6 Other and unspecified fasicular block Diagnosis ICD-10-CM 144.60 Unspecified fascicular block Diagnosis ICD-10-CM 144.7 Left bundle-branch block, unspecified Diagnosis ICD-10-CM 145.7 Other conduction disorders Diagnosis ICD-10-CM 145.0 Rijkin fascicular block Diagnosis ICD-10-CM 145.1 Other and unspecified right bundle-branch block Diagnosis ICD-10-CM 145.1 Other end unspecified right bundle-branch block Diagnosis ICD-10-CM 145.1.2 Unspecified right bundle-branch block Diagnosis ICD-10-CM 145.2 Bifascicular block Diagnosis ICD-10-CM 145.3 Trifascicular block Diagnosis ICD-10-CM 145.4 Nonspecific intraventricular block Diagnosis ICD-10-CM 145.5 Other specified heart block Diagnosis ICD-10-CM 145.6 Pre-excitation syndrome Diagnosis ICD-10-CM 145.8 Other specified conduction disorders Diagnosis ICD-10-CM <t< td=""><td>144.4</td><td>Left anterior fascicular block</td><td>Diagnosis</td><td>ICD-10-CM</td></t<>	144.4	Left anterior fascicular block	Diagnosis	ICD-10-CM
144.60 Unspecified fascicular block Diagnosis ICD-10-CM 144.67 Left bundle-branch block, unspecified Diagnosis ICD-10-CM 145 Other conduction disorders Diagnosis ICD-10-CM 145.0 Right fascicular block Diagnosis ICD-10-CM 145.1 Other and unspecified right bundle-branch block Diagnosis ICD-10-CM 145.10 Unspecified right bundle-branch block Diagnosis ICD-10-CM 145.10 Unspecified right bundle-branch block Diagnosis ICD-10-CM 145.12 Other right bundle-branch block Diagnosis ICD-10-CM 145.2 Bifascicular block Diagnosis ICD-10-CM 145.3 Trifascicular block Diagnosis ICD-10-CM 145.4 Nonspecified heart block Diagnosis ICD-10-CM 145.5 Other specified beart block Diagnosis ICD-10-CM 145.6 Pre-excitation syndrome Diagnosis ICD-10-CM 145.8 Other specified conduction disorders Diagnosis ICD-10-CM 145.9	144.5	Left posterior fascicular block	Diagnosis	ICD-10-CM
144.69 Other fascicular block Diagnosis ICD-10-CM 144.7 Left bundle-branch block, unspecified Diagnosis ICD-10-CM 145 Other conduction disorders Diagnosis ICD-10-CM 145.0 Right fascicular block Diagnosis ICD-10-CM 145.1 Other and unspecified right bundle-branch block Diagnosis ICD-10-CM 145.10 Unspecified right bundle-branch block Diagnosis ICD-10-CM 145.2 Bifascicular block Diagnosis ICD-10-CM 145.3 Trifascicular block Diagnosis ICD-10-CM 145.3 Trifascicular block Diagnosis ICD-10-CM 145.4 Nonspecific intraventricular block Diagnosis ICD-10-CM 145.5 Other specified beart block Diagnosis ICD-10-CM 145.6 Pre-excitation syndrome Diagnosis ICD-10-CM 145.8 Other specified conduction disorders Diagnosis ICD-10-CM 145.9 Conduction disorder, unspecified Diagnosis ICD-10-CM 146.2 Cardi	144.6	Other and unspecified fasicular block	Diagnosis	ICD-10-CM
144.7 Left bundle-branch block, unspecified Diagnosis ICD-10-CM 145 Other conduction disorders Diagnosis ICD-10-CM 145.0 Right fascicular block Diagnosis ICD-10-CM 145.1 Other and unspecified right bundle-branch block Diagnosis ICD-10-CM 145.10 Unspecified right bundle-branch block Diagnosis ICD-10-CM 145.19 Other right bundle-branch block Diagnosis ICD-10-CM 145.2 Bifascicular block Diagnosis ICD-10-CM 145.3 Trifascicular block Diagnosis ICD-10-CM 145.4 Nonspecifie dheart block Diagnosis ICD-10-CM 145.5 Other specified heart block Diagnosis ICD-10-CM 145.6 Pre-excitation syndrome Diagnosis ICD-10-CM 145.8 Other specified conduction disorders Diagnosis ICD-10-CM 145.8 Other specified conduction disorders Diagnosis ICD-10-CM 145.9 Conduction disorder, unspecified Diagnosis ICD-10-CM 146.2 Cardiac arrest due to underlying cardiac condition Diagnosis ICD-10-CM 146.8 Cardiac arrest due to other underlying condition Diagnosis ICD-10-CM 146.9	144.60	Unspecified fascicular block	Diagnosis	ICD-10-CM
145Other conduction disordersDiagnosisICD-10-CM145.0Right fascicular blockDiagnosisICD-10-CM145.1Other and unspecified right bundle-branch blockDiagnosisICD-10-CM145.19Unspecified right bundle-branch blockDiagnosisICD-10-CM145.2Bifascicular blockDiagnosisICD-10-CM145.2Bifascicular blockDiagnosisICD-10-CM145.3Trifascicular blockDiagnosisICD-10-CM145.4Nonspecific intraventricular blockDiagnosisICD-10-CM145.5Other specified heart blockDiagnosisICD-10-CM145.6Pre-excitation syndromeDiagnosisICD-10-CM145.8Other specified conduction disordersDiagnosisICD-10-CM145.8Other specified conduction disordersDiagnosisICD-10-CM145.9Conduction disorder, unspecifiedDiagnosisICD-10-CM146.0Cardiac arrest due to underlying cardiac conditionDiagnosisICD-10-CM146.2Cardiac arrest due to other underlying conditionDiagnosisICD-10-CM146.9Cardiac arrest due to other underlying conditionDiagnosisICD-10-CM147.0Re-entry ventricular arrhythmiaDiagnosisICD-10-CM147.1Supraventricular arrhythmiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM148.3Atrial fibrillation and flutterDiagnosisICD-10-CM148.1Persistent atrial fibril	144.69	Other fascicular block	Diagnosis	ICD-10-CM
145.0Right fascicular blockDiagnosisICD-10-CM145.1Other and unspecified right bundle-branch blockDiagnosisICD-10-CM145.10Unspecified right bundle-branch blockDiagnosisICD-10-CM145.2Other right bundle-branch blockDiagnosisICD-10-CM145.2Bifascicular blockDiagnosisICD-10-CM145.3Trifascicular blockDiagnosisICD-10-CM145.4Nonspecified intraventricular blockDiagnosisICD-10-CM145.5Other specified chart blockDiagnosisICD-10-CM145.6Pre-excitation syndromeDiagnosisICD-10-CM145.8Other specified conduction disordersDiagnosisICD-10-CM145.8Other specified conduction disordersDiagnosisICD-10-CM145.9Conduction disorder, unspecifiedDiagnosisICD-10-CM146.0Cardiac arrest due to underlying cardiac conditionDiagnosisICD-10-CM146.2Cardiac arrest due to underlying conditionDiagnosisICD-10-CM147.0Re-entry ventricular arrhythmiaDiagnosisICD-10-CM147.1Supraventricular arrhythmiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM147.1Supraventricular arrhythmiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM148.3Atrial fibrillation and flutterDiagnosisICD-10-CM148.1Persistent atrial fibrillation <td< td=""><td>144.7</td><td>Left bundle-branch block, unspecified</td><td>Diagnosis</td><td>ICD-10-CM</td></td<>	144.7	Left bundle-branch block, unspecified	Diagnosis	ICD-10-CM
145.1 Other and unspecified right bundle-branch block Diagnosis ICD-10-CM 145.19 Other right bundle-branch block Diagnosis ICD-10-CM 145.2 Bifascicular block Diagnosis ICD-10-CM 145.3 Trifascicular block Diagnosis ICD-10-CM 145.4 Nonspecific intraventricular block Diagnosis ICD-10-CM 145.5 Other specified heart block Diagnosis ICD-10-CM 145.6 Pre-excitation syndrome Diagnosis ICD-10-CM 145.8 Other specified conduction disorders Diagnosis ICD-10-CM 145.8.9 Other specified conduction disorders Diagnosis ICD-10-CM 145.9 Conduction disorder, unspecified Diagnosis ICD-10-CM 146.0 Cardiac arrest due to underlying cardiac condition Diagnosis ICD-10-CM 146.2 Cardiac arrest due to other underlying condition Diagnosis ICD-10-CM 146.9 Cardiac arrest, cause unspecified Diagnosis ICD-10-CM 147.1 Paroxysmal tachycardia Diagnosis ICD-10-CM 147.1 Supraventricular archycardia Diagnosis ICD-10-CM 147.2 Ventricular tachycardia, unspecified Diagnosis ICD-10-CM 14	145	Other conduction disorders	Diagnosis	ICD-10-CM
145.10Unspecified right bundle-branch blockDiagnosisICD-10-CM145.19Other right bundle-branch blockDiagnosisICD-10-CM145.2Bifascicular blockDiagnosisICD-10-CM145.3Trifascicular blockDiagnosisICD-10-CM145.4Nonspecific intraventricular blockDiagnosisICD-10-CM145.5Other specified heart blockDiagnosisICD-10-CM145.6Pre-excitation syndromeDiagnosisICD-10-CM145.8Other specified conduction disordersDiagnosisICD-10-CM145.8.9Other specified conduction disordersDiagnosisICD-10-CM145.9Conduction disorder, unspecifiedDiagnosisICD-10-CM146.1Cardiac arrest due to underlying cardiac conditionDiagnosisICD-10-CM146.2Cardiac arrest due to underlying conditionDiagnosisICD-10-CM146.9Cardiac arrest due to other underlying conditionDiagnosisICD-10-CM147.0Re-entry ventricular rarrhythmiaDiagnosisICD-10-CM147.1Paroxysmal tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM148.0Paroxysmal tarial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.1Permanent atrial fibrillation <td>145.0</td> <td>Right fascicular block</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	145.0	Right fascicular block	Diagnosis	ICD-10-CM
145.19Other right bundle-branch blockDiagnosisICD-10-CM145.2Bifascicular blockDiagnosisICD-10-CM145.3Trifascicular blockDiagnosisICD-10-CM145.4Nonspecific intraventricular blockDiagnosisICD-10-CM145.5Other specified heart blockDiagnosisICD-10-CM145.6Pre-excitation syndromeDiagnosisICD-10-CM145.8Other specified conduction disordersDiagnosisICD-10-CM145.89Other specified conduction disordersDiagnosisICD-10-CM145.9Conduction disorder, unspecifiedDiagnosisICD-10-CM146.0Cardiac arrestDiagnosisICD-10-CM146.1Cardiac arrest due to underlying cardiac conditionDiagnosisICD-10-CM146.9Cardiac arrest due to other underlying conditionDiagnosisICD-10-CM147.0Re-entry ventricular arrhythmiaDiagnosisICD-10-CM147.1Supraventricular arrhythmiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148.0Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.2.1Chronic atrial fibrillationDiagnosis<	145.1	Other and unspecified right bundle-branch block	Diagnosis	ICD-10-CM
145.2Bifascicular blockDiagnosisICD-10-CM145.3Trifascicular blockDiagnosisICD-10-CM145.4Nonspecific intraventricular blockDiagnosisICD-10-CM145.5Other specified heart blockDiagnosisICD-10-CM145.6Pre-excitation syndromeDiagnosisICD-10-CM145.8Other specified conduction disordersDiagnosisICD-10-CM145.89Other specified conduction disordersDiagnosisICD-10-CM145.99Conduction disorder, unspecifiedDiagnosisICD-10-CM146.10Cardiac arrestDiagnosisICD-10-CM146.2Cardiac arrest due to underlying cardiac conditionDiagnosisICD-10-CM146.9Cardiac arrest, cause unspecifiedDiagnosisICD-10-CM147.0Paroxysmal tachycardiaDiagnosisICD-10-CM147.1Supraventricular arrhythmiaDiagnosisICD-10-CM147.1Supraventricular tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardia, unspecifiedDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.2.1Permanent atrial fibrillationDiagnosisICD-10-C	145.10	Unspecified right bundle-branch block	Diagnosis	ICD-10-CM
145.3Trifascicular blockDiagnosisICD-10-CM145.4Nonspecific intraventricular blockDiagnosisICD-10-CM145.5Other specified heart blockDiagnosisICD-10-CM145.6Pre-excitation syndromeDiagnosisICD-10-CM145.8Other specified conduction disordersDiagnosisICD-10-CM145.8.9Other specified conduction disordersDiagnosisICD-10-CM145.9Conduction disorder, unspecifiedDiagnosisICD-10-CM146Cardiac arrestDiagnosisICD-10-CM146.2Cardiac arrest due to underlying cardiac conditionDiagnosisICD-10-CM146.8Cardiac arrest due to other underlying conditionDiagnosisICD-10-CM146.9Cardiac arrest, cause unspecifiedDiagnosisICD-10-CM147Paroxysmal tachycardiaDiagnosisICD-10-CM147.1Supraventricular tarhythmiaDiagnosisICD-10-CM147.2Ventricular tarhycardiaDiagnosisICD-10-CM147.3Supraventricular tachycardiaDiagnosisICD-10-CM148Atrial fibrillation and flutterDiagnosisICD-10-CM148.1Persoxysmal atrial fibrillationDiagnosisICD-10-CM148.1Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosis <td>145.19</td> <td>Other right bundle-branch block</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	145.19	Other right bundle-branch block	Diagnosis	ICD-10-CM
145.4Nonspecific intraventricular blockDiagnosisICD-10-CM145.5Other specified heart blockDiagnosisICD-10-CM145.6Pre-excitation syndromeDiagnosisICD-10-CM145.8Other specified conduction disordersDiagnosisICD-10-CM145.89Other specified conduction disordersDiagnosisICD-10-CM145.9Conduction disorder, unspecifiedDiagnosisICD-10-CM146Cardiac arrestDiagnosisICD-10-CM146.2Cardiac arrest due to underlying cardiac conditionDiagnosisICD-10-CM146.9Cardiac arrest, cause unspecifiedDiagnosisICD-10-CM147Paroxysmal tachycardiaDiagnosisICD-10-CM147.1Paroxysmal tachycardiaDiagnosisICD-10-CM147.1Supraventricular tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.1Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10	145.2	Bifascicular block	Diagnosis	ICD-10-CM
145.5Other specified heart blockDiagnosisICD-10-CM145.6Pre-excitation syndromeDiagnosisICD-10-CM145.8Other specified conduction disordersDiagnosisICD-10-CM145.89Other specified conduction disordersDiagnosisICD-10-CM145.9Conduction disorder, unspecifiedDiagnosisICD-10-CM146Cardiac arrestDiagnosisICD-10-CM146.2Cardiac arrest due to underlying cardiac conditionDiagnosisICD-10-CM146.8Cardiac arrest, cause unspecifiedDiagnosisICD-10-CM147.0Re-entry expressionDiagnosisICD-10-CM147.1Supraventricular arrhythmiaDiagnosisICD-10-CM147.1Supraventricular tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148.0Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.2Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.11Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-1	145.3	Trifascicular block	Diagnosis	ICD-10-CM
145.6Pre-excitation syndromeDiagnosisICD-10-CM145.8Other specified conduction disordersDiagnosisICD-10-CM145.89Other specified conduction disordersDiagnosisICD-10-CM145.90Conduction disorder, unspecifiedDiagnosisICD-10-CM146Cardiac arrestDiagnosisICD-10-CM146.2Cardiac arrest due to underlying cardiac conditionDiagnosisICD-10-CM146.8Cardiac arrest due to other underlying conditionDiagnosisICD-10-CM146.9Cardiac arrest, cause unspecifiedDiagnosisICD-10-CM147Paroxysmal tachycardiaDiagnosisICD-10-CM147.1Supraventricular tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.1Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.1Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.2.1Permanent atrial fibrillationDiagnosisICD-10-CM148.2.2Chronic atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutter	145.4	Nonspecific intraventricular block	Diagnosis	ICD-10-CM
145.8Other specified conduction disordersDiagnosisICD-10-CM145.89Other specified conduction disordersDiagnosisICD-10-CM145.9Conduction disorder, unspecifiedDiagnosisICD-10-CM146Cardiac arrestDiagnosisICD-10-CM146.2Cardiac arrest due to underlying cardiac conditionDiagnosisICD-10-CM146.8Cardiac arrest, cause unspecifiedDiagnosisICD-10-CM146.9Cardiac arrest, cause unspecifiedDiagnosisICD-10-CM147Paroxysmal tachycardiaDiagnosisICD-10-CM147.0Re-entry ventricular arrhythmiaDiagnosisICD-10-CM147.1Supraventricular tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.2.1Permanent atrial fibrillationDiagnosisICD-10-CM148.2.2Chronic atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosis<	145.5	Other specified heart block	Diagnosis	ICD-10-CM
145.89Other specified conduction disordersDiagnosisICD-10-CM145.9Conduction disorder, unspecifiedDiagnosisICD-10-CM146Cardiac arrestDiagnosisICD-10-CM146.2Cardiac arrest due to underlying cardiac conditionDiagnosisICD-10-CM146.8Cardiac arrest, cause unspecifiedDiagnosisICD-10-CM147.0Paroxysmal tachycardiaDiagnosisICD-10-CM147.0Re-entry ventricular arrhythmiaDiagnosisICD-10-CM147.1Supraventricular tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.1Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.11Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.12Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.20Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.21Permanent atrial fibrillationDiagnosisICD-10-CM148.23Typical atrial flutterDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrill	145.6	Pre-excitation syndrome	Diagnosis	ICD-10-CM
145.9Conduction disorder, unspecifiedDiagnosisICD-10-CM146Cardiac arrestDiagnosisICD-10-CM146.2Cardiac arrest due to underlying cardiac conditionDiagnosisICD-10-CM146.8Cardiac arrest, cause unspecifiedDiagnosisICD-10-CM147Paroxysmal tachycardiaDiagnosisICD-10-CM147.0Re-entry ventricular arrhythmiaDiagnosisICD-10-CM147.1Supraventricular tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148.0Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.1Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.19Other persistent atrial fibrillationDiagnosisICD-10-CM148.20Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.21Permanent atrial fibrillationDiagnosisICD-10-CM148.23Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM	145.8	Other specified conduction disorders	Diagnosis	ICD-10-CM
146Cardiac arrestDiagnosisICD-10-CM146.2Cardiac arrest due to underlying cardiac conditionDiagnosisICD-10-CM146.8Cardiac arrest due to other underlying conditionDiagnosisICD-10-CM146.9Cardiac arrest, cause unspecifiedDiagnosisICD-10-CM147Paroxysmal tachycardiaDiagnosisICD-10-CM147.0Re-entry ventricular arrhythmiaDiagnosisICD-10-CM147.1Supraventricular tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillation and flutterDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.11Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.12Chronic atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.2Permanent atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM	145.89	Other specified conduction disorders	Diagnosis	ICD-10-CM
146.2Cardiac arrest due to underlying cardiac conditionDiagnosisICD-10-CM146.8Cardiac arrest due to other underlying conditionDiagnosisICD-10-CM146.9Cardiac arrest, cause unspecifiedDiagnosisICD-10-CM147Paroxysmal tachycardiaDiagnosisICD-10-CM147.0Re-entry ventricular arrhythmiaDiagnosisICD-10-CM147.1Supraventricular tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.1Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.1Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.2Permanent atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillationDiagnosisICD-10-CM	145.9	Conduction disorder, unspecified	Diagnosis	ICD-10-CM
146.8Cardiac arrest due to other underlying conditionDiagnosisICD-10-CM146.9Cardiac arrest, cause unspecifiedDiagnosisICD-10-CM147Paroxysmal tachycardiaDiagnosisICD-10-CM147.0Re-entry ventricular arrhythmiaDiagnosisICD-10-CM147.1Supraventricular tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148Atrial fibrillation and flutterDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.1Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.19Other persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.2Permanent atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillationDiagnosisICD-10-CM	146	Cardiac arrest	Diagnosis	ICD-10-CM
146.9Cardiac arrest, cause unspecifiedDiagnosisICD-10-CM147Paroxysmal tachycardiaDiagnosisICD-10-CM147.0Re-entry ventricular arrhythmiaDiagnosisICD-10-CM147.1Supraventricular tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardia, unspecifiedDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148Atrial fibrillation and flutterDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.11Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.19Other persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.20Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	146.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
147Paroxysmal tachycardiaDiagnosisICD-10-CM147.0Re-entry ventricular arrhythmiaDiagnosisICD-10-CM147.1Supraventricular tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148Atrial fibrillation and flutterDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.11Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.19Other persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.20Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.21Permanent atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	146.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
147.0Re-entry ventricular arrhythmiaDiagnosisICD-10-CM147.1Supraventricular tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148Atrial fibrillation and flutterDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.11Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.19Other persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.20Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.21Permanent atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	146.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
147.1Supraventricular tachycardiaDiagnosisICD-10-CM147.2Ventricular tachycardiaDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148Atrial fibrillation and flutterDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.11Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.19Other persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.20Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.21Permanent atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	147	Paroxysmal tachycardia	Diagnosis	ICD-10-CM
147.2Ventricular tachycardiaDiagnosisICD-10-CM147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148Atrial fibrillation and flutterDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.11Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.19Other persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.20Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.21Permanent atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	147.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
147.9Paroxysmal tachycardia, unspecifiedDiagnosisICD-10-CM148Atrial fibrillation and flutterDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.11Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.19Other persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.20Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.21Permanent atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	147.1	Supraventricular tachycardia	Diagnosis	ICD-10-CM
148Atrial fibrillation and flutterDiagnosisICD-10-CM148.0Paroxysmal atrial fibrillationDiagnosisICD-10-CM148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.11Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.19Other persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.20Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.21Permanent atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	147.2	Ventricular tachycardia	Diagnosis	ICD-10-CM
148.0 Paroxysmal atrial fibrillation Diagnosis ICD-10-CM 148.1 Persistent atrial fibrillation Diagnosis ICD-10-CM 148.11 Longstanding persistent atrial fibrillation Diagnosis ICD-10-CM 148.19 Other persistent atrial fibrillation Diagnosis ICD-10-CM 148.2 Chronic atrial fibrillation Diagnosis ICD-10-CM 148.20 Chronic atrial fibrillation, unspecified Diagnosis ICD-10-CM 148.21 Permanent atrial fibrillation Diagnosis ICD-10-CM 148.3 Typical atrial flutter Diagnosis ICD-10-CM 148.4 Atypical atrial flutter Diagnosis ICD-10-CM 148.9 Unspecified atrial fibrillation and atrial flutter 148.9 Unspecified atrial fibrillation Diagnosis ICD-10-CM 148.91 Unspecified atrial fibrillation Diagnosis ICD-10-CM	147.9	Paroxysmal tachycardia, unspecified	Diagnosis	ICD-10-CM
148.1Persistent atrial fibrillationDiagnosisICD-10-CM148.11Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.19Other persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.20Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.21Permanent atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	148	Atrial fibrillation and flutter	Diagnosis	ICD-10-CM
148.11Longstanding persistent atrial fibrillationDiagnosisICD-10-CM148.19Other persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.20Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.21Permanent atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	148.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
148.19Other persistent atrial fibrillationDiagnosisICD-10-CM148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.20Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.21Permanent atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	148.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
148.2Chronic atrial fibrillationDiagnosisICD-10-CM148.20Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.21Permanent atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	148.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
148.20Chronic atrial fibrillation, unspecifiedDiagnosisICD-10-CM148.21Permanent atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	148.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
148.21Permanent atrial fibrillationDiagnosisICD-10-CM148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	148.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	148.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
148.3Typical atrial flutterDiagnosisICD-10-CM148.4Atypical atrial flutterDiagnosisICD-10-CM148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	148.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
148.9 Unspecified atrial fibrillation and atrial flutter Diagnosis ICD-10-CM 148.91 Unspecified atrial fibrillation Diagnosis ICD-10-CM	148.3	Typical atrial flutter		ICD-10-CM
148.9Unspecified atrial fibrillation and atrial flutterDiagnosisICD-10-CM148.91Unspecified atrial fibrillationDiagnosisICD-10-CM	148.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
148.91 Unspecified atrial fibrillation Diagnosis ICD-10-CM	148.9	**	=	ICD-10-CM
·	148.91	•	=	ICD-10-CM
	148.92	•	=	

cder_mpl1p_wp077 Page 736 of 1023



	Codes Osed to Define Baseline Characteristics in this request	Code	
Code	Description	Category	Code Type
149	Other cardiac arrhythmias	Diagnosis	ICD-10-CM
149.0	Ventricular fibrillation and flutter	Diagnosis	ICD-10-CM
149.01	Ventricular fibrillation	Diagnosis	ICD-10-CM
149.02	Ventricular flutter	Diagnosis	ICD-10-CM
149.1	Atrial premature depolarization	Diagnosis	ICD-10-CM
149.2	Junctional premature depolarization	Diagnosis	ICD-10-CM
149.3	Ventricular premature depolarization	Diagnosis	ICD-10-CM
149.4	Other and unspecified premature depolarization	Diagnosis	ICD-10-CM
149.40	Unspecified premature depolarization	Diagnosis	ICD-10-CM
149.49	Other premature depolarization	Diagnosis	ICD-10-CM
149.5	Sick sinus syndrome	Diagnosis	ICD-10-CM
149.8	Other specified cardiac arrhythmias	Diagnosis	ICD-10-CM
149.9	Cardiac arrhythmia, unspecified	Diagnosis	ICD-10-CM
R00	Abnormalities of heart beat	Diagnosis	ICD-10-CM
R00.0	Tachycardia, unspecified	Diagnosis	ICD-10-CM
R00.1	Bradycardia, unspecified	Diagnosis	ICD-10-CM
R00.2	Palpitations	Diagnosis	ICD-10-CM
R00.8	Other abnormalities of heart beat	Diagnosis	ICD-10-CM
R00.9	Unspecified abnormalities of heart beat	Diagnosis	ICD-10-CM
	Cerebrovascular Disease/Stroke/Transient Ischemic Attack		
G43.5	Persistent migraine aura without cerebral infarction	Diagnosis	ICD-10-CM
G43.50	Persistent migraine aura without cerebral infarction, not intractable	Diagnosis	ICD-10-CM
G43.501	Persistent migraine aura without cerebral infarction, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.509	Persistent migraine aura without cerebral infarction, not intractable, without status	Diagnosis	ICD-10-CM
043.309	migrainosus	Diagnosis	ICD-10-CIVI
G43.51	Persistent migraine aura without cerebral infarction, intractable	Diagnosis	ICD-10-CM
G43.511	Persistent migraine aura without cerebral infarction, intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.519	Persistent migraine aura without cerebral infarction, intractable, without status	Diagnosis	ICD-10-CM
	migrainosus		
G43.6	Persistent migraine aura with cerebral infarction	Diagnosis	ICD-10-CM
G43.60	Persistent migraine aura with cerebral infarction, not intractable	Diagnosis	ICD-10-CM
G43.601	Persistent migraine aura with cerebral infarction, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.609	Persistent migraine aura with cerebral infarction, not intractable, without status	Diagnosis	ICD-10-CM
	migrainosus		
G43.61	Persistent migraine aura with cerebral infarction, intractable	Diagnosis	ICD-10-CM
G43.611 G43.619	Persistent migraine aura with cerebral infarction, intractable, with status migrainosus Persistent migraine aura with cerebral infarction, intractable, without status migrainosus	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
G45.619	Transient cerebral ischemic attacks and related syndromes	_	ICD-10-CM
G45 G45.0	Vertebro-basilar artery syndrome	Diagnosis Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 737 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.4	Transient global amnesia	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
160	Nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
160.0	Nontraumatic subarachnoid hemorrhage from carotid siphon and bifurcation	Diagnosis	ICD-10-CM
160.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
160.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
160.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
160.1	Nontraumatic subarachnoid hemorrhage from middle cerebral artery	Diagnosis	ICD-10-CM
160.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
160.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
160.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
160.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
160.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
160.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
160.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
160.3	Nontraumatic subarachnoid hemorrhage from posterior communicating artery	Diagnosis	ICD-10-CM
160.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
160.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
160.31	Nontraumatic subaractinoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
160.32	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
160.5	Nontraumatic subarachnoid hemorrhage from vertebral artery	Diagnosis	ICD-10-CM
160.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
160.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
160.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
160.52	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
160.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
160.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
160.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
161	Nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
161.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
161.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
161.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
161.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
161.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
161.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
161.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
161.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
161.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
162	Other and unspecified nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
162.0	Nontraumatic subdural hemorrhage	Diagnosis	ICD-10-CM
162.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
102.00	nona damade subdutat nemorriage, anspecifica	Diagnosis	ICD TO-CIVI

cder_mpl1p_wp077 Page 738 of 1023



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
162.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
162.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
162.03	Nontraumatic chronic subdural hemorrhage	Diagnosis	ICD-10-CM
162.1	Nontraumatic extradural hemorrhage	Diagnosis	ICD-10-CM
162.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
163	Cerebral infarction	Diagnosis	ICD-10-CM
163.0	Cerebral infarction due to thrombosis of precerebral arteries	Diagnosis	ICD-10-CM
163.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
163.01	Cerebral infarction due to thrombosis of vertebral artery	Diagnosis	ICD-10-CM
163.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
163.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
163.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
163.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
163.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
163.03	Cerebral infarction due to thrombosis of carotid artery	Diagnosis	ICD-10-CM
163.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
163.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
163.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
163.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
163.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
163.1	Cerebral infarction due to embolism of precerebral arteries	Diagnosis	ICD-10-CM
163.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
163.11	Cerebral infarction due to embolism of vertebral artery	Diagnosis	ICD-10-CM
163.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
163.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
163.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
163.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
163.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
163.13	Cerebral infarction due to embolism of carotid artery	Diagnosis	ICD-10-CM
163.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
163.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
163.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
163.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
163.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
163.2	Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries	Diagnosis	ICD-10-CM
163.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral	Diagnosis	ICD-10-CM
	arteries	- 100.1011	
163.21	Cerebral infarction due to unspecified occlusion or stenosis of vertebral arteries	Diagnosis	ICD-10-CM
163.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
163.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
163.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
		- 100.1011	
163.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
163.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
163.23	Cerebral infarction due to unspecified occlusion or stenosis of carotid arteries	Diagnosis	ICD-10-CM
163.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
163.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
103.232	cerestia intarction due to unspecimed occidsion of stemosis of left carotia afteries	Diagnosis	ICD TO-CIVI

cder_mpl1p_wp077 Page 739 of 1023



Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries Diagnosis ICI	D-10-CM
Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries Diagnosis ICI	D-10-CM D-10-CM D-10-CM D-10-CM D-10-CM D-10-CM
Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid artery Diagnosis ICI 163.29 Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries Diagnosis ICI 163.30 Cerebral infarction due to thrombosis of cerebral arteries Diagnosis ICI 163.31 Cerebral infarction due to thrombosis of unspecified cerebral artery Diagnosis ICI 163.31 Cerebral infarction due to thrombosis of middle cerebral artery Diagnosis ICI 163.311 Cerebral infarction due to thrombosis of right middle cerebral artery Diagnosis ICI 163.312 Cerebral infarction due to thrombosis of left middle cerebral artery Diagnosis ICI 163.313 Cerebral infarction due to thrombosis of bilateral middle cerebral artery Diagnosis ICI 163.319 Cerebral infarction due to thrombosis of unspecified middle cerebral artery Diagnosis ICI 163.320 Cerebral infarction due to thrombosis of right anterior cerebral artery Diagnosis ICI 163.321 Cerebral infarction due to thrombosis of right anterior cerebral artery Diagnosis ICI 163.322 Cerebral infarction due to thrombosis of bilateral anterior cerebral artery Diagnosis ICI 163.323 Cerebral infarction due to thrombosis of bilateral anterior cerebral artery Diagnosis ICI 163.323 Cerebral infarction due to thrombosis of bilateral anterior cerebral artery Diagnosis ICI 163.331 Cerebral infarction due to thrombosis of posterior cerebral artery Diagnosis ICI 163.332 Cerebral infarction due to thrombosis of posterior cerebral artery Diagnosis ICI 163.333 Cerebral infarction due to thrombosis of posterior cerebral artery Diagnosis ICI 163.333 Cerebral infarction due to thrombosis of posterior cerebral artery Diagnosis ICI 163.334 Cerebral infarction due to thrombosis of posterior cerebral artery Diagnosis ICI 163.340 Cerebral infarction due to thrombosis of left posterior cerebral arteries Diagnosis ICI 163.341 Cerebral infarction due to thrombosis of inspecified posterior cerebral arteries Diagnosis ICI 163.342 Cerebral infarction d	D-10-CM D-10-CM D-10-CM D-10-CM
163.29 Cerebral infarction due to thrombosis of cerebral arteries Diagnosis ICI	D-10-CM D-10-CM D-10-CM D-10-CM
163.3 Cerebral infarction due to thrombosis of cerebral arteries Diagnosis ICI	D-10-CM D-10-CM D-10-CM
163.3 Cerebral infarction due to thrombosis of cerebral arteries Diagnosis ICI 163.30 Cerebral infarction due to thrombosis of unspecified cerebral artery Diagnosis ICI 163.31 Cerebral infarction due to thrombosis of middle cerebral artery Diagnosis ICI 163.311 Cerebral infarction due to thrombosis of right middle cerebral artery Diagnosis ICI 163.312 Cerebral infarction due to thrombosis of left middle cerebral artery Diagnosis ICI 163.313 Cerebral infarction due to thrombosis of bilateral middle cerebral arteries Diagnosis ICI 163.319 Cerebral infarction due to thrombosis of unspecified middle cerebral artery Diagnosis ICI 163.321 Cerebral infarction due to thrombosis of anterior cerebral artery Diagnosis ICI 163.322 Cerebral infarction due to thrombosis of right anterior cerebral artery Diagnosis ICI 163.323 Cerebral infarction due to thrombosis of left anterior cerebral artery Diagnosis ICI 163.322 Cerebral infarction due to thrombosis of left anterior cerebral arteries Diagnosis ICI 163.323 Cerebral infarction due to thrombosis of unspecified anterior cerebral artery Diagnosis ICI 163.324 Cerebral infarction due to thrombosis of posterior cerebral artery Diagnosis ICI 163.335 Cerebral infarction due to thrombosis of posterior cerebral artery Diagnosis ICI 163.336 Cerebral infarction due to thrombosis of left posterior cerebral artery Diagnosis ICI 163.337 Cerebral infarction due to thrombosis of left posterior cerebral artery Diagnosis ICI 163.340 Cerebral infarction due to thrombosis of unspecified posterior cerebral artery Diagnosis ICI 163.341 Cerebral infarction due to thrombosis of cerebellar artery Diagnosis ICI 163.342 Cerebral infarction due to thrombosis of cerebellar artery Diagnosis ICI 163.343 Cerebral infarction due to thrombosis of liateral cerebellar artery Diagnosis ICI 163.344 Cerebral inf	D-10-CM D-10-CM D-10-CM
163.3 Cerebral infarction due to thrombosis of cerebral arteries Diagnosis ICI 163.30 Cerebral infarction due to thrombosis of unspecified cerebral artery Diagnosis ICI 163.31 Cerebral infarction due to thrombosis of middle cerebral artery Diagnosis ICI 163.311 Cerebral infarction due to thrombosis of right middle cerebral artery Diagnosis ICI 163.312 Cerebral infarction due to thrombosis of left middle cerebral artery Diagnosis ICI 163.313 Cerebral infarction due to thrombosis of bilateral middle cerebral arteries Diagnosis ICI 163.319 Cerebral infarction due to thrombosis of unspecified middle cerebral artery Diagnosis ICI 163.321 Cerebral infarction due to thrombosis of anterior cerebral artery Diagnosis ICI 163.322 Cerebral infarction due to thrombosis of right anterior cerebral artery Diagnosis ICI 163.323 Cerebral infarction due to thrombosis of left anterior cerebral artery Diagnosis ICI 163.322 Cerebral infarction due to thrombosis of left anterior cerebral arteries Diagnosis ICI 163.323 Cerebral infarction due to thrombosis of unspecified anterior cerebral artery Diagnosis ICI 163.324 Cerebral infarction due to thrombosis of posterior cerebral artery Diagnosis ICI 163.335 Cerebral infarction due to thrombosis of posterior cerebral artery Diagnosis ICI 163.336 Cerebral infarction due to thrombosis of left posterior cerebral artery Diagnosis ICI 163.337 Cerebral infarction due to thrombosis of left posterior cerebral artery Diagnosis ICI 163.340 Cerebral infarction due to thrombosis of unspecified posterior cerebral artery Diagnosis ICI 163.341 Cerebral infarction due to thrombosis of cerebellar artery Diagnosis ICI 163.342 Cerebral infarction due to thrombosis of cerebellar artery Diagnosis ICI 163.343 Cerebral infarction due to thrombosis of liateral cerebellar artery Diagnosis ICI 163.344 Cerebral inf	D-10-CM D-10-CM D-10-CM
I63.30 Cerebral infarction due to thrombosis of unspecified cerebral artery Diagnosis ICI	D-10-CM D-10-CM
I63.30 Cerebral infarction due to thrombosis of unspecified cerebral artery Diagnosis ICI	D-10-CM D-10-CM
IGA.311 Cerebral infarction due to thrombosis of middle cerebral artery Diagnosis ICI IGA.312 Cerebral infarction due to thrombosis of right middle cerebral artery Diagnosis ICI IGA.313 Cerebral infarction due to thrombosis of left middle cerebral artery Diagnosis ICI IGA.314 Cerebral infarction due to thrombosis of bilateral middle cerebral arteries Diagnosis ICI IGA.315 Cerebral infarction due to thrombosis of unspecified middle cerebral artery Diagnosis ICI IGA.316 Cerebral infarction due to thrombosis of unspecified artery Diagnosis ICI IGA.321 Cerebral infarction due to thrombosis of right anterior cerebral artery Diagnosis ICI IGA.322 Cerebral infarction due to thrombosis of left anterior cerebral artery Diagnosis ICI IGA.323 Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries Diagnosis ICI IGA.329 Cerebral infarction due to thrombosis of unspecified anterior cerebral artery Diagnosis ICI IGA.331 Cerebral infarction due to thrombosis of posterior cerebral artery Diagnosis ICI IGA.332 Cerebral infarction due to thrombosis of right posterior cerebral artery Diagnosis ICI IGA.333 Cerebral infarction due to thrombosis of left posterior cerebral artery Diagnosis ICI IGA.334 Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries Diagnosis ICI IGA.341 Cerebral infarction due to thrombosis of unspecified posterior cerebral artery Diagnosis ICI IGA.342 Cerebral infarction due to thrombosis of right cerebellar artery Diagnosis ICI IGA.343 Cerebral infarction due to thrombosis of left cerebellar artery Diagnosis ICI IGA.344 Cerebral infarction due to thrombosis of left cerebellar artery Diagnosis ICI IGA.345 Cerebral infarction due to thrombosis of bilateral cerebellar artery Diagnosis ICI IGA.346 Cerebral infarction due to thrombosis of other cerebral artery Diagnosis ICI IGA.347 Cerebral infarction due t	D-10-CM
163.311 Cerebral infarction due to thrombosis of right middle cerebral artery Diagnosis ICI	
IGA.312 Cerebral infarction due to thrombosis of left middle cerebral artery Diagnosis ICI	
163.313Cerebral infarction due to thrombosis of bilateral middle cerebral arteriesDiagnosisICI163.319Cerebral infarction due to thrombosis of unspecified middle cerebral arteryDiagnosisICI163.32Cerebral infarction due to thrombosis of anterior cerebral arteryDiagnosisICI163.321Cerebral infarction due to thrombosis of right anterior cerebral arteryDiagnosisICI163.322Cerebral infarction due to thrombosis of left anterior cerebral arteryDiagnosisICI163.323Cerebral infarction due to thrombosis of bilateral anterior cerebral arteryDiagnosisICI163.329Cerebral infarction due to thrombosis of unspecified anterior cerebral arteryDiagnosisICI163.331Cerebral infarction due to thrombosis of posterior cerebral arteryDiagnosisICI163.332Cerebral infarction due to thrombosis of left posterior cerebral arteryDiagnosisICI163.333Cerebral infarction due to thrombosis of left posterior cerebral arteriesDiagnosisICI163.333Cerebral infarction due to thrombosis of unspecified posterior cerebral arteriesDiagnosisICI163.341Cerebral infarction due to thrombosis of cerebellar arteryDiagnosisICI163.342Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.343Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.349Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.349Cer	D-10-CM
163.319Cerebral infarction due to thrombosis of unspecified middle cerebral arteryDiagnosisICI163.32Cerebral infarction due to thrombosis of anterior cerebral arteryDiagnosisICI163.321Cerebral infarction due to thrombosis of right anterior cerebral arteryDiagnosisICI163.322Cerebral infarction due to thrombosis of left anterior cerebral arteryDiagnosisICI163.323Cerebral infarction due to thrombosis of bilateral anterior cerebral arteriesDiagnosisICI163.329Cerebral infarction due to thrombosis of unspecified anterior cerebral arteryDiagnosisICI163.331Cerebral infarction due to thrombosis of posterior cerebral arteryDiagnosisICI163.332Cerebral infarction due to thrombosis of left posterior cerebral arteryDiagnosisICI163.333Cerebral infarction due to thrombosis of bilateral posterior cerebral arteriesDiagnosisICI163.339Cerebral infarction due to thrombosis of unspecified posterior cerebral arteryDiagnosisICI163.341Cerebral infarction due to thrombosis of right cerebellar arteryDiagnosisICI163.342Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.343Cerebral infarction due to thrombosis of unspecified cerebellar arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4 <td< td=""><td>D-10-CM</td></td<>	D-10-CM
163.32Cerebral infarction due to thrombosis of anterior cerebral arteryDiagnosisICI163.321Cerebral infarction due to thrombosis of right anterior cerebral arteryDiagnosisICI163.322Cerebral infarction due to thrombosis of left anterior cerebral arteryDiagnosisICI163.323Cerebral infarction due to thrombosis of bilateral anterior cerebral arteriesDiagnosisICI163.329Cerebral infarction due to thrombosis of unspecified anterior cerebral arteryDiagnosisICI163.33Cerebral infarction due to thrombosis of posterior cerebral arteryDiagnosisICI163.331Cerebral infarction due to thrombosis of right posterior cerebral arteryDiagnosisICI163.332Cerebral infarction due to thrombosis of left posterior cerebral arteryDiagnosisICI163.333Cerebral infarction due to thrombosis of bilateral posterior cerebral arteriesDiagnosisICI163.341Cerebral infarction due to thrombosis of cerebellar arteryDiagnosisICI163.342Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.343Cerebral infarction due to thrombosis of bilateral cerebellar arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4Cerebral infarction due to t	D-10-CM
163.321Cerebral infarction due to thrombosis of right anterior cerebral arteryDiagnosisICI163.322Cerebral infarction due to thrombosis of left anterior cerebral arteryDiagnosisICI163.323Cerebral infarction due to thrombosis of bilateral anterior cerebral arteryDiagnosisICI163.329Cerebral infarction due to thrombosis of unspecified anterior cerebral arteryDiagnosisICI163.33Cerebral infarction due to thrombosis of posterior cerebral arteryDiagnosisICI163.331Cerebral infarction due to thrombosis of right posterior cerebral arteryDiagnosisICI163.332Cerebral infarction due to thrombosis of left posterior cerebral arteriesDiagnosisICI163.333Cerebral infarction due to thrombosis of bilateral posterior cerebral arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of right cerebellar arteryDiagnosisICI163.340Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.341Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.342Cerebral infarction due to thrombosis of unspecified cerebellar arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4Cerebral infarction due to embolism of cerebral arteriesDiagnosisICI	D-10-CM
163.322Cerebral infarction due to thrombosis of left anterior cerebral arteryDiagnosisICI163.323Cerebral infarction due to thrombosis of bilateral anterior cerebral arteriesDiagnosisICI163.329Cerebral infarction due to thrombosis of unspecified anterior cerebral arteryDiagnosisICI163.33Cerebral infarction due to thrombosis of posterior cerebral arteryDiagnosisICI163.331Cerebral infarction due to thrombosis of right posterior cerebral arteryDiagnosisICI163.332Cerebral infarction due to thrombosis of left posterior cerebral arteriesDiagnosisICI163.333Cerebral infarction due to thrombosis of bilateral posterior cerebral arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of cerebellar arteryDiagnosisICI163.341Cerebral infarction due to thrombosis of right cerebellar arteryDiagnosisICI163.342Cerebral infarction due to thrombosis of bilateral cerebellar arteriesDiagnosisICI163.343Cerebral infarction due to thrombosis of bilateral cerebellar arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4Cerebral infarction due to embolism of cerebral arteriesDiagnosisICI	D-10-CM
163.323Cerebral infarction due to thrombosis of bilateral anterior cerebral arteriesDiagnosisICI163.329Cerebral infarction due to thrombosis of unspecified anterior cerebral arteryDiagnosisICI163.33Cerebral infarction due to thrombosis of posterior cerebral arteryDiagnosisICI163.331Cerebral infarction due to thrombosis of right posterior cerebral arteryDiagnosisICI163.332Cerebral infarction due to thrombosis of left posterior cerebral arteryDiagnosisICI163.333Cerebral infarction due to thrombosis of bilateral posterior cerebral arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of cerebellar arteryDiagnosisICI163.340Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.341Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.342Cerebral infarction due to thrombosis of bilateral cerebellar arteriesDiagnosisICI163.343Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.349Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4Cerebral infarction due to embolism of cerebral arteriesDiagnosisICI	D-10-CM
163.329Cerebral infarction due to thrombosis of unspecified anterior cerebral arteryDiagnosisICI163.33Cerebral infarction due to thrombosis of posterior cerebral arteryDiagnosisICI163.331Cerebral infarction due to thrombosis of right posterior cerebral arteryDiagnosisICI163.332Cerebral infarction due to thrombosis of left posterior cerebral arteryDiagnosisICI163.333Cerebral infarction due to thrombosis of bilateral posterior cerebral arteriesDiagnosisICI163.340Cerebral infarction due to thrombosis of cerebellar arteryDiagnosisICI163.341Cerebral infarction due to thrombosis of right cerebellar arteryDiagnosisICI163.342Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.343Cerebral infarction due to thrombosis of bilateral cerebellar arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4Cerebral infarction due to embolism of cerebral arteriesDiagnosisICI	D-10-CM
163.33Cerebral infarction due to thrombosis of posterior cerebral arteryDiagnosisICI163.331Cerebral infarction due to thrombosis of right posterior cerebral arteryDiagnosisICI163.332Cerebral infarction due to thrombosis of left posterior cerebral arteryDiagnosisICI163.333Cerebral infarction due to thrombosis of bilateral posterior cerebral arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of cerebellar arteryDiagnosisICI163.341Cerebral infarction due to thrombosis of right cerebellar arteryDiagnosisICI163.342Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.343Cerebral infarction due to thrombosis of bilateral cerebellar arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4Cerebral infarction due to embolism of cerebral arteriesDiagnosisICI	D-10-CM
163.331Cerebral infarction due to thrombosis of right posterior cerebral arteryDiagnosisICI163.332Cerebral infarction due to thrombosis of left posterior cerebral arteryDiagnosisICI163.333Cerebral infarction due to thrombosis of bilateral posterior cerebral arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of cerebellar arteryDiagnosisICI163.341Cerebral infarction due to thrombosis of right cerebellar arteryDiagnosisICI163.342Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.343Cerebral infarction due to thrombosis of bilateral cerebellar arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4Cerebral infarction due to embolism of cerebral arteriesDiagnosisICI	D-10-CM
163.332Cerebral infarction due to thrombosis of left posterior cerebral arteryDiagnosisICI163.333Cerebral infarction due to thrombosis of bilateral posterior cerebral arteriesDiagnosisICI163.339Cerebral infarction due to thrombosis of unspecified posterior cerebral arteryDiagnosisICI163.34Cerebral infarction due to thrombosis of cerebellar arteryDiagnosisICI163.341Cerebral infarction due to thrombosis of right cerebellar arteryDiagnosisICI163.342Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.343Cerebral infarction due to thrombosis of bilateral cerebellar arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4Cerebral infarction due to embolism of cerebral arteriesDiagnosisICI	0-10-CM
163.333Cerebral infarction due to thrombosis of bilateral posterior cerebral arteriesDiagnosisICI163.339Cerebral infarction due to thrombosis of unspecified posterior cerebral arteryDiagnosisICI163.34Cerebral infarction due to thrombosis of cerebellar arteryDiagnosisICI163.341Cerebral infarction due to thrombosis of right cerebellar arteryDiagnosisICI163.342Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.343Cerebral infarction due to thrombosis of bilateral cerebellar arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4Cerebral infarction due to embolism of cerebral arteriesDiagnosisICI	0-10-CM
163.339Cerebral infarction due to thrombosis of unspecified posterior cerebral arteryDiagnosisICI163.34Cerebral infarction due to thrombosis of cerebellar arteryDiagnosisICI163.341Cerebral infarction due to thrombosis of right cerebellar arteryDiagnosisICI163.342Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.343Cerebral infarction due to thrombosis of bilateral cerebellar arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4Cerebral infarction due to embolism of cerebral arteriesDiagnosisICI	0-10-CM
163.34Cerebral infarction due to thrombosis of cerebellar arteryDiagnosisICI163.341Cerebral infarction due to thrombosis of right cerebellar arteryDiagnosisICI163.342Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.343Cerebral infarction due to thrombosis of bilateral cerebellar arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4Cerebral infarction due to embolism of cerebral arteriesDiagnosisICI	D-10-CIVI
163.341Cerebral infarction due to thrombosis of right cerebellar arteryDiagnosisICI163.342Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.343Cerebral infarction due to thrombosis of bilateral cerebellar arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4Cerebral infarction due to embolism of cerebral arteriesDiagnosisICI	D-10-CIVI D-10-CM
163.342Cerebral infarction due to thrombosis of left cerebellar arteryDiagnosisICI163.343Cerebral infarction due to thrombosis of bilateral cerebellar arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4Cerebral infarction due to embolism of cerebral arteriesDiagnosisICI	D-10-CIVI D-10-CM
163.343Cerebral infarction due to thrombosis of bilateral cerebellar arteriesDiagnosisICI163.349Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4Cerebral infarction due to embolism of cerebral arteriesDiagnosisICI	D-10-CIVI D-10-CM
163.349Cerebral infarction due to thrombosis of unspecified cerebellar arteryDiagnosisICI163.39Cerebral infarction due to thrombosis of other cerebral arteryDiagnosisICI163.4Cerebral infarction due to embolism of cerebral arteriesDiagnosisICI	
163.39 Cerebral infarction due to thrombosis of other cerebral artery Diagnosis ICI 163.4 Cerebral infarction due to embolism of cerebral arteries Diagnosis ICI	D-10-CM D-10-CM
163.4 Cerebral infarction due to embolism of cerebral arteries Diagnosis ICI	
-	D-10-CM
	D-10-CM
	D-10-CM
•	D-10-CM
	D-10-CM
	D-10-CM
<u>u</u>	D-10-CM
	D-10-CM
-	D-10-CM
	D-10-CM
	D-10-CM
	D-10-CM
·	D-10-CM
· · · · · · · · · · · · · · · · · · ·	D-10-CM
	D-10-CM
· · · · · · · · · · · · · · · · · · ·	D-10-CM
163.433 Cerebral infarction due to embolism of bilateral posterior cerebral arteries Diagnosis ICI	D-10-CM
- · · · · · · · · · · · · · · · · · · ·	
· · · · · · · · · · · · · · · · · · ·	D-10-CM
163.441 Cerebral infarction due to embolism of right cerebellar artery Diagnosis ICI	
163.442 Cerebral infarction due to embolism of left cerebellar artery Diagnosis ICI	D-10-CM

cder_mpl1p_wp077 Page 740 of 1023



riocedule	codes osed to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
163.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
163.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
163.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
163.5	Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries	Diagnosis	ICD-10-CM
163.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
163.51	Cerebral infarction due to unspecified occlusion or stenosis of middle cerebral artery	Diagnosis	ICD-10-CM
163.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
163.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
103.312	cerebral infaretion due to dispective occidation of steriosis of fert infade cerebral aftery	Diagnosis	ICD TO CIVI
163.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral	Diagnosis	ICD-10-CM
	arteries		
163.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral	Diagnosis	ICD-10-CM
	artery		
163.52	Cerebral infarction due to unspecified occlusion or stenosis of anterior cerebral artery	Diagnosis	ICD-10-CM
163.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral	Diagnosis	ICD-10-CM
	artery		
163.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
163.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral	Diagnosis	ICD-10-CM
	arteries		
163.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior	Diagnosis	ICD-10-CM
	cerebral artery		
163.53	Cerebral infarction due to unspecified occlusion or stenosis of posterior cerebral artery	Diagnosis	ICD-10-CM
163.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral	Diagnosis	ICD-10-CM
	artery		
163.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral	Diagnosis	ICD-10-CM
	artery		
163.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral	Diagnosis	ICD-10-CM
	arteries		
163.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior	Diagnosis	ICD-10-CM
	cerebral artery		
163.54	Cerebral infarction due to unspecified occlusion or stenosis of cerebellar artery	Diagnosis	ICD-10-CM
163.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
163.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
163.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
163.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar	Diagnosis	ICD-10-CM
	artery		
163.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
163.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
163.8	Other cerebral infarction	Diagnosis	ICD-10-CM
163.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
163.89	Other cerebral infarction	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 741 of 1023



	e Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
163.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
165	Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction	Diagnosis	ICD-10-CM
165.0	Occlusion and stenosis of vertebral artery	Diagnosis	ICD-10-CM
165.01	Occlusion and stenosis of right vertebral artery	Diagnosis	ICD-10-CM
165.02	Occlusion and stenosis of left vertebral artery	Diagnosis	ICD-10-CM
165.03	Occlusion and stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
165.09	Occlusion and stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
165.1	Occlusion and stenosis of basilar artery	Diagnosis	ICD-10-CM
165.2	Occlusion and stenosis of carotid artery	Diagnosis	ICD-10-CM
165.21	Occlusion and stenosis of right carotid artery	Diagnosis	ICD-10-CM
165.22	Occlusion and stenosis of left carotid artery	Diagnosis	ICD-10-CM
165.23	Occlusion and stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
165.29	Occlusion and stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
165.8	Occlusion and stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
165.9	Occlusion and stenosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
166	Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction	Diagnosis	ICD-10-CM
166.0	Occlusion and stenosis of middle cerebral artery	Diagnosis	ICD-10-CM
166.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
166.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
166.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
166.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
166.1	Occlusion and stenosis of anterior cerebral artery	Diagnosis	ICD-10-CM
166.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
166.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
166.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
166.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
166.2	Occlusion and stenosis of posterior cerebral artery	Diagnosis	ICD-10-CM
166.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
166.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
166.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
166.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
166.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
166.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
166.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
167	Other cerebrovascular diseases	Diagnosis	ICD-10-CM
167.0	Dissection of cerebral arteries, nonruptured	Diagnosis	ICD-10-CM
167.1	Cerebral aneurysm, nonruptured	Diagnosis	ICD-10-CM
167.2	Cerebral atherosclerosis	Diagnosis	ICD-10-CM
167.3	Progressive vascular leukoencephalopathy	Diagnosis	ICD-10-CM
167.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
167.5	Moyamoya disease	Diagnosis	ICD-10-CM
167.7	Cerebral arteritis, not elsewhere classified	Diagnosis	ICD-10-CM
167.8	Other specified cerebrovascular diseases	Diagnosis	ICD-10-CM
167.81	Acute cerebrovascular insufficiency	Diagnosis	ICD-10-CM
167.82	Cerebral ischemia	Diagnosis	ICD-10-CM
167.83	Posterior reversible encephalopathy syndrome	Diagnosis	ICD-10-CM
167.84	Cerebral vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
167.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
167.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 742 of 1023



		Code	
Code	Description	Category	Code Type
167.850	Cerebral autosomal dominant arteriopathy with subcortical infarcts and	Diagnosis	ICD-10-CM
	leukoencephalopathy		
167.858	Other hereditary cerebrovascular disease	Diagnosis	ICD-10-CM
167.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
167.9	Cerebrovascular disease, unspecified	Diagnosis	ICD-10-CM
168	Cerebrovascular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
168.0	Cerebral amyloid angiopathy	Diagnosis	ICD-10-CM
168.2	Cerebral arteritis in other diseases classified elsewhere	Diagnosis	ICD-10-CM
168.8	Other cerebrovascular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
169	Sequelae of cerebrovascular disease	Diagnosis	ICD-10-CM
169.0	Sequelae of nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.00	Unspecified sequelae of nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.01	Cognitive deficits following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.010	Attention and concentration deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.011	Memory deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.012	Visuospatial deficit and spatial neglect following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
		Ü	
169.013	Psychomotor deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.014	Frontal lobe and executive function deficit following nontraumatic subarachnoid	Diagnosis	ICD-10-CM
103.014	_	Diagnosis	ICD-10-CIVI
	hemorrhage		
169.015	Cognitive social or emotional deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.018	Other symptoms and signs involving cognitive functions following nontraumatic	Diagnosis	ICD-10-CM
	subarachnoid hemorrhage		
169.019	Unspecified symptoms and signs involving cognitive functions following nontraumatic	Diagnosis	ICD-10-CM
	subarachnoid hemorrhage		
169.02	Speech and language deficits following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.020	Aphasia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.021	Dysphasia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.022	Dysarthria following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.023	Fluency disorder following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.028	Other speech and language deficits following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.03	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.031	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting	Diagnosis	ICD-10-CM
103.001	right dominant side	Diagnosis	100 10 0111
100 022		Diamasia	ICD 10 CM
169.032	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting	Diagnosis	ICD-10-CM
	left dominant side		
169.033	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting	Diagnosis	ICD-10-CM
	right non-dominant side		
169.034	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting	Diagnosis	ICD-10-CM
	left non-dominant side	-	
160 030	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting	Diagnosis	ICD-10-CM
169.039		Diagnosis	ICD-10-CM
	unspecified side		
169.04	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.041	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting	Diagnosis	ICD-10-CM
	right dominant side		

cder_mpl1p_wp077 Page 743 of 1023



		Code	
Code	Description	Category	Code Type
169.042	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.043	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
169.044	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.049	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
169.05	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.051	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
169.052	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.053	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
169.054	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.059	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
169.06	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.061	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
169.062	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.063	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
169.064	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.065 169.069	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage, bilateral Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
	unspecified side		
169.09	Other sequelae of nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.090	Apraxia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.091	Dysphagia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.092	Facial weakness following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.093	Ataxia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.098	Other sequelae following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
169.1	Sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.10	Unspecified sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.11	Cognitive deficits following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.110	Attention and concentration deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.111	Memory deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.112	Visuospatial deficit and spatial neglect following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.113	Psychomotor deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 744 of 1023



		Code	
Code	Description	Category	Code Type
169.114	Frontal lobe and executive function deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.115 169.118	Cognitive social or emotional deficit following nontraumatic intracerebral hemorrhage Other symptoms and signs involving cognitive functions following nontraumatic intracerebral hemorrhage	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.119	Unspecified symptoms and signs involving cognitive functions following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.12 169.120 169.121 169.122	Speech and language deficits following nontraumatic intracerebral hemorrhage Aphasia following nontraumatic intracerebral hemorrhage Dysphasia following nontraumatic intracerebral hemorrhage Dysarthria following nontraumatic intracerebral hemorrhage	Diagnosis Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
169.123 169.128 169.13 169.131	Fluency disorder following nontraumatic intracerebral hemorrhage Other speech and language deficits following nontraumatic intracerebral hemorrhage Monoplegia of upper limb following nontraumatic intracerebral hemorrhage Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting	Diagnosis Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
169.132	right dominant side Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left dominant side	_	ICD-10-CM
169.133	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
169.134	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.139	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
169.14 169.141	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.142	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.143	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
169.144	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.149	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
169.15 169.151	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.152	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.153	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 745 of 1023



		Code	
Code	Description	Category	Code Type
169.154	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting	Diagnosis	ICD-10-CM
	left non-dominant side		
169.159	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting	Diagnosis	ICD-10-CM
	unspecified side		
169.16	Other paralytic syndrome following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.161	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting	Diagnosis	ICD-10-CM
	right dominant side		
169.162	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting left	Diagnosis	ICD-10-CM
	dominant side		
169.163	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting	Diagnosis	ICD-10-CM
	right non-dominant side		
169.164	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting left	Diagnosis	ICD-10-CM
	non-dominant side	J	
169.165	Other paralytic syndrome following nontraumatic intracerebral hemorrhage, bilateral	Diagnosis	ICD-10-CM
169.169	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting	Diagnosis	ICD-10-CM
	unspecified side		
169.19	Other sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.190	Apraxia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.191	Dysphagia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.192	Facial weakness following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.193	Ataxia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.198	Other sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
169.2	Sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.20	Unspecified sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.21	Cognitive deficits following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.210	Attention and concentration deficit following other nontraumatic intracranial	Diagnosis	ICD-10-CM
	hemorrhage		
169.211	Memory deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.212	Visuospatial deficit and spatial neglect following other nontraumatic intracranial	Diagnosis	ICD-10-CM
	hemorrhage	Ü	
169.213	Psychomotor deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.214	Frontal lobe and executive function deficit following other nontraumatic intracranial	Diagnosis	ICD-10-CM
	hemorrhage	J	
169.215	Cognitive social or emotional deficit following other nontraumatic intracranial	Diagnosis	ICD-10-CM
	hemorrhage	- 10.011212	
169.218	Other symptoms and signs involving cognitive functions following other nontraumatic	Diagnosis	ICD-10-CM
103.210	intracranial hemorrhage	Diagnosis	102 20 0.01
160 210	-	Diagnosis	ICD 10 CM
169.219	Unspecified symptoms and signs involving cognitive functions following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
100.33	•	Dia = - : -	ICD 10 Ch 1
169.22	Speech and language deficits following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.220	Aphasia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.221	Dysphasia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.222	Dysarthria following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.223	Fluency disorder following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 746 of 1023



Troccaure	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
169.228	Other speech and language deficits following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.23	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.231	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
169.232	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.233	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
169.234	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.239	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
169.24	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.241	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
169.242	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.243	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
169.244	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.249	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
169.25	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.251	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
169.252	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.253	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
169.254	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
169.259	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
169.26 169.261	Other paralytic syndrome following other nontraumatic intracranial hemorrhage Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.262	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
169.263	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 747 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
169.264	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting	Diagnosis	ICD-10-CM
	left non-dominant side		
169.265	Other paralytic syndrome following other nontraumatic intracranial hemorrhage, bilateral	Diagnosis	ICD-10-CM
	0	. 0	
169.269	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting	Diagnosis	ICD-10-CM
105.205	unspecified side	Diagnosis	ICD 10 CIVI
160.20	·	Diagnosis	ICD 10 CM
169.29 169.290	Other sequelae of other nontraumatic intracranial hemorrhage Apraxia following other nontraumatic intracranial hemorrhage	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.291	Dysphagia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.291	Facial weakness following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.293	Ataxia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.298	Other sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
169.3	Sequelae of cerebral infarction	Diagnosis	ICD-10-CM
169.30	Unspecified sequelae of cerebral infarction	Diagnosis	ICD-10-CM
169.31	Cognitive deficits following cerebral infarction	Diagnosis	ICD-10-CM
169.310	Attention and concentration deficit following cerebral infarction	Diagnosis	ICD-10-CM
169.311	Memory deficit following cerebral infarction	Diagnosis	ICD-10-CM
169.312	Visuospatial deficit and spatial neglect following cerebral infarction	Diagnosis	ICD-10-CM
169.313	Psychomotor deficit following cerebral infarction	Diagnosis	ICD-10-CM
169.314	Frontal lobe and executive function deficit following cerebral infarction	Diagnosis	ICD-10-CM
169.315	Cognitive social or emotional deficit following cerebral infarction	Diagnosis	ICD-10-CM
169.318	Other symptoms and signs involving cognitive functions following cerebral infarction	Diagnosis	ICD-10-CM
169.319	Unspecified symptoms and signs involving cognitive functions following cerebral	Diagnosis	ICD-10-CM
.00.010	infarction	2108.100.0	.02 20 0
160.22		Diagnosis	ICD 10 CM
169.32 169.320	Speech and language deficits following cerebral infarction	Diagnosis	ICD-10-CM
169.320	Aphasia following cerebral infarction Dysphasia following cerebral infarction	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
169.322	Dysarthria following cerebral infarction	Diagnosis	ICD-10-CM
169.323	Fluency disorder following cerebral infarction	Diagnosis	ICD-10-CM
169.328	Other speech and language deficits following cerebral infarction	Diagnosis	ICD-10-CM
169.33	Monoplegia of upper limb following cerebral infarction	Diagnosis	ICD-10-CM
169.331	Monoplegia of upper limb following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM
169.332	Monoplegia of upper limb following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
169.333	Monoplegia of upper limb following cerebral infarction affecting right non-dominant side	Diagnosis	ICD-10-CM
103.333	Worldpiegla of apper limb following cerebral infared on affecting right from administration	Біабіїозіз	100 10 0111
169.334	Monoplegia of upper limb following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
105.554	Monopiegia of upper little following cerebral infarction affecting left flori-dominant side	Diagnosis	ICD-10-CIVI
100 220	Managera of warm limb fellowing combant information officialing warms if ad aid	Diamasia	ICD 10 CM
169.339	Monoplegia of upper limb following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CM
169.34	Monoplegia of lower limb following cerebral infarction	Diagnosis	ICD-10-CM
169.341	Monoplegia of lower limb following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM
169.342	Monoplegia of lower limb following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
169.343	Monoplegia of lower limb following cerebral infarction affecting right non-dominant side	Diagnosis	ICD-10-CM
100 244		5	100 40 014
169.344	Monoplegia of lower limb following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
169.349	Monoplegia of lower limb following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CM
169.35	Hemiplegia and hemiparesis following cerebral infarction	Diagnosis	ICD-10-CM
169.351	Hemiplegia and hemiparesis following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 748 of 1023



riocedure	Codes osed to Define baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
169.352	Hemiplegia and hemiparesis following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
169.353	Hemiplegia and hemiparesis following cerebral infarction affecting right non-dominant	Diagnosis	ICD-10-CM
	side		
169.354	Hemiplegia and hemiparesis following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
		J	
169.359	Hemiplegia and hemiparesis following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CM
169.36	Other paralytic syndrome following cerebral infarction	Diagnosis	ICD-10-CM
169.361	Other paralytic syndrome following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM
169.362	Other paralytic syndrome following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
169.363	Other paralytic syndrome following cerebral infarction affecting right non-dominant side	Diagnosis	ICD-10-CM
169.364	Other paralytic syndrome following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
169.365	Other paralytic syndrome following cerebral infarction, bilateral	Diagnosis	ICD-10-CM
169.369	Other paralytic syndrome following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CM
169.39	Other sequelae of cerebral infarction	Diagnosis	ICD-10-CM
169.390	Apraxia following cerebral infarction	Diagnosis	ICD-10-CM
169.391	Dysphagia following cerebral infarction	Diagnosis	ICD-10-CM
169.392	Facial weakness following cerebral infarction	Diagnosis	ICD-10-CM
169.393	Ataxia following cerebral infarction	Diagnosis	ICD-10-CM
169.398	Other sequelae of cerebral infarction	Diagnosis	ICD-10-CM
169.8	Sequelae of other cerebrovascular diseases	Diagnosis	ICD-10-CM
169.80	Unspecified sequelae of other cerebrovascular disease	Diagnosis	ICD-10-CM
169.81	Cognitive deficits following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.810	Attention and concentration deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.811	Memory deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.812	Visuospatial deficit and spatial neglect following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.813	Psychomotor deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.814	Frontal lobe and executive function deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.815	Cognitive social or emotional deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.818	Other symptoms and signs involving cognitive functions following other cerebrovascular	Diagnosis	ICD-10-CM
105.010	disease	Diagnosis	ICD-10-CIVI
169.819	Unspecified symptoms and signs involving cognitive functions following other	Diagnosis	ICD-10-CM
	cerebrovascular disease		
169.82	Speech and language deficits following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.820	Aphasia following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.821	Dysphasia following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.822	Dysarthria following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.823	Fluency disorder following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.828	Other speech and language deficits following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.83	Monoplegia of upper limb following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.831	Monoplegia of upper limb following other cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
	dominant side	Ü	
169.832	Monoplegia of upper limb following other cerebrovascular disease affecting left dominant	Diagnosis	ICD-10-CM
	side		
169.833	Monoplegia of upper limb following other cerebrovascular disease affecting right non-	Diagnosis	ICD-10-CM
	dominant side		

cder_mpl1p_wp077 Page 749 of 1023



		Code	_
Code	Description	Category	Code Type
169.834	Monoplegia of upper limb following other cerebrovascular disease affecting left non- dominant side	Diagnosis	ICD-10-CM
169.839	Monoplegia of upper limb following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
169.84	Monoplegia of lower limb following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.841	Monoplegia of lower limb following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
169.842	Monoplegia of lower limb following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
169.843	Monoplegia of lower limb following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
169.844	Monoplegia of lower limb following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
169.849	Monoplegia of lower limb following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
169.85	Hemiplegia and hemiparesis following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.851	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
169.852	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
169.853	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
169.854	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
169.859	Hemiplegia and hemiparesis following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
169.86	Other paralytic syndrome following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.861	Other paralytic syndrome following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
169.862	Other paralytic syndrome following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
169.863	Other paralytic syndrome following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
169.864	Other paralytic syndrome following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
169.865	Other paralytic syndrome following other cerebrovascular disease, bilateral	Diagnosis	ICD-10-CM
169.869	Other paralytic syndrome following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
169.89	Other sequelae of other cerebrovascular disease	Diagnosis	ICD-10-CM
169.890	Apraxia following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.891	Dysphagia following other cerebrovascular disease	Diagnosis	ICD-10-CM
169.892 169.893	Facial weakness following other cerebrovascular disease Ataxia following other cerebrovascular disease	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
105.053	Atania following other terebrovastular disease	Diagilosis	ICD-TO-CIVI

cder_mpl1p_wp077 Page 750 of 1023



	codes osca to beline baseline characteristics in this nequest	Code	
Code	Description	Category	Code Type
169.898	Other sequelae of other cerebrovascular disease	Diagnosis	ICD-10-CM
169.9	Sequelae of unspecified cerebrovascular diseases	Diagnosis	ICD-10-CM
169.90	Unspecified sequelae of unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.91	Cognitive deficits following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.910	Attention and concentration deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.911	Memory deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.912	Visuospatial deficit and spatial neglect following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.913	Psychomotor deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.914	Frontal lobe and executive function deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.915	Cognitive social or emotional deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.918	Other symptoms and signs involving cognitive functions following unspecified	Diagnosis	ICD-10-CM
169.919	cerebrovascular disease Unspecified symptoms and signs involving cognitive functions following unspecified	Diagnosis	ICD-10-CM
169.92	cerebrovascular disease Speech and language deficits following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.920	Aphasia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.921	Dysphasia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.922	Dysarthria following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.923	Fluency disorder following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.928	Other speech and language deficits following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.93	Monoplegia of upper limb following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.931	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
169.932	dominant side Monoplegia of upper limb following unspecified cerebrovascular disease affecting left	Diagnosis	ICD-10-CM
169.933	dominant side Monoplegia of upper limb following unspecified cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
169.934	non-dominant side Monoplegia of upper limb following unspecified cerebrovascular disease affecting left non	- Diagnosis	ICD-10-CM
169.939	dominant side Monoplegia of upper limb following unspecified cerebrovascular disease affecting	Diagnosis	ICD-10-CM
169.94	unspecified side Monoplegia of lower limb following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.941	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
103.541	dominant side	Diagnosis	ICD 10 CIVI
169.942	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left	Diagnosis	ICD-10-CM
169.943	dominant side Monoplegia of lower limb following unspecified cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
169.944	non-dominant side Monoplegia of lower limb following unspecified cerebrovascular disease affecting left non-	- Diagnosis	ICD-10-CM
169.949	dominant side Monoplegia of lower limb following unspecified cerebrovascular disease affecting	Diagnosis	ICD-10-CM
160.05	unspecified side	Diagnosis	ICD 10 CN4
169.95	Hemiplegia and hemiparesis following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.951	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
169.952	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
	uominant side		

cder_mpl1p_wp077 Page 751 of 1023



Toccadie	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
169.953	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
	non-dominant side		
169.954	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left	Diagnosis	ICD-10-CM
	non-dominant side		
169.959	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting	Diagnosis	ICD-10-CM
100.00	unspecified side	Dii-	ICD 40 CM
169.96 169.961	Other paralytic syndrome following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
109.901	Other paralytic syndrome following unspecified cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
169.962	dominant side Other paralytic syndrome following unspecified cerebrovascular disease affecting left	Diagnosis	ICD-10-CM
103.302	dominant side	Diagnosis	ICD-10-CIVI
169.963	Other paralytic syndrome following unspecified cerebrovascular disease affecting right	Diagnosis	ICD-10-CM
.00.000	non-dominant side	2.0800.0	.02 20 0
169.964	Other paralytic syndrome following unspecified cerebrovascular disease affecting left non-	- Diagnosis	ICD-10-CM
	dominant side	_	
169.965	Other paralytic syndrome following unspecified cerebrovascular disease, bilateral	Diagnosis	ICD-10-CM
169.969	Other paralytic syndrome following unspecified cerebrovascular disease affecting	Diagnosis	ICD-10-CM
	unspecified side		
169.99	Other sequelae of unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.990	Apraxia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.991	Dysphagia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.992	Facial weakness following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.993	Ataxia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
169.998 P91.82	Other sequelae following unspecified cerebrovascular disease Neonatal cerebral infarction	Diagnosis	ICD-10-CM
P91.82 P91.821	Neonatal cerebral infarction Neonatal cerebral infarction, right side of brain	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
P91.821	Neonatal cerebral infarction, left side of brain	Diagnosis	ICD-10-CM
P91.823	Neonatal cerebral infarction, bilateral	Diagnosis	ICD-10-CM
P91.829	Neonatal cerebral infarction, unspecified side	Diagnosis	ICD-10-CM
Q28.0	Arteriovenous malformation of precerebral vessels	Diagnosis	ICD-10-CM
Q28.2	Arteriovenous malformation of cerebral vessels	Diagnosis	ICD-10-CM
Z86.73	Personal history of transient ischemic attack (TIA), and cerebral infarction without	Diagnosis	ICD-10-CM
	residual deficits	_	
61630	Balloon angioplasty, intracranial (eg, atherosclerotic stenosis), percutaneous	Procedure	CPT-4
61635	Transcatheter placement of intravascular stent(s), intracranial (eg, atherosclerotic	Procedure	CPT-4
	stenosis). including balloon angioplasty. if performed		
E08.22	Chronic Kidney Disease Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.22 E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
112.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage	Diagnosis	ICD-10-CM
	renal disease	J	
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease,	Diagnosis	ICD-10-CM
	or unspecified chronic kidnev disease		
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through	Diagnosis	ICD-10-CM
	stage 4 chronic kidney disease, or unspecified chronic kidney disease		
I13.1	Hypertensive heart and chronic kidney disease without heart failure	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 752 of 1023



	e Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through	Diagnosis	ICD-10-CM
l13.11	stage 4 chronic kidnev disease, or unspecified chronic kidnev disease Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic	Diagnosis	ICD-10-CM
I13.2	kidnev disease, or end stage renal disease Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic	Diagnosis	ICD-10-CM
	kidney disease, or end stage renal disease		
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
R34	Anuria and oliguria	Diagnosis	ICD-10-CM
Z49.01	Encounter for fitting and adjustment of extracorporeal dialysis catheter	Diagnosis	ICD-10-CM
Z49.02	Encounter for fitting and adjustment of peritoneal dialysis catheter	Diagnosis	ICD-10-CM
Z49.31	Encounter for adequacy testing for hemodialysis	Diagnosis	ICD-10-CM
Z49.32	Encounter for adequacy testing for peritoneal dialysis	Diagnosis	ICD-10-CM
Z99.2	Dependence on renal dialysis	Diagnosis	ICD-10-CM
36147	Introduction of needle and/or catheter, arteriovenous shunt created for dialysis	Procedure	CPT-4
	(graft/fistula); initial access with complete radiological evaluation of dialysis access,		
	including fluoroscopy, image documentation and report (includes access of shunt,		
	injection[s] of contrast, and all necessary imaging from the arterial anastomosis and		
	adjacent artery through entire venous outflow including the inferior or superior vena		
	cava)		
36148	Introduction of needle and/or catheter, arteriovenous shunt created for dialysis	Procedure	CPT-4
	(graft/fistula); additional access for therapeutic intervention (List separately in addition to		
	code for primary procedure)		
36818	Arteriovenous anastomosis, open; by upper arm cephalic vein transposition	Procedure	CPT-4
36819	Arteriovenous anastomosis, open; by upper arm basilic vein transposition	Procedure	CPT-4
36820	Arteriovenous anastomosis, open; by forearm vein transposition	Procedure	CPT-4
36821	Arteriovenous anastomosis, open; direct, any site (eg, Cimino type) (separate procedure)	Procedure	CPT-4
36825	Creation of arteriovenous fistula by other than direct arteriovenous anastomosis	Procedure	CPT-4
	(separate procedure): autogenous graft		
36830	Creation of arteriovenous fistula by other than direct arteriovenous anastomosis	Procedure	CPT-4
	(separate procedure); nonautogenous graft (eg. biological collagen, thermoplastic graft)		
36831	Thrombectomy, open, arteriovenous fistula without revision, autogenous or	Procedure	CPT-4
	nonautogenous dialysis graft (separate procedure)		
36832	Revision, open, arteriovenous fistula; without thrombectomy, autogenous or	Procedure	CPT-4
	nonautogenous dialysis graft (separate procedure)		
36833	Revision, open, arteriovenous fistula; with thrombectomy, autogenous or nonautogenous	Procedure	CPT-4
	dialysis graft (separate procedure)		
36870	Thrombectomy, percutaneous, arteriovenous fistula, autogenous or nonautogenous graft	Procedure	CPT-4
	(includes mechanical thrombus extraction and intra-graft thrombolysis)		
50360	Renal allotransplantation, implantation of graft; without recipient nephrectomy	Procedure	CPT-4
50365	Renal allotransplantation, implantation of graft; with recipient nephrectomy	Procedure	CPT-4

cder_mpl1p_wp077 Page 753 of 1023



		Code	
Code	Description	Category	Code Type
75791	Angiography, arteriovenous shunt (eg, dialysis patient fistula/graft), complete evaluation of dialysis access, including fluoroscopy, image documentation and report (includes injections of contrast and all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava), radiological supervision and interpretation	Procedure	CPT-4
90935	Hemodialysis procedure with single evaluation by a physician or other qualified health care professional	Procedure	CPT-4
90937	Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription	Procedure	CPT-4
90945	Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies), with single evaluation by a physician or other qualified health care professional	Procedure	CPT-4
90947	Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies) requiring repeated evaluations by a physician or other qualified health care professional, with or without substantial revision of dialysis prescription	Procedure	CPT-4
90951	End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90952	End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90953	End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4
90954	End-stage renal disease (ESRD) related services monthly, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90955	End-stage renal disease (ESRD) related services monthly, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90956	End-stage renal disease (ESRD) related services monthly, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4

cder_mpl1p_wp077 Page 754 of 1023



		Code	
Code	Description	Category	Code Type
90957	End-stage renal disease (ESRD) related services monthly, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90958	End-stage renal disease (ESRD) related services monthly, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90959	End-stage renal disease (ESRD) related services monthly, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4
90960	End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90961	End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90962	End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4
90963	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents	Procedure	CPT-4
90964	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents	Procedure	CPT-4
90965	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents	Procedure	CPT-4
90966	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 20 years of age and older	Procedure	CPT-4
90967	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients younger than 2 years of age	Procedure	CPT-4
90968	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 2-11 years of age	Procedure	CPT-4
90969	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 12-19 years of age	Procedure	CPT-4
90970	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 20 years of age and older	Procedure	CPT-4
	Chronic Obstructive Pulmonary Disease		
J44.0 J44.1	Chronic obstructive pulmonary disease with (acute) lower respiratory infection Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM

cder_mpl1p_wp077 Page 755 of 1023



	codes osculto Denne Busenne enuruetensues in uns ricquest	Code	
Code	Description	Category	Code Type
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
	Congenital Heart Disease		
197.13	Postprocedural heart failure	Diagnosis	ICD-10-CM
197.130	Postprocedural heart failure following cardiac surgery	Diagnosis	ICD-10-CM
197.131	Postprocedural heart failure following other surgery	Diagnosis	ICD-10-CM
P29.3	Persistent fetal circulation	Diagnosis	ICD-10-CM
P29.38	Other persistent fetal circulation	Diagnosis	ICD-10-CM
P29.8	Other cardiovascular disorders originating in the perinatal period	Diagnosis	ICD-10-CM
Q20	Congenital malformations of cardiac chambers and connections	Diagnosis	ICD-10-CM
Q20.0	Common arterial trunk	Diagnosis	ICD-10-CM
Q20.1	Double outlet right ventricle	Diagnosis	ICD-10-CM
Q20.2	Double outlet left ventricle	Diagnosis	ICD-10-CM
Q20.3	Discordant ventriculoarterial connection	Diagnosis	ICD-10-CM
Q20.4	Double inlet ventricle	Diagnosis	ICD-10-CM
Q20.5	Discordant atrioventricular connection	Diagnosis	ICD-10-CM
Q20.6	Isomerism of atrial appendages	Diagnosis	ICD-10-CM
Q20.8	Other congenital malformations of cardiac chambers and connections	Diagnosis	ICD-10-CM
Q20.9	Congenital malformation of cardiac chambers and connections, unspecified	Diagnosis	ICD-10-CM
Q21	Congenital malformations of cardiac septa	Diagnosis	ICD-10-CM
Q21.0	Ventricular septal defect	Diagnosis	ICD-10-CM
Q21.1	Atrial septal defect	Diagnosis	ICD-10-CM
Q21.2	Atrioventricular septal defect	Diagnosis	ICD-10-CM
Q21.3	Tetralogy of Fallot	Diagnosis	ICD-10-CM
Q21.4	Aortopulmonary septal defect	Diagnosis	ICD-10-CM
Q21.8	Other congenital malformations of cardiac septa	Diagnosis	ICD-10-CM
Q21.9	Congenital malformation of cardiac septum, unspecified	Diagnosis	ICD-10-CM
Q22	Congenital malformations of pulmonary and tricuspid valves	Diagnosis	ICD-10-CM
Q22.0	Pulmonary valve atresia	Diagnosis	ICD-10-CM
Q22.1	Congenital pulmonary valve stenosis	Diagnosis	ICD-10-CM
Q22.2	Congenital pulmonary valve insufficiency	Diagnosis	ICD-10-CM
Q22.3	Other congenital malformations of pulmonary valve	Diagnosis	ICD-10-CM
Q22.4	Congenital tricuspid stenosis	Diagnosis	ICD-10-CM
Q22.5	Ebstein's anomaly	Diagnosis	ICD-10-CM
Q22.6	Hypoplastic right heart syndrome	Diagnosis	ICD-10-CM
Q22.8	Other congenital malformations of tricuspid valve	Diagnosis	ICD-10-CM
Q22.9	Congenital malformation of tricuspid valve, unspecified	Diagnosis	ICD-10-CM
Q23	Congenital malformations of aortic and mitral valves	Diagnosis	ICD-10-CM
Q23.0	Congenital stenosis of aortic valve	Diagnosis	ICD-10-CM
Q23.1	Congenital insufficiency of aortic valve	Diagnosis	ICD-10-CM
Q23.2	Congenital mitral stenosis	Diagnosis	ICD-10-CM
Q23.3	Congenital mitral insufficiency	Diagnosis	ICD-10-CM
Q23.4	Hypoplastic left heart syndrome	Diagnosis	ICD-10-CM
Q23.8	Other congenital malformations of aortic and mitral valves	Diagnosis	ICD-10-CM
Q23.9	Congenital malformation of aortic and mitral valves, unspecified	Diagnosis	ICD-10-CM
Q24	Other congenital malformations of heart	Diagnosis	ICD-10-CM
Q24.0	Dextrocardia	Diagnosis	ICD-10-CM
Q24.1	Levocardia	Diagnosis	ICD-10-CM
Q24.2	Cor triatriatum	Diagnosis	ICD-10-CM
Q24.3	Pulmonary infundibular stenosis	Diagnosis	ICD-10-CM
Q24.4	Congenital subaortic stenosis	Diagnosis	ICD-10-CM
≪ - 11		PidPilo3i3	.CD IO CIVI

cder_mpl1p_wp077 Page 756 of 1023



	·	Code	
Code	Description	Category	Code Type
Q24.5	Malformation of coronary vessels	Diagnosis	ICD-10-CM
Q24.6	Congenital heart block	Diagnosis	ICD-10-CM
Q24.8	Other specified congenital malformations of heart	Diagnosis	ICD-10-CM
Q24.9	Congenital malformation of heart, unspecified	Diagnosis	ICD-10-CM
Q25.0	Patent ductus arteriosus	Diagnosis	ICD-10-CM
Q25.1	Coarctation of aorta	Diagnosis	ICD-10-CM
Q25.21	Interruption of aortic arch	Diagnosis	ICD-10-CM
Q25.29	Other atresia of aorta	Diagnosis	ICD-10-CM
Q25.3	Supravalvular aortic stenosis	Diagnosis	ICD-10-CM
Q25.40	Congenital malformation of aorta unspecified	Diagnosis	ICD-10-CM
Q25.41	Absence and aplasia of aorta	Diagnosis	ICD-10-CM
Q25.42	Hypoplasia of aorta	Diagnosis	ICD-10-CM
Q25.43	Congenital aneurysm of aorta	Diagnosis	ICD-10-CM
Q25.44	Congenital dilation of aorta	Diagnosis	ICD-10-CM
Q25.45	Double aortic arch	Diagnosis	ICD-10-CM
Q25.46	Tortuous aortic arch	Diagnosis	ICD-10-CM
Q25.47	Right aortic arch	Diagnosis	ICD-10-CM
Q25.48	Anomalous origin of subclavian artery	Diagnosis	ICD-10-CM
Q25.49	Other congenital malformations of aorta	Diagnosis	ICD-10-CM
Q25.5	Atresia of pulmonary artery	Diagnosis	ICD-10-CM
Q25.6	Stenosis of pulmonary artery	Diagnosis	ICD-10-CM
Q25.71	Coarctation of pulmonary artery	Diagnosis	ICD-10-CM
Q25.72	Congenital pulmonary arteriovenous malformation	Diagnosis	ICD-10-CM
Q25.79	Other congenital malformations of pulmonary artery	Diagnosis	ICD-10-CM
Q25.8	Other congenital malformations of other great arteries	Diagnosis	ICD-10-CM
Q25.9	Congenital malformation of great arteries, unspecified	Diagnosis	ICD-10-CM
Q26.0	Congenital stenosis of vena cava	Diagnosis	ICD-10-CM
Q26.1	Persistent left superior vena cava	Diagnosis	ICD-10-CM
Q26.2	Total anomalous pulmonary venous connection	Diagnosis	ICD-10-CM
Q26.3	Partial anomalous pulmonary venous connection	Diagnosis	ICD-10-CM
Q26.4	Anomalous pulmonary venous connection, unspecified	Diagnosis	ICD-10-CM
Q87.40	Marfan's syndrome, unspecified	Diagnosis	ICD-10-CM
Q87.41	Marfan's syndrome with cardiovascular manifestations	Diagnosis	ICD-10-CM
Q87.410	Marfan's syndrome with aortic dilation	Diagnosis	ICD-10-CM
Q87.418	Marfan's syndrome with other cardiovascular manifestations	Diagnosis	ICD-10-CM
Q87.82	Arterial tortuosity syndrome	Diagnosis	ICD-10-CM
Q90.0	Trisomy 21, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.1	Trisomy 21, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.2	Trisomy 21, translocation	Diagnosis	ICD-10-CM
Q90.9	Down syndrome, unspecified	Diagnosis	ICD-10-CM
Q91.0	Trisomy 18, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.1	Trisomy 18, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.2	Trisomy 18, translocation	Diagnosis	ICD-10-CM
Q91.3	Trisomy 18, unspecified	Diagnosis	ICD-10-CM
Q91.4	Trisomy 13, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.5	Trisomy 13, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.6	Trisomy 13, translocation	Diagnosis	ICD-10-CM
Q91.7	Trisomy 13, unspecified	Diagnosis	ICD-10-CM
Q93.81	Velo-cardio-facial syndrome	Diagnosis	ICD-10-CM
Q93.82	Williams syndrome	Diagnosis	ICD-10-CM
Q91.6 Q91.7 Q93.81	Trisomy 13, translocation Trisomy 13, unspecified Velo-cardio-facial syndrome	Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM

cder_mpl1p_wp077 Page 757 of 1023



	·	Code	
Code	Description	Category	Code Type
02Q50ZZ	Repair Atrial Septum, Open Approach	Procedure	ICD-10-PCS
02QM0ZZ	Repair Ventricular Septum, Open Approach	Procedure	ICD-10-PCS
02U507Z	Supplement Atrial Septum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02U50JZ	Supplement Atrial Septum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02U53JZ	Supplement Atrial Septum with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02UM07Z	Supplement Ventricular Septum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02UM0JZ	Supplement Ventricular Septum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02UM3JZ	Supplement Ventricular Septum with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
33647	Repair of atrial septal defect and ventricular septal defect, with direct or patch closure	Procedure	CPT-4
33720	Repair sinus of Valsalva aneurysm, with cardiopulmonary bypass	Procedure	CPT-4
33741	Transcatheter atrial septostomy (TAS) for congenital cardiac anomalies to create effective atrial flow, including all imaging guidance by the proceduralist, when performed, any method (eg, Rashkind, Sang-Park, balloon, cutting balloon, blade)	Procedure	CPT-4
33745	Transcatheter intracardiac shunt (TIS) creation by stent placement for congenital cardiac anomalies to establish effective intracardiac flow, including all imaging guidance by the proceduralist, when performed, left and right heart diagnostic cardiac catherization for congenital cardiac anomalies, and target zone angioplasty, when performed (eg, atrial septum, Fontan fenestration, right ventricular outflow tract, Mustard/Senning/Warden baffles); initial intracardiac shunt	Procedure	CPT-4
33746	Transcatheter intracardiac shunt (TIS) creation by stent placement for congenital cardiac anomalies to establish effective intracardiac flow, including all imaging guidance by the proceduralist, when performed, left and right heart diagnostic cardiac catherization for congenital cardiac anomalies, and target zone angioplasty, when performed (eg, atrial septum, Fontan fenestration, right ventricular outflow tract, Mustard/Senning/Warden baffles); each additional intracardiac shunt location (List separately in addition to code for primary procedure)	Procedure	CPT-4
33924	Ligation and takedown of a systemic-to-pulmonary artery shunt, performed in conjunction with a congenital heart procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4
75572	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)	Procedure	CPT-4
75573	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image postprocessing, assessment of LV cardiac function, RV structure and function and evaluation of venous structures, if performed)	Procedure	CPT-4
93303	Transthoracic echocardiography for congenital cardiac anomalies; complete	Procedure	CPT-4
93304	Transthoracic echocardiography for congenital cardiac anomalies; follow-up or limited study	Procedure	CPT-4
93315	Transesophageal echocardiography for congenital cardiac anomalies; including probe placement. image acquisition. interpretation and report	Procedure	CPT-4
93316	Transesophageal echocardiography for congenital cardiac anomalies; placement of transesophageal probe only	Procedure	CPT-4

cder_mpl1p_wp077 Page 758 of 1023



		Code	
Code	Description	Category	Code Type
3317	Transesophageal echocardiography for congenital cardiac anomalies; image acquisition,	Procedure	CPT-4
	interpretation and report only		
93530	Right heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
3531	Combined right heart catheterization and retrograde left heart catheterization, for	Procedure	CPT-4
	congenital cardiac anomalies		
93532	Combined right heart catheterization and transseptal left heart catheterization through	Procedure	CPT-4
	intact septum with or without retrograde left heart catheterization, for congenital cardiac		
	anomalies		
93533	Combined right heart catheterization and transseptal left heart catheterization through	Procedure	CPT-4
,5555	existing septal opening, with or without retrograde left heart catheterization, for	Troccaure	CITY
	congenital cardiac anomalies		
93563	Injection procedure during cardiac catheterization including imaging supervision,	Procedure	CPT-4
	interpretation, and report; for selective coronary angiography during congenital heart		
	catheterization (List separately in addition to code for primary procedure)		
93564	Injection procedure during cardiac catheterization including imaging supervision,	Procedure	CPT-4
	interpretation, and report; for selective opacification of aortocoronary venous or arterial	. roccaure	O
	bypass graft(s) (eg, aortocoronary saphenous vein, free radial artery, or free mammary		
	artery graft) to one or more coronary arteries and in situ arterial conduits (eg, internal		
	mammary), whether native or used for bypass to one or more coronary arteries during		
	congenital heart catheterization, when performed (List separately in addition to code for		
	primary procedure)		
3580	Percutaneous transcatheter closure of congenital interatrial communication (ie, Fontan	Procedure	CPT-4
	fenestration, atrial septal defect) with implant		
3581	Percutaneous transcatheter closure of a congenital ventricular septal defect with implant	Procedure	CPT-4
	Heart Failure		
9.81	Rheumatic heart failure	Diagnosis	ICD-10-CN
11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CN
13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through	Diagnosis	ICD-10-CN
	stage 4 chronic kidnev disease. or unspecified chronic kidnev disease	2.0800.0	.02 20 0.
13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic	Diagnosis	ICD-10-CN
	kidnev disease. or end stage renal disease	2.0800.0	.02 20 0
50	Heart failure	Diagnosis	ICD-10-CN
50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CN
50.2	Systolic (congestive) heart failure	Diagnosis	ICD-10-CN
50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CN
50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CN
50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CN
50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CN
50.25	Diastolic (congestive) heart failure	Diagnosis	ICD-10-CN
50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CN
50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CN
50.32	Chronic diastolic (congestive) heart failure		
		Diagnosis	ICD-10-CN
50.33 50.4	Acute on chronic diastolic (congestive) heart failure Combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CN
30171	Compined Systolic (congestive) and diastolic (congestive) neart failure	Diagnosis	ICD-10-CN
50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CN

cder_mpl1p_wp077 Page 759 of 1023



		Code	
Code	Description	Category	Code Type
150.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.8	Other heart failure	Diagnosis	ICD-10-CM
150.81	Right heart failure	Diagnosis	ICD-10-CM
150.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
150.811	Acute right heart failure	Diagnosis	ICD-10-CM
150.812	Chronic right heart failure	Diagnosis	ICD-10-CM
150.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
150.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
150.82	Biventricular heart failure	Diagnosis	ICD-10-CM
150.83	High output heart failure	Diagnosis	ICD-10-CM
150.84	End stage heart failure	Diagnosis	ICD-10-CM
150.89	Other heart failure	Diagnosis	ICD-10-CM
150.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
197.13	Postprocedural heart failure	Diagnosis	ICD-10-CM
197.130	Postprocedural heart failure following cardiac surgery	Diagnosis	ICD-10-CM
197.131	Postprocedural heart failure following other surgery	Diagnosis	ICD-10-CM
	Hyperlipidemia		
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
	Hypertensive Disease		
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
111.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
112.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage	Diagnosis	ICD-10-CM
	renal disease		
112.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease,	Diagnosis	ICD-10-CM
	or unspecified chronic kidney disease		
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through	Diagnosis	ICD-10-CM
142.4	stage 4 chronic kidney disease, or unspecified chronic kidney disease	5	100 40 684
113.1	Hypertensive heart and chronic kidney disease without heart failure	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through	וםagnosis	ICD-10-CM
I13.11	stage 4 chronic kidnev disease. or unspecified chronic kidnev disease Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic	Diagnosis	ICD-10-CM
14.2.2	kidnev disease. or end stage renal disease	Diam.	100 40 654
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic	Diagnosis	ICD-10-CM
I15.0	kidnev disease. or end stage renal disease Renovascular hypertension	Diagnosis	ICD-10-CM
115.0	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
113.1	ripper tension secondary to other renardisorders	Piagilosis	ICD-TO-CIAI

cder_mpl1p_wp077 Page 760 of 1023



		Code	
Code	Description	Category	Code Type
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
115.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
116.0	Hypertensive urgency	Diagnosis	ICD-10-CM
116.1	Hypertensive emergency	Diagnosis	ICD-10-CM
116.9	Hypertensive crisis, unspecified	Diagnosis	ICD-10-CM
167.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
	Thyroid Disease		
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
	Ischemic Heart Disease/Coronary Artery Disease/Myocardial Infarction		
120	Angina pectoris	Diagnosis	ICD-10-CM
120.0	Unstable angina	Diagnosis	ICD-10-CM
120.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
120.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
120.9		2.00.00.0	
	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
	Angina pectoris, unspecified ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis Diagnosis	ICD-10-CM
121.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary		
121.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis Diagnosis	ICD-10-CM
I21.01 I21.02 I21.09	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
I21.01 I21.02 I21.09	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM
I21.01 I21.02 I21.09	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
I21.01 I21.02 I21.09 I21.11 I21.19	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.01 I21.02 I21.09 I21.11 I21.19	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.01 I21.02 I21.09 I21.11 I21.19 I21.21 I21.29	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.01 I21.02 I21.09 I21.11 I21.19 I21.21 I21.29 I21.3	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.01 I21.02 I21.09 I21.11 I21.19 I21.21 I21.29 I21.3 I21.4	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites ST elevation (STEMI) myocardial infarction of unspecified site Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.01 I21.02 I21.09 I21.11 I21.19 I21.21 I21.29 I21.3 I21.4 I21.9	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites ST elevation (STEMI) myocardial infarction of unspecified site Non-ST elevation (NSTEMI) myocardial infarction Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.01 I21.02 I21.09 I21.11 I21.19 I21.21 I21.29 I21.3 I21.4 I21.9 I21.A1	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites ST elevation (STEMI) myocardial infarction of unspecified site Non-ST elevation (NSTEMI) myocardial infarction Acute myocardial infarction, unspecified Myocardial infarction type 2	Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.01 I21.02 I21.09 I21.11 I21.19 I21.21 I21.29 I21.3 I21.4 I21.9 I21.A1 I21.A9	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites ST elevation (STEMI) myocardial infarction of unspecified site Non-ST elevation (NSTEMI) myocardial infarction Acute myocardial infarction, unspecified Myocardial infarction type 2 Other myocardial infarction type	Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.01 I21.02 I21.09 I21.11 I21.19 I21.21 I21.29 I21.3 I21.4 I21.9 I21.A1 I21.A9 I22.0	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites ST elevation (STEMI) myocardial infarction of unspecified site Non-ST elevation (NSTEMI) myocardial infarction Acute myocardial infarction, unspecified Myocardial infarction type 2 Other myocardial infarction type Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.01 I21.02 I21.09 I21.11 I21.19 I21.21 I21.29 I21.3 I21.4 I21.9 I21.A1 I21.A9 I22.0 I22.1	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites ST elevation (STEMI) myocardial infarction of unspecified site Non-ST elevation (NSTEMI) myocardial infarction Acute myocardial infarction, unspecified Myocardial infarction type 2 Other myocardial infarction type Subsequent ST elevation (STEMI) myocardial infarction of anterior wall Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM
I21.01 I21.02 I21.09 I21.11 I21.19 I21.21 I21.29 I21.3 I21.4 I21.9 I21.A1 I21.A9 I22.0	ST elevation (STEMI) myocardial infarction involving left main coronary artery ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall ST elevation (STEMI) myocardial infarction involving right coronary artery ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery ST elevation (STEMI) myocardial infarction involving other sites ST elevation (STEMI) myocardial infarction of unspecified site Non-ST elevation (NSTEMI) myocardial infarction Acute myocardial infarction, unspecified Myocardial infarction type 2 Other myocardial infarction type Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM ICD-10-CM

cder_mpl1p_wp077 Page 761 of 1023



	codes Oseu to Define Basenne Characteristics in this nequest	Code	
Code	Description	Category	Code Type
122.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
123.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
123.7	Postinfarction angina	Diagnosis	ICD-10-CM
123.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
124	Other acute ischemic heart diseases	Diagnosis	ICD-10-CM
124.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
124.1	Dressler's syndrome	Diagnosis	ICD-10-CM
124.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
124.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
125.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
125.11	Atherosclerotic heart disease of native coronary artery with angina pectoris	Diagnosis	ICD-10-CM
125.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
123.110	Atheroscierotic heart disease of hative coronary artery with distable alignia pectoris	Diagnosis	ICD-10-CIVI
125.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.118	Atherosclerotic heart disease of native coronary artery with other forms of angina	Diagnosis	ICD-10-CM
	pectoris	- 10.0	
125.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
		Ū	
125.3	Aneurysm of heart	Diagnosis	ICD-10-CM
125.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
125.42	Coronary artery dissection	Diagnosis	ICD-10-CM
125.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
125.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
125.7	Atherosclerosis of coronary artery bypass graft(s) and coronary artery of transplanted	Diagnosis	ICD-10-CM
	heart with angina pectoris		
125.70	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris	Diagnosis	ICD-10-CM
125.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
125.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina	Diagnosis	ICD 10 CM
	pectoris	_	ICD-10-CM
125.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.71	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
125.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 762 of 1023



riocedure	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
125.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
	with documented spasm		
125.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina	Diagnosis	ICD-10-CM
	pectoris		
125.72	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
125.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina	Diagnosis	ICD-10-CM
105 704	pectoris		105 10 011
125.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.73	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
125.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
125.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina	Diagnosis	ICD-10-CM
125 720	pectoris with documented spasm	5	100 40 604
125.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.75	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris	Diagnosis	ICD-10-CM
125.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
125.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.76	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris	Diagnosis	ICD-10-CM
125.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
125.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 763 of 1023



Troccaure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
125.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified	Diagnosis	ICD-10-CM
	angina pectoris		
125.79	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
125.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
125.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
125.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
125.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
125.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
125.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
125.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
125.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
125.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
146.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
146.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
146.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
147.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
147.2	Ventricular tachycardia	Diagnosis	ICD-10-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
0210083	Bypass Coronary Artery, One Artery from Coronary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0210088	Bypass Coronary Artery, One Artery from Right Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0210089	Bypass Coronary Artery, One Artery from Left Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0210093	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0210098	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0210099	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0210483	Bypass Coronary Artery, One Artery from Coronary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0210488	Bypass Coronary Artery, One Artery from Right Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 764 of 1023



Troccadie	Codes osed to Define baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
0210489	Bypass Coronary Artery, One Artery from Left Internal Mammary with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0210493	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0210498	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Percutaneous Endoscopic Approach		
0210499	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
0211083	Bypass Coronary Artery, Two Arteries from Coronary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0211088	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Zooplastic	Procedure	ICD-10-PCS
0211000	Tissue, Open Approach	rrocedure	1CD-10-1 C3
0211089	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0211093	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		
0211098	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Open Approach		
0211099	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Open Approach		
0211483	Bypass Coronary Artery, Two Arteries from Coronary Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
0244400	Percutaneous Endoscopic Approach		100 40 000
0211488	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Zooplastic	Procedure	ICD-10-PCS
0211400	Tissue, Percutaneous Endoscopic Approach	Dragoduro	ICD 10 DCC
0211489	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211493	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Venous	Procedure	ICD-10-PCS
0211433	Tissue, Percutaneous Endoscopic Approach	Troccaure	100 101 05
0211498	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Percutaneous Endoscopic Approach		
0211499	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Percutaneous Endoscopic Approach		
0212083	Bypass Coronary Artery, Three Arteries from Coronary Artery with Zooplastic Tissue, Open	Procedure	ICD-10-PCS
	Approach		
0212088	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Zooplastic	Procedure	ICD-10-PCS
	Tissue, Open Approach		
0212089	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Zooplastic	Procedure	ICD-10-PCS
	Tissue, Open Approach		
0212093	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		
0212098	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
0242000	Venous Tissue, Open Approach		100 40 500
0212099	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Open Approach		

cder_mpl1p_wp077 Page 765 of 1023



	Codes Osed to Define baseline Characteristics in this request	Code	
Code	Description	Category	Code Type
0212483	Bypass Coronary Artery, Three Arteries from Coronary Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0212488	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Zooplastic	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
0212489	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Zooplastic	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
0212493	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
0212498	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Percutaneous Endoscopic Approach		
0212499	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous	Procedure	ICD-10-PCS
0242002	Venous Tissue, Percutaneous Endoscopic Approach	Dunandous	100 40 000
0213083	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Zooplastic	Procedure	ICD-10-PCS
0212000	Tissue, Open Approach Pyross Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD 10 DCS
0213088	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0213089	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
0213009	Zooplastic Tissue, Open Approach	riocedure	1CD-10-FC3
0213093	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous	Procedure	ICD-10-PCS
0210030	Venous Tissue, Open Approach	rroccaare	105 10 1 00
0213098	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
	Autologous Venous Tissue, Open Approach		
0213099	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
	Autologous Venous Tissue, Open Approach		
0213483	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Zooplastic	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
0213488	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
	Zooplastic Tissue, Percutaneous Endoscopic Approach		
0213489	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
	Zooplastic Tissue, Percutaneous Endoscopic Approach		
0213493	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Percutaneous Endoscopic Approach		
0213498	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
	Autologous Venous Tissue, Percutaneous Endoscopic Approach		
0213499	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
	Autologous Venous Tissue, Percutaneous Endoscopic Approach		
0270046	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0270056	Device, Open Approach	Dunandous	100 40 000
0270056	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0270066	Devices, Open Approach Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0270000	Devices, Open Approach	riocedule	ICD-10-4C3
0270076	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
0270070	Intraluminal Devices, Open Approach	Tocedure	ICD TO-LC3

cder_mpl1p_wp077 Page 766 of 1023



Tocedure	codes osed to Define baseline characteristics in this nequest	Code	
Code	Description	Category	Code Type
0270346	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Device, Percutaneous Approach		
0270356	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
0270366	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
0270376	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
0070446	Intraluminal Devices, Percutaneous Approach		100 10 000
0270446	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0270456	Device, Percutaneous Endoscopic Approach	Donasadous	100 40 000
0270456	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270466	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal	Drocoduro	ICD-10-PCS
0270400	Devices, Percutaneous Endoscopic Approach	riocedule	ICD-10-PC3
0270476	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
02/04/0	Intraluminal Devices, Percutaneous Endoscopic Approach	rioccaure	100 101 05
0271046	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
02720.0	Device, Open Approach		.02 20 . 00
0271056	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
0271066	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
0271076	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
0271346	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Device, Percutaneous Approach		
0271356	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
0271366	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
0271276	Intraluminal Devices, Percutaneous Approach	Dunnadium	ICD 10 DCC
0271376	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271446	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0271440	Device, Percutaneous Endoscopic Approach	riocedure	ICD-10-FC3
0271456	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0272130	Devices, Percutaneous Endoscopic Approach	rioccaare	102 10 1 03
0271466	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
0271476	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
0272046	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Device, Open Approach		
0272056	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		

cder_mpl1p_wp077 Page 767 of 1023



		Code	
Code	Description	Category	Code Type
0272066	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
0272076	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
0272346	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Device, Percutaneous Approach		
0272356	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
0272366	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
0272376	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
0272446	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0070456	Device, Percutaneous Endoscopic Approach		100 10 000
0272456	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting	Procedure	ICD-10-PCS
0272466	Intraluminal Devices, Percutaneous Endoscopic Approach		100 10 000
0272466	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
0272476	Intraluminal Devices, Percutaneous Endoscopic Approach	Duesediine	ICD 10 DCC
0272476	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
0272046	Intraluminal Devices, Percutaneous Endoscopic Approach	Dracadura	ICD 10 DCC
0273046	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting	Procedure	ICD-10-PCS
0273056	Intraluminal Device, Open Approach Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting	Drocoduro	ICD 10 DCS
02/3030	Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0273066	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
02/3000	Intraluminal Devices, Open Approach	Procedure	10-10-703
0273076	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-	Procedure	ICD-10-PCS
0273070	eluting Intraluminal Devices, Open Approach	rrocedure	100-10-1 03
0273346	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting	Procedure	ICD-10-PCS
0273310	Intraluminal Device, Percutaneous Approach	110000010	105 10 1 05
0273356	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting	Procedure	ICD-10-PCS
02/0000	Intraluminal Devices, Percutaneous Approach		.02 20 . 00
0273366	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
0273376	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-	Procedure	ICD-10-PCS
	eluting Intraluminal Devices, Percutaneous Approach		
0273446	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Device, Percutaneous Endoscopic Approach		
0273456	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
0273466	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
0273476	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-	Procedure	ICD-10-PCS
	eluting Intraluminal Devices, Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 768 of 1023



Toccadie	codes osed to Define baseline characteristics in this nequest	Code	
Code	Description	Category	Code Type
02700E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
02703E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
0070456	Percutaneous Approach		160 40 066
02704E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
02710E6	Percutaneous Endoscopic Approach Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
0271010	Open Approach	riocedure	ICD-10-FC3
02713E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
02714E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02720E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
02723E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
02724E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
0272056	Percutaneous Endoscopic Approach	Dragodura	ICD 10 DCS
02730E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02733E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal	Procedure	ICD-10-PCS
0273320	Devices, Percutaneous Approach	rroccaare	165 10 1 65
02734E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
021008C	Bypass Coronary Artery, One Artery from Thoracic Artery with Zooplastic Tissue, Open	Procedure	ICD-10-PCS
	Approach		
021008F	Bypass Coronary Artery, One Artery from Abdominal Artery with Zooplastic Tissue, Open	Procedure	ICD-10-PCS
	Approach		
021008W	Bypass Coronary Artery, One Artery from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0210000	Dunges Coronary Artery One Artery from Theresis Artery with Autologous Veneus Tissue	Dragodura	ICD 10 DCS
021009C	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021009F	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Venous	Procedure	ICD-10-PCS
0210031	Tissue, Open Approach	rroccaare	165 10 1 65
021009W	Bypass Coronary Artery, One Artery from Aorta with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
02100A3	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
02100A8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Open Approach		
02100A9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Arterial	Procedure	ICD-10-PCS
0210040	Tissue, Open Approach	Dragodina	ICD 10 DCC
02100AC	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
	Open Approach		

cder_mpl1p_wp077 Page 769 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
02100AF	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
02100AW	Bypass Coronary Artery, One Artery from Aorta with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
02100J3	Bypass Coronary Artery, One Artery from Coronary Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
02100J8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Synthetic	Procedure	ICD-10-PCS
0040010	Substitute, Open Approach		105 10 500
02100J9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Synthetic	Procedure	ICD-10-PCS
0240016	Substitute, Open Approach	Dun andrum	ICD 40 DCC
02100JC	Bypass Coronary Artery, One Artery from Thoracic Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
02100JF	Approach Bypass Coronary Artery, One Artery from Abdominal Artery with Synthetic Substitute,	Drocoduro	ICD-10-PCS
U21UUJF	Open Approach	Procedure	ICD-10-PC3
02100JW	Bypass Coronary Artery, One Artery from Aorta with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021003	by pass coronary Artery, one Artery from Aorta with synthetic substitute, Open Approach	Trocedure	ICD-10-I C3
02100K3	Bypass Coronary Artery, One Artery from Coronary Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
02100N3	Substitute, Open Approach	Troccaare	100 101 05
02100K8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Nonautologous	Procedure	ICD-10-PCS
	Tissue Substitute, Open Approach		
02100K9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Nonautologous	Procedure	ICD-10-PCS
	Tissue Substitute, Open Approach		
02100KC	Bypass Coronary Artery, One Artery from Thoracic Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
02100KF	Bypass Coronary Artery, One Artery from Abdominal Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
02100KW	Bypass Coronary Artery, One Artery from Aorta with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
02100Z3	Bypass Coronary Artery, One Artery from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02100Z8	Bypass Coronary Artery, One Artery from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02100Z9	Bypass Coronary Artery, One Artery from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02100ZC	Bypass Coronary Artery, One Artery from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS ICD-10-PCS
02100ZF	Bypass Coronary Artery, One Artery from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021048C	Bypass Coronary Artery, One Artery from Thoracic Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
021048F	Bypass Coronary Artery, One Artery from Abdominal Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
0210401	Percutaneous Endoscopic Approach	rroccaare	100 101 05
021048W	Bypass Coronary Artery, One Artery from Aorta with Zooplastic Tissue, Percutaneous	Procedure	ICD-10-PCS
0220.011	Endoscopic Approach		.02 20 . 00
021049C	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021049F	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Venous	Procedure	ICD-10-PCS
-	Tissue, Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 770 of 1023



Trocedure	codes osed to Define baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
021049W	Bypass Coronary Artery, One Artery from Aorta with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02104A3	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02104A8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
0210440	Arterial Tissue, Percutaneous Endoscopic Approach	Dunnadiina	ICD 10 DCC
02104A9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104AC	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
02104710	Percutaneous Endoscopic Approach	rroccaure	100 101 05
02104AF	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
02104AW	Bypass Coronary Artery, One Artery from Aorta with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02104J3	Bypass Coronary Artery, One Artery from Coronary Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02104J8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Synthetic	Procedure	ICD-10-PCS
0240410	Substitute, Percutaneous Endoscopic Approach	Dunnadiina	ICD 10 DCC
02104J9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104JC	Bypass Coronary Artery, One Artery from Thoracic Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
0210-30	Percutaneous Endoscopic Approach	rroccaure	100 101 05
02104JF	Bypass Coronary Artery, One Artery from Abdominal Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02104JW	Bypass Coronary Artery, One Artery from Aorta with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02104K3	Bypass Coronary Artery, One Artery from Coronary Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02104K8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Nonautologous	Procedure	ICD-10-PCS
02104K9	Tissue Substitute, Percutaneous Endoscopic Approach	Dragodura	ICD 10 DCS
02104K9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104KC	Bypass Coronary Artery, One Artery from Thoracic Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0210-IKC	Substitute, Percutaneous Endoscopic Approach	rroccaure	100 101 05
02104KF	Bypass Coronary Artery, One Artery from Abdominal Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02104KW	Bypass Coronary Artery, One Artery from Aorta with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02104Z3	Bypass Coronary Artery, One Artery from Coronary Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02104Z8	Bypass Coronary Artery, One Artery from Right Internal Mammary, Percutaneous	Procedure	ICD-10-PCS
0240470	Endoscopic Approach	Dun I	100 40 500
02104Z9	Bypass Coronary Artery, One Artery from Left Internal Mammary, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 771 of 1023



Jecaui C	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
02104ZC	Bypass Coronary Artery, One Artery from Thoracic Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02104ZF	Bypass Coronary Artery, One Artery from Abdominal Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
021108C	Approach Bypass Coronary Artery, Two Arteries from Thoracic Artery with Zooplastic Tissue, Open	Procedure	ICD-10-PCS
0211060	Approach	riocedule	ICD-10-FC3
021108F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Zooplastic Tissue, Open	Procedure	ICD-10-PCS
	Approach		
021108W	Bypass Coronary Artery, Two Arteries from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021109C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Venous	Procedure	ICD-10-PCS
021109C	Tissue, Open Approach	riocedule	ICD-10-PC3
021109F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		
021109W	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
02110A3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Arterial	Procedure	ICD-10-PCS
02110A8	Tissue, Open Approach Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
UZIIUAO	Arterial Tissue, Open Approach	riocedule	ICD-10-FC3
02110A9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Open Approach		
02110AC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
02110AF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Arterial	Procedure	ICD-10-PCS
02110AW	Tissue, Open Approach Bypass Coronary Artery, Two Arteries from Aorta with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
02110/11	Approach	Troccaure	100 101 03
02110J3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
02110J8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Synthetic	Procedure	ICD-10-PCS
0044040	Substitute, Open Approach		105 10 500
02110J9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110JC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
0211030	Open Approach	110000010	107 10 1 00
02110JF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
02110JW	Bypass Coronary Artery, Two Arteries from Aorta with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0044040	Approach		105 10 500
02110K3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
02110K8	Substitute, Open Approach Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Nonautologous	Procedure	ICD-10-PCS
OZIIONO	Tissue Substitute, Open Approach	Trocedure	ICD-10-LC3

cder_mpl1p_wp077 Page 772 of 1023



Troccuare	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
02110K9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Nonautologous	Procedure	ICD-10-PCS
	Tissue Substitute, Open Approach		
02110KC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
02110KF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
02110KW	Bypass Coronary Artery, Two Arteries from Aorta with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
02110Z3	Bypass Coronary Artery, Two Arteries from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02110Z8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02110Z9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02110ZC	Bypass Coronary Artery, Two Arteries from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
02110ZF	Bypass Coronary Artery, Two Arteries from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021148C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021148F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021148W	Bypass Coronary Artery, Two Arteries from Aorta with Zooplastic Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
021149C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
021149F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
021149W	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02114A3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
02114A8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
02220	Arterial Tissue, Percutaneous Endoscopic Approach		.02 20 . 00
02114A9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous	Procedure	ICD-10-PCS
0	Arterial Tissue, Percutaneous Endoscopic Approach		.02 20 . 00
02114AC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Arterial	Procedure	ICD-10-PCS
02114710	Tissue, Percutaneous Endoscopic Approach	rioccaare	100 10 1 05
02114AF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Arterial	Procedure	ICD-10-PCS
02114AI	Tissue, Percutaneous Endoscopic Approach	riocedure	10-10-703
02114014		Dunnadiii	ICD 10 DCC
02114AW	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0244412	Percutaneous Endoscopic Approach	5 1	100 40 000
02114J3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02114J8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Synthetic	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02114J9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Synthetic	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 773 of 1023



. roccaare	codes osed to Define baseline characteristics in this nequest	Code	
Code	Description	Category	Code Type
02114JC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02114JF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02114JW	Bypass Coronary Artery, Two Arteries from Aorta with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
024441/2	Endoscopic Approach		100 40 000
02114K3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114K8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114K9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114KC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114KF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
OZIITKI	Substitute, Percutaneous Endoscopic Approach	Troccaure	100 101 05
02114KW	Bypass Coronary Artery, Two Arteries from Aorta with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02114Z3	Bypass Coronary Artery, Two Arteries from Coronary Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02114Z8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02114ZC	Bypass Coronary Artery, Two Arteries from Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114ZF	Bypass Coronary Artery, Two Arteries from Abdominal Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
021208C	Approach Bypass Coronary Artery, Three Arteries from Thoracic Artery with Zooplastic Tissue, Open	Procedure	ICD-10-PCS
U212U6C	Approach	Procedure	ICD-10-PC3
021208F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Open Approach		
021208W	Bypass Coronary Artery, Three Arteries from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021209C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		
021209F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		
021209W	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
0242042	Approach	Dunnali	ICD 40 DCC
02120A3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120A8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 774 of 1023



. rocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
02120A9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Open Approach		
02120AC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
02120AF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120AW	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
02120J3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120J8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic	Procedure	ICD-10-PCS
0212010	Substitute, Open Approach Propos Coronary Artery Three Arteries from Left Internal Mamman, with Synthetic	Dragadura	ICD 10 DCS
02120J9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120JC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
02120JF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
02120JW	Open Approach Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Open	Procedure	ICD 10 DCS
02120100	Approach	Procedure	ICD-10-PCS
02120K3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
02120K8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
	Nonautologous Tissue Substitute, Open Approach		
02120K9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous	Procedure	ICD-10-PCS
	Tissue Substitute, Open Approach		
02120KC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0242045	Substitute, Open Approach	Dan and dans	ICD 40 DCC
02120KF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous	Procedure	ICD-10-PCS
02120KW	Tissue Substitute, Open Approach Bypass Coronary Artery, Three Arteries from Aorta with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
UZIZUKVV	Open Approach	riocedule	ICD-10-PC3
02120Z3	Bypass Coronary Artery, Three Arteries from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02120Z8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02120Z9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02120ZC	Bypass Coronary Artery, Three Arteries from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
02120ZF	Bypass Coronary Artery, Three Arteries from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021248C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021248F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021248W	Bypass Coronary Artery, Three Arteries from Aorta with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 775 of 1023



	codes osed to beline baseline characteristics in this nequest	Code	
Code	Description	Category	Code Type
021249C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
021249F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
021249W	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02124A3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
02124A8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Percutaneous Endoscopic Approach		
02124A9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Percutaneous Endoscopic Approach		
02124AC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
02124AF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
02124AW	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02124J3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach	_	
02124J8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02124J9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02124JC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
0242415	Percutaneous Endoscopic Approach		100 40 000
02124JF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
02424114/	Percutaneous Endoscopic Approach	Dunandana	ICD 40 DCC
02124JW	Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute,	Procedure	ICD-10-PCS
024241/2	Percutaneous Endoscopic Approach	Dunandana	ICD 40 DCC
02124K3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0212410	Substitute, Percutaneous Endoscopic Approach	Duesedine	ICD 10 DCC
02124K8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
021241/0	Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Drocoduro	ICD 10 DCS
02124K9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous	Procedure	ICD-10-PCS
02124KC	Tissue Substitute, Percutaneous Endoscopic Approach Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue	Procedure	ICD 10 DCS
UZIZANC	Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021246		Drocoduro	ICD 10 DCS
02124KF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124KW	Bypass Coronary Artery, Three Arteries from Aorta with Nonautologous Tissue Substitute,	Drocedure	ICD-10-PCS
UZIZ4N VV	Percutaneous Endoscopic Approach	rrocedure	ICD-10-LC3
02124Z3	Bypass Coronary Artery, Three Arteries from Coronary Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0212423	Approach	Trocedure	ICD-10-LC3

cder_mpl1p_wp077 Page 776 of 1023



Troccadie	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
02124Z8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02124Z9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02124ZC	Bypass Coronary Artery, Three Arteries from Thoracic Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0242475	Approach		160 40 066
02124ZF	Bypass Coronary Artery, Three Arteries from Abdominal Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
021308C	Approach Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Zooplastic	Procedure	ICD-10-PCS
U213U6C	Tissue, Open Approach	riocedule	ICD-10-PC3
021308F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Zooplastic	Procedure	ICD-10-PCS
0213001	Tissue, Open Approach	Troccaure	100 10 1 05
021308W	Bypass Coronary Artery, Four or More Arteries from Aorta with Zooplastic Tissue, Open	Procedure	ICD-10-PCS
	Approach		
021309C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Open Approach		
021309F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Open Approach		
021309W	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		
02130A3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous	Procedure	ICD-10-PCS
0212040	Arterial Tissue, Open Approach	Dunnanduun	ICD 10 DCC
02130A8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130A9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
02130A3	Autologous Arterial Tissue, Open Approach	Trocedure	1CD-10-1 C3
02130AC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Open Approach		
02130AF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Open Approach		
02130AW	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
02130J3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Synthetic	Procedure	ICD-10-PCS
	Substitute, Open Approach		
02130J8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
0242010	Synthetic Substitute, Open Approach	Dunnanduun	ICD 10 DCC
02130J9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130JC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Synthetic	Procedure	ICD-10-PCS
02130JC	Substitute, Open Approach	rrocedure	ICD-10-FC3
02130JF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Synthetic	Procedure	ICD-10-PCS
	Substitute, Open Approach		
02130JW	Bypass Coronary Artery, Four or More Arteries from Aorta with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		

cder_mpl1p_wp077 Page 777 of 1023



		Code	
Code	Description	Category	Code Type
02130K3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Nonautologous	Procedure	ICD-10-PCS
	Tissue Substitute, Open Approach		
02130K8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
	Nonautologous Tissue Substitute, Open Approach		
02130K9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
	Nonautologous Tissue Substitute, Open Approach		
02130KC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Nonautologous	Procedure	ICD-10-PCS
	Tissue Substitute, Open Approach		
02130KF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with	Procedure	ICD-10-PCS
	Nonautologous Tissue Substitute, Open Approach		
02130KW	Bypass Coronary Artery, Four or More Arteries from Aorta with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130Z3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02130Z8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary, Open	Procedure	ICD-10-PCS
	Approach		
02130Z9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary, Open	Procedure	ICD-10-PCS
0040070	Approach		100 10 000
02130ZC 02130ZF	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery, Open Approach Bypass Coronary Artery, Four or More Arteries from Abdominal Artery, Open Approach	Procedure Procedure	ICD-10-PCS
UZ13UZF	bypass Coronary Artery, Four or More Arteries from Abdominar Artery, Open Approach	Procedure	ICD-10-PCS
021348C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Zooplastic	Procedure	ICD-10-PCS
0210 100	Tissue, Percutaneous Endoscopic Approach		105 10 1 05
021348F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Zooplastic	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
021348W	Bypass Coronary Artery, Four or More Arteries from Aorta with Zooplastic Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021349C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Percutaneous Endoscopic Approach		
021349F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous	Procedure	ICD-10-PCS
	Venous Tissue, Percutaneous Endoscopic Approach		
021349W	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
02134A3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Percutaneous Endoscopic Approach		
02134A8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
	Autologous Arterial Tissue, Percutaneous Endoscopic Approach		
02134A9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
	Autologous Arterial Tissue, Percutaneous Endoscopic Approach		
02134AC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous	Procedure	ICD-10-PCS
	Arterial Tissue, Percutaneous Endoscopic Approach		
02134AF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous	Procedure	ICD-10-PCS
00404444	Arterial Tissue, Percutaneous Endoscopic Approach		100 40 500
02134AW	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 778 of 1023



. roccadie	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
02134J3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Synthetic	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02134J8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
	Synthetic Substitute, Percutaneous Endoscopic Approach		
02134J9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
	Synthetic Substitute, Percutaneous Endoscopic Approach		
02134JC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Synthetic	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02134JF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Synthetic	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02134JW	Bypass Coronary Artery, Four or More Arteries from Aorta with Synthetic Substitute,	Procedure	ICD-10-PCS
024241/2	Percutaneous Endoscopic Approach	Danasakana	ICD 40 DCC
02134K3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Nonautologous	Procedure	ICD-10-PCS
0212410	Tissue Substitute, Percutaneous Endoscopic Approach	Duanadium	ICD 10 DCC
02134K8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with	Procedure	ICD-10-PCS
02134K9	Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with	Procedure	ICD-10-PCS
UZ134N9	Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
02134KC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Nonautologous	Procedure	ICD-10-PCS
02134NC	Tissue Substitute, Percutaneous Endoscopic Approach	rrocedure	1CD-10-1 C3
02134KF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with	Procedure	ICD-10-PCS
0213 1111	Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach		102 10 1 00
02134KW	Bypass Coronary Artery, Four or More Arteries from Aorta with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
02134Z3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02134Z8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02134Z9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02134ZC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02134ZF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
021K0Z8	Bypass Right Ventricle to Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021K0Z9	Bypass Right Ventricle to Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021K0ZC	Bypass Right Ventricle to Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
021K0ZF	Bypass Right Ventricle to Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021K0ZW	Bypass Right Ventricle to Aorta, Open Approach	Procedure	ICD-10-PCS
021K4Z8	Bypass Right Ventricle to Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K4Z9	Bypass Right Ventricle to Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
UZ1N4ZJ	by pass right ventilitie to Left internal Manimary, refeatableous Endoscopic Approach	TOCEUUIE	ICD-10-4C3
021K4ZC	Bypass Right Ventricle to Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K4ZF	Bypass Right Ventricle to Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
	,,		

cder_mpl1p_wp077 Page 779 of 1023



riocedure	codes osed to Define baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
021K4ZW	Bypass Right Ventricle to Aorta, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L08P	Bypass Left Ventricle to Pulmonary Trunk with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021L08Q	Bypass Left Ventricle to Right Pulmonary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021L08R	Bypass Left Ventricle to Left Pulmonary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021L09P	Bypass Left Ventricle to Pulmonary Trunk with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021L09Q	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021L09R	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021L0AP	Bypass Left Ventricle to Pulmonary Trunk with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
021L0AQ	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
021L0AR	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
021L0JP	Bypass Left Ventricle to Pulmonary Trunk with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021L0JQ	Bypass Left Ventricle to Right Pulmonary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021L0JR	Bypass Left Ventricle to Left Pulmonary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021L0KP	Bypass Left Ventricle to Pulmonary Trunk with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
021L0KQ	Bypass Left Ventricle to Right Pulmonary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
021L0KR	Bypass Left Ventricle to Left Pulmonary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
021L0Z8	Bypass Left Ventricle to Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021L0Z9	Bypass Left Ventricle to Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021L0ZC	Bypass Left Ventricle to Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
021L0ZF	Bypass Left Ventricle to Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021L0ZP	Bypass Left Ventricle to Pulmonary Trunk, Open Approach	Procedure	ICD-10-PCS
021L0ZQ	Bypass Left Ventricle to Right Pulmonary Artery, Open Approach	Procedure	ICD-10-PCS
021L0ZR	Bypass Left Ventricle to Left Pulmonary Artery, Open Approach	Procedure	ICD-10-PCS
021L48P	Bypass Left Ventricle to Pulmonary Trunk with Zooplastic Tissue, Percutaneous	Procedure	ICD-10-PCS
021L48Q	Endoscopic Approach Bypass Left Ventricle to Right Pulmonary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L48R	Bypass Left Ventricle to Left Pulmonary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L49P	Bypass Left Ventricle to Pulmonary Trunk with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 780 of 1023



		Code	
Code	Description	Category	Code Type
021L49Q	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
)21L49R	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021L4AP	Bypass Left Ventricle to Pulmonary Trunk with Autologous Arterial Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
021L4AQ	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021L4AR	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
021L4JP	Bypass Left Ventricle to Pulmonary Trunk with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
021L4JQ	Bypass Left Ventricle to Right Pulmonary Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
0	Endoscopic Approach		.02 20 . 00
021L4JR	Bypass Left Ventricle to Left Pulmonary Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
0211-311	Endoscopic Approach	rroccaare	100 10 1 03
021L4KP	Bypass Left Ventricle to Pulmonary Trunk with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
UZIL4KI	Percutaneous Endoscopic Approach	rrocedure	ICD-10-I C3
021L4KQ	Bypass Left Ventricle to Right Pulmonary Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
021L4NQ	Percutaneous Endoscopic Approach	rrocedure	100-10-1 03
021L4KR	Bypass Left Ventricle to Left Pulmonary Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
UZIL4KK		Procedure	ICD-10-PC3
0241.470	Percutaneous Endoscopic Approach Percutaneous Endoscopic Approach Percutaneous Endoscopic Approach	Dracadura	ICD 10 DCC
021L4Z8	Bypass Left Ventricle to Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4Z9	Bypass Left Ventricle to Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZC	Bypass Left Ventricle to Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZF	Bypass Left Ventricle to Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZP	Bypass Left Ventricle to Pulmonary Trunk, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZQ	Bypass Left Ventricle to Right Pulmonary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZR	Bypass Left Ventricle to Left Pulmonary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027004Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
027005Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
027006Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
027007Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0270072	Devices, Open Approach		102 10 1 03
02700D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Open	Procedure	ICD-10-PCS
0270000	Approach	rioccuure	100 10-1 03
02700DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700DZ 02700EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
J27 00LL	blactori of coronary Artery, one Artery with two intradminar bevices, Open Approach	rioccuure	100 10-1 03
02700F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
02/00/0		riocedule	1CD-10-4C2
	Open Approach		

cder_mpl1p_wp077 Page 781 of 1023



Toccaute	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
02700FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700Z6	Dilation of Coronary Artery, One Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02700ZZ	Dilation of Coronary Artery, One Artery, Open Approach	Procedure	ICD-10-PCS
027034Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027035Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027036Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027037Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027044Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027045Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027046Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 782 of 1023



riocedure	codes osed to Define baseline characteristics in this kequest	Code	
Code	Description	Category	Code Type
027047Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
02704D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02704DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02704EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0070456	Endoscopic Approach		ICD 40 DCC
02704F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
0270457	Percutaneous Endoscopic Approach Dilation of Caronary Artery One Artery with Three Introluminal Devices Percutaneous	Dracadura	ICD 10 DCS
02704FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
0270400	Devices, Percutaneous Endoscopic Approach	rioccaure	100 101 05
02704GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02704T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02704TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
027104Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
027105Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
027106Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0074077	Open Approach		100 10 000
027107Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0271000	Devices, Open Approach	Dunnadium	ICD 10 DCC
02710D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02710DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02710DZ 02710EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
02710FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
02710GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
02710T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal	Procedure	ICD-10-PCS
	Device, Open Approach		

cder_mpl1p_wp077 Page 783 of 1023



		Code	
Code	Description	Category	Code Type
02710TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02710Z6	Dilation of Coronary Artery, Two Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02710ZZ	Dilation of Coronary Artery, Two Arteries, Open Approach	Procedure	ICD-10-PCS
027134Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
027135Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027136Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027137Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
02713GZ	Devices, Percutaneous Approach Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
02713T6	Percutaneous Approach Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
027144Z	Percutaneous Approach Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
027145Z	Percutaneous Endoscopic Approach Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
027146Z	Percutaneous Endoscopic Approach Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
027147Z	Percutaneous Endoscopic Approach Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
02714D6	Devices, Percutaneous Endoscopic Approach Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
02714DZ	Percutaneous Endoscopic Approach Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 784 of 1023



Troccaure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
02714F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02714FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027204Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027205Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027206Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027207Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Open Approach		ICD-10-PCS
02720F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720Z6	Dilation of Coronary Artery, Three Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02720ZZ	Dilation of Coronary Artery, Three Arteries, Open Approach	Procedure	ICD-10-PCS
027234Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027235Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 785 of 1023



Toccadie	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
027236Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
027237Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
02723D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
0272207	Percutaneous Approach		100 40 000
02723DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
02723EZ	Approach Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
02/2362	Approach	riocedule	ICD-10-PC3
02723F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
0272310	Percutaneous Approach	rioccaure	100 101 05
02723FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
02723G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
02723GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
02723T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal	Procedure	ICD-10-PCS
	Device, Percutaneous Approach		
02723TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
0272447	Percutaneous Approach		100 40 000
027244Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
027245Z	Percutaneous Endoscopic Approach Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
02/2432	Percutaneous Endoscopic Approach	riocedule	ICD-10-PC3
027246Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
027247Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
02724D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02724DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02724EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0272456	Endoscopic Approach	Dunnadium	ICD 10 DCC
02724F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous	Drocadura	ICD-10-PCS
0272412	Endoscopic Approach	riocedure	ICD-10-FC3
02724G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
02724GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 786 of 1023



		Code	
Code	Description	Category	Code Type
02724T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal	Procedure	ICD-10-PCS
	Device, Percutaneous Endoscopic Approach		
02724TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
027304Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Open Approach		
027305Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
027306Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
027307Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		100 10 000
02730D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
0272007	Open Approach	Duagadiina	ICD 10 DCC
02730DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Open	Procedure	ICD-10-PCS
0272057	Approach Diletion of Coronary Artony, Four or More Artories with Two Introluminal Devices, Onen	Dracadura	ICD 10 DCC
02730EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal	Procedure	ICD-10-PCS
02730F0	Devices, Open Approach	riocedule	ICD-10-PC3
02730FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
0273012	Approach	Trocedure	100-10-1 03
02730G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More	Procedure	ICD-10-PCS
0273000	Intraluminal Devices, Open Approach	rroccaare	100 10 1 05
02730GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal	Procedure	ICD-10-PCS
0270002	Devices, Open Approach	1100000010	100 10 1 00
02730T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive	Procedure	ICD-10-PCS
	Intraluminal Device, Open Approach		
02730TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
	Open Approach		
02730Z6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02730ZZ	Dilation of Coronary Artery, Four or More Arteries, Open Approach	Procedure	ICD-10-PCS
027334Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
027335Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
027336Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
027337Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
02733D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
02733DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 787 of 1023



Troccadie	Codes osed to Define baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
02733EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
02733F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
02733FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
02733G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More	Procedure	ICD-10-PCS
0272267	Intraluminal Devices, Percutaneous Approach	Duagadiina	ICD 10 DCC
02733GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive	Procedure	ICD-10-PCS
02/3310	Intraluminal Device, Percutaneous Approach	riocedure	ICD-10-FC3
02733TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
027344Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
027345Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
027346Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
027347Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
02734D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
0272407	Percutaneous Endoscopic Approach Dilation of Caronary Artery Courses Mars Arteries with Introducinal Davies Bareutaneous	Dragodura	ICD 10 DCC
02734DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices,	Procedure	ICD-10-PCS
0275122	Percutaneous Endoscopic Approach	110000000	100 10 1 00
02734F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
02734FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
02734G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
02734GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
02734T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive	Procedure	ICD-10-PCS
0272477	Intraluminal Device, Percutaneous Endoscopic Approach	Duagadiina	ICD 10 DCC
02734TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device,	Procedure	ICD-10-PCS
02C00Z6	Percutaneous Endoscopic Approach Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C00Z0	Extirpation of Matter from Coronary Artery, One Artery, Open Approach	Procedure	ICD-10-PCS
02C03Z6	Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 788 of 1023



riocedure	Codes osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
02C03ZZ	Extirpation of Matter from Coronary Artery, One Artery, Percutaneous Approach	Procedure	ICD-10-PCS
02C04Z6	Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02C04ZZ	Extirpation of Matter from Coronary Artery, One Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02C10Z6	Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C10ZZ	Extirpation of Matter from Coronary Artery, Two Arteries, Open Approach	Procedure	ICD-10-PCS
02C13Z6	Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02C13ZZ	Extirpation of Matter from Coronary Artery, Two Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
02C14Z6	Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02C14ZZ	Extirpation of Matter from Coronary Artery, Two Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02C20Z6	Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C20ZZ	Extirpation of Matter from Coronary Artery, Three Arteries, Open Approach	Procedure	ICD-10-PCS
02C23Z6	Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
02C23ZZ	Approach Extirpation of Matter from Coronary Artery, Three Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
02C23ZZ 02C24Z6	Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
0202420	Endoscopic Approach	rroccaare	100 10 1 03
02C24ZZ	Extirpation of Matter from Coronary Artery, Three Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02C30Z6	Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation, Open	Procedure	ICD-10-PCS
0262077	Approach		160 40 066
02C30ZZ	Extirpation of Matter from Coronary Artery, Four or More Arteries, Open Approach Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation,	Procedure	ICD-10-PCS ICD-10-PCS
02C33Z6	Percutaneous Approach	Procedure	ICD-10-PC3
02C33ZZ	Extirpation of Matter from Coronary Artery, Four or More Arteries, Percutaneous	Procedure	ICD-10-PCS
0203322	Approach	rrocedure	ICD-10-I C3
02C34Z6	Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation,	Procedure	ICD-10-PCS
0200 .20	Percutaneous Endoscopic Approach		.02 20 . 00
02C34ZZ	Extirpation of Matter from Coronary Artery, Four or More Arteries, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
3E07017	Introduction of Other Thrombolytic into Coronary Artery, Open Approach	Procedure	ICD-10-PCS
3E070PZ	Introduction of Platelet Inhibitor into Coronary Artery, Open Approach	Procedure	ICD-10-PCS
3E07317	Introduction of Other Thrombolytic into Coronary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E073PZ	Introduction of Platelet Inhibitor into Coronary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
X2C0361	Extirpation of Matter from Coronary Artery, One Artery using Orbital Atherectomy	Procedure	ICD-10-PCS
	Technology, Percutaneous Approach, New Technology Group 1		
X2C1361	Extirpation of Matter from Coronary Artery, Two Arteries using Orbital Atherectomy	Procedure	ICD-10-PCS
	Technology, Percutaneous Approach, New Technology Group 1		

cder_mpl1p_wp077 Page 789 of 1023



		Code	
Code	Description	Category	Code Type
X2C2361	Extirpation of Matter from Coronary Artery, Three Arteries using Orbital Atherectomy	Procedure	ICD-10-PCS
	Technology, Percutaneous Approach, New Technology Group 1		
X2C3361	Extirpation of Matter from Coronary Artery, Four or More Arteries using Orbital	Procedure	ICD-10-PCS
	Atherectomy Technology, Percutaneous Approach, New Technology Group 1		
33510	Coronary artery bypass, vein only; single coronary venous graft	Procedure	CPT-4
33511	Coronary artery bypass, vein only; 2 coronary venous grafts	Procedure	CPT-4
33512	Coronary artery bypass, vein only; 3 coronary venous grafts	Procedure	CPT-4
33513	Coronary artery bypass, vein only; 4 coronary venous grafts	Procedure	CPT-4
33514	Coronary artery bypass, vein only; 5 coronary venous grafts	Procedure	CPT-4
33516	Coronary artery bypass, vein only; 6 or more coronary venous grafts	Procedure	CPT-4
33517	Coronary artery bypass, using venous graft(s) and arterial graft(s); single vein graft (List	Procedure	CPT-4
	separately in addition to code for primary procedure)		
33518	Coronary artery bypass, using venous graft(s) and arterial graft(s); 2 venous grafts (List	Procedure	CPT-4
	separately in addition to code for primary procedure)		
33519	Coronary artery bypass, using venous graft(s) and arterial graft(s); 3 venous grafts (List	Procedure	CPT-4
	separately in addition to code for primary procedure)		-
33520	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Single Graft	Procedure	CPT-4
33320	coronary Artery bypass, Norlautogenous Graft (eg, Synthetic Or Cadaver), Single Graft	rrocedure	CI I-4
22524	Coronary artery bypass, using vanous graft(s) and arterial graft(s). A vanous grafts (List	Procedure	CDT 4
33521	Coronary artery bypass, using venous graft(s) and arterial graft(s); 4 venous grafts (List	Procedure	CPT-4
	separately in addition to code for primary procedure)		
33522	Coronary artery bypass, using venous graft(s) and arterial graft(s); 5 venous grafts (List	Procedure	CPT-4
	separately in addition to code for primary procedure)		
33523	Coronary artery bypass, using venous graft(s) and arterial graft(s); 6 or more venous grafts	Procedure	CPT-4
	(List separately in addition to code for primary procedure)		
33525	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Two Coronary	Procedure	CPT-4
	Grafts		
33528	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Three Or More	Procedure	CPT-4
	Coronary Grafts		
33530	Reoperation, coronary artery bypass procedure or valve procedure, more than 1 month	Procedure	CPT-4
	after original operation (List separately in addition to code for primary procedure)		
	and on give a separation (List separation) in dual tion to dead for primary products of		
22522	Caranamy artemy by mass, using arterial graft/s), single arterial graft	Dracadura	CPT-4
33533 33534	Coronary artery bypass, using arterial graft(s); single arterial graft Coronary artery bypass, using arterial graft(s); 2 coronary arterial grafts	Procedure Procedure	CPT-4 CPT-4
33535 33535	Coronary artery bypass, using arterial graft(s), 2 coronary arterial grafts	Procedure	CPT-4 CPT-4
33536	Coronary artery bypass, using arterial graft(s), 3 coronary arterial grafts	Procedure	CPT-4 CPT-4
33560	Myocardial Operation Combined With Coronary Bypass Procedure	Procedure	CPT-4
33570	CORONARY ANGIOPLASTY W/BYPASS	Procedure	CPT-4
33572	Coronary endarterectomy, open, any method, of left anterior descending, circumflex, or	Procedure	CPT-4
0007_	right coronary artery performed in conjunction with coronary artery bypass graft		C.
	procedure, each vessel (List separately in addition to primary procedure)		
	procedure, each vessel (List separately in addition to primary procedure)		
33575	CORON ANGIOPLSTY W/BYPASS; COMBO W/VASCULARIZAT	Procedure	CPT-4
35600	Harvest of upper extremity artery, 1 segment, for coronary artery bypass procedure (List	Procedure	CPT-4
	separately in addition to code for primary procedure)		

cder_mpl1p_wp077 Page 790 of 1023



		Code	
Code	Description	Category	Code Type
92920	Percutaneous transluminal coronary angioplasty; single major coronary artery or branch	Procedure	CPT-4
92921	Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92924	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92925	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92928	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92929	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92933	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92934	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92937	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel	Procedure	CPT-4
92938	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
92941	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel	Procedure	CPT-4
92943	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; single vessel	Procedure ,	CPT-4
92944	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
92973	Percutaneous transluminal coronary thrombectomy mechanical (List separately in addition to code for primary procedure)	Procedure	CPT-4

cder_mpl1p_wp077 Page 791 of 1023



		Code	
Code	Description	Category	Code Type
92974	Transcatheter placement of radiation delivery device for subsequent coronary	Procedure	CPT-4
02077	intravascular brachytherapy (List separately in addition to code for primary procedure)	5 .	CDT 4
92977	Thrombolysis, coronary; by intravenous infusion	Procedure	CPT-4
92980	Transcatheter placement of an intracoronary stent(s), percutaneous, with or without	Procedure	CPT-4
22224	other therapeutic intervention, any method; single vessel		ODT 4
92981	Transcatheter placement of an intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
92982	Percutaneous transluminal coronary balloon angioplasty; single vessel	Procedure	CPT-4
92984	Percutaneous transluminal coronary balloon angioplasty; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
92995	Percutaneous transluminal coronary atherectomy, by mechanical or other method, with or without balloon angioplasty; single vessel	Procedure	CPT-4
92996	Percutaneous transluminal coronary atherectomy, by mechanical or other method, with or without balloon angioplasty; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
C1034	Catheter, coronary angioplasty, surpass superfusion catheter, long 30 surpass superfusion catheter	Procedure	HCPCS
C1100	Guide wire, percutaneous transluminal coronary angioplasty, medtronic ave gt1 guide wire, medtronic ave gt2 fusion guide wire, interventional technologies trackwire, interventional technologies trackwire support, interventional technologies trackwire extra support	Procedure	HCPCS
C1101	Catheter, percutaneous transluminal coronary angioplasty guide, medtronic ave 5f, 6f, 7f, 8f, 9f zuma guide catheter, medtronic ave z2 5f, 6f, 7f, 8f, 9f zuma guide catheter, medtronic ave vector x guide catheter. note: only the medtronic ave z2 zuma guide catheters are effective october 1, 2000. the medtronic ave zuma guide catheters were effective august 1, 2000.	Procedure	HCPCS
C1366	Guide wire, percutaneous transluminal coronary angioplasty, hi-torque iron man, hi-torque balance middleweight, hi-torque all star, hi-torque balance heavyweight, hi-torque balance trek	Procedure	HCPCS
C1367	Guide wire, percutaneous transluminal coronary angioplasty, hi-torque cross it, hi-torque cross-it 100xt, hi-torque cross-it 200xt, hi-torque cross-it 300xt, hi-torque wiggle	Procedure	HCPCS
C1500	Atherectomy system, peripheral, rotablator rotational angioplasty system with rotalink exchangeable catheter, advancer, and guide wire	Procedure	HCPCS
C1725	Catheter, transluminal angioplasty, nonlaser (may include guidance, infusion/perfusion capability)	Procedure	HCPCS
C1885 C1930	Catheter, transluminal angioplasty, laser Catheter, percutaneous transluminal coronary angioplasty, coyote dilatation catheter 20mm/30mm/40mm	Procedure Procedure	HCPCS HCPCS

cder_mpl1p_wp077 Page 792 of 1023



		Code	
Code	Description	Category	Code Type
C1933	Catheter, opti-plast centurion 5.5f pta catheter (shaft length 50 cm to 120 cm), opti-plast xl 5.5f pta catheter (shaft length 75 cm to 120 cm), opti-plast pta catheter (5.5 fr), tru trac 5fr percutaneous transluminal angioplasty balloon dilatation catheter, optiplast xt 5 fr percutaneous transluminal angioplasty catheter (various sizes)	Procedure	HCPCS
C1948	Catheter, pursuit balloon angioplasty catheter, cook accent balloon angioplasty catheter	Procedure	HCPCS
C1981	Catheter ,coronary angioplasty balloon, adante, bonnie, bonnie 15mm, bonnie monorail 30mm or 40mm, bonnie sliding rail, bypass speedy, chubby, chubby sliding rail, coyote 20mm, coyote 9/15/25mm, maxxum, nc ranger, nc ranger 9mm, ranger 20mm, long ranger 30mm or 40mm, nc ranger 16/18mm, nc ranger 22/25/30mm, nc big ranger, quantum ranger, quantum ranger 1/4 sizes, quantum ranger 9/16/18mm, quantum ranger 22/30mm, quantum ranger 25mm, ranger lp 20/30/40, viva/long viva, ace - 1cm, ace - 2cm, ace graft, long ace, pivot cobra (10, 14, 18, 30, 40mm in lengths) note: only the bonnie monorail 30mm or 40mm, long ranger 30mm or 40mm, and ranger 20mm are effective 01/01/01. the other catheters were effective 08/01/00.	Procedure	HCPCS
C2605	Catheter, spectranetics extreme laser catheter, spectranetics extreme 0.9mm coronary angioplasty catheter (model 110-001)	Procedure	HCPCS
C2623	Catheter, transluminal angioplasty, drug-coated, nonlaser	Procedure	HCPCS
C3551	Guide wire, percutaneous transluminal coronary angioplasty, choice, luge, patriot, pt graphix intermediate, trooper, mailman 182/300 cm, glidewire gold guidewire, platinum plus guidewire, platinum plus guidewire with glidex hydrophilic coating, jagwire single-use high performance guide wire, merit medical systems extender guidewire, merit medical systems tomcat ptca guidewire, platinum plus guidewire (0.014 and 0.018 in diameters)	Procedure	HCPCS
C8526 C9600	Optiplast xt 5f percutaneous transluminal angioplasty catheter (various sizes) Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure Procedure	HCPCS HCPCS
C9601	Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9602	Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9603	Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9604	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel	Procedure	HCPCS

cder_mpl1p_wp077 Page 793 of 1023



	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
C9605	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9606	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel	Procedure	HCPCS
C9607	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	HCPCS
C9608	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (list separately in addition to code for primary	Procedure	HCPCS
G0290	Transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel	Procedure	HCPCS
G0291	Transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel	Procedure	HCPCS
52205	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), single coronary arterial graft	Procedure	HCPCS
52206	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), 2 coronary arterial grafts	Procedure	HCPCS
52207	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using venous graft only, single coronary venous graft	Procedure	HCPCS
52208	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using single arterial and venous graft(s), single venous graft	Procedure	HCPCS
52209	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using 2 arterial grafts and single venous graft	Procedure	HCPCS
	Left Ventricular Hypertrophy		
42.1 42.2 51.7	Obstructive hypertrophic cardiomyopathy Other hypertrophic cardiomyopathy Cardiomegaly	Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM ICD-10-CM
170.4	Peripheral Artery Disease	Dia :	ICD 40 Ch:
170.1 170.201	Atherosclerosis of renal artery Unspecified atherosclerosis of native arteries of extremities, right leg	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM

cder_mpl1p_wp077 Page 794 of 1023



riocedure	Codes osed to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
170.202	Unspecified atherosclerosis of native arteries of extremities, left leg	Diagnosis	ICD-10-CM
170.203	Unspecified atherosclerosis of native arteries of extremities, bilateral legs	Diagnosis	ICD-10-CM
170.208	Unspecified atherosclerosis of native arteries of extremities, other extremity	Diagnosis	ICD-10-CM
170.209	Unspecified atherosclerosis of native arteries of extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.211	Atherosclerosis of native arteries of extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
		Ü	
170.212	Atherosclerosis of native arteries of extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
170.213	Atherosclerosis of native arteries of extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
170.218	Atherosclerosis of native arteries of extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
170.219	Atherosclerosis of native arteries of extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
170.221	Atherosclerosis of native arteries of extremities with rest pain, right leg	Diagnosis	ICD-10-CM
170.222	Atherosclerosis of native arteries of extremities with rest pain, left leg	Diagnosis	ICD-10-CM
170.223	Atherosclerosis of native arteries of extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
170.228	Atherosclerosis of native arteries of extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
170.229	Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
170.231	Atherosclerosis of native arteries of right leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.232	Atherosclerosis of native arteries of right leg with ulceration of calf	Diagnosis	ICD-10-CM
170.233	Atherosclerosis of native arteries of right leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.234	Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.235	Atherosclerosis of native arteries of right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.238	Atherosclerosis of native arteries of right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.239	Atherosclerosis of native arteries of right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.241	Atherosclerosis of native arteries of left leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.242	Atherosclerosis of native arteries of left leg with ulceration of calf	Diagnosis	ICD-10-CM
170.243	Atherosclerosis of native arteries of left leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.244	Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.245	Atherosclerosis of native arteries of left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.248	Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.249	Atherosclerosis of native arteries of left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.25	Atherosclerosis of native arteries of other extremities with ulceration	Diagnosis	ICD-10-CM
170.261	Atherosclerosis of native arteries of extremities with gangrene, right leg	Diagnosis	ICD-10-CM
170.262	Atherosclerosis of native arteries of extremities with gangrene, left leg	Diagnosis	ICD-10-CM
170.263	Atherosclerosis of native arteries of extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
170.268	Atherosclerosis of native arteries of extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
170.269	Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
170 204	Ohban ahban andan air af nativa antania af antananith a minit la	Diame!-	ICD 10 CM
170.291	Other atherosclerosis of native arteries of extremities, right leg	Diagnosis	ICD-10-CM
170.292	Other atherosclerosis of native arteries of extremities, left leg	Diagnosis	ICD-10-CM
170.293	Other atherosclerosis of native arteries of extremities, bilateral legs	Diagnosis	ICD-10-CM
170.298	Other atherosclerosis of native arteries of extremities, other extremity	Diagnosis	ICD-10-CM
170.299	Other atherosclerosis of native arteries of extremities, unspecified extremity	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 795 of 1023



riocedure	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
170.301	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
170.302	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
170.303	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.308	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
170.309	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.311	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
170.312	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
170.313	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
170.318	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
170.319	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
170.321	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
170.322	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
170.323	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
170.328	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
170.329	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
170.331	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.332	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
170.333	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.334	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.335	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.338	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 796 of 1023



	codes Oseu to Define Basenne Characteristics in this nequest	Code	
Code	Description	Category	Code Type
170.339	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.341	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.342	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
170.343	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.344	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.345	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.348	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.349	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.35	Atherosclerosis of unspecified type of bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
170.361	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
170.362	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
170.363	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
170.368	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
170.369	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
170.391	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
170.392	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
170.393	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.398	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
170.399	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.501	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
170.502	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 797 of 1023



		Code	
Code	Description	Category	Code Type
170.503	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.508	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
170.509	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.511	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
170.512	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
170.513	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
170.518	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
170.519	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
170.521	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
170.522	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
170.523	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
170.528	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
170.529	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
170.531	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.532	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
170.533	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.534	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.535	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.538	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.539	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.541	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 798 of 1023



		Code	
Code	Description	Category	Code Type
170.542	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
170.543	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.544	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.545	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.548	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.549	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.55	Atherosclerosis of nonautologous biological bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
170.561	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
170.562	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
170.563	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
170.568	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
170.569	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
170.591	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
170.592	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
170.593	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.598	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
170.599	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.601	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
170.602	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
170.603	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.608	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 799 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
170.609	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.611	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
170.612	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
170.613	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
170.618	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
170.619	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
170.621	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
170.622	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
170.623	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
170.628	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
170.629	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
170.631	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.632	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
170.633	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.634	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.635	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.638	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.639	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.641	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.642 170.643	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of calf Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of ankle	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM

cder_mpl1p_wp077 Page 800 of 1023



		Code	
Code	Description	Category	Code Type
170.644	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.645	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.648	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.649	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.65	Atherosclerosis of nonbiological bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
170.661	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
170.662	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
170.663	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
170.668	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
170.669	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
170.691	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
170.692	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
170.693	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.698	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
170.699	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.701	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
170.702	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
170.703	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.708	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
170.709	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.711	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
170.712	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 801 of 1023



	e Codes Used to Define Baseline Characteristics in this Request C		
Code	Description	Category	Code Type
170.713	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
170.718	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
170.719	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
170.721	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
170.722	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
170.723	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
170.728	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
170.729	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
170.731	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.732 170.733	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of calf Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of ankle	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
170.734	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.735	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.738	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.739	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.741	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.742	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
170.743	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.744	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.745	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.748	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.749	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.75	Atherosclerosis of other type of bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 802 of 1023



	·	Code	
Code	Description	Category	Code Type
170.761	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
170.762	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
170.763	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
170.768	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
170.769	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
170.791	Other atherosclerosis of other type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
170.792	Other atherosclerosis of other type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
170.793	Other atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
170.798	Other atherosclerosis of other type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
170.799	Other atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
170.8	Atherosclerosis of other arteries	Diagnosis	ICD-10-CM
170.90	Unspecified atherosclerosis	Diagnosis	ICD-10-CM
170.91	Generalized atherosclerosis	Diagnosis	ICD-10-CM
170.92	Chronic total occlusion of artery of the extremities	Diagnosis	ICD-10-CM
172.0	Aneurysm of carotid artery	Diagnosis	ICD-10-CM
172.1	Aneurysm of artery of upper extremity	Diagnosis	ICD-10-CM
172.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
172.3	Aneurysm of iliac artery	Diagnosis	ICD-10-CM
172.4	Aneurysm of artery of lower extremity	Diagnosis	ICD-10-CM
172.8	Aneurysm of other specified arteries	Diagnosis	ICD-10-CM
172.9	Aneurysm of unspecified site	Diagnosis	ICD-10-CM
173.89	Other specified peripheral vascular diseases	Diagnosis	ICD-10-CM
173.9	Peripheral vascular disease, unspecified	Diagnosis	ICD-10-CM
177.71	Dissection of carotid artery	Diagnosis	ICD-10-CM
177.72	Dissection of iliac artery	Diagnosis	ICD-10-CM
177.73	Dissection of renal artery	Diagnosis	ICD-10-CM
177.74	Dissection of vertebral artery	Diagnosis	ICD-10-CM
177.79	Dissection of other specified artery	Diagnosis	ICD-10-CM
179.8	Other disorders of arteries, arterioles and capillaries in diseases classified elsewhere	Diagnosis	ICD-10-CM
Z95.820	Peripheral vascular angioplasty status with implants and grafts	Diagnosis	ICD-10-CM
Z95.828	Presence of other vascular implants and grafts	Diagnosis	ICD-10-CM
0312090	Bypass Innominate Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312091	Bypass Innominate Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 803 of 1023



riocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
0312092	Bypass Innominate Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312093	Bypass Innominate Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312094	Bypass Innominate Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312095	Bypass Innominate Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312096	Bypass Innominate Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312097	Bypass Innominate Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312098	Bypass Innominate Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312099	Bypass Innominate Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313090	Bypass Right Subclavian Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313091	Bypass Right Subclavian Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313092	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313093	Bypass Right Subclavian Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313094	Bypass Right Subclavian Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313095	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313096	Bypass Right Subclavian Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313097	Bypass Right Subclavian Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313098	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313099	Bypass Right Subclavian Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314090	Bypass Left Subclavian Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314091	Bypass Left Subclavian Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314092	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 804 of 1023



	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
0314093	Bypass Left Subclavian Artery to Right Lower Arm Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0244004	Open Approach		100 40 000
0314094	Bypass Left Subclavian Artery to Left Lower Arm Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0314095	Open Approach Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Autologous Venous	Procedure	ICD-10-PCS
0314093	Tissue, Open Approach	riocedure	ICD-10-PC3
0314096	Bypass Left Subclavian Artery to Right Upper Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0314097	Bypass Left Subclavian Artery to Left Upper Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0314098	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		
0314099	Bypass Left Subclavian Artery to Right Lower Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0315090	Bypass Right Axillary Artery to Right Upper Arm Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0215001	Open Approach Bypass Right Axillary Artery to Left Upper Arm Artery with Autologous Venous Tissue,	Drocoduro	ICD 10 DCS
0315091	Open Approach	Procedure	ICD-10-PCS
0315092	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0010001	Open Approach		.02 20 . 00
0315093	Bypass Right Axillary Artery to Right Lower Arm Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0315094	Bypass Right Axillary Artery to Left Lower Arm Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0315095	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0045006	Open Approach		100 10 000
0315096	Bypass Right Axillary Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315097	Bypass Right Axillary Artery to Left Upper Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0313037	Open Approach	rrocedure	1CD-10-1 C3
0315098	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0315099	Bypass Right Axillary Artery to Right Lower Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0316090	Bypass Left Axillary Artery to Right Upper Arm Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0316091	Bypass Left Axillary Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
0316092	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0316003	Open Approach Bypass Left Axillary Artery to Right Lower Arm Artery with Autologous Venous Tissue,	Procedure	ICD. 10 PCS
0316093	Open Approach	riocedure	ICD-10-PCS
	open/approach		

cder_mpl1p_wp077 Page 805 of 1023



	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
0316094	Bypass Left Axillary Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316095	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316096	Bypass Left Axillary Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316097	Bypass Left Axillary Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316098	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316099	Bypass Left Axillary Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0317090	Bypass Right Brachial Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0317093	Bypass Right Brachial Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0318091	Bypass Left Brachial Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0318094	Bypass Left Brachial Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0319093	Bypass Right Ulnar Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0373046	Dilation of Right Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0373056	Dilation of Right Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0373066	Dilation of Right Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0373076	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0373346	Dilation of Right Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0373356	Dilation of Right Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0373366	Dilation of Right Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0373376	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0373446	Dilation of Right Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0373456	Dilation of Right Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 806 of 1023



Troccaure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
0373466	Dilation of Right Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
0373476	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
0274046	Intraluminal Devices, Percutaneous Endoscopic Approach	Dragodura	ICD 10 DCS
0374046	Dilation of Left Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0374056	Dilation of Left Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
0374066	Dilation of Left Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
0374076	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
0374346	Dilation of Left Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0374356	Dilation of Left Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0274266	Percutaneous Approach	Dunandous	ICD 40 DCC
0374366	Dilation of Left Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0374376	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
0374370	Intraluminal Devices, Percutaneous Approach	rrocedure	100-10-1 05
0374446	Dilation of Left Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0374456	Dilation of Left Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0374466	Dilation of Left Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
0374476	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
0375046	Dilation of Right Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
0375056	Dilation of Right Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0275066	Open Approach	Dunnadium	ICD 10 DCC
0375066	Dilation of Right Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0375076	Dilation of Right Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
03/30/0	Devices, Open Approach	riocedure	ICD-10-FC3
0375346	Dilation of Right Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0373310	Percutaneous Approach	rioccaare	100 10 1 00
0375356	Dilation of Right Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0375366	Dilation of Right Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		

cder_mpl1p_wp077 Page 807 of 1023



	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
0375376	Dilation of Right Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0375446	Dilation of Right Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0375456	Dilation of Right Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0375466	Dilation of Right Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0375476	Dilation of Right Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0376046	Dilation of Left Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0376056	Dilation of Left Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0376066	Dilation of Left Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0376076	Dilation of Left Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0376346	Dilation of Left Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0376356	Dilation of Left Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0376366	Dilation of Left Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0376376	Dilation of Left Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0376446	Dilation of Left Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0376456	Dilation of Left Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0376466	Dilation of Left Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0376476	Dilation of Left Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0377046		Procedure	ICD-10-PCS
0377056	Dilation of Right Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0377066	Dilation of Right Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0377076	Dilation of Right Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 808 of 1023



riocedure	Codes Osed to Define basefine Characteristics in this nequest	Code	
Code	Description	Category	Code Type
0377346	Dilation of Right Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0377356	Dilation of Right Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0377366	Dilation of Right Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0377376	Devices, Percutaneous Approach Dilation of Right Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
03//3/0	Devices, Percutaneous Approach	riocedule	ICD-10-PC3
0377446	Dilation of Right Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		.02 20 . 00
0377456	Dilation of Right Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0377466	Dilation of Right Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
0377476	Dilation of Right Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
0378046	Dilation of Left Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
0270056	Approach	Dua aa duus	ICD 10 DCC
0378056	Dilation of Left Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0378066	Dilation of Left Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
037000	Open Approach	110000000	102 10 1 00
0378076	Dilation of Left Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
0378346	Dilation of Left Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0378356	Dilation of Left Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0070066	Percutaneous Approach		105 10 500
0378366	Dilation of Left Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0378376	Percutaneous Approach Dilation of Left Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
03/63/0	Devices, Percutaneous Approach	Procedure	ICD-10-PC3
0378446	Dilation of Left Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0370110	Percutaneous Endoscopic Approach	110000000	102 10 1 00
0378456	Dilation of Left Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0378466	Dilation of Left Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0378476	Dilation of Left Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
0379046	Dilation of Right Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 809 of 1023



	<u> </u>	Code	
Code	Description	Category	Code Type
0379056	Dilation of Right Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
0379066	Dilation of Right Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0270076	Open Approach	Dunnadii	ICD 10 DCS
0379076	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0379346	Dilation of Right Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0373340	Percutaneous Approach	Troccaure	100 10 1 05
0379356	Dilation of Right Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0379366	Dilation of Right Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0379376	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
0379446	Dilation of Right Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0379456	Dilation of Right Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0270466	Percutaneous Endoscopic Approach		100 40 000
0379466	Dilation of Right Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0379476	Percutaneous Endoscopic Approach Dilation of Right Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
03/34/0	Devices, Percutaneous Endoscopic Approach	riocedule	10-10-103
0410096	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0410097	Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
0410098	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		
0410099	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0440406	Open Approach		100 10 000
0410496	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0410497	Percutaneous Endoscopic Approach Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0410437	Percutaneous Endoscopic Approach	riocedule	ICD-10-PC3
0410498	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
0410499	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0470046	Dilation of Abdominal Aorta, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
0470056	Dilation of Abdominal Aorta, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		

cder_mpl1p_wp077 Page 810 of 1023



riocedure	Codes Osed to Define basefine Characteristics in this nequest	Code	
Code	Description	Category	Code Type
0470066	Dilation of Abdominal Aorta, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
0470076	Dilation of Abdominal Aorta, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
0470346	Dilation of Abdominal Aorta, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0470356	Dilation of Abdominal Aorta, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0470330	Percutaneous Approach	riocedule	ICD-10-FC3
0470366	Dilation of Abdominal Aorta, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
0470376	Dilation of Abdominal Aorta, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
0470446	Dilation of Abdominal Aorta, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0470456	Dilation of Abdominal Aorta, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
0470466	Dilation of Abdominal Aorta, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0470476	Percutaneous Endoscopic Approach Dilation of Abdominal Aorta, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
04/04/0	Devices, Percutaneous Endoscopic Approach	riocedule	ICD-10-PC3
03730E6	Dilation of Right Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
03733E6	Dilation of Right Subclavian Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03734E6	Dilation of Right Subclavian Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03740E6	Dilation of Left Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
03743E6	Approach Dilation of Left Subclavian Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
0374320	Percutaneous Approach	riocedule	ICD-10-PC3
03744E6	Dilation of Left Subclavian Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03750E6	Dilation of Right Axillary Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
03753E6	Dilation of Right Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03754E6	Dilation of Right Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03760E6	Dilation of Left Axillary Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03763E6	Dilation of Left Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
337 JJLU	Approach	Toccuure	.00 10 1 03
	• •		

cder_mpl1p_wp077 Page 811 of 1023



	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
03764E6	Dilation of Left Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
03770E6	Endoscopic Approach Dilation of Right Brachial Artery, Bifurcation, with Two Intraluminal Devices, Open	Dracadura	ICD-10-PCS
0377020	Approach	Procedure	ICD-10-PC3
03773E6	Dilation of Right Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03774E6	Dilation of Right Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03780E6	Dilation of Left Brachial Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
03783E6	Approach Dilation of Left Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0370320	Approach	Troccaure	100 101 05
03784E6	Dilation of Left Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03790E6	Dilation of Right Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03793E6	Dilation of Right Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0373320	Approach	Trocedure	1CD-10-1 C3
03794E6	Dilation of Right Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
04700E6	Dilation of Abdominal Aorta, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
04703E6	Dilation of Abdominal Aorta, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0470320	Approach	Troccaure	100 101 05
04704E6	Dilation of Abdominal Aorta, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047E041	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
047E046	Coated Balloon, Open Approach Dilation of Right Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0472040	Open Approach	Trocedure	1CD-10-1 C3
047E056	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047E066	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0475076	Devices, Open Approach Diletion of Right Internal High Artery Differentian with Four or More Drug cluting	Dragodura	ICD 10 DCC
047E076	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
031209B	Bypass Innominate Artery to Left Lower Leg Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
031209C	Bypass Innominate Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		.==
03120A0	Bypass Innominate Artery to Right Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		

cder_mpl1p_wp077 Page 812 of 1023



	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
03120A1	Bypass Innominate Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A2	Bypass Innominate Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A3	Bypass Innominate Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A4	Bypass Innominate Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A5	Bypass Innominate Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A6	Bypass Innominate Artery to Right Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A7	Bypass Innominate Artery to Left Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A8	Bypass Innominate Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A9	Bypass Innominate Artery to Right Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120AB	Bypass Innominate Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120AC	Bypass Innominate Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120J0	Bypass Innominate Artery to Right Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J1	Bypass Innominate Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J2	Bypass Innominate Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J3	Bypass Innominate Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J4	Bypass Innominate Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J5	Bypass Innominate Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J6	Bypass Innominate Artery to Right Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J7	Bypass Innominate Artery to Left Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J8	Bypass Innominate Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J9	Bypass Innominate Artery to Right Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 813 of 1023



riocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
03120JB	Bypass Innominate Artery to Left Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03120JC	Bypass Innominate Artery to Bilateral Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03120K0	Bypass Innominate Artery to Right Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03120K1	Bypass Innominate Artery to Left Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
001101	Substitute, Open Approach		.02 20 . 00
03120K2	Bypass Innominate Artery to Bilateral Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
OSIZORZ	Substitute, Open Approach	rroccaare	100 10 1 05
03120K3	Bypass Innominate Artery to Right Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
U312UN3	Substitute, Open Approach	riocedule	ICD-10-PC3
0212014		Drocoduro	ICD 10 DCS
03120K4	Bypass Innominate Artery to Left Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0242045	Substitute, Open Approach	Dunnali	ICD 40 DCC
03120K5	Bypass Innominate Artery to Bilateral Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03120K6	Bypass Innominate Artery to Right Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03120K7	Bypass Innominate Artery to Left Upper Leg Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
03120K8	Bypass Innominate Artery to Bilateral Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03120K9	Bypass Innominate Artery to Right Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03120KB	Bypass Innominate Artery to Left Lower Leg Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
03120KC	Bypass Innominate Artery to Bilateral Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03120Z0	Bypass Innominate Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z1	Bypass Innominate Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z2	Bypass Innominate Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z3	Bypass Innominate Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z4	Bypass Innominate Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z5	Bypass Innominate Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z6	Bypass Innominate Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03120Z7	Bypass Innominate Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03120Z8	Bypass Innominate Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03120Z9	Bypass Innominate Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03120ZB	Bypass Innominate Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03120ZB 03120ZC	Bypass Innominate Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
	Bypass Right Subclavian Artery to Left Lower Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
031309B		riocedule	10-10-403
0212000	Open Approach Press Right Subglavian Artery to Bilateral Lewer Lea Artery with Autologous Veneus	Dropodii	ICD 10 DCC
031309C	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		

cder_mpl1p_wp077 Page 814 of 1023



Toccadie	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
03130A0	Bypass Right Subclavian Artery to Right Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03130A1	Bypass Right Subclavian Artery to Left Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03130A2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Autologous Arterial	Procedure	ICD-10-PCS
0242042	Tissue, Open Approach	Dunanduun	ICD 10 DCC
03130A3	Bypass Right Subclavian Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A4	Bypass Right Subclavian Artery to Left Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0313074	Open Approach	Trocedure	1CD-10-1 C3
03130A5	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Autologous Arterial	Procedure	ICD-10-PCS
002007.0	Tissue, Open Approach		.02 20 . 00
03130A6	Bypass Right Subclavian Artery to Right Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03130A7	Bypass Right Subclavian Artery to Left Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03130A8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
03130A9	Bypass Right Subclavian Artery to Right Lower Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0242040	Open Approach		160 40 066
03130AB	Bypass Right Subclavian Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130AC	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery with Autologous Arterial	Procedure	ICD-10-PCS
03130AC	Tissue, Open Approach	riocedure	ICD-10-PC3
03130J0	Bypass Right Subclavian Artery to Right Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
002000	Approach		.02 20 . 00
03130J1	Bypass Right Subclavian Artery to Left Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03130J2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
03130J3	Bypass Right Subclavian Artery to Right Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03130J4	Bypass Right Subclavian Artery to Left Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0212015	Approach Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Synthetic Substitute,	Drocoduro	ICD 10 DCS
03130J5	Open Approach	Procedure	ICD-10-PCS
03130J6	Bypass Right Subclavian Artery to Right Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0313030	Approach	rroccaare	100 10 1 00
03130J7	Bypass Right Subclavian Artery to Left Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03130J8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
03130J9	Bypass Right Subclavian Artery to Right Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 815 of 1023



riocedure	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
03130JB	Bypass Right Subclavian Artery to Left Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03130JC	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
03130K0	Bypass Right Subclavian Artery to Right Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K1	Bypass Right Subclavian Artery to Left Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K3	Bypass Right Subclavian Artery to Right Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K4	Bypass Right Subclavian Artery to Left Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K5	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K6	Bypass Right Subclavian Artery to Right Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K7	Bypass Right Subclavian Artery to Left Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130K9	Bypass Right Subclavian Artery to Right Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130KB	Bypass Right Subclavian Artery to Left Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130KC	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03130Z0	Bypass Right Subclavian Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z1	Bypass Right Subclavian Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z3	Bypass Right Subclavian Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z4	Bypass Right Subclavian Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z5	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z6 03130Z7	Bypass Right Subclavian Artery to Right Upper Leg Artery, Open Approach Bypass Right Subclavian Artery to Left Upper Leg Artery, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
03130Z7 03130Z8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130Z8 03130Z9	Bypass Right Subclavian Artery to Bilateral Opper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130ZB	Bypass Right Subclavian Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130ZC	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
031409B	Bypass Left Subclavian Artery to Left Lower Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
031409C	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		

cder_mpl1p_wp077 Page 816 of 1023



	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
03140A0	Bypass Left Subclavian Artery to Right Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03140A1	Bypass Left Subclavian Artery to Left Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03140A2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Autologous Arterial	Procedure	ICD-10-PCS
0244042	Tissue, Open Approach		100 40 000
03140A3	Bypass Left Subclavian Artery to Right Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
03140A4	Open Approach Bypass Left Subclavian Artery to Left Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
U314UA4	Open Approach	riocedule	ICD-10-PC3
03140A5	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Autologous Arterial	Procedure	ICD-10-PCS
03140/3	Tissue, Open Approach	rroccaarc	100 101 05
03140A6	Bypass Left Subclavian Artery to Right Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03140A7	Bypass Left Subclavian Artery to Left Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03140A8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
03140A9	Bypass Left Subclavian Artery to Right Lower Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03140AB	Bypass Left Subclavian Artery to Left Lower Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0244046	Open Approach		100 40 000
03140AC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Autologous Arterial	Procedure	ICD-10-PCS
03140J0	Tissue, Open Approach Bypass Left Subclavian Artery to Right Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0314010	Approach	riocedule	ICD-10-PC3
03140J1	Bypass Left Subclavian Artery to Left Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
001.001	Approach		.02 20 . 00
03140J2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
03140J3	Bypass Left Subclavian Artery to Right Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03140J4	Bypass Left Subclavian Artery to Left Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03140J5	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
03140J6	Bypass Left Subclavian Artery to Right Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0214017	Approach Proposed off Subglavian Artery to Left Hanney Leg Artery with Sunthetic Substitute Open	Dragodura	ICD 10 DCC
03140J7	Bypass Left Subclavian Artery to Left Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
3317010	Open Approach	rioccuare	.00 10 1 03
03140J9	Bypass Left Subclavian Artery to Right Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 817 of 1023



		Code	
Code	Description	Category	Code Type
03140JB	Bypass Left Subclavian Artery to Left Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03140JC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
03140K0	Bypass Left Subclavian Artery to Right Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03140K1	Bypass Left Subclavian Artery to Left Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03140K2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03140K3	Bypass Left Subclavian Artery to Right Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03140K4	Bypass Left Subclavian Artery to Left Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03140K5	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03140K6	Bypass Left Subclavian Artery to Right Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03140K7	Bypass Left Subclavian Artery to Left Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03140K8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03140K9	Bypass Left Subclavian Artery to Right Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03140KB	Bypass Left Subclavian Artery to Left Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03140KC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03140Z0	Bypass Left Subclavian Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z1	Bypass Left Subclavian Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z3 03140Z4	Bypass Left Subclavian Artery to Right Lower Arm Artery, Open Approach Bypass Left Subclavian Artery to Left Lower Arm Artery, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
03140Z4 03140Z5	Bypass Left Subclavian Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z6	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z7	Bypass Left Subclavian Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03140Z8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03140Z9	Bypass Left Subclavian Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03140ZB	Bypass Left Subclavian Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03140ZC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
031509B	Bypass Right Axillary Artery to Left Lower Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
031509C	Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		

cder_mpl1p_wp077 Page 818 of 1023



Toccadie	Codes Osed to Define basefine Characteristics in this nequest	Code	
Code	Description	Category	Code Type
03150A0	Bypass Right Axillary Artery to Right Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03150A1	Bypass Right Axillary Artery to Left Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03150A2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0245042	Open Approach	Dunnadium	ICD 10 DCC
03150A3	Bypass Right Axillary Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A4	Bypass Right Axillary Artery to Left Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0313074	Open Approach	rrocedure	ICD-10-I C3
03150A5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03150A6	Bypass Right Axillary Artery to Right Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03150A7	Bypass Right Axillary Artery to Left Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03150A8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03150A9	Bypass Right Axillary Artery to Right Lower Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0245040	Open Approach	Dunnadium	ICD 10 DCC
03150AB	Bypass Right Axillary Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150AC	Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
OSISOAC	Open Approach	rroccaare	100 101 05
03150J0	Bypass Right Axillary Artery to Right Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03150J1	Bypass Right Axillary Artery to Left Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03150J2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03150J3	Bypass Right Axillary Artery to Right Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0245014	Approach		100 40 000
03150J4	Bypass Right Axillary Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open	Drocadura	ICD-10-PCS
0313033	Approach	rroccaare	100 101 05
03150J6	Bypass Right Axillary Artery to Right Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03150J7	Bypass Right Axillary Artery to Left Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03150J8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03150J9	Bypass Right Axillary Artery to Right Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 819 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
03150JB	Bypass Right Axillary Artery to Left Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03150JC	Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03150K0	Bypass Right Axillary Artery to Right Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03150K1	Bypass Right Axillary Artery to Left Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03150K2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03150K3	Bypass Right Axillary Artery to Right Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03150K4	Bypass Right Axillary Artery to Left Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03150K5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03150K6	Bypass Right Axillary Artery to Right Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03150K7	Bypass Right Axillary Artery to Left Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03150K8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03150K9	Bypass Right Axillary Artery to Right Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03150KB	Bypass Right Axillary Artery to Left Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03150KC	Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03150Z0	Bypass Right Axillary Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z1	Bypass Right Axillary Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z3	Bypass Right Axillary Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z4	Bypass Right Axillary Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z6	Bypass Right Axillary Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150Z7	Bypass Right Axillary Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150Z8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150Z9 03150ZB	Bypass Right Axillary Artery to Right Lower Leg Artery, Open Approach Bypass Right Axillary Artery to Left Lower Leg Artery, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
03150ZB	Bypass Right Axillary Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
031502C 031609B	Bypass Left Axillary Artery to Left Lower Leg Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
5510055	Approach	. roccaare	.02 10 1 03
031609C	Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
5510050	Open Approach	roccuure	.02 10 1 03
	Open Approach		

cder_mpl1p_wp077 Page 820 of 1023



		Code	
Code	Description	Category	Code Type
03160A0	Bypass Left Axillary Artery to Right Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03160A1	Bypass Left Axillary Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
03160A2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
021 00 4 2	Open Approach	Dunnadiina	ICD 10 DCC
03160A3	Bypass Left Axillary Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A4	Bypass Left Axillary Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
03100/4	Approach	rrocedure	100-10-1 03
03160A5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
002001.0	Open Approach		.02 20 . 00
03160A6	Bypass Left Axillary Artery to Right Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03160A7	Bypass Left Axillary Artery to Left Upper Leg Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
03160A8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03160A9	Bypass Left Axillary Artery to Right Lower Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0046040	Open Approach		100 10 000
03160AB	Bypass Left Axillary Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
03160AC	Approach Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
03100AC	Open Approach	riocedule	10-10-103
03160J0	Bypass Left Axillary Artery to Right Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
001000	Approach	110000010	105 10 1 05
03160J1	Bypass Left Axillary Artery to Left Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03160J2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03160J3	Bypass Left Axillary Artery to Right Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03160J4	Bypass Left Axillary Artery to Left Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
024 6015	Approach	Dan and dans	100 40 000
03160J5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
03160J6	Approach Bypass Left Axillary Artery to Right Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0310010	Approach	riocedule	ICD-10-PC3
03160J7	Bypass Left Axillary Artery to Left Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		.02 20 1 00
03160J8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03160J9	Bypass Left Axillary Artery to Right Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 821 of 1023



riocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
03160JB	Bypass Left Axillary Artery to Left Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03160JC	Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03160K0	Bypass Left Axillary Artery to Right Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03160K1	Bypass Left Axillary Artery to Left Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03160K2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03160K3	Bypass Left Axillary Artery to Right Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03160K4	Bypass Left Axillary Artery to Left Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03160K5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03160K6	Bypass Left Axillary Artery to Right Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03160K7	Bypass Left Axillary Artery to Left Upper Leg Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
03160K8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03160K9	Bypass Left Axillary Artery to Right Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03160KB	Bypass Left Axillary Artery to Left Lower Leg Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
03160KC	Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03160Z0	Bypass Left Axillary Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z1	Bypass Left Axillary Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z3	Bypass Left Axillary Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z4	Bypass Left Axillary Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z6 03160Z7	Bypass Left Axillary Artery to Right Upper Leg Artery, Open Approach Bypass Left Axillary Artery to Left Upper Leg Artery, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
03160Z7 03160Z8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160Z9	Bypass Left Axillary Artery to Bildter opper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160ZB	Bypass Left Axillary Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160ZC	Bypass Left Axillary Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03170A0	Bypass Right Brachial Artery to Right Upper Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03170A3	Bypass Right Brachial Artery to Right Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		

cder_mpl1p_wp077 Page 822 of 1023



	Codes Osed to Define Baseline Characteristics in this request	Code	
Code	Description	Category	Code Type
03170J0	Bypass Right Brachial Artery to Right Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03170J3	Bypass Right Brachial Artery to Right Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03170K0	Bypass Right Brachial Artery to Right Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03170K3	Bypass Right Brachial Artery to Right Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03170Z0	Bypass Right Brachial Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03170Z3 03180A1	Bypass Right Brachial Artery to Right Lower Arm Artery, Open Approach Bypass Left Brachial Artery to Left Upper Arm Artery with Autologous Arterial Tissue,	Procedure Procedure	ICD-10-PCS ICD-10-PCS
03160A1	Open Approach	riocedule	ICD-10-PC3
03180A4	Bypass Left Brachial Artery to Left Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
03100/14	Open Approach	rroccaare	100 101 05
03180J1	Bypass Left Brachial Artery to Left Upper Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0010001	Approach		.02 20 . 00
03180J4	Bypass Left Brachial Artery to Left Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03180K1	Bypass Left Brachial Artery to Left Upper Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03180K4	Bypass Left Brachial Artery to Left Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
03180Z1	Bypass Left Brachial Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03180Z4	Bypass Left Brachial Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03190A3	Bypass Right Ulnar Artery to Right Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
03190J3	Bypass Right Ulnar Artery to Right Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
03190K3	Bypass Right Ulnar Artery to Right Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0240072	Substitute, Open Approach		100 40 000
03190Z3 031A094	Bypass Right Ulnar Artery to Right Lower Arm Artery, Open Approach Bypass Left Ulnar Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open	Procedure Procedure	ICD-10-PCS ICD-10-PCS
U31AU34	Approach	riocedure	ICD-10-FC3
031A0A4	Bypass Left Ulnar Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
031/10/14	Approach	rroccaare	100 101 05
031A0J4	Bypass Left Ulnar Artery to Left Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
031A0K4	Bypass Left Ulnar Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
031A0Z4	Bypass Left Ulnar Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
031B093	Bypass Right Radial Artery to Right Lower Arm Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
031B0A3	Bypass Right Radial Artery to Right Lower Arm Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		

cder_mpl1p_wp077 Page 823 of 1023



		Code	
Code	Description	Category	Code Type
031B0J3	Bypass Right Radial Artery to Right Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
031B0K3	Bypass Right Radial Artery to Right Lower Arm Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
031B0Z3	Bypass Right Radial Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
031C094	Bypass Left Radial Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
031C0A4	Bypass Left Radial Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
031C0J4	Bypass Left Radial Artery to Left Lower Arm Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0310034	Approach	Troccaure	100 10 1 05
031C0K4	Bypass Left Radial Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
UJICUN4	Open Approach	Trocedure	ICD-10-1 C3
031C0Z4	Bypass Left Radial Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
031C024	Dilation of Right Subclavian Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0373042	blaction of right substantial victory with brag clathing intratarillar bevice, open approach	rroccaare	100 10 1 05
037305Z	Dilation of Right Subclavian Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
0373032	Approach	Troccaure	100 10 1 05
037306Z	Dilation of Right Subclavian Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
0373002	Approach	riocedure	ICD-10-FC3
0272077	• •	Dunnanduun	ICD 10 DCC
037307Z	Dilation of Right Subclavian Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0272006	Open Approach	Dun andrus	ICD 40 DCC
03730D6	Dilation of Right Subclavian Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0272007	Dilation of Diabt Cub device Automovith Introduction Device Once Augustah	Dunnanduun	ICD 10 DCC
03730DZ 03730EZ	Dilation of Right Subclavian Artery with Intraluminal Device, Open Approach Dilation of Right Subclavian Artery with Two Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
03730E2 03730F6	Dilation of Right Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
0373010	Approach	Troccaure	100 10 1 05
03730FZ	Dilation of Right Subclavian Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03730F2 03730G6	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0373000	Open Approach	Troccaure	100 10 1 05
03730GZ	Dilation of Right Subclavian Artery with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
0373002	Approach	Procedure	ICD-10-PC3
03730Z6	Dilation of Right Subclavian Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03730Z6 03730ZZ	Dilation of Right Subclavian Artery, Open Approach	Procedure	ICD-10-PCS
037302Z 037334Z	Dilation of Right Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0373342	Approach	rroccaare	100 10 1 05
037335Z	Dilation of Right Subclavian Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
037333 <u>L</u>	Percutaneous Approach	rioccuure	1CD 10-1 C3
037336Z	Dilation of Right Subclavian Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
03/3302	Percutaneous Approach	riocedure	1CD-10-LC2
027227	••	Droopeling	ICD 10 DCC
037337Z	Dilation of Right Subclavian Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		

cder_mpl1p_wp077 Page 824 of 1023



	·	Code	
Code	Description	Category	Code Type
03733D6	Dilation of Right Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03733DZ	Dilation of Right Subclavian Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03733EZ	Dilation of Right Subclavian Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733F6	Dilation of Right Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733FZ	Dilation of Right Subclavian Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733G6	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733GZ	Dilation of Right Subclavian Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733Z6	Dilation of Right Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03733ZZ	Dilation of Right Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037344Z	Dilation of Right Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037345Z	Dilation of Right Subclavian Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037346Z	Dilation of Right Subclavian Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037347Z	Dilation of Right Subclavian Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734D6	Dilation of Right Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734DZ	Dilation of Right Subclavian Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734EZ	Dilation of Right Subclavian Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734F6	Dilation of Right Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734FZ	Dilation of Right Subclavian Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734G6	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734GZ	Dilation of Right Subclavian Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734Z6 03734ZZ 037404Z	Dilation of Right Subclavian Artery, Bifurcation, Percutaneous Endoscopic Approach Dilation of Right Subclavian Artery, Percutaneous Endoscopic Approach Dilation of Left Subclavian Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS

cder_mpl1p_wp077 Page 825 of 1023



Trocedure	codes osed to Define baseline Characteristics in this Nequest	Code	
Code	Description	Category	Code Type
037405Z	Dilation of Left Subclavian Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037406Z	Dilation of Left Subclavian Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037407Z	Dilation of Left Subclavian Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
03740D6	Dilation of Left Subclavian Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03740DZ	Dilation of Left Subclavian Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03740EZ	Dilation of Left Subclavian Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740F6	Dilation of Left Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
03740FZ	Dilation of Left Subclavian Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740G6	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
03740GZ	Dilation of Left Subclavian Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740Z6	Dilation of Left Subclavian Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03740ZZ	Dilation of Left Subclavian Artery, Open Approach	Procedure	ICD-10-PCS
037434Z	Dilation of Left Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037435Z	Dilation of Left Subclavian Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037436Z	Dilation of Left Subclavian Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037437Z	Dilation of Left Subclavian Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03743D6	Dilation of Left Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03743DZ	Dilation of Left Subclavian Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03743EZ	Dilation of Left Subclavian Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743F6	Dilation of Left Subclavian Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03743FZ	Dilation of Left Subclavian Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03743G6	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03743GZ	Dilation of Left Subclavian Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03743Z6	Dilation of Left Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03743ZZ	Dilation of Left Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037444Z	Dilation of Left Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 826 of 1023



		Code	
Code	Description	Category	Code Type
037445Z	Dilation of Left Subclavian Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037446Z	Dilation of Left Subclavian Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037447Z	Dilation of Left Subclavian Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03744D6	Dilation of Left Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03744DZ	Dilation of Left Subclavian Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
03744EZ	Dilation of Left Subclavian Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03744F6	Dilation of Left Subclavian Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03744FZ	Dilation of Left Subclavian Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03744G6	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03744GZ	Dilation of Left Subclavian Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03744Z6	Dilation of Left Subclavian Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744ZZ	Dilation of Left Subclavian Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037504Z	Dilation of Right Axillary Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037505Z	Dilation of Right Axillary Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037506Z	Dilation of Right Axillary Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037507Z	Dilation of Right Axillary Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
03750D6	Dilation of Right Axillary Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03750DZ	Dilation of Right Axillary Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03750EZ	Dilation of Right Axillary Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750F6	Dilation of Right Axillary Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
03750FZ	Dilation of Right Axillary Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750G6	Dilation of Right Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
03750GZ	Dilation of Right Axillary Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750Z6	Dilation of Right Axillary Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03750ZZ	Dilation of Right Axillary Artery, Open Approach	Procedure	ICD-10-PCS
037534Z	Dilation of Right Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 827 of 1023



TTOCCUUTC	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
037535Z	Dilation of Right Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037536Z	Dilation of Right Axillary Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037537Z	Dilation of Right Axillary Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03753D6	Dilation of Right Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03753DZ	Dilation of Right Axillary Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03753EZ	Dilation of Right Axillary Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753F6	Dilation of Right Axillary Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03753FZ	Dilation of Right Axillary Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753G6	Dilation of Right Axillary Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03753GZ	Dilation of Right Axillary Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03753Z6	Dilation of Right Axillary Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03753ZZ	Dilation of Right Axillary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037544Z	Dilation of Right Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037545Z	Dilation of Right Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037546Z	Dilation of Right Axillary Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0075477	Percutaneous Endoscopic Approach		100 10 000
037547Z	Dilation of Right Axillary Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0275456	Percutaneous Endoscopic Approach	Dunandous	ICD 10 DCC
03754D6	Dilation of Right Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0275407	Endoscopic Approach Diletion of Right Avillary Artery with Introlyminal Davies, Persystensous Endoscopic	Dragodura	ICD 10 DCC
03754DZ	Dilation of Right Axillary Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
03754EZ	Approach Dilation of Right Axillary Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
03/3462	Approach	riocedule	ICD-10-PC3
03754F6	Dilation of Right Axillary Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
0373410	Percutaneous Endoscopic Approach	rrocedure	100-10-1 03
03754FZ	Dilation of Right Axillary Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
33,341 L	Approach	. roccuure	.00 10 1 03
03754G6	Dilation of Right Axillary Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
20.0100	Percutaneous Endoscopic Approach		102 20 1 00
03754GZ	Dilation of Right Axillary Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03754Z6	Dilation of Right Axillary Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
-	, , , , , , , , , , , , , , , , , , ,		

cder_mpl1p_wp077 Page 828 of 1023



		Code	
Code	Description	Category	Code Type
03754ZZ	Dilation of Right Axillary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037604Z	Dilation of Left Axillary Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037605Z	Dilation of Left Axillary Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0276067	Dilation of Left Avillan, Astonovith Three Days shaking between its Daying Once	Dunnandous	ICD 40 DCC
037606Z	Dilation of Left Axillary Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037607Z	Dilation of Left Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760D6	Dilation of Left Axillary Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03760DZ	Dilation of Left Axillary Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03760EZ	Dilation of Left Axillary Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760F6	Dilation of Left Axillary Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760FZ	Dilation of Left Axillary Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760G6	Dilation of Left Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760GZ	Dilation of Left Axillary Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760Z6	Dilation of Left Axillary Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03760ZZ	Dilation of Left Axillary Artery, Open Approach	Procedure	ICD-10-PCS
037634Z	Dilation of Left Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037635Z	Dilation of Left Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037636Z	Dilation of Left Axillary Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037637Z	Dilation of Left Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763D6	Dilation of Left Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03763DZ 03763EZ	Dilation of Left Axillary Artery with Intraluminal Device, Percutaneous Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
U3703EZ	Dilation of Left Axillary Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PC3
03763F6	Dilation of Left Axillary Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763FZ	Dilation of Left Axillary Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763G6	Dilation of Left Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763GZ	Dilation of Left Axillary Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763Z6 03763ZZ 037644Z	Dilation of Left Axillary Artery, Bifurcation, Percutaneous Approach Dilation of Left Axillary Artery, Percutaneous Approach Dilation of Left Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS

cder_mpl1p_wp077 Page 829 of 1023



		Code	
Code	Description	Category	Code Type
037645Z	Dilation of Left Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037646Z	Dilation of Left Axillary Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037647Z	Dilation of Left Axillary Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03764D6	Dilation of Left Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03764DZ	Dilation of Left Axillary Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
03764EZ	Dilation of Left Axillary Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
03764F6	Dilation of Left Axillary Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03764FZ	Dilation of Left Axillary Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
03764G6	Dilation of Left Axillary Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03764GZ	Dilation of Left Axillary Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03764Z6	Dilation of Left Axillary Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764ZZ	Dilation of Left Axillary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037704Z	Dilation of Right Brachial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037705Z	Dilation of Right Brachial Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037706Z	Dilation of Right Brachial Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037707Z	Dilation of Right Brachial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
03770D6	Dilation of Right Brachial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03770DZ	Dilation of Right Brachial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03770EZ	Dilation of Right Brachial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770F6	Dilation of Right Brachial Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
03770FZ	Dilation of Right Brachial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770G6	Dilation of Right Brachial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
03770GZ	Dilation of Right Brachial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770Z6	Dilation of Right Brachial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03770ZU	Dilation of Right Brachial Artery, Open Approach	Procedure	ICD-10-PCS
037734Z	Dilation of Right Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
	• •		

cder_mpl1p_wp077 Page 830 of 1023



riocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
037735Z	Dilation of Right Brachial Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037736Z	Dilation of Right Brachial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037737Z	Dilation of Right Brachial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03773D6	Dilation of Right Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03773DZ	Dilation of Right Brachial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03773EZ	Dilation of Right Brachial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773F6	Dilation of Right Brachial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03773FZ	Dilation of Right Brachial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773G6	Dilation of Right Brachial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03773GZ	Dilation of Right Brachial Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03773Z6	Dilation of Right Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03773ZZ	Dilation of Right Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037744Z	Dilation of Right Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037745Z	Dilation of Right Brachial Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037746Z	Dilation of Right Brachial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037747Z	Dilation of Right Brachial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03774D6	Dilation of Right Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03774DZ	Dilation of Right Brachial Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
03774EZ	Dilation of Right Brachial Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
03774F6	Dilation of Right Brachial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03774FZ	Dilation of Right Brachial Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03774G6	Dilation of Right Brachial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03774GZ	Dilation of Right Brachial Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03774Z6	Dilation of Right Brachial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 831 of 1023



riocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
03774ZZ	Dilation of Right Brachial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037804Z	Dilation of Left Brachial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037805Z	Dilation of Left Brachial Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037806Z	Dilation of Left Brachial Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037807Z	Dilation of Left Brachial Artery with Four or More Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
03780D6	Dilation of Left Brachial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03780DZ	Dilation of Left Brachial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03780EZ	Dilation of Left Brachial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780F6	Dilation of Left Brachial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780FZ	Dilation of Left Brachial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780G6	Dilation of Left Brachial Artery, Bifurcation, with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
0370000	Approach	Troccaure	100 10 1 05
03780GZ	Dilation of Left Brachial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
	, , , , , , , , , , , , , , , , , , ,		
03780Z6	Dilation of Left Brachial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03780ZZ	Dilation of Left Brachial Artery, Open Approach	Procedure	ICD-10-PCS
037834Z	Dilation of Left Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037835Z	Dilation of Left Brachial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037836Z	Dilation of Left Brachial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037837Z	Dilation of Left Brachial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03783D6	Dilation of Left Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03783DZ	Dilation of Left Brachial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03783EZ	Dilation of Left Brachial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270256	Dilation of Left Develop Autom. Differentian with Three lates beginning Devices. Develop	Due e e el core	ICD 40 DCC
03783F6	Dilation of Left Brachial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0270257	Approach Dilation of Left Brachial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD 10 DCS
03783FZ	Dilation of Left Bracillal Aftery with Tiffee intradmillal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783G6	Dilation of Left Brachial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0370300	Percutaneous Approach	rroccaare	100 10 1 05
03783GZ	Dilation of Left Brachial Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
33,3332	Approach	. roccaare	
03783Z6	Dilation of Left Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03783ZZ	Dilation of Left Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
55,0022	=		.02 10 1 00

cder_mpl1p_wp077 Page 832 of 1023



		Code	
Code	Description	Category	Code Type
037844Z	Dilation of Left Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037845Z	Dilation of Left Brachial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037846Z	Dilation of Left Brachial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037847Z	Dilation of Left Brachial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
03784D6	Dilation of Left Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
03784DZ	Dilation of Left Brachial Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0070.52	Approach		.02 20 . 00
03784EZ	Dilation of Left Brachial Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0370462	Approach	Troccadic	100 10 1 03
03784F6	Dilation of Left Brachial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0370410	Endoscopic Approach	Trocedure	ICD-10-1 C3
03784FZ	Dilation of Left Brachial Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
U3/04FZ	·	Procedure	ICD-10-PC3
0270406	Approach Pilotion of Loft Brachiel Artery, Bifurcation, with Four or More Introluminal Devices	Dragodura	ICD 10 DCS
03784G6	Dilation of Left Brachial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0070467	Percutaneous Endoscopic Approach	5 1	100 40 000
03784GZ	Dilation of Left Brachial Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0070476	Endoscopic Approach		100 10 000
03784Z6	Dilation of Left Brachial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784ZZ 037904Z	Dilation of Left Brachial Artery, Percutaneous Endoscopic Approach	Procedure Procedure	ICD-10-PCS
037904Z 037905Z	Dilation of Right Ulnar Artery with Drug-eluting Intraluminal Device, Open Approach Dilation of Right Ulnar Artery with Two Drug-eluting Intraluminal Devices, Open Approach		ICD-10-PCS
0373032	bilation of right offial Artery with two brug-cluting intradminal bevices, Open Approach	Trocedure	1CD-10-1 C3
037906Z	Dilation of Right Ulnar Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
0373002	Approach	Troccaure	100 101 05
037907Z	Dilation of Right Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
03/30/2	Approach	riocedule	ICD-10-PC3
0270006		Dragodura	ICD 10 DCS
03790D6 03790DZ	Dilation of Right Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach Dilation of Right Ulnar Artery with Intraluminal Device, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
03790EZ	Dilation of Right Ulnar Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790F6	Dilation of Right Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		.02 20 . 00
03790FZ	Dilation of Right Ulnar Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790G6	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		.02 10 1 00
03790GZ	Dilation of Right Ulnar Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
557 JUUL	Shadon of Mant office y with roat of wore intradminal bevices, Open Approach	TOCCUUIC	ICD-TO-LC3
03790Z6	Dilation of Right Ulnar Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
	Dilation of Right Ulnar Artery, Brurcation, Open Approach Dilation of Right Ulnar Artery, Open Approach	Procedure	ICD-10-PCS
113/901/	PHATION OF MISHE OFFICE A COUNT ADDITIONAL	rioccuure	1CD TO-1 C3
03790ZZ 037934Z	Dilation of Right Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 833 of 1023



		Code	
Code	Description	Category	Code Type
037935Z	Dilation of Right Ulnar Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037936Z	Dilation of Right Ulnar Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037937Z	Dilation of Right Ulnar Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03793D6	Dilation of Right Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03793DZ	Dilation of Right Ulnar Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03793EZ	Dilation of Right Ulnar Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793F6	Dilation of Right Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03793FZ	Dilation of Right Ulnar Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793G6	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
03793GZ	Dilation of Right Ulnar Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
03793Z6	Dilation of Right Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03793ZZ	Dilation of Right Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037944Z	Dilation of Right Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037945Z	Dilation of Right Ulnar Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0070467	Endoscopic Approach		100 40 000
037946Z	Dilation of Right Ulnar Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0070477	Endoscopic Approach		100 40 000
037947Z	Dilation of Right Ulnar Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0270406	Percutaneous Endoscopic Approach		100 40 000
03794D6	Dilation of Right Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0270407	Endoscopic Approach	Dan and dans	ICD 40 DCC
03794DZ	Dilation of Right Ulnar Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0270457	Approach	Duanadiina	ICD 10 DCC
03794EZ	Dilation of Right Ulnar Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0270456	Approach Dilation of Right I lines Arteny Rifuscation, with Three Introluminal Devices, Rescutaneous	Procedure	ICD 10 DCS
03794F6	Dilation of Right Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794FZ	Dilation of Right Ulnar Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
03/34/2	Approach	riocedule	ICD-10-PC3
03794G6	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
33,3400	Percutaneous Endoscopic Approach	Toccuure	100 10 1 03
03794GZ	Dilation of Right Ulnar Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
33, J+GL	Endoscopic Approach	Toccuure	100 101 03
03794Z6	Dilation of Right Ulnar Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
33,3420	Single of Might Office / State of the Control of th	. roccuure	100 10 1 03

cder_mpl1p_wp077 Page 834 of 1023



Trocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
03794ZZ	Dilation of Right Ulnar Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A046	Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037A04Z	Dilation of Left Ulnar Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037A056	Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
037A05Z	Dilation of Left Ulnar Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A066	Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A06Z	Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A076	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
037A07Z	Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0D6	Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037A0DZ	Dilation of Left Ulnar Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037A0E6	Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0EZ	Dilation of Left Ulnar Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0F6	Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach		ICD-10-PCS
037A0FZ	Dilation of Left Ulnar Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0G6	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0GZ	Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0Z6	Dilation of Left Ulnar Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037A0ZZ	Dilation of Left Ulnar Artery, Open Approach	Procedure	ICD-10-PCS
037A346	Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037A34Z	Dilation of Left Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037A356	Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A35Z	Dilation of Left Ulnar Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A366	Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A36Z	Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A376	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A37Z	Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 835 of 1023



		Code	<u></u>
Code	Description	Category	Code Type
037A3D6	Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037A3DZ	Dilation of Left Ulnar Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037A3E6	Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037A3EZ	Dilation of Left Ulnar Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A3F6	Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037A3FZ	Dilation of Left Ulnar Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A3G6	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037A3GZ	Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037A3Z6	Dilation of Left Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037A3ZZ	Dilation of Left Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037A446	Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037A44Z	Dilation of Left Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037A456	Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037A45Z	Dilation of Left Ulnar Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037A466	Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037A46Z	Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
00///	Endoscopic Approach		.02 20 . 00
037A476	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
03771470	Devices, Percutaneous Endoscopic Approach	rroccaare	100 10 1 05
037A47Z	Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
03/14/2	Percutaneous Endoscopic Approach	riocedure	ICD-10-I C3
0274406	Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous	Drocoduro	ICD 10 DCS
037A4D6	••	Procedure	ICD-10-PCS
0274407	Endoscopic Approach	Dun and dun	ICD 40 DCC
037A4DZ	Dilation of Left Ulnar Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4E6	Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037A4EZ	Dilation of Left Ulnar Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
JJ//\TLL	Approach	. roccuure	.00 10 1 03
037A4F6	Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
03/A4F0	•	riocedule	10-10-403
0274457	Endoscopic Approach Dilation of Left Ulary Arten with Three Introluminal Devices Persutaneous Endoscopic	Dragoding	ICD 10 DCC
037A4FZ	Dilation of Left Ulnar Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 836 of 1023



		Code	
Code	Description	Category	Code Type
037A4G6	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037A4GZ	Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037A4Z6	Dilation of Left Ulnar Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4ZZ	Dilation of Left Ulnar Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B046	Dilation of Right Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037B04Z	Dilation of Right Radial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037B056	Dilation of Right Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B05Z	Dilation of Right Radial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B066	Dilation of Right Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B06Z	Dilation of Right Radial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B076	Dilation of Right Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B07Z	Dilation of Right Radial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0D6	Dilation of Right Radial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037B0DZ	Dilation of Right Radial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037B0E6	Dilation of Right Radial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0EZ	Dilation of Right Radial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0F6	Dilation of Right Radial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0FZ	Dilation of Right Radial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0G6	Dilation of Right Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0GZ	Dilation of Right Radial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0Z6	Dilation of Right Radial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037B0ZZ	Dilation of Right Radial Artery, Open Approach	Procedure	ICD-10-PCS
037B346	Dilation of Right Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037B34Z	Dilation of Right Radial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037B356	Dilation of Right Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B35Z	Dilation of Right Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 837 of 1023



		Code	
Code	Description	Category	Code Type
037B366	Dilation of Right Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B36Z	Dilation of Right Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B376	Dilation of Right Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B37Z	Dilation of Right Radial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3D6	Dilation of Right Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037B3DZ 037B3E6	Dilation of Right Radial Artery with Intraluminal Device, Percutaneous Approach Dilation of Right Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
037B3EZ	Dilation of Right Radial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3F6	Dilation of Right Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3FZ	Dilation of Right Radial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3G6	Dilation of Right Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3GZ	Dilation of Right Radial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3Z6	Dilation of Right Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037B3ZZ	Dilation of Right Radial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037B446	Dilation of Right Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B44Z	Dilation of Right Radial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B456	Dilation of Right Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B45Z	Dilation of Right Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B466	Dilation of Right Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B46Z	Dilation of Right Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B476	Dilation of Right Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B47Z	Dilation of Right Radial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4D6	Dilation of Right Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 838 of 1023



		Code	
Code	Description	Category	Code Type
037B4DZ	Dilation of Right Radial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4E6	Dilation of Right Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
037B4EZ	Endoscopic Approach Dilation of Right Radial Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
037B4F6	Approach Dilation of Right Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
037B4FZ	Endoscopic Approach Dilation of Right Radial Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
037B4G6	Approach Dilation of Right Radial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
037B4GZ	Percutaneous Endoscopic Approach Dilation of Right Radial Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037B4Z6	Dilation of Right Radial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4ZZ	Dilation of Right Radial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C046	Dilation of Left Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C04Z	Dilation of Left Radial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C056	Dilation of Left Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C05Z	Dilation of Left Radial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C066	Dilation of Left Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C06Z	Dilation of Left Radial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C076	Dilation of Left Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C07Z	Dilation of Left Radial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0D6	Dilation of Left Radial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C0DZ	Dilation of Left Radial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C0E6	Dilation of Left Radial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0EZ	Dilation of Left Radial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0F6	Dilation of Left Radial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0FZ	Dilation of Left Radial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0G6	Dilation of Left Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0GZ	Dilation of Left Radial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0Z6	Dilation of Left Radial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037C0ZZ	Dilation of Left Radial Artery, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 839 of 1023



	·	Code	
Code	Description	Category	Code Type
037C346	Dilation of Left Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037C34Z	Dilation of Left Radial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037C356	Dilation of Left Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037C35Z	Dilation of Left Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037C366	Dilation of Left Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037C36Z	Dilation of Left Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
007 0002	Approach		.02 20 . 00
037C376	Dilation of Left Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
037 037 0	Devices, Percutaneous Approach	rroccaare	102 10 1 03
037C37Z	Dilation of Left Radial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0370372	Percutaneous Approach	rroccaare	100 10 1 05
037C3D6	Dilation of Left Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0376300	Approach	riocedure	ICD-10-FC3
037C3DZ	Dilation of Left Radial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037C3D2 037C3E6	Dilation of Left Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0376360	Approach	rrocedure	ICD-10-1 C3
037C3EZ	Dilation of Left Radial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3E2	Dilation of Left Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
037 031 0	Approach	rroccaare	100 10 1 05
037C3FZ	Dilation of Left Radial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037 031 2	bilation of Left Radial Artery with Timee intratallinal bevices, i creataneous Approach	rroccaare	100 10 1 05
037C3G6	Dilation of Left Radial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
0370300	Percutaneous Approach	rroccaare	100 10 1 05
037C3GZ	Dilation of Left Radial Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0376362	Approach	rroccaare	100 10 1 05
037C3Z6	Dilation of Left Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037C3ZZ	Dilation of Left Radial Artery, Brutcation, Percutaneous Approach	Procedure	ICD-10-PCS
037C446	Dilation of Left Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		.02 20 . 00
037C44Z	Dilation of Left Radial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
037 0112	Endoscopic Approach	rroccaare	100 10 1 05
037C456	Dilation of Left Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0370430	Percutaneous Endoscopic Approach	rrocedure	1CD-10-1 C3
0276457	· ··	Drocodura	ICD 10 DCs
037C45Z	Dilation of Left Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0270466	Endoscopic Approach Dilation of Loft Radial Artony Rifurcation, with Three Drug cluting Intraluminal Devices	Drocodure	ICD 10 DCc
037C466	Dilation of Left Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0276467	Percutaneous Endoscopic Approach	D !	100 40 000
037C46Z	Dilation of Left Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 840 of 1023



riocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
037C476	Dilation of Left Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
037C47Z	Dilation of Left Radial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037C4D6	Dilation of Left Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037C4DZ	Dilation of Left Radial Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
037C4E6	Dilation of Left Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037C4EZ	Dilation of Left Radial Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0276456	Approach	Dunnali	ICD 40 DCC
037C4F6	Dilation of Left Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
037C4FZ	Endoscopic Approach Dilation of Left Radial Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0370472	Approach	riocedure	ICD-10-PC3
037C4G6	Dilation of Left Radial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
037 C+00	Percutaneous Endoscopic Approach	rroccaare	100 10 1 05
037C4GZ	Dilation of Left Radial Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
037C4Z6	Dilation of Left Radial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4ZZ	Dilation of Left Radial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D046	Dilation of Right Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
037D04Z	Dilation of Right Hand Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037D056	Dilation of Right Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
037D05Z	Dilation of Right Hand Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0270066			100 40 000
037D066	Dilation of Right Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0270007	Open Approach	Dunnadium	ICD 10 DCC
037D06Z	Dilation of Right Hand Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D076	Dilation of Right Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
03/00/0	Devices, Open Approach	riocedure	ICD-10-PC3
037D07Z	Dilation of Right Hand Artery with Four or More Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
03/00/2	Approach	riocedure	ICD-10-FC3
037D0D6	Dilation of Right Hand Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037D0D0	Dilation of Right Hand Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037D0E6	Dilation of Right Hand Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0EZ	Dilation of Right Hand Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0F6	Dilation of Right Hand Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 841 of 1023



		Code	
Code	Description	Category	Code Type
037D0FZ	Dilation of Right Hand Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0G6	Dilation of Right Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
0270007	Approach	Dunnanduun	ICD 10 DCC
037D0GZ	Dilation of Right Hand Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0Z6	Dilation of Right Hand Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037D0ZZ	Dilation of Right Hand Artery, Open Approach	Procedure	ICD-10-PCS
037D346	Dilation of Right Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037D34Z	Dilation of Right Hand Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037D356	Dilation of Right Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D35Z	Dilation of Right Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D366	Dilation of Right Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D36Z	Dilation of Right Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D376	Dilation of Right Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D37Z	Dilation of Right Hand Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3D6	Dilation of Right Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037D3DZ 037D3E6	Dilation of Right Hand Artery with Intraluminal Device, Percutaneous Approach Dilation of Right Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
037D3EZ	Dilation of Right Hand Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3F6	Dilation of Right Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3FZ	Dilation of Right Hand Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3G6	Dilation of Right Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3GZ	Dilation of Right Hand Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3Z6	Dilation of Right Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037D3ZZ	Dilation of Right Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037D446	Dilation of Right Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
037D44Z	Dilation of Right Hand Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 842 of 1023



Troccaure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
037D456	Dilation of Right Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D45Z	Dilation of Right Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D466	Dilation of Right Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D46Z	Dilation of Right Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D476	Dilation of Right Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D47Z	Dilation of Right Hand Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4D6	Dilation of Right Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4DZ	Dilation of Right Hand Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4E6	Dilation of Right Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4EZ	Dilation of Right Hand Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4F6	Dilation of Right Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4FZ	Dilation of Right Hand Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4G6	Dilation of Right Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4GZ	Dilation of Right Hand Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4Z6 037D4ZZ 037F046	Dilation of Right Hand Artery, Bifurcation, Percutaneous Endoscopic Approach Dilation of Right Hand Artery, Percutaneous Endoscopic Approach Dilation of Left Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS
037F04Z	Dilation of Left Hand Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037F056	Dilation of Left Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F05Z	Dilation of Left Hand Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F066	Dilation of Left Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F06Z	Dilation of Left Hand Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 843 of 1023



riocedure	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
037F076	Dilation of Left Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
037F07Z	Dilation of Left Hand Artery with Four or More Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
037F0D6	Dilation of Left Hand Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037F0DZ	Dilation of Left Hand Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037F0E6	Dilation of Left Hand Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0EZ	Dilation of Left Hand Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0F6	Dilation of Left Hand Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0FZ	Dilation of Left Hand Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0G6	Dilation of Left Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
037F0GZ	Approach Dilation of Left Hand Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0Z6	Dilation of Left Hand Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037F0ZZ	Dilation of Left Hand Artery, Open Approach	Procedure	ICD-10-PCS
037F346	Dilation of Left Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
037F34Z	Dilation of Left Hand Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037F356	Dilation of Left Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F35Z	Dilation of Left Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F366	Dilation of Left Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F36Z	Dilation of Left Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F376	Dilation of Left Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F37Z	Dilation of Left Hand Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3D6	Dilation of Left Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037F3DZ 037F3E6	Dilation of Left Hand Artery with Intraluminal Device, Percutaneous Approach Dilation of Left Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
037F3EZ 037F3F6	Dilation of Left Hand Artery with Two Intraluminal Devices, Percutaneous Approach Dilation of Left Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
037F3FZ 037F3G6	Dilation of Left Hand Artery with Three Intraluminal Devices, Percutaneous Approach Dilation of Left Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS

cder_mpl1p_wp077 Page 844 of 1023



	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
037F3GZ	Dilation of Left Hand Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
037F3Z6	Dilation of Left Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037F3ZZ	Dilation of Left Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037F446	Dilation of Left Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
037F44Z	Percutaneous Endoscopic Approach Dilation of Left Hand Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F456	Dilation of Left Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F45Z	Dilation of Left Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F466	Dilation of Left Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F46Z	Dilation of Left Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F476	Dilation of Left Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F47Z	Dilation of Left Hand Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4D6	Dilation of Left Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4DZ	Dilation of Left Hand Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4E6	Dilation of Left Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4EZ	Dilation of Left Hand Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4F6	Dilation of Left Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4FZ	Dilation of Left Hand Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4G6	Dilation of Left Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4GZ	Dilation of Left Hand Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4Z6	Dilation of Left Hand Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4ZZ	Dilation of Left Hand Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03C33Z6	Extirpation of Matter from Right Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C33ZZ	Extirpation of Matter from Right Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C43Z6	Extirpation of Matter from Left Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C43ZZ	Extirpation of Matter from Left Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 845 of 1023



riocedure	codes osed to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
03C53Z6	Extirpation of Matter from Right Axillary Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C53ZZ	Extirpation of Matter from Right Axillary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C63Z6	Extirpation of Matter from Left Axillary Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C63ZZ	Extirpation of Matter from Left Axillary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C73Z6	Extirpation of Matter from Right Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C73ZZ	Extirpation of Matter from Right Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C83Z6	Extirpation of Matter from Left Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C83ZZ	Extirpation of Matter from Left Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C93Z6	Extirpation of Matter from Right Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C93ZZ	Extirpation of Matter from Right Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CA3Z6	Extirpation of Matter from Left Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CA3ZZ	Extirpation of Matter from Left Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CB3Z6	Extirpation of Matter from Right Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CB3ZZ	Extirpation of Matter from Right Radial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CC3Z6	Extirpation of Matter from Left Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CC3ZZ	Extirpation of Matter from Left Radial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CD3Z6	Extirpation of Matter from Right Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CD3ZZ	Extirpation of Matter from Right Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CF3Z6	Extirpation of Matter from Left Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CF3ZZ	Extirpation of Matter from Left Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
041009B	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Venous Tissue, Open		ICD-10-PCS
0410035	Approach	Troccaare	100 10 1 05
041009C	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0410030	Open Approach	rroccaure	100 10 1 05
041009D	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041009F	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041009G	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0.2000	Open Approach		.02 20 . 00
041009H	Bypass Abdominal Aorta to Right Femoral Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
04100311	Approach	Troccaure	100 10 1 05
0410001		Dragadura	ICD 10 DCC
041009J	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
0.44.0001/	Approach	5 1	ICD 40 DCC
041009K	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041009Q	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
04100A6	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
04100A7	Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
04100A8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Arterial	Procedure	ICD-10-PCS
04100A0		Trocedure	ICD-10-FC3
	Tissue, Open Approach		

cder_mpl1p_wp077 Page 846 of 1023



Tocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
04100A9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
04100AB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
04100AC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
04100AD	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
0410045	Open Approach	Dunnadium	ICD 10 DCC
04100AF	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
04100AG	Approach Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Arterial Tissue,	Dracadura	ICD-10-PCS
04100AG	Open Approach	Procedure	ICD-10-PC3
04100AH	Bypass Abdominal Aorta to Right Femoral Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
04100/111	Approach	rroccaare	100 10 1 05
04100AJ	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
04100AK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
04100AQ	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
04100AR	Bypass Abdominal Aorta to Lower Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
0440016			100 40 000
04100J6	Bypass Abdominal Aorta to Right Common Iliac Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
04100J7	Approach Bypass Abdominal Aorta to Left Common Iliac Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0410017	Approach	Procedure	ICD-10-PC3
04100J8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
0410030	Open Approach	rroccaare	100 10 1 00
04100J9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
04100JB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
04100JC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
04100JD	Bypass Abdominal Aorta to Right External Iliac Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
04100JF	Bypass Abdominal Aorta to Left External Iliac Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0440010	Approach		100 10 000
04100JG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0/10014	Approach Bypass Abdominal Aorta to Right Femoral Artery with Synthetic Substitute, Open	Procedure	ICD 10 DCS
04100JH	Approach	FIOCEGUIE	ICD-10-PCS
04100JJ	Bypass Abdominal Aorta to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
2-11000	2, pass / Substitute / Open Approach	. roccuare	.00 10 1 03

cder_mpl1p_wp077 Page 847 of 1023



ode ategory rocedure rocedure	Code Type ICD-10-PCS
	ICD-10-PCS
rocedure	
rocedure	
	ICD-10-PCS
	100 40 000
rocedure	ICD-10-PCS
rocoduro	ICD-10-PCS
rocedure	ICD-10-PC3
rocedure	ICD-10-PCS
roccaure	100 10 1 05
rocedure	ICD-10-PCS
rocedure	ICD-10-PCS
	ICD 10 DCC
rocedure	ICD-10-PCS
rocedure	ICD-10-PCS
rocedure	10-10-1 03
rocedure	ICD-10-PCS
rocedure	ICD-10-PCS
racadura	ICD 10 DCS
rocedure	ICD-10-PCS
rocedure	ICD-10-PCS
Jocquie	10 1 (3
rocedure	ICD-10-PCS
rocedure	ICD-10-PCS
r r r r r r r r r	rocedure

cder_mpl1p_wp077 Page 848 of 1023



Flocedule	codes osed to Define baseline characteristics in this kequest	Code	
Code	Description	Category	Code Type
04100ZD	Bypass Abdominal Aorta to Right External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100ZF	Bypass Abdominal Aorta to Left External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100ZG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries, Open Approach	Procedure	ICD-10-PCS
04100ZH	Bypass Abdominal Aorta to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04100ZJ	Bypass Abdominal Aorta to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04100ZK	Bypass Abdominal Aorta to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
04100ZQ	Bypass Abdominal Aorta to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041049B	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049C	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049D	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049F	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049G	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049H	Bypass Abdominal Aorta to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049J	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049K	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049Q	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104A6	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104A7	Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104A8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104A9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 849 of 1023



	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
04104AD	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104AF	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104AG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104AH	Bypass Abdominal Aorta to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104AJ	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104AK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104AQ	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104J6	Bypass Abdominal Aorta to Right Common Iliac Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104J7	Bypass Abdominal Aorta to Left Common Iliac Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104J8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104J9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104JB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104JC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104JD	Bypass Abdominal Aorta to Right External Iliac Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104JF	Bypass Abdominal Aorta to Left External Iliac Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104JG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104JH	Bypass Abdominal Aorta to Right Femoral Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
04104JJ	Bypass Abdominal Aorta to Left Femoral Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
04104JK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104JQ	Bypass Abdominal Aorta to Lower Extremity Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
0440446	Percutaneous Endoscopic Approach		100 40 505
04104K6	Bypass Abdominal Aorta to Right Common Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0440447	Substitute, Percutaneous Endoscopic Approach	Dun and	ICD 40 DCC
04104K7	Bypass Abdominal Aorta to Left Common Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 850 of 1023



. roccaare	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
04104K8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
04104K9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
04104KB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
04104KC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
04104KD	Bypass Abdominal Aorta to Right External Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
04104KF	Bypass Abdominal Aorta to Left External Iliac Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
04104KG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
04104KH	Bypass Abdominal Aorta to Right Femoral Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
04104KJ	Bypass Abdominal Aorta to Left Femoral Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
04404111	Percutaneous Endoscopic Approach		100 40 000
04104KK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
0440410	Substitute, Percutaneous Endoscopic Approach	Dan and dan	ICD 40 DCC
04104KQ	Bypass Abdominal Aorta to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104Z6	Bypass Abdominal Aorta to Right Common Iliac Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0410420	Approach	Procedure	ICD-10-PC3
04104Z7	Bypass Abdominal Aorta to Left Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0410427	by pass Abdominal Aorta to Left Common mac Artery, refeutancous Endoscopic Approach	rrocedure	1CD-10-1 C3
04104Z8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04104Z9	Bypass Abdominal Aorta to Right Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
	,, , , , , , , , , , , , , , , , , , , ,		
04104ZB	Bypass Abdominal Aorta to Left Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04104ZD	Bypass Abdominal Aorta to Right External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZF	Bypass Abdominal Aorta to Left External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04104ZH	Bypass Abdominal Aorta to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZJ	Bypass Abdominal Aorta to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 851 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
04104ZK	Bypass Abdominal Aorta to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZQ	Bypass Abdominal Aorta to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C09H	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041C09J	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041C09K	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041C0AH	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041C0AJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041C0AK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041C0JH	Bypass Right Common Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041COJJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041C0JK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041C0KH	Bypass Right Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041C0KJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041C0KK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041C0ZH	Bypass Right Common Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041C0ZJ	Bypass Right Common Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041C0ZK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041C49H	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041C49J	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C49K	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
041C4AH	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
044644	Percutaneous Endoscopic Approach	Dun and	100 40 500
041C4AJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4AK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 852 of 1023



	e codes osed to Define baseline characteristics in this nequest	Code	
Code	Description	Category	Code Type
041C4JH	Bypass Right Common Iliac Artery to Right Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041C4JJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041C4JK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
04464111	Percutaneous Endoscopic Approach		100 40 000
041C4KH	Bypass Right Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4KJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4KK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4ZH	Bypass Right Common Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
041C4ZJ	Approach Bypass Right Common Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0-110-125	Approach	rroccaure	100 101 05
041C4ZK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D09H	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
041D09J	Open Approach Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0410033	Open Approach	rroccaure	100 101 05
041D09K	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041D0AH	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
041D0AJ	Open Approach Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041D0AK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041D0JH	Bypass Left Common Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
041D0JJ	Approach Bypass Left Common Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0445011/	Approach	5 1	ICD 40 DCC
041D0JK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041D0KH	Bypass Left Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041D0KJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
041D0KK	Substitute, Open Approach Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041D0ZH 041D0ZJ	Bypass Left Common Iliac Artery to Right Femoral Artery, Open Approach Bypass Left Common Iliac Artery to Left Femoral Artery, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
0410021	bypass Left Common mac Artery to Left remoral Artery, Open Approach	Tocedule	1CD-10-LC3

cder_mpl1p_wp077 Page 853 of 1023



	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
041D0ZK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041D49H	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041D49J	Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0445401	Percutaneous Endoscopic Approach	5 .	ICD 40 DCC
041D49K	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
04104411	Tissue, Percutaneous Endoscopic Approach	Dragodura	ICD 10 DCC
041D4AH	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4AJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
U41D4AJ	Percutaneous Endoscopic Approach	riocedure	ICD-10-FC3
041D4AK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial	Procedure	ICD-10-PCS
041047111	Tissue, Percutaneous Endoscopic Approach	rroccaare	100 10 1 05
041D4JH	Bypass Left Common Iliac Artery to Right Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041D4JJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041D4JK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041D4KH	Bypass Left Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041D4KJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041D4KK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041D4ZH	Bypass Left Common Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0440471	Approach		100 10 000
041D4ZJ	Bypass Left Common Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
041D4ZK	Approach Bypass Left Common Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
U41D4ZK	Approach	riocedule	ICD-10-PC3
041E09H	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
04120311	Open Approach	rroccaarc	100 10 1 05
041E09J	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0.22000	Open Approach		.02 20 . 00
041E09K	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		
041E0AH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041E0AJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041E0AK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		

cder_mpl1p_wp077 Page 854 of 1023



	Codes Osed to Define baseline Characteristics in this request	Code	
Code	Description	Category	Code Type
041E0JH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041E0JJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041E0JK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
041E0KH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041E0KJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0.44.501/1/	Substitute, Open Approach	Dan and dan	100 10 000
041E0KK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041E0ZH	Bypass Right Internal Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041E0ZH	Bypass Right Internal Iliac Artery to Right Pernoral Artery, Open Approach	Procedure	ICD-10-PCS
041E0ZK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041E49H	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041E49J	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041E49K	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
041E4AH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041E4AJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041E4AK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
041E4JH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041E4JJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041E4JK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041E4KH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041E4KJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041E4KK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041E4ZH	Bypass Right Internal Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
041E4ZJ	Bypass Right Internal Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 855 of 1023



	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
041E4ZK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
041F09H	Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041F09J	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041F09K	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		
041F0AH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041F0AJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041F0AK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
041F0JH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041F0JJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041F0JK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
041F0KH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041F0KJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041F0KK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041F0ZH	Bypass Left Internal Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041F0ZJ	Bypass Left Internal Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041F0ZK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041F49H	Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041F49J	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041F49K	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
041F4AH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041F4AJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041F4AK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
041F4JH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 856 of 1023



		Code	
Code	Description	Category	Code Type
041F4JJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041F4JK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041F4KH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041F4KJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0.44.5.41/1/	Substitute, Percutaneous Endoscopic Approach		160 40 066
041F4KK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4ZH	Bypass Left Internal Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
041F4ZJ	Bypass Left Internal Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
041F4ZK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
041H09H	Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0.4411001	Open Approach	Dunnandous	ICD 40 DCC
041H09J	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041H09K	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
U41HU9K	Tissue, Open Approach	Procedure	ICD-10-PC3
041H0AH	Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
041110/11	Open Approach	rroccaure	100 10 1 05
041H0AJ	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041H0AK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		
041H0JH	Bypass Right External Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041H0JJ	Bypass Right External Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041H0JK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
041H0KH	Bypass Right External Iliac Artery to Right Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041H0KJ	Bypass Right External Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0.441101414	Substitute, Open Approach	Donas I	100 40 500
041H0KK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
044110711	Substitute, Open Approach Dignet Fytograph History to Bight Formard Artory Open Approach	Droosdiiis	ICD 10 DCC
041H0ZH 041H0ZJ	Bypass Right External Iliac Artery to Right Femoral Artery, Open Approach Bypass Right External Iliac Artery to Left Femoral Artery, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
041H0ZK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
-		· · · · · ·	

cder_mpl1p_wp077 Page 857 of 1023



	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
041H49H	Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041H49J	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0.44114014	Percutaneous Endoscopic Approach	5 .	100 40 000
041H49K	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
041H4AH	Tissue, Percutaneous Endoscopic Approach Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue,	Drocoduro	ICD-10-PCS
041П4АП	Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
041H4AJ	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
041114/3	Percutaneous Endoscopic Approach	Troccaure	100 101 05
041H4AK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial	Procedure	ICD-10-PCS
0 1211 17 110	Tissue, Percutaneous Endoscopic Approach	1100000010	102 10 1 00
041H4JH	Bypass Right External Iliac Artery to Right Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041H4JJ	Bypass Right External Iliac Artery to Left Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041H4JK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041H4KH	Bypass Right External Iliac Artery to Right Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041H4KJ	Bypass Right External Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041H4KK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
044114711	Substitute, Percutaneous Endoscopic Approach	D	100 40 000
041H4ZH	Bypass Right External Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4ZJ	Bypass Right External Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
04111423	Approach	Trocedure	1CD-10-1 C3
041H4ZK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic	Procedure	ICD-10-PCS
•	Approach		
041J09H	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041J09J	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041J09K	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Open Approach		
041J0AH	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041J0AJ	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
044.000	Open Approach		
041J0AK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Open Approach		

cder_mpl1p_wp077 Page 858 of 1023



	<u> </u>	Code	
Code	Description	Category	Code Type
041J0JH	Bypass Left External Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041J0JJ	Bypass Left External Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041J0JK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Open Approach		
041J0KH	Bypass Left External Iliac Artery to Right Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041J0KJ	Bypass Left External Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041J0KK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Open Approach		
041J0ZH	Bypass Left External Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041J0ZJ	Bypass Left External Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041J0ZK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041J49H	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041J49J	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041J49K	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
041J4AH	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041J4AJ	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041J4AK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial	Procedure	ICD-10-PCS
	Tissue, Percutaneous Endoscopic Approach		
041J4JH	Bypass Left External Iliac Artery to Right Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041J4JJ	Bypass Left External Iliac Artery to Left Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041J4JK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041J4KH	Bypass Left External Iliac Artery to Right Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041J4KJ	Bypass Left External Iliac Artery to Left Femoral Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041J4KK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041J4ZH	Bypass Left External Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
041J4ZJ	Bypass Left External Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 859 of 1023



		Code	
Code	Description	Category	Code Type
041J4ZK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K09H	Bypass Right Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09J	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09K	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09L	Bypass Right Femoral Artery to Popliteal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09M	Bypass Right Femoral Artery to Peroneal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09N	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09P	Bypass Right Femoral Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09Q	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09S	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AH	Bypass Right Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AJ	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AL	Bypass Right Femoral Artery to Popliteal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AM	Bypass Right Femoral Artery to Peroneal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AN	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AP	Bypass Right Femoral Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AQ	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AS	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0JH	Bypass Right Femoral Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041KOJJ	Bypass Right Femoral Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 860 of 1023



Procedure			
Code	Description	Category	Code Type
041K0JK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JL	Bypass Right Femoral Artery to Popliteal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JM	Bypass Right Femoral Artery to Peroneal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041KOJN	Bypass Right Femoral Artery to Posterior Tibial Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JP 041K0JQ	Bypass Right Femoral Artery to Foot Artery with Synthetic Substitute, Open Approach Bypass Right Femoral Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
041K0JS	Bypass Right Femoral Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KH	Bypass Right Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KJ	Bypass Right Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KL	Bypass Right Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KM	Bypass Right Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KN	Bypass Right Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KP	Bypass Right Femoral Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KQ	Bypass Right Femoral Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KS	Bypass Right Femoral Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0ZH 041K0ZJ 041K0ZK 041K0ZL 041K0ZM 041K0ZN 041K0ZP 041K0ZQ 041K0ZS 041K49H	Bypass Right Femoral Artery to Right Femoral Artery, Open Approach Bypass Right Femoral Artery to Left Femoral Artery, Open Approach Bypass Right Femoral Artery to Bilateral Femoral Arteries, Open Approach Bypass Right Femoral Artery to Popliteal Artery, Open Approach Bypass Right Femoral Artery to Peroneal Artery, Open Approach Bypass Right Femoral Artery to Posterior Tibial Artery, Open Approach Bypass Right Femoral Artery to Foot Artery, Open Approach Bypass Right Femoral Artery to Lower Extremity Artery, Open Approach Bypass Right Femoral Artery to Lower Extremity Vein, Open Approach Bypass Right Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure Procedure Procedure Procedure Procedure Procedure Procedure Procedure Procedure	ICD-10-PCS
041K49J	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 861 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041K49K	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041K49L	Bypass Right Femoral Artery to Popliteal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49M	Bypass Right Femoral Artery to Peroneal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49N	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49P	Bypass Right Femoral Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49Q	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49S	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AH	Bypass Right Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AJ	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AL	Bypass Right Femoral Artery to Popliteal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AM	Bypass Right Femoral Artery to Peroneal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AN	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AP	Bypass Right Femoral Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AQ	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AS	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JH	Bypass Right Femoral Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JJ	Bypass Right Femoral Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JL	Bypass Right Femoral Artery to Popliteal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JM	Bypass Right Femoral Artery to Peroneal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 862 of 1023



		Code	
Code	Description	Category	Code Type
041K4JN	Bypass Right Femoral Artery to Posterior Tibial Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JP	Bypass Right Femoral Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JQ	Bypass Right Femoral Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JS	Bypass Right Femoral Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KH	Bypass Right Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KJ	Bypass Right Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KL	Bypass Right Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KM	Bypass Right Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KN	Bypass Right Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KP	Bypass Right Femoral Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KQ	Bypass Right Femoral Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KS	Bypass Right Femoral Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZH	Bypass Right Femoral Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZJ	Bypass Right Femoral Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZK	Bypass Right Femoral Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZL	Bypass Right Femoral Artery to Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZM	Bypass Right Femoral Artery to Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZN	Bypass Right Femoral Artery to Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZP	Bypass Right Femoral Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZQ	Bypass Right Femoral Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZS	Bypass Right Femoral Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 863 of 1023



	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
041L09H	Bypass Left Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09J	Bypass Left Femoral Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09K	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09L	Bypass Left Femoral Artery to Popliteal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09M	Bypass Left Femoral Artery to Peroneal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09N	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09P	Bypass Left Femoral Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09Q	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09S	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AH	Bypass Left Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AJ	Bypass Left Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AL	Bypass Left Femoral Artery to Popliteal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AM	Bypass Left Femoral Artery to Peroneal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AN	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AP	Bypass Left Femoral Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AQ	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AS	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0JH	Bypass Left Femoral Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041LOJJ	Bypass Left Femoral Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 864 of 1023



	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
041L0JL	Bypass Left Femoral Artery to Popliteal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JM	Bypass Left Femoral Artery to Peroneal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JN	Bypass Left Femoral Artery to Posterior Tibial Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JP 041L0JQ	Bypass Left Femoral Artery to Foot Artery with Synthetic Substitute, Open Approach Bypass Left Femoral Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
041L0JS	Bypass Left Femoral Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KH	Bypass Left Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KJ	Bypass Left Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KL	Bypass Left Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KM	Bypass Left Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KN	Bypass Left Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KP	Bypass Left Femoral Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KQ	Bypass Left Femoral Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KS	Bypass Left Femoral Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0ZJ 041L0ZK 041L0ZL 041L0ZM 041L0ZN 041L0ZP 041L0ZQ 041L0ZS 041L49H	Bypass Left Femoral Artery to Left Femoral Artery, Open Approach Bypass Left Femoral Artery to Bilateral Femoral Arteries, Open Approach Bypass Left Femoral Artery to Popliteal Artery, Open Approach Bypass Left Femoral Artery to Peroneal Artery, Open Approach Bypass Left Femoral Artery to Posterior Tibial Artery, Open Approach Bypass Left Femoral Artery to Foot Artery, Open Approach Bypass Left Femoral Artery to Lower Extremity Artery, Open Approach Bypass Left Femoral Artery to Lower Extremity Vein, Open Approach Bypass Left Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach Bypass Left Femoral Artery to Left Femoral Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
041L49K	Percutaneous Endoscopic Approach Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 865 of 1023



		Code	
Code	Description	Category	Code Type
041L49L	Bypass Left Femoral Artery to Popliteal Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L49M	Bypass Left Femoral Artery to Peroneal Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L49N	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L49P	Bypass Left Femoral Artery to Foot Artery with Autologous Venous Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
041L49Q	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49S	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0 112 133	Percutaneous Endoscopic Approach	1100000010	102 10 1 03
041L4AH	Bypass Left Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4AJ	Bypass Left Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4AK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4AL	Bypass Left Femoral Artery to Popliteal Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4AM	Bypass Left Femoral Artery to Peroneal Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4AN	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4AP	Bypass Left Femoral Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
041L4AQ	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4AS	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4JH	Bypass Left Femoral Artery to Right Femoral Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4JJ	Bypass Left Femoral Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		100 10 000
041L4JK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute,	Procedure	ICD-10-PCS
0441411	Percutaneous Endoscopic Approach		100 40 000
041L4JL	Bypass Left Femoral Artery to Popliteal Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
24414184	Endoscopic Approach	Dunnadiina	ICD 10 DCC
041L4JM	Bypass Left Femoral Artery to Peroneal Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
041L4JN	Endoscopic Approach Bypass Left Femoral Artery to Posterior Tibial Artery with Synthetic Substitute,	Procedure	ICD 10 DCC
J41L4JIN	Percutaneous Endoscopic Approach	riocedure	ICD-10-PCS
041L4JP	Bypass Left Femoral Artery to Foot Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
ンユエドサント		riocedure	1CD-10-LC2
	Endoscopic Approach		

cder_mpl1p_wp077 Page 866 of 1023



riocedure	codes osed to Define baseline characteristics in this kequest	Code	
Code	Description	Category	Code Type
041L4JQ	Bypass Left Femoral Artery to Lower Extremity Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4JS	Bypass Left Femoral Artery to Lower Extremity Vein with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041L4KH	Bypass Left Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KJ	Bypass Left Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KL	Bypass Left Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KM	Bypass Left Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KN	Bypass Left Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KP	Bypass Left Femoral Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KQ	Bypass Left Femoral Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KS	Bypass Left Femoral Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZH	Bypass Left Femoral Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZJ	Bypass Left Femoral Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZK	Bypass Left Femoral Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZL	Bypass Left Femoral Artery to Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZM	Bypass Left Femoral Artery to Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZN	Bypass Left Femoral Artery to Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZP	Bypass Left Femoral Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZQ	Bypass Left Femoral Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZS	Bypass Left Femoral Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M09L	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041M09M	Bypass Right Popliteal Artery to Peroneal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041M09P	Bypass Right Popliteal Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 867 of 1023



	Lodes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041M09Q	Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041M09S	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AL	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AM	Bypass Right Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AP	Bypass Right Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AS	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0JL	Bypass Right Popliteal Artery to Popliteal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0JM	Bypass Right Popliteal Artery to Peroneal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0JP	Bypass Right Popliteal Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0JQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0JS	Bypass Right Popliteal Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0KL	Bypass Right Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041M0KM	Bypass Right Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041M0KP	Bypass Right Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041M0KQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041M0KS	Bypass Right Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041M0ZL	Bypass Right Popliteal Artery to Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
041M0ZM	Bypass Right Popliteal Artery to Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
041M0ZP	Bypass Right Popliteal Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041M0ZQ	Bypass Right Popliteal Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041M0ZS	Bypass Right Popliteal Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041M49L	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
041M49M	Percutaneous Endoscopic Approach Bypass Right Popliteal Artery to Peroneal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 868 of 1023



		Code	
Code	Description	Category	Code Type
041M49P	Bypass Right Popliteal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M49Q	Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M49S	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
)41M4AL	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4AM	Bypass Right Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
)41M4AP	Bypass Right Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
)41M4AQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
)41M4AS	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
)41M4JL	Bypass Right Popliteal Artery to Popliteal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
41M4JM	Bypass Right Popliteal Artery to Peroneal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
)41M4JP	Bypass Right Popliteal Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4JQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4JS	Bypass Right Popliteal Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4KL	Bypass Right Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
)41M4KM	Bypass Right Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
)41M4KP	Bypass Right Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4KQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
41M4KS	Bypass Right Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
41M4ZL	Bypass Right Popliteal Artery to Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4ZM 041M4ZP 041M4ZQ	Bypass Right Popliteal Artery to Peroneal Artery, Percutaneous Endoscopic Approach Bypass Right Popliteal Artery to Foot Artery, Percutaneous Endoscopic Approach Bypass Right Popliteal Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS
041M4ZS	Bypass Right Popliteal Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 869 of 1023



···occadic	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
041N09L	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041N09M	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041N09P	Bypass Left Popliteal Artery to Foot Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041N09Q	Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041N09S	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041N0AL	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041N0AM	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
04411040	Approach		100 40 000
041N0AP	Bypass Left Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
041 NOA O	Approach Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue,	Drocoduro	ICD 10 DCS
041N0AQ	Open Approach	Procedure	ICD-10-PCS
041N0AS	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
U4INUAS	Open Approach	riocedure	ICD-10-FC3
041N0JL	Bypass Left Popliteal Artery to Popliteal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0.2002	2, pass 2017 spinous, 1110, y to 1 spinous, 1110, y this spinous substitutes, spen 7, pp 1000.		.02 20 . 00
041N0JM	Bypass Left Popliteal Artery to Peroneal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041N0JP	Bypass Left Popliteal Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041N0JQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041N0JS	Bypass Left Popliteal Artery to Lower Extremity Vein with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041N0KL	Bypass Left Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
041N0KM	Bypass Left Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
0.44 NIOKO	Open Approach	Dunnalium	ICD 40 DCC
041N0KP	Bypass Left Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute, Open	Procedure	ICD-10-PCS
041 NOVO	Approach Bypass Left Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue	Procedure	ICD 10 DCS
041N0KQ	Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KS	Bypass Left Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue	Procedure	ICD-10-PCS
2-11401/2	Substitute, Open Approach	Toccuure	.00 10 1 03
041N0ZL	Bypass Left Popliteal Artery to Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZM	Bypass Left Popliteal Artery to Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZP	Bypass Left Popliteal Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZQ	Bypass Left Popliteal Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZS	Bypass Left Popliteal Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 870 of 1023



	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
041N49L	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041N49M	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041N49P	Bypass Left Popliteal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
041N49Q	Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041N49S	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041N4AL	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041N4AM	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041N4AP	Bypass Left Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
041N4AQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041N4AS	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041N4JL	Bypass Left Popliteal Artery to Popliteal Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
041N4JM	Bypass Left Popliteal Artery to Peroneal Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
0444441	Endoscopic Approach		100 10 000
041N4JP	Bypass Left Popliteal Artery to Foot Artery with Synthetic Substitute, Percutaneous	Procedure	ICD-10-PCS
04411410	Endoscopic Approach	Dun and	ICD 40 DCC
041N4JQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
041 N 4 I C	Percutaneous Endoscopic Approach	Drogoduro	ICD 10 DCS
041N4JS	Bypass Left Popliteal Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4KL	Bypass Left Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
U41N4KL	Percutaneous Endoscopic Approach	Procedure	ICD-10-PC3
041N4KM	Bypass Left Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
041114KIVI	Percutaneous Endoscopic Approach	riocedure	ICD-10-FC3
041N4KP	Bypass Left Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
041144(1	Percutaneous Endoscopic Approach	rroccaare	100 101 05
041N4KQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
OHINHIQ	Substitute, Percutaneous Endoscopic Approach	rroccaare	100 101 05
041N4KS	Bypass Left Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue	Procedure	ICD-10-PCS
312117113	Substitute, Percutaneous Endoscopic Approach	. roccaure	.02 10 1 03
041N4ZL	Bypass Left Popliteal Artery to Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4ZM	Bypass Left Popliteal Artery to Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4ZP	Bypass Left Popliteal Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 871 of 1023



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041N4ZQ	Bypass Left Popliteal Artery to Lower Extremity Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
041N4ZS	Bypass Left Popliteal Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T09P	Bypass Right Peroneal Artery to Foot Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041T09Q	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041T09S	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041T0AP	Bypass Right Peroneal Artery to Foot Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041T0AQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041T0AS	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041T0JP	Bypass Right Peroneal Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041T0JQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
0447016	Approach	Dunandous	ICD 40 DCC
041T0JS	Bypass Right Peroneal Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041T0KP	Bypass Right Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041T0KQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
0.44.70.46	Substitute, Open Approach		100 10 000
041T0KS	Bypass Right Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041T0ZP	Bypass Right Peroneal Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041T0ZQ	Bypass Right Peroneal Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041T0ZS	Bypass Right Peroneal Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041T49P	Bypass Right Peroneal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T49Q	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T49S	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4AP	Bypass Right Peroneal Artery to Foot Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
04474	Percutaneous Endoscopic Approach	Dara I	100 40 500
041T4AQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4AS	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4JP	Bypass Right Peroneal Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 872 of 1023



	doubt docume buseline distributes in this hequest	Code	
Code	Description	Category	Code Type
041T4JQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041T4JS	Bypass Right Peroneal Artery to Lower Extremity Vein with Synthetic Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041T4KP	Bypass Right Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041T4KQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
044741/6	Substitute, Percutaneous Endoscopic Approach	Dunnalium	ICD 40 DCC
041T4KS	Bypass Right Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue	Procedure	ICD-10-PCS
041T4ZP	Substitute, Percutaneous Endoscopic Approach Bypass Right Peroneal Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4ZP 041T4ZQ	Bypass Right Peroneal Artery to Lower Extremity Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0.1	Approach		.02 20 . 00
041T4ZS	Bypass Right Peroneal Artery to Lower Extremity Vein, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
041U09P	Bypass Left Peroneal Artery to Foot Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041U09Q	Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041U09S	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue,	Procedure	ICD-10-PCS
0.44110.4.0	Open Approach		100 40 000
041U0AP	Bypass Left Peroneal Artery to Foot Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
041U0AQ	Approach Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
04100AQ	Open Approach	rrocedure	1CD-10-1 C3
041U0AS	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
	Open Approach		
041U0JP	Bypass Left Peroneal Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041U0JQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041U0JS	Bypass Left Peroneal Artery to Lower Extremity Vein with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041U0KP	Bypass Left Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute, Open	Procedure	ICD-10-PCS
0411101/0	Approach Propose Left Personal Artery to Lewer Futromity Artery with Nepaytologous Tissue	Dragoduro	ICD 10 DCC
041U0KQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041U0KS	Bypass Left Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue	Procedure	ICD-10-PCS
0410003	Substitute, Open Approach	rrocedure	1CD-10-1 C3
041U0ZP	Bypass Left Peroneal Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041U0ZQ	Bypass Left Peroneal Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041U0ZS	Bypass Left Peroneal Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041U49P	Bypass Left Peroneal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 873 of 1023



	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
041U49Q	Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041U49S	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041U4AP	Bypass Left Peroneal Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
041U4AQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
04411446	Percutaneous Endoscopic Approach	Dunandous	ICD 40 DCC
041U4AS	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue,	Procedure	ICD-10-PCS
04111410	Percutaneous Endoscopic Approach	Dragodura	ICD 10 DCS
041U4JP	Bypass Left Peroneal Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4JQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Synthetic Substitute,	Procedure	ICD-10-PCS
0410410	Percutaneous Endoscopic Approach	Trocedure	1CD-10-1 C3
041U4JS	Bypass Left Peroneal Artery to Lower Extremity Vein with Synthetic Substitute,	Procedure	ICD-10-PCS
0.120.00	Percutaneous Endoscopic Approach		.02 20 . 00
041U4KP	Bypass Left Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041U4KQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041U4KS	Bypass Left Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue	Procedure	ICD-10-PCS
	Substitute, Percutaneous Endoscopic Approach		
041U4ZP	Bypass Left Peroneal Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4ZQ	Bypass Left Peroneal Artery to Lower Extremity Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
041U4ZS	Bypass Left Peroneal Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0411/000	Dynass Dight Foot Astory to Foot Astory with Autologous Vangus Tissue, Onen Annyoneh	Dragodura	ICD 10 DCS
041V09P	Bypass Right Foot Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041V09Q	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
041V0JQ	Approach	Trocedure	1CD-10-1 C3
041V09S	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Open	Procedure	ICD-10-PCS
0.21000	Approach		.02 20 . 00
041V0AP	Bypass Right Foot Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041V0AQ	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041V0AS	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open	Procedure	ICD-10-PCS
	Approach		
041V0JP	Bypass Right Foot Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041V0JQ	Bypass Right Foot Artery to Lower Extremity Artery with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041V0JS	Bypass Right Foot Artery to Lower Extremity Vein with Synthetic Substitute, Open	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 874 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041V0KP	Bypass Right Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Open	Procedure	ICD-10-PCS
	Approach		
041V0KQ	Bypass Right Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Open Approach		
041V0KS	Bypass Right Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041V0ZP	Bypass Right Foot Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041V0ZQ	Bypass Right Foot Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041V0ZS	Bypass Right Foot Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041V49P	Bypass Right Foot Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V49Q	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V49S	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4AP	Bypass Right Foot Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4AQ	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4AS	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4JP	Bypass Right Foot Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4JQ	Bypass Right Foot Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4JS	Bypass Right Foot Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4KP	Bypass Right Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4KQ	Bypass Right Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4KS	Bypass Right Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4ZP	Bypass Right Foot Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4ZQ	Bypass Right Foot Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4ZS	Bypass Right Foot Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W09P	Bypass Left Foot Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041W09Q	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 875 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
041W09S	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041W0AP	Bypass Left Foot Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041W0AQ	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041W0AS	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041W0JP 041W0JQ	Bypass Left Foot Artery to Foot Artery with Synthetic Substitute, Open Approach Bypass Left Foot Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
041W0JS	Bypass Left Foot Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041W0KP	Bypass Left Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041W0KQ	Bypass Left Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041W0KS	Bypass Left Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041W0ZP 041W0ZQ 041W0ZS 041W49P	Bypass Left Foot Artery to Foot Artery, Open Approach Bypass Left Foot Artery to Lower Extremity Artery, Open Approach Bypass Left Foot Artery to Lower Extremity Vein, Open Approach Bypass Left Foot Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS ICD-10-PCS
041W49Q	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W49S	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4AP	Bypass Left Foot Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4AQ	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4AS	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4JP	Bypass Left Foot Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4JQ	Bypass Left Foot Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4JS	Bypass Left Foot Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4KP	Bypass Left Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 876 of 1023



		Code	
Code	Description	Category	Code Type
041W4KQ	Bypass Left Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
041W4KS	Bypass Left Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4ZP	Bypass Left Foot Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4ZQ	Bypass Left Foot Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4ZS	Bypass Left Foot Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04700D6	Dilation of Abdominal Aorta, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
04700F6	Dilation of Abdominal Aorta, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
04700G6	Dilation of Abdominal Aorta, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
04700Z6	Dilation of Abdominal Aorta, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04703D6	Dilation of Abdominal Aorta, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
04703F6	Dilation of Abdominal Aorta, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
04703G6	Dilation of Abdominal Aorta, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
04703Z6	Dilation of Abdominal Aorta, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04704D6	Dilation of Abdominal Aorta, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04704F6	Dilation of Abdominal Aorta, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04704G6	Dilation of Abdominal Aorta, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04704Z6	Dilation of Abdominal Aorta, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C041	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047C046	Dilation of Right Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047C04Z	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047C056	Dilation of Right Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C05Z	Dilation of Right Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C066	Dilation of Right Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C06Z	Dilation of Right Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 877 of 1023



		Code	
Code	Description	Category	Code Type
047C076	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C07Z	Dilation of Right Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0D1	Dilation of Right Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047C0D6	Dilation of Right Common Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047C0DZ 047C0E6	Dilation of Right Common Iliac Artery with Intraluminal Device, Open Approach Dilation of Right Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047C0EZ	Dilation of Right Common Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0F6	Dilation of Right Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0FZ	Dilation of Right Common Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0G6	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0GZ	Dilation of Right Common Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0Z1 047C0Z6 047C0ZZ 047C341	Dilation of Right Common Iliac Artery using Drug-Coated Balloon, Open Approach Dilation of Right Common Iliac Artery, Bifurcation, Open Approach Dilation of Right Common Iliac Artery, Open Approach Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS ICD-10-PCS
047C346	Dilation of Right Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047C34Z	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047C356	Dilation of Right Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C35Z	Dilation of Right Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C366	Dilation of Right Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C36Z	Dilation of Right Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C376	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C37Z	Dilation of Right Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 878 of 1023



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047C3D1	Dilation of Right Common Iliac Artery with Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Approach		
047C3D6	Dilation of Right Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047C3DZ	Dilation of Right Common Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047C3E6	Dilation of Right Common Iliac Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
047 C3L0	Percutaneous Approach	Trocedure	1CD-10-1 C3
047C3EZ	Dilation of Right Common Iliac Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047C3F6	Dilation of Right Common Iliac Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047C3FZ	Dilation of Right Common Iliac Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047C3G6	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
047C3GZ	Devices, Percutaneous Approach Dilation of Right Common Iliac Artery with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
047C3GZ	Percutaneous Approach	riocedule	ICD-10-PC3
047C3Z1	Dilation of Right Common Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
	, , , , , , , , , , , , , , , , , , ,		
047C3Z6	Dilation of Right Common Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047C3ZZ	Dilation of Right Common Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047C441	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
0476446	Coated Balloon, Percutaneous Endoscopic Approach	Dua aa duua	ICD 10 DCC
047C446	Dilation of Right Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C44Z	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0170112	Endoscopic Approach	1100000010	105 10 1 00
047C456	Dilation of Right Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047C45Z	Dilation of Right Common Iliac Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047C466	Dilation of Right Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0476467	Devices, Percutaneous Endoscopic Approach	Due e e el core	ICD 40 DCC
047C46Z	Dilation of Right Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C476	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
047 C47 0	Intraluminal Devices, Percutaneous Endoscopic Approach	Troccaure	100 101 05
047C47Z	Dilation of Right Common Iliac Artery with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047C4D1	Dilation of Right Common Iliac Artery with Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 879 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047C4D6	Dilation of Right Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4DZ	Dilation of Right Common Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4E6	Dilation of Right Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4EZ	Dilation of Right Common Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4F6	Dilation of Right Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4FZ	Dilation of Right Common Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4G6	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4GZ	Dilation of Right Common Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4Z1	Dilation of Right Common Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4Z6	Dilation of Right Common Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4ZZ 047D041	Dilation of Right Common Iliac Artery, Percutaneous Endoscopic Approach Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047D046	Dilation of Left Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D04Z	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D056	Dilation of Left Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D05Z	Dilation of Left Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D066	Dilation of Left Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D06Z	Dilation of Left Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D076	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D07Z	Dilation of Left Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0D1	Dilation of Left Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 880 of 1023



		Code	
Code	Description	Category	Code Type
047D0D6	Dilation of Left Common Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D0DZ	Dilation of Left Common Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D0E6	Dilation of Left Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0EZ	Dilation of Left Common Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0F6	Dilation of Left Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0FZ	Dilation of Left Common Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0G6	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0GZ	Dilation of Left Common Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0Z1	Dilation of Left Common Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047D0Z6	Dilation of Left Common Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047D0ZZ	Dilation of Left Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047D341	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047D346	Dilation of Left Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D34Z	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D356	Dilation of Left Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D35Z	Dilation of Left Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D366	Dilation of Left Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D36Z	Dilation of Left Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D376	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D37Z	Dilation of Left Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3D1	Dilation of Left Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047D3D6	Dilation of Left Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D3DZ	Dilation of Left Common Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D3E6	Dilation of Left Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 881 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047D3EZ	Dilation of Left Common Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3F6	Dilation of Left Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3FZ	Dilation of Left Common Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3G6	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3GZ	Dilation of Left Common Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3Z1	Dilation of Left Common Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047D3Z6 047D3ZZ 047D441	Dilation of Left Common Iliac Artery, Bifurcation, Percutaneous Approach Dilation of Left Common Iliac Artery, Percutaneous Approach Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS
047D446	Dilation of Left Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D44Z	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D456	Dilation of Left Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D45Z	Dilation of Left Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D466	Dilation of Left Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D46Z	Dilation of Left Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D476	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D47Z	Dilation of Left Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4D1	Dilation of Left Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4D6	Dilation of Left Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4DZ	Dilation of Left Common Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4E6	Dilation of Left Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4EZ	Dilation of Left Common Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 882 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047D4F6	Dilation of Left Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4FZ	Dilation of Left Common Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4G6	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4GZ	Dilation of Left Common Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4Z1	Dilation of Left Common Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4Z6	Dilation of Left Common Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4ZZ 047E04Z	Dilation of Left Common Iliac Artery, Percutaneous Endoscopic Approach Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047E05Z	Dilation of Right Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E06Z	Dilation of Right Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E07Z	Dilation of Right Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0D1	Dilation of Right Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047E0D6	Dilation of Right Internal Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047E0DZ 047E0E6	Dilation of Right Internal Iliac Artery with Intraluminal Device, Open Approach Dilation of Right Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047E0EZ 047E0F6	Dilation of Right Internal Iliac Artery with Two Intraluminal Devices, Open Approach Dilation of Right Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047E0FZ	Dilation of Right Internal Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0G6	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0GZ	Dilation of Right Internal Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0Z1 047E0Z6 047E0ZZ 047E341	Dilation of Right Internal Iliac Artery using Drug-Coated Balloon, Open Approach Dilation of Right Internal Iliac Artery, Bifurcation, Open Approach Dilation of Right Internal Iliac Artery, Open Approach Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS ICD-10-PCS

cder_mpl1p_wp077 Page 883 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047E346	Dilation of Right Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047E34Z	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047E356	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E35Z	Dilation of Right Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E366	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E36Z	Dilation of Right Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E376	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E37Z	Dilation of Right Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3D1	Dilation of Right Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047E3D6	Dilation of Right Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047E3DZ	Dilation of Right Internal Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047E3E6	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3EZ	Dilation of Right Internal Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3F6	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3FZ	Dilation of Right Internal Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3G6	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3GZ	Dilation of Right Internal Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3Z1	Dilation of Right Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047E3Z6	Dilation of Right Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047E3ZZ	Dilation of Right Internal Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047E441	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E446	Dilation of Right Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 884 of 1023



	Coues osed to Define Baseline Characteristics in this request	Code	
Code	Description	Category	Code Type
047E44Z	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047E456	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047E45Z	Dilation of Right Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E466	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E46Z	Dilation of Right Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E476	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E47Z	Dilation of Right Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4D1	Dilation of Right Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4D6	Dilation of Right Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4DZ	Dilation of Right Internal Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4E6	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4EZ	Dilation of Right Internal Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4F6	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4FZ	Dilation of Right Internal Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4G6	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4GZ	Dilation of Right Internal Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4Z1	Dilation of Right Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4Z6	Dilation of Right Internal Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4ZZ 047F041	Dilation of Right Internal Iliac Artery, Percutaneous Endoscopic Approach Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047F046	Dilation of Left Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047F04Z	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 885 of 1023



		Code	
Code	Description	Category	Code Type
047F056	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047F05Z	Dilation of Left Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047F066	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047F06Z	Dilation of Left Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047F076	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
047F07Z	Dilation of Left Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047F0D1	Dilation of Left Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Open Approach		
047F0D6	Dilation of Left Internal Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047F0DZ	Dilation of Left Internal Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047F0E6	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047F0EZ	Dilation of Left Internal Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0F6	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047F0FZ	Dilation of Left Internal Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0G6	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047F0GZ	Dilation of Left Internal Iliac Artery with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047F0Z1	Dilation of Left Internal Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047F0Z6	Dilation of Left Internal Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047F0ZZ 047F341	Dilation of Left Internal Iliac Artery, Open Approach	Procedure Procedure	ICD-10-PCS
04/F341	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
0475246	•	Dragodura	ICD 10 DCC
047F346	Dilation of Left Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0475247	Percutaneous Approach	Dan and dans	ICD 40 DCC
047F34Z	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0.47525.6	Approach		16D 40 D66
047F356	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0.475057	Devices, Percutaneous Approach		100 10 000
047F35Z	Dilation of Left Internal Iliac Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0.477057	Percutaneous Approach		100 10
047F366	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047F36Z	Dilation of Left Internal Iliac Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		

cder_mpl1p_wp077 Page 886 of 1023



	Coues osed to Define Dasenne Characteristics in this request	Code	
Code	Description	Category	Code Type
047F376	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
047F37Z	Dilation of Left Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047F3D1	Dilation of Left Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047F3D6	Dilation of Left Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047F3DZ	Dilation of Left Internal Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047F3E6	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3EZ	Dilation of Left Internal Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3F6	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3FZ	Dilation of Left Internal Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3G6	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3GZ	Dilation of Left Internal Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3Z1	Dilation of Left Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047F3Z6	Dilation of Left Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047F3ZZ	Dilation of Left Internal Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047F441	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F446	Dilation of Left Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F44Z	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F456	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F45Z	Dilation of Left Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F466	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F46Z	Dilation of Left Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F476	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 887 of 1023



	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
047F47Z	Dilation of Left Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047F4D1	Dilation of Left Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047F4D6	Dilation of Left Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4DZ	Dilation of Left Internal Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4E6	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4EZ	Dilation of Left Internal Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4F6	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4FZ	Dilation of Left Internal Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4G6	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4GZ	Dilation of Left Internal Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4Z1	Dilation of Left Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4Z6	Dilation of Left Internal Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4ZZ	Dilation of Left Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H041	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047H046	Dilation of Right External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047H04Z	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047H056	Dilation of Right External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H05Z	Dilation of Right External Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H066	Dilation of Right External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H06Z	Dilation of Right External Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H076	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H07Z	Dilation of Right External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 888 of 1023



		Code	
Code	Description	Category	Code Type
047H0D1	Dilation of Right External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Open Approach		
047H0D6	Dilation of Right External Iliac Artery, Bifurcation, with Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047H0DZ	Dilation of Right External Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047H0E6	Dilation of Right External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0EZ	Dilation of Right External Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0F6	Dilation of Right External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0FZ	Dilation of Right External Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0G6	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0GZ	Dilation of Right External Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0Z1	Dilation of Right External Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047H0Z6	Dilation of Right External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047H0ZZ	Dilation of Right External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047H341	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047H346	Dilation of Right External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047H34Z	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047H356	Dilation of Right External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H35Z	Dilation of Right External Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H366	Dilation of Right External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H36Z	Dilation of Right External Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H376	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H37Z	Dilation of Right External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3D1	Dilation of Right External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047H3D6	Dilation of Right External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047H3DZ	Dilation of Right External Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 889 of 1023



Code	Description	Category	Code Type
047H3E6	Dilation of Right External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3EZ	Dilation of Right External Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3F6	Dilation of Right External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3FZ	Dilation of Right External Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3G6	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3GZ	Dilation of Right External Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3Z1	Dilation of Right External Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047H3Z6	Dilation of Right External Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047H3ZZ	Dilation of Right External Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047H441	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H446	Dilation of Right External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H44Z	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H456	Dilation of Right External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H45Z	Dilation of Right External Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H466	Dilation of Right External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H46Z	Dilation of Right External Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H476	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H47Z	Dilation of Right External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4D1	Dilation of Right External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4D6	Dilation of Right External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4DZ	Dilation of Right External Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4E6	Dilation of Right External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 890 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047H4EZ	Dilation of Right External Iliac Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047H4F6	Dilation of Right External Iliac Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
0.4711.457	Percutaneous Endoscopic Approach		100 40 000
047H4FZ	Dilation of Right External Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4G6	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4GZ	Dilation of Right External Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4Z1	Dilation of Right External Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4Z6	Dilation of Right External Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4ZZ	Dilation of Right External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J041	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047J046	Dilation of Left External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047J04Z	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047J056	Dilation of Left External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J05Z	Dilation of Left External Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J066	Dilation of Left External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J06Z	Dilation of Left External Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J076	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J07Z	Dilation of Left External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0D1	Dilation of Left External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047J0D6	Dilation of Left External Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047J0DZ 047J0E6	Dilation of Left External Iliac Artery with Intraluminal Device, Open Approach Dilation of Left External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047J0EZ 047J0F6	Dilation of Left External Iliac Artery with Two Intraluminal Devices, Open Approach Dilation of Left External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS

cder_mpl1p_wp077 Page 891 of 1023



Code	Description	Category	Code Type
047J0FZ	Dilation of Left External Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0G6	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047J0GZ	Dilation of Left External Iliac Artery with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047J0Z1	Dilation of Left External Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047J0Z6	Dilation of Left External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047J0ZZ	Dilation of Left External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047J341	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047J346	Dilation of Left External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047J34Z	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047J356	Dilation of Left External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047J35Z	Dilation of Left External Iliac Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047J366	Dilation of Left External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047J36Z	Dilation of Left External Iliac Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047J376	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Approach		
047J37Z	Dilation of Left External Iliac Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047J3D1	Dilation of Left External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047J3D6	Dilation of Left External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047J3DZ	Dilation of Left External Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
	,		
047J3E6	Dilation of Left External Iliac Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047J3EZ	Dilation of Left External Iliac Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047J3F6	Dilation of Left External Iliac Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047J3FZ	Dilation of Left External Iliac Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach	. roccaure	.02 20 1 03
047J3G6	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach	. roccaure	.02 20 1 00
	- Croataneous ripproudit		

cder_mpl1p_wp077 Page 892 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047J3GZ	Dilation of Left External Iliac Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0471271	Approach Dilation of Loft Fitograph High Arten vising Days Control Balloon, Development Approach	Dunnanduun	ICD 10 DCC
047J3Z1	Dilation of Left External Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047J3Z6	Dilation of Left External Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047J3ZZ	Dilation of Left External Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047J441	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J446	Dilation of Left External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J44Z	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J456	Dilation of Left External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J45Z	Dilation of Left External Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J466	Dilation of Left External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J46Z	Dilation of Left External Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J476	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J47Z	Dilation of Left External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4D1	Dilation of Left External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4D6	Dilation of Left External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4DZ	Dilation of Left External Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4E6	Dilation of Left External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4EZ	Dilation of Left External Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4F6	Dilation of Left External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4FZ	Dilation of Left External Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4G6	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4GZ	Dilation of Left External Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 893 of 1023



	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
047J4Z1	Dilation of Left External Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047J4Z6	Dilation of Left External Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4ZZ	Dilation of Left External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K041	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Open Approach		
047K046	Dilation of Right Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K04Z	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K056	Dilation of Right Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K05Z	Dilation of Right Femoral Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K066	Dilation of Right Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K06Z	Dilation of Right Femoral Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K076	Dilation of Right Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K07Z	Dilation of Right Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0D1	Dilation of Right Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047K0D6	Dilation of Right Femoral Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K0DZ	Dilation of Right Femoral Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K0E6	Dilation of Right Femoral Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0EZ	Dilation of Right Femoral Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0F6	Dilation of Right Femoral Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0FZ	Dilation of Right Femoral Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0G6	Dilation of Right Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0GZ	Dilation of Right Femoral Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0Z1	Dilation of Right Femoral Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047K0Z6	Dilation of Right Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047K0ZZ	Dilation of Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
047K341	, , , , , , , , , , , , , , , , , , , ,	Procedure	ICD-10-PCS
	Balloon, Percutaneous Approach		

cder_mpl1p_wp077 Page 894 of 1023



	•	Code	
Code	Description	Category	Code Type
047K346	Dilation of Right Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K34Z	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047K356	Dilation of Right Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K35Z	Dilation of Right Femoral Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K366	Dilation of Right Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047K36Z	Dilation of Right Femoral Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K376	Dilation of Right Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047K37Z	Dilation of Right Femoral Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K3D1	Dilation of Right Femoral Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K3D6	Dilation of Right Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047K3DZ	Dilation of Right Femoral Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047K3E6	Dilation of Right Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047K3EZ	Dilation of Right Femoral Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3F6	Dilation of Right Femoral Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K3FZ	Dilation of Right Femoral Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3G6	Dilation of Right Femoral Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047K3GZ	Dilation of Right Femoral Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047K3Z1	Dilation of Right Femoral Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047K3Z6	Dilation of Right Femoral Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047K3ZZ	Dilation of Right Femoral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047K441	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Endoscopic Approach		
047K446	Dilation of Right Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047K44Z	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 895 of 1023



		Code	
Code	Description	Category	Code Type
047K456	Dilation of Right Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047K45Z	Dilation of Right Femoral Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047K466	Dilation of Right Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047K46Z	Dilation of Right Femoral Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047K476	Dilation of Right Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047K47Z	Dilation of Right Femoral Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047K4D1	Dilation of Right Femoral Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047K4D6	Dilation of Right Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047K4DZ	Dilation of Right Femoral Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047K4E6	Dilation of Right Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047K4EZ	Dilation of Right Femoral Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047K4F6	Dilation of Right Femoral Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047K4FZ	Dilation of Right Femoral Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047K4G6	Dilation of Right Femoral Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047K4GZ	Dilation of Right Femoral Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047K4Z1	Dilation of Right Femoral Artery using Drug-Coated Balloon, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047K4Z6	Dilation of Right Femoral Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4ZZ	Dilation of Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L041	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Open Approach		
047L046	Dilation of Left Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047L04Z	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047L056	Dilation of Left Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		

cder_mpl1p_wp077 Page 896 of 1023



		Code	
Code	Description	Category	Code Type
047L05Z	Dilation of Left Femoral Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047L066	Dilation of Left Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047L06Z	Dilation of Left Femoral Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047L076	Dilation of Left Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047L07Z	Dilation of Left Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047L0D1	Dilation of Left Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Open	Procedure	ICD-10-PCS
	Approach		
047L0D6	Dilation of Left Femoral Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
	, , , , , , , , , , , , , , , , , , , ,		
047L0DZ	Dilation of Left Femoral Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047L0E6	Dilation of Left Femoral Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047L0EZ	Dilation of Left Femoral Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0F6	Dilation of Left Femoral Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047L0FZ	Dilation of Left Femoral Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0G6	Dilation of Left Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047L0GZ	Dilation of Left Femoral Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0Z1	Dilation of Left Femoral Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047L0Z6	Dilation of Left Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047L0ZZ	Dilation of Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
047L341	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
0471246	,	Dunnadiina	ICD 10 DCC
047L346	Dilation of Left Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0471247	Percutaneous Approach	Dunandana	100 10 000
047L34Z	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0471056	Approach		105 10 500
047L356	Dilation of Left Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047L35Z	Dilation of Left Femoral Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047L366	Dilation of Left Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047L36Z	Dilation of Left Femoral Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
	r creataneous Approach		

cder_mpl1p_wp077 Page 897 of 1023



		Code	
Code	Description	Category	Code Type
047L376	Dilation of Left Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L37Z	Dilation of Left Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3D1	Dilation of Left Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047L3D6	Dilation of Left Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047L3DZ 047L3E6	Dilation of Left Femoral Artery with Intraluminal Device, Percutaneous Approach Dilation of Left Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047L3EZ	Dilation of Left Femoral Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3F6	Dilation of Left Femoral Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3FZ	Dilation of Left Femoral Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3G6	Dilation of Left Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3GZ	Dilation of Left Femoral Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3Z1 047L3Z6 047L3ZZ 047L441	Dilation of Left Femoral Artery using Drug-Coated Balloon, Percutaneous Approach Dilation of Left Femoral Artery, Bifurcation, Percutaneous Approach Dilation of Left Femoral Artery, Percutaneous Approach Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS ICD-10-PCS
047L446	Dilation of Left Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L44Z	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L456	Dilation of Left Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L45Z	Dilation of Left Femoral Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L466	Dilation of Left Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L46Z	Dilation of Left Femoral Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L476	Dilation of Left Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L47Z	Dilation of Left Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 898 of 1023



	·	Code	
Code	Description	Category	Code Type
047L4D1	Dilation of Left Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4D6	Dilation of Left Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4DZ	Dilation of Left Femoral Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4E6	Dilation of Left Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4EZ	Dilation of Left Femoral Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4F6	Dilation of Left Femoral Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4FZ	Dilation of Left Femoral Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4G6	Dilation of Left Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4GZ	Dilation of Left Femoral Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4Z1	Dilation of Left Femoral Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4Z6	Dilation of Left Femoral Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4ZZ	Dilation of Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M041	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047M046	Dilation of Right Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047M04Z	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047M056	Dilation of Right Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M05Z	Dilation of Right Popliteal Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M066	Dilation of Right Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M06Z	Dilation of Right Popliteal Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M076	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M07Z	Dilation of Right Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0D1	Dilation of Right Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 899 of 1023



	Codes Osed to Define baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047M0D6	Dilation of Right Popliteal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047M0DZ	Dilation of Right Popliteal Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047M0E6	Dilation of Right Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0EZ 047M0F6	Dilation of Right Popliteal Artery with Two Intraluminal Devices, Open Approach Dilation of Right Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047M0FZ 047M0G6	Dilation of Right Popliteal Artery with Three Intraluminal Devices, Open Approach Dilation of Right Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047M0GZ	Dilation of Right Popliteal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0Z1 047M0Z6 047M0ZZ	Dilation of Right Popliteal Artery using Drug-Coated Balloon, Open Approach Dilation of Right Popliteal Artery, Bifurcation, Open Approach Dilation of Right Popliteal Artery, Open Approach	Procedure Procedure Procedure	ICD-10-PCS ICD-10-PCS ICD-10-PCS
047M341	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047M346	Dilation of Right Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047M34Z	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047M356	Dilation of Right Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M35Z	Dilation of Right Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M366	Dilation of Right Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M36Z	Dilation of Right Popliteal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M376	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M37Z	Dilation of Right Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3D1	Dilation of Right Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047M3D6	Dilation of Right Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047M3DZ 047M3E6	Dilation of Right Popliteal Artery with Intraluminal Device, Percutaneous Approach Dilation of Right Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047M3EZ	Dilation of Right Popliteal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 900 of 1023



riocedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047M3F6	Dilation of Right Popliteal Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047M3FZ	Dilation of Right Popliteal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3G6	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3GZ	Dilation of Right Popliteal Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3Z1	Dilation of Right Popliteal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047M3Z6	Dilation of Right Popliteal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047M3ZZ	Dilation of Right Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047M441	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M446	Dilation of Right Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M44Z	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M456	Dilation of Right Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M45Z	Dilation of Right Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M466	Dilation of Right Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M46Z	Dilation of Right Popliteal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M476	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M47Z	Dilation of Right Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4D1	Dilation of Right Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4D6	Dilation of Right Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4DZ	Dilation of Right Popliteal Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4E6	Dilation of Right Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4EZ	Dilation of Right Popliteal Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4F6	Dilation of Right Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 901 of 1023



		Code	
Code	Description	Category	Code Type
047M4FZ	Dilation of Right Popliteal Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047M4G6	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047M4GZ	Dilation of Right Popliteal Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047M4Z1	Dilation of Right Popliteal Artery using Drug-Coated Balloon, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047M4Z6	Dilation of Right Popliteal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
)47M4ZZ	Dilation of Right Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N041	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Open Approach		
047N046	Dilation of Left Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047N04Z	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047N056	Dilation of Left Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047N05Z	Dilation of Left Popliteal Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
71711032	Approach	rroccaare	100 10 1 0
047N066	Dilation of Left Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PC
,,,,,,,,,,	Open Approach	rroccaare	100 10 1 0
047N06Z	Dilation of Left Popliteal Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PC
J 171100L	Approach	rroccaare	100 10 1 00
047N076	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
J471 10 70	Devices, Open Approach	Trocedure	ICD-10-1 CC
047N07Z	Dilation of Left Popliteal Artery with Four or More Drug-eluting Intraluminal Devices,	Drocoduro	ICD 10 DC
)4/NU/Z	Open Approach	Procedure	ICD-10-PCS
0.47NOD4		Procedure	ICD 10 DC
047N0D1	Dilation of Left Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
.4711006	Open Approach	n 1	100 40 00
047N0D6	Dilation of Left Popliteal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
.4711007		5 .	100 40 00
047N0DZ	Dilation of Left Popliteal Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047N0E6	Dilation of Left Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PC
4711057	Approach		100 10 00
)47N0EZ	Dilation of Left Popliteal Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PC
)47N0F6	Dilation of Left Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PC
	Approach		105 15 7 7
047N0FZ	Dilation of Left Popliteal Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0G6	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PC
	Open Approach		
047N0GZ	Dilation of Left Popliteal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 902 of 1023



1 TOCEGUIE	codes osed to Define baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047N0Z1	Dilation of Left Popliteal Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047N0Z6	Dilation of Left Popliteal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047N0ZZ	Dilation of Left Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
047N341	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Approach		
047N346	Dilation of Left Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047N34Z	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0 17 110 12	Approach		.02 20 . 00
047N356	Dilation of Left Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
04/11556		Procedure	ICD-10-PC3
	Percutaneous Approach		
047N35Z	Dilation of Left Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047N366	Dilation of Left Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047N36Z	Dilation of Left Popliteal Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047N376	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0 17 110 7 0	Devices, Percutaneous Approach		.02 20 . 00
047N37Z	Dilation of Left Popliteal Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
04/113/2		riocedule	ICD-10-PC3
0.4711204	Percutaneous Approach		160 40 066
047N3D1	Dilation of Left Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047N3D6	Dilation of Left Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047N3DZ	Dilation of Left Popliteal Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047N3E6	Dilation of Left Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047N3EZ	Dilation of Left Popliteal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3F6	Dilation of Left Popliteal Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
01711313	Percutaneous Approach		100 10 1 00
047N3FZ	Dilation of Left Popliteal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
U4/N3FZ	Dilation of Left Popilteal Aftery with Tillee intratuminal Devices, Percutaneous Approach	Procedure	ICD-10-PC3
047N3G6	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047N3GZ	Dilation of Left Popliteal Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047N3Z1	Dilation of Left Popliteal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047N3Z6	Dilation of Left Popliteal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047N3ZZ	Dilation of Left Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047N441	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 903 of 1023



		Code	
Code	Description	Category	Code Type
047N446	Dilation of Left Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N44Z	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N456	Dilation of Left Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N45Z	Dilation of Left Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N466	Dilation of Left Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N46Z	Dilation of Left Popliteal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N476	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N47Z	Dilation of Left Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4D1	Dilation of Left Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4D6	Dilation of Left Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4DZ	Dilation of Left Popliteal Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4E6	Dilation of Left Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4EZ	Dilation of Left Popliteal Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4F6	Dilation of Left Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4FZ	Dilation of Left Popliteal Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4G6	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4GZ	Dilation of Left Popliteal Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4Z1	Dilation of Left Popliteal Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4Z6	Dilation of Left Popliteal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4ZZ 047P041	Dilation of Left Popliteal Artery, Percutaneous Endoscopic Approach Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS

cder_mpl1p_wp077 Page 904 of 1023



	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
047P046	Dilation of Right Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Open Approach		
047P04Z	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047P056	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047P05Z	Dilation of Right Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047P066	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047P06Z	Dilation of Right Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
• • • •	Approach		
047P076	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
047P07Z	Dilation of Right Anterior Tibial Artery with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
• • . =	Devices, Open Approach		
047P0D1	Dilation of Right Anterior Tibial Artery with Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
0 171 02 2	Balloon, Open Approach		.02 20 . 00
047P0D6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Open	Procedure	ICD-10-PCS
0 171 02 0	Approach		.02 20 . 00
047P0DZ	Dilation of Right Anterior Tibial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047P0E6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047P0EZ	Dilation of Right Anterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0F6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047P0FZ	Dilation of Right Anterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0G6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047P0GZ	Dilation of Right Anterior Tibial Artery with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047P0Z1	Dilation of Right Anterior Tibial Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047P0Z6	Dilation of Right Anterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047P0ZZ	Dilation of Right Anterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
047P341	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Percutaneous Approach		
047P346	Dilation of Right Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047P34Z	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		

cder_mpl1p_wp077 Page 905 of 1023



		Code	
Code	Description	Category	Code Type
047P356	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P35Z	Dilation of Right Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
)47P366	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
)47P36Z	Dilation of Right Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
)47P376	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
)47P37Z	Dilation of Right Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
)47P3D1	Dilation of Right Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047P3D6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047P3DZ	Dilation of Right Anterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
)47P3E6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3EZ	Dilation of Right Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
)47P3F6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
)47P3FZ	Dilation of Right Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3G6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
)47P3GZ	Dilation of Right Anterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
)47P3Z1	Dilation of Right Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
)47P3Z6)47P3ZZ	Dilation of Right Anterior Tibial Artery, Bifurcation, Percutaneous Approach Dilation of Right Anterior Tibial Artery, Percutaneous Approach	Procedure Procedure	ICD-10-PCS
)47P441	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
)47P446	Dilation of Right Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
)47P44Z	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P456	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 906 of 1023



	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
047P45Z	Dilation of Right Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047P466	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047P46Z	Dilation of Right Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047P476	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
047P47Z	Dilation of Right Anterior Tibial Artery with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0.470.40.4	Devices, Percutaneous Endoscopic Approach		100 10 000
047P4D1	Dilation of Right Anterior Tibial Artery with Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
0470406	Balloon, Percutaneous Endoscopic Approach	Duanadiina	ICD 10 DCC
047P4D6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
047P4DZ	Percutaneous Endoscopic Approach Dilation of Right Antonior Tibiol Artony with Introluminal Device Percutaneous Endoscopic	Drocoduro	ICD 10 DCS
0477402	Dilation of Right Anterior Tibial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4E6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
047F4L0	Percutaneous Endoscopic Approach	riocedure	ICD-10-FC3
047P4EZ	Dilation of Right Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0 171 122	Endoscopic Approach	rroccaare	102 10 1 03
047P4F6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047P4FZ	Dilation of Right Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047P4G6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047P4GZ	Dilation of Right Anterior Tibial Artery with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047P4Z1	Dilation of Right Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047P4Z6	Dilation of Right Anterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4ZZ	Dilation of Right Anterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q041	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
0470046	Coated Balloon, Open Approach	Duanadiina	ICD 10 DCC
047Q046	Dilation of Left Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
047Q04Z	Open Approach Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
047Q04Z	Approach	riocedule	ICD-10-PC3
047Q056	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
047 Q030	Devices, Open Approach	riocedure	10-10-103
047Q05Z	Dilation of Left Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
J QUJL	Approach	. roccaare	.02 20 1 03
	. de la		

cder_mpl1p_wp077 Page 907 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047Q066	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q06Z	Dilation of Left Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q076	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q07Z	Dilation of Left Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0D1	Dilation of Left Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047Q0D6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047Q0DZ	Dilation of Left Anterior Tibial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047Q0E6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0EZ	Dilation of Left Anterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0F6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0FZ	Dilation of Left Anterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0G6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0GZ	Dilation of Left Anterior Tibial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0Z1	Dilation of Left Anterior Tibial Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047Q0Z6	Dilation of Left Anterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047Q0ZZ 047Q341	Dilation of Left Anterior Tibial Artery, Open Approach Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047Q341	Coated Balloon, Percutaneous Approach	riocedure	ICD-10-PC3
047Q346	Dilation of Left Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047Q34Z	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047Q356	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q35Z	Dilation of Left Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q366	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q36Z	Dilation of Left Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q376	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 908 of 1023



		Code	
Code	Description	Category	Code Type
047Q37Z	Dilation of Left Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047Q3D1	Dilation of Left Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047Q3D6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047Q3DZ	Dilation of Left Anterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3E6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047Q3EZ	Dilation of Left Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047Q3F6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047Q3FZ	Dilation of Left Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047Q3G6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047Q3GZ	Dilation of Left Anterior Tibial Artery with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047Q3Z1	Dilation of Left Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3Z6	Dilation of Left Anterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3ZZ	Dilation of Left Anterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047Q441	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Percutaneous Endoscopic Approach		
047Q446	Dilation of Left Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047Q44Z	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047Q456	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047Q45Z	Dilation of Left Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047Q466	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047Q46Z	Dilation of Left Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047Q476	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
047Q47Z	Dilation of Left Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047Q4D1	Dilation of Left Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		

cder_mpl1p_wp077 Page 909 of 1023



2 2 2 2 2 2	Codes osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
047Q4D6	,	Procedure	ICD-10-PCS
	Endoscopic Approach		
047Q4DZ	Dilation of Left Anterior Tibial Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047Q4E6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
0.470.457	Percutaneous Endoscopic Approach		100 10 000
047Q4EZ	Dilation of Left Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
047Q4F6	Endoscopic Approach Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
047Q4F0	Percutaneous Endoscopic Approach	riocedule	ICD-10-PC3
047Q4FZ	Dilation of Left Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0174112	Endoscopic Approach	rioccaare	107 10 1 00
047Q4G6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047Q4GZ	Dilation of Left Anterior Tibial Artery with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047Q4Z1	Dilation of Left Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047Q4Z6	Dilation of Left Anterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4ZZ	Dilation of Left Anterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R041	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047R046	Dilation of Right Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047R04Z	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047R056	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R05Z	Dilation of Right Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R066	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047R06Z	Dilation of Right Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
047R076	Open Approach Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
04711070	Intraluminal Devices, Open Approach	riocedure	ICD-10-FC3
047R07Z	Dilation of Right Posterior Tibial Artery with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047R0D1	Dilation of Right Posterior Tibial Artery with Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Open Approach		
047R0D6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047R0DZ	Dilation of Right Posterior Tibial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 910 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047R0E6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047R0EZ	Dilation of Right Posterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0F6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047R0FZ	Dilation of Right Posterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0G6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0GZ	Dilation of Right Posterior Tibial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0Z1	Dilation of Right Posterior Tibial Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047R0Z6	Dilation of Right Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047R0ZZ	Dilation of Right Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
047R341	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug- Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047R346	Dilation of Right Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047R34Z	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047R356	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R35Z	Dilation of Right Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047R366	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R36Z	Dilation of Right Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R376	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R37Z	Dilation of Right Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R3D1	Dilation of Right Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047R3D6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
047R3DZ	Percutaneous Approach Dilation of Right Posterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047R3E6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R3EZ	Dilation of Right Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 911 of 1023



		Code	
Code	Description	Category	Code Type
047R3F6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047R3FZ	Dilation of Right Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047R3G6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047R3GZ	Dilation of Right Posterior Tibial Artery with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047R3Z1	Dilation of Right Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047R3Z6	Dilation of Right Posterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047R3ZZ	Dilation of Right Posterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047R441	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Percutaneous Endoscopic Approach		
047R446	Dilation of Right Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047R44Z	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047R456	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047R45Z	Dilation of Right Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047R466	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047R46Z	Dilation of Right Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047R476	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Percutaneous Endoscopic Approach		
047R47Z	Dilation of Right Posterior Tibial Artery with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047R4D1	Dilation of Right Posterior Tibial Artery with Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Endoscopic Approach		
047R4D6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047R4DZ	Dilation of Right Posterior Tibial Artery with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047R4E6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047R4EZ	Dilation of Right Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047R4F6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047R4FZ	Dilation of Right Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 912 of 1023



	Codes Osed to Define baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
047R4G6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047R4GZ	Dilation of Right Posterior Tibial Artery with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047R4Z1	Dilation of Right Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047R4Z6	Dilation of Right Posterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4ZZ	Dilation of Right Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S041	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Open Approach		
047S046	Dilation of Left Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Open Approach		
047S04Z	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047S056	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047S05Z	Dilation of Left Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047S066	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047S06Z	Dilation of Left Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047S076	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting	Procedure	ICD-10-PCS
	Intraluminal Devices, Open Approach		
047S07Z	Dilation of Left Posterior Tibial Artery with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047S0D1	Dilation of Left Posterior Tibial Artery with Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Open Approach		
047S0D6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047S0DZ	Dilation of Left Posterior Tibial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047S0E6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047S0EZ	Dilation of Left Posterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S0F6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
0.700.0	Approach		.02 20 . 00
047S0FZ	Dilation of Left Posterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S0G6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047S0GZ	Dilation of Left Posterior Tibial Artery with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
	••		

cder_mpl1p_wp077 Page 913 of 1023



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047S0Z1	Dilation of Left Posterior Tibial Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047S0Z6	Dilation of Left Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047S0ZZ	Dilation of Left Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
047S341	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-	Procedure	ICD-10-PCS
	Coated Balloon, Percutaneous Approach		
047S346	Dilation of Left Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0476247	Percutaneous Approach	Dun and dun	ICD 40 DCC
047S34Z	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047S356	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S35Z	Dilation of Left Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S366	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S36Z	Dilation of Left Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S376	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S37Z	Dilation of Left Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3D1	Dilation of Left Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047S3D6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047S3DZ	Dilation of Left Posterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047S3E6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3EZ	Dilation of Left Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3F6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3FZ	Dilation of Left Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3G6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3GZ	Dilation of Left Posterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3Z1	Dilation of Left Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047S3Z6 047S3ZZ	Dilation of Left Posterior Tibial Artery, Bifurcation, Percutaneous Approach Dilation of Left Posterior Tibial Artery, Percutaneous Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS

cder_mpl1p_wp077 Page 914 of 1023



		Code	
Code	Description	Category	Code Type
047S441	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S446	Dilation of Left Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S44Z	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S456	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S45Z	Dilation of Left Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S466	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S46Z	Dilation of Left Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S476	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S47Z	Dilation of Left Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4D1	Dilation of Left Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4D6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4DZ	Dilation of Left Posterior Tibial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4E6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4EZ	Dilation of Left Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4F6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4FZ	Dilation of Left Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4G6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4GZ	Dilation of Left Posterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4Z1	Dilation of Left Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4Z6	Dilation of Left Posterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4ZZ 047T041	Dilation of Left Posterior Tibial Artery, Percutaneous Endoscopic Approach Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS

cder_mpl1p_wp077 Page 915 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047T046	Dilation of Right Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open		ICD-10-PCS
	Approach		
047T04Z	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047T056	Dilation of Right Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047T05Z	Dilation of Right Peroneal Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047T066	Dilation of Right Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047T06Z	Dilation of Right Peroneal Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047T076	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
0.477077	Devices, Open Approach	5 1	100 40 000
047T07Z	Dilation of Right Peroneal Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
0477004	Open Approach	Duagadiina	ICD 10 DCC
047T0D1	Dilation of Right Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
047T0D6	Open Approach Dilation of Right Peroneal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0471000	bilation of Right Peroneal Artery, Bildication, with intradminal Device, Open Approach	riocedure	ICD-10-PC3
047T0DZ	Dilation of Right Peroneal Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047T0E6	Dilation of Right Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047T0EZ	Dilation of Right Peroneal Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0F6	Dilation of Right Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047T0FZ	Dilation of Right Peroneal Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0G6	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047T0GZ	Dilation of Right Peroneal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0.477074			100 10 000
047T0Z1	Dilation of Right Peroneal Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047T0Z6 047T0ZZ	Dilation of Right Peroneal Artery, Bifurcation, Open Approach Dilation of Right Peroneal Artery, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
047T0ZZ 047T341	Dilation of Right Peroneal Artery, Open Approach Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated		ICD-10-PCS
04/1341	Balloon, Percutaneous Approach	riocedule	ICD-10-FC3
047T346	Dilation of Right Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0471340	Percutaneous Approach	riocedure	ICD-10-FC3
047T34Z	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0471342	Approach	Troccaure	100 10 1 05
047T356	Dilation of Right Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
3	Percutaneous Approach		
047T35Z	Dilation of Right Peroneal Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		

cder_mpl1p_wp077 Page 916 of 1023



		Code	
Code	Description	Category	Code Type
047T366	Dilation of Right Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047T36Z	Dilation of Right Peroneal Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047T376	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047T37Z	Dilation of Right Peroneal Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047T3D1	Dilation of Right Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047T3D6	Dilation of Right Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047T3DZ	Dilation of Right Peroneal Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047T3E6	Dilation of Right Peroneal Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
0477257	Percutaneous Approach Dilation of Dight December Astronomist Two Introduction Devices Percutaneous Approach	Dragodura	ICD 10 DCS
047T3EZ	Dilation of Right Peroneal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3F6	Dilation of Right Peroneal Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
0471310	Percutaneous Approach	riocedule	1CD-10-FC3
047T3FZ	Dilation of Right Peroneal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0471312	billation of right refored Artery with three intradaminar bevices, refeatanceds Approach	rroccaure	100 10 1 05
047T3G6	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047T3GZ	Dilation of Right Peroneal Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047T3Z1	Dilation of Right Peroneal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047T3Z6	Dilation of Right Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047T3ZZ	Dilation of Right Peroneal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047T441	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Endoscopic Approach		
047T446	Dilation of Right Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
0477447	Percutaneous Endoscopic Approach		100 40 000
047T44Z	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0477456	Endoscopic Approach	Dan and dans	100 40 000
047T456	Dilation of Right Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
047T45Z	Percutaneous Endoscopic Approach Dilation of Right Peroneal Artery with Two Drug-eluting Intraluminal Devices,	Procedure	ICD 10 DCS
04/1432	Percutaneous Endoscopic Approach	riocedule	ICD-10-PCS
047T466	Dilation of Right Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal	Procedure	ICD-10-PCS
07/1400	Devices, Percutaneous Endoscopic Approach	Trocedure	1CD-10-FC3
047T46Z	Dilation of Right Peroneal Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
31,1702	Percutaneous Endoscopic Approach	occuure	.02 10 1 03
	. c. catanecas Endoscopio Approach		

cder_mpl1p_wp077 Page 917 of 1023



		Code	
Code	Description	Category	Code Type
047T476	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047T47Z	Dilation of Right Peroneal Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047T4D1	Dilation of Right Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047T4D6	Dilation of Right Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047T4DZ	Dilation of Right Peroneal Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047T4E6	Dilation of Right Peroneal Artery, Bifurcation, with Two Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047T4EZ	Dilation of Right Peroneal Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
-	Approach		
047T4F6	Dilation of Right Peroneal Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		.02 20 . 00
047T4FZ	Dilation of Right Peroneal Artery with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
747 1412	Endoscopic Approach	Troccadic	100 10 1 03
047T4G6	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
7471400	Percutaneous Endoscopic Approach	Trocedure	ICD-10-1 CS
047T4GZ	Dilation of Right Peroneal Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
J4714GZ	Endoscopic Approach	riocedule	ICD-10-PC3
NATTAT1		Dragodura	ICD 10 DC
047T4Z1	Dilation of Right Peroneal Artery using Drug-Coated Balloon, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0.477.476	Approach	Dunganahan	ICD 40 DCC
047T4Z6 047T4ZZ	Dilation of Right Peroneal Artery, Bifurcation, Percutaneous Endoscopic Approach Dilation of Right Peroneal Artery, Percutaneous Endoscopic Approach	Procedure Procedure	ICD-10-PCS
0471422 047U041	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
5470041	Balloon, Open Approach	Trocedure	ICD-10-I C3
047U046	Dilation of Left Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
0470046		Procedure	ICD-10-PC3
24711047	Approach	Dunnandii	ICD 10 DCC
047U04Z	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
24711056	Dilation of Left Designation of the True Designation with True Designation of the Designa	Dan en al con-	ICD 40 DCC
047U056	Dilation of Left Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		100 40 000
047U05Z	Dilation of Left Peroneal Artery with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047U066	Dilation of Left Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047U06Z	Dilation of Left Peroneal Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047U076	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047U07Z	Dilation of Left Peroneal Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		

cder_mpl1p_wp077 Page 918 of 1023



riocedule	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047U0D1	Dilation of Left Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Open Approach		
047U0D6	Dilation of Left Peroneal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047U0DZ	Dilation of Left Peroneal Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047U0E6	Dilation of Left Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0EZ	Dilation of Left Peroneal Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0F6	Dilation of Left Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0FZ	Dilation of Left Peroneal Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0G6	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0GZ	Dilation of Left Peroneal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0Z1	Dilation of Left Peroneal Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047U0Z6	Dilation of Left Peroneal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047U0ZZ	Dilation of Left Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
047U341	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047U346	Dilation of Left Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U34Z	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U356	Dilation of Left Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U35Z	Dilation of Left Peroneal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U366	Dilation of Left Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U36Z	Dilation of Left Peroneal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U376	• •	Procedure	ICD-10-PCS
047U37Z	Dilation of Left Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3D1	Dilation of Left Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047U3D6	Dilation of Left Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U3DZ	Dilation of Left Peroneal Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U3E6	Dilation of Left Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3EZ	Dilation of Left Peroneal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 919 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
047U3F6	Dilation of Left Peroneal Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047U3FZ	Dilation of Left Peroneal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3G6	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047U3GZ	Dilation of Left Peroneal Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3Z1	Dilation of Left Peroneal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047U3Z6	Dilation of Left Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047U3ZZ	Dilation of Left Peroneal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047U441	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Endoscopic Approach		
047U446	Dilation of Left Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047U44Z	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047U456	Dilation of Left Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047U45Z	Dilation of Left Peroneal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047U466	Dilation of Left Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047U46Z	Dilation of Left Peroneal Artery with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047U476	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U47Z	Dilation of Left Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4D1	Dilation of Left Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047U4D6	Dilation of Left Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047U4DZ	Dilation of Left Peroneal Artery with Intraluminal Device, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047U4E6	Dilation of Left Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047U4EZ	Dilation of Left Peroneal Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047U4F6	Dilation of Left Peroneal Artery, Bifurcation, with Three Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047U4FZ	Dilation of Left Peroneal Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 920 of 1023



	•	Code	
Code	Description	Category	Code Type
047U4G6	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047U4GZ	Dilation of Left Peroneal Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047U4Z1	Dilation of Left Peroneal Artery using Drug-Coated Balloon, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047U4Z6	Dilation of Left Peroneal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4ZZ	Dilation of Left Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V041	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Open Approach		
047V046	Dilation of Right Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047V04Z	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047V056	Dilation of Right Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047V05Z	Dilation of Right Foot Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V066	Dilation of Right Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047V06Z	Dilation of Right Foot Artery with Three Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047V076	Dilation of Right Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		.02 20 . 00
047V07Z	Dilation of Right Foot Artery with Four or More Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		.02 20 . 00
047V0D1	Dilation of Right Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Open	Procedure	ICD-10-PCS
047 (051	Approach	rroccaare	100 10 1 05
047V0D6	Dilation of Right Foot Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047V0D0	Dilation of Right Foot Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047V0E6	Dilation of Right Foot Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
	, , , , , , , , , , , , , , , , , , ,		
047V0EZ	Dilation of Right Foot Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0F6	Dilation of Right Foot Artery, Bifurcation, with Three Intraluminal Devices, Open Approach		ICD-10-PCS
047V0FZ	Dilation of Right Foot Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0G6	Dilation of Right Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047V0GZ	Dilation of Right Foot Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0Z1	Dilation of Right Foot Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047V0Z6	Dilation of Right Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047V0ZZ	Dilation of Right Foot Artery, Open Approach	Procedure	ICD-10-PCS
047V341	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Approach		
047V346	Dilation of Right Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Approach		

cder_mpl1p_wp077 Page 921 of 1023



	Codes Osed to Define Dasenile Characteristics in this Nequest	Code	
Code	Description	Category	Code Type
047V34Z	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047V356	Dilation of Right Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047V35Z	Dilation of Right Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047V366	Dilation of Right Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047V36Z	Dilation of Right Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047V376	Dilation of Right Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047V37Z	Dilation of Right Foot Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047V3D1	Dilation of Right Foot Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047V3D6	Dilation of Right Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047V3DZ	Dilation of Right Foot Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047V3E6	Dilation of Right Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047V3EZ	Dilation of Right Foot Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3F6	Dilation of Right Foot Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
0.471.4057	Approach		100 40 000
047V3FZ	Dilation of Right Foot Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3G6	Dilation of Right Foot Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
047 7300	Percutaneous Approach	rrocedure	1CD-10-1 C3
047V3GZ	Dilation of Right Foot Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
047 V3GZ	Approach	rroccaare	100 101 05
047V3Z1	Dilation of Right Foot Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047V3Z6	Dilation of Right Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047V3ZZ	Dilation of Right Foot Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047V441	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Endoscopic Approach		
047V446	Dilation of Right Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047V44Z	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047V456	Dilation of Right Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047V45Z	Dilation of Right Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		

cder_mpl1p_wp077 Page 922 of 1023



	Codes osed to Define baseline characteristics in this nequest	Code	
Code	Description	Category	Code Type
047V466	Dilation of Right Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047V46Z	Dilation of Right Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047V476	Dilation of Right Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047V47Z	Dilation of Right Foot Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047V4D1	Dilation of Right Foot Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047V4D6	Dilation of Right Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047V4DZ	Dilation of Right Foot Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4E6	Dilation of Right Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047V4EZ	Dilation of Right Foot Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047V4F6	Dilation of Right Foot Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047V4FZ	Dilation of Right Foot Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047V4G6	Dilation of Right Foot Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047V4GZ	Dilation of Right Foot Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047V4Z1	Dilation of Right Foot Artery using Drug-Coated Balloon, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047V4Z6	Dilation of Right Foot Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4ZZ	Dilation of Right Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W041	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Open Approach		
047W046	Dilation of Left Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open	Procedure	ICD-10-PCS
	Approach		
047W04Z	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047W056	Dilation of Left Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047W05Z	Dilation of Left Foot Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W066	Dilation of Left Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Open Approach		
047W06Z	Dilation of Left Foot Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 923 of 1023



		Code	·
Code	Description	Category	Code Type
047W076	Dilation of Left Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Open Approach		
047W07Z	Dilation of Left Foot Artery with Four or More Drug-eluting Intraluminal Devices, Open	Procedure	ICD-10-PCS
	Approach		
047W0D1	Dilation of Left Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Open	Procedure	ICD-10-PCS
	Approach		
047W0D6	Dilation of Left Foot Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047W0DZ	Dilation of Left Foot Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047W0E6	Dilation of Left Foot Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0EZ	Dilation of Left Foot Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0F6	Dilation of Left Foot Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0FZ	Dilation of Left Foot Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0G6	Dilation of Left Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Open	Procedure	ICD-10-PCS
047W0GZ	Approach Dilation of Left Foot Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0GZ	Dilation of Left Foot Artery with Four of More Intradminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0Z6	Dilation of Left Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047W0ZZ	Dilation of Left Foot Artery, Open Approach	Procedure	ICD-10-PCS
047W341	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Approach		
047W346	Dilation of Left Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
047W34Z	Percutaneous Approach Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047W356	Dilation of Left Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
047 00330	Percutaneous Approach	riocedure	ICD-10-PC3
047W35Z	Dilation of Left Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047W366	Dilation of Left Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
047W36Z	Percutaneous Approach Dilation of Left Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
047 00302	Approach	riocedule	ICD-10-PC3
047W376	Dilation of Left Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Approach		
047W37Z	Dilation of Left Foot Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047W3D1	Dilation of Left Foot Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
·	Percutaneous Approach		
047W3D6	Dilation of Left Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
04714/257	Dilation of Loft Foot Artony with Introduction Device Devices	Drocadii	ICD 40 DCC
047W3DZ 047W3E6	Dilation of Left Foot Artery with Intraluminal Device, Percutaneous Approach Dilation of Left Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure Procedure	ICD-10-PCS ICD-10-PCS
U4/ W 3ED	Approach	riocedule	ICD-10-LC2

cder_mpl1p_wp077 Page 924 of 1023



		Code	
Code	Description	Category	Code Type
047W3EZ	Dilation of Left Foot Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3F6	Dilation of Left Foot Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047W3FZ	Dilation of Left Foot Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3G6	Dilation of Left Foot Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Approach		
047W3GZ	Dilation of Left Foot Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Approach		
047W3Z1	Dilation of Left Foot Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047W3Z6	Dilation of Left Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047W3ZZ	Dilation of Left Foot Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047W441	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated	Procedure	ICD-10-PCS
	Balloon, Percutaneous Endoscopic Approach		
047W446	Dilation of Left Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047W44Z	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047W456	Dilation of Left Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047W45Z	Dilation of Left Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047W466	Dilation of Left Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047W46Z	Dilation of Left Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047W476	Dilation of Left Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal	Procedure	ICD-10-PCS
	Devices, Percutaneous Endoscopic Approach		
047W47Z	Dilation of Left Foot Artery with Four or More Drug-eluting Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047W4D1	Dilation of Left Foot Artery with Intraluminal Device, using Drug-Coated Balloon,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047W4D6	Dilation of Left Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous	Procedure	ICD-10-PCS
0 17 11 12 0	Endoscopic Approach		.02 20 . 00
047W4DZ	Dilation of Left Foot Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047 ******	Blatton of Left 1 oot 74 telly with intradaminal bevice, 1 electrones Enabscopie Approach	rroccaare	100 10 1 05
047W4E6	Dilation of Left Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
047 00460	Endoscopic Approach	rrocedure	1CD-10-1 C3
047W4EZ	Dilation of Left Foot Artery with Two Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
047 VV4EZ	Approach	Procedure	ICD-10-PC3
047)4/456		Duagadiina	ICD 10 DCC
047W4F6	Dilation of Left Foot Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
04714457	Endoscopic Approach Dilation of Left Foot Astory with Three Introduction Devices Persystemacy: Endoscopic	Dwo	ICD 40 DCC
047W4FZ	Dilation of Left Foot Artery with Three Intraluminal Devices, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 925 of 1023



	codes osed to Define baseline characteristics in this nequest	Code	
Code	Description	Category	Code Type
047W4G6	Dilation of Left Foot Artery, Bifurcation, with Four or More Intraluminal Devices,	Procedure	ICD-10-PCS
	Percutaneous Endoscopic Approach		
047W4GZ	Dilation of Left Foot Artery with Four or More Intraluminal Devices, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
047W4Z1	Dilation of Left Foot Artery using Drug-Coated Balloon, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
047W4Z6	Dilation of Left Foot Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4ZZ	Dilation of Left Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04C00Z6	Extirpation of Matter from Abdominal Aorta, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04C03Z6	Extirpation of Matter from Abdominal Aorta, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04C04Z6	Extirpation of Matter from Abdominal Aorta, Bifurcation, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CC0Z6	Extirpation of Matter from Right Common Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CC0ZZ	Extirpation of Matter from Right Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CC3Z6	Extirpation of Matter from Right Common Iliac Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Approach		
04CC3ZZ	Extirpation of Matter from Right Common Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CC4Z6	Extirpation of Matter from Right Common Iliac Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
04CC4ZZ	Extirpation of Matter from Right Common Iliac Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CD0Z6	Extirpation of Matter from Left Common Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CD0ZZ	Extirpation of Matter from Left Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CD3Z6	Extirpation of Matter from Left Common Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CD3ZZ	Extirpation of Matter from Left Common Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CD4Z6	Extirpation of Matter from Left Common Iliac Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
04CD4ZZ	Extirpation of Matter from Left Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0.100.122	Extripation of Matter Home East common macriticary, i croataneous Enacocopie Approach	rroccaare	105 10 1 05
04CE0Z6	Extirpation of Matter from Right Internal Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CE0ZZ	Extirpation of Matter from Right Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CE3Z6	Extirpation of Matter from Right Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CE3ZZ	Extirpation of Matter from Right Internal Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CE4Z6	Extirpation of Matter from Right Internal Iliac Artery, Percentage Approach	Procedure	ICD-10-PCS
0.02.20	Endoscopic Approach	rioccaare	105 10 1 05
04CE4ZZ	Extirpation of Matter from Right Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
UTCLTZZ	Extripation of Matter from hight internal flat Artery, i creataneous Endoscopie Approach	Troccaure	100 101 05
04CF0Z6	Extirpation of Matter from Left Internal Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CF0ZZ	Extirpation of Matter from Left Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CF3Z6	Extirpation of Matter from Left Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CF3ZZ	Extirpation of Matter from Left Internal Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CF4Z6	Extirpation of Matter from Left Internal Iliac Artery, Percutaneous Approach Extirpation of Matter from Left Internal Iliac Artery, Bifurcation, Percutaneous Endoscopic		ICD-10-PCS
3-101	Approach	Toccaure	.00 10 1 03
	Approach		

cder_mpl1p_wp077 Page 926 of 1023



Trocedure	codes osed to Define baseline characteristics in this kequest	Code	
Code	Description	Category	Code Type
04CF4ZZ	Extirpation of Matter from Left Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CH0Z6	Extirpation of Matter from Right External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CH0ZZ	Extirpation of Matter from Right External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CH3Z6	Extirpation of Matter from Right External Iliac Artery, Bifurcation, Percutaneous Approach		ICD-10-PCS
04CH3ZZ	Extirpation of Matter from Right External Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CH4Z6	Extirpation of Matter from Right External Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CH4ZZ	Extirpation of Matter from Right External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CJ0Z6	Extirpation of Matter from Left External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CJ0ZZ	Extirpation of Matter from Left External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CJ3Z6	Extirpation of Matter from Left External Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CJ3ZZ	Extirpation of Matter from Left External Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CJ4Z6	Extirpation of Matter from Left External Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CJ4ZZ	Extirpation of Matter from Left External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CK0Z6	Extirpation of Matter from Right Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CK0ZZ	Extirpation of Matter from Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04CK3Z6	Extirpation of Matter from Right Femoral Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CK3ZZ	Extirpation of Matter from Right Femoral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CK4Z6	Extirpation of Matter from Right Femoral Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CK4ZZ	Extirpation of Matter from Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CL0Z6	Extirpation of Matter from Left Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CL0ZZ	Extirpation of Matter from Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04CL3Z6	Extirpation of Matter from Left Femoral Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CL3ZZ	Extirpation of Matter from Left Femoral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CL4Z6	Extirpation of Matter from Left Femoral Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CL4ZZ	Extirpation of Matter from Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CM0Z6	Extirpation of Matter from Right Popliteal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CM0ZZ	Extirpation of Matter from Right Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
04CM3Z6	Extirpation of Matter from Right Popliteal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CM3ZZ	Extirpation of Matter from Right Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CM4Z6	Extirpation of Matter from Right Popliteal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CM4ZZ	Extirpation of Matter from Right Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CN0Z6	Extirpation of Matter from Left Popliteal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CN0ZZ	Extirpation of Matter from Left Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
04CN3Z6	Extirpation of Matter from Left Popliteal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 927 of 1023



		Code	
Code	Description	Category	Code Type
04CN3ZZ	Extirpation of Matter from Left Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CN4Z6	Extirpation of Matter from Left Popliteal Artery, Bifurcation, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CN4ZZ	Extirpation of Matter from Left Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CP0Z6	Extirpation of Matter from Right Anterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CP0ZZ	Extirpation of Matter from Right Anterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CP3Z6	Extirpation of Matter from Right Anterior Tibial Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Approach		
04CP3ZZ	Extirpation of Matter from Right Anterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CP4Z6	Extirpation of Matter from Right Anterior Tibial Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
04CP4ZZ	Extirpation of Matter from Right Anterior Tibial Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CQ0Z6	Extirpation of Matter from Left Anterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CQ0ZZ	Extirpation of Matter from Left Anterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CQ3Z6	Extirpation of Matter from Left Anterior Tibial Artery, Bifurcation, Percutaneous Approach		ICD-10-PCS
04CQ3ZZ	Extirpation of Matter from Left Anterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CQ4Z6	Extirpation of Matter from Left Anterior Tibial Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
0.100.120	Endoscopic Approach		102 10 1 00
04CQ4ZZ	Extirpation of Matter from Left Anterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0400422	Extripation of Matter from Left Afterior Holar Aftery, Fercutarieous Endoscopic Approach	Trocedure	1CD-10-1 C5
04CR0Z6	Extirpation of Matter from Right Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CR0ZZ	Extirpation of Matter from Right Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CR3Z6	Extirpation of Matter from Right Posterior Tibial Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Approach		
04CR3ZZ	Extirpation of Matter from Right Posterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CR4Z6	Extirpation of Matter from Right Posterior Tibial Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
04CR4ZZ	Extirpation of Matter from Right Posterior Tibial Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CS0Z6	Extirpation of Matter from Left Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CS0ZZ	Extirpation of Matter from Left Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CS3Z6	Extirpation of Matter from Left Posterior Tibial Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
	Approach		
04CS3ZZ	Extirpation of Matter from Left Posterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CS4Z6	Extirpation of Matter from Left Posterior Tibial Artery, Bifurcation, Percutaneous	Procedure	ICD-10-PCS
0 .00 .20	Endoscopic Approach		.02 20 . 00
04CS4ZZ	Extirpation of Matter from Left Posterior Tibial Artery, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0403422	•	riocedure	ICD-10-FC3
0467076	Approach Extirpation of Matter from Right Peroneal Artery, Bifurcation, Open Approach	Procedure	ICD 10 DCs
04CT0Z6 04CT0ZZ	Extirpation of Matter from Right Peroneal Artery, Birdreation, Open Approach Extirpation of Matter from Right Peroneal Artery, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
04CT0ZZ 04CT3Z6	Extirpation of Matter from Right Peroneal Artery, Open Approach Extirpation of Matter from Right Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
0701320	Extripation of Matter from Might Feroneal Aftery, Diffrication, Fercutaneous Approach	Tocedure	1CD-10-LC3
04CT3ZZ	Extirpation of Matter from Right Peroneal Artery, Percutaneous Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 928 of 1023



		Code	
Code	Description	Category	Code Type
04CT4Z6	Extirpation of Matter from Right Peroneal Artery, Bifurcation, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CT4ZZ	Extirpation of Matter from Right Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CU0Z6	Extirpation of Matter from Left Peroneal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CU0ZZ	Extirpation of Matter from Left Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
04CU3Z6	Extirpation of Matter from Left Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CU3ZZ	Extirpation of Matter from Left Peroneal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CU4Z6	Extirpation of Matter from Left Peroneal Artery, Bifurcation, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CU4ZZ	Extirpation of Matter from Left Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CV0Z6	Extirpation of Matter from Right Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CV0ZZ	Extirpation of Matter from Right Foot Artery, Open Approach	Procedure	ICD-10-PCS
04CV3Z6	Extirpation of Matter from Right Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CV3ZZ	Extirpation of Matter from Right Foot Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CV4Z6	Extirpation of Matter from Right Foot Artery, Bifurcation, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CV4ZZ	Extirpation of Matter from Right Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CW0Z6	Extirpation of Matter from Left Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CW0ZZ	Extirpation of Matter from Left Foot Artery, Open Approach	Procedure	ICD-10-PCS
04CW3Z6	Extirpation of Matter from Left Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CW3ZZ	Extirpation of Matter from Left Foot Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CW4Z6	Extirpation of Matter from Left Foot Artery, Bifurcation, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
04CW4ZZ	Extirpation of Matter from Left Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Y6C0Z1	Detachment at Right Upper Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6C0Z2	Detachment at Right Upper Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6C0Z3	Detachment at Right Upper Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6D0Z1	Detachment at Left Upper Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6D0Z2	Detachment at Left Upper Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6D0Z3	Detachment at Left Upper Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6F0ZZ	Detachment at Right Knee Region, Open Approach	Procedure	ICD-10-PCS
0Y6G0ZZ	Detachment at Left Knee Region, Open Approach	Procedure	ICD-10-PCS
0Y6H0Z1	Detachment at Right Lower Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6H0Z2	Detachment at Right Lower Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6H0Z3	Detachment at Right Lower Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6J0Z1	Detachment at Left Lower Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6J0Z2	Detachment at Left Lower Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6J0Z3	Detachment at Left Lower Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z0	Detachment at Right Foot, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z4	Detachment at Right Foot, Complete 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z5	Detachment at Right Foot, Complete 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z6	Detachment at Right Foot, Complete 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z7	Detachment at Right Foot, Complete 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z8	Detachment at Right Foot, Complete 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z9	Detachment at Right Foot, Partial 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0ZB 0Y6M0ZC	Detachment at Right Foot, Partial 2nd Ray, Open Approach Detachment at Right Foot, Partial 3rd Ray, Open Approach	Procedure Procedure	ICD-10-PCS ICD-10-PCS
OTOIVIUZC	Detachment at Night Foot, Fartial Stu Ray, Open Approach	riocedule	ICD-10-5C2

cder_mpl1p_wp077 Page 929 of 1023



	codes osca to benne basenne enaracteristics in this request	Code	
Code	Description	Category	Code Type
0Y6M0ZD	Detachment at Right Foot, Partial 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0ZF	Detachment at Right Foot, Partial 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z0	Detachment at Left Foot, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z4	Detachment at Left Foot, Complete 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z5	Detachment at Left Foot, Complete 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z6	Detachment at Left Foot, Complete 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z7	Detachment at Left Foot, Complete 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z8	Detachment at Left Foot, Complete 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z9	Detachment at Left Foot, Partial 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZB	Detachment at Left Foot, Partial 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZC	Detachment at Left Foot, Partial 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZD	Detachment at Left Foot, Partial 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZF	Detachment at Left Foot, Partial 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6P0Z0	Detachment at Right 1st Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6P0Z1	Detachment at Right 1st Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6P0Z2	Detachment at Right 1st Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6P0Z3	Detachment at Right 1st Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z0	Detachment at Left 1st Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z1	Detachment at Left 1st Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z2	Detachment at Left 1st Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z3	Detachment at Left 1st Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z0	Detachment at Right 2nd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z1	Detachment at Right 2nd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z2	Detachment at Right 2nd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z3	Detachment at Right 2nd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z0	Detachment at Left 2nd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z1	Detachment at Left 2nd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z2	Detachment at Left 2nd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z3	Detachment at Left 2nd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z0	Detachment at Right 3rd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z1	Detachment at Right 3rd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z2	Detachment at Right 3rd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z3	Detachment at Right 3rd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z0	Detachment at Left 3rd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z1	Detachment at Left 3rd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z2	Detachment at Left 3rd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z3	Detachment at Left 3rd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z0	Detachment at Right 4th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z1	Detachment at Right 4th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z1	Detachment at Right 4th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z3	Detachment at Right 4th Toe, Iow, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z0	Detachment at Night 4th Toe, complete, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z1	Detachment at Left 4th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z1	Detachment at Left 4th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z3	Detachment at Left 4th Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z0	Detachment at Right 5th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z1	Detachment at Right 5th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z2	Detachment at Right 5th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z3	Detachment at Right 5th Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6Y0Z0	Detachment at Left 5th Toe, Complete, Open Approach	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 930 of 1023



riocedure	Code		
Code	Description	Category	Code Type
0Y6Y0Z1	Detachment at Left 5th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6Y0Z2	Detachment at Left 5th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6Y0Z3	Detachment at Left 5th Toe, Low, Open Approach	Procedure	ICD-10-PCS
33877	Repair of thoracoabdominal aortic aneurysm with graft, with or without cardiopulmonary bypass	Procedure	CPT-4
34151	Embolectomy or thrombectomy, with or without catheter; renal, celiac, mesentery, aortoiliac artery, by abdominal incision	Procedure	CPT-4
34201	Embolectomy or thrombectomy, with or without catheter; femoropopliteal, aortoiliac artery, by leg incision	Procedure	CPT-4
34808	Endovascular placement of iliac artery occlusion device (List separately in addition to code for primary procedure)	Procedure	CPT-4
34820	Open iliac artery exposure for delivery of endovascular prosthesis or iliac occlusion during endovascular therapy, by abdominal or retroperitoneal incision, unilateral (List separately in addition to code for primary procedure)	Procedure	CPT-4
34825	Placement of proximal or distal extension prosthesis for endovascular repair of infrarenal abdominal aortic or iliac aneurysm, false aneurysm, or dissection; initial vessel	Procedure	CPT-4
34826	Placement of proximal or distal extension prosthesis for endovascular repair of infrarenal abdominal aortic or iliac aneurysm, false aneurysm, or dissection; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
35081	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, abdominal aorta	Procedure	CPT-4
35102	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, abdominal aorta involving iliac vessels (common, hypogastric, external)	Procedure	CPT-4
35131	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, iliac artery (common, hypogastric, external)	Procedure	CPT-4
35132	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for ruptured aneurysm, iliac artery (common, hypogastric, external)	Procedure	CPT-4
35141	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, common femoral artery (profunda femoris, superficial femoral)	Procedure	CPT-4
35142	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for ruptured aneurysm, common femoral artery (profunda femoris, superficial femoral)	Procedure	CPT-4
35450	Transluminal balloon angioplasty, open; renal or other visceral artery	Procedure	CPT-4
35452 35454	Transluminal balloon angioplasty, open; aortic Transluminal balloon angioplasty, open; iliac	Procedure Procedure	CPT-4 CPT-4

cder_mpl1p_wp077 Page 931 of 1023



	e Coues osed to Define baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
35471	Transluminal balloon angioplasty, percutaneous; renal or visceral artery	Procedure	CPT-4
35472	Transluminal balloon angioplasty, percutaneous; aortic	Procedure	CPT-4
35473	Transluminal balloon angioplasty, percutaneous; iliac	Procedure	CPT-4
35480	Transluminal peripheral atherectomy, open; renal or other visceral artery	Procedure	CPT-4
35490	Transluminal peripheral atherectomy, percutaneous; renal or other visceral artery	Procedure	CPT-4
35537	Bypass graft, with vein; aortoiliac	Procedure	CPT-4
35538	Bypass graft, with vein; aortobi-iliac	Procedure	CPT-4
35540	Bypass graft, with vein; aortobifemoral	Procedure	CPT-4
35548	Bypass graft, with vein; aortoiliofemoral, unilateral	Procedure	CPT-4
35549	Bypass graft, with vein; aortoiliofemoral, bilateral	Procedure	CPT-4
35563	Bypass graft, with vein; ilioiliac	Procedure	CPT-4
35566	Bypass graft, with vein; femoral-anterior tibial, posterior tibial, peroneal artery or other	Procedure	CPT-4
	distal vessels		
35621	Bypass graft, with other than vein; axillary-femoral	Procedure	CPT-4
35637	Bypass graft, with other than vein; aortoiliac	Procedure	CPT-4
35638	Bypass graft, with other than vein; aortobi-iliac	Procedure	CPT-4
35646	Bypass graft, with other than vein; aortobifemoral	Procedure	CPT-4
35647	Bypass graft, with other than vein; aortofemoral	Procedure	CPT-4
35651	Bypass graft, with other than vein; aortofemoral-popliteal	Procedure	CPT-4
35654	Bypass graft, with other than vein; axillary-femoral-femoral	Procedure	CPT-4
35656	Bypass graft, with other than vein; femoral-popliteal	Procedure	CPT-4
35661	Bypass graft, with other than vein; femoral-femoral	Procedure	CPT-4
35663	Bypass graft, with other than vein; ilioiliac	Procedure	CPT-4
35665	Bypass graft, with other than vein; iliofemoral	Procedure	CPT-4
35666	Bypass graft, with other than vein; femoral-anterior tibial, posterior tibial, or peroneal	Procedure	CPT-4
	artery		
	Valvular/Mitral Valve Disease		
105.0	Rheumatic mitral stenosis	Diagnosis	ICD-10-CM
105.1	Rheumatic mitral insufficiency	Diagnosis	ICD-10-CM
105.2	Rheumatic mitral stenosis with insufficiency	Diagnosis	ICD-10-CM
105.8	Other rheumatic mitral valve diseases	Diagnosis	ICD-10-CM
105.9	Rheumatic mitral valve disease, unspecified	Diagnosis	ICD-10-CM
106.0	Rheumatic aortic stenosis	Diagnosis	ICD-10-CM
106.1	Rheumatic aortic insufficiency	Diagnosis	ICD-10-CM
106.2	Rheumatic aortic stenosis with insufficiency	Diagnosis	ICD-10-CM
106.8	Other rheumatic aortic valve diseases	Diagnosis	ICD-10-CM
106.9	Rheumatic aortic valve disease, unspecified	Diagnosis	ICD-10-CM
107.0	Rheumatic tricuspid stenosis	Diagnosis	ICD-10-CM
107.1	Rheumatic tricuspid insufficiency	Diagnosis	ICD-10-CM
107.2	Rheumatic tricuspid stenosis and insufficiency	Diagnosis	ICD-10-CM
107.8	Other rheumatic tricuspid valve diseases	Diagnosis	ICD-10-CM
107.9	Rheumatic tricuspid valve disease, unspecified	Diagnosis	ICD-10-CM
	Rheumatic disorders of both mitral and aortic valves	Diagnosis	ICD-10-CM
0.801		_	
108.1	Rheumatic disorders of both mitral and tricuspid valves	Diagnosis	ICD-10-CM
108.1 108.2		_	ICD-10-CM ICD-10-CM
108.1	Rheumatic disorders of both mitral and tricuspid valves	Diagnosis	
108.1 108.2 108.3 108.8	Rheumatic disorders of both mitral and tricuspid valves Rheumatic disorders of both aortic and tricuspid valves	Diagnosis Diagnosis	ICD-10-CM
108.1 108.2 108.3	Rheumatic disorders of both mitral and tricuspid valves Rheumatic disorders of both aortic and tricuspid valves Combined rheumatic disorders of mitral, aortic and tricuspid valves	Diagnosis Diagnosis Diagnosis	ICD-10-CM ICD-10-CM

cder_mpl1p_wp077 Page 932 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
109.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
109.89	Other specified rheumatic heart diseases	Diagnosis	ICD-10-CM
109.9	Rheumatic heart disease, unspecified	Diagnosis	ICD-10-CM
Z95.2	Presence of prosthetic heart valve	Diagnosis	ICD-10-CM
Z95.3	Presence of xenogenic heart valve	Diagnosis	ICD-10-CM
Z95.4	Presence of other heart-valve replacement	Diagnosis	ICD-10-CM
027F04Z	Dilation of Aortic Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027F0DZ	Dilation of Aortic Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027F0ZZ	Dilation of Aortic Valve, Open Approach	Procedure	ICD-10-PCS
027G04Z	Dilation of Mitral Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027G0DZ	Dilation of Mitral Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027G0ZZ	Dilation of Mitral Valve, Open Approach	Procedure	ICD-10-PCS
027H04Z	Dilation of Pulmonary Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027H0DZ	Dilation of Pulmonary Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027H0ZZ	Dilation of Pulmonary Valve, Open Approach	Procedure	ICD-10-PCS
027J04Z	Dilation of Tricuspid Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027J0DZ	Dilation of Tricuspid Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027J0ZZ	Dilation of Tricuspid Valve, Open Approach	Procedure	ICD-10-PCS
02NF0ZZ	Release Aortic Valve, Open Approach	Procedure	ICD-10-PCS
02NG0ZZ	Release Mitral Valve, Open Approach	Procedure	ICD-10-PCS
02NH0ZZ	Release Pulmonary Valve, Open Approach	Procedure	ICD-10-PCS
02NJ0ZZ	Release Tricuspid Valve, Open Approach	Procedure	ICD-10-PCS
02QF0ZZ	Repair Aortic Valve, Open Approach	Procedure	ICD-10-PCS
02QG0ZZ	Repair Mitral Valve, Open Approach	Procedure	ICD-10-PCS
02QH0ZZ	Repair Pulmonary Valve, Open Approach	Procedure	ICD-10-PCS
02QJ0ZZ	Repair Tricuspid Valve, Open Approach	Procedure	ICD-10-PCS
02RF07Z	Replacement of Aortic Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RF08Z	Replacement of Aortic Valve with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
02RF0JZ	Replacement of Aortic Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RF0KZ	Replacement of Aortic Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RF47Z	Replacement of Aortic Valve with Autologous Tissue Substitute, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02RF48Z	Replacement of Aortic Valve with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RF4JZ	Replacement of Aortic Valve with Synthetic Substitute, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02RF4KZ	Replacement of Aortic Valve with Nonautologous Tissue Substitute, Percutaneous	Procedure	ICD-10-PCS
	Endoscopic Approach		
02RG07Z	Replacement of Mitral Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RG08Z	Replacement of Mitral Valve with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
02RG0JZ	Replacement of Mitral Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RG0KZ	Replacement of Mitral Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RG37Z	Replacement of Mitral Valve with Autologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RG38Z	Replacement of Mitral Valve with Zooplastic Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
02RG3JZ	Replacement of Mitral Valve with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RG3KZ	Replacement of Mitral Valve with Nonautologous Tissue Substitute, Percutaneous	Procedure	ICD-10-PCS
	Approach		

cder_mpl1p_wp077 Page 933 of 1023



	·		
Code	Description	Category	Code Type
02RG47Z	Replacement of Mitral Valve with Autologous Tissue Substitute, Percutaneous Endoscopic	Procedure	ICD-10-PCS
	Approach		
02RG48Z	Replacement of Mitral Valve with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RG4JZ	Replacement of Mitral Valve with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RG4KZ	Replacement of Mitral Valve with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH07Z	Replacement of Pulmonary Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RH08Z	Replacement of Pulmonary Valve with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
02RH0JZ	Replacement of Pulmonary Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RH0KZ	Replacement of Pulmonary Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RH47Z	Replacement of Pulmonary Valve with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH48Z	Replacement of Pulmonary Valve with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH4JZ	Replacement of Pulmonary Valve with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH4KZ	Replacement of Pulmonary Valve with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ07Z	Replacement of Tricuspid Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RJ08Z	Replacement of Tricuspid Valve with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
02RJ0JZ	Replacement of Tricuspid Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RJ0KZ	Replacement of Tricuspid Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RJ37Z	Replacement of Tricuspid Valve with Autologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ38Z	Replacement of Tricuspid Valve with Zooplastic Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ3JZ	Replacement of Tricuspid Valve with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ3KZ	Replacement of Tricuspid Valve with Nonautologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ47Z	Replacement of Tricuspid Valve with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ48Z	Replacement of Tricuspid Valve with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ4JZ	Replacement of Tricuspid Valve with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ4KZ	Replacement of Tricuspid Valve with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02VG0ZZ	Restriction of Mitral Valve, Open Approach	Procedure	ICD-10-PCS
X2RF032	Replacement of Aortic Valve using Zooplastic Tissue, Rapid Deployment Technique, Open Approach, New Technology Group 2	Procedure	ICD-10-PCS
X2RF432	Replacement of Aortic Valve using Zooplastic Tissue, Rapid Deployment Technique, Percutaneous Endoscopic Approach, New Technology Group 2	Procedure	ICD-10-PCS

cder_mpl1p_wp077 Page 934 of 1023



	coues Oseu to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
0257T	Implantation of catheter-delivered prosthetic aortic heart valve; open thoracic approach	Procedure	CPT-4,
	(eg, transapical, transventricular)		Category III
D258T	Transthoracic cardiac exposure (eg, sternotomy, thoracotomy, subxiphoid) for catheter-	Procedure	CPT-4,
	delivered aortic valve replacement; without cardiopulmonary bypass		Category III
0259T	Transthoracic cardiac exposure (eg, sternotomy, thoracotomy, subxiphoid) for catheter-	Procedure	CPT-4,
	delivered aortic valve replacement; with cardiopulmonary bypass		Category III
0262T	Implantation of catheter-delivered prosthetic pulmonary valve, endovascular approach	Procedure	CPT-4,
J2021	implantation of catheter-delivered prostrictic pullionary valve, endovascular approach	rrocedure	Category III
22400	Valvuloplasty, aortic valve; open, with cardiopulmonary bypass	Procedure	CPT-4
33400 33401	Valvuloplasty, aortic valve; open, with cardiopulmonary bypass Valvuloplasty, aortic valve; open, with inflow occlusion	Procedure	CPT-4 CPT-4
33401 33403	Valvuloplasty, aortic valve; open, with innow occusion Valvuloplasty, aortic valve; using transventricular dilation, with cardiopulmonary bypass	Procedure	CPT-4 CPT-4
55405	valvuloplasty, aortic valve, using transventricular dilation, with cardiopulinonary bypass	Procedure	CP1-4
33420	Valvotomy, mitral valve; closed heart	Procedure	CPT-4
33422	Valvotomy, mitral valve; open heart, with cardiopulmonary bypass	Procedure	CPT-4
33425	Valvuloplasty, mitral valve, with cardiopulmonary bypass;	Procedure	CPT-4
33426	Valvuloplasty, mitral valve, with cardiopulmonary bypass; with prosthetic ring	Procedure	CPT-4
33427	Valvuloplasty, mitral valve, with cardiopulmonary bypass; radical reconstruction, with or	Procedure	CPT-4
	without ring		
33430	Replacement, mitral valve, with cardiopulmonary bypass	Procedure	CPT-4
3460	Valvectomy, tricuspid valve, with cardiopulmonary bypass	Procedure	CPT-4
3463	Valvuloplasty, tricuspid valve; without ring insertion	Procedure	CPT-4
3464	Valvuloplasty, tricuspid valve; with ring insertion	Procedure	CPT-4
3465	Replacement, tricuspid valve, with cardiopulmonary bypass	Procedure	CPT-4
3468	Tricuspid valve repositioning and plication for Ebstein anomaly	Procedure	CPT-4
3475	Replacement, pulmonary valve	Procedure	CPT-4
33496	Repair of non-structural prosthetic valve dysfunction with cardiopulmonary bypass	Procedure	CPT-4
	(separate procedure)		
33660	Repair of incomplete or partial atrioventricular canal (ostium primum atrial septal defect),	Procedure	CPT-4
	with or without atrioventricular valve repair		
33665	Repair of intermediate or transitional atrioventricular canal, with or without	Procedure	CPT-4
	atrioventricular valve repair		
	Diseases of Veins and Lymphatics and Other Diseases of the Circulatory Syst	em	
80	Phlebitis and thrombophlebitis	Diagnosis	ICD-10-CM
80.0	Phlebitis and thrombophlebitis of superficial vessels of lower extremities	Diagnosis	ICD-10-CM
80.00	Phlebitis and thrombophlebitis of superficial vessels of unspecified lower extremity	Diagnosis	ICD-10-CM
80.01	Phlebitis and thrombophlebitis of superficial vessels of right lower extremity	Diagnosis	ICD-10-CM
80.02	Phlebitis and thrombophlebitis of superficial vessels of left lower extremity	Diagnosis	ICD-10-CM
80.03	Phlebitis and thrombophlebitis of superficial vessels of lower extremities, bilateral	Diagnosis	ICD-10-CM
80.1	Phlebitis and thrombophlebitis of femoral vein	Diagnosis	ICD-10-CM
80.10	Phlebitis and thrombophlebitis of unspecified femoral vein	Diagnosis	ICD-10-CM
80.11	Phlebitis and thrombophlebitis of right femoral vein	Diagnosis	ICD-10-CM
80.12	Phlebitis and thrombophlebitis of left femoral vein	Diagnosis	ICD-10-CM
VII 11 J	Phlebitis and thrombophlebitis of femoral vein, bilateral	Diagnosis	ICD-10-CM
	Phlebitis and thrombophlebitis of other and unspecified deep vessels of lower extremities	Diagnosis	ICD-10-CIVI
80.13 80.2 80.20	Philebitis and thrombophiebitis of other and unspecified deep vessels of lower extremities Philebitis and thrombophiebitis of unspecified deep vessels of lower extremities	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 935 of 1023



riocedure	codes osed to befine baseline characteristics in this nequest	Code	
Code	Description	Category	Code Type
180.202	Phlebitis and thrombophlebitis of unspecified deep vessels of left lower extremity	Diagnosis	ICD-10-CM
180.203	Phlebitis and thrombophlebitis of unspecified deep vessels of lower extremities, bilateral	Diagnosis	ICD-10-CM
		_	
180.209	Phlebitis and thrombophlebitis of unspecified deep vessels of unspecified lower extremity	Diagnosis	ICD-10-CM
		J	
180.21	Phlebitis and thrombophlebitis of iliac vein	Diagnosis	ICD-10-CM
180.211	Phlebitis and thrombophlebitis of right iliac vein	Diagnosis	ICD-10-CM
180.212	Phlebitis and thrombophlebitis of left iliac vein	Diagnosis	ICD-10-CM
180.213	Phlebitis and thrombophlebitis of iliac vein, bilateral	Diagnosis	ICD-10-CM
180.219	Phlebitis and thrombophlebitis of unspecified iliac vein	Diagnosis	ICD-10-CM
180.22	Phlebitis and thrombophlebitis of popliteal vein	Diagnosis	ICD-10-CM
180.221	Phlebitis and thrombophlebitis of right popliteal vein	Diagnosis	ICD-10-CM
180.222	Phlebitis and thrombophlebitis of left popliteal vein	Diagnosis	ICD-10-CM
180.223	Phlebitis and thrombophlebitis of popliteal vein, bilateral	Diagnosis	ICD-10-CM
180.229	Phlebitis and thrombophlebitis of unspecified popliteal vein	Diagnosis	ICD-10-CM
180.23	Phlebitis and thrombophlebitis of tibial vein	Diagnosis	ICD-10-CM
180.231	Phlebitis and thrombophlebitis of right tibial vein	Diagnosis	ICD-10-CM
180.232	Phlebitis and thrombophlebitis of left tibial vein	Diagnosis	ICD-10-CM
180.233	Phlebitis and thrombophlebitis of tibial vein, bilateral	Diagnosis	ICD-10-CM
180.239	Phlebitis and thrombophlebitis of unspecified tibial vein	Diagnosis	ICD-10-CM
180.24	Phlebitis and thrombophlebitis of peroneal vein	Diagnosis	ICD-10-CM
180.241	Phlebitis and thrombophlebitis of right peroneal vein	Diagnosis	ICD-10-CM
180.242	Phlebitis and thrombophlebitis of left peroneal vein	Diagnosis	ICD-10-CM
180.243	Phlebitis and thrombophlebitis of peroneal vein, bilateral	Diagnosis	ICD-10-CM
180.249	Phlebitis and thrombophlebitis of unspecified peroneal vein	Diagnosis	ICD-10-CM
180.25	Phlebitis and thrombophlebitis of calf muscular vein	Diagnosis	ICD-10-CM
180.251	Phlebitis and thrombophlebitis of right calf muscular vein	Diagnosis	ICD-10-CM
180.252	Phlebitis and thrombophlebitis of left calf muscular vein	Diagnosis	ICD-10-CM
180.253	Phlebitis and thrombophlebitis of calf muscular vein, bilateral	Diagnosis	ICD-10-CM
180.259	Phlebitis and thrombophlebitis of unspecified calf muscular vein	Diagnosis	ICD-10-CM
180.29	Phlebitis and thrombophlebitis of other deep vessels of lower extremities	Diagnosis	ICD-10-CM
180.291	Phlebitis and thrombophlebitis of other deep vessels of right lower extremity	Diagnosis	ICD-10-CM
180.292	Phlebitis and thrombophlebitis of other deep vessels of left lower extremity	Diagnosis	ICD-10-CM
180.292	Phlebitis and thrombophlebitis of other deep vessels of lower extremity, bilateral	Diagnosis	ICD-10-CM
180.299	Phlebitis and thrombophlebitis of other deep vessels of unspecified lower extremity	Diagnosis	ICD-10-CM
180.233	Phlebitis and thrombophlebitis of lower extremities, unspecified	Diagnosis	ICD-10-CM
180.3	Phlebitis and thrombophlebitis of other sites	Diagnosis	ICD-10-CM
180.9	Phlebitis and thrombophlebitis of unspecified site	Diagnosis	ICD-10-CM
180.3 181	Portal vein thrombosis	Diagnosis	ICD-10-CM
182	Other venous embolism and thrombosis	Diagnosis	ICD-10-CM
182.0	Budd-Chiari syndrome	Diagnosis	ICD-10-CM
182.0		Diagnosis	
	Thrombophlebitis migrans		ICD-10-CM
182.2	Embolism and thrombosis of vena cava and other thoracic veins	Diagnosis	ICD-10-CM
182.21	Embolism and thrombosis of superior vena cava	Diagnosis	ICD-10-CM
182.210	Acute embolism and thrombosis of superior vena cava	Diagnosis	ICD-10-CM
182.211	Chronic embolism and thrombosis of superior vena cava	Diagnosis	ICD-10-CM
182.22	Embolism and thrombosis of inferior vena cava	Diagnosis	ICD-10-CM
182.220	Acute embolism and thrombosis of inferior vena cava	Diagnosis	ICD-10-CM
182.221	Chronic embolism and thrombosis of inferior vena cava	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 936 of 1023



	·	Code	
Code	Description	Category	Code Type
182.29	Embolism and thrombosis of other thoracic veins	Diagnosis	ICD-10-CM
182.290	Acute embolism and thrombosis of other thoracic veins	Diagnosis	ICD-10-CM
182.291	Chronic embolism and thrombosis of other thoracic veins	Diagnosis	ICD-10-CM
182.3	Embolism and thrombosis of renal vein	Diagnosis	ICD-10-CM
182.4	Acute embolism and thrombosis of deep veins of lower extremity	Diagnosis	ICD-10-CM
182.40	Acute embolism and thrombosis of unspecified deep veins of lower extremity	Diagnosis	ICD-10-CM
182.401	Acute embolism and thrombosis of unspecified deep veins of right lower extremity	Diagnosis	ICD-10-CM
182.402	Acute embolism and thrombosis of unspecified deep veins of left lower extremity	Diagnosis	ICD-10-CM
182.403	Acute embolism and thrombosis of unspecified deep veins of lower extremity, bilateral	Diagnosis	ICD-10-CM
182.409	Acute embolism and thrombosis of unspecified deep veins of unspecified lower extremity	Diagnosis	ICD-10-CM
182.41	Acute embolism and thrombosis of femoral vein	Diagnosis	ICD-10-CM
182.411	Acute embolism and thrombosis of right femoral vein	Diagnosis	ICD-10-CM
182.412	Acute embolism and thrombosis of left femoral vein	Diagnosis	ICD-10-CM
182.413	Acute embolism and thrombosis of femoral vein, bilateral	Diagnosis	ICD-10-CM
182.419	Acute embolism and thrombosis of unspecified femoral vein	Diagnosis	ICD-10-CM
182.42	Acute embolism and thrombosis of iliac vein	Diagnosis	ICD-10-CM
182.421	Acute embolism and thrombosis of right iliac vein	Diagnosis	ICD-10-CM
182.422	Acute embolism and thrombosis of left iliac vein	Diagnosis	ICD-10-CM
182.423	Acute embolism and thrombosis of iliac vein, bilateral	Diagnosis	ICD-10-CM
182.429	Acute embolism and thrombosis of unspecified iliac vein	Diagnosis	ICD-10-CM
182.43	Acute embolism and thrombosis of popliteal vein	Diagnosis	ICD-10-CM
182.431	Acute embolism and thrombosis of right popliteal vein	Diagnosis	ICD-10-CM
182.432	Acute embolism and thrombosis of left popliteal vein	Diagnosis	ICD-10-CM
182.433	Acute embolism and thrombosis of popliteal vein, bilateral	Diagnosis	ICD-10-CM
182.439	Acute embolism and thrombosis of unspecified popliteal vein	Diagnosis	ICD-10-CM
182.44	Acute embolism and thrombosis of tibial vein	Diagnosis	ICD-10-CM
182.441	Acute embolism and thrombosis of right tibial vein	Diagnosis	ICD-10-CM
182.442	Acute embolism and thrombosis of left tibial vein	Diagnosis	ICD-10-CM
182.443	Acute embolism and thrombosis of tibial vein, bilateral	Diagnosis	ICD-10-CM
182.449	Acute embolism and thrombosis of unspecified tibial vein	Diagnosis	ICD-10-CM
182.45	Acute embolism and thrombosis of peroneal vein	Diagnosis	ICD-10-CM
182.451	Acute embolism and thrombosis of right peroneal vein	Diagnosis	ICD-10-CM
182.452	Acute embolism and thrombosis of left peroneal vein	Diagnosis	ICD-10-CM
182.453	Acute embolism and thrombosis of peroneal vein, bilateral	Diagnosis	ICD-10-CM
182.459	Acute embolism and thrombosis of unspecified peroneal vein	Diagnosis	ICD-10-CM
182.46	Acute embolism and thrombosis of calf muscular vein	Diagnosis	ICD-10-CM
182.461	Acute embolism and thrombosis of right calf muscular vein	Diagnosis	ICD-10-CM
182.462	Acute embolism and thrombosis of left calf muscular vein	Diagnosis	ICD-10-CM
182.463	Acute embolism and thrombosis of calf muscular vein, bilateral	Diagnosis	ICD-10-CM
182.469	Acute embolism and thrombosis of unspecified calf muscular vein	Diagnosis	ICD-10-CM
182.49	Acute embolism and thrombosis of other specified deep vein of lower extremity	Diagnosis	ICD-10-CM
182.491	Acute embolism and thrombosis of other specified deep vein of right lower extremity	Diagnosis	ICD-10-CM
182.492	Acute embolism and thrombosis of other specified deep vein of left lower extremity	Diagnosis	ICD-10-CM
182.493	Acute embolism and thrombosis of other specified deep vein of lower extremity, bilateral	Diagnosis	ICD-10-CM
182.499	Acute embolism and thrombosis of other specified deep vein of unspecified lower extremity	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 937 of 1023



- 1		Code	
Code	Description	Category	Code Type
182.4Y	Acute embolism and thrombosis of unspecified deep veins of proximal lower extremity	Diagnosis	ICD-10-CM
I82.4Y1	Acute embolism and thrombosis of unspecified deep veins of right proximal lower	Diagnosis	ICD-10-CM
182.4Y2	extremity Acute embolism and thrombosis of unspecified deep veins of left proximal lower	Diagnosis	ICD-10-CM
	extremity		
182.4Y3	Acute embolism and thrombosis of unspecified deep veins of proximal lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.4Y9	Acute embolism and thrombosis of unspecified deep veins of unspecified proximal lower extremity	Diagnosis	ICD-10-CM
182.4Z	Acute embolism and thrombosis of unspecified deep veins of distal lower extremity	Diagnosis	ICD-10-CM
I82.4Z1	Acute embolism and thrombosis of unspecified deep veins of right distal lower extremity	Diagnosis	ICD-10-CM
182.4Z2	Acute embolism and thrombosis of unspecified deep veins of left distal lower extremity	Diagnosis	ICD-10-CM
182.4Z3	Acute embolism and thrombosis of unspecified deep veins of distal lower extremity, bilateral	Diagnosis	ICD-10-CM
182.4Z9	Acute embolism and thrombosis of unspecified deep veins of unspecified distal lower extremity	Diagnosis	ICD-10-CM
182.5	Chronic embolism and thrombosis of deep veins of lower extremity	Diagnosis	ICD-10-CM
182.50	Chronic embolism and thrombosis of unspecified deep veins of lower extremity	Diagnosis	ICD-10-CM
182.501	Chronic embolism and thrombosis of unspecified deep veins of right lower extremity	Diagnosis	ICD-10-CM
182.502	Chronic embolism and thrombosis of unspecified deep veins of left lower extremity	Diagnosis	ICD-10-CM
182.503	Chronic embolism and thrombosis of unspecified deep veins of lower extremity, bilateral	Diagnosis	ICD-10-CM
182.509	Chronic embolism and thrombosis of unspecified deep veins of unspecified lower extremity	Diagnosis	ICD-10-CM
182.51	Chronic embolism and thrombosis of femoral vein	Diagnosis	ICD-10-CM
182.511	Chronic embolism and thrombosis of right femoral vein	Diagnosis	ICD-10-CM
182.511	Chronic embolism and thrombosis of light femoral vein	Diagnosis	ICD-10-CM
182.513	Chronic embolism and thrombosis of femoral vein, bilateral	Diagnosis	ICD-10-CM
182.519	Chronic embolism and thrombosis of unspecified femoral vein	Diagnosis	ICD-10-CM
182.52	Chronic embolism and thrombosis of iliac vein	Diagnosis	ICD-10-CM
182.521	Chronic embolism and thrombosis of right iliac vein	Diagnosis	ICD-10-CM
182.522	Chronic embolism and thrombosis of left iliac vein	Diagnosis	ICD-10-CM
182.523	Chronic embolism and thrombosis of iliac vein, bilateral	Diagnosis	ICD-10-CM
182.529	Chronic embolism and thrombosis of unspecified iliac vein	Diagnosis	ICD-10-CM
182.53	Chronic embolism and thrombosis of popliteal vein	Diagnosis	ICD-10-CM
182.531	Chronic embolism and thrombosis of right popliteal vein	Diagnosis	ICD-10-CM
182.532	Chronic embolism and thrombosis of left popliteal vein	Diagnosis	ICD-10-CM
182.533	Chronic embolism and thrombosis of popliteal vein, bilateral	Diagnosis	ICD-10-CM
182.539	Chronic embolism and thrombosis of unspecified popliteal vein	Diagnosis	ICD-10-CM
182.54	Chronic embolism and thrombosis of tibial vein	Diagnosis	ICD-10-CM
182.541	Chronic embolism and thrombosis of right tibial vein	Diagnosis	ICD-10-CM
	Chronic embolism and thrombosis of left tibial vein	Diagnosis	ICD-10-CM
164.544		J	
182.542 182.543	Chronic embolism and thrombosis of tibial vein, bilateral	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 938 of 1023



		Code	
Code	Description	Category	Code Type
182.55	Chronic embolism and thrombosis of peroneal vein	Diagnosis	ICD-10-CM
182.551	Chronic embolism and thrombosis of right peroneal vein	Diagnosis	ICD-10-CM
182.552	Chronic embolism and thrombosis of left peroneal vein	Diagnosis	ICD-10-CM
182.553	Chronic embolism and thrombosis of peroneal vein, bilateral	Diagnosis	ICD-10-CM
182.559	Chronic embolism and thrombosis of unspecified peroneal vein	Diagnosis	ICD-10-CM
182.56	Chronic embolism and thrombosis of calf muscular vein	Diagnosis	ICD-10-CM
182.561	Chronic embolism and thrombosis of right calf muscular vein	Diagnosis	ICD-10-CM
182.562	Chronic embolism and thrombosis of left calf muscular vein	Diagnosis	ICD-10-CM
182.563	Chronic embolism and thrombosis of calf muscular vein, bilateral	Diagnosis	ICD-10-CM
182.569	Chronic embolism and thrombosis of unspecified calf muscular vein	Diagnosis	ICD-10-CM
182.59	Chronic embolism and thrombosis of other specified deep vein of lower extremity	Diagnosis	ICD-10-CM
182.591	Chronic embolism and thrombosis of other specified deep vein of right lower extremity	Diagnosis	ICD-10-CM
182.592	Chronic embolism and thrombosis of other specified deep vein of left lower extremity	Diagnosis	ICD-10-CM
182.593	Chronic embolism and thrombosis of other specified deep vein of lower extremity, bilateral	Diagnosis	ICD-10-CM
182.599	Chronic embolism and thrombosis of other specified deep vein of unspecified lower extremity	Diagnosis	ICD-10-CM
182.5Y	Chronic embolism and thrombosis of unspecified deep veins of proximal lower extremity	Diagnosis	ICD-10-CM
I82.5Y1	Chronic embolism and thrombosis of unspecified deep veins of right proximal lower extremity	Diagnosis	ICD-10-CM
182.5Y2	Chronic embolism and thrombosis of unspecified deep veins of left proximal lower extremity	Diagnosis	ICD-10-CM
182.5Y3	Chronic embolism and thrombosis of unspecified deep veins of proximal lower extremity, bilateral	Diagnosis	ICD-10-CM
182.5Y9	Chronic embolism and thrombosis of unspecified deep veins of unspecified proximal lower extremity	Diagnosis	ICD-10-CM
182.5Z	Chronic embolism and thrombosis of unspecified deep veins of distal lower extremity	Diagnosis	ICD-10-CM
182.5Z1	Chronic embolism and thrombosis of unspecified deep veins of right distal lower extremity	Diagnosis	ICD-10-CM
182.5Z2	Chronic embolism and thrombosis of unspecified deep veins of left distal lower extremity	Diagnosis	ICD-10-CM
182.5Z3	Chronic embolism and thrombosis of unspecified deep veins of distal lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.5Z9	Chronic embolism and thrombosis of unspecified deep veins of unspecified distal lower extremity	Diagnosis	ICD-10-CM
182.6	Acute embolism and thrombosis of veins of upper extremity	Diagnosis	ICD-10-CM
182.60	Acute embolism and thrombosis of unspecified veins of upper extremity	Diagnosis	ICD-10-CM
182.601	Acute embolism and thrombosis of unspecified veins of right upper extremity	Diagnosis	ICD-10-CM
182.602	Acute embolism and thrombosis of unspecified veins of left upper extremity	Diagnosis	ICD-10-CM
182.603	Acute embolism and thrombosis of unspecified veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
182.609	Acute embolism and thrombosis of unspecified veins of unspecified upper extremity	Diagnosis	ICD-10-CM
182.61	Acute embolism and thrombosis of superficial veins of upper extremity	Diagnosis	ICD-10-CM
		_	

cder_mpl1p_wp077 Page 939 of 1023



Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
182.611	Acute embolism and thrombosis of superficial veins of right upper extremity	Diagnosis	ICD-10-CM
182.612	Acute embolism and thrombosis of superficial veins of left upper extremity	Diagnosis	ICD-10-CM
182.613	Acute embolism and thrombosis of superficial veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
182.619	Acute embolism and thrombosis of superficial veins of unspecified upper extremity	Diagnosis	ICD-10-CM
182.62	Acute embolism and thrombosis of deep veins of upper extremity	Diagnosis	ICD-10-CM
182.621	Acute embolism and thrombosis of deep veins of right upper extremity	Diagnosis	ICD-10-CM
182.622	Acute embolism and thrombosis of deep veins of left upper extremity	Diagnosis	ICD-10-CM
182.623	Acute embolism and thrombosis of deep veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
182.629	Acute embolism and thrombosis of deep veins of unspecified upper extremity	Diagnosis	ICD-10-CM
182.7	Chronic embolism and thrombosis of veins of upper extremity	Diagnosis	ICD-10-CM
182.70	Chronic embolism and thrombosis of unspecified veins of upper extremity	Diagnosis	ICD-10-CM
182.701	Chronic embolism and thrombosis of unspecified veins of right upper extremity	Diagnosis	ICD-10-CM
182.702	Chronic embolism and thrombosis of unspecified veins of left upper extremity	Diagnosis	ICD-10-CM
182.703	Chronic embolism and thrombosis of unspecified veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
182.709	Chronic embolism and thrombosis of unspecified veins of unspecified upper extremity	Diagnosis	ICD-10-CM
102.703	emonic embonsin and emonibosis of anspectica veins of anspectica appearextenity	Diagnosis	ICD 10 CIVI
182.71	Chronic embolism and thrombosis of superficial veins of upper extremity	Diagnosis	ICD-10-CM
182.711	Chronic embolism and thrombosis of superficial veins of right upper extremity	Diagnosis	ICD-10-CM
182.712	Chronic embolism and thrombosis of superficial veins of left upper extremity	Diagnosis	ICD-10-CM
182.713	Chronic embolism and thrombosis of superficial veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
182.719	Chronic embolism and thrombosis of superficial veins of unspecified upper extremity	Diagnosis	ICD-10-CM
	,		
182.72	Chronic embolism and thrombosis of deep veins of upper extremity	Diagnosis	ICD-10-CM
182.721	Chronic embolism and thrombosis of deep veins of right upper extremity	Diagnosis	ICD-10-CM
182.722	Chronic embolism and thrombosis of deep veins of left upper extremity	Diagnosis	ICD-10-CM
182.723	Chronic embolism and thrombosis of deep veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
182.729	Chronic embolism and thrombosis of deep veins of unspecified upper extremity	Diagnosis	ICD-10-CM
182.8	Embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
182.81	Embolism and thrombosis of superficial veins of lower extremities	Diagnosis	ICD-10-CM
182.811	Embolism and thrombosis of superficial veins of right lower extremity	Diagnosis	ICD-10-CM
182.812	Embolism and thrombosis of superficial veins of left lower extremity	Diagnosis	ICD-10-CM
182.813	Embolism and thrombosis of superficial veins of lower extremities, bilateral	Diagnosis	ICD-10-CM
182.819	Embolism and thrombosis of superficial veins of unspecified lower extremity	Diagnosis	ICD-10-CM
182.89	Embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
182.890	Acute embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
182.891	Chronic embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
182.9	Embolism and thrombosis of unspecified vein	Diagnosis	ICD-10-CM
182.90	Acute embolism and thrombosis of unspecified vein	Diagnosis	ICD-10-CM
182.91	Chronic embolism and thrombosis of unspecified vein	Diagnosis	ICD-10-CM
182.A	Embolism and thrombosis of axillary vein	Diagnosis	ICD-10-CM
182.A1	Acute embolism and thrombosis of axillary vein	Diagnosis	ICD-10-CM
182.A11	Acute embolism and thrombosis of right axillary vein	Diagnosis	ICD-10-CM
182.A12	Acute embolism and thrombosis of left axillary vein	Diagnosis	ICD-10-CM
I82.A13	Acute embolism and thrombosis of axillary vein, bilateral	Diagnosis	ICD-10-CM
182.A19	Acute embolism and thrombosis of unspecified axillary vein	Diagnosis	ICD-10-CM
182.A2	Chronic embolism and thrombosis of axillary vein	Diagnosis	ICD-10-CM
182.A21	Chronic embolism and thrombosis of right axillary vein	Diagnosis	ICD-10-CM
182.A22	Chronic embolism and thrombosis of left axillary vein	Diagnosis	ICD-10-CM
182.A23	Chronic embolism and thrombosis of axillary vein, bilateral	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 940 of 1023



	codes osca to befine baseline diaracteristics in this nequest	Code	
Code	Description	Category	Code Type
182.A29	Chronic embolism and thrombosis of unspecified axillary vein	Diagnosis	ICD-10-CM
182.B	Embolism and thrombosis of subclavian vein	Diagnosis	ICD-10-CM
182.B1	Acute embolism and thrombosis of subclavian vein	Diagnosis	ICD-10-CM
182.B11	Acute embolism and thrombosis of right subclavian vein	Diagnosis	ICD-10-CM
182.B12	Acute embolism and thrombosis of left subclavian vein	Diagnosis	ICD-10-CM
182.B13	Acute embolism and thrombosis of subclavian vein, bilateral	Diagnosis	ICD-10-CM
182.B19	Acute embolism and thrombosis of unspecified subclavian vein	Diagnosis	ICD-10-CM
182.B2	Chronic embolism and thrombosis of subclavian vein	Diagnosis	ICD-10-CM
182.B21	Chronic embolism and thrombosis of right subclavian vein	Diagnosis	ICD-10-CM
182.B22	Chronic embolism and thrombosis of left subclavian vein	Diagnosis	ICD-10-CM
182.B23	Chronic embolism and thrombosis of subclavian vein, bilateral	Diagnosis	ICD-10-CM
182.B29	Chronic embolism and thrombosis of unspecified subclavian vein	Diagnosis	ICD-10-CM
182.C	Embolism and thrombosis of internal jugular vein	Diagnosis	ICD-10-CM
182.C1	Acute embolism and thrombosis of internal jugular vein	Diagnosis	ICD-10-CM
182.C11	Acute embolism and thrombosis of right internal jugular vein	Diagnosis	ICD-10-CM
182.C12	Acute embolism and thrombosis of left internal jugular vein	Diagnosis	ICD-10-CM
182.C13	Acute embolism and thrombosis of internal jugular vein, bilateral	Diagnosis	ICD-10-CM
182.C19	Acute embolism and thrombosis of unspecified internal jugular vein	Diagnosis	ICD-10-CM
182.C2	Chronic embolism and thrombosis of internal jugular vein	Diagnosis	ICD-10-CM
182.C21	Chronic embolism and thrombosis of right internal jugular vein	Diagnosis	ICD-10-CM
182.C22	Chronic embolism and thrombosis of left internal jugular vein	Diagnosis	ICD-10-CM
182.C23	Chronic embolism and thrombosis of internal jugular vein, bilateral	Diagnosis	ICD-10-CM
182.C29	Chronic embolism and thrombosis of unspecified internal jugular vein	Diagnosis	ICD-10-CM
183	Varicose veins of lower extremities	Diagnosis	ICD-10-CM
183.0	Varicose veins of lower extremities with ulcer	Diagnosis	ICD-10-CM
183.00	Varicose veins of unspecified lower extremity with ulcer	Diagnosis	ICD-10-CM
183.001	Varicose veins of unspecified lower extremity with ulcer of thigh	Diagnosis	ICD-10-CM
183.002	Varicose veins of unspecified lower extremity with ulcer of calf	Diagnosis	ICD-10-CM
183.003	Varicose veins of unspecified lower extremity with ulcer of ankle	Diagnosis	ICD-10-CM
183.004	Varicose veins of unspecified lower extremity with ulcer of heel and midfoot	Diagnosis	ICD-10-CM
183.005	Varicose veins of unspecified lower extremity with ulcer other part of foot	Diagnosis	ICD-10-CM
183.008	Varicose veins of unspecified lower extremity with ulcer other part of lower leg	Diagnosis	ICD-10-CM
183.009	Varicose veins of unspecified lower extremity with ulcer of unspecified site	Diagnosis	ICD-10-CM
183.01	Varicose veins of right lower extremity with ulcer	Diagnosis	ICD-10-CM
183.011	Varicose veins of right lower extremity with ulcer of thigh	Diagnosis	ICD-10-CM
183.012	Varicose veins of right lower extremity with ulcer of calf	Diagnosis	ICD-10-CM
183.013	Varicose veins of right lower extremity with ulcer of ankle	Diagnosis	ICD-10-CM
183.014	Varicose veins of right lower extremity with ulcer of heel and midfoot	Diagnosis	ICD-10-CM
183.015	Varicose veins of right lower extremity with ulcer other part of foot	Diagnosis	ICD-10-CM
183.018	Varicose veins of right lower extremity with ulcer other part of lower leg	Diagnosis	ICD-10-CM
183.019	Varicose veins of right lower extremity with ulcer of unspecified site	Diagnosis	ICD-10-CM
183.02	Varicose veins of left lower extremity with ulcer	Diagnosis	ICD-10-CM
183.021	Varicose veins of left lower extremity with ulcer of thigh	Diagnosis	ICD-10-CM
183.022	Varicose veins of left lower extremity with ulcer of calf	Diagnosis	ICD-10-CM
183.023	Varicose veins of left lower extremity with ulcer of ankle	Diagnosis	ICD-10-CM
183.024	Varicose veins of left lower extremity with ulcer of heel and midfoot	Diagnosis	ICD-10-CM
183.025	Varicose veins of left lower extremity with ulcer other part of foot	Diagnosis	ICD-10-CM
183.028	Varicose veins of left lower extremity with ulcer other part of lower leg	Diagnosis	ICD-10-CM
183.029	Varicose veins of left lower extremity with ulcer of unspecified site	Diagnosis	ICD-10-CM
183.029 183.1	Varicose veins of lever extremities with inflammation	Diagnosis	ICD-10-CM
103.1	variouse veins of lower extremities with inhamination	Diagnosis	ICD TO-CIVI

cder_mpl1p_wp077 Page 941 of 1023



		Code	
Code	Description	Category	Code Type
183.10	Varicose veins of unspecified lower extremity with inflammation	Diagnosis	ICD-10-CM
183.11	Varicose veins of right lower extremity with inflammation	Diagnosis	ICD-10-CM
183.12	Varicose veins of left lower extremity with inflammation	Diagnosis	ICD-10-CM
183.2	Varicose veins of lower extremities with both ulcer and inflammation	Diagnosis	ICD-10-CM
183.20	Varicose veins of unspecified lower extremity with both ulcer and inflammation	Diagnosis	ICD-10-CM
183.201	Varicose veins of unspecified lower extremity with both ulcer of thigh and inflammation	Diagnosis	ICD-10-CM
183.202	Varicose veins of unspecified lower extremity with both ulcer of calf and inflammation	Diagnosis	ICD-10-CM
183.203	Varicose veins of unspecified lower extremity with both ulcer of ankle and inflammation	Diagnosis	ICD-10-CM
183.204	Varicose veins of unspecified lower extremity with both ulcer of heel and midfoot and inflammation	Diagnosis	ICD-10-CM
183.205	Varicose veins of unspecified lower extremity with both ulcer other part of foot and inflammation	Diagnosis	ICD-10-CM
183.208	Varicose veins of unspecified lower extremity with both ulcer of other part of lower extremity and inflammation	Diagnosis	ICD-10-CM
183.209	Varicose veins of unspecified lower extremity with both ulcer of unspecified site and inflammation	Diagnosis	ICD-10-CM
183.21	Varicose veins of right lower extremity with both ulcer and inflammation	Diagnosis	ICD-10-CM
183.211	Varicose veins of right lower extremity with both ulcer of thigh and inflammation	Diagnosis	ICD-10-CM
183.212	Varicose veins of right lower extremity with both ulcer of calf and inflammation	Diagnosis	ICD-10-CM
183.213	Varicose veins of right lower extremity with both ulcer of ankle and inflammation	Diagnosis	ICD-10-CM
I83.214	Varicose veins of right lower extremity with both ulcer of heel and midfoot and inflammation	Diagnosis	ICD-10-CM
I83.215	Varicose veins of right lower extremity with both ulcer other part of foot and inflammation	Diagnosis	ICD-10-CM
183.218	Varicose veins of right lower extremity with both ulcer of other part of lower extremity and inflammation	Diagnosis	ICD-10-CM
183.219	Varicose veins of right lower extremity with both ulcer of unspecified site and inflammation	Diagnosis	ICD-10-CM
183.22	Varicose veins of left lower extremity with both ulcer and inflammation	Diagnosis	ICD-10-CM
183.221	Varicose veins of left lower extremity with both ulcer of thigh and inflammation	Diagnosis	ICD-10-CM
183.222	Varicose veins of left lower extremity with both ulcer of calf and inflammation	Diagnosis	ICD-10-CM
183.223	Varicose veins of left lower extremity with both ulcer of ankle and inflammation	Diagnosis	ICD-10-CM
183.224	Varicose veins of left lower extremity with both ulcer of heel and midfoot and inflammation	Diagnosis	ICD-10-CM
183.225	Varicose veins of left lower extremity with both ulcer other part of foot and inflammation	Diagnosis	ICD-10-CM
183.228	Varicose veins of left lower extremity with both ulcer of other part of lower extremity and inflammation	Diagnosis	ICD-10-CM
183.229	Varicose veins of left lower extremity with both ulcer of unspecified site and inflammation	Diagnosis	ICD-10-CM
183.8	Varicose veins of lower extremities with other complications	Diagnosis	ICD-10-CM
183.81	Varicose veins of lower extremities with pain	Diagnosis	ICD-10-CM
183.811	Varicose veins of right lower extremity with pain	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 942 of 1023



Code Description Category Code Type 183.812 Variose veins of left lower extremity with pain Diagnosis ICD-ID-CM 183.813 Variose veins of bilateral lower extremities with pain Diagnosis ICD-ID-CM 183.819 Variose veins of unspecified lower extremity with pain Diagnosis ICD-ID-CM 183.891 Variose veins of lower extremities with other complications Diagnosis ICD-ID-CM 183.892 Variose veins of left lower extremity with other complications Diagnosis ICD-ID-CM 183.893 Variose veins of bilateral lower extremity with other complications Diagnosis ICD-ID-CM 183.893 Variose veins of bilateral lower extremity with other complications Diagnosis ICD-ID-CM 183.90 Asymptomatic variose veins of lower extremity Diagnosis ICD-ID-CM 183.91 Asymptomatic variose veins of right lower extremity Diagnosis ICD-ID-CM 183.92 Asymptomatic variose veins of right lower extremity Diagnosis ICD-ID-CM 183.93 Asymptomatic variose veins of lateral lower extremity Diagnosis ICD-ID-CM 185.0	Procedure	Codes Used to Define Baseline Characteristics in this Request	Code	
183.812 Varicose veins of left lower extremity with pain Diagnosis ICD-10-CM 183.813 Varicose veins of bilateral lower extremity with pain Diagnosis ICD-10-CM 183.839 Varicose veins of lower extremities with other complications Diagnosis ICD-10-CM 183.891 Varicose veins of lower extremity with other complications Diagnosis ICD-10-CM 183.892 Varicose veins of fight lower extremity with other complications Diagnosis ICD-10-CM 183.893 Varicose veins of bilateral lower extremity with other complications Diagnosis ICD-10-CM 183.893 Varicose veins of bilateral lower extremity with other complications Diagnosis ICD-10-CM 183.93 Asymptomatic varicose veins of lower extremity Diagnosis ICD-10-CM 183.93 Asymptomatic varicose veins of lower extremity Diagnosis ICD-10-CM 183.93 Asymptomatic varicose veins of light lower extremity Diagnosis ICD-10-CM 183.93 Asymptomatic varicose veins of light lower extremity Diagnosis ICD-10-CM 183.94 Asymptomatic varicose veins of light lower extremity Diagnosis ICD-10-CM 183.95 Asymptomatic varicose veins of ligh	Code	Description		Code Type
I83.819 Varicose veins of lower extremitity with other complications Diagnosis ICD-10-CM I83.891 Varicose veins of lower extremitity with other complications Diagnosis ICD-10-CM I83.892 Varicose veins of leit lower extremity with other complications Diagnosis ICD-10-CM I83.893 Varicose veins of leit lower extremity with other complications Diagnosis ICD-10-CM I83.899 Varicose veins of bilateral lower extremity with other complications Diagnosis ICD-10-CM I83.99 Varicose veins of unspecified lower extremity Diagnosis ICD-10-CM I83.91 Asymptomatic varicose veins of lower extremity Diagnosis ICD-10-CM I83.91 Asymptomatic varicose veins of right lower extremity Diagnosis ICD-10-CM I83.92 Asymptomatic varicose veins of bilateral lower extremity Diagnosis ICD-10-CM I83.93 Asymptomatic varicose veins of bilateral lower extremity Diagnosis ICD-10-CM I83.94 Asymptomatic varicose veins of bilateral lower extremity Diagnosis ICD-10-CM I85.0 Esophageal varices Diagnosis ICD-10-CM	183.812		Diagnosis	
183.89 Varicose veins of lower extremities with other complications Diagnosis ICD-10-CM 183.891 Varicose veins of right lower extremity with other complications Diagnosis ICD-10-CM 183.893 Varicose veins of leit lower extremity with other complications Diagnosis ICD-10-CM 183.893 Varicose veins of unspecified lower extremity with other complications Diagnosis ICD-10-CM 183.99 Asymptomatic varicose veins of lower extremity with other complications Diagnosis ICD-10-CM 183.90 Asymptomatic varicose veins of lower extremity Diagnosis ICD-10-CM 183.91 Asymptomatic varicose veins of leit lower extremity Diagnosis ICD-10-CM 183.92 Asymptomatic varicose veins of leit lower extremity Diagnosis ICD-10-CM 183.93 Asymptomatic varicose veins of leit lower extremities Diagnosis ICD-10-CM 185.0 Esophageal varices Diagnosis ICD-10-CM 185.0 Esophageal varices Diagnosis ICD-10-CM 185.0 Esophageal varices with bleeding Diagnosis ICD-10-CM 185.1 Secondary esophageal va	183.813			ICD-10-CM
183.891Varicose veins of light lower extremity with other complicationsDiagnosisICD-10-CM183.892Varicose veins of light lower extremity with other complicationsDiagnosisICD-10-CM183.893Varicose veins of unspecified lower extremities with other complicationsDiagnosisICD-10-CM183.99Varicose veins of unspecified lower extremity with other complicationsDiagnosisICD-10-CM183.90Asymptomatic varicose veins of lower extremityDiagnosisICD-10-CM183.91Asymptomatic varicose veins of light lower extremityDiagnosisICD-10-CM183.92Asymptomatic varicose veins of light lower extremityDiagnosisICD-10-CM183.93Asymptomatic varicose veins of light lower extremityDiagnosisICD-10-CM185.0Esophageal varicesDiagnosisICD-10-CM185.0Esophageal varicesDiagnosisICD-10-CM185.0Esophageal varicesDiagnosisICD-10-CM185.1Secondary esophageal varices with bleedingDiagnosisICD-10-CM185.1Secondary esophageal varices with bleedingDiagnosisICD-10-CM185.1Secondary esophageal varices with bleedingDiagnosisICD-10-CM186.1Varicose veins of other sitesDiagnosisICD-10-CM186.1Secondary esophageal varices with bleedingDiagnosisICD-10-CM186.1Secondary esophageal varices with bleedingDiagnosisICD-10-CM186.2Pelvic varicesDiagnosisICD-10-CM186.3Va	183.819	Varicose veins of unspecified lower extremity with pain	Diagnosis	ICD-10-CM
183.892Varicose veins of left lower extremities with other complicationsDiagnosisICD-10-CM183.893Varicose veins of bilateral lower extremities with other complicationsDiagnosisICD-10-CM183.399Asymptomatic varicose veins of lower extremity with other complicationsDiagnosisICD-10-CM183.90Asymptomatic varicose veins of unspecified lower extremityDiagnosisICD-10-CM183.91Asymptomatic varicose veins of right lower extremityDiagnosisICD-10-CM183.92Asymptomatic varicose veins of right lower extremityDiagnosisICD-10-CM183.93Asymptomatic varicose veins of bilateral lower extremitiesDiagnosisICD-10-CM185.0Esophageal varicesDiagnosisICD-10-CM185.0Esophageal varicesDiagnosisICD-10-CM185.0Esophageal varices without bleedingDiagnosisICD-10-CM185.1Secondary esophageal varices without bleedingDiagnosisICD-10-CM185.1Secondary esophageal varices without bleedingDiagnosisICD-10-CM185.1Secondary esophageal varices with bleedingDiagnosisICD-10-CM186.0Varicose veins of other sitesDiagnosisICD-10-CM186.1Scrotal varicesDiagnosisICD-10-CM186.2Pelvic varicesDiagnosisICD-10-CM186.3Vulval varicesDiagnosisICD-10-CM186.4Gastric varicesDiagnosisICD-10-CM187.0Postthrombotic syndrome without complications of light lower extre	183.89	Varicose veins of lower extremities with other complications	Diagnosis	ICD-10-CM
183.833Varicose veins of bilateral lower extremities with other complicationsDiagnosisICD-10-CM183.899Varicose veins of unspecified lower extremitiesDiagnosisICD-10-CM183.90Asymptomatic varicose veins of lower extremitityDiagnosisICD-10-CM183.91Asymptomatic varicose veins of right lower extremityDiagnosisICD-10-CM183.92Asymptomatic varicose veins of right lower extremityDiagnosisICD-10-CM183.93Asymptomatic varicose veins of bilateral lower extremityDiagnosisICD-10-CM185.01Esophageal varicesDiagnosisICD-10-CM185.02Esophageal varicesDiagnosisICD-10-CM185.03Esophageal varicesDiagnosisICD-10-CM185.04Esophageal varices with bleedingDiagnosisICD-10-CM185.15Secondary esophageal varices without bleedingDiagnosisICD-10-CM185.10Secondary esophageal varices with bleedingDiagnosisICD-10-CM185.11Secondary esophageal varices with bleedingDiagnosisICD-10-CM186.0Sublingual varicesDiagnosisICD-10-CM186.1Secondary esophageal varices with bleedingDiagnosisICD-10-CM186.2Pelvic varicesDiagnosisICD-10-CM186.3Varicose veins of other sitesDiagnosisICD-10-CM186.4Gastric varicesDiagnosisICD-10-CM186.5Varicose veins of other specified sitesDiagnosisICD-10-CM187.0Postthrombot	183.891	Varicose veins of right lower extremity with other complications	Diagnosis	ICD-10-CM
183.89 Varicose veins of unspecified lower extremitity with other complications Diagnosis ICD-10-CM 183.90 Asymptomatic varicose veins of unspecified lower extremity Diagnosis ICD-10-CM 183.91 Asymptomatic varicose veins of unspecified lower extremity Diagnosis ICD-10-CM 183.92 Asymptomatic varicose veins of left lower extremity Diagnosis ICD-10-CM 185.9 Esophageal varices Diagnosis ICD-10-CM 185.0 Esophageal varices Diagnosis ICD-10-CM 185.0 Esophageal varices without bleeding Diagnosis ICD-10-CM 185.0 Esophageal varices with bleeding Diagnosis ICD-10-CM 185.0 Esophageal varices with bleeding Diagnosis ICD-10-CM 185.1 Secondary esophageal varices with bleeding Diagnosis ICD-10-CM 185.1 Secondary esophageal varices with bleeding Diagnosis ICD-10-CM 186.1 Varicose veins of other sites Diagnosis ICD-10-CM 186.2 Varicose veins of other sites Diagnosis ICD-10-CM 186.3 Vulval varices Diagnosis ICD-10-CM <	183.892	Varicose veins of left lower extremity with other complications	Diagnosis	ICD-10-CM
IR3.9 Asymptomatic varicose veins of lower extremities Diagnosis ICD-10-CM IR3.90 Asymptomatic varicose veins of inspecified lower extremity Diagnosis ICD-10-CM IR3.91 Asymptomatic varicose veins of right lower extremity Diagnosis ICD-10-CM IR3.92 Asymptomatic varicose veins of bilateral lower extremities Diagnosis ICD-10-CM IR5.0 Esophageal varices Diagnosis ICD-10-CM IR5.0 Esophageal varices without bleeding Diagnosis ICD-10-CM IR5.0 Esophageal varices with bleeding Diagnosis ICD-10-CM IR5.1 Secondary esophageal varices without bleeding Diagnosis ICD-10-CM IR5.1 Secondary esophageal varices without bleeding Diagnosis ICD-10-CM IR5.1 Secondary esophageal varices with bleeding Diagnosis ICD-10-CM IR6.1 Secondary esophageal varices with bleeding Diagnosis ICD-10-CM IR6.2 Secondary esophageal varices with bleeding Diagnosis ICD-10-CM IR6.3 Varicose veins of other sites Diagnosis ICD-10-CM	183.893	Varicose veins of bilateral lower extremities with other complications	Diagnosis	ICD-10-CM
IRB3.90Asymptomatic varicose veins of inspecified lower extremityDiagnosisICD-10-CMIRB3.91Asymptomatic varicose veins of left lower extremityDiagnosisICD-10-CMIRB3.92Asymptomatic varicose veins of left lower extremitiesDiagnosisICD-10-CMIRB5Esophageal varicesDiagnosisICD-10-CMIRB5.0Esophageal varicesDiagnosisICD-10-CMIRB5.0Esophageal varices without bleedingDiagnosisICD-10-CMIRB5.1Secondary esophageal varices without bleedingDiagnosisICD-10-CMIRB5.1Secondary esophageal varices without bleedingDiagnosisICD-10-CMIRB5.1Secondary esophageal varices without bleedingDiagnosisICD-10-CMIRB5.1Secondary esophageal varices with bleedingDiagnosisICD-10-CMIRB6.0Varicose veins of other sitesDiagnosisICD-10-CMIRB6.1Sublingual varicesDiagnosisICD-10-CMIRB6.2Pelvic varicesDiagnosisICD-10-CMIRB6.3Varicose veins of other specified sitesDiagnosisICD-10-CMIRB6.4Gastric varicesDiagnosisICD-10-CMIRB6.5Varicose veins of other specified sitesDiagnosisICD-10-CMIRB6.4Gastric varicesDiagnosisICD-10-CMIRB6.5Varicose veins of other specified sitesDiagnosisICD-10-CMIRB6.6Varicose veins of other specified sitesDiagnosisICD-10-CMIRB6.7Postthrombotic syndrome without complications	183.899	Varicose veins of unspecified lower extremity with other complications	Diagnosis	ICD-10-CM
183.91Asymptomatic varicose veins of right lower extremityDiagnosisICD-10-CM183.92Asymptomatic varicose veins of left lower extremitiesDiagnosisICD-10-CM185Esophageal varicesDiagnosisICD-10-CM185.0Esophageal varicesDiagnosisICD-10-CM185.0Esophageal varices without bleedingDiagnosisICD-10-CM185.01Esophageal varices with bleedingDiagnosisICD-10-CM185.1Secondary esophageal varices with bleedingDiagnosisICD-10-CM185.10Secondary esophageal varices without bleedingDiagnosisICD-10-CM185.11Secondary esophageal varices with bleedingDiagnosisICD-10-CM186.0Sublingual varicesDiagnosisICD-10-CM186.1Secondary esophageal varices with bleedingDiagnosisICD-10-CM186.0Sublingual varicesDiagnosisICD-10-CM186.1Secondary esophageal varices with bleedingDiagnosisICD-10-CM186.2Pelvic varicesDiagnosisICD-10-CM186.3Vulval varicesDiagnosisICD-10-CM186.4Gastric varicesDiagnosisICD-10-CM186.5Postthrombotic syndromeDiagnosisICD-10-CM187.0Postthrombotic syndrome without complicationsDiagnosisICD-10-CM187.0Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CM187.001Postthrombotic syndrome without complications of lalteral lower extremity <td< td=""><td>183.9</td><td>Asymptomatic varicose veins of lower extremities</td><td>Diagnosis</td><td>ICD-10-CM</td></td<>	183.9	Asymptomatic varicose veins of lower extremities	Diagnosis	ICD-10-CM
IRB3.92Asymptomatic varicose veins of left lower extremityDiagnosisICD-10-CMIRB3.93Asymptomatic varicose veins of bilateral lower extremitiesDiagnosisICD-10-CMIRB5.01Esophageal varicesDiagnosisICD-10-CMIRB5.01Esophageal varices without bleedingDiagnosisICD-10-CMIRB5.01Esophageal varices without bleedingDiagnosisICD-10-CMIRB5.11Secondary esophageal varices without bleedingDiagnosisICD-10-CMIRB5.12Secondary esophageal varices with bleedingDiagnosisICD-10-CMIRB5.13Secondary esophageal varices with bleedingDiagnosisICD-10-CMIRB6.0Varicose veins of other sitesDiagnosisICD-10-CMIRB6.1Scrotal varicesDiagnosisICD-10-CMIRB6.2Pelvic varicesDiagnosisICD-10-CMIRB6.3Vulval varicesDiagnosisICD-10-CMIRB6.4Gastric varicesDiagnosisICD-10-CMIRB6.8Varicose veins of other specified sitesDiagnosisICD-10-CMIRB6.8Varicose veins of other specified sitesDiagnosisICD-10-CMIRB7.0Postthrombotic syndromeDiagnosisICD-10-CMIRB7.0Postthrombotic syndrome without complicationsDiagnosisICD-10-CMIRB7.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CMIRB7.002Postthrombotic syndrome with ulcer of bilateral lower extremityDiagnosisICD-10-CMIRB7.003 <t< td=""><td>183.90</td><td>Asymptomatic varicose veins of unspecified lower extremity</td><td>Diagnosis</td><td>ICD-10-CM</td></t<>	183.90	Asymptomatic varicose veins of unspecified lower extremity	Diagnosis	ICD-10-CM
83.93Asymptomatic varicose veins of bilateral lower extremitiesDiagnosisICD-10-CM185.Esophageal varicesDiagnosisICD-10-CM185.00Esophageal varices without bleedingDiagnosisICD-10-CM185.01Esophageal varices with bleedingDiagnosisICD-10-CM185.11Secondary esophageal varices without bleedingDiagnosisICD-10-CM185.11Secondary esophageal varices without bleedingDiagnosisICD-10-CM185.11Secondary esophageal varices with bleedingDiagnosisICD-10-CM186.Varicose veins of other sitesDiagnosisICD-10-CM186.0Sublingual varicesDiagnosisICD-10-CM186.1Scrotal varicesDiagnosisICD-10-CM186.2Pelvic varicesDiagnosisICD-10-CM186.3Vulval varicesDiagnosisICD-10-CM186.4Gastric varicesDiagnosisICD-10-CM186.8Varicose veins of other specified sitesDiagnosisICD-10-CM187.0Other disorders of veinsDiagnosisICD-10-CM187.0Postthrombotic syndromeDiagnosisICD-10-CM187.00Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CM187.001Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CM187.002Postthrombotic syndrome without complications of unspecified extremityDiagnosisICD-10-CM187.011Postthrombotic syndrome with ulcer of r	183.91	Asymptomatic varicose veins of right lower extremity	Diagnosis	ICD-10-CM
IRSEsophageal varicesDiagnosisICD-10-CMIRS.00Esophageal varices without bleedingDiagnosisICD-10-CMIRS.01Esophageal varices with bleedingDiagnosisICD-10-CMIRS.10Esophageal varices with bleedingDiagnosisICD-10-CMIRS.11Secondary esophageal varices without bleedingDiagnosisICD-10-CMIRS.11Secondary esophageal varices with bleedingDiagnosisICD-10-CMIRS.11Secondary esophageal varices with bleedingDiagnosisICD-10-CMIRS.01Varicose veins of other sitesDiagnosisICD-10-CMIRS.02Sublingual varicesDiagnosisICD-10-CMIRS.13Scrotal varicesDiagnosisICD-10-CMIRS.24Pelvic varicesDiagnosisICD-10-CMIRS.32Vulval varicesDiagnosisICD-10-CMIRS.33Vulval varicesDiagnosisICD-10-CMIRS.44Gastric varicesDiagnosisICD-10-CMIRS.05Varicose veins of other specified sitesDiagnosisICD-10-CMIRS.00Postthrombotic syndrome without complicationsDiagnosisICD-10-CMIRS.00Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CMIRS.001Postthrombotic syndrome without complications of bilateral lower extremityDiagnosisICD-10-CMIRS.002Postthrombotic syndrome with ulcer of inght lower extremityDiagnosisICD-10-CMIRS.003Postthrombotic syndrome with ulcer of inght lower ex	183.92	Asymptomatic varicose veins of left lower extremity	Diagnosis	ICD-10-CM
I85.0Esophageal varicesICD-10-CMI85.00Esophageal varices without bleedingDiagnosisICD-10-CMI85.1Secondary esophageal varices without bleedingDiagnosisICD-10-CMI85.1Secondary esophageal varices without bleedingDiagnosisICD-10-CMI85.11Secondary esophageal varices without bleedingDiagnosisICD-10-CMI86.1Secondary esophageal varices with bleedingDiagnosisICD-10-CMI86.2Varicose veins of other sitesDiagnosisICD-10-CMI86.3Sublingual varicesDiagnosisICD-10-CMI86.4Scrotal varicesDiagnosisICD-10-CMI86.3Yulval varicesDiagnosisICD-10-CMI86.4Gastric varicesDiagnosisICD-10-CMI86.5Varicose veins of other specified sitesDiagnosisICD-10-CMI87.0Other disorders of veinsDiagnosisICD-10-CMI87.0Postthrombotic syndrome without complicationsDiagnosisICD-10-CMI87.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CMI87.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CMI87.003Postthrombotic syndrome without complications of liaberal lower extremityDiagnosisICD-10-CMI87.001Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CMI87.011Postthrombotic syndrome with ulcer of with ulcer of unspecified extremityDiagnosis <t< td=""><td>183.93</td><td>Asymptomatic varicose veins of bilateral lower extremities</td><td>Diagnosis</td><td>ICD-10-CM</td></t<>	183.93	Asymptomatic varicose veins of bilateral lower extremities	Diagnosis	ICD-10-CM
I85.00Esophageal varices with bleedingDiagnosisICD-10-CMI85.11Esophageal varices with bleedingDiagnosisICD-10-CMI85.10Secondary esophageal varices without bleedingDiagnosisICD-10-CMI85.11Secondary esophageal varices with bleedingDiagnosisICD-10-CMI86.12Secondary esophageal varices with bleedingDiagnosisICD-10-CMI86.0Sublingual varicesDiagnosisICD-10-CMI86.1Scrotal varicesDiagnosisICD-10-CMI86.2Pelvic varicesDiagnosisICD-10-CMI86.3Vulval varicesDiagnosisICD-10-CMI86.4Gastric varicesDiagnosisICD-10-CMI86.8Varicose veins of other specified sitesDiagnosisICD-10-CMI87.0Postthrombotic syndrome without complicationsDiagnosisICD-10-CMI87.00Postthrombotic syndrome without complicationsDiagnosisICD-10-CMI87.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CMI87.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CMI87.003Postthrombotic syndrome without complications of liaberal lower extremityDiagnosisICD-10-CMI87.001Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CMI87.011Postthrombotic syndrome with ulcer of with lower extremityDiagnosisICD-10-CMI87.012Postthrombotic syndrome with ulcer of with lowe	185	Esophageal varices	Diagnosis	ICD-10-CM
I85.01Esophageal varices with bleedingDiagnosisICD-10-CMI85.1.1Secondary esophageal varices without bleedingDiagnosisICD-10-CMI85.1.1Secondary esophageal varices without bleedingDiagnosisICD-10-CMI85.1.1Secondary esophageal varices with bleedingDiagnosisICD-10-CMI86.1Varicose veins of other sitesDiagnosisICD-10-CMI86.2Sublingual varicesDiagnosisICD-10-CMI86.3Scrotal varicesDiagnosisICD-10-CMI86.4Pelvic varicesDiagnosisICD-10-CMI86.3Vulval varicesDiagnosisICD-10-CMI86.4Gastric varicesDiagnosisICD-10-CMI86.8Varicose veins of other specified sitesDiagnosisICD-10-CMI87.0Postthrombotic syndromeDiagnosisICD-10-CMI87.0Postthrombotic syndrome without complicationsDiagnosisICD-10-CMI87.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CMI87.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CMI87.003Postthrombotic syndrome without complications of unspecified extremityDiagnosisICD-10-CMI87.01Postthrombotic syndrome with ulcerDiagnosisICD-10-CMI87.01Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CMI87.012Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CM </td <td>185.0</td> <td>Esophageal varices</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	185.0	Esophageal varices	Diagnosis	ICD-10-CM
I85.1Secondary esophageal varicesDiagnosisICD-10-CMI85.10Secondary esophageal varices without bleedingDiagnosisICD-10-CMI85.11Secondary esophageal varices with bleedingDiagnosisICD-10-CMI86Varicose veins of other sitesDiagnosisICD-10-CMI86.0Sublingual varicesDiagnosisICD-10-CMI86.1Scrotal varicesDiagnosisICD-10-CMI86.2Pelvic varicesDiagnosisICD-10-CMI86.3Vulval varicesDiagnosisICD-10-CMI86.4Gastric varicesDiagnosisICD-10-CMI86.8Varicose veins of other specified sitesDiagnosisICD-10-CMI87.0Other disorders of veinsDiagnosisICD-10-CMI87.0Postthrombotic syndrome without complicationsDiagnosisICD-10-CMI87.00Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CMI87.001Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CMI87.002Postthrombotic syndrome without complications of unspecified extremityDiagnosisICD-10-CMI87.001Postthrombotic syndrome with ulcerDiagnosisICD-10-CMI87.011Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CMI87.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CMI87.013Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosis <td< td=""><td>185.00</td><td>Esophageal varices without bleeding</td><td>Diagnosis</td><td>ICD-10-CM</td></td<>	185.00	Esophageal varices without bleeding	Diagnosis	ICD-10-CM
I85.10Secondary esophageal varices without bleedingDiagnosisICD-10-CMI85.11Secondary esophageal varices with bleedingDiagnosisICD-10-CMI86Varicose veins of other sitesDiagnosisICD-10-CMI86.0Sublingual varicesDiagnosisICD-10-CMI86.1Scrotal varicesDiagnosisICD-10-CMI86.2Pelvic varicesDiagnosisICD-10-CMI86.3Vulval varicesDiagnosisICD-10-CMI86.4Gastric varicesDiagnosisICD-10-CMI86.8Varicose veins of other specified sitesDiagnosisICD-10-CMI87.0Postthrombotic syndromeDiagnosisICD-10-CMI87.00Postthrombotic syndrome without complicationsDiagnosisICD-10-CMI87.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CMI87.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CMI87.003Postthrombotic syndrome without complications of bilateral lower extremityDiagnosisICD-10-CMI87.001Postthrombotic syndrome with ulcerDiagnosisICD-10-CMI87.011Postthrombotic syndrome with ulcerDiagnosisICD-10-CMI87.012Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CMI87.013Postthrombotic syndrome with ulcer of bilateral lower extremityDiagnosisICD-10-CMI87.020Postthrombotic syndrome with inflammationDiagnosisICD-1	185.01	Esophageal varices with bleeding	Diagnosis	ICD-10-CM
I85.11Secondary esophageal varices with bleedingDiagnosisICD-10-CM186Varicose veins of other sitesDiagnosisICD-10-CM186.0Sublingual varicesDiagnosisICD-10-CM186.1Scrotal varicesDiagnosisICD-10-CM186.2Pelvic varicesDiagnosisICD-10-CM186.3Vulval varicesDiagnosisICD-10-CM186.4Gastric varicesDiagnosisICD-10-CM186.8Varicose veins of other specified sitesDiagnosisICD-10-CM187.0Other disorders of veinsDiagnosisICD-10-CM187.00Postthrombotic syndrome without complicationsDiagnosisICD-10-CM187.00Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CM187.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CM187.003Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CM187.01Postthrombotic syndrome without complications of unspecified extremityDiagnosisICD-10-CM187.02Postthrombotic syndrome with ulcerDiagnosisICD-10-CM187.01Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CM187.012Postthrombotic syndrome with ulcer of bilateral lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.021Postthrombotic syndrome	185.1	Secondary esophageal varices	Diagnosis	ICD-10-CM
186Varicose veins of other sitesDiagnosisICD-10-CM186.0Sublingual varicesDiagnosisICD-10-CM186.1Scrotal varicesDiagnosisICD-10-CM186.2Pelvic varicesDiagnosisICD-10-CM186.3Vulval varicesDiagnosisICD-10-CM186.4Gastric varicesDiagnosisICD-10-CM186.8Varicose veins of other specified sitesDiagnosisICD-10-CM187Other disorders of veinsDiagnosisICD-10-CM187.0Postthrombotic syndromeDiagnosisICD-10-CM187.00Postthrombotic syndrome without complicationsDiagnosisICD-10-CM187.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CM187.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CM187.003Postthrombotic syndrome without complications of bilateral lower extremityDiagnosisICD-10-CM187.001Postthrombotic syndrome with ulcerDiagnosisICD-10-CM187.011Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CM187.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of lower extremityDiagnosisICD-10-CM187.021Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of right lower ex	185.10	Secondary esophageal varices without bleeding	Diagnosis	ICD-10-CM
I86.0Sublingual varicesDiagnosisICD-10-CMI86.1Scrotal varicesDiagnosisICD-10-CMI86.2Pelvic varicesDiagnosisICD-10-CMI86.3Vulval varicesDiagnosisICD-10-CMI86.4Gastric varicesDiagnosisICD-10-CMI86.8Varicose veins of other specified sitesDiagnosisICD-10-CMI87Other disorders of veinsDiagnosisICD-10-CMI87.0Postthrombotic syndromeDiagnosisICD-10-CMI87.00Postthrombotic syndrome without complicationsDiagnosisICD-10-CMI87.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CMI87.002Postthrombotic syndrome without complications of bilateral lower extremityDiagnosisICD-10-CMI87.003Postthrombotic syndrome without complications of unspecified extremityDiagnosisICD-10-CMI87.01Postthrombotic syndrome without complications of unspecified extremityDiagnosisICD-10-CMI87.01Postthrombotic syndrome with ulcerDiagnosisICD-10-CMI87.01Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CMI87.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CMI87.013Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosisICD-10-CMI87.021Postthrombotic syndrome with inflammationDiagnosisICD-10-CMI87.022Postthrombotic syndrome with	185.11	Secondary esophageal varices with bleeding	Diagnosis	ICD-10-CM
I86.1Scrotal varicesDiagnosisICD-10-CMI86.2Pelvic varicesDiagnosisICD-10-CMI86.3Vulval varicesDiagnosisICD-10-CMI86.4Gastric varicesDiagnosisICD-10-CMI86.8Varicose veins of other specified sitesDiagnosisICD-10-CMI87Other disorders of veinsDiagnosisICD-10-CMI87.0Postthrombotic syndromeDiagnosisICD-10-CMI87.00Postthrombotic syndrome without complicationsDiagnosisICD-10-CMI87.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CMI87.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CMI87.003Postthrombotic syndrome without complications of bilateral lower extremityDiagnosisICD-10-CMI87.001Postthrombotic syndrome with ulcerDiagnosisICD-10-CMI87.011Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CMI87.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CMI87.013Postthrombotic syndrome with ulcer of inspecified lower extremityDiagnosisICD-10-CMI87.014Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CMI87.025Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CMI87.026Postthrombotic syndrome with inflammation of bilateral lower extremityDiagnosis <td>186</td> <td>Varicose veins of other sites</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	186	Varicose veins of other sites	Diagnosis	ICD-10-CM
186.2Pelvic varicesDiagnosisICD-10-CM186.3Vulval varicesDiagnosisICD-10-CM186.4Gastric varicesDiagnosisICD-10-CM186.8Varicose veins of other specified sitesDiagnosisICD-10-CM187Other disorders of veinsDiagnosisICD-10-CM187.0Postthrombotic syndromeDiagnosisICD-10-CM187.00Postthrombotic syndrome without complicationsDiagnosisICD-10-CM187.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CM187.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CM187.003Postthrombotic syndrome without complications of bilateral lower extremityDiagnosisICD-10-CM187.010Postthrombotic syndrome with ulcerDiagnosisICD-10-CM187.011Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CM187.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.020Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of unspecified lower extremit	186.0	Sublingual varices	Diagnosis	ICD-10-CM
186.3Vulval varicesDiagnosisICD-10-CM186.4Gastric varicesDiagnosisICD-10-CM186.8Varicose veins of other specified sitesDiagnosisICD-10-CM187Other disorders of veinsDiagnosisICD-10-CM187.0Postthrombotic syndromeDiagnosisICD-10-CM187.00Postthrombotic syndrome without complicationsDiagnosisICD-10-CM187.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CM187.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CM187.003Postthrombotic syndrome without complications of bilateral lower extremityDiagnosisICD-10-CM187.010Postthrombotic syndrome without complications of unspecified extremityDiagnosisICD-10-CM187.011Postthrombotic syndrome with ulcerDiagnosisICD-10-CM187.012Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of bilateral lower extremityDiagnosisICD-10-CM187.020Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.031 <td>186.1</td> <td>Scrotal varices</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	186.1	Scrotal varices	Diagnosis	ICD-10-CM
186.4Gastric varicesDiagnosisICD-10-CM186.8Varicose veins of other specified sitesDiagnosisICD-10-CM187Other disorders of veinsDiagnosisICD-10-CM187.0Postthrombotic syndromeDiagnosisICD-10-CM187.00Postthrombotic syndrome without complicationsDiagnosisICD-10-CM187.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CM187.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CM187.003Postthrombotic syndrome without complications of bilateral lower extremityDiagnosisICD-10-CM187.009Postthrombotic syndrome without complications of unspecified extremityDiagnosisICD-10-CM187.011Postthrombotic syndrome with ulcerDiagnosisICD-10-CM187.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of bilateral lower extremityDiagnosisICD-10-CM187.019Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammationDiagnosis	186.2	Pelvic varices	Diagnosis	ICD-10-CM
186.8Varicose veins of other specified sitesDiagnosisICD-10-CM187Other disorders of veinsDiagnosisICD-10-CM187.0Postthrombotic syndromeDiagnosisICD-10-CM187.00Postthrombotic syndrome without complicationsDiagnosisICD-10-CM187.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CM187.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CM187.003Postthrombotic syndrome without complications of bilateral lower extremityDiagnosisICD-10-CM187.009Postthrombotic syndrome without complications of unspecified extremityDiagnosisICD-10-CM187.011Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CM187.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of bilateral lower extremityDiagnosisICD-10-CM187.019Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosisICD-10-CM187.019Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndro	186.3	Vulval varices	Diagnosis	ICD-10-CM
187Other disorders of veinsDiagnosisICD-10-CM187.0Postthrombotic syndromeDiagnosisICD-10-CM187.00Postthrombotic syndrome without complicationsDiagnosisICD-10-CM187.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CM187.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CM187.003Postthrombotic syndrome without complications of bilateral lower extremityDiagnosisICD-10-CM187.009Postthrombotic syndrome with ulcerDiagnosisICD-10-CM187.011Postthrombotic syndrome with ulcerDiagnosisICD-10-CM187.012Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of bilateral lower extremityDiagnosisICD-10-CM187.019Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosisICD-10-CM187.020Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of bilateral lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of bilateral lower extremityDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and infl	186.4	Gastric varices	Diagnosis	ICD-10-CM
187.0Postthrombotic syndromeDiagnosisICD-10-CM187.00Postthrombotic syndrome without complicationsDiagnosisICD-10-CM187.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CM187.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CM187.003Postthrombotic syndrome without complications of bilateral lower extremityDiagnosisICD-10-CM187.009Postthrombotic syndrome without complications of unspecified extremityDiagnosisICD-10-CM187.01Postthrombotic syndrome with ulcerDiagnosisICD-10-CM187.011Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CM187.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosisICD-10-CM187.02Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.02Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.020Postthrombotic syndrome with inflammation of bilateral lower extremityDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammation of bilateral lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10	186.8	Varicose veins of other specified sites	Diagnosis	ICD-10-CM
187.00Postthrombotic syndrome without complicationsDiagnosisICD-10-CM187.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CM187.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CM187.003Postthrombotic syndrome without complications of bilateral lower extremityDiagnosisICD-10-CM187.009Postthrombotic syndrome without complications of unspecified extremityDiagnosisICD-10-CM187.01Postthrombotic syndrome with ulcerDiagnosisICD-10-CM187.011Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosisICD-10-CM187.020Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187	Other disorders of veins	Diagnosis	ICD-10-CM
187.001Postthrombotic syndrome without complications of right lower extremityDiagnosisICD-10-CM187.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CM187.003Postthrombotic syndrome without complications of bilateral lower extremityDiagnosisICD-10-CM187.009Postthrombotic syndrome without complications of unspecified extremityDiagnosisICD-10-CM187.01Postthrombotic syndrome with ulcerDiagnosisICD-10-CM187.011Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CM187.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of bilateral lower extremityDiagnosisICD-10-CM187.02Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.02Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.02Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.02Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.03Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.0	Postthrombotic syndrome	Diagnosis	ICD-10-CM
187.002Postthrombotic syndrome without complications of left lower extremityDiagnosisICD-10-CM187.003Postthrombotic syndrome without complications of bilateral lower extremityDiagnosisICD-10-CM187.009Postthrombotic syndrome without complications of unspecified extremityDiagnosisICD-10-CM187.01Postthrombotic syndrome with ulcerDiagnosisICD-10-CM187.011Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CM187.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of bilateral lower extremityDiagnosisICD-10-CM187.02Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.02Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of bilateral lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.00	Postthrombotic syndrome without complications	Diagnosis	ICD-10-CM
187.003Postthrombotic syndrome without complications of bilateral lower extremityDiagnosisICD-10-CM187.009Postthrombotic syndrome without complications of unspecified extremityDiagnosisICD-10-CM187.01Postthrombotic syndrome with ulcerDiagnosisICD-10-CM187.011Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CM187.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosisICD-10-CM187.02Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.03Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammation of right lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.001	Postthrombotic syndrome without complications of right lower extremity	Diagnosis	ICD-10-CM
187.009Postthrombotic syndrome without complications of unspecified extremityDiagnosisICD-10-CM187.01Postthrombotic syndrome with ulcerDiagnosisICD-10-CM187.011Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CM187.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of bilateral lower extremityDiagnosisICD-10-CM187.019Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosisICD-10-CM187.02Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.03Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammation of right lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.002	Postthrombotic syndrome without complications of left lower extremity	Diagnosis	ICD-10-CM
187.01Postthrombotic syndrome with ulcerDiagnosisICD-10-CM187.011Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CM187.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of bilateral lower extremityDiagnosisICD-10-CM187.019Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosisICD-10-CM187.02Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.03Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammation of right lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.003	Postthrombotic syndrome without complications of bilateral lower extremity	Diagnosis	ICD-10-CM
187.011Postthrombotic syndrome with ulcer of right lower extremityDiagnosisICD-10-CM187.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of bilateral lower extremityDiagnosisICD-10-CM187.019Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosisICD-10-CM187.02Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of bilateral lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.03Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammation of right lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.009	Postthrombotic syndrome without complications of unspecified extremity	Diagnosis	ICD-10-CM
187.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of bilateral lower extremityDiagnosisICD-10-CM187.019Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosisICD-10-CM187.02Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of bilateral lower extremityDiagnosisICD-10-CM187.029Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.03Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.01	Postthrombotic syndrome with ulcer	Diagnosis	ICD-10-CM
187.012Postthrombotic syndrome with ulcer of left lower extremityDiagnosisICD-10-CM187.013Postthrombotic syndrome with ulcer of bilateral lower extremityDiagnosisICD-10-CM187.019Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosisICD-10-CM187.02Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.03Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammation of right lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.011	Postthrombotic syndrome with ulcer of right lower extremity	Diagnosis	ICD-10-CM
187.019Postthrombotic syndrome with ulcer of unspecified lower extremityDiagnosisICD-10-CM187.02Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of bilateral lower extremityDiagnosisICD-10-CM187.029Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.03Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.012	Postthrombotic syndrome with ulcer of left lower extremity		ICD-10-CM
187.02Postthrombotic syndrome with inflammationDiagnosisICD-10-CM187.021Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of bilateral lower extremityDiagnosisICD-10-CM187.029Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.03Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammation of right lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.013	Postthrombotic syndrome with ulcer of bilateral lower extremity	Diagnosis	ICD-10-CM
187.021Postthrombotic syndrome with inflammation of right lower extremityDiagnosisICD-10-CM187.022Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of bilateral lower extremityDiagnosisICD-10-CM187.029Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.03Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammation of right lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.019	Postthrombotic syndrome with ulcer of unspecified lower extremity		ICD-10-CM
187.022Postthrombotic syndrome with inflammation of left lower extremityDiagnosisICD-10-CM187.023Postthrombotic syndrome with inflammation of bilateral lower extremityDiagnosisICD-10-CM187.029Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.03Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammation of right lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.02	Postthrombotic syndrome with inflammation	Diagnosis	ICD-10-CM
187.023Postthrombotic syndrome with inflammation of bilateral lower extremityDiagnosisICD-10-CM187.029Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.03Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammation of right lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.021	Postthrombotic syndrome with inflammation of right lower extremity	Diagnosis	ICD-10-CM
187.029Postthrombotic syndrome with inflammation of unspecified lower extremityDiagnosisICD-10-CM187.03Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammation of right lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.022	Postthrombotic syndrome with inflammation of left lower extremity	Diagnosis	ICD-10-CM
187.03Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammation of right lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.023	Postthrombotic syndrome with inflammation of bilateral lower extremity	Diagnosis	ICD-10-CM
187.03Postthrombotic syndrome with ulcer and inflammationDiagnosisICD-10-CM187.031Postthrombotic syndrome with ulcer and inflammation of right lower extremityDiagnosisICD-10-CM187.032Postthrombotic syndrome with ulcer and inflammation of left lower extremityDiagnosisICD-10-CM	187.029	Postthrombotic syndrome with inflammation of unspecified lower extremity		ICD-10-CM
187.031 Postthrombotic syndrome with ulcer and inflammation of right lower extremity Diagnosis ICD-10-CM Postthrombotic syndrome with ulcer and inflammation of left lower extremity Diagnosis ICD-10-CM	187.03			ICD-10-CM
187.032 Postthrombotic syndrome with ulcer and inflammation of left lower extremity Diagnosis ICD-10-CM		·		ICD-10-CM
			_	

cder_mpl1p_wp077 Page 943 of 1023



	Codes Used to Define Baseline Characteristics in this Request	Code	
Code	Description	Category	Code Type
187.039	Postthrombotic syndrome with ulcer and inflammation of unspecified lower extremity	Diagnosis	ICD-10-CM
187.09	Postthrombotic syndrome with other complications	Diagnosis	ICD-10-CM
187.091	Postthrombotic syndrome with other complications of right lower extremity	Diagnosis	ICD-10-CM
187.092	Postthrombotic syndrome with other complications of left lower extremity	Diagnosis	ICD-10-CM
187.093	Postthrombotic syndrome with other complications of bilateral lower extremity	Diagnosis	ICD-10-CM
187.099	Postthrombotic syndrome with other complications of unspecified lower extremity	Diagnosis	ICD-10-CM
187.1	Compression of vein	Diagnosis	ICD-10-CM
187.2	Venous insufficiency (chronic) (peripheral)	Diagnosis	ICD-10-CM
187.3	Chronic venous hypertension (idiopathic)	Diagnosis	ICD-10-CM
187.30	Chronic venous hypertension (idiopathic) without complications	Diagnosis	ICD-10-CM
187.301	Chronic venous hypertension (idiopathic) without complications of right lower extremity	Diagnosis	ICD-10-CM
187.302	Chronic venous hypertension (idiopathic) without complications of left lower extremity	Diagnosis	ICD-10-CM
187.303	Chronic venous hypertension (idiopathic) without complications of bilateral lower extremity	Diagnosis	ICD-10-CM
187.309	Chronic venous hypertension (idiopathic) without complications of unspecified lower extremity	Diagnosis	ICD-10-CM
187.31	Chronic venous hypertension (idiopathic) with ulcer	Diagnosis	ICD-10-CM
187.311	Chronic venous hypertension (idiopathic) with ulcer of right lower extremity	Diagnosis	ICD-10-CM
187.312	Chronic venous hypertension (idiopathic) with ulcer of left lower extremity	Diagnosis	ICD-10-CM
187.313	Chronic venous hypertension (idiopathic) with ulcer of bilateral lower extremity	Diagnosis	ICD-10-CM
187.319	Chronic venous hypertension (idiopathic) with ulcer of unspecified lower extremity	Diagnosis	ICD-10-CM
187.32	Chronic venous hypertension (idiopathic) with inflammation	Diagnosis	ICD-10-CM
187.321	Chronic venous hypertension (idiopathic) with inflammation of right lower extremity	Diagnosis	ICD-10-CM
187.322	Chronic venous hypertension (idiopathic) with inflammation of left lower extremity	Diagnosis	ICD-10-CM
187.323	Chronic venous hypertension (idiopathic) with inflammation of bilateral lower extremity	Diagnosis	ICD-10-CM
187.329	Chronic venous hypertension (idiopathic) with inflammation of unspecified lower extremity	Diagnosis	ICD-10-CM
187.33	Chronic venous hypertension (idiopathic) with ulcer and inflammation	Diagnosis	ICD-10-CM
187.331	Chronic venous hypertension (idiopathic) with ulcer and inflammation of right lower extremity	Diagnosis	ICD-10-CM
187.332	Chronic venous hypertension (idiopathic) with ulcer and inflammation of left lower extremity	Diagnosis	ICD-10-CM
187.333	Chronic venous hypertension (idiopathic) with ulcer and inflammation of bilateral lower extremity	Diagnosis	ICD-10-CM
187.339	Chronic venous hypertension (idiopathic) with ulcer and inflammation of unspecified lower extremity	Diagnosis	ICD-10-CM
187.39 187.391	Chronic venous hypertension (idiopathic) with other complications Chronic venous hypertension (idiopathic) with other complications of right lower	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
187.392	extremity Chronic venous hypertension (idiopathic) with other complications of left lower extremity	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 944 of 1023



	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
187.393	Chronic venous hypertension (idiopathic) with other complications of bilateral lower	Diagnosis	ICD-10-CM
	extremity		
187.399	Chronic venous hypertension (idiopathic) with other complications of unspecified lower	Diagnosis	ICD-10-CM
	extremity		
187.8	Other specified disorders of veins	Diagnosis	ICD-10-CM
187.9	Disorder of vein, unspecified	Diagnosis	ICD-10-CM
188	Nonspecific lymphadenitis	Diagnosis	ICD-10-CM
188.0	Nonspecific mesenteric lymphadenitis	Diagnosis	ICD-10-CM
188.1	Chronic lymphadenitis, except mesenteric	Diagnosis	ICD-10-CM
188.8	Other nonspecific lymphadenitis	Diagnosis	ICD-10-CM
188.9	Nonspecific lymphadenitis, unspecified	Diagnosis	ICD-10-CM
189	Other noninfective disorders of lymphatic vessels and lymph nodes	Diagnosis	ICD-10-CM
189.0	Lymphedema, not elsewhere classified	Diagnosis	ICD-10-CM
189.1	Lymphangitis	Diagnosis	ICD-10-CM
189.8	Other specified noninfective disorders of lymphatic vessels and lymph nodes	Diagnosis	ICD-10-CM
189.9	Noninfective disorder of lymphatic vessels and lymph nodes, unspecified	Diagnosis	ICD-10-CM
195	Hypotension	Diagnosis	ICD-10-CM
195.0	Idiopathic hypotension	Diagnosis	ICD-10-CM
195.1	Orthostatic hypotension	Diagnosis	ICD-10-CM
195.2	Hypotension due to drugs	Diagnosis	ICD-10-CM
195.3	Hypotension of hemodialysis	Diagnosis	ICD-10-CM
195.8	Other hypotension	Diagnosis	ICD-10-CM
195.81	Postprocedural hypotension	Diagnosis	ICD-10-CM
195.89	Other hypotension	Diagnosis	ICD-10-CM
195.9	Hypotension, unspecified	Diagnosis	ICD-10-CM
196	Gangrene, not elsewhere classified	Diagnosis	ICD-10-CM
197	Intraoperative and postprocedural complications and disorders of circulatory system, not	Diagnosis	ICD-10-CM
	elsewhere classified		
197.0	Postcardiotomy syndrome	Diagnosis	ICD-10-CM
197.1	Other postprocedural cardiac functional disturbances	Diagnosis	ICD-10-CM
197.11	Postprocedural cardiac insufficiency	Diagnosis	ICD-10-CM
197.110	Postprocedural cardiac insufficiency following cardiac surgery	Diagnosis	ICD-10-CM
197.111	Postprocedural cardiac insufficiency following other surgery	Diagnosis	ICD-10-CM
197.12	Postprocedural cardiac arrest	Diagnosis	ICD-10-CM
197.120	Postprocedural cardiac arrest following cardiac surgery	Diagnosis	ICD-10-CM
197.121	Postprocedural cardiac arrest following other surgery	Diagnosis	ICD-10-CM
197.13	Postprocedural heart failure	Diagnosis	ICD-10-CM
197.130	Postprocedural heart failure following cardiac surgery	Diagnosis	ICD-10-CM
197.131	Postprocedural heart failure following other surgery	Diagnosis	ICD-10-CM
197.19	Other postprocedural cardiac functional disturbances	Diagnosis	ICD-10-CM
197.190	Other postprocedural cardiac functional disturbances following cardiac surgery	Diagnosis	ICD-10-CM
197.191	Other postprocedural cardiac functional disturbances following other surgery	Diagnosis	ICD-10-CM
197.2	Postmastectomy lymphedema syndrome	Diagnosis	ICD-10-CM
197.3	Postprocedural hypertension	Diagnosis	ICD-10-CM
197.4	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure	Diagnosis	ICD-10-CM
	complicating a procedure		
197.41	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure	Diagnosis	ICD-10-CM
	complicating a circulatory system procedure		

cder_mpl1p_wp077 Page 945 of 1023



Troccaure	Codes Osed to Define Baseline Characteristics in this nequest	Code	
Code	Description	Category	Code Type
197.410	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating a cardiac catheterization	Diagnosis	ICD-10-CM
197.411	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating a cardiac bypass	Diagnosis	ICD-10-CM
197.418	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating other circulatory system procedure	Diagnosis	ICD-10-CM
197.42	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
197.5	Accidental puncture and laceration of a circulatory system organ or structure during a procedure	Diagnosis	ICD-10-CM
197.51	Accidental puncture and laceration of a circulatory system organ or structure during a circulatory system procedure	Diagnosis	ICD-10-CM
197.52	Accidental puncture and laceration of a circulatory system organ or structure during other procedure	Diagnosis	ICD-10-CM
197.6	Postprocedural hemorrhage, hematoma and seroma of a circulatory system organ or structure following a procedure	Diagnosis	ICD-10-CM
197.61	Postprocedural hemorrhage of a circulatory system organ or structure following a circulatory system procedure	Diagnosis	ICD-10-CM
197.610	Postprocedural hemorrhage of a circulatory system organ or structure following a cardiac catheterization	Diagnosis	ICD-10-CM
197.611	Postprocedural hemorrhage of a circulatory system organ or structure following cardiac bypass	Diagnosis	ICD-10-CM
197.618	Postprocedural hemorrhage of a circulatory system organ or structure following other circulatory system procedure	Diagnosis	ICD-10-CM
197.62	Postprocedural hemorrhage, hematoma and seroma of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
197.620	Postprocedural hemorrhage of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
197.621	Postprocedural hematoma of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
197.622	Postprocedural seroma of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
197.63	Postprocedural hematoma of a circulatory system organ or structure following a circulatory system procedure	Diagnosis	ICD-10-CM
197.630	Postprocedural hematoma of a circulatory system organ or structure following a cardiac catheterization	Diagnosis	ICD-10-CM
197.631	Postprocedural hematoma of a circulatory system organ or structure following cardiac bypass	Diagnosis	ICD-10-CM
197.638	Postprocedural hematoma of a circulatory system organ or structure following other circulatory system procedure	Diagnosis	ICD-10-CM
197.64	Postprocedural seroma of a circulatory system organ or structure following a circulatory system procedure	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 946 of 1023



Toccaure	coues osed to benne baseline characteristics in this request	Code	
Code	Description	Category	Code Type
197.640	Postprocedural seroma of a circulatory system organ or structure following a cardiac	Diagnosis	ICD-10-CM
	catheterization		
197.641	Postprocedural seroma of a circulatory system organ or structure following cardiac bypass	Diagnosis	ICD-10-CM
197.648	Postprocedural seroma of a circulatory system organ or structure following other	Diagnosis	ICD-10-CM
	circulatory system procedure		
197.7	Intraoperative cardiac functional disturbances	Diagnosis	ICD-10-CM
197.71	Intraoperative cardiac arrest	Diagnosis	ICD-10-CM
197.710	Intraoperative cardiac arrest during cardiac surgery	Diagnosis	ICD-10-CM
197.711	Intraoperative cardiac arrest during other surgery	Diagnosis	ICD-10-CM
197.79	Other intraoperative cardiac functional disturbances	Diagnosis	ICD-10-CM
197.790	Other intraoperative cardiac functional disturbances during cardiac surgery	Diagnosis	ICD-10-CM
197.791	Other intraoperative cardiac functional disturbances during other surgery	Diagnosis	ICD-10-CM
197.8	Other intraoperative and postprocedural complications and disorders of the circulatory	Diagnosis	ICD-10-CM
	system, not elsewhere classified		
197.81	Intraoperative cerebrovascular infarction	Diagnosis	ICD-10-CM
197.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
197.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
197.82	Postprocedural cerebrovascular infarction	Diagnosis	ICD-10-CM
197.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
197.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM
197.88	Other intraoperative complications of the circulatory system, not elsewhere classified	Diagnosis	ICD-10-CM
197.89	Other postprocedural complications and disorders of the circulatory system, not	Diagnosis	ICD-10-CM
	elsewhere classified		
199	Other and unspecified disorders of circulatory system	Diagnosis	ICD-10-CM
199.8	Other disorder of circulatory system	Diagnosis	ICD-10-CM
199.9	Unspecified disorder of circulatory system	Diagnosis	ICD-10-CM
	Obstructive Sleep Apnea		
G47.3	Sleep apnea	Diagnosis	ICD-10-CM
G47.30	Sleep apnea, unspecified	Diagnosis	ICD-10-CM
G47.31	Primary central sleep apnea	Diagnosis	ICD-10-CM
G47.33	Obstructive sleep apnea (adult) (pediatric)	Diagnosis	ICD-10-CM
G47.37	Central sleep apnea in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.39	Other sleep apnea	Diagnosis	ICD-10-CM
R06.81	Apnea, not elsewhere classified	Diagnosis	ICD-10-CM
	Hypertrophic Cardiomyopathy		
142.1	Obstructive hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
142.2	Other hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
142.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
142.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
142.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
142.9	Cardiomyopathy, unspecified	Diagnosis	ICD-10-CM
143	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
090.3	Peripartum cardiomyopathy	Diagnosis	ICD-10-CM
142	Cardiomyopathy	Diagnosis	ICD-10-CM
142.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
A36.81	Diphtheritic cardiomyopathy	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 947 of 1023



	codes osed to befine baseline characteristics in this nequest	Code			
Code	Description	Category	Code Type		
125.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM		
142.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM		
B33.24	Viral cardiomyopathy	Diagnosis	ICD-10-CM		
142.3	Endomyocardial (eosinophilic) disease	Diagnosis	ICD-10-CM		
142.4	Endocardial fibroelastosis	Diagnosis	ICD-10-CM		
	Tachyarrhythmia				
146	Cardiac arrest	Diagnosis	ICD-10-CM		
146.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM		
146.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM		
146.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM		
147	Paroxysmal tachycardia	Diagnosis	ICD-10-CM		
147.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM		
147.1	Supraventricular tachycardia	Diagnosis	ICD-10-CM		
147.2	Ventricular tachycardia	Diagnosis	ICD-10-CM		
147.9	Paroxysmal tachycardia, unspecified	Diagnosis	ICD-10-CM		
148	Atrial fibrillation and flutter	Diagnosis	ICD-10-CM		
148.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM		
148.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM		
148.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM		
148.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM		
148.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM		
148.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM		
148.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM		
148.3	Typical atrial flutter	Diagnosis	ICD-10-CM		
148.4	Atypical atrial flutter	Diagnosis	ICD-10-CM		
148.9	Unspecified atrial fibrillation and atrial flutter	Diagnosis	ICD-10-CM		
148.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM		
148.92	Unspecified atrial flutter	Diagnosis	ICD-10-CM		
149	Other cardiac arrhythmias	Diagnosis	ICD-10-CM		
149.0	Ventricular fibrillation and flutter	Diagnosis	ICD-10-CM		
149.01	Ventricular fibrillation	Diagnosis	ICD-10-CM		
149.02	Ventricular flutter	Diagnosis	ICD-10-CM		
149.1	Atrial premature depolarization	Diagnosis	ICD-10-CM		
149.2	Junctional premature depolarization	Diagnosis	ICD-10-CM		
149.3	Ventricular premature depolarization	Diagnosis	ICD-10-CM		
149.4	Other and unspecified premature depolarization	Diagnosis	ICD-10-CM		
149.40	Unspecified premature depolarization	Diagnosis	ICD-10-CM		
149.49	Other premature depolarization	Diagnosis	ICD-10-CM		
149.8	Other specified cardiac arrhythmias	Diagnosis	ICD-10-CM		
149.9	Cardiac arrhythmia, unspecified	Diagnosis	ICD-10-CM		
R00.0	Tachycardia, unspecified	Diagnosis	ICD-10-CM		
History of Serious Hypoglycemia					
E08.64	Diabetes mellitus due to underlying condition with hypoglycemia	Diagnosis	ICD-10-CM		
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM		
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM		
E09.64	Drug or chemical induced diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM		
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM		
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM		
E11.64	Type 2 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM		
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM		

cder_mpl1p_wp077 Page 948 of 1023



		Code	
Code	Description	Category	Code Type
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.64	Other specified diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E16.0	Drug-induced hypoglycemia without coma	Diagnosis	ICD-10-CM
E16.1	Other hypoglycemia	Diagnosis	ICD-10-CM
E16.2	Hypoglycemia, unspecified	Diagnosis	ICD-10-CM
P70.3	latrogenic neonatal hypoglycemia	Diagnosis	ICD-10-CM
P70.4	Other neonatal hypoglycemia	Diagnosis	ICD-10-CM

cder_mpl1p_wp077 Page 949 of 1023



Appendix G. Generic and Brand Names of Medical Products Generic Name	Brand Name	
	sidase Inhibitor	
acarbose	acarbose	
acarbose	Precose	
miglitol	miglitol	
	n Analogs	
pramlintide acetate	SymlinPen 60	
pramlintide acetate	SymlinPen 120	
•	se 4 (DPP-4) Inhibitors	
alogliptin benzoate	alogliptin	
alogliptin benzoate	Nesina	
dapagliflozin propanediol/saxagliptin HCl	Qtern	
empagliflozin/linagliptin	Glyxambi	
ertugliflozin pidolate/sitagliptin phosphate	Steglujan	
linagliptin	Tradjenta	
saxagliptin HCl	Onglyza	
sitagliptin phosphate	Januvia	
	n Mimetics	
dulaglutide	Trulicity	
exenatide	Byetta	
exenatide microspheres	Bydureon	
exenatide microspheres	Bydureon BCise	
insulin degludec/liraglutide	Xultophy 100/3.6	
insulin glargine, human recombinant analog/lixisenatide	Soliqua 100/33	
liraglutide	Saxenda	
liraglutide	Victoza 2-Pak	
liraglutide	Victoza 3-Pak	
lixisenatide	Adlyxin	
semaglutide	Ozempic	
semaglutide	Rybelsus	
semaglutide	Wegovy	
tirzepatide	Mounjaro	
	litinides	
nateglinide	nateglinide	
repaglinide	repaglinide	
repaglinide/metformin HCl	repaglinide-metformin	
	isulin	
insulin aspart	insulin aspart U-100	
insulin aspart	Novolog FlexPen U-100 Insulin	
insulin aspart	Novolog PenFill U-100 Insulin	
insulin aspart	Novolog U-100 Insulin aspart	
insulin aspart (niacinamide)	Fiasp FlexTouch U-100 Insulin	
insulin aspart (niacinamide)	Fiasp Penfill U-100 Insulin	
insulin aspart (niacinamide) insulin aspart protamine human/insulin aspart	Fiasp U-100 Insulin	
insulin aspart protamine numan/insulin aspart	insulin asp prt-insulin aspart Novolog Mix 70-30 U-100 Insuln	
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30 0-100 Insuin Novolog Mix 70-30FlexPen U-100	
insulin degludec insulin degludec	Tresiba FlexTouch U-100	
insulin degludec	Tresiba FlexTouch U-200	
insulin degludec	Tresiba U-100 Insulin	
insulin degiddec	Levemir FlexPen	
insulin determir Levemir FlexTouch U-100 Insuln		
insulin determi	Levemir U-100 Insulin	
insulin glargine,human recombinant analog	Basaglar KwikPen U-100 Insulin	
madin Biargine, naman recombinant analog	PagaRiai KMIKI CII O-TOO III2AIIII	

cder_mpl1p_wp077 Page 950 of 1023



Generic Name	Brand Name		
nsulin glargine,human recombinant analog	Basaglar Tempo Pen(U-100)InsIn		
nsulin glargine,human recombinant analog	insulin glargine		
nsulin glargine,human recombinant analog	Lantus Solostar U-100 Insulin		
nsulin glargine,human recombinant analog	Lantus U-100 Insulin		
nsulin glargine,human recombinant analog	Semglee Pen U-100 Insulin		
nsulin glargine,human recombinant analog	Semglee U-100 Insulin		
nsulin glargine,human recombinant analog	Toujeo Max U-300 SoloStar		
nsulin glargine,human recombinant analog	Toujeo SoloStar U-300 Insulin		
nsulin glargine-yfgn	insulin glargine-yfgn		
nsulin glargine-yfgn	Semglee(insulin glargine-yfgn)		
nsulin glargine-yfgn	Semglee(insulin glarg-yfgn)Pen		
nsulin glulisine	Apidra SoloStar U-100 Insulin		
nsulin glulisine	Apidra U-100 Insulin		
nsulin lispro	Admelog SoloStar U-100 Insulin		
nsulin lispro	Admelog U-100 Insulin lispro		
nsulin lispro	Humalog Junior KwikPen U-100		
nsulin lispro	Humalog KwikPen Insulin		
nsulin lispro	Humalog Tempo Pen(U-100)Insuln		
nsulin lispro	Humalog U-100 Insulin		
nsulin lispro	insulin lispro		
nsulin lispro protamine and insulin lispro	Humalog Mix 50-50 Insuln U-100		
nsulin lispro protamine and insulin lispro	Humalog Mix 50-50 KwikPen		
nsulin lispro protamine and insulin lispro	Humalog Mix 75-25 KwikPen		
nsulin lispro protamine and insulin lispro	Humalog Mix 75-25(U-100)Insuln		
nsulin lispro protamine and insulin lispro	insulin lispro protamin-lispro		
nsulin lispro-aabc	Lyumjev KwikPen U-100 Insulin		
nsulin lispro-aabc	Lyumjev KwikPen U-200 Insulin		
nsulin lispro-aabc	Lyumjev Tempo Pen(U-100)Insuln		
nsulin lispro-aabc	Lyumjev U-100 Insulin		
nsulin NPH human isophane	Humulin N NPH Insulin KwikPen		
nsulin NPH human isophane	Humulin N NPH U-100 Insulin		
nsulin NPH human isophane	Novolin N FlexPen		
nsulin NPH human isophane	Novolin N NPH U-100 Insulin		
nsulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 Insulin		
nsulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 KwikPen		
nsulin NPH human isophane/insulin regular, human	Novolin 70/30 U-100 Insulin		
nsulin NPH human isophane/insulin regular, human	Novolin 70-30 FlexPen U-100		
nsulin regular, human	Afrezza		
nsulin regular, human	Humulin R Regular U-100 Insuln		
nsulin regular, human	Humulin R U-500 (Conc) Insulin		
nsulin regular, human	Humulin R U-500 (Conc) Kwikpen		
nsulin regular, human	Novolin R FlexPen		
nsulin regular, human	Novolin R Regular U-100 Insuln		
U /	Myxredlin		

alogliptin benzoate/metformin HCl	alogliptin-metformin
alogliptin benzoate/metformin HCl	Kazano
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
dapagliflozin propanediol/metformin HCl	Xigduo XR
empagliflozin/linagliptin/metformin HCl	Trijardy XR
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate/metformin HCl	Segluromet

cder_mpl1p_wp077 Page 951 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Appendix G. Generic and Brand Names of Medical Products U Generic Name	Brand Name		
glipizide/metformin HCl	glipizide-metformin		
glyburide/metformin HCl	glyburide-metformin		
linagliptin/metformin HCl	Jentadueto		
linagliptin/metformin HCl	Jentadueto XR		
metformin HCl	Fortamet		
metformin HCl	Glumetza		
metformin HCl	metformin		
metformin HCl	Riomet		
metformin HCl	Riomet ER		
pioglitazone HCI/metformin HCI	Actoplus MET		
pioglitazone HCI/metformin HCI	pioglitazone-metformin		
repaglinide/metformin HCl	repaglinide-metformin		
saxagliptin HCI/metformin HCI	Kombiglyze XR		
sitagliptin phosphate/metformin HCl	Janumet		
sitagliptin phosphate/metformin HCl	Janumet XR		
Sodium-Glucose Cotranspo			
canagliflozin	Invokana		
dapagliflozin propanediol	Farxiga		
dapagliflozin propanediol/saxagliptin HCl	Qtern		
empagliflozin	Jardiance		
empagliflozin/linagliptin	Glyxambi		
ertugliflozin pidolate	Steglatro		
ertugliflozin pidolate/sitagliptin phosphate	Steglujan		
Sulfon			
glimepiride	Amaryl		
glimepiride	glimepiride		
glipizide	glipizide		
glipizide	Glucotrol		
glipizide	Glucotrol XL		
glipizide/metformin HCl	glipizide-metformin		
glyburide	glyburide		
glyburide,micronized	glyburide micronized		
glyburide,micronized	Glynase		
glyburide/metformin HCl	glyburide-metformin		
pioglitazone HCl/glimepiride	DUETACT		
pioglitazone HCl/glimepiride	pioglitazone-glimepiride		
Thiazolidi			
alogliptin benzoate/pioglitazone HCl	alogliptin-pioglitazone		
alogliptin benzoate/pioglitazone HCl	Oseni		
pioglitazone HCl	Actos		
pioglitazone HCl	pioglitazone		
pioglitazone HCl/glimepiride	DUETACT		
pioglitazone HCI/glimepiride	pioglitazone-glimepiride		
pioglitazone HCI/metformin HCI	Actoplus MET		
pioglitazone HCI/metformin HCI	pioglitazone-metformin		
Other Antidiabetic Drugs (Bromocriptine, Mifepristone)			
	omocriptine, Mifepristone)		
bromocriptine mesylate	omocriptine, Mifepristone) Cycloset		
bromocriptine mesylate mifepristone	omocriptine, Mifepristone) Cycloset Korlym		
bromocriptine mesylate mifepristone Sodium Char	omocriptine, Mifepristone) Cycloset Korlym nnel Blocker		
bromocriptine mesylate mifepristone Sodium Char disopyramide phosphate	Cycloset Korlym nnel Blocker disopyramide phosphate		
bromocriptine mesylate mifepristone Sodium Char disopyramide phosphate disopyramide phosphate	Cycloset Korlym nnel Blocker disopyramide phosphate Norpace		
bromocriptine mesylate mifepristone Sodium Char disopyramide phosphate disopyramide phosphate disopyramide phosphate	Cycloset Korlym nnel Blocker disopyramide phosphate Norpace Norpace CR		
bromocriptine mesylate mifepristone Sodium Char disopyramide phosphate disopyramide phosphate	Cycloset Korlym nnel Blocker disopyramide phosphate Norpace		

cder_mpl1p_wp077 Page 952 of 1023



Generic Name	Brand Name	
lidocaine HCl in sodium chloride, iso-osmotic/PF	lidocaine in NaCl,iso-osmo(PF)	
idocaine HCI/PF	lidocaine (PF)	
idocaine HCI/PF	Xylocaine (Cardiac) (PF)	
mexiletine HCl	mexiletine	
phenytoin sodium	phenytoin sodium	
procainamide HCl	procainamide	
propafenone HCl	propafenone	
propafenone HCl	Rythmol SR	
quinidine gluconate	quinidine gluconate	
quinidine sulfate	quinidine sulfate	
	Beta Blocker	
cebutolol HCl	acebutolol	
atenolol	atenolol	
itenolol	Tenormin	
atenolol/chlorthalidone	atenolol-chlorthalidone	
atenolol/chlorthalidone	Tenoretic 100	
itenolol/chlorthalidone	Tenoretic 50	
petaxolol HCl	betaxolol	
petaxolol rici pisoprolol fumarate	bisoprolol fumarate	
pisoprolol fumarate/hydrochlorothiazide	bisoprolol-hydrochlorothiazide	
oisoprolol fumarate/hydrochlorothiazide	Ziac	
ranakinumab/PF		
arvedilol	Ilaris (PF)	
	carvedilol	
arvedilol	Coreg	
carvedilol phosphate	carvedilol phosphate	
arvedilol phosphate	Coreg CR Brevibloc	
esmolol HCl esmolol HCl	esmolol	
esmolol HCl in sodium chloride, iso-osmotic	Brevibloc in NaCl (iso-osm)	
esmolol HCl in sodium chloride, iso-osmotic	esmolol in NaCl (iso-osm)	
esmolol HCl in sterile water	esmolol in sterile water	
abetalol HCl	labetalol	
abetalol HCl in dextrose, iso-osmotic	labetalol in dextrose,iso-osm	
abetalol HCl in sodium chloride, iso-osmotic	labetalol in NaCl (iso-osmot)	
netoprolol succinate	Kapspargo Sprinkle	
metoprolol succinate	metoprolol succinate	
netoprolol succinate	Toprol XL	
netoprolol succinate/hydrochlorothiazide	Dutoprol	
netoprolol tartrate	Lopressor	
netoprolol tartrate	metoprolol tartrate	
netoprolol tartrate/hydrochlorothiazide	metoprolol ta-hydrochlorothiaz	
nadolol	Corgard	
nadolol	nadolol	
nebivolol HCl	Bystolic	
nebivolol HCl	nebivolol	
oindolol	pindolol	
propranolol HCl	Hemangeol	
propranolol HCl	Inderal LA	
propranolol HCl	Inderal XL	
propranolol HCl	InnoPran XL	
propranolol HCl	propranolol	
propranolol HCl/hydrochlorothiazide	propranolol-hydrochlorothiazid	
sotalol HCl	Betapace	
cotalal HCl	Potanaco AE	

Page 953 of 1023 cder_mpl1p_wp077

sotalol HCl

Betapace AF



Appendix G. Generic and Brand Names of Medical Pr	roducts Used to Define Baseline Characteristics in this Request	
Generic Name	Brand Name	
sotalol HCl	Sorine	
sotalol HCl	sotalol	
sotalol HCl Sotalol AF		
sotalol HCl	Sotylize	
timolol maleate	timolol maleate	
Potassiun	n Channel Blocker/Openers	
amiodarone HCl	amiodarone	
amiodarone HCl	Pacerone	
amiodarone HCI/dextrose 5 % in water	amiodarone in dextrose 5 %	
amiodarone in dextrose, iso-osmotic	Nexterone	
bretylium tosylate	bretylium tosylate	
dofetilide	dofetilide	
dofetilide	Tikosyn	
dronedarone HCl	Multag	
ibutilide fumarate	Corvert	
ibutilide fumarate	ibutilide fumarate	
	rridine Calcium Channel Blockers	
diltiazem HCl	diltiazem HCl	
verapamil HCl	verapamil	
	Digoxin	
digoxin	Digitek	
digoxin	Digox	
digoxin	digoxin	
digoxin	Lanoxin	
digoxin	Lanoxin Pediatric	
	Antiarrhythmic Agents	
adenosine	adenosine	
	nverting-Enzyme (ACE) Inhibitors	
amlodipine besylate/benazepril HCl	amlodipine-benazepril	
amlodipine besylate/benazepril HCl	Lotrel	
benazepril HCl	benazepril	
benazepril HCl	Lotensin	
benazepril HCl/hydrochlorothiazide	benazepril-hydrochlorothiazide	
benazepril HCl/hydrochlorothiazide	Lotensin HCT	
captopril	captopril	
captopril/hydrochlorothiazide	captopril-hydrochlorothiazide	
enalapril maleate	enalapril maleate	
enalapril maleate	Epaned	
enalapril maleate	Vasotec	
enalapril maleate/hydrochlorothiazide	enalapril-hydrochlorothiazide	
enalapril maleate/hydrochlorothiazide	Vaseretic	
enalaprilat dihydrate	enalaprilat	
fosinopril sodium	fosinopril	
fosinopril sodium/hydrochlorothiazide	fosinoprii fosinopril-hydrochlorothiazide	
lisinopril	lisinopril	
noniopin	Prinivil	
lisinopril		
lisinopril lisinopril	Qbrelis	
lisinopril lisinopril	Qbrelis Zestril	
lisinopril lisinopril lisinopril lisinopril/hydrochlorothiazide	Qbrelis Zestril Iisinopril-hydrochlorothiazide	
lisinopril lisinopril lisinopril lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide	Qbrelis Zestril lisinopril-hydrochlorothiazide Zestoretic	
lisinopril lisinopril lisinopril lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide moexipril HCl	Qbrelis Zestril Iisinopril-hydrochlorothiazide Zestoretic moexipril	
lisinopril lisinopril lisinopril lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide moexipril HCl perindopril arginine/amlodipine besylate	Qbrelis Zestril lisinopril-hydrochlorothiazide Zestoretic moexipril Prestalia	
lisinopril lisinopril lisinopril lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide moexipril HCl perindopril arginine/amlodipine besylate perindopril erbumine	Qbrelis Zestril lisinopril-hydrochlorothiazide Zestoretic moexipril Prestalia perindopril erbumine	
lisinopril lisinopril lisinopril lisinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide moexipril HCl perindopril arginine/amlodipine besylate	Qbrelis Zestril lisinopril-hydrochlorothiazide Zestoretic moexipril Prestalia	

cder_mpl1p_wp077 Page 954 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
quinapril HCl	quinapril
quinapril HCl/hydrochlorothiazide	Accuretic
quinapril HCl/hydrochlorothiazide	quinapril-hydrochlorothiazide
ramipril	Altace
ramipril	ramipril
trandolapril	trandolapril
trandolapril/verapamil HCl	Tarka
trandolapril/verapamil HCl	trandolapril-verapamil

Angiotensin II Receptor Blockers (ARBs)

amlodipine besylate/olmesartan medoxomil amlodipine-olmesartan

amlodipine besylate/olmesartan medoxomil Azor

amlodipine besylate/valsartan amlodipine-valsartan

amlodipine besylate/valsartan Exforge

amlodipine besylate/valsartan/hydrochlorothiazide amlodipine-valsartan-hcthiazid

amlodipine besylate/valsartan/hydrochlorothiazide
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
candesartan cilexetil
candesartan cilexetil
candesartan cilexetil/hydrochlorothiazide

Exforge HCT
Edarbi
Edarbi
Edarbyclor
Atacand
candesartan cilexetil
candesartan
Candesartan cilexetil/hydrochlorothiazide

candesartan cilexetil/hydrochlorothiazide candesartan-hydrochlorothiazid

eprosartan mesylate eprosartan irbesartan Avapro irbesartan irbesartan irbesartan Avalide Avalide

irbesartan/hydrochlorothiazide irbesartan-hydrochlorothiazide

Iosartan potassiumCozaarIosartan potassiumIosartanIosartan potassium/hydrochlorothiazideHyzaar

losartan potassium/hydrochlorothiazide losartan-hydrochlorothiazide

olmesartan medoxomil Benicar olmesartan medoxomil olmesartan

olmesartan medoxomil/amlodipine

besylate/hydrochlorothiazide olmesartan-amlodipin-hcthiazid

olmesartan medoxomil/amlodipine

besylate/hydrochlorothiazide Tribenzor olmesartan medoxomil/hydrochlorothiazide Benicar HCT

olmesartan medoxomil/hydrochlorothiazide olmesartan-hydrochlorothiazide

sacubitril/valsartan Entresto
telmisartan Micardis
telmisartan telmisartan

telmisartan/amlodipine besylate telmisartan-amlodipine

telmisartan/amlodipine besylate Twynsta telmisartan/hydrochlorothiazide Micardis HCT

telmisartan/hydrochlorothiazide telmisartan-hydrochlorothiazid

valsartanDiovanvalsartanvalsartanvalsartan/hydrochlorothiazideDiovan HCT

valsartan/hydrochlorothiazide valsartan-hydrochlorothiazide

Dihydropyridines

amlodipine benzoate Katerzia
amlodipine besylate amlodipine besylate Norliqva
amlodipine besylate Norvasc

cder_mpl1p_wp077 Page 955 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name	
amlodipine besylate/celecoxib	Consensi	
clevidipine butyrate	Cleviprex	
felodipine	felodipine	
isradipine	isradipine	
levamlodipine maleate	Conjupri	
levamlodipine maleate	levamlodipine	
nicardipine HCl	Cardene IV	
nicardipine HCl	nicardipine	
nicardipine HCl in 0.9 % sodium chloride	nicardipine in 0.9 % sod chlor	
nicardipine in dextrose, iso-osmotic	Cardene IV in dextrose	
nicardipine in sodium chloride, iso-osmotic	Cardene IV in sodium chloride	
nicardipine in sodium chloride, iso-osmotic	nicardipine in NaCl (iso-os)	
nifedipine	nifedipine	
nifedipine	Procardia	
nifedipine	Procardia XL	
nimodipine	nimodipine	
nimodipine	Nymalize	
nisoldipine	nisoldipine	
nisoldipine	Sular	
Diuretics		

ח		~+	-
U	iur	eu	CS

acetazolamide acetazolamide acetazolamide sodium acetazolamide sodium amiloride HCl amiloride

amiloride HCl/hydrochlorothiazide amiloride-hydrochlorothiazide

bumetanide bumetanide chlorothiazide Diuril

chlorothiazide sodium chlorothiazide sodium

chlorothiazide sodium Diuril IV chlorthalidone chlorthalidone chlorthalidone Thalitone

conivaptan HCI/dextrose 5 % in water Vaprisol in 5 % dextrose

eplerenone eplerenone eplerenone Inspra

ethacrynate sodium ethacrynate sodium ethacrynate sodium Sodium Edecrin

ethacrynic acid Edecrin ethacrynic acid ethacrynic acid furosemide **Furoscix** furosemide furosemide furosemide Lasix

furosemide in 0.9 % sodium chloride furosemide in 0.9 % NaCl hydrochlorothiazide hydrochlorothiazide

indapamide indapamide methazolamide methazolamide metolazone metolazone spironolactone Aldactone spironolactone CaroSpir spironolactone spironolactone spironolactone/hydrochlorothiazide Aldactazide

spironolactone/hydrochlorothiazide spironolacton-hydrochlorothiaz

tolvaptan Samsca tolvaptan tolvaptan torsemide Soaanz torsemide torsemide

Page 956 of 1023 cder_mpl1p_wp077



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
triamterene	Dyrenium
triamterene	triamterene
triamterene/hydrochlorothiazide	Maxzide
triamterene/hydrochlorothiazide	Maxzide-25mg
triamtorono/hydrochlorothiazido	triamtorono hydrochlorothiazid

triamterene/hydrochlorothiazide triamterene-hydrochlorothiazid

Other Antihypertensives

aliskiren hemifumaratealiskirenaliskiren hemifumarateTekturnaaliskiren hemifumarate/hydrochlorothiazideTekturna HCT

atenolol/chlorthalidone atenolol-chlorthalidone

atenolol/chlorthalidone Tenoretic 100 atenolol/chlorthalidone Tenoretic 50

bisoprolol fumarate/hydrochlorothiazide bisoprolol-hydrochlorothiazide

bisoprolol fumarate/hydrochlorothiazide Ziac

clonidine Catapres-TTS-1 clonidine Catapres-TTS-2 clonidine Catapres-TTS-3 clonidine clonidine clonidine HCl clonidine HCl Nexiclon XR clonidine HCl doxazosin mesylate Cardura doxazosin mesylate Cardura XL doxazosin mesylate doxazosin fenoldopam mesylate Corlopam finerenone Kerendia

guanfacine HCl guanfacine hydralazine HCl hydralazine HCl BiDil

isosorbide dinitrate/hydralazine HCl isosorbide-hydralazine

isoxsuprine HCl isoxsuprine mecamylamine HCl Vecamyl methyldopa methyldopa

methyldopa/hydrochlorothiazide methyldopa-hydrochlorothiazide

methyldopate HCl methyldopate metoprolol succinate/hydrochlorothiazide Dutoprol

metoprolol tartrate/hydrochlorothiazide metoprolol ta-hydrochlorothiaz

metyrosineDemsermetyrosinemetyrosineminoxidilminoxidilnitroprusside sodiumNitropress

nitroprusside sodium sodium nitroprusside

nitroprusside sodium in 0.9 % sodium chloride
papaverine HCl
phenoxybenzamine HCl
phenoxybenzamine HCl
phenoxybenzamine HCl
phenoxybenzamine HCl
phenoxybenzamine
phentolamine mesylate
phentolamine
prazosin HCl
Minipress
prazosin

propranolol HCI/hydrochlorothiazide propranolol-hydrochlorothiazid

terazosin HCl terazosin

Oral Anticoagulants

apixaban Eliquis

apixaban Eliquis DVT-PE Treat 30D Start

dabigatran etexilate dabigatran etexilate dabigatran etexilate

cder_mpl1p_wp077 Page 957 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
dabigatran etexilate mesylate	Pradaxa
edoxaban tosylate	Savaysa
rivaroxaban	Xarelto
rivaroxaban	Xarelto DVT-PE Treat 30d Start

Warfarin sodium Jantoven warfarin sodium warfarin

Other Cardiac Medications (Not Including Oral Anticoagulants or Vitamin K Antagonists)

ambrisentan
ambrisentan

ambrisentan

Letairis

amyl nitrite
bosentan
bosentan

bosentan

rracleer
epoprostenol sodium
epoprostenol sodium

Veletri

epoprostenol sodium (glycine) epoprostenol (glycine)

epoprostenol sodium (glycine)
iloprost tromethamine
isosorbide dinitrate
isosorbide dinitrate
isosorbide dinitrate
isosorbide dinitrate
isosorbide dinitrate

isosorbide dinitrate Isordil Titradose isosorbide dinitrate isosorbide mononitrate isosorbide mononitrate

ivabradine HCl Corlanor Opsumit macitentan GoNitro nitroglycerin nitroglycerin Minitran nitroglycerin Nitro-Bid nitroglycerin Nitro-Dur nitroglycerin nitroglycerin nitroglycerin Nitrolingual nitroglycerin **Nitromist** nitroglycerin **Nitrostat** nitroglycerin Nitro-Time

nitroglycerin in 5 % dextrose in water nitroglycerin in 5 % dextrose

ranolazine Aspruzyo Sprinkle

ranolazine Ranexa ranolazine ranolazine ranolazine ranolazine selexipag Uptravi sildenafil citrate Revatio

sildenafil citrate sildenafil (pulm.hypertension)

tadalafil Adcirca tadalafil Alyq

tadalafil tadalafil (pulm. hypertension)

tadalafil Tadliq
treprostinil Tyvaso
treprostinil Tyvaso DPI
treprostinil diolamine Orenitram
treprostinil sodium Remodulin
treprostinil sodium treprostinil/nebulizer accessories Tyvaso Refill Kit

treprostinil/nebulizer and accessories Tyvaso Institutional Start Kit

treprostinil/nebulizer and accessories Tyvaso Starter Kit

cder_mpl1p_wp077 Page 958 of 1023



Generic Name	Brand Name	
vericiguat	Verquvo	
Lipid Lowering Therapy		
alirocumab	Praluent Pen	
ımlodipine besylate/atorvastatin calcium	amlodipine-atorvastatin	
ımlodipine besylate/atorvastatin calcium	Caduet	
torvastatin calcium	atorvastatin	
torvastatin calcium	Lipitor	
empedoic acid	Nexletol	
empedoic acid/ezetimibe	Nexlizet	
holestyramine (with sugar)	cholestyramine (with sugar)	
holestyramine (with sugar)	Questran	
holestyramine/aspartame	Cholestyramine Light	
holestyramine/aspartame	cholestyramine-aspartame	
holestyramine/aspartame	Prevalite	
holestyramine/aspartame	Questran Light	
olesevelam HCl	colesevelam	
olesevelam HCl	WelChol	
olestipol HCl	Colestid	
olestipol HCl	Colestid Flavored	
olestipol HCl	colestipol	
vinacumab-dgnb	Evkeeza	
volocumab	Repatha Pushtronex	
volocumab	Repatha SureClick	
volocumab	Repatha Syringe	
zetimibe	ezetimibe	
zetimibe	Zetia	
zetimibe/atorvastatin calcium	ezetimibe-atorvastatin	
zetimibe/rosuvastatin calcium	ezetimibe-rosuvastatin	
zetimibe/rosuvastatin calcium	Roszet	
zetimibe/simvastatin	ezetimibe-simvastatin	
zetimibe/simvastatin	Vytorin 10-10	
zetimibe/simvastatin	Vytorin 10-20	
zetimibe/simvastatin	Vytorin 10-40	
zetimibe/simvastatin	Vytorin 10-80	
enofibrate	fenofibrate	
enofibrate	Fenoglide	
enofibrate	Lipofen	
enofibrate nanocrystallized	fenofibrate nanocrystallized	
enofibrate nanocrystallized	Tricor	
enofibrate,micronized	Antara	
enofibrate,micronized	fenofibrate micronized	
enofibric acid	fenofibric acid	
enofibric acid	Fibricor	
enofibric acid (choline)	fenofibric acid (choline)	
enofibric acid (choline)	Trilipix	
uvastatin sodium	fluvastatin	
uvastatin sodium	Lescol XL	
emfibrozil	gemfibrozil	
emfibrozil	Lopid	
cosapent ethyl	icosapent ethyl	
cosapent ethyl	Vascepa	
nclisiran sodium	Leqvio	
omitapide mesylate	Juxtapid	
ovastatin	Altoprov	

cder_mpl1p_wp077 Page 959 of 1023

lovastatin

Altoprev



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
lovastatin	lovastatin
niacin	niacin
niacin	Niacor
niacin	Niaspan Extended-Release
omega-3 acid ethyl esters	Lovaza
omega-3 acid ethyl esters	omega-3 acid ethyl esters
pitavastatin calcium	Livalo
pitavastatin magnesium	Zypitamag
pravastatin sodium	pravastatin
rosuvastatin calcium	Crestor
rosuvastatin calcium	Ezallor Sprinkle
rosuvastatin calcium	rosuvastatin
simvastatin	FloLipid
simvastatin	simvastatin
simvastatin	Zocor

Drugs with a Known Risk of Prolonged QT and Torsades de Pointes

amiodarone HCl	amiodarone
amiodarone HCl	Pacerone

amiodarone HCl/dextrose 5 % in water amiodarone in dextrose 5 %

amiodarone in dextrose, iso-osmotic Nexterone anagrelide HCl Agrylin anagrelide HCl anagrelide arsenic trioxide arsenic trioxide arsenic trioxide Trisenox azithromycin AzaSite azithromycin azithromycin azithromycin Zithromax azithromycin Zithromax TRI-PAK azithromycin Zithromax Z-Pak

azithromycin/chondroitin sulfate A sodium/PF Klarity-A (azithro-chondr)(PF) chloroquine phosphate chloroquine phosphate chlorpromazine HCl chlorpromazine cilostazol cilostazol ciprofloxacin Cipro ciprofloxacin ciprofloxacin ciprofloxacin Otiprio Cetraxal ciprofloxacin HCl

ciprofloxacin HCl
ciprofloxacin HCl
ciprofloxacin HCl
ciprofloxacin HCl
ciprofloxacin HCl
ciprofloxacin HCl/dexamethasone

Ciloxan
Cipro
Ciprofloxacin HCl
Ciprofloxacin HCl/dexamethasone

ciprofloxacin HCl/dexamethasone ciprofloxacin HCl/fluocinolone acetonide ciprofloxacin-dexamethasone

ciprofloxacin HCI/fluocinolone acetonide Otovel ciprofloxacin HCI/hydrocortisone Cipro HC

ciprofloxacin lactate/dextrose 5 % in water ciprofloxacin in 5 % dextrose

citalopram hydrobromideCelexacitalopram hydrobromidecitalopramclarithromycinclarithromycincocaine HClcocainecocaine HClGopreltococaine HClNumbrino

dexamethasone sod ph/moxifloxacin HCl in NaCl,iso-osmotic/PF dexameth-moxiflox(PF)-NaCl,iso

cder_mpl1p_wp077 Page 960 of 1023



Generic Name Brand Name

dexamethasone sod ph/moxifloxacin HCl/ketorolac/sod chlor/PF dexamet-moxifl-ketoro-NaCl(PF)

dextromethorphan Hbr/quinidine sulfate Nuedexta

disopyramide phosphate disopyramide phosphate

disopyramide phosphate Norpace disopyramide phosphate Norpace CR dofetilide dofetilide dofetilide Tikosvn donepezil HCl Adlarity donepezil HCl Aricept donepezil HCl donepezil dronedarone HCl Multag droperidol droperidol erythromycin base Ery-Tab

erythromycin base erythromycin erythromycin ethylsuccinate E.E.S. 400 erythromycin ethylsuccinate EryPed 200 erythromycin ethylsuccinate EryPed 400

erythromycin ethylsuccinate erythromycin ethylsuccinate

erythromycin lactobionate Erythrocin

erythromycin lactobionate erythromycin stearate Erythrocin (as stearate) erythromycin stearate erythromycin stearate escitalopram oxalate escitalopram oxalate

escitalopram oxalate Lexapro flecainide acetate fluconazole Diflucan fluconazole fluconazole

fluconazole in sodium chloride, iso-osmotic fluconazole in NaCl (iso-osm)

gatifloxacingatifloxacingatifloxacinZymaxidhaloperidolhaloperidolhaloperidol decanoateHaldol Decanoatehaloperidol decanoatehaloperidol decanoate

haloperidol lactate Haldol

haloperidol lactate
hydroxychloroquine sulfate
hydroxychloroquine

hydroxychloroquine sulfate Plaquenil ibutilide fumarate Corvert

ibutilide fumarate ibutilide fumarate

lansoprazole/amoxicillin trihydrate/clarithromycin amoxicil-clarithromy-lansopraz

levofloxacin levofloxacin

levofloxacin/dextrose 5 % in water levofloxacin in D5W

memantine HCI/donepezil HCI
methadone HCI
methadone HCI
methadone HCI
methadone

methadone HCl Methadone Intensol

methadone HCl Methadose

methadone hydrochloride in 0.9 % sodium chloride methadone in 0.9 % sod.chlorid midazolam/ketamine HCl/ondansetron HCl MKO (Midazolam-Ketamine-Ondan)

mobocertinib succinate Exkivity
moxifloxacin HCl Moxeza

moxifloxacin HCl Moxeza moxifloxacin HCl moxifloxacin

cder mpl1p wp077 Page 961 of 1023



Generic Name	Brand Name
moxifloxacin HCl	Vigamox
moxifloxacin HCl in balanced salt solution no.2/PF	moxifloxacin (PF)-BSS
moxifloxacin HCl in sodium acetate and sulfate, water, iso-osm	moxifloxacin-sod.ace,sul-water
moxifloxacin HCl in sodium chloride, iso-osmotic	Avelox in NaCl (iso-osmotic)
moxifloxacin HCl in sodium chloride, iso-osmotic	moxifloxacin-sod.chloride(iso)
moxifloxacin HCl in sodium chloride, iso-osmotic/PF	moxifloxacin-sod chlor,iso(PF)
omeprazole/clarithromycin/amoxicillin trihydrate	Omeclamox-Pak
ondansetron	ondansetron
ondansetron	Zuplenz
ondansetron HCl	ondansetron HCl
ondansetron HCl	Zofran
ondansetron HCl in 0.9 % sodium chloride	ondansetron in 0.9 % sod chlor
ondansetron HCI/PF	ondansetron HCI (PF)
oxaliplatin	oxaliplatin
papaverine HCl	papaverine
papaverine HCl/phentolamine mesylate in water	IFE-BiMix 30/1
papaverine HCl/phentolamine mesylate/alprostadil	Tri-Mix (papavrn-phntlmn-PGE1)
pentamidine isethionate	Nebupent
pentamidine isethionate	Pentam
pentamidine isethionate	pentamidine
pimozide	pimozide
prednisolone acetate/gatifloxacin	prednisolone acet-gatifloxacin
prednisolone acetate/gatifloxacin/bromfenac sodium	prednisol ace-gatiflox-bromfen
prednisolone acetate/moxifloxacin HCl	prednisolone-moxifloxacin HCl
prednisolone acetate/moxifloxacin HCl/bromfenac sodium	prednisolone-moxiflox-bromfen
prednisolone acetate/moxifloxacin HCI/nepafenac	prednisolone-moxiflo-nepafenac
prednisolone sodium phosphate/gatifloxacin/bromfenac sodium	prednisoln sp-gatiflox-bromfen
prednisolone sodium phosphate/moxifloxacin HCl	prednisolone sod ph-moxiflox
prednisolone sodium phosphate/moxifloxacin HCl/bromfenac	
sod	prednisoln sp-moxiflox-bromfen
procainamide HCl	procainamide
propofol	Anesthesia S/I-40 (propofol)
propofol	Anesthesia S/I-40A (propofol)
propofol	Anesthesia S/I-40H (propofol)
propofol	Anesthesia S/I-40S (propofol)
propofol	Anesthesia S/I-60 (propofol)
propofol	Diprivan
propofol	propofol Propofol Linux (DE)
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propofol-Lipuro (PF)
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propoven (EUA) (PF)
quinidine gluconate	quinidine gluconate
quinidine sulfate sevoflurane	quinidine sulfate sevoflurane
sevoflurane sotalol HCl	Ultane
sotalol HCl	Betapace Potapace AF
sotalol HCl	Betapace AF Sorine
sotalol HCl	sotalol
sotalol HCl	Sotalol AF
sotalol HCl	
terlipressin acetate	Sotylize Terlivaz
•	thioridazine
thioridazine HCl triamcinolone acetonide/moxifloxacin HCl/water/PF	triamcinolon-moxiflox-watr(PF)
thanicholone acetonide/inoxinoxaciii nci/water/pr	u iaincinolon-moximox-wati (FF)

cder_mpl1p_wp077 Page 962 of 1023



Generic Name	Brand Name
vandetanib	Caprelsa

vonoprazan fumarate/amoxicillin trihydrate/clarithromycin Voquezna Triple Pak

Drugs with a Known/Possible/Conditional Risk of Prolonged QT and Torsades de Pointes

abiraterone acetate abiraterone
abiraterone acetate Zytiga
abiraterone acetate, submicronized Yonsa
acetaminophen/diphenhydramine citrate Goody's PM
acetaminophen/diphenhydramine citrate Headache Relief PM

acetaminophen/diphenhydramine citrate Midol PM acetaminophen/diphenhydramine HCl Acetadryl

acetaminophen/diphenhydramine HCl Acetaminophen PM

acetaminophen/diphenhydramine HCl Acetaminophen PM Extra Str

acetaminophen/diphenhydramine HCl EaZZZe The Pain acetaminophen/diphenhydramine HCl Headache PM

acetaminophen/diphenhydramine HCl Night Time Pain Medicine

acetaminophen/diphenhydramine HCl Non-Aspirin PM acetaminophen/diphenhydramine HCl Pain and Sleep acetaminophen/diphenhydramine HCl Pain Relief PM

acetaminophen/diphenhydramine HCl Pain Relief PM Rapid Release acetaminophen/diphenhydramine HCl Pain Reliever PM Ex-Strength

acetaminophen/diphenhydramine HCl Percogesic

acetaminophen/diphenhydramine HCl Percogesic Extra Strength

acetaminophen/diphenhydramine HCl Severe Allergy

acetaminophen/diphenhydramine HCl Tylenol PM Extra Strength

acetaminophen/diphenhydramine HCl Unisom PM Pain acetaminophen/diphenhydramine HCl Wal-Nadol PM adagrasib Krazati

alfuzosin HCl alfuzosin
alfuzosin HCl Uroxatral
aliskiren hemifumarate/hydrochlorothiazide Tekturna HCT
amantadine HCl amantadine HCl

amantadine HCl amantadine II Gocovri amantadine HCl Osmolex ER

amiloride HCl/hydrochlorothiazide amiloride-hydrochlorothiazide

amiodarone HCl amiodarone amiodarone HCl Pacerone

amiodarone HCl/dextrose 5 % in water amiodarone in dextrose 5 %

amiodarone in dextrose, iso-osmotic

amisulpride

amitriptyline HCl

amitriptyline

amitriptyline HCl/chlordiazepoxide amlodipine besylate/valsartan/hydrochlorothiazide amlodipine-valsartan-hcthiazid

amlodipine besylate/valsartan/hydrochlorothiazide Exforge HCT
amphetamine Adzenys ER
amphetamine Adzenys XR-ODT
amphetamine amphetamine Dyanavel XR

amphetamine sulfate amphetamine sulfate

amphetamine sulfateEvekeoamphetamine sulfateEvekeo ODTamphotericin Bamphotericin B

amphotericin B lipid complex Abelcet amphotericin B liposome AmBisome

amphotericin B liposome amphotericin B liposome

cder_mpl1p_wp077 Page 963 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
anagrelide HCl	Agrylin
anagrelide HCl	anagrelide
apalutamide	Erleada
apomorphine HCl	APOKYN
apomorphine HCl	apomorphine
apomorphine HCl	Kynmobi
aripiprazole	Abilify
aripiprazole	Abilify Maintena
aripiprazole	Abilify MyCite
aripiprazole	Abilify MyCite Maintenance Kit
aripiprazole	Abilify MyCite Starter Kit
aripiprazole	aripiprazole
aripiprazole lauroxil	Aristada
aripiprazole lauroxil, submicronized	Aristada Initio
arsenic trioxide	arsenic trioxide
arsenic trioxide	Trisenox
artemether/lumefantrine	Coartem
asenapine	Secuado
asenapine maleate	asenapine maleate
asenapine maleate	Saphris
aspirin/acetaminophen/diphenhydramine citrate	Pain Relief PM (w-aspirin)
aspirin/diphenhydramine citrate	Bayer PM
aspirin/omeprazole	aspirin-omeprazole
aspirin/omeprazole	Yosprala
atazanavir sulfate	atazanavir
atazanavir sulfate	Reyataz
atazanavir sulfate/cobicistat	Evotaz
atomoxetine HCl	atomoxetine
atomoxetine HCl	Strattera
azithromycin	AzaSite
azithromycin	azithromycin
azithromycin	Zithromax
azithromycin	Zithromax TRI-PAK
azithromycin	Zithromax Z-Pak
azithromycin/chondroitin sulfate A sodium/PF	Klarity-A (azithro-chondr)(PF)
bedaquiline fumarate	Sirturo
benazepril HCl/hydrochlorothiazide	benazepril-hydrochlorothiazide
benazepril HCl/hydrochlorothiazide	Lotensin HCT
bendamustine HCl	Belrapzo
bendamustine HCl	bendamustine
bendamustine HCl	Bendeka
bendamustine HCl	Treanda
bendamustine HCl	Vivimusta
benzhydrocodone HCl/acetaminophen	Apadaz
benzhydrocodone HCI/acetaminophen	benzhydrocodone-acetaminophen
bicalutamide	bicalutamide
bicalutamide	Casodex
bismuth subsalicylate/metronidazole/tetracycline HCl	Helidac
bisoprolol fumarate/hydrochlorothiazide	bisoprolol-hydrochlorothiazide
bisoprolol fumarate/hydrochlorothiazide	Ziac
bortezomib	bortezomib
bortezomib	Velcade
bosutinib	Bosulif
buprenorphine	buprenorphine
oupi enoi pinne	ναριτιοιριπιτ

cder_mpl1p_wp077 Page 964 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
buprenorphine	Butrans
puprenorphine	Sublocade
ouprenorphine HCl	Belbuca
ouprenorphine HCl	Buprenex
ouprenorphine HCl	buprenorphine HCl
ouprenorphine HCl	Probuphine
buprenorphine HCl/naloxone HCl	Bunavail
buprenorphine HCl/naloxone HCl	buprenorphine-naloxone
buprenorphine HCI/naloxone HCI	Suboxone
buprenorphine HCI/naloxone HCI	Zubsolv
cabotegravir/rilpivirine	Cabenuva
cabozantinib s-malate	Cabometyx
cabozantinib s-malate	Cometriq
candesartan cilexetil/hydrochlorothiazide	Atacand HCT
candesartan cilexetil/hydrochlorothiazide	candesartan-hydrochlorothiazid
capecitabine	capecitabine
capecitabine	Xeloda
captopril/hydrochlorothiazide	captopril-hydrochlorothiazide
ceritinib	Zykadia
chloroquine phosphate	chloroquine phosphate
chlorpromazine HCl	chlorpromazine
cilostazol	cilostazol
cimetidine	Acid Reducer (cimetidine)
cimetidine	cimetidine
cimetidine	Heartburn Relief (cimetidine)
cimetidine	Tagamet HB
cimetidine HCl	cimetidine HCl
ciprofloxacin	Cipro
ciprofloxacin	ciprofloxacin
ciprofloxacin	Otiprio
ciprofloxacin HCl	Cetraxal
ciprofloxacin HCl	Ciloxan
ciprofloxacin HCl	Cipro
ciprofloxacin HCl	ciprofloxacin HCl
ciprofloxacin HCI/dexamethasone	Ciprodex
ciprofloxacin HCI/dexamethasone	ciprofloxacin-dexamethasone
ciprofloxacin HCl/fluocinolone acetonide	ciprofloxacin-fluocinolone
ciprofloxacin HCl/fluocinolone acetonide	Otovel
ciprofloxacin HCl/hydrocortisone	Cipro HC
ciprofloxacin factate/dextrose 5 % in water	ciprofloxacin in 5 % dextrose
citalopram hydrobromide	Celexa
citalopram hydrobromide	citalopram
clarithromycin	clarithromycin
clantinomycin clomipramine HCl	Anafranil
clomipramine HCl	
	clomipramine
clozapine	clozapine Clozaril
clozapine	
clozapine	Versacloz
cobimetinib fumarate	Cotellic
cocaine HCl	cocaine
cocaine HCl	Goprelto
cocaine HCl	Numbrino
colloidal bismuth subcitrate/metronidazole/tetracycline HCl	Pylera
crizotinib	Xalkori

cder_mpl1p_wp077 Page 965 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
labrafenib mesylate	Tafinlar
lasatinib	Sprycel
legarelix acetate	Firmagon
legarelix acetate	Firmagon kit w diluent syringe
lesipramine HCl	desipramine
lesipramine HCl	Norpramin
lesvenlafaxine	desvenlafaxine
lesvenlafaxine succinate	desvenlafaxine succinate
lesvenlafaxine succinate	Pristiq
leutetrabenazine	Austedo
leutetrabenazine	Austedo 12mg Start Titr(Wk1-4)
leutetrabenazine	Austedo TD Titratn Pk (Wk 1-2)
dexamethasone sod ph/moxifloxacin HCl in NaCl,iso-osmotic/PF	dexameth-moxiflox(PF)-NaCl,iso
lexamethasone sod ph/moxifloxacin HCI/ketorolac/sod chlor/PF	dexamet-moxifl-ketoro-NaCl(PF)
exlansoprazole	Dexilant
lexlansoprazole	dexlansoprazole
exmedetomidine HCl	dexmedetomidine
exmedetomidine HCl	Igalmi
exmedetomidine HCl	Precedex
exmedetomidine HCl in 0.9 % sodium chloride	dexmedetomidine in 0.9 % NaCl
exmedetomidine HCl in 0.9 % sodium chloride	Precedex in 0.9 % sodium chlor
exmedetomidine in 5 % dextrose in water	dexmedetomidine in dextrose 5%
extroamphetamine	Xelstrym
extroamphetamine sulfate	Dexedrine Spansule
extroamphetamine sulfate	dextroamphetamine sulfate
extroamphetamine sulfate	ProCentra
extroamphetamine sulfate	Zenzedi
extroamphetamine sulf-saccharate/amphetamine sulf-	
spartate	Adderall
lextroamphetamine sulf-saccharate/amphetamine sulf-	7.000.011
spartate	Adderall XR
extroamphetamine sulf-saccharate/amphetamine sulf-	7.000.0117.11
spartate	dextroamphetamine-amphetamine
extroamphetamine sulf-saccharate/amphetamine sulf-	dextrodiffpretariffe diffpretariffe
spartate	Mydayis
lextromethorphan HBr/acetaminophen/diphenhydramine HCl	Diabetic Tussin Night Time
lextromethorphan Hbr/quinidine sulfate	Nuedexta
extromethorphan/phenylephrine/acetaminophen/diphenhydra	
nine	Day-Night Severe Cold-Flu
extromethorphan/phenylephrine/acetaminophen/diphenhydra	Day Might Severe Colu-1 lu
nine	HerbioMed Deep Cold-Flu Night
inne lextromethorphan/phenylephrine/acetaminophen/diphenhydra	
nine	Multi-Symptom Severe Cold-Nt
inne lextromethorphan/phenylephrine/acetaminophen/diphenhydra	maid Symptom Severe Colu-Int
nine	Wal-Flu Day-Night Cold-Cough
iltiazem HCl	
	Cardizem CD
liltiazem HCl	Cardizem CD
liltiazem HCl	Cardizem LA
iltiazem HCl	Cartia XT
liltiazem HCl	diltiazem HCl
iltiazem HCl	DILT-XR
liltiazem HCl	Matzim LA
liltiazem HCl	Taztia XT

cder_mpl1p_wp077 Page 966 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
diltiazem HCl	Tiadylt ER
diltiazem HCl	Tiazac
diltiazem HCl in 0.9 % sodium chloride	diltiazem HCl in 0.9% NaCl
diltiazem HCl/dextrose 5 % in water	diltiazem in dextrose 5 %
diluent for lefamulin(10mM citrate buffered 0.9 % sod chlor)	Diluent for lefamulin(Xenleta)
diluent for leuprolide (polyglactin)	Diluent for Eligard
diluent for romidepsin (propylene glycol)	Diluent For Istodax
diluent for romidepsin (propylene glycol)	diluent, romidepsin (prop gly)
diphenhydramine HCl	Aler-Cap
diphenhydramine HCl	Alka-Seltzer Plus Allergy
diphenhydramine HCl	Aller-G-Time
diphenhydramine HCl	Allergy
diphenhydramine HCl	Allergy (diphenhydramine)
diphenhydramine HCl	Allergy Medication
liphenhydramine HCl	Allergy Medicine
liphenhydramine HCl	Allergy Relief(diphenhydramin)
liphenhydramine HCl	Banophen
liphenhydramine HCl	Benadryl
liphenhydramine HCl	Benadryl Allergy
liphenhydramine HCl	Child Allergy Relief (diphen)
diphenhydramine HCl	Children's Allergy (diphenhyd)
diphenhydramine HCl	Children's Benadryl Allergy
liphenhydramine HCl	Children's Diphenhydramine
liphenhydramine HCl	Children's Wal-Dryl Allergy
liphenhydramine HCl	Complete Allergy
liphenhydramine HCl	Complete Allergy Medicine
DIPHENHYDRAMINE HCL	Dicopanol
liphenhydramine HCl	Diphedryl
diphenhydramine HCl	Diphedryl Allergy
diphenhydramine HCl	Diphen
liphenhydramine HCl	Diphenhist
diphenhydramine HCl	diphenhydramine HCl
diphenhydramine HCl	EZ Nite Sleep
diphenhydramine HCl	Geri-Dryl
liphenhydramine HCl	M-Dryl
liphenhydramine HCl	Naramin
liphenhydramine HCl	Nightime Sleep
liphenhydramine HCl	Nighttime Allergy Relief
liphenhydramine HCl	NightTime Sleep Aid (diphen)
liphenhydramine HCl	Nytol
liphenhydramine HCl	PediaClear Cough
liphenhydramine HCl	Pharbedryl
liphenhydramine HCl	Siladryl SA
liphenhydramine HCl	Simply Sleep
liphenhydramine HCl	Sleep Aid (diphenhydramine)
liphenhydramine HCl	Sleep Aid Max Str (diphenhydr)
liphenhydramine HCl	Sleep II
liphenhydramine HCl	Sleep Tablet (diphenhydramine)
liphenhydramine HCl	Sleep Time
liphenhydramine HCl	Sleeping Sleep Tabs
diphenhydramine HCl	Sleep-Tabs
liphenhydramine HCl	Sominex
diphenhydramine HCl	Sominex Maximum Strength
liphenhydramine HCl	Total Allergy Medicine

cder_mpl1p_wp077 Page 967 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Appendix G. Generic and brand Names of Medical Froducts ose	
Generic Name	Brand Name
diphenhydramine HCl	Unisom (diphenhydramine)
diphenhydramine HCl	Unisom SleepGels
diphenhydramine HCl	Unisom SleepMelts
diphenhydramine HCl	Unisom SleepMinis
diphenhydramine HCl	Wal-Dryl Allergy
diphenhydramine HCl	Wal-Sleep Z
diphenhydramine HCl	Wal-Som (diphenhydramine)
diphenhydramine HCl	Z-Sleep
diphenhydramine HCl	ZzzQuil
diphenhydramine HCl in 0.9 % sodium chloride	diphenhydramine-0.9 % sod.chlr
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Allergy Sinus Headache (PE)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Child Delsym Cough-Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Child Mucinex M-S Cold Night
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Children Dimetapp M-S Cold-Flu
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Children's Mucinex Night Time
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Cold and Flu Relief(diphen-pe)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Cough and Severe Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Delsym Cough-Cold NightTime
diphenhydramine HCI/phenylephrine HCI/acetaminophen	Flu Severe Cold-Night(diph-pe)
diphenhydramine HCI/phenylephrine HCI/acetaminophen	Flu-Severe Cold-Cough Night
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Herbiomed Allergy Cold-Sinus
diphenhydramine HCI/phenylephrine HCI/acetaminophen	Mucinex Fast-Max Nite Cold-Flu
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Mucinex Sinus-Max Nite Congest
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Robitussin Cold-Flu Night (PE)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Allergy-Sinus Headache
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Cold Cough-Flu
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Cold PE
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Theraflu ExpressMax Cold Night
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Theraflu Night Severe Cold-Cgh
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Theraflu Nighttime PowerPod
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Dryl Severe Allergy-Sinus
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Flu Night Severe Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Flu Severe Cold and Cough
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Phed PE Nighttime Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-phed PE Severe Cold
diphenhydramine HCl/phenylephrine HCl/dextromethorphan diphenhydramine	Child Cold-Cough Day-Night
HCl/phenylephrine/acetaminophen/guaifenesin diphenhydramine	Mucinex Sinus-Max D-N (diphen)
HCI/phenylephrine/acetaminophen/guaifenesin diphenhydramine/brompheniramine/phenyleph/dextromethorp	Sinus Relief Max Str Day-Night
han diphenhydramine/phenylephrin/dextromethorph/acetaminophe	Children's Dimetapp Day Night
	Child Dalawa Cauch Diva Dv Nt
n/GG diphenhydramine/phenylephrin/dextromethorph/acetaminophe	Child Delsym Cough Plus Dy-Nt
n/GG diphenhydramine/phenylephrin/dextromethorph/acetaminophe	Child Mucinex M-S Cold Day-Nte
n/GG diphenhydramine/phenylephrin/dextromethorph/acetaminophe	Children's M-S Cold Day-Night
n/GG	Daytime-Cold Nighttime-Cld-Flu
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	
n/GG	Delsym Cough Plus Day-Night
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	
n/GG	Mucinex Fast-Max Day-Nite Cold

cder_mpl1p_wp077 Page 968 of 1023



Generic Name	Brand Name
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	
n/GG	Mucinex Fast-Max Day-Nite Cong
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	
n/GG	Mucinex Fst-Mx Dy-Nt Cold(dph)
diphenhydramine/phenylephrin/dextromethorph/acetaminophe	
n/GG	Wal-Phed PE Day-Night
disopyramide phosphate	disopyramide phosphate
disopyramide phosphate	Norpace
disopyramide phosphate	Norpace CR
dofetilide	dofetilide
dofetilide	Tikosyn
dolasetron mesylate	Anzemet
dolutegravir sodium/rilpivirine HCl	Juluca
donepezil HCl	Adlarity
donepezil HCl	Aricept
donepezil HCl	donepezil
doxepin HCl	doxepin
doxepin HCl	Silenor
dronedarone HCl	Multaq
droperidol	droperidol
efavirenz	efavirenz
efavirenz	Sustiva
efavirenz/emtricitabine/tenofovir disoproxil fumarate	Atripla
efavirenz/emtricitabine/tenofovir disoproxil fumarate	efavirenz-emtricitabin-tenofov
efavirenz/lamivudine/tenofovir disoproxil fumarate	efavirenz-lamivu-tenofov disop
efavirenz/lamivudine/tenofovir disoproxil fumarate	Symfi
efavirenz/lamivudine/tenofovir disoproxil fumarate	Symfi Lo
eliglustat tartrate	Cerdelga
emtricitabine/rilpivirine HCl/tenofovir alafenamide fumarate	Odefsey
emtricitabine/rilpivirine HCl/tenofovir disoproxil fumarate	Complera
enalapril maleate/hydrochlorothiazide	enalapril-hydrochlorothiazide
enalapril maleate/hydrochlorothiazide	Vaseretic
encorafenib	Braftovi
entrectinib	Rozlytrek
epirubicin HCl	Ellence
epirubicin HCl	epirubicin
eribulin mesylate	Halaven
erythromycin base	Ery-Tab
erythromycin base	erythromycin
erythromycin ethylsuccinate	E.E.S. 400
erythromycin ethylsuccinate	E.E.S. Granules
erythromycin ethylsuccinate	EryPed 200
erythromycin ethylsuccinate	EryPed 400
erythromycin ethylsuccinate	erythromycin ethylsuccinate
erythromycin lactobionate	Erythrocin
erythromycin lactobionate	erythromycin lactobionate
erythromycin stearate	Erythrocin (as stearate)
erythromycin stearate	erythromycin stearate
escitalopram oxalate	escitalopram oxalate
escitalopram oxalate	Lexapro
esomeprazole magnesium	esomeprazole magnesium
esomeprazole magnesium	Nexium
esomeprazole magnesium	Nexium 24HR
esomeprazole magnesium	Nexium Packet

cder_mpl1p_wp077 Page 969 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
esomeprazole magnesium/glycerin	Esomep-EZS
esome prazole sodium	esomeprazole sodium
esomeprazole sodium	Nexium IV
esomeprazole strontium	esomeprazole strontium
amotidine	Acid Controller
amotidine	Acid Reducer (famotidine)
amotidine	Acid-Pep
amotidine	famotidine
amotidine	Heartburn Prevention
amotidine	Heartburn Relief (famotidine)
amotidine	Pepcid
amotidine	Pepcid AC
amotidine	Pepcid AC Maximum Strength
amotidine	Zantac-360 (famotidine)
amotidine in sodium chloride, iso-osmotic/PF	famotidine (PF)-NaCl (iso-os)
amotidine/calcium carbonate/magnesium hydroxide	Acid Controller Complete
amotidine/calcium carbonate/magnesium hydroxide	Acid Reducer Complete (famot)
amotidine/calcium carbonate/magnesium hydroxide	Complete
amotidine/calcium carbonate/magnesium hydroxide	Dual Action Complete
amotidine/calcium carbonate/magnesium hydroxide	Pepcid Complete
amotidine/calcium carbonate/magnesium hydroxide	Tums Dual Action (famotidine)
amotidine/PF	famotidine (PF)
elbamate	felbamate
elbamate	Felbatol
ingolimod HCl	fingolimod
ingolimod HCl	Gilenya
ingolimod lauryl sulfate	Tascenso ODT
lecainide acetate	flecainide
luconazole	Diflucan
luconazole	fluconazole
luconazole in sodium chloride, iso-osmotic	fluconazole in NaCl (iso-osm)
iluorouracil	Adrucil
luorouracil	fluorouracil
luoxetine HCl	fluoxetine
luoxetine HCl	Prozac
luvoxamine maleate	fluvoxamine
osinopril sodium/hydrochlorothiazide	fosinopril-hydrochlorothiazide
osnetupitant chloride HCl/palonosetron HCl	Akynzeo (fosnetupitant)
urosemide	Furoscix
urosemide	furosemide
urosemide	Lasix
urosemide in 0.9 % sodium chloride	furosemide in 0.9 % NaCl
galantamine HBr	galantamine
galantamine HBr	Razadyne ER
gatifloxacin	gatifloxacin
gatifloxacin	Zymaxid
gemifloxacin mesylate	Factive
rilteritinib fumarate	Xospata
glasdegib maleate	Daurismo
granisetron	Sancuso
granisetron	Sustol
granisetron HCl	granisetron HCl
,	
granisetron HCI/PF	granisetron (PF)

cder_mpl1p_wp077 Page 970 of 1023



ieneric Name	Brand Name
aloperidol decanoate	Haldol Decanoate
aloperidol decanoate	haloperidol decanoate
aloperidol lactate	Haldol
aloperidol lactate	haloperidol lactate
ydrochlorothiazide	hydrochlorothiazide
ydrocodone bitartrate	hydrocodone bitartrate
ydrocodone bitartrate	Hysingla ER
ydrocodone bitartrate	Zohydro ER
ydrocodone bitartrate/acetaminophen	hydrocodone-acetaminophen
ydrocodone bitartrate/acetaminophen	Lortab Elixir
ydrocodone bitartrate/guaifenesin	Obredon
ydrocodone bitartrate/homatropine methylbromide	Hycodan
ydrocodone bitartrate/homatropine methylbromide	Hycodan (with homatropine)
ydrocodone bitartrate/homatropine methylbromide	Hydrocodone Compound
ydrocodone bitartrate/homatropine methylbromide	hydrocodone-homatropine
ydrocodone bitartrate/homatropine methylbromide	Hydromet
ydrocodone polistirex/chlorpheniramine polistirex	hydrocodone-chlorpheniramine
ydrocodone polistirex/chlorpheniramine polistirex	TussiCaps
ydrocodone/ibuprofen	hydrocodone-ibuprofen
ydroxyamphetamine hbr/tropicamide	Paremyd
ydroxychloroquine sulfate	hydroxychloroquine
ydroxychloroquine sulfate	Plaquenil
ydroxyzine HCl	hydroxyzine HCl
ydroxyzine pamoate	hydroxyzine pamoate
ydroxyzine pamoate	Vistaril
puprofen/diphenhydramine citrate	Advil PM
puprofen/diphenhydramine citrate	Ibuprofen PM
puprofen/diphenhydramine citrate	Motrin PM
puprofen/diphenhydramine HCl	Advil PM Liqui-Gels
puprofen/diphenhydramine HCl	Ibuprofen PM
puprofen/famotidine	Duexis
puprofen/famotidine	ibuprofen-famotidine
putilide fumarate	Corvert
putilide fumarate	ibutilide fumarate
operidone	Fanapt
matinib mesylate	Gleevec
matinib mesylate	imatinib
nipramine HCl	imipramine HCl
nipramine pamoate	imipramine pamoate
ndapamide	indapamide
notuzumab ozogamicin	Besponsa
besartan/hydrochlorothiazide	Avalide
besartan/hydrochlorothiazide	irbesartan-hydrochlorothiazide
sradipine	isradipine
raconazole	itraconazole
raconazole	Sporanox
raconazole	Sporanox Pulsepak
raconazole	Tolsura
vabradine HCl	Corlanor
vosidenib	Tibsovo
etoconazole	ketoconazole
	FIRST-Lansoprazole
	EID AT-LAUSUULAZUIE
ANSOPRAZOLE ansoprazole	lansoprazole

cder_mpl1p_wp077 Page 971 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
lansoprazole	Prevacid 24Hr
lansoprazole	Prevacid SoluTab
lansoprazole/amoxicillin trihydrate/clarithromycin	amoxicil-clarithromy-lansopraz
lapatinib ditosylate	lapatinib
lapatinib ditosylate	Tykerb
lefamulin acetate	Xenleta
lenvatinib mesylate	Lenvima
leuprolide acetate	Eligard
leuprolide acetate	Eligard (3 month)
leuprolide acetate	Eligard (4 month)
leuprolide acetate	Eligard (6 month)
leuprolide acetate	Fensolvi
leuprolide acetate	leuprolide
leuprolide acetate	leuprolide (3 month)
leuprolide acetate	Lupron Depot
leuprolide acetate	Lupron Depot (3 month)
leuprolide acetate	Lupron Depot (4 month)
leuprolide acetate	Lupron Depot (6 Month)
leuprolide acetate	Lupron Depot-Ped
leuprolide acetate	Lupron Depot-Ped (3 month)
leuprolide acetate/norethindrone acetate	Lupaneta Pack (1 month)
leuprolide acetate/norethindrone acetate	Lupaneta Pack (3 month)
leuprolide mesylate	Camcevi (6 month)
levetiracetam	Elepsia XR
levetiracetam	Keppra
levetiracetam	Keppra XR
levetiracetam	levetiracetam
levetiracetam	Roweepra
levetiracetam	Roweepra XR
levetiracetam	Spritam
levetiracetam in sodium chloride, iso-osmotic	levetiracetam in NaCl (iso-os)
levofloxacin	levofloxacin
levofloxacin/dextrose 5 % in water	levofloxacin in D5W
levoketoconazole	Recorley
lisinopril/hydrochlorothiazide	lisinopril-hydrochlorothiazide
lisinopril/hydrochlorothiazide	Zestoretic
lithium aspartate	Lithate
lithium carbonate	lithium carbonate
lithium carbonate	Lithobid
lofexidine HCl	Lucemyra
loperamide HCl	Anti-Diarrheal (loperamide)
loperamide HCl	Diamode
loperamide HCl	Imodium A-D
loperamide HCl	loperamide
loperamide HCl	Ultra A-D
loperamide HCI/simethicone	Anti-Diarrheal (lope)-Anti-Gas
loperamide HCI/simethicone	Imodium Multi-Symptom Relief
loperamide HCI/simethicone	loperamide-simethicone
lopinavir/ritonavir	Kaletra
lopinavir/ritonavir	lopinavir-ritonavir
losartan potassium/hydrochlorothiazide	•
	Hyzaar Josephan-hydrochlorothiazida
losartan potassium/hydrochlorothiazide	losartan-hydrochlorothiazide
lumateperone tosylate	Caplyta
lurasidone HCl	Latuda

cder_mpl1p_wp077 Page 972 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
macimorelin acetate MAG HYDROXIDE/AL	Macrilen
HYDROXIDE/SIMETH/DIPHENHYDRAMINE/LIDOCAINE	FIRST-Mouthwash BLM
memantine HCI/donepezil HCl	Namzaric
methadone HCl	Diskets
methadone HCl	methadone
methadone HCl	Methadone Intensol
methadone HCl	Methadose
methadone hydrochloride in 0.9 % sodium chloride	methadone in 0.9 % sod.chlorid
methamphetamine HCl	Desoxyn
methamphetamine HCl	methamphetamine
methyldopa/hydrochlorothiazide	methyldopa-hydrochlorothiazide
metoclopramide HCl	Gimoti
metoclopramide HCl	metoclopramide HCl
metoclopramide HCl	Reglan
metolazone	metolazone
metoprolol succinate/hydrochlorothiazide	Dutoprol
metoprolol tartrate/hydrochlorothiazide	metoprolol ta-hydrochlorothiaz
metronidazole	Flagyl
metronidazole	Metrogel Vaginal
metronidazole	metronidazole
metronidazole	Nuvessa
metronidazole	Vandazole
metronidazole in sodium chloride	Metro I.V.
metronidazole in sodium chloride	metronidazole in NaCl (iso-os)
midazolam/ketamine HCl/ondansetron HCl	MKO (Midazolam-Ketamine-Ondan)
midostaurin	Rydapt
mifepristone	Korlym
mifepristone	Mifeprex
mifepristone	mifepristone
mirabegron	Myrbetriq
mirtazapine	mirtazapine
mirtazapine	Remeron
mirtazapine	Remeron SolTab
mobocertinib succinate	Exkivity
moxifloxacin HCl	Moxeza
moxifloxacin HCl	moxifloxacin
moxifloxacin HCl	Vigamox
moxifloxacin HCl in balanced salt solution no.2/PF	moxifloxacin (PF)-BSS
moxifloxacin HCl in sodium acetate and sulfate, water, iso-osm	moxifloxacin-sod.ace,sul-water
moxifloxacin HCl in sodium chloride, iso-osmotic	Avelox in NaCl (iso-osmotic)
moxifloxacin HCl in sodium chloride, iso-osmotic	moxifloxacin-sod.chloride(iso)
moxifloxacin HCl in sodium chloride,iso-osmotic/PF	moxifloxacin-sod chlor,iso(PF)
naproxen sodium/diphenhydramine HCl	Aleve PM
naproxen/esomeprazole magnesium	naproxen-esomeprazole
naproxen/esomeprazole magnesium	Vimovo
necitumumab	Portrazza
nelfinavir mesylate	Viracept
netupitant/palonosetron HCl	Akynzeo (netupitant)
nicardipine HCl	Cardene IV
nicardipine HCl	nicardipine
nicardipine HCl in 0.9 % sodium chloride	nicardipine in 0.9 % sod chlor
nicardipine in dextrose, iso-osmotic	Cardene IV in dextrose
nicardipine in dextrose, iso-osmotic	Cardene IV in dextrose Cardene IV in sodium chloride
meararpine in socialit cilionae, 150-031110tic	caractic iv in socialii cilionae

cder_mpl1p_wp077 Page 973 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

ieneric Name	Brand Name
icardipine in sodium chloride, iso-osmotic	nicardipine in NaCl (iso-os)
ilotinib HCl	Tasigna
ortriptyline HCl	nortriptyline
ortriptyline HCl	Pamelor
usinersen sodium/PF	Spinraza (PF)
IYSTATIN/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Duke's
IYSTATIN/LIDOCAINE HCL/DIPHENHYDRAMINE HCL	First-BXN
IYSTATIN/TETRACYCLINE	
ICL/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Mary's Mouthwash
floxacin	Ocuflox
floxacin	ofloxacin
lanzapine	olanzapine
lanzapine	Zyprexa
lanzapine	Zyprexa Zydis
lanzapine pamoate	Zyprexa Relprevv
lanzapine/fluoxetine HCl	olanzapine-fluoxetine
lanzapine/fluoxetine HCl	Symbyax
lanzapine/samidorphan malate	Lybalvi
liceridine fumarate	Olinvyk
lmesartan medoxomil/amlodipine	
esylate/hydrochlorothiazide	olmesartan-amlodipin-hcthiazid
lmesartan medoxomil/amlodipine	
esylate/hydrochlorothiazide	Tribenzor
lmesartan medoxomil/hydrochlorothiazide	Benicar HCT
lmesartan medoxomil/hydrochlorothiazide	olmesartan-hydrochlorothiazide
MEPRAZOLE	FIRST-Omeprazole
meprazole	omeprazole
OMEPRAZOLE	Omeprazole+SyrSpend SF Alka
meprazole magnesium	Acid Reducer (omeprazole)
meprazole magnesium	omeprazole magnesium
meprazole magnesium	Prilosec
meprazole magnesium	Prilosec OTC
meprazole magnesium/amoxicillin trihydrate/rifabutin	Talicia
meprazole/clarithromycin/amoxicillin trihydrate	Omeclamox-Pak
meprazole/sodium bicarbonate	omeprazole-sodium bicarbonate
meprazole/sodium bicarbonate	Zegerid
meprazole/sodium bicarbonate	Zegerid OTC
ndansetron	ondansetron
ndansetron	Zuplenz
ndansetron HCl	ondansetron HCl
ndansetron HCl	Zofran
ndansetron HCl in 0.9 % sodium chloride	ondansetron in 0.9 % sod chlor
ndansetron HCI/PF	ondansetron HCl (PF)
silodrostat phosphate	Isturisa
simertinib mesylate	Tagrisso
xaliplatin	oxaliplatin
xytocin	oxytocin
xytocin	Pitocin
xytocin in 0.9 % sodium chloride	oxytocin in 0.9 % sod chloride
xytocin in dextrose 5 %-lactated ringers	oxytocin in dextrose 5 % in LR
xytocin/Ringer's solution,lactated	oxytocin in lactated ringers
· · · · · · · · · · · · · · · · · · ·	Zeposia
zanimod hydrochloride	Zeposia
zanimod hydrochloride zanimod hydrochloride	Zeposia Zeposia Starter Kit

cder_mpl1p_wp077 Page 974 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
paliperidone	Invega
paliperidone	paliperidone
paliperidone palmitate	Invega Hafyera
paliperidone palmitate	Invega Sustenna
paliperidone palmitate	Invega Trinza
palonosetron HCl	palonosetron
panobinostat lactate	Farydak
pantoprazole sodium	pantoprazole
pantoprazole sodium	Protonix
papaverine HCl	papaverine
papaverine HCl/phentolamine mesylate in water	IFE-BiMix 30/1
papaverine HCl/phentolamine mesylate/alprostadil	Tri-Mix (papavrn-phntlmn-PGE1)
paroxetine HCl	paroxetine HCl
paroxetine HCl	Paxil
paroxetine HCl	Paxil CR
paroxetine mesylate	Brisdelle
paroxetine mesylate	paroxetine mesylate(menop.sym)
paroxetine mesylate	Pexeva
pasireotide diaspartate	Signifor
pasireotide pamoate	Signifor LAR
pazopanib HCl	Votrient
pentamidine isethionate	Nebupent
pentamidine isethionate	Pentam
pentamidine isethionate	pentamidine
perphenazine	perphenazine
perphenazine/amitriptyline HCl	perphenazine-amitriptyline
phenylephrine HCl/diphenhydramine HCl	Allergy and Sinus Relief
phenylephrine HCl/diphenhydramine HCl	Benadryl Allergy Plus Congest
phenylephrine HCl/diphenhydramine HCl	Child Allergy Plus Congestion
phenylephrine HCl/diphenhydramine HCl	Child Benadryl Plus Congestion
phenylephrine HCl/diphenhydramine HCl	Children Night Time Cold-Cough
phenylephrine HCl/diphenhydramine HCl	Childs Triacting Cold-Cough
phenylephrine HCl/diphenhydramine HCl	Dimetapp Cold-Congestion
phenylephrine HCl/diphenhydramine HCl	Dr Manzanilla Cough-Cold
phenylephrine HCl/diphenhydramine HCl	KinderMed Kid Night Cold-Cough
phenylephrine HCl/diphenhydramine HCl	Sudafed PE Day and Night
phenylephrine HCl/diphenhydramine HCl	Triaminic Cold and CoughNT(PE)
phenylephrine HCl/diphenhydramine HCl	Wal-Dryl-D Allergy and Sinus
phenylephrine HCl/promethazine HCl	Promethazine VC
phenylephrine HCI/promethazine HCI	promethazine-phenylephrine
oimavanserin tartrate	Nuplazid
pimozide	pimozide
opperacillin and tazobactam in dextrose, iso-osmotic	Zosyn in dextrose (iso-osm)
piperacillin sodium/tazobactam sodium	piperacillin-tazobactam
oitolisant HCl	Wakix
ponesimod	Ponvory
ponesimod	Ponvory 14-Day Starter Pack
posaconazole	Noxafil
posaconazole	posaconazole
pralsetinib	Gavreto
prednisolone acetate/gatifloxacin	prednisolone acet-gatifloxacin
prednisolone acetate/gatifloxacin/bromfenac sodium	prednisol ace-gatiflox-bromfen
orednisolone acetate/moxifloxacin HCl	prednisolone-moxifloxacin HCl
orednisolone acetate/moxifloxacin HCl/bromfenac sodium	prednisolone-moxiflox-bromfen

cder_mpl1p_wp077 Page 975 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
prednisolone acetate/moxifloxacin HCl/nepafenac	prednisolone-moxiflo-nepafenac
	The second secon
prednisolone sodium phosphate/gatifloxacin/bromfenac sodium	prednisoln sp-gatiflox-bromfen
prednisolone sodium phosphate/moxifloxacin HCl	prednisolone sod ph-moxiflox
prednisolone sodium phosphate/moxifloxacin HCI/bromfenac	
sod	prednisoln sp-moxiflox-bromfen
pretomanid	pretomanid
primaquine phosphate	primaquine
procainamide HCl	procainamide
promethazine HCl	Phenergan
promethazine HCl	promethazine
promethazine HCl	Promethegan
promethazine HCl in 0.9 % sodium chloride	promethazine in 0.9 % NaCl
promethazine HCl/codeine	promethazine-codeine
promethazine HCl/dextromethorphan HBr	promethazine-DM
promethazine/phenylephrine HCl/codeine	Promethazine VC-Codeine
promethazine/phenylephrine HCl/codeine	promethazine-phenyleph-codeine
propafenone HCl	propafenone
propafenone HCl	Rythmol SR
propofol	Anesthesia S/I-40 (propofol)
propofol	Anesthesia S/I-40A (propofol)
propofol	Anesthesia S/I-40H (propofol)
propofol	Anesthesia S/I-40S (propofol)
propofol	Anesthesia S/I-60 (propofol)
propofol	Diprivan
propofol	propofol
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propofol-Lipuro (PF)
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propoven (EUA) (PF)
propranolol HCl/hydrochlorothiazide	propranolol-hydrochlorothiazid
quetiapine fumarate	quetiapine
quetiapine fumarate	Seroquel
quetiapine fumarate	Seroquel XR
quinapril HCl/hydrochlorothiazide	Accuretic
quinapril HCl/hydrochlorothiazide	quinapril-hydrochlorothiazide
quinidine gluconate	quinidine gluconate
quinidine sulfate	quinidine sulfate
quinine sulfate	Qualaquin
quinine sulfate	quinine sulfate
ranolazine	Aspruzyo Sprinkle
ranolazine	Ranexa
ranolazine	ranolazine
relugolix	Orgovyx Myfamhrae
relugolix/estradiol/norethindrone acetate remdesivir	Myfembree remdesivir
remdesivir	Veklury
reminazolam besylate	Byfavo
ribociclib succinate	Kisqali
ribociclib succinate/letrozole	Kisqali Femara Co-Pack
rilpivirine	rilpivirine
rilpivirine rilpivirine HCl	Edurant
risperidone	Perseris
risperidone	Risperdal
risperidone	risperidone
risperidone risperidone microspheres	Risperdal Consta
паретионе пнегозрнегез	nisperaul Collista

cder_mpl1p_wp077 Page 976 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
romidepsin	Istodax
romidepsin	romidepsin
rucaparib camsylate	Rubraca
saquinavir mesylate	Invirase
selpercatinib	Reteymo
sertraline HCl	sertraline
sertraline HCl	Zoloft
sevoflurane	sevoflurane
sevoflurane	Ultane
siponimod	Mayzent
siponimod	Mayzent Starter(for 1mg maint)
siponimod	Mayzent Starter(for 2mg maint)
solifenacin succinate	solifenacin
solifenacin succinate	Vesicare
solifenacin succinate	Vesicare LS
sorafenib tosylate	Nexavar
sorafenib tosylate	sorafenib
sotalol HCl	Betapace
sotalol HCl	Betapace AF
sotalol HCl	Sorine
sotalol HCl	sotalol
sotalol HCl	Sotalol AF
sotalol HCl	Sotylize
spironolactone/hydrochlorothiazide	Aldactazide
spironolactone/hydrochlorothiazide	spironolacton-hydrochlorothiaz
sunitinib malate	sunitinib
sunitinib malate	Sutent
tacrolimus	Astagraf XL
tacrolimus	Envarsus XR
tacrolimus	Prograf
tacrolimus	tacrolimus
tamoxifen citrate	Soltamox
tamoxifen citrate	tamoxifen
tazemetostat hydrobromide	Tazverik
tebentafusp-tebn	Kimmtrak
telavancin HCl	Vibativ
telmisartan/hydrochlorothiazide	Micardis HCT
telmisartan/hydrochlorothiazide	telmisartan-hydrochlorothiazid
terlipressin acetate	Terlivaz
tetrabenazine	tetrabenazine
tetrabenazine	Xenazine
thioridazine HCl	thioridazine
tizanidine HCl	tizanidine
tizanidine HCl	Zanaflex
tizanidine HCl/irritant counter-irritants combination no.2	Comfort Pac-tizanidine
tolterodine tartrate	Detrol
tolterodine tartrate	Detrol LA
tolterodine tartrate	tolterodine
toremifene citrate	Fareston
toremifene citrate	toremifene
torsemide	Soaanz
torsemide	torsemide
tramadol HCl	ConZip
tramadol HCl	Qdolo

cder_mpl1p_wp077 Page 977 of 1023



Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
tramadol HCl	tramadol
tramadol HCl	Ultram
tramadol HCI/acetaminophen	tramadol-acetaminophen
tramadol HCI/acetaminophen	Ultracet
tramadol HCI/celecoxib	Seglentis
TRAMADOL HCL/GLUCOSAMINE SULFATE	Synapryn
trazodone HCl	trazodone
triamcinolone acetonide/moxifloxacin HCl/water/PF	triamcinolon-moxiflox-watr(PF)
triamterene/hydrochlorothiazide	Maxzide
triamterene/hydrochlorothiazide	Maxzide-25mg
triamterene/hydrochlorothiazide	triamterene-hydrochlorothiazid
trifluridine/tipiracil HCl	Lonsurf
trimipramine maleate	trimipramine
valbenazine tosylate	Ingrezza
valbenazine tosylate	Ingrezza Initiation Pack
valsartan/hydrochlorothiazide	Diovan HCT
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide
vandetanib	Caprelsa
vardenafil HCl	vardenafil
vemurafenib	Zelboraf
venlafaxine besylate	venlafaxine besylate
venlafaxine HCl	Effexor XR
venlafaxine HCl	venlafaxine
voclosporin	Lupkynis
vonoprazan fumarate/amoxicillin trihydrate/clarithromycin	Voquezna Triple Pak
voriconazole	Vfend
voriconazole	Vfend IV
voriconazole	voriconazole
vorinostat	Zolinza
ziprasidone HCl	Geodon
ziprasidone HCl	ziprasidone HCl
ziprasidone mesylate	Geodon
ziprasidone mesylate	ziprasidone mesylate

cder_mpl1p_wp077 Page 978 of 1023



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3)

To describe the incidence rate of hospitalized tachyarrhythmia, defined as principal diagnosis of tachyarrhythmia in the emergency department visit or inpatient hospital setting, overall and by subtype, that occurred between May 13, 2022 (the approval date of Mounjaro in the U.S.) to June 30, 2023 (the end date of the latest available data), in adult type 2 diabetes mellitus (T2DM) patients who newly initiated tirzepatide or other long-acting glucagon-like peptide 1 (GLP-1) receptor agonists (RAs), by product and patient characteristics including race/ethnicity groups.

- report 01 has a preindex enrollment requirement of 365 days

Query period start date (binds Index Date): May 13, 2022 (tirzepatide approval date in U.S.)

Query period end date (binds Index Date): June 30, 2023

Coverage requirement: Medical & Drug Coverage

Pre-index enrollment requirement: 365 days
Post-index enrollment requirement: N/A
Enrollment gap: 45 days

Age groups: 0-40, 41-64, 65-74, 75-84, ≥85 years old

Sex groups: Male, Female

Race groups: White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Unknown,

Multi-Racial

Stratifications: Age group (0-40, 41-64, 65-74, 75-84, ≥85)

Sex (M F) Calendar Year

Race (White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander,

Unknown, Multi-Racial) Calendar Year * Race Age group * Race Arrhythmia at baseline

Other cardiac disease at baseline (heart failure, ischemic heart disease/coronary artery disease/myocardial infarction,

hypertension, valvular disease, obstructive sleep apnea, and hypertrophic cardiomyopathy)

Censor output stratifications: Categorical (0-30 31-60 61-90 91-183 184-365 366-455+)

Continuous

Follow up time stratifications: Categorical (0-30 31-60 61-90 91-183 184-365 366-455+)

Continuous

Envelope macro: No reclassification

Features: Censoring table, follow-up time table, exposure/HOI code distribution tables

Plus programming:

- Disease severity risk score and comorbidity score categorical bins

- Report baseline characteristics, effect estimates by race

- Truncation code distribution

Freeze data: No Notes: N/A

cder mpl1p wp077 Page 979 of 1023



	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Exposure	Tirzepatide	Exenatide synthetic	Semaglutide
	(Mounjaro)	(Bydureon, Bydureon BCISE)	(Ozempic)
Code Details (type, days supply,	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),	Dispensings (Dispensings table o
etc.)	native days supply	native days supply	native days supply
Care Setting	N/A	N/A	N/A
Incident with respect to:	Long-acting GLP-1 RA	Long-acting GLP-1 RA	Long-acting GLP-1 RA
	(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mou
	Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Tru
	Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)
	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)	(Implemented as exclusion crite
Code Details (type, days supply,	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),	Dispensings (Dispensings table o
etc.)	native days supply	native days supply	native days supply
Care Setting	N/A	N/A	N/A
Washout (days)	365 days	365 days	365 days
	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)	(Implemented as exclusion crite
Exposure Episode Truncation	*Death	*Death	*Death
Criteria	*Disenrollment	*Disenrollment	*Disenrollment
	*DP end date	*DP end date	*DP end date
	*Study period end date	*Study period end date	*Study period end date
	*Pregnancy	*Pregnancy	*Pregnancy
	*IP or ED encounter (other than HOI-	*IP or ED encounter (other than HOI-	*IP or ED encounter (other than
	defining hospitalized tachyarrhythmia)	defining hospitalized tachyarrhythmia)	defining hospitalized tachyarrhyt
	*non-index long-acting GLP-1 RA	*non-index long-acting GLP-1 RA	*non-index long-acting GLP-1
	(see Combo Tool tab for more details on	(see Combo Tool tab for more details on	(see Combo Tool tab for more det
	implementation)	implementation)	implementation)
Only consider dispensing date	No	No	No
.			
when considering washout, i.e.			
when considering washout, i.e. ignore days supply (after			
_			
ignore days supply (after			

Page 980 of 1023



	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Forced supply to attach to codes	N/A	N/A	N/A
Cohort Definition	Only the first valid treatment episode during the query period (01)	Only the first valid treatment episode during the query period (01)	Only the first valid treatment episode during the query period (01)
Prevalent Cohort creation?	No	No	No
Exposure Episode Gap	5 days	5 days	5 days
Exposure Extension Period	5 days	5 days	5 days
Minimum Episode Duration	1 day	1 day	1 day
Minimum Days Supplied	1 day	1 day	1 day
Point Exposure?	No	No	No
Maximum Episode Duration	N/A	N/A	N/A
-			
Ī	[out] = all	[out] = all	[out] = all
Event/Outcome	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia
Lvent/ Outcome	nospitalized tachyarrhytillila	nospitalized tachyarrhythilia	nospitalizeu tacilyarriiytiiilia
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Code Details (type, days supply,	· · · · · · · · · · · · · · · · · · ·		1 1
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Code Details (type, days supply, etc.) Care Setting/PDX	Diagnosis (DX) codes IPP, ED*	Diagnosis (DX) codes IPP, ED*	Diagnosis (DX) codes IPP, ED*
Code Details (type, days supply, etc.) Care Setting/PDX Event Incidence with Respect to Event Incidence Criteria	Diagnosis (DX) codes IPP, ED* N/A	Diagnosis (DX) codes IPP, ED* N/A	Diagnosis (DX) codes IPP, ED* N/A
Code Details (type, days supply, etc.) Care Setting/PDX Event Incidence with Respect to Event Incidence Criteria Care Setting / PDX	Diagnosis (DX) codes IPP, ED* N/A N/A	Diagnosis (DX) codes IPP, ED* N/A N/A	Diagnosis (DX) codes IPP, ED* N/A N/A O days All occurrences of an HOI during ar
Code Details (type, days supply, etc.) Care Setting/PDX Event Incidence with Respect to Event Incidence Criteria Care Setting / PDX Event washout (days)	Diagnosis (DX) codes IPP, ED* N/A N/A O days All occurrences of an HOI during an exposure episode are counted for all	Diagnosis (DX) codes IPP, ED* N/A N/A O days All occurrences of an HOI during an exposure episode are counted for all	Diagnosis (DX) codes IPP, ED* N/A N/A O days All occurrences of an HOI during ar exposure episode are counted for a
Code Details (type, days supply, etc.) Care Setting/PDX Event Incidence with Respect to Event Incidence Criteria Care Setting / PDX Event washout (days) Event de-duplication Only consider dispensing date when considering washout, i.e. ignore days supply (after	Diagnosis (DX) codes IPP, ED* N/A N/A O days All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	Diagnosis (DX) codes IPP, ED* N/A N/A O days All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	Diagnosis (DX) codes IPP, ED* N/A N/A O days All occurrences of an HOI during ar exposure episode are counted for a event characteristics (0)
Code Details (type, days supply, etc.) Care Setting/PDX Event Incidence with Respect to Event Incidence Criteria Care Setting / PDX Event washout (days) Event de-duplication Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	Diagnosis (DX) codes IPP, ED* N/A N/A O days All occurrences of an HOI during an exposure episode are counted for all event characteristics (0) No	Diagnosis (DX) codes IPP, ED* N/A N/A O days All occurrences of an HOI during an exposure episode are counted for all event characteristics (0) No	Diagnosis (DX) codes IPP, ED* N/A N/A O days All occurrences of an HOI during ar exposure episode are counted for a event characteristics (0) No



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3) **Cohort Group 1 Cohort Group 2 Cohort Group 3** Tirzepatide **Exenatide synthetic** Semaglutide (Bydureon, Bydureon BCISE) (Mounjaro) (Ozempic) Event/Outcome Atrial fibrillation and flutter Atrial fibrillation and flutter Atrial fibrillation and flutter Code Details (type, days supply, Diagnosis (DX) codes Diagnosis (DX) codes Diagnosis (DX) codes etc.) Care Setting/PDX IPP, ED* IPP, ED* IPP, ED* Event Incidence with Respect to N/A N/A N/A N/A N/A N/A Event Incidence Criteria Care Setting / PDX 0 davs 0 davs 0 davs Event washout (days) All occurrences of an HOI during an All occurrences of an HOI during an All occurrences of an HOI during an exposure episode are counted for all exposure episode are counted for all exposure episode are counted for all Event de-duplication event characteristics (0) event characteristics (0) event characteristics (0) Only consider dispensing date No No No when considering washout, i.e. ignore days supply (after stockpiling)? Forced supply to attach to codes N/A N/A N/A Start of at-risk period N/A N/A N/A Blackout Period 1 day 1 day 1 day Event/Outcome Sinus tachycardia Sinus tachycardia Sinus tachycardia Code Details (type, days supply, Diagnosis (DX) codes Diagnosis (DX) codes Diagnosis (DX) codes etc.) Care Setting/PDX IPP, ED* IPP, ED* IPP, ED* N/A N/A N/A Event Incidence with Respect to **Event Incidence Criteria** N/A N/A N/A Care Setting / PDX Event washout (days) 0 days 0 days 0 days All occurrences of an HOI during an All occurrences of an HOI during an All occurrences of an HOI during an exposure episode are counted for all exposure episode are counted for all exposure episode are counted for all Event de-duplication event characteristics (0) event characteristics (0) event characteristics (0)



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3) **Cohort Group 1 Cohort Group 2 Cohort Group 3** Tirzepatide **Exenatide synthetic** Semaglutide (Bydureon, Bydureon BCISE) (Mounjaro) (Ozempic) Only consider dispensing date No No No when considering washout, i.e. ignore days supply (after stockpiling)? Forced supply to attach to codes N/A N/A N/A Start of at-risk period N/A N/A N/A Blackout Period 1 day 1 day 1 day Event/Outcome Supraventricular tachycardia Supraventricular tachycardia Supraventricular tachycardia Code Details (type, days supply, Diagnosis (DX) codes Diagnosis (DX) codes Diagnosis (DX) codes etc.) Care Setting/PDX IPP, ED* IPP, ED* IPP, ED* Event Incidence with Respect to N/A N/A N/A **Event Incidence Criteria** N/A N/A N/A Care Setting / PDX 0 days Event washout (days) 0 days 0 days All occurrences of an HOI during an All occurrences of an HOI during an All occurrences of an HOI during an exposure episode are counted for all exposure episode are counted for all exposure episode are counted for all Event de-duplication event characteristics (0) event characteristics (0) event characteristics (0) Only consider dispensing date No No No when considering washout, i.e. ignore days supply (after stockpiling)? Forced supply to attach to codes N/A N/A N/A N/A N/A N/A Start of at-risk period 1 dav 1 day 1 day Blackout Period Event/Outcome Other tachycardia Other tachycardia Other tachycardia Code Details (type, days supply, Diagnosis (DX) codes Diagnosis (DX) codes Diagnosis (DX) codes etc.) Care Setting/PDX IPP, ED* IPP, ED* IPP, ED* **Event Incidence with Respect to** N/A N/A N/A

Page 983 of 1023



	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide
			(Ozempic)
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during a
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for a
	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Event/Outcome	Cardiac arrest	Cardiac arrest	Cardiac arrest
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during a
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for
	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day

Page 984 of 1023



	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Event/Outcome	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
Event washout (days)	0 days	0 days	0 days
Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during ar exposure episode are counted for a event characteristics (0)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Event/Outcome	Ventricular tachycardia	Ventricular tachycardia	Ventricular tachycardia
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
Event washout (days)	0 days	0 days	0 days



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3) **Cohort Group 1 Cohort Group 2 Cohort Group 3** Tirzepatide **Exenatide synthetic** Semaglutide (Mounjaro) (Bydureon, Bydureon BCISE) (Ozempic) All occurrences of an HOI during an All occurrences of an HOI during an All occurrences of an HOI during an exposure episode are counted for all exposure episode are counted for all exposure episode are counted for all Event de-duplication event characteristics (0) event characteristics (0) event characteristics (0) Only consider dispensing date No No No when considering washout, i.e. ignore days supply (after stockpiling)? Forced supply to attach to codes N/A N/A N/A Start of at-risk period N/A N/A N/A Blackout Period 1 day 1 day 1 day Include or Exclude Inclusion Inclusion Inclusion **Conditions** Type 2 Diabetes Type 2 Diabetes Type 2 Diabetes Code Details (type, days supply, Diagnosis (DX) codes Diagnosis (DX) codes Diagnosis (DX) codes etc.) Care Setting/PDX Anv Anv Anv Lookback Period (-365, -1) (-365, -1)(-365, -1)Inclusion/Exclusion Criteria Only consider dispensing date No No No when considering washout, i.e. ignore days supply (after stockpiling)? Forced supply to attach to codes N/A N/A N/A Number of Code Occurrences 1x 1x 1x AND AND AND Include or Exclude Inclusion Inclusion Inclusion Conditions Any oral anti-diabetic drug Any oral anti-diabetic drug Any oral anti-diabetic drug Code Details (type, days supply, Dispensing (RX) codes Dispensing (RX) codes Dispensing (RX) codes etc.) Care Setting/PDX Any Any Any **Lookback Period** (-365, -1)(-365, -1)(-365, -1)



	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide	Exenatide synthetic	Semaglutide
	(Mounjaro)	(Bydureon, Bydureon BCISE)	(Ozempic)
Only consider dispensing date	No	No	No
when considering washout, i.e. ignore days supply (after			
stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
	AND (AND (AND (
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Insulin	Insulin	Insulin
Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
	AND NOT	AND NOT	AND NOT
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Any anti-diabetic drug other than insulin	Any anti-diabetic drug other than insulin	Any anti-diabetic drug other than in
Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A



	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide	Exenatide synthetic	Semaglutide
	(Mounjaro)	(Bydureon, Bydureon BCISE)	(Ozempic)
Number of Code Occurrences	1x	1x	1x
) OR) OR) OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Type 1 Diabetes	Type 1 Diabetes	Type 1 Diabetes
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Gestational Diabetes	Gestational Diabetes	Gestational Diabetes
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Other secondary diabetes illness	Other secondary diabetes illness	Other secondary diabetes ill
Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes

Page 988 of 1023



	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide	Exenatide synthetic	Semaglutide
	(Mounjaro)	(Bydureon, Bydureon BCISE)	(Ozempic)
Care Setting/PDX	Any	Any	Any
Lookback Period	(-365, -1)	(-365, -1)	(-365 <i>,</i> -1)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
when considering washout, i.e. ignore days supply (after stockpiling)? Forced supply to attach to codes Number of Code Occurrences Include or Exclude Conditions	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Short-acting GLP-1 RA	Short-acting GLP-1 RA	Short-acting GLP-1 RA
	(Byetta, Adlyxin, Soliqua)	(Byetta, Adlyxin, Soliqua)	(Byetta, Adlyxin, Soliqua
Code Details (type, days supply,	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
etc.)			
Care Setting/PDX	Any	Any	Any
Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			
stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
_	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Pregnancy	Pregnancy	Pregnancy
Code Details (type, days supply,	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
etc.)			
Care Setting/PDX	Any	Any	Any
Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
Only consider dispensing date	No	No	No
when considering washout, i.e.			
ignore days supply (after			



	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide	Exenatide synthetic	Semaglutide
	(Mounjaro)	(Bydureon, Bydureon BCISE)	(Ozempic)
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
	Long-acting GLP-1 RA	Long-acting GLP-1 RA	Long-acting GLP-1 RA
H _a	(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mounjaro,	(Bydureon, Bydureon BCISE, Mounjaro
Conditions	Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Trulicity,	Ozempic, Rybelsus, Saxenda, Trulicity,
	Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)	Victoza, Wegovy, Xultophy)
Code Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
Care Setting/PDX	Any	Any	Any
Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
Conditions Code Details (type, days supply, etc.) Care Setting/PDX Lookback Period Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
_			
Group(s) Affected by Custom	Long or Short-acting GLP-1 RAs by brand	Long or Short-acting GLP-1 RAs by brand	Long or Short-acting GLP-1 RAs by brar
Stockpiling Rules	name	name	name
	(for Victoza, both brand names	(for Victoza, both brand names	(for Victoza, both brand names
	consolidated to one stockgroup)	consolidated to one stockgroup)	consolidated to one stockgroup)
	(Other RXs by generic name, default	(Other RXs by generic name, default	(Other RXs by generic name, default
	stockpiling rules)	stockpiling rules)	stockpiling rules)
Same Day Processing (days supply)	Max	Max	Max
Same Day Processing (amount supply)	Max	Max	Max
Allowable Range (days supply)	Greater than 0	Greater than 0	Greater than 0
Allowable halige (days supply)	Greater than 5		

Page 990 of 1023



		ers for this Request (Primary Analysis, Col Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide	Exenatide synthetic	Semaglutide
		(Mounjaro)	(Bydureon, Bydureon BCISE)	(Ozempic)
	Maximum Amount of	0%	0%	0%
	Percentage Overlap Allowed	(No shifting of index date;	(No shifting of index date;	(No shifting of index date;
	Prior to Shifting Dispensing Date	truncate previous dispensing at any	truncate previous dispensing at any	truncate previous dispensing at any
		overlap with next dispensing)	overlap with next dispensing)	overlap with next dispensing)
-		(2)		
	Covariates	(See Appendix I)	(See Appendix I)	(See Appendix I)
Baseline Covariates	Code Details (type, days supply, etc.)	(See Appendix I)	(See Appendix I)	(See Appendix I)
ase	Care Setting/PDX	N/A	N/A	N/A
C	Covariate evaluation window	(See Appendix I)	(See Appendix I)	(See Appendix I)
L	(days)			
a)	Comorbidity Score evaluation	(-365, -1)	(-365, -1)	(-365, -1)
n/ Score	window (days)			
on/ Sy St	Medical Utilization Evaluation	(-365, -1)	(-365, -1)	(-365, -1)
Utilization/ Comorbidity So	Window			
iii al	Medical Utilization Care setting	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED
_ E	Drug Utilization Evaluation	(-365, -1)	(-365, -1)	(-365, -1)
0	Window			

Abbreviations:

DP: Data Partner IP: Inpatient

ED: Emergency Department HOI: Health Outcome of Interest

PDX: Principal Discharge Diagnosis Flag

IPP: Inpatient Hospital Stays, Principal Diagnoses

IS: Non-acute Institutional Stay

AV: Ambulatory Visits

OA: Other Ambulatory Visits

N/A: Not applicable



		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide	Semaglutide	Liraglutide
		(Rybelsus)	(Wegovy)	(Saxenda)
	Exposure	Semaglutide	Semaglutide	Liraglutide
	Exposure	(Rybelsus)	(Wegovy)	(Saxenda)
	Code Details (type, days supply, etc.)	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),	Dispensings (Dispensings table only)
	code Details (type) days supply, etc.,	native days supply	native days supply	native days supply
	Care Setting	N/A	N/A	N/A
	Incident with respect to:	Long-acting GLP-1 RA	Long-acting GLP-1 RA	Long-acting GLP-1 RA
	·	(Bydureon, Bydureon BCISE,	(Bydureon, Bydureon BCISE,	(Bydureon, Bydureon BCISE,
		Mounjaro, Ozempic, Rybelsus,	Mounjaro, Ozempic, Rybelsus,	Mounjaro, Ozempic, Rybelsus,
		Saxenda, Trulicity, Victoza, Wegovy,	Saxenda, Trulicity, Victoza, Wegovy,	Saxenda, Trulicity, Victoza, Wegovy,
		Xultophy)	Xultophy)	Xultophy)
		(Implemented as exclusion criteria)	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)
	Code Details (type, days supply, etc.)	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),	Dispensings (Dispensings table only)
		native days supply	native days supply	native days supply
	Care Setting	N/A	N/A	N/A
	Washout (days)	365 days (Implemented as exclusion	365 days (Implemented as exclusion	365 days (Implemented as exclusion
		criteria)	criteria)	criteria)
	Exposure Episode Truncation Criteria	*Death	*Death	*Death
		*Disenrollment	*Disenrollment	*Disenrollment
υ		*DP end date	*DP end date	*DP end date
orug/exposure		*Study period end date	*Study period end date	*Study period end date
ă X		*Pregnancy	*Pregnancy	*Pregnancy
2/2		*IP or ED encounter (other than HOI-	*IP or ED encounter (other than HOI-	*IP or ED encounter (other than HOI
3		defining hospitalized	defining hospitalized	defining hospitalized
		tachyarrhythmia)	tachyarrhythmia)	tachyarrhythmia)
1		*non-index long-acting GLP-1 RA	*non-index long-acting GLP-1 RA	*non-index long-acting GLP-1 RA
1		(see Combo Tool tab for more details	(see Combo Tool tab for more details	(see Combo Tool tab for more detail
1		on implementation)	on implementation)	on implementation)



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 4-6) (Continued)

	Cohort Group 4	Cohort Group 5	Cohort Group 6
	Semaglutide	Semaglutide	Liraglutide
	(Rybelsus)	(Wegovy)	(Saxenda)
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days supply			
(after stockpiling)?			
(This does not apply to index-defining			
criteria)			
Forced supply to attach to codes	N/A	N/A	N/A
Cohort Definition	Only the first valid treatment episode	Only the first valid treatment episode	Only the first valid treatment episode
	during the query period (01)	during the query period (01)	during the query period (01)
Prevalent Cohort creation?	No	No	No
Exposure Episode Gap	5 days	5 days	5 days
Exposure Extension Period	5 days	5 days	5 days
Minimum Episode Duration	1 day	1 day	1 day
Minimum Days Supplied	1 day	1 day	1 day
Point Exposure?	No	No	No
Maximum Episode Duration	N/A	N/A	N/A

	[out] = all	[out] = all	[out] = all
Event/Outcome	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day

Base Cohort Outcome



	Cohort Group 4	Cohort Group 5	Cohort Group 6
	Semaglutide	Semaglutide	Liraglutide
	(Rybelsus)	(Wegovy)	(Saxenda)
Frank (Outrom)		I	A
Event/Outcome	Atrial fibrillation and flutter	Atrial fibrillation and flutter	Atrial fibrillation and flutter
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
Event washout (days)	0 days	0 days	0 days
	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for
•	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days supply	-		
(after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Event/Outcome	Sinus tachycardia	Sinus tachycardia	Sinus tachycardia
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX	,		.,,
Event washout (days)	0 davs	0 davs	0 davs
	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted fo
	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days supply	_		
(after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A



Code Details (type, days supply, etc.) Diagnosis (DX) codes Di		Cohort Group 4	Cohort Group 5	Cohort Group 6
Blackout Period		Semaglutide	Semaglutide	Liraglutide
Event/Outcome Code Details (type, days supply, etc.) Diagnosis (DX) codes Diagnosis ((Rybelsus)	(Wegovy)	(Saxenda)
Diagnosis (DX) codes	Blackout Period	1 day	1 day	1 day
Eare Setting/PDX IPP, ED* IPP, ED* IPP, ED* IPP, ED*	Event/Outcome	Supraventricular tachycardia	Supraventricular tachycardia	Supraventricular tachycardia
Event Incidence With Respect to N/A	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Event Incidence Criteria Care Setting / PDX Event washout (days) All occurrences of an HOI during an exposure episode are counted for all event characteristics (0) Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? Forced supply to attach to codes N/A N/A N/A N/A N/A N/A N/A N/	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event washout (days) Event de-duplication All occurrences of an HOI during an exposure episode are counted for all event characteristics (0) Event characteristics (0) No No No No No No No No No N	Event Incidence with Respect to			N/A
Event washout (days) All occurrences of an HOI during an exposure episode are counted for all event characteristics (0) Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? Forced supply to attach to codes Start of at-risk period Dother tachycardia Code Details (type, days supply, etc.) Diagnosis (DX) codes Diagnosis	Event Incidence Criteria	N/A	N/A	N/A
Event washout (days) All occurrences of an HOI during an exposure episode are counted for all event characteristics (0) Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? Forced supply to attach to codes N/A Blackout Period Other tachycardia	Care Setting / PDX			
All occurrences of an HOI during an exposure episode are counted for all event characteristics (0) No		0 days	0 days	0 days
Event de-duplication exposure episode are counted for all event characteristics (0) exposure episode are counted for all event characteristics (0) exposure episode are counted for all event characteristics (0) exposure episode are counted for all event characteristics (0) exposure episode are counted for all event characteristics (0) exposure episode are counted for all event characteristics (0) exposure episode are counted for all event characteristics (0) exposure episode are counted for all event characteristics (0) event characteristics (0) No No Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpilling)? N/A N/A N/A N/A N/A N/A N/	, , ,			All occurrences of an HOI during an
event characteristics (0) event characterist	Event de-duplication	-	_	exposure episode are counted for all
considering washout, i.e. ignore days supply (after stockpiling)? Forced supply to attach to codes N/A Start of at-risk period N/A Blackout Period Other tachycardia Other tachyc		1 .		event characteristics (0)
Code Care Setting PDX Care Setting PDX	Only consider dispensing date when	No	No	No
(after stockpiling)? N/A N/A N/A Forced supply to attach to codes N/A N/A N/A Start of at-risk period N/A N/A N/A Blackout Period 1 day 1 day 1 day Event/Outcome Other tachycardia Other tachycardia Other tachycardia Code Details (type, days supply, etc.) Diagnosis (DX) codes Diagnosis (DX) codes Care Setting/PDX IPP, ED* IPP, ED* Event Incidence with Respect to N/A N/A N/A Event Incidence Criteria N/A N/A N/A N/A Care Setting / PDX O days O days O days O days Event washout (days) O days O days O days O days Event de-duplication All occurrences of an HOI during an exposure episode are counted for all event characteristics (0) event characteristics (0) No No Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? No No No	considering washout, i.e. ignore days supply			
Start of at-risk period				
Event/Outcome Other tachycardia Other ta	Forced supply to attach to codes	N/A	N/A	N/A
Event/Outcome Other tachycardia			N/A	N/A
Code Details (type, days supply, etc.) Diagnosis (DX) codes IPP, ED* N/A N/A N/A N/A N/A N/A N/A O days All occurrences of an HOI during an exposure episode are counted for all exposure episode are counted for all event characteristics (0) Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	Blackout Period	1 day	1 day	1 day
Code Details (type, days supply, etc.) Diagnosis (DX) codes IPP, ED* N/A N/A N/A N/A N/A N/A N/A O days All occurrences of an HOI during an exposure episode are counted for all exposure episode are counted for all event characteristics (0) Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?				
Care Setting/PDXIPP, ED*IPP, ED*IPP, ED*Event Incidence with Respect toN/AN/AN/AEvent Incidence CriteriaN/AN/AN/ACare Setting / PDXN/AN/AN/AEvent washout (days)O daysO daysO daysAll occurrences of an HOI during an exposure episode are counted for all event characteristics (0)All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)Event characteristics (0)Event characteristics (0)Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?NoNoNo	Event/Outcome	Other tachycardia	Other tachycardia	Other tachycardia
Event Incidence with Respect to N/A N/A N/A N/A N/A N/A Event Incidence Criteria N/A N/A N/A N/A N/A Care Setting / PDX Event washout (days) O days O days O days All occurrences of an HOI during an exposure episode are counted for all event characteristics (0) event characteristics (0) Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	Code Details (type, days supply, etc.)	Diagnosis (DX) codes		Diagnosis (DX) codes
Event Incidence Criteria Care Setting / PDX Event washout (days) All occurrences of an HOI during an exposure episode are counted for all event characteristics (0) Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? N/A N/A N/A N/A N/A N/A N/A N/		IPP, ED*	IPP, ED*	IPP, ED*
Care Setting / PDX Event washout (days) All occurrences of an HOI during an exposure episode are counted for all event characteristics (0) Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? O days O days All occurrences of an HOI during an exposure episode are counted for all exposure ep	Event Incidence with Respect to	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·
Event washout (days) O days All occurrences of an HOI during an exposure episode are counted for all event characteristics (0) Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? O days All occurrences of an HOI during an exposure episode are counted for all event characteristics (0) No No No No No No No No No N	Event Incidence Criteria	N/A	N/A	N/A
Event de-duplication All occurrences of an HOI during an exposure episode are counted for all event characteristics (0) Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? All occurrences of an HOI during an exposure episode are counted for all exposure episode episode episode episode episode episode episode episode episode epi	Care Setting / PDX			
Event de-duplication exposure episode are counted for all event characteristics (0) event characteristics (0) event characteristics (0) Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? exposure episode are counted for all exposure episode are counted for all event characteristics (0) NO NO NO NO NO NO NO NO NO N	Event washout (days)	0 days	0 days	0 days
event characteristics (0) event characteristics (0) event characteristics (0) Only consider dispensing date when No No No No No Considering washout, i.e. ignore days supply (after stockpiling)?		All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
event characteristics (0) event characteristics (0) event characteristics (0) Only consider dispensing date when No No No No Considering washout, i.e. ignore days supply (after stockpiling)?	Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for al
considering washout, i.e. ignore days supply (after stockpiling)?		· · · · · · · · · · · · · · · · · · ·		event characteristics (0)
considering washout, i.e. ignore days supply (after stockpiling)?	Only consider dispensing date when	No	No	No
(after stockpiling)?				-
, , ,				
	Forced supply to attach to codes	N/A	N/A	N/A



	Cohort Group 4	Cohort Group 5	Cohort Group 6
	Semaglutide	Semaglutide	Liraglutide
	(Rybelsus)	(Wegovy)	(Saxenda)
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Event/Outcome	Cardiac arrest	Cardiac arrest	Cardiac arrest
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) code
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX	<u> </u>	<u> </u>	
Event washout (days)	0 days	0 days	0 days
	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI of
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are coun
•	event characteristics (0)	event characteristics (0)	event characteristics
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days supply (after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Event/Outcome	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter	Ventricular fibrillation and
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) code
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX	1	,	1,,,,
Event washout (days)	0 days	0 days	0 days
· , ,	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI of
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are coun
Event de dapheation	event characteristics (0)	event characteristics (0)	event characteristics
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days supply			
(after stockpiling)?			



	Cohort Group 4	Cohort Group 5	Cohort Group 6
	Semaglutide	Semaglutide	Liraglutide
	(Rybelsus)	(Wegovy)	(Saxenda)
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Event/Outcome	Ventricular tachycardia	Ventricular tachycardia	Ventricular tachycardia
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX	·	·	·
Event washout (days)	0 days	0 days	0 days
- con manufacturity	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during ar
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for a
Livelit de duplication	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispension date when	, ,	, ,	, ,
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days supply			
(after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Include or Evelude	Inclusion	Inclusion	Inclusion
Include or Exclude Conditions	Type 2 Diabetes	Type 2 Diabetes	Type 2 Diabetes
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
Only consider dispensing date when	(-303, -1) No	No	(-303, -1) No
considering washout, i.e. ignore days supply	140	140	NO
(after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
	AND	AND	AND
Include or Exclude	Inclusion	Inclusion	Inclusion



		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide	Semaglutide	Liraglutide
		(Rybelsus)	(Wegovy)	(Saxenda)
	Conditions	Any oral anti-diabetic drug	Any oral anti-diabetic drug	Any oral anti-diabetic drug
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
σ	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
כונפומ	Only consider dispensing date when	No	No	No
5	considering washout, i.e. ignore days supply			
	(after stockpiling)?			
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		AND (AND (AND (
в	Include or Exclude	Exclusion	Exclusion	Exclusion
teri	Conditions	Insulin	Insulin	Insulin
<u>:</u>	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
L C	Care Setting/PDX	Any	Any	Any
usi	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
×	Only consider dispensing date when	No	No	No
Ę	considering washout, i.e. ignore days supply			
Inclusion/Exclusion Criteria	(after stockpiling)?			
5	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		AND NOT	AND NOT	AND NOT
	Include or Exclude	Exclusion	Exclusion	Exclusion
<u>-</u> .	Conditions	Any anti-diabetic drug other than	Any anti-diabetic drug other than	Any anti-diabetic drug other tha
ite	Conditions	insulin	insulin	insulin
۲	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
Θ̈́	Care Setting/PDX	Any	Any	Any
ä	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
Ĕ	Only consider dispensing date when	No	No	No
on/	considering washout, i.e. ignore days supply			
Inclusion/Exclusion Criteria	(after stockpiling)?			
lnc	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
Г	Include or Exclude	Exclusion	Exclusion	Exclusion



	Cohort Group 4	Cohort Group 5	Cohort Group 6
	Semaglutide	Semaglutide	Liraglutide
	(Rybelsus)	(Wegovy)	(Saxenda)
Conditions	Type 1 Diabetes	Type 1 Diabetes	Type 1 Diabetes
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days supply			
(after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
) OR) OR) OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Gestational Diabetes	Gestational Diabetes	Gestational Diabetes
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days supply			
(after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Other secondary diabetes illness	Other secondary diabetes illness	Other secondary diabetes illne
Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days supply			
(after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion



		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Code Care Lool Only cons (after	ditions	Short-acting GLP-1 RA (Byetta, Adlyxin, Soliqua)	Short-acting GLP-1 RA (Byetta, Adlyxin, Soliqua)	Short-acting GLP-1 RA (Byetta, Adlyxin, Soliqua)
Code	e Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
Care	e Setting/PDX	Any	Any	Any
Look	kback Period	(-365, -1)	(-365, -1)	(-365, -1)
Only	y consider dispensing date when	No	No	No
cons (afte	sidering washout, i.e. ignore days supply er stockpiling)?			
Forc	ced supply to attach to codes	N/A	N/A	N/A
Nun	nber of Code Occurrences	1x	1x	1x
	·	OR	OR	OR
Inclu	ude or Exclude	Exclusion	Exclusion	Exclusion
Con	ditions	Pregnancy	Pregnancy	Pregnancy
Condition Condit	e Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care	e Setting/PDX	Any	Any	Any
Look	kback Period	(-365, -1)	(-365, -1)	(-365, -1)
Only	y consider dispensing date when	No	No	No
cons (afte	sidering washout, i.e. ignore days supply er stockpiling)?			
Forc	ced supply to attach to codes	N/A	N/A	N/A
Num	nber of Code Occurrences	1x	1x	1x
		OR	OR	OR
Inclu	ude or Exclude	Exclusion	Exclusion	Exclusion
		Long-acting GLP-1 RA (Bydureon, Bydureon BCISE,	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE,	Long-acting GLP-1 RA (Bydureon, Bydureon BCIS)
Con	ditions	Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy,	Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy,	Mounjaro, Ozempic, Rybels Saxenda, Trulicity, Victoza, We
		Xultophy)	Xultophy)	Xultophy)
	e Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
	e Setting/PDX	Any	Any	Any
Lool	kback Period	(-365, -1)	(-365, -1)	(-365, -1)



		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide	Semaglutide	Liraglutide
		(Rybelsus)	(Wegovy)	(Saxenda)
	Only consider dispensing date when	No	No	No
	considering washout, i.e. ignore days supply			
	(after stockpiling)?			
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
	Group(s) Affected by Custom Stockpiling	Long or Short-acting GLP-1 RAs by	Long or Short-acting GLP-1 RAs by	Long or Short-acting GLP-1 RAs I
	Rules	brand name	brand name	brand name
		(for Victoza, both brand names	(for Victoza, both brand names	(for Victoza, both brand name
		consolidated to one stockgroup)	consolidated to one stockgroup)	consolidated to one stockgroup
		(Other RXs by generic name, default	(Other RXs by generic name, default	(Other RXs by generic name, defa
		stockpiling rules)	stockpiling rules)	stockpiling rules)
	Same Day Processing (days supply)	Max	Max	Max
	Same Day Processing (amount supply)	Max	Max	Max
	Allowable Range (days supply)	Greater than 0	Greater than 0	Greater than 0
	Allowable Range (amount supply)	Greater than 0	Greater than 0	Greater than 0
	Maximum Amount of Percentage Overlap	0%	0%	0%
	Allowed Prior to Shifting Dispensing Date	(No shifting of index date;	(No shifting of index date;	(No shifting of index date;
		truncate previous dispensing at any	truncate previous dispensing at any	truncate previous dispensing at a
		overlap with next dispensing)	overlap with next dispensing)	overlap with next dispensing)
	Covariates	(See Appendix I)	(See Appendix I)	(See Appendix I)
	Code Details (type, days supply, etc.)	(See Appendix I)	(See Appendix I)	(See Appendix I)
	Care Setting/PDX	N/A	N/A	N/A
	Covariate evaluation window (days)	(See Appendix I)	(See Appendix I)	(See Appendix I)
г	Comorbidity Score evaluation window (days)	(-365, -1)	(-365, -1)	(-365, -1)
	Medical Utilization Evaluation Window	(-365, -1)	(-365, -1)	(-365, -1)
	Medical Utilization Care setting	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED
	Drug Utilization Evaluation Window	(-365, -1)	(-365, -1)	(-365, -1)



Abbreviations: DP: Data Partner

IP: Inpatient

ED: Emergency Department HOI: Health Outcome of Interest

PDX: Principal Discharge Diagnosis Flag

IPP: Inpatient Hospital Stays, Principal Diagnoses

IS: Non-acute Institutional Stay

AV: Ambulatory Visits

OA: Other Ambulatory Visits

N/A: Not applicable



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

Cohort Group 7	Cohort Group 8	Cohort Group 9
Liraglutide	Dulaglutide	Insulin degludec and liraglutide
(Victoza)	(Trulicity)	(Xultophy)

	. ,	` ''	` ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Exposure	Liraglutide	Dulaglutide	Insulin degludec and liraglutide
	(Victoza)	(Trulicity)	(Xultophy)
Code Details (type, days supply, etc.)	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),
	native davs supply	native davs supply	native davs supply
Care Setting	N/A	N/A	N/A
Incident with respect to:	Long-acting GLP-1 RA	Long-acting GLP-1 RA	Long-acting GLP-1 RA
	(Bydureon, Bydureon BCISE,	(Bydureon, Bydureon BCISE,	(Bydureon, Bydureon BCISE,
	Mounjaro, Ozempic, Rybelsus,	Mounjaro, Ozempic, Rybelsus,	Mounjaro, Ozempic, Rybelsus,
	Saxenda, Trulicity, Victoza, Wegovy,	Saxenda, Trulicity, Victoza, Wegovy,	Saxenda, Trulicity, Victoza, Wegovy,
	Xultophy)	Xultophy)	Xultophy)
	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)
Code Details (type, days supply, etc.)	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),	Dispensings (Dispensings table only),
	native days supply	native days supply	native days supply
Care Setting	N/A	N/A	N/A
Washout (days)	365 days	365 days	365 days
	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)	(Implemented as exclusion criteria)
5 5 1 T 1' 0'' '			, .
Exposure Episode Truncation Criteria	*Death	*Death	*Death
Exposure Episode Truncation Criteria	*Death *Disenrollment	*Death *Disenrollment	
Exposure Episode Truncation Criteria			*Death
Exposure Episode Truncation Criteria	*Disenrollment	*Disenrollment	*Death *Disenrollment
Exposure Episode Truncation Criteria	*Disenrollment *DP end date	*Disenrollment *DP end date	*Death *Disenrollment *DP end date
Exposure Episode Truncation Criteria	*Disenrollment *DP end date *Study period end date *Pregnancy	*Disenrollment *DP end date *Study period end date	*Death *Disenrollment *DP end date *Study period end date *Pregnancy
Exposure Episode Truncation Criteria	*Disenrollment *DP end date *Study period end date *Pregnancy	*Disenrollment *DP end date *Study period end date *Pregnancy	*Death *Disenrollment *DP end date *Study period end date *Pregnancy
Exposure Episode Truncation Criteria	*Disenrollment	*Disenrollment	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HO
Exposure Episode Truncation Criteria	*Disenrollment	*Disenrollment	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI defining hospitalized
Exposure Episode Truncation Criteria	*Disenrollment	*Disenrollment	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI defining hospitalized tachyarrhythmia)

Drug/Exnos



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

	Cohort Group 7	Cohort Group 8	Cohort Group 9
	Liraglutide	Dulaglutide	Insulin degludec and liraglutide
	(Victoza)	(Trulicity)	(Xultophy)
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days			
supply (after stockpiling)?			
(This does not apply to index-defining			
criteria)			
Forced supply to attach to codes	N/A	N/A	N/A
Cohort Definition	Only the first valid treatment	Only the first valid treatment	Only the first valid treatment
	episode during the query period (01)	episode during the query period (01)	episode during the query period (01)
Prevalent Cohort creation?	No	No	No
Exposure Episode Gap	5 days	5 days	5 days
Exposure Extension Period	5 days	5 days	5 days
Minimum Episode Duration	1 day	1 day	1 day
Minimum Days Supplied	1 day	1 day	1 day
Point Exposure?	No	No	No
Maximum Episode Duration	N/A	N/A	N/A

Event/Outcome	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day

Event/Outcome	Atrial fibrillation and flutter	Atrial fibrillation and flutter	Atrial fibrillation and flutter
---------------	---------------------------------	---------------------------------	---------------------------------

Base Cohort Outcome



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

	Cohort Group 7	Cohort Group 8	Cohort Group 9
	Liraglutide	Dulaglutide	Insulin degludec and liraglutide
	(Victoza)	(Trulicity)	(Xultophy)
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for all
	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days			
sunnly (after stockniling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day

Event/Outcome	Sinus tachycardia	Sinus tachycardia	Sinus tachycardia
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for all
	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days			
supply (after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

	Cohort Group 7	Cohort Group 8	Cohort Group 9
	Liraglutide	Dulaglutide	Insulin degludec and liraglutide
	(Victoza)	(Trulicity)	(Xultophy)
Event/Outcome	Supraventricular tachycardia	Supraventricular tachycardia	Supraventricular tachycardia
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for all
	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days			
supply (after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day

Event/Outcome	Other tachycardia	Other tachycardia	Other tachycardia
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for all
	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days			
supply (after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Event/Outcome	Cardiac arrest	Cardiac arrest	Cardiac arrest

outcome



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

	Cohort Group 7	Cohort Group 8	Cohort Group 9
	Liraglutide	Dulaglutide	Insulin degludec and liraglutide
	(Victoza)	(Trulicity)	(Xultophy)
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for all
	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days			
supply (after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day

Event/Outcome	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
Event de-duplication	exposure episode are counted for all	exposure episode are counted for all	exposure episode are counted for all
	event characteristics (0)	event characteristics (0)	event characteristics (0)
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days			
supply (after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Event/Outcome	Ventricular tachycardia	Ventricular tachycardia	Ventricular tachycardia
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide	Dulaglutide	Insulin degludec and liraglutide
		(Victoza)	(Trulicity)	(Xultophy)
1	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence With Respect to	N/A N/A	N/A N/A	N/A
	Care Setting / PDX	N/A	N/A	N/A
	Event washout (days)	0 days	0 days	0 days
e Je	Event washout (adys)	All occurrences of an HOI during an	All occurrences of an HOI during an	All occurrences of an HOI during an
Outcome	Event de-duplication	_	exposure episode are counted for all	exposure episode are counted for all
ř.	Event de-dupiication	event characteristics (0)	event characteristics (0)	event characteristics (0)
0		` '	` '	` '
	Only consider dispensing date when	No	No	No
	considering washout, i.e. ignore days			
	supply (after stockpiling)?			
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
		•		
a	Include or Exclude	Inclusion	Inclusion	Inclusion
eri	Conditions	Type 2 Diabetes	Type 2 Diabetes	Type 2 Diabetes
iż I	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
۾	Care Setting/PDX	Any	Any	Any
rsic	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
) K	Only consider dispensing date when	No	No	No
J/E	considering washout, i.e. ignore days			
Inclusion/Exclusion Criteria	supply (after stockpiling)?			
n Jo	Forced supply to attach to codes	N/A	N/A	N/A
<u>-</u> L	Number of Code Occurrences	1x	1x	1x
		AND	AND	AND
	Include or Exclude	Inclusion	Inclusion	Inclusion
	Conditions	Any oral anti-diabetic drug	Any oral anti-diabetic drug	Any oral anti-diabetic drug
_	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
eria	Care Setting/PDX	Any	Any	Any
Criteria	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
٥	Only consider dispensing date when	No	No	No
	considering washout, i.e. ignore days			
	supply (after stockpiling)?			

Inclusion/Exclusion



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9	
		Liraglutide	Dulaglutide	Insulin degludec and liraglutide	
		(Victoza)	(Trulicity)	(Xultophy)	
I	Forced supply to attach to codes	N/A	N/A	N/A	
	Number of Code Occurrences	1x	1x	1x	
_		AND (AND (AND (
_π [Include or Exclude	Exclusion	Exclusion	Exclusion	
eri	Conditions	Insulin	Insulin	Insulin	
Crit	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes	
٦	Care Setting/PDX	Any	Any	Any	
Isic	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)	
ਹੁ 	Only consider dispensing date when	No	No	No	
Ĵ.	considering washout, i.e. ignore days				
Inclusion/Exclusion Criteria	supply (after stockpiling)?				
	Forced supply to attach to codes	N/A	N/A	N/A	
=	Number of Code Occurrences	1x	1x	1x	
		AND NOT	AND NOT	AND NOT	
	Include or Exclude	Exclusion	Exclusion	Exclusion	
<u>ä</u> .	Conditions	Any anti-diabetic drug other than	Any anti-diabetic drug other than	Any anti-diabetic drug other than	
ite	Conditions	insulin	insulin	insulin	
ت	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes	
į.	Care Setting/PDX	Any	Any	Any	
Sin I	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)	
Ĕ	Only consider dispensing date when	No	No	No	
on/	considering washout, i.e. ignore days				
nclusion/Exclusion Criteria	supply (after stockpiling)?				
luc	Forced supply to attach to codes	N/A	N/A	N/A	
	Number of Code Occurrences	1x	1x	1x	
	_	OR	OR	OR	
	Include or Exclude	Exclusion	Exclusion	Exclusion	
	Conditions	Type 1 Diabetes	Type 1 Diabetes	Type 1 Diabetes	
_	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes	
Criteria	Care Setting/PDX	Any	Any	Any	
ŢŢ.	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)	
٥	Only consider dispensing date when	No	No	No	
	considering washout, i.e. ignore days				
	supply (after stockpiling)?				



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide	Dulaglutide	Insulin degludec and liraglutide
		(Victoza)	(Trulicity)	(Xultophy)
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
в	Include or Exclude	Exclusion	Exclusion	Exclusion
eri	Conditions	Gestational Diabetes	Gestational Diabetes	Gestational Diabetes
Ċ	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Ľ	Care Setting/PDX	Any	Any	Any
usic	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
×C	Only consider dispensing date when	No	No	No
J/E	considering washout, i.e. ignore days			
Siol	supply (after stockpiling)?			
nclusion/Exclusion Criteria	Forced supply to attach to codes	N/A	N/A	N/A
드	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
a	Include or Exclude	Exclusion	Exclusion	Exclusion
ēĽ	Conditions Other secondary diabetes illness		Other secondary diabetes illness	Other secondary diabetes illness
Ë	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
Ë	Care Setting/PDX	Any	Any	Any
usic	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
×C	Only consider dispensing date when	No	No	No
J/E	considering washout, i.e. ignore days			
nclusion/Exclusion Criteria	supply (after stockpiling)?			
n C	Forced supply to attach to codes	N/A	N/A	N/A
ב	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Short-acting GLP-1 RA	Short-acting GLP-1 RA	Short-acting GLP-1 RA
	Conditions	(Byetta, Adlyxin, Soligua)	(Bvetta, Adlyxin, Soliqua)	(Byetta, Adlyxin, Soligua)
<u>.</u>	Code Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
Criteria	Care Setting/PDX	Any	Any	Any
Ċ	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when	No	No	No
	considering washout, i.e. ignore days			
	supply (after stockpiling)?			



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

	Cohort Group 7	Cohort Group 8	Cohort Group 9
	Liraglutide	Dulaglutide	Insulin degludec and liraglutide
	(Victoza)	(Trulicity)	(Xultophy)
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
Conditions	Pregnancy	Pregnancy	Pregnancy
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	Any	Any	Any
Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days			
supply (after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x
_	OR	OR	OR
Include or Exclude	Exclusion	Exclusion	Exclusion
	Long-acting GLP-1 RA	Long-acting GLP-1 RA	Long-acting GLP-1 RA
	(Bydureon, Bydureon BCISE,	(Bydureon, Bydureon BCISE,	(Bydureon, Bydureon BCISE,
Conditions	Mounjaro, Ozempic, Rybelsus,	Mounjaro, Ozempic, Rybelsus,	Mounjaro, Ozempic, Rybelsus,
	Saxenda, Trulicity, Victoza, Wegovy,		Saxenda, Trulicity, Victoza, Wegovy,
	Xultophy)	Xultophy)	Xultophy)
Code Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
Care Setting/PDX	Any	Any	Any
Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
Only consider dispensing date when	No	No	No
considering washout, i.e. ignore days			
supply (after stockpiling)?			
Forced supply to attach to codes	N/A	N/A	N/A
Number of Code Occurrences	1x	1x	1x



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

			Cohort Group 7	Cohort Group 8	Cohort Group 9
			Liraglutide	Dulaglutide	Insulin degludec and liraglutide
			(Victoza)	(Trulicity)	(Xultophy)
		Group(s) Affected by Custom Stockpiling	Long or Short-acting GLP-1 RAs by	Long or Short-acting GLP-1 RAs by	Long or Short-acting GLP-1 RAs by
		Rules	brand name	brand name	brand name
			(for Victoza, both brand names	(for Victoza, both brand names	(for Victoza, both brand names
			consolidated to one stockgroup)	consolidated to one stockgroup)	consolidated to one stockgroup)
			(Other RXs by generic name, default	(Other RXs by generic name, default	(Other RXs by generic name, default
Stockpiling			stockpiling rules)	stockpiling rules)	stockpiling rules)
ė,		Same Day Processing (days supply)	Max	Max	Max
Š		Same Day Processing (amount supply)	Max	Max	Max
St		Allowable Range (days supply)	Greater than 0	Greater than 0	Greater than 0
		Allowable Range (amount supply)	Greater than 0	Greater than 0	Greater than 0
	Maximum Amount of Percentage Overlap		0%	0%	0%
		Allowed Prior to Shifting Dispensing Date	(No shifting of index date;	(No shifting of index date;	(No shifting of index date;
			truncate previous dispensing at any	truncate previous dispensing at any	truncate previous dispensing at any
			overlap with next dispensing)	overlap with next dispensing)	overlap with next dispensing)
e tes		Covariates	(See Appendix I)	(See Appendix I)	(See Appendix I)
Baseline Covariates		Code Details (type, days supply, etc.)	(See Appendix I)	(See Appendix I)	(See Appendix I)
as(Care Setting/PDX	N/A	N/A	N/A
۳ S		Covariate evaluation window (days)	(See Appendix I)	(See Appendix I)	(See Appendix I)
<u>i</u> t		Comorbidity Score evaluation window	(-365, -1)	(-365, -1)	(-365, -1)
norbid Score		Medical Utilization Evaluation Window	(-365, -1)	(-365, -1)	(-365, -1)
Sco		Medical Utilization Care setting	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED
Comorbidity Score		Drug Utilization Evaluation Window	(-365, -1)	(-365, -1)	(-365, -1)



Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

Cohort Group 7	Cohort Group 8	Cohort Group 9
Liraglutide	Dulaglutide	Insulin degludec and liraglutide
(Victoza)	(Trulicity)	(Xultophy)

Abbreviations:

DP: Data Partner

IP: Inpatient

ED: Emergency Department

HOI: Health Outcome of Interest

PDX: Principal Discharge Diagnosis Flag

IPP: Inpatient Hospital Stays, Principal Diagnoses

IS: Non-acute Institutional Stay

AV: Ambulatory Visits

OA: Other Ambulatory Visits

N/A: Not applicable



Group	No.	Covariate	Care Setting	Covariate Window	Code Type	Minimum # of Instances	Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?	Forced supply to attach to codes
Demographic	N/A	Continuous age	N/A	Index Day	N/A	N/A	N/A	N/A
Characteristics	N/A N/A	Age groups (0-40, 41-64, 65-74, 75-84, ≥85)	N/A N/A	Index Day	N/A N/A	N/A N/A	N/A	N/A N/A
Characteristics	N/A N/A	Race (White, Black or African American, Asian,	N/A N/A	Index Day	N/A N/A	N/A N/A	N/A	N/A
	IN/A	American Indian or Alaska Native, Native	IN/A	illuex Day	IN/A	IN/A	IN/A	IN/A
		•						
		Hawaiian or Other Pacific Islander, Unknown,						
		Multi-Racial)						
	N/A	Sex (M F)	N/A	Index Day	N/A	N/A	N/A	N/A
	N/A	Calendar year	N/A	Index Day	N/A	N/A	N/A	N/A
Lifestyle Risk	1	Alcohol use or abuse	Any	(-365 <i>,</i> -1)	Diagnosis	1x	No	N/A
Factor	2	Obesity	Any	(-365, -1)	Diagnosis	1x	N/A	N/A
	3	Tobacco Use	Any	(-365, -1)	Diagnosis	1x	No	N/A
Medical	4	Arrhythmia	Any	(-365, -1)	Diagnosis	1x	No	N/A
History	5	Cerebrovascular disease/stroke/transient	Any	(-365, -1)	Diagnosis	1x	No	N/A
		ischemic attack						
	6	Chronic kidney disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	7	Chronic obstructive pulmonary disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	8	Congenital heart disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	9	Heart failure	Any	(-365, -1)	Diagnosis	1x	No	N/A
	10	Hyperlipidemia	Any	(-365, -1)	Diagnosis	1x	No	N/A
	11	Hypertensive disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	12	Thyroid disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	13	Ischemic heart disease/coronary artery	Any	(-365, -1)	Diagnosis	1x	No	N/A
		disease/myocardial infarction						
	14	Left ventricular hypertrophy	Any	(-365, -1)	Diagnosis	1x	No	N/A
	15	Peripheral artery disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	16	Valvular/mitral valve disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	17	Diseases of veins and lymphatics, and other	Any	(-365 <i>,</i> -1)	Diagnosis	1x	No	N/A
		diseases of circulatory system						
	18	Obstructive sleep apnea	Any	(-365, -1)	Diagnosis	1x	No	N/A
	19	Hypertrophic cardiomyopathy	Any	(-365, -1)	Diagnosis	1x	No	N/A



Group	No.	Covariate	Care Setting	Covariate Window	Code Type	Minimum # of	Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?	Forced supply to attach to codes
<u> </u>	20	Other cardiac disease (heart failure, ischemic	N/A	N/A	Complex	N/A	N/A	N/A
		heart disease/coronary artery disease/myocardial	1 '	'	Covariate	 	'	'
		infarction, hypertension, valvular disease,						
		obstructive sleep apnea, and hypertrophic						
		cardiomyopathy)						
	21	Tachyarrhythmia Day 0	Any	(0, 0)	Diagnosis	1x	No	N/A
	22	Hospitalized Tachyarrhythmia Day 0	ED*, IP*	(0, 0)	Diagnosis	1x	No	N/A
		Charlson/Elixhauser combined comorbidity index	N/A	(-365, -1)	N/A	N/A	N/A	N/A
		-	N/A	(-365, -1)	Custom Coding	N/A	N/A	N/A
	(custom)	I' '						
		Charlson/Elixhauser combined comorbidity index	N/A	(-365, -1)	Custom Coding	N/A	N/A	N/A
	(custom)							
		Charlson/Elixhauser combined comorbidity index	N/A	(-365, -1)	Custom Coding	N/A	N/A	N/A
	(custom)	(3 or 4)						
	Risk score	Charlson/Elixhauser combined comorbidity index	N/A	(-365, -1)	Custom Coding	N/A	N/A	N/A
		(5 or greater)						
Severity of		Diabetes complications severity index	Any	(-365, -1)	Risk Score	1x	No	N/A
Diabetes		Diabetes complications severity index (0)	Any	(-365, -1)	Custom Coding	1x	No	N/A
	(custom)							
		Diabetes complications severity index (1)	Any	(-365, -1)	Custom Coding	1x	No	N/A
	(custom)							
		Diabetes complications severity index (2)	Any	(-365, -1)	Custom Coding	1x	No	N/A
	(custom)							
		Diabetes complications severity index (3)	Any	(-365, -1)	Custom Coding	1x	No	N/A
	(custom)							
		Diabetes complications severity index (4)	Any	(-365, -1)	Custom Coding	1x	No	N/A
	(custom)							
		Diabetes complications severity index (5 or	Any	(-365, -1)	Custom Coding	1x	No	N/A
	(custom)	greater)						



Group	No.	Covariate	Care Setting	Covariate Window	Code Type	Minimum # of	Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?	Forced supply to attach to codes
	25	History of serious hypoglycemia (emergency department visit and/or inpatient care)	ED*, IP*	(-365, -1)	Diagnosis	1x	No No	N/A
Baseline Use of Antidiabetic Drug	26	Alpha-glucosidase inhibitors	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	27	Amylin analogs (Pramlintide)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	28	Dipeptidyl peptidase 4 (DPP-4) inhibitors	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	29	Incretin mimetics (Dipeptidyl peptidase 4 (DPP-4) inhibitors, Victoza, Byetta, Bydureon, Bydureon BCISE)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	30	Meglitinides	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	31	Insulin	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	32	Biguanides (metformin)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	33	SGLT2 Inhibitors	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A



Group	No.	Covariate	Care Setting	Covariate Window	Code Type	Minimum # of Instances	Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?	Forced supply to attach to codes
	34	Sulfonylurea	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	35	Thiazolidinedione			,			
	36	No baseline use of any of the above antidiabetic drugs	N/A	N/A	Complex Covariate	N/A	N/A	N/A
	37	Other antidiabetic drugs (bromocriptine, mifepristone)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
Baseline Use of Other Medications	38	Sodium channel blockers	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	39	Beta blockers	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	40	Potassium channel blockers/openers	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	41	Non-dihydropyridine calcium channel blockers	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	42	Digoxin	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A



Group	No. 43	Covariate Other antiarrhythmic agents	Care Setting N/A	Covariate Window (-365, -1)	Code Type Dispensings (Dispensings Table)	Minimum # of Instances	Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)? No	Forced supply to attach to codes
	44	Antiarrhythmic agents (any of the above antiarrhythmic agents)	N/A	N/A	Complex Covariate	N/A	N/A	N/A
	45	Angiotensin-converting-enzyme (ACE) inhibitor	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	46	Angiotensin II receptor blockers (ARB)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	47	Dihydropyridines	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	48	Diuretics	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	49	Other antihypertensives	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	50	Antihypertensives (any of the above antihypertensives)	N/A	N/A	Complex Covariate	N/A	N/A	N/A
	51	Oral anticoagulants	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	52	Vitamin K antagonists	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A



Group	No.	Covariate	Care Setting	Covariate Window	Code Type	Minimum # of Instances	Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?	Forced supply to attach to codes
	53	Other cardiac medications (not including oral anticoagulants or vitamin K antagonists)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	54	Other cardiac medications (any of above "other" medications")	N/A	N/A	Complex Covariate	N/A	N/A	N/A
	55	Lipid lowering therapy	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	56	Drugs with a known risk of prolonged QT and Torsades de Pointes	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	57	Drugs with a known/possible/conditional risk of prolonged QT and Torsades de Pointes	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
Concomitant use of drugs with a risk of	58	Drugs with a known risk of prolonged QT and Torsades de Pointes	N/A	(0, 0)	Dispensings (Dispensings Table)	1x	No	N/A
prolonged QT and Torsades de Pointes	59	Drugs with a known/possible/conditional risk of prolonged QT and Torsades de Pointes	N/A	(0, 0)	Dispensings (Dispensings Table)	1x	No	N/A
Intensity of Health Care Utilization	N/A N/A N/A N/A	Number of inpatient hospital stays Number of non-acute institutional stays Number of emergency department visits Number of ambulatory visits Number of other ambulatory visits (includes other non overnight ambulatory encounters such as home health visits, telemedicine, telephone and email consultations)	IP* IS* ED* AV* OA*	(-365, -1) (-365, -1) (-365, -1) (-365, -1) (-365, -1)	N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A	N/A N/A N/A N/A N/A
Intensity of	N/A	Number of dispensings	N/A	(-365, -1)	N/A	N/A	N/A	N/A



Appendix I. Specifications Defining Parameters for Baseline Characteristics in this Request (Primary Analysis)										
							Only consider dispensing date when			
							considering baseline characteristics, i.e.			
			Care	Covariate		Minimum # of	ignore days supply	Forced supply to		
Group	No.	Covariate	Setting	Window	Code Type	Instances	(after stockpiling)?	attach to codes		
отоир					T		1 .			
Drug	N/A	Number of unique generics dispensed	N/A	(-365, -1)	N/A	N/A	N/A	N/A		
Utilization	N/A	Number of unique drug classes dispensed	N/A	(-365, -1)	N/A	N/A	N/A	N/A		

N/A: Not Applicable

Page 1020 of 1023 cder_mpl1p_wp077



Appendix J. Specifications Defining Combination Code Parameters Used in this Request (Primary Analysis)

						Time					
				Order		window	dow AND /		New	New	
	Combo			within	Base	between	AND	Combined-to	Anchor	Episode	
Order	description	Purpose		Combo	component	components	NOT?	component	Date	Length	Details
1	IP encounter	Truncation	RX	1	IP or ED	(0, 0)	AND	Pregnancy (any)	Start date of	Start date	- This will prevent IP/ED
	Other than Non-		(IPENCOUNTER)		encounter		NOT	or	base	of IP	encounters from reporting IP/ED
	HOI Hospitalized				(EN01)			Tachyarrhythmia	component	encounter	pregnancy codes in the code
	Tachyarrhythmia							(any)			distribution for truncation codes.
											- All tachyarrhythmia codes in all
											care settings are excluded in this
											combo so that hospitalized
											tachyarrhythmia (IPP, ED*) will be
											used as truncation criteria for
											cohorts where the hospitalized
											tachyarrhythmia code is not used
2	ED encounter	Truncation	RX	1	IP or ED	(0, 0)	AND	Pregnancy (any)	Start date of	Start date	- This will prevent IP/ED
	Other than Non-		(EDENCOUNTER)		encounter		NOT	or		of ED	encounters from reporting IP/ED
	HOI Hospitalized				(EN01)			Tachyarrhythmia	component	encounter	pregnancy codes in the code
	Tachyarrhythmia							(any)			distribution for truncation codes.
											- All tachyarrhythmia codes in all
											care settings are excluded in this
											combo so that hospitalized
											tachyarrhythmia (IPP, ED*) will be
											used as truncation criteria for
											cohorts where the hospitalized
											tachyarrhythmia code is not used

Abbreviations:


IP: Inpatient

ED: Emergency Department

N/A: Not applicable



Type 2 design diagram: Primary analysis



Abbreviations:

DP: Data Partner

ER: Emergency Room

HOI: Health Outcome of Interest

GLP-1 RA: Glucagon-like Peptide 1 Receptor Agonist



Appendix K. Design Diagram for this Request

*Exclusion Criteria

Window 1: use of insulin without other antidiabetic drugs, type 1 diabetes, gestational diabetes, other secondary diabetes illnesses, short-acting GLP-1 RAs, pregnancy, long-acting GLP-1 RAs

**Inclusion Criteria

Window A: type 2 diabetes, any oral anti- Window I: Age, year, race, sex diabetic drug

***Covariates:

Window II: Charlson/Elixhauser combined comorbidity index, adapted Diabetes Complications Severity Index (ADCSI), alcohol use or abuse, obesity, tobacco use, arrhythmia, cerebrovascular disease/stroke/transient ischemic attack, chronic kidney disease, COPD, congenital heart disease, heart failure, hyperlipidemia, hypertensive disease, thyroid disease, ischemic heart disease/coronary artery disease/myocardial infarction, left ventricular hypertrophy, peripheral artery disease, valvular/mitral valve disease, diseases of veins and lymphatics and other diseases of circulatory system, obstructive sleep apnea, hypertrophic cardiomyopathy, other cardiac diseases, history of serious hypoglycemia, alphaglucosidase inhibitor, amylin analogs (pramlintide), DPP-4 inhibitors, incretin mimetics, meglitinides, insulin, biguanides, SGLT-2 inhibitors, sulfonylurea, thiazolidinedione, no baseline use of above mentioned antidiabetic drugs, sodium channel blocker, beta blocker, potassium channel blockers/openers, non-dihydropyridine calcium channel blockers, digoxin, other antiarrhythmic agents, any of the above mentioned antiarrhythmic agents, ACE inhibitor, ARBs, dihydropyridines, diuretic, other antihypertensives, any of the above mentioned antihypertensives, oral anticoagulants, vitamin K antagonists, other cardiac medications (not including oral anticoagulants or vitamin K antagonists), any of the above mentioned "other" medications, lipid lowering therapy, drugs with a known risk of Prolong QT and Torsades de Pointes, drugs with a known/possible/conditional risk of Prolong QT and Torsades de Pointes, healthcare and utilization metrics

Window III: tachyarrhythmia, hospitalized tachyarrhythmia, drugs with a known risk of Prolong QT and Torsades de Pointes, drugs with a known/possible/conditional risk of Prolong QT and Torsades de Pointes

Page 1023 of 1023 cder_mpl1p_wp077